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Hematology encompasses the physiology and pathology of blood and of the blood-
forming organs. In common with other areas of medicine, the pace of change in 
hematology has been breathtaking over recent years. There are now many treatment 
options available to the modern hematologist and, happily, a greatly improved outlook 
for the vast majority of patients with blood disorders and malignancies. Improvements 
in the clinic reflect, and in many respects are driven by, advances in our scientific 
understanding of hematological processes under both normal and disease conditions. 
Hematology - Science and Practice consists of a selection of essays which aim to 
inform both specialist and non-specialist readers about some of the latest advances in 
hematology, in both laboratory and clinic.
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Preface 
‘Blood, blood, glorious blood,
Thicker than water and nicer than mud’ 
Humphrey Kay - The Hematologist’s Song 
Hematology encompasses the physiology and pathology of blood and of the blood-
forming organs. In common with other areas of medicine, the pace of change in
hematology has been breathtaking over recent years. There is now a plethora of
treatment options available to the hematologist which happily coincides with a greatly 
improved outlook for the vast majority of patients with blood disorders, in particular
those with hematological malignancies. Improvements in the clinic reflect, and in 
many respects are driven by, advances in our scientific understanding of 
hematological processes under both normal and disease conditions. This book which 
consists of a selection of essays  aims to inform both specialist and non-specialist
readers about some of the latest advances in hematology, in both laboratory and clinic.
The first section of this book (Section 1 - Blood Physiology) is concerned with the
study of the molecular and cellular mechanisms behind the physiological functioning 
of the blood system. The first three chapters deal with the mechanisms behind early
hematopoiesis, the process occurring almost exclusively in the bone marrow by which 
all mature blood cells are generated from multi-potent hematopoietic stem cells
(HSCs). This is a finely balanced process that is tightly controlled by a complex 
network of inter-related signaling pathways and molecular components. In Chapter 1, 
Fiedler and Brunner review some of the intricate regulatory mechanisms involved in 
this process, in particular focusing on the role of transcription factors in early lineage 
control and lineage commitment. In Chapter 2, Velazquez describes the role that
negative regulation plays in hematopoiesis, and in particular the function of members
of the inhibitory adaptor family such as DOK, Lnk and SOCS, their role in cytokine
signaling pathways and hematological pathologies. This chapter also explores the 
potential therapeutic use of these inhibitors and associated regulators. Expanding 
upon the theme of hematopoiesis, Goossens and Jody, in Chapter 3, discuss the role of 
modulators of the epithelial to mesenchymal transition (EMT) pathway focusing on
the function of SNAI family members, snail and slug, and interestingly how they can 
be involved in leukemic transformation. 
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X Preface 
 
The ability of the HSC (and other cells along the hematopoietic pathway) to divide 
into two functionally distinct daughter cells, one that is differentiated whilst the other 
retains self-renewal properties and can continue to proliferate, is crucial to the 
maintenance of the hematopoietic system. So-called asymmetric division is discussed 
in Chapter 4 by Jimenez-Teja et al. The authors outline the historical perspective 
behind this field before going into a detailed review of the function of asymmetric 
division in both hematopoietic and immune systems, as well as the latest evidence to 
suggest that asymmetric division and in particular abnormal functioning of cell fate 
determinant molecules can lead to cancer. 
After the initial commitment step the HSC loses its ability to self-renew and the 
hematopoietic pathway bifurcates with formation of either the common lymphoid 
progenitor (CLP) or common myeloid-erythroid progenitor (CMEP) cells. CLPs can 
give rise to mature NK, B and T cells, whilst the CMEPs can form erythrocyte, 
megakaryocyte, granulocyte and monocyte populations. In Chapter 5, Čokić et al. 
describe the role of nitric oxide/cyclic nucleotide regulation in erythropoiesis, the 
formation of red blood cells (erythrocytes). In this chapter the authors provide an 
overview of the erythropoietic pathway including the crucial role that GATA1/2 plays 
in hemoglobin switching. They present some novel findings whereby they used 
microarrays to measure changes in expression levels of globin-related genes during 
ontogenesis, and later on provide evidence to show that NO and cGMP can induce 
globin gene expression.  
Platelets play an essential role in hemostasis and thrombosis, initiating clot formation 
in response to cellular damage. Central to the clotting process is platelet aggregation 
mediated by the cross-linking of intergrin αIIbβ3 to fibrinogen, von Willebrand factor 
and other soluble ligands. Aside from their role in physiological processes, platelets 
may also form pathological thrombi which can lead to myocardial infarction or stroke. 
Therefore inhibitors of αIIbβ3 are of great clinical interest. In Chapter 6, Chen et al. use 
a proteomic approach to identify binding partners to αIIb and the αIIbβ3 heterodimer 
expressed in cord-blood derived megakaryocytes. Using this technique they identified 
and validated DNAJC10 as a novel binding partner of the immature form of αIIbβ3, 
and showed that it binds early on in the biogenic pathway. Furthermore, the authors 
found that silencing of DNAJC10 could modulate levels of αIIbβ3 in megakaryocytes 
as well as HEK293 cells transfected with aIIb and b3 cDNA constructs.  
Chapter 7 by Gottimukkala, Burute and Galande concerns the role of the transcription 
factor SATB1 in the development and differentiation of T-cells, in particular, the key 
role that this molecule plays in TH differentiation. The authors also describe how the 
loss of SATB1 function may be associated with the T-cell lymphoma, Sézary 
syndrome.  
Cell polarization is necessary for the migration of cells in many processes including 
embryogenesis, inflammation and tumor metastasis. Chemoattractant recruitment of 
neutrophils to trauma sites is an essential process of the inflammatory response. 
        Preface XI 
 
Neutrophil polarization involves directional sensing of external stimuli via cell surface 
receptors resulting in a reorganization of the cortical cytoskeleton. In Chapter 8, 
Cerecedo discusses the molecular mechanisms behind neutrophil migration focusing 
on the role of proteins and protein complexes that promote cell polarization. This 
theme is expanded in Chapter 9 where Massena and Philipson review leukocyte 
recruitment during inflammation, particularly the mechanisms behind the recently 
described phenomenon of intravascular leukocyte chemotaxis.  
The formation of new blood vessels, or neovascularization, can occur either de novo 
(vasculogenesis) or arise from pre-existing vasculature (angiogenesis). Angiogenesis is 
a vital process in growth and development as well as in wound healing. It is also 
fundamental in the transition of tumors to a malignant state. Angiogenesis involves 
multiple cellular processes including cell proliferation, migration, adhesion and 
morphogenesis. This process is controlled by a multitude of signaling proteins. Their 
membrane trafficking and associated endothelial-cell dynamics are reviewed in 
Chapter 10 by Tiwari et al.  
In the second section of this book (Section 2 - Hematological Pathologies), the focus 
shifts onto discussion of the diseases of the blood system. This section starts with a 
chapter by Khanna-Gupta and Abayasekara (Chapter 11) that reviews diseases of the 
myeloid system/lineage. This chapter focuses on the role that translational control 
plays in myeloid cells under normal and disease conditions. In particular the role 
C/EBPα, PU.1, and components of the mTOR pathway are described as well as the role 
of post-transcriptional regulation by microRNAs in these processes. 
Myeloproliferative neoplasms (MPNs) are a subset of clonal disorders of the myeloid 
system that includes diseases of the granulocytes (chronic myeloid leukemia), 
erythrocytes (polycythemia vera) and platelets (essential thrombocythemia). Although 
essentially chronic in clinical progression, patients have a finite risk of undergoing 
evolution to acute leukemic disease. In Chapter 12, Rinaldi et al. review these diseases 
and provide a detailed discussion about the role of constitutive activation of tyrosine 
kinases, in particularly members of the JAK2 pathway, and how these discoveries are 
translating into new therapeutic options. 
The next chapters in this section concern malignancies of the lymphoid lineage. In 
Chapter 13 Vitale et al. review physiological and pathological features of NK (natural 
killer) cells. NK cells are a fascinating lymphoid subset which, relative to the more 
commonly studied B and T cells, are very poorly understood. They are a major 
component of the innate immune system and play an important role in tumor 
immunity and viral defenses. This chapter describes what is known of cellular 
interactions between NK cells and other immune components such as dendritic cells, 
as well as the molecular pathways involved in these interactions including the pivotal 
role of TRAIL. Although rare, NK neoplasms represent a very distinct class of 
disorders that can range in their clinical presentation from very indolent to very 
aggressive. The latest advances in understanding these diseases are presented in this 
chapter along with a discussion of current and future therapeutic options.  
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XII Preface 
 
Lymphomas are classified as malignancies of NK cells, B lymphocytes or T 
lymphocytes. Lymphoma is the fifth most common cancer type in the Western world 
and, worryingly, its incidence appears to have steadily increased during recent years. 
Chapter 14 concerns the most common form of low-grade lymphoma, follicular 
lymphoma (FL). FL accounts for approximately one third of lymphomas in the US and 
consequently is a common encounter in the hematology clinic. Despite its high 
frequency surprisingly there is no consensus regarding the best treatment protocol for 
FL patients, and patients will eventually succumb to the disease with a heterogeneous 
range of survival times ranging from less than one year to more than 20 years (median 
OS ~10 years). Consequently, a more robust grading and/or stratification scheme 
would help refine and define treatment options for FL patients. Chapter 14 reviews the 
various techniques currently used in the clinic in respect of FL patients including 
clinical, cytogenetic and molecular methods as well as the various algorithms used, 
and discusses their relative strengths and weaknesses.  
Approximately 30% of FL cases will undergo high-grade transformation to an 
aggressive lymphoma that is histologically indistinguishable from diffuse large B-cell 
lymphoma (DLBCL). Transformed FL patients have a particularly poor outcome with 
a median survival of less than 14 months. The molecular basis of FL transformation is 
only poorly understood and importantly to date there are no reliable biomarkers that 
can identify FL patients at risk of transformation. Chapter 15 poses the tantalizing 
possibility that microRNAs may prove to be suitable biomarkers for these at-risk 
patients. The chapter presents the author’s (largely) microarray data suggesting that 
biopsies from FL patients that undergo transformation have a microRNA signature 
that differs from those that do not undergo transformation. The implication being that 
patients can be tested for the presence of this signature and so those that might benefit 
from a more aggressive therapy regimen up-front can be identified. 
Despite only formally being recognized for just over 10 years, the field of microRNAs 
is a useful illustration of the speed of scientific discovery today. In the first two years 
after microRNAs were first named (I.e. 2003), there were just over 50 publications; this 
number has been growing exponentially since, and there are now more than 15,000 
publications (source PubMed; search string= “microRNA”; date=”11/01/12”). 
MicroRNAs are now known to play key regulatory roles in virtually every 
physiological and pathological aspect of human biology including that of the 
hematological system (discussed briefly in Chapter 15). In addition to their utility in 
higher organisms, microRNAs also form part of the armory of many pathogens 
including viruses. Chapter 16 reviews the function and characterization of microRNAs 
encoded by Epstein-Barr virus (EBV), a pathogen intimately involved in 
lymphogenesis. As with other herpesvirus family members, the genome of EBV 
encodes for multiple microRNAs that are differentially expressed at various stages of 
the infectious cycle. EBV-encoded microRNAs have been shown to direct modulate 
host cells, for example changing the immune response to favor infection. Indeed, it has 
been suggested that these microRNAs play a fundamental role in the maintenance 
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(though not necessarily establishment) of EBV-associated cancers such as Burkitt’s 
lymphoma and Hodgkin’s disease.  
Lymphoproliferative disorders (LPD) is a term used to describe a heterogeneous 
group of disorders characterized by the presence of monoclonal or oligoclonal 
lymphoid cell expansion. The LPDs includes lymphomas, lymphoid leukemias, 
multiple myeloma as well as more rarely encountered entities such as post-transplant 
lymphoproliferative disorders (PTLD) and Waldenström’s macroglobulinemia. An 
essential tool in understanding the pathogenesis of these diseases is the availability of 
a suitable animal model. In Chapter 17 Tsingotjidou tackles this subject with particular 
focus on a murine model of Waldenström’s macroglobulinemia developed in the 
laboratory of the author.  
Systemic mastocytosis (SM) is rare disorder characterized by the presence of excess 
mast cells in internal organs in addition to involvement of the skin. SM is a clonal 
disorder and can occur in association with hematological malignancies. The most 
frequently observed partner malignancies are myeloid in origin. By contrast, there are 
very few instances in the literature of SM presenting in concert with lymphoid 
malignancies. In Chapter 18, Antonia et al. present a thorough review of what little is 
known about SM and its pathology as well as discussing the treatment options 
available to the hematologist. 
In the third and final section of the book (Section 3 - Hematology in the Clinic), we 
turn our attention to the practice of clinical hematology. Essays in this section include 
proposals to advance the current treatment regimens of blood disorders as well as 
possible novel therapeutics for these diseases. Chapter 19 considers the use of 
adoptive immunotherapy in order to target minimal residual disease (MRD) in acute 
myeloid leukemia (AML). Although improvements in chemotherapy have greatly 
advanced complete remission rates in this malignancy, a significant proportion of 
responders retain MRD that is refractory to further treatment interventions, eventually 
leading to relapse and disease progression. This chapter presents some novel solutions 
to this problem focusing on the use of NK cells as vehicles of adoptive immunotherapy 
against AML tumor cells. In addition, the use of leukemia vaccines is discussed 
including the various pros and cons of promising antigens identified by the latest 
research studies.  
The ubiquitin-proteasome system (UPS) is essential for many cellular processes 
including cell cycle regulation, gene expression, cellular stress responses and 
regulation of immune function. The UPS system is also associated with many different 
disease types including inflammatory, cardiovascular and cancer. As a consequence, 
inhibitors of the UPS system, and proteosome inhibitors in particular, have been 
targeted as useful anti-cancer therapeutics. Chapter 20 by Mao reviews the functioning 
of the UPS system with particular emphasis on its involvement in hematological 
malignancies. The author discusses the discovery, mechanism and use of the most 
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widely available proteosome inhibitor, bortezomib. Bortezomib is licensed as second 
line therapy for patients with relapsed multiple myeloma and mantle cell lymphoma 
in the US. Although bortezomib is effective in achieving remission for 35% of relapsed 
and refractory myeloma patients, complete remission is only achieved in less than 5% 
of patients and 65% of patients do not respond at all. Therefore the need for alternative 
therapies is clear and in the final part of this chapter the authors review some of the 
latest research looking at the development of novel proteasome inhibitors.      
Heparin is a very widely available anticoagulant used to prevent the formation of 
venous thromboembolism, particularly in patients with angina, acute myocardial 
infarction and patients that have undergone vascular surgery, as well as in the 
treatment of venous thrombosis and pulmonary embolism. However, heparin 
treatment in five to 10% of patients can in itself lead to potentially fatal heparin-
induced thrombocytopenia (HIT). HIT is characterized by a low platelet count and 
predisposition to thrombosis. Chapter 21 reviews this phenomenon, including the 
epidemiology, pathophysiology and diagnosis of HIT in patients as well as current 
and future treatment options for patients. 
Chapter 22 considers the flip side of the ever increasing range of treatment options and 
patient data available to the modern day hematologist; how to prioritize and deal with 
potential information overload in the context of an ever-increasing workload, 
efficiency audits and accountability practices. The interface between the diagnostic 
instrument and the physician is known as middleware. This chapter considers the 
optimal way to achieve clarity in presentation of data to the clinician through proper 
design of middleware and its output. Bernstein et al. review this subject thoroughly in 
the context of data generated by the most commonly used diagnostic test of all, the 
hematocrit.  
Chapters 23 and 24 move away from human clinical hematology to its use in the 
veterinary field. Chapter 23 describes the use of a porcine model as a surrogate 
investigative tool for the human surgical procedures, splenectomy and the still 
controversial procedure, autologous spleen transplantation. The authors carried out 
these procedures and measured the effect on blood count and cell morphology and 
well as spleen tissue functionality via measurements of rates of erythrocyte having 
Howell-Jolly bodies from the blood stream. Chapter 24 considers the use of 
hematological measurements in the veterinary treatment and management of horses, 
with special emphasis on race horses. Satué et al. consider the variability in equine 
hematological profiles in the context of physiological differences including the 
influence of gender, age, season, circadian rhythm, training and race history etc., as 
well as technical variability induced by sample handling, method of venipuncture, 
accuracy of measurement and so on. The authors conclude that although widely used 
as an indicator of general health in routine equine veterinary practice, the 
interpretation of data should be treated with caution due to the many exogenous and 
endogenous factors that can influence these measurements. 
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In summary, these essays cover a wide range of subjects pertaining to hematology, 
both theoretical and clinical, and aptly illustrate both the complexity and challenges 
that face the hematologist today and in the future. 
This book is dedicated to my wonderful and understanding wife María, and my two 
beautiful children, Julia and Carlos. Special thanks should also be given to Dr. Chris 
Hatton (Director of Clinical Medicine at the John Radcliffe Hospital, Oxford) for his 
inspiration and continual support over the years. 
 
Charles H. Lawrie 
Biodonostia Research Institute, 
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Hematopoiesis – the generation of blood cells that proceeds mainly in the bone marrow - is a 
well-controlled process constantly occurring throughout the live of the mammalian 
organism. Generally, blood cells are relatively short-lived cells with a life span ranging from 
few hours to several weeks causing the need for a sustained replenishment of functional 
erythroid, lymphoid and myeloid cells. The development of mature hematopoietic cells in a 
hierarchical manner from a pluripotent hematopoietic stem cell over multipotent 
progenitors that further develop to oligopotent and then to lineage-restricted progenitors 
requires several control mechanisms at different levels. Transcription factors important for 
the expression of lineage-specific genes play a major role in the regulation of hematopoietic 
stem cell maintenance as well as hematopoietic lineage decision. Moreover, the discovery of 
so-called master transcription factors determining the fate of a terminally differentiated cell 
population indicates on one side the coordinated processes of hematopoietic cell 
differentiation but on the other side the complex mechanisms of transcriptional activation 
and/or repression of specific genes. However, what in turn regulates the expression of 
transcription factors that finally determine the lineage and differentiation choice of a certain 
progenitor or immature cell? Is the development into one or another cell type a definitive 
event or is there some plasticity observed? Which factors are necessary and which sufficient 
for hematopoietic cell differentiation? These and several other important questions 
concerning the regulation of development and differentiation of blood cells will be 
discussed. This chapter summarizes the current knowledge about cell intrinsic, 
environmental as well as epigenetic mechanisms involved in the control of hematopoiesis 
under homeostatic as well as infectious conditions. 
1.1 Hematopoiesis 
The hematopoietic system is traditionally categorized into two separate lineages, the 
lymphoid lineage responsible for adaptive immunity and the myeloid lineage embracing 
morphologically, phenotypically and functionally distinct cell types like innate immune 
cells as well as erythrocytes and platelets. Mature hematopoietic cells, except some rare 
lymphoid cell types, are relatively short-lived with life spans ranging from few hours for 
granulocytes to a couple of weeks for erythrocytes demanding a continued replenishment of 
functional cells. This process is named hematopoiesis and takes place primarily in the bone 
marrow, where few hematopoietic stem cells give rise to a differentiated progeny following 
a series of more or less well-defined steps of multipotent progenitors and lineage-restricted 
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precursors leading to a hierarchical structure of the process. During the course of 
hematopoiesis cells lose their proliferative potential as well as multi-lineage differentiation 
capacity and progressively acquire characteristics of terminally differentiated mature cells. 
1.2 Hematopoietic stem cells 
In the hematopoietic differentiation hierarchy, the most primitive cells with highest 
multipotent activity are long-term repopulating hematopoietic stem cells (LT-HSC). One of 
the first definitions of true HSC meaning LT-HSC came from bone marrow transplantation 
experiments in mice determining HSC by their capacity to reconstitute several times the 
hematopoietic system of lethally irradiated adult organisms. Such experiments have 
demonstrated that HSC possess multi-potentiality as well as the ability to produce exact 
replicas upon cell division, named self-renewal capacity. In contrast to real HSC, short-term 
repopulating HSC (ST-HSC) defined by their ability to contribute transiently to the 
production of lymphoid and myeloid cells in lethally irradiated recipients, are often 
described misleadingly as self-renewing cells. The contemporary model of hematopoietic 
stem cells proposes the affiliation of ST-HSC to the group of multipotent progenitors (MPP), 
which are characterized by a more limited proliferative potential, but retained ability to 
differentiate into various hematopoietic lineages (Kondo et al., 2003; Weissman & Shizuru, 
2008). Concerning MPP hierarchy, a defined model is not available at the moment, because 
several studies have demonstrated different types of multipotent progenitors with myelo-
lymphoid or myelo-erythroid potential, such as the lymphoid-primed multipotent 
progenitor (LMPP) (Iwasaki & Akashi, 2007). 
Additionally, a lot of research concerning prospective isolation and characterization of HSC 
and multipotent progenitors has provided insight into the surface marker expression on 
these types of cells leading to the definition of HSC and multipotent progenitors as cells 
being mainly negative for lineage markers but positive for the surface markers Sca1 and Kit. 
This fraction of bone marrow cells is also named LSK-fraction (Lin-Sca1+Kit+) and comprises 
all stem cell capacity of the hematopoietic system, whereby HSC are defined as Lin-
Kit+Sca1+Flt3- and MPP as Lin-Kit+Sca1+Flt3+. Furthermore, the Slam (signaling lymphocyte 
activation molecule) family receptors CD150 and CD48 are useful surface markers allowing 
to distinguish inside the LSK-fraction between HSC (CD150+CD48-) and multipotent 
progenitors (CD150-CD48-) as well as the most restricted progenitors (CD48+) (Kiel et al., 
2005). 
Under homeostatic conditions, the number of HSC remains relatively constant and the 
majority of HSC stays in a quiescent state that contributes not only to their long-term 
maintenance, but also allows a rapid cell cycle entry upon a variety of differentiation cues. 
The minority of HSC is in an active and dividing state and gives rise to all hematopoietic 
cells meaning that these few active HSC not only have to self-renew, but also have to 
produce all differentiated progeny. These different cell fates can only be achieved by an 
asymmetric division of the HSC, which allows the generation of two non-identical daughter 
cells, one maintaining stem cell identity and the other becoming a differentiated cell. Two 
different mechanisms are proposed by which asymmetry could be achieved: first by 
divisional asymmetry that is introduced by unequally redistributed cell-fate determinants in 
the cytoplasm (Florian & Geiger, 2010). An alternative possibility would be the 
environmental asymmetry, which is caused by different extrinsic signals provided by 
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distinct local microenvironments and provokes different cell fate decisions of two identical 
daughter cells (Wilson, A. & Trumpp, 2006). 
1.3 Lineage-committed progenitors 
Downstream of the HSC and MPP populations with high proliferative and self-renewal 
capacity starts the differentiation process in hematopoiesis leading to oligopotent and later 
on to lineage-committed progenitors with a diminished proliferation but increased 
differentiation. The contemporary model of hematopoiesis (Figure 1) assumes that the 
decision for differentiation into the lymphoid/myeloid or megakaryocyte/erythrocyte 
lineages probably occurs very early in hematopoiesis. Several studies have demonstrated 
that multipotent progenitors like the lymphoid-primed multipotent progenitor (LMPP, Lin-
Kit+Sca1+CD150-CD34+Flt3hi) retain only minor megakaryocyte/erythrocyte lineage 
potential, whereas the vast majority of progenitors appears to be committed to the 
granulocyte/monocyte as well as the lymphoid lineage (Iwasaki & Akashi, 2007). 
In the next step of ongoing differentiation oligopotent progenitors with differentiation 
capacity for several hematopoietic lineages develop from an ancestor, the common 
lymphoid progenitor (CLP) (Kondo et al., 1997) and the common myeloid progenitor (CMP) 
(Akashi et al., 2000). The CLP is the earliest population in the lineage-negative fraction that 
upregulates the receptor for interleukin 7 (IL-7), an essential cytokine for T and B cell 
development. Furthermore, the CLP carries differentiation potential for all types of 
lymphoid cells including B cells, T cells and NK cells. The surface marker profile of CLP is 
defined as Lin-Sca1loKitloIL7R+ (Kondo et al., 1997). In contrast to CLP, the CMP resides in 
the Lin-Sca1-Kit+ population in bone marrow that can be further fractioned by expression of 
the Fc receptor II/III (FcRII/III) and CD34 leading to three distinct progenitor 
populations.  
The CMP is defined as FcRII/IIIloCD34+ and can give rise to all types of myeloid colonies in 
clonogenic assays, while the FcRII/IIIhiCD34+ granulocyte-monocyte progenitor (GMP) is 
restricted to granulocytes and macrophages. The FcRII/IIIloCD34- megakaryocyte-erythrocyte 
progenitor (MEP) is delimitated to megakaryocytes and erythrocytes (Akashi et al., 2000). 
Still a matter of dispute is the dendritic cell (DC) development, because DC mainly are the 
progeny of GMP, but can also be generated from lymphoid progenitors such as CLP and 
pro T cells under certain conditions (Manz et al., 2001). However, the majority of 
plasmacytoid DC (pDC) and conventional or myeloid DC (mDC) develop successively by 
several commitment steps downstream of the GMP in the bone marrow. The first step is 
the development of the monocyte/macrophage and DC precursor (MDP) (Fogg et al., 
2006) (MDP) out of the GMP that has lost differentiation potential for granulocytes and 
expresses the FcRII/III and CD34 at a comparable level to the GMP, but is also 
KitloCX3CR1+. Further differentiation of MDP, which is accompanied by the loss of 
monocyte potential, leads to the common DC precursor (CDP) defined as Lin-
KitintFlt3+M-CSFR+ population that can only give rise to pDC and mDC (Geissmann et al., 
2010; Naik et al., 2007; Onai et al., 2007).  
Besides the characterization of MDP and CDP by several studies, further progenitor 
populations for eosinophils, basophils and mast cells have been isolated downstream of the 
GMP and their position in the hematopoietic hierarchy is depicted in Figure 1. Moreover,    
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decision for differentiation into the lymphoid/myeloid or megakaryocyte/erythrocyte 
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Besides the characterization of MDP and CDP by several studies, further progenitor 
populations for eosinophils, basophils and mast cells have been isolated downstream of the 
GMP and their position in the hematopoietic hierarchy is depicted in Figure 1. Moreover,    
 




Fig. 1. Model of the hematopoietic hierarchy in the mouse.  
The developmental course shown in the scheme is proposed using results generated by 
prospective isolation and characterization of different progenitors. HSC, hematopoietic stem 
cell; MPP, multipotent progenitor; LMPP, lymphoid-primed multipotent progenitor; CLP, 
common lymphoid progenitor; CMP, common myeloid progenitor; MEP, megakaryocyte-
erythrocyte progenitor; GMP, granulocyte-macrophage progenitor; MDP, monocyte-
dendritic cell progenitor; TNK, T cell NK cell progenitor; EP, erythroid progenitor; MKP, 
megakaryocyte progenitor; MCP, mast cell progenitor; EoP, eosinophil progenitor; BaP, 
basophil progenitor; CDP, common dendritic cell progenitor. 
the monopotent megakaryocyte lineage-committed progenitor (MKP) (Pronk et al., 2007) 
and erythroid progenitor (EP) (Terszowski et al., 2005) have been described downstream of 
the MEP. Only for the monocyte/macrophage lineage and the neutrophil granulocytes, a 
putative committed precursor downstream of the GMP has not been identified to 
date (Iwasaki & Akashi, 2007). With regard to lymphoid development one committed 
precursor downstream of the CLP is the bipotent T/NK cell progenitor that resides in the 
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bone marrow and is able to generate thymic- and bone marrow-dependent NK cells as well 
as T cells (Nozad Charoudeh et al., 2010).  
1.4 Factors involved in the regulation of hematopoiesis 
The highly regulated differentiation process of quiescent HSC towards different progeny of 
mature hematopoietic cells is associated with a variety of cell fate choices at every single 
step of hematopoiesis. These different choices comprise quiescence, self-renewal or 
differentiation at HSC level as well as proliferation, lineage commitment and terminal 
differentiation at the progenitor or precursor level. Of course, different cell fate choices 
require at each step in the hematopoietic hierarchy a process of decision-making that is 
presumed to be dependent on and regulated by a combination of intrinsic factors that 
embrace lineage-determining transcription factors and their epigenetic regulation as well as 
extrinsic regulators such as cytokines. 
1.4.1 Maintenance of HSC characteristics 
For the maintenance of HSC with respect to quiescence, self-renewal and suppression of 
differentiation, the major intrinsic factors belong to the Bmi1-p53 axis of cell cycle regulators 
and the PI3K signaling pathway. Bmi1 is a member of the Polycomb group gene family that 
controls cell proliferation via repression of the Ink4/Arf locus. Therefore, Bmi1 supports self-
renewal by suppressing transcription of the cell cycle inhibitors p16Ink4a and p19ARF, which 
are encoded in the Ink4/Arf locus, whereas the tumor suppressor p53 contributes to the 
regulation of HSC quiescence via inhibition of cell cycle (Warr et al., 2011). In contrast, the 
PI3K signaling pathway controls cell proliferation, growth and survival via integration of 
numerous upstream signals, including growth factors, nutrients and oxygen status. 
Additionally, several extrinsic factors have been identified that are necessary for 
preservation of HSC stemness. The extrinsic regulators embrace soluble membrane-bound 
extrinsic factors including cytokines (fms-related tyrosine kinase 3-ligand, stem cell factor), 
chemokines (CXCL12) and growth factors (Angiopoietin-1, granulocyte-CSF, granulocyte-
macrophage-CSF), as well as Wnt (wingless type), Notch, Hedgehog and the TGF 
(transforming growth factor ) family of cytokines. These extrinsic factors are provided by a 
specialized microenvironment in the bone marrow, the so-called stem cell niche that resides 
in the endosteal and vascular compartments of the bone. In these areas, the bone marrow 
cells of hematopoietic and non-hematopoietic origin like megakaryocytes, osteoblasts, 
endothelial cells and CXCL12-abundant reticular (CAR) cells create a supportive 
microenvironment via physical interaction with HSC and production of soluble 
factors (Warr et al., 2011). 
1.4.2 Transcription factors involved in lineage commitment 
At the cellular level the differentiation process from HSC into lineage-committed 
hematopoietic cells involves the selective activation of lineage-specific genes as well as the 
silencing of lineage-foreign genes and developmental regulators in a defined order. The 
orchestration of such complex lineage-determining programs is dependent on several 
factors, but extensive research has emphasized the essential role of gene regulatory 
networks in directing cell fate choice and lineage restriction. These gene regulatory 
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cells of hematopoietic and non-hematopoietic origin like megakaryocytes, osteoblasts, 
endothelial cells and CXCL12-abundant reticular (CAR) cells create a supportive 
microenvironment via physical interaction with HSC and production of soluble 
factors (Warr et al., 2011). 
1.4.2 Transcription factors involved in lineage commitment 
At the cellular level the differentiation process from HSC into lineage-committed 
hematopoietic cells involves the selective activation of lineage-specific genes as well as the 
silencing of lineage-foreign genes and developmental regulators in a defined order. The 
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factors, but extensive research has emphasized the essential role of gene regulatory 
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networks are composed of several master transcription factors that join special features, 
such as mutual regulation of transcriptional activity by antagonism as well as lineage-
determining functions via activation of lineage-specific genes and repression of lineage-
foreign genes. The first example pointing out the importance of such transcription factors is 
the transition from self-renewing HSC towards more committed MPP that is dependent on 
the transcription factor CCAAT-enhancer binding protein  (C/EBP). The prototype of the 
C/EBP family displays all characteristic features of the transcription factor family, such as 
the N-terminal transactivation domain as well as the C-terminal DNA-binding domain 
consisting of a highly conserved basic region and a leucine zipper dimerization domain. 
Prerequisite for binding of C/EBP to the cognate DNA-site is the homo- or 
heterodimerization with another transcription factor via the leucine zipper domain that in 
turn allows the basic region to bind to the CCAAT motif (Johnson, 2005; Lekstrom-Himes, J. 
& Xanthopoulos, 1998). Evidences for the function of C/EBP in hematopoietic 
differentiation revealed from studies on conditional C/EBP-deficient mice, which 
demonstrated a competitive advantage of C/EBP-deficient HSC over wild type HSC in 
reconstitution experiments. Further analyses of the transcriptome of C/EBP-deficient HSC 
have confirmed that the expression of the self-renewal factor Bmi1 is increased in these cells, 
suggesting C/EBP as a pro-differentiation factor in HSC fate decision (Zhang et al., 2004). 
1.4.2.1 Erythroid-megakaryocyte lineage commitment 
Probably, the next step in decision-making during differentiation is the choice for erythroid 
versus myeloid-lymphoid lineage restriction at the transition from MPP to LMPP or MEP 
that is regulated by the E-twenty six (Ets) family transcription factor PU.1 and the 
transcription factor GATA-binding protein 1 (GATA-1). GATA-1 is expressed in erythroid, 
megakaryocyte and mast cell as well as eosinophil lineages and contains zinc fingers, which 
mediate DNA binding to the WGATAR DNA sequence as well as protein-protein 
interaction (Bresnick et al., 2010; Morceau et al., 2004). In contrast to GATA-1, PU.1 is 
restricted to monocyte as well as B lymphoid lineages and consists of a N-terminal 
transactivation domain, a PEST-domain (proline, glutamic acid, serine and threonine rich 
sequence) and the eponymous Ets-domain at the C-terminus, which mediate DNA binding 
to an 11 bp sequence with a central GGAA motif (Gangenahalli et al., 2005; Sharrocks, 2001). 
Additionally, both transcription factors are detectable in MPP and gene disruption studies 
have demonstrated the indispensable functions of GATA-1 and PU.1 for 
megakaryocyte/erythrocyte and myeloid/lymphoid development, respectively. Analyses of 
systemic PU.1-deficient mice revealed a complete loss of CMP, GMP and CLP populations 
but normal numbers of MEP causing impaired lymphoid and myeloid cell development as 
well as retained megakaryocyte/erythrocyte development (Scott et al., 1994). In contrast, 
GATA-1-deficient mice die between embryonic day 10.5 and 11.5 due to severe anemia 
resulting from a maturation arrest of erythroid cells (Fujiwara et al., 1996). Further support 
for the lineage instructive role of GATA-1 originated from the forced expression of GATA-1 
in lineage-committed progenitors like GMP and CLP that exclusively leads to 
megakaryocyte/erythrocyte development (Iwasaki et al., 2003). Several other studies 
dealing with certain aspects of the molecular interaction of PU.1 and GATA-1 as well as 
their gene regulatory capacity revealed the cross-antagonism between these proteins 
involving direct physical interaction of both factors that results in an inhibition of the 
transactivation potential of the counterpart (Laslo et al., 2008). Based on these findings, 
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GATA-1 is prospected as the erythrocyte/megakaryocyte lineage determinant, whereas 
PU.1 is regarded as the myeloid/lymphoid lineage determinant. Regarding the regulation of 
erythrocyte versus megakaryocyte development, the detailed molecular mechanisms are not 
fully understood, but several transcription factors involved in this process are described 
such as Friend of GATA-1 (FOG-1), Fli-1 or Krueppel-like factor 1 (KLF1) (Kerenyi & Orkin, 
2010; Szalai et al., 2006). 
1.4.2.2 Myeloid lineage commitment 
Downstream of LMPP, lineage choice embraces myeloid, as well as B or T lymphoid lineage 
and mainly depends on the transcription factors PU.1, early B cell factor 1 (EBF1) and Notch. 
For myeloid lineage restriction, a high expression level of PU.1 is necessary, whereas low 
levels of PU.1 plus EBF1 expression establish the B lymphoid lineage restriction and Notch 
instructs the T lymphoid lineage choice. Regarding granulocyte and monocyte 
development, besides PU.1, the transcription factor C/EBP has to be enumerated. Studies 
have demonstrated that conditional deletion of C/EBP in bone marrow cells of mice using 
the Mx1-Cre system leads to a total lack of mature granulocytes and a partial lack of 
monocytes due to a differentiation block at the transition from CMP to GMP (Zhang et al., 
2004). Moreover, lineage choice between monocytes and granulocytes depends on the 
expression level of PU.1 and C/EBP, which has been shown by studies using different 
mouse as well as in vitro models for diminished PU.1 expression in the hematopoietic 
system. In all experimental setups, reduced expression of PU.1 is followed by an augmented 
granulopoiesis to the disadvantage of monopoiesis. Additionally, gene expression analyses 
of PU.1-deficient progenitors have demonstrated a decreased or even absent expression of 
several monocyte-specific genes, like the macrophage scavenger receptor or the M-CSF 
receptor. Furthermore, the need for C/EBP during the transition from CMP to GMP is 
possibly due to the transcriptional upregulation of PU.1, since forced C/EBP expression in 
hematopoietic progenitors favors monopoiesis and not granulopoiesis, whereas exogenous 
C/EBP in myeloid cell lines directs granulopoiesis (Friedman, 2007). Nevertheless, 
C/EBP is probably indispensable for granulocyte development due to the transcriptional 
upregulation of several granulocyte-specific factors. One of these factors is the 
transcriptional repressor growth factor independent 1 (Gfi1), which is necessary for the 
repression of proliferation and of monocyte lineage-promoting factors such as M-
CSF (Borregaard, 2010). Another important target of C/EBP is the transcription factor 
C/EBP that is important for terminal granulocyte differentiation, because of the 
transcriptional control of granule-specific genes (lactoferrin and gelatinase) as well as genes 
necessary for cell cycle regulation (Borregaard, 2010). 
Besides the upregulation of other transcription factors, C/EBP forces granulocyte 
development additionally by transactivation of various genes, such as G-CSF 
receptor (Hohaus et al., 1995; Smith, L. T. et al., 1996) or myeloperoxidase (MPO) (Wang, W. 
et al., 2001), and downregulation of proliferation by direct interaction with the cell cycle 
regulator E2F (D'Alo et al., 2003; Theilgaard-Monch et al., 2005). In line with these 
experimental results is the association of inactivating C/EBP mutations with 
hematopoietic malignancies like acute myeloid leukemia and high-risk myelodysplastic 
syndrome proposing that C/EBP possesses the ability to arrest cell proliferation and to 
drive terminal differentiation (Koschmieder et al., 2009). Taken together, the plethora of 
studies implicates the following model for monocyte versus granulocyte lineage choice: First  
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Fig. 2. Transcription factor network regulating lineage commitment. 
The scheme displays a simplified overview of gene regulatory networks, which have a 
major influence on hematopoietic lineage choice during hematopoiesis. Supposed (dashed 
lines) and proved (continuous lines) cross-antagonisms between key transcription factors 
which function to regulate binary cell fate choices are noted in the scheme. Additionally, 
transcription factors that are important for the generation of particular intermediates are 
noted in white. HSC, hematopoietic stem cell; MPP, multipotent progenitor; LMPP, 
lymphoid-primed multipotent progenitor; CLP, common lymphoid progenitor; CMP, 
common myeloid progenitor; MEP, megakaryocyte-erythrocyte progenitor; GMP, 
granulocyte-macrophage progenitor; NP, neutrophil progenitor; MDP, monocyte-dendritic 
cell progenitor; TNK, T cell NK cell progenitor; EP, erythroid progenitor; MKP, 
megakaryocyte progenitor. 
of all, C/EBP is needed for the transition from CMP to GMP by induction of PU.1 
expression. High protein levels of PU.1 induce monopoiesis via interaction with other 
transcription factors like interferon regulatory factor 8 (IRF8) or activating protein-1 family 
transcription factors (AP-1/Jun proteins) and the transcriptional activation of monocyte-
specific genes (Friedman, 2007). However, AP-1 family transcription factors are also able to 
heterodimerize with C/EBP (Cai et al., 2008) implicating an inhibition mechanism of PU.1 
for granulocyte development by sequestering the binding partners of C/EBP. In contrast to 
the high protein levels of PU.1 that favor monopoiesis, insufficient activation of PU.1 
transcription allows C/EBP to induce the granulopoiesis program accompanied by 
suppression of monopoiesis (Figure 2). 
Terminal granulopoiesis starts with the myeloblast and promyelocyte state, where the 
switch from proliferation to differentiation takes place, displayed by the loss of ability for 
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cell division after the promyelocyte state. Moreover, the formation of the first granules 
starts, which are named primary or azurophilic granules. The most important transcription 
factors at myeloblast/promyelocyte stage are C/EBP and Gfi1, which are necessary for the 
suppression of monocyte development and proliferation as well as for the transcriptional 
activation of granulocyte-specific genes like MPO, ELANE or CEBPE (Borregaard, 2010; 
Koschmieder et al., 2009; Theilgaard-Monch et al., 2005). The importance of Gfi1 and 
ELANE has been demonstrated by studies analyzing the genetic background of severe 
congenital neutropenia (SCN) and other forms of neutropenia. These studies revealed that 
one of the major causes for loss of neutrophil differentiation beyond promyelocyte state are 
mutations in the ELANE gene (Dale et al., 2000; Horwitz et al., 1999), but in rare cases of 
SCN also mutations of the GFI1 gene have been described (Person et al., 2003). Detailed 
analyses of Gfi1 in mice further supported the function of Gfi1 as molecular switch towards 
granulocyte development by suppression of monocyte-specific genes, like Csf1 (M-CSF) and 
Csf1r (M-CSFR) (Zarebski et al., 2008).  
Ongoing differentiation beyond promyelocytes leads to the development of myelocytes and 
metamyelocytes, which are defined by the beginning of nuclear segmentation and the 
appearance of secondary (also called specific) granules as well as the exit from cell cycle. 
The regulation of secondary granule protein expression and the exit from cell cycle mainly 
depends on the transcription factor C/EBP, whose expression peaks in myelocytes and 
metamyelocytes (Bjerregaard et al., 2003; Theilgaard-Monch et al., 2005). Based on studies 
using C/EBP-deficient mice, which displayed neutrophil-specific defects including bilobed 
nuclei, abnormal respiratory burst and compromised bactericidal activity as well as 
impaired chemotaxis (Lekstrom-Himes, J. & Xanthopoulos, 1999; Yamanaka et al., 1997), the 
genetic cause of a very rare congenital disorder named neutrophil specific granule 
deficiency (SGD) has been delineated to the CEBPE locus (Lekstrom-Himes, J. A. et al., 
1999). Additional studies have revealed the essential functions of C/EBP for the expression 
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demonstrated the direct interaction of C/EBP with E2F1 and Rb protein, finally leading to 
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neutrophils leads to mature neutrophils with finally segmented nuclei and tertiary as well as 
secretory granules. In the course of neutrophil terminal differentiation, C/EBP expression 
gradually diminishes during the myeloblast stage. C/EBP peaks at the 
myelocyte/metamyelocyte stage, whereas the expression level of the transcription factors 
PU.1, C/EBP, C/EBP and C/EBP increases subsequently to the metamyelocyte 
stage (Bjerregaard et al., 2003). However, gene deletion studies using C/EBP- or C/EBP-
deficient mice revealed no hematopoietic abnormalities with regard to terminal 
granulopoiesis. Still, Hirai and colleagues have demonstrated the indispensable role of 
C/EBP during emergency granulopoiesis in response to cytokine treatment or fungal 
infection in contrast to C/EBP and C/EBP, which were not upregulated under these 
conditions (Hirai et al., 2006). In the case of the transcription factor PU.1, a conditional gene 
deletion model has evidenced a PU.1-dependent transcriptional activation of gp91phox, a 
component of the NADPH oxidase, as well as of Mac-1/CD11b (Dakic et al., 2005) (Figure 3). 
Terminal differentiation during monopoiesis leads to monocytes, macrophages as well as 
dendritic cells and involves again the selection of specific gene expression programs to  
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Fig. 3. Terminal granulopoiesis in the bone marrow. 
The terminal granulopoiesis that is characterized by sequential formation of different 
granule types and segmentation of the nucleus starts at the myeloblast/promyelocyte stage 
and ends with mature neutrophils. Granule types not only differ in the time point at which 
they are formed, but also in their specific content, which is described at the bottom of the 
figure. Above the line in the boxes matrix content is depicted and beneath the proteins that 
are located to the vesicle membrane. At different stages of terminal granulopoiesis several 
transcription factors, which are indicated on top of the figure, are important for the 
regulation of maturation and timed expression of granule proteins. 
determine cell fates. Additionally, several subtypes of macrophages or DC have been 
described in recent years bringing more complexity into monopoietic differentiation. 
Nevertheless, some key transcription factors with indispensable functions for monopoiesis 
are known already. For example, PU.1 is not only required for myeloid lineage commitment, 
but also for macrophage versus DC lineage choice during late myelopoiesis. Intermediate 
PU.1 expression at GMP stage results in the activation of the macrophage-specific 
transcription factors Egr-1 and Egr-2 (Laslo et al., 2006), whereas high expression of PU.1 
promotes the induction of DC fate via repression of the macrophage-inducing transcription 
factors c-Maf and MafB (Bakri et al., 2005). In addition, gain-of-function experiments have 
demonstrated that ectopic expression of MafB, c-Maf, Egr-1 or IRF8 in early progenitors can 
drive monocyte or macrophage lineage commitment. In contrast, RelB induces DC 
differentiation and SpiB pDC differentiation in monocytic intermediates (Auffray et al., 
2009; Geissmann et al., 2010). However, the detailed molecular mechanisms driving terminal 
monopoiesis remains to be elucidated. 
1.4.2.3 B cell lineage commitment 
B cells develop from CLP in the bone marrow, where several stages of B cell development 
have been defined. The earliest B lineage precursors are the pre/pro B cells, which begin to 
express the B lineage specific marker B220 at their surfaces. The transition of pre/pro B cells 
to the pre B cell stage is characterized by the upregulation of the surface marker CD19 as 
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well as by the rearrangement of the immunoglobulin (Ig) heavy chain gene locus. Successful 
rearrangement of the Ig light chain locus is the prerequisite for the development to 
immature IgM expressing B cells. At this stage the antigen-independent phase of B cell 
development is almost complete. IgM+ cells are ready to leave the bone marrow to enter 
peripheral secondary lymphoid organs where they first develop via the IgM+IgD+ stage to 
mature IgD+ B cells. These cells undergo final maturation during the antigen-dependent 
phase of B cell development.  
In addition to cytokines and cytokine receptors, several key transcription factors have been 
identified necessary for the B lineage commitment as well as for the maintenance of the B 
cell fate, like Ikaros, Gfi1, PU.1, E2A, EBF1 and Pax5. Prior to the differentiation of CLP, 
PU.1 is involved in the expression of components of the IL-7 signaling pathways (DeKoter et 
al., 2007) essential for EBF1-dependent lineage restriction in early lymphoid progenitors 
(Tsapogas et al., 2011). Additionally, the level of PU.1 expression predicts the decision 
between the myeloid and the B cell lineage.  Low levels of PU.1 favors B cell development 
whereas high levels promote myeloid cell differentiation (DeKoter & Singh, 2000). The 
upregulation of the transcriptional repressor Gfi1 was suggested to be responsible for the 
down-modulation of PU.1 expression in early progenitors by displacing PU.1 from its 
upstream autoregulatory element and therefore for the promotion of B lineage decision 
(Spooner et al., 2009). In MPP, Gfi1 is upregulated by Ikaros to antagonize PU.1 expression, 
thus favoring B cell development (Spooner et al., 2009). CLP begin to express genes 
associated with committed B cells including E2A as well as EBF1 at the onset of B 
lymphopoiesis (Roessler et al., 2007; Seet et al., 2004; Smith, E. M. et al., 2002). The deficiency 
of these factors leads to a block of B cell development at a very early stage, even before DH-
JH rearrangement of the IgH gene (Bain et al., 1994; Lin, H. & Grosschedl, 1995; Zhuang et 
al., 1994). In contrast, forced expression of E2A and EBF1 revealed that both factors 
cooperate in the upregulation of several B cell-specific genes, like Pax5, the surrogate light 
chain 5 gene, the VpreB, Ig and Iggenes, plus the genes coding for Rag1 and Rag2 (Kee & 
Murre, 1998; O'Riordan & Grosschedl, 1999; Sigvardsson et al., 1997). In addition, the 
transcriptional co-activator Pou2af1 (BOB.1/OBF.1; OCA-B) and the transcription factor 
FoxO1 were identified as direct targets of EBF1 (Zandi et al., 2008). In CLP the expression of 
Pax5 is still low. Consistent with the observation that Pax5 is essential for B lineage 
commitment, CLP still retain T cell developmental potential. The expression of Pax5 is 
detectable at the pro B cell where Pax5 antagonizes T cell development by blocking Notch1 
(Souabni et al., 2002). Additionally, Pax5 interferes with the developmental potential to 
differentiate into several other hematopoietic lineages, since in the absence of Pax5 but in 
the presence of appropriate cytokines pro B cells are able to differentiate in vitro into NK 
cells, dendritic cells, macrophages, granulocytes and osteoclasts (Nutt, S. L. et al., 1999) 
indicating that the expression E2A and EBF1 is not sufficient to commit B cell progenitors to 
the B cell lineage in the absence of Pax5. Therefore, Pax5 plays an essential and dual role in 
B lineage development, it represses non-B cell-specific genes, like the genes coding for the 
M-CSFR or for MPO (Nutt, S. L. et al., 1999), whereas in the same time it activates the B 
lineage-specific gene program (Nutt, S. L. et al., 1998; Schebesta et al., 2002). Thus, Pax5 
controls the pre-BCR signaling by promoting the V to DJ recombination at the IgH locus 
(Nutt, S. L. et al., 1997) and also by regulating directly the expression of the signaling 
molecule BLNK (Schebesta et al., 2002). Additionally, Pax5 is essential for the upregulation 
of CD19 and Iggene expression (Kozmik et al., 1992; Nutt, S. L. et al., 1997). Pax5-deficient 
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well as by the rearrangement of the immunoglobulin (Ig) heavy chain gene locus. Successful 
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FoxO1 were identified as direct targets of EBF1 (Zandi et al., 2008). In CLP the expression of 
Pax5 is still low. Consistent with the observation that Pax5 is essential for B lineage 
commitment, CLP still retain T cell developmental potential. The expression of Pax5 is 
detectable at the pro B cell where Pax5 antagonizes T cell development by blocking Notch1 
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differentiate into several other hematopoietic lineages, since in the absence of Pax5 but in 
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Hematology – Science and Practice 
 
14
B cells are arrested at the pro B cell stage while expressing normal levels of E2A and EBF1 as 
well as of their target genes (Nutt, S. L. et al., 1998; Nutt, S.L. et al., 1997), indicating that 
E2A and EBF1 are upstream of Pax5 in the hierarchical order of lineage-determining 
transcription factor expression.  
 
Fig. 4. Key transcription factors involved in B lymphopoiesis. 
B cell development is driven by the consecutive activation of lineage-determining 
transcription factors like E2A, EBF1 and Pax5 and the repression of lineage-foreign genes. 
Transcription factors are highlighted in bold. HSC, hematopoietic stem cell; MPP, 
multipotent progenitor; CLP, common lymphoid progenitor. 
However, sustained expression of EBF1 in Pax5-deficient hematopoietic precursor cells 
efficiently blocks myeloid and T lineage potential in vivo. Moreover, overexpression of EBF1 in 
Pax5-deficient pro B cells represses alternative lineage potential indicating that EBF1 promotes 
the commitment of the B cell lineage independently of Pax5 (Pongubala et al., 2008) (Figure 4). 
E2A in turn is required for the initiation but also for the maintenance of the expression of 
EBF1, Pax5 and the B cell-specific gene program at the pro B cell stage (Kwon et al., 2008). E2A 
exerts its instructive role not only in the bone marrow at the pro and pre B cell stage as well as 
at the immature B cell stage, but also in peripheral lymphatic organs during the formation of 
germinal center B cells (Kwon et al., 2008). In contrast, E2A is dispensable for Ig class switch 
recombination as well as for the generation of mature splenic subpopulations, like marginal 
zone B cells, follicular B cells and B1 cells. Also, the memory B cell subpopulation and the 
plasma cell generation is unaffected by the loss of E2A (Kwon et al., 2008).  
Conditional inactivation of Pax5 revealed its requirement for the maintenance of B cell 
identity also during late B cell development in peripheral lymphatic organs (Horcher et al., 
2001). Upon exposure to an antigen B lymphocytes can either maintain their B cell identity 
and differentiate into memory B cells or rapidly change their gene expression program and 
develop into germinal center (GC) and plasma cells (PC). During GC formation pre GC B 
cells upregulate the expression of the transcriptional repressor Bcl6 that controls the GC B 
cell differentiation. Bcl6-deficiency results in a complete block of GC B cell reaction, 
necessary for the generation of high-affinity antibodies by somatic hypermutation and class-
switch recombination. In contrast, plasma cell generation occurs normally in Bcl6-deficient 
mice (Dent et al., 1997; Fukuda et al., 1997). The transcription factor IRF8 directly regulates, 
possibly in concert with other transcription factors, Bcl6 upregulation in GC B cells (Lee, C. 
H. et al., 2006). Bcl6 is able to repress several targets including the transcriptional repressor 
Blimp1  (B lymphocyte induced maturation protein 1) (Shaffer et al., 2000; Tunyaplin et al., 
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2004). Therefore, during the GC reaction, Bcl6 represses the gene program for plasma cell 
generation in GC B cells (Shaffer et al., 2000). 
Blimp1 is a key transcription factor for plasma cell (PC) differentiation, where it initiates a 
gene program, which leads to the inhibition of cell division, to the repression of genes 
defining the identity of GC B cells, and to the induction of genes necessary for Ig secretion 
(Kallies et al., 2007; Shaffer et al., 2002). Besides Blimp1, the transcription factors XBP-1 and 
IRF4 play an essential role for PC differentiation (Sciammas et al., 2006; Shaffer et al., 2004). 
During PC generation the GC gene program should be downregulated, which is achieved 
by Blimp1 that represses the expression of Bcl6 and also Pax5 (Diehl et al., 2008; Lin, K. I. et 
al., 2002) (Figure 5). 
In general, the hierarchical expression and the cooperative action of transcription factors as 
well as epigenetic modulators cause the initiation of a gene program characteristic and 
irreversible for a certain committed lineage. However, under certain conditions, committed 
lineages exhibit a high degree of plasticity. For example, TLR engagement drives lymphoid 
progenitor cells to differentiate into dendritic cells (Nagai et al., 2006), a mechanism that 
possibly ensures the generation of sufficient numbers of myeloid cells during an acute 
infection. Today we know that the overexpression of few transcription factors Oct3/4, Sox2, 
c-Myc and Klf4 in adult murine or human fibroblasts can re-differentiate these cells into 
multipotent embryonic stem cell-like cells with pluripotent potential in vitro as well as in 
vivo (Takahashi et al., 2007; Takahashi & Yamanaka, 2006; Wernig et al., 2007). Therefore, it 
is not longer surprising that in the hematopoietic system the overexpression of lineage-
determining transcription factors in committed cells leads to re-differentiation and lineage 
conversion. Thus, T cell progenitors could be converted into dendritic cells and mast cells by 
ectopic expression of PU.1 or GATA-3, respectively (Laiosa et al., 2006; Taghon et al., 2007). 
Also B cells could be re-differentiated into macrophages upon overexpression of 
C/EBP(Xie et al., 2004). Nevertheless, these studies revealed the high instructive capacity 
of lineage-determining transcription factors.  
 
Fig. 5. Cross-regulatory control of germinal center B cell versus plasma cell fate. 
Cell fate decision of mature B cells upon antigen exposure is regulated by key transcription 
factors (bold) that activate cell-specific genes and mutually repress transcription factors 
necessary for alternative cell differentiation. 
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Fig. 5. Cross-regulatory control of germinal center B cell versus plasma cell fate. 
Cell fate decision of mature B cells upon antigen exposure is regulated by key transcription 
factors (bold) that activate cell-specific genes and mutually repress transcription factors 
necessary for alternative cell differentiation. 
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In B cells, the lineage commitment and the maintenance of the B cell fate throughout B cell 
development is achieved by a single transcription factor – Pax5 (Cobaleda et al., 2007; Nutt, 
S. L. et al., 1999). As already mentioned, deletion of Pax5 leads to a block of B cell 
development at the pro B cell stage and Pax5-/- pro B cells can be re-differentiate in the 
presence of appropriate cytokines into osteoclasts, NK cells, dendritic cells, macrophages 
and granulocytes (Nutt, S. L. et al., 1999). More recently it was shown, that the conditional 
deletion of Pax5 in mature B cells from peripheral lymphoid organs, despite their advanced 
differentiation state, leads to a de-differentiation back to early uncommitted progenitors in 
the bone marrow, which even rescued T cell development in T cell-deficient mice (Cobaleda 
et al., 2007). However, the molecular mechanisms for these reprogramming processes are 
not finally clear. Since the complete loss of Pax5 in mature B cells also caused the 
development of aggressive lymphomas, Pax5 was identified as a tumor suppressor for the B 
cell lineage (Cobaleda et al., 2007).  
1.4.2.4 T cell lineage commitment 
Multiple bone marrow-derived hematopoietic precursor populations that belong mainly to 
the MPP or the CLP subsets are able to enter the thymus (Saran et al., 2010; Serwold et al., 
2009), where they represent the population of early thymic progenitors (ETP), the initial 
source for the development of T cells. At this developmental stage the ETP still retain beside 
the T cell developmental potential also the capability to develop into B cells, macrophages, 
granulocytes, dendritic cells, and NK cells. Thymic environmental factors, like IL-7, Kit-
ligand as well as ligands activating Notch signaling, operate in an inductive manner to force 
T cell development (Petrie & Zuniga-Pflucker, 2007) and at the same time to down-modulate 
the capacity to develop into the NK, B or myeloid lineage. Notch signaling blocks these 
alternative developmental processes and, in addition, is necessary to maintain T cell 
specification and differentiation (Feyerabend et al., 2009; Franco et al., 2006; Laiosa et al., 
2006; Schmitt et al., 2004; Taghon et al., 2007). Very recently it became evident, that besides 
blocking alternative lineage development Notch signaling drives T cell lineage commitment 
by upregulating the expression of T lineage-specific transcription factors like TCF-1 
necessary for the induction of several T cell-specific genes, like GATA-3, Bcl11b, and genes 
coding for components of the T cell receptor (Weber et al., 2011). The Krueppel-like C2H2 
type zinc finger transcription factor Bcl11b in turn is required for the repression of NK cell 
associated genes as well as for the downregulation of stem cell or progenitor cell genes not 
longer required for committed T cells (Li, L. et al., 2010) (Figure 6). 
After initial T lineage commitment a subsequent lineage decision is made – the choice to 
develop into either  or  T cell sub-lineages. At the double negative stage (DN; CD4-CD8) 
thymocytes begin to rearrange their TCR and  genes. These cells that productively 
rearranged their TCRandgenes develop to  T cells, which remain largely CD4-CD8-. 
Thymocytes that rearranged efficiently their TCR locus are committed to the  lineage 
and express a pre-TCR complex composed of functional TCR chains paired with the 
invariant pre-TCR (pT) chain. Committed  T cells undergo a strong proliferative burst 
and develop further to CD4+CD8+ double positive (DP) thymocytes that start to rearrange 
their TCR locus. The precise mechanisms by which DN thymocytes develop into  or  T 
cells are not well understood. Currently mainly two models are discussed: the stochastic 
and the TCR signal strength model, where strong TCR signals favor  and weak signals  
lineage choice (reviewed in (Kreslavsky et al., 2010)). Beside TCR signaling also the  
 




Fig. 6. T lineage-determining transcription factors. 
The key transcription factor for T lineage commitment is Notch that suppresses lineage-
foreign gene programs and upregulates the lineage-determining transcription factor TCF-1. 
Finally, lineage commitment is achieved by upregulation of the transcription factors GATA-
3 and Bcl11b. Transcription factors are highlighted in bold. 
Lymphotoxin-mediated as well as Notch signaling are important for the  versus  lineage 
commitment (Ciofani et al., 2004; Garbe et al., 2006; Garcia-Peydro et al., 2003; Hayes et al., 
2005; Kang et al., 2001; Silva-Santos et al., 2005; Van de Walle et al., 2009). Additionally, several 
transcription factors were identified as important regulators of  versus  lineage decision. 
The high-mobility group transcription factor Sox13, for example, promotes  T cell 
development while opposing  T cell differentiation by antagonizing TCF-1 (Melichar et al., 
2007), which is required, similar to RORt (Guo, J. et al., 2002), for the survival of CD4+CD8+  
thymocytes (Ioannidis et al., 2001). Also, the TCR-signal strength dependent upregulation of 
the Zn-finger transcription factor ThPOK (T-helper inducing POZ-Krueppel factor) was shown 
to be an important regulator of  T cell development and maturation (Park, K. et al., 2010). 
Additionally, by integrating TCR and Notch signals as well as by interacting with and thereby 
suppressing E protein targets, also the helix-loop-helix transcription factor Id3 promotes  T 
cell fate (Lauritsen et al., 2009). The AP-1 family member c-Jun in turn controls directly the 
expression of the IL-7R gene important for thymocyte development. Deletion of c-Jun results 
in an enhanced  T cell generation indicating the importance of IL-7 receptor signaling for the 
regulation of / T cell fate decision (Riera-Sans & Behrens, 2007). 
CD4+CD8+ DP cells expressing a mature TCR further undergo positive and negative 
selection processes based on their ability to recognize self-peptide:self-MHC-complexes as 
well as their affinity to such complexes. During these selection processes DP cells develop to 
functionally competent single positive CD4+CD8- or CD4-CD8+ T cells equipped with a 
specific gene expression program characteristic for CD4+ T helper or CD8+ cytotoxic T 
lymphocytes. Mainly two transcription factors – ThPOK and Runx3 – are important for 
directing the development of DP thymocytes either into the CD4+ T helper or CD8+ cytotoxic 
T cell population (Egawa & Littman, 2008; He et al., 2008; Taniuchi et al., 2002; Wang, L. et 
al., 2008). Therefore, ThPOK is required for the commitment to CD4+ T helper cells by 
repressing the characteristic genes for CD8+ cells including Runx3, whereas Runx3 mediates 
the silencing of the CD4 locus in CD8+ cells. These dual regulative processes, leading to the 
exclusion of Runx3 expression in CD4+ cells by ThPOK as well as the exclusion of the 
expression of ThPOK in CD8+ cells by Runx3, result finally in CD4-CD8 lineage 
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commitment. Transcription factors involved in ThPOK upregulation in MHCII-restricted 
T lymphocytes are GATA-3 (Wang, L. et al., 2008) together with the HMG protein Tox 
(Aliahmad & Kaye, 2008). In contrast, IL-7-mediated activation of the STAT5 transcription 
factor promotes the upregulation of Runx3 in CD8+ cells (Park, J. H. et al., 2010) indicating a 
differential requirement of cytokine signaling for CD4 and CD8 lineage development. After 
CD4+ or CD8+ single positive  T cells are generated they are ready to leave the thymus 
and enter via the blood stream peripheral lymphatic organs, where their terminal 
differentiation occurs. 
From the CD4+CD8+ DP pool of thymocytes not only conventional  T cells arise, but also 
natural killer (NK) T cells. In contrast to conventional  T cells that are restricted by MHCI 
or MHCII molecules, invariant NK T cells undergo positive and negative selection processes 
during their thymic maturation, which are mediated by the recognition of glycolipids 
presented by the MHCI-like molecule CD1d. Additionally, they also require signals from the 
Slam family of receptors. Different types of NK T cells are described. However, the most 
common and best-studied NK T cells are the invariant NK (iNK) T cells expressing an 
invariant TCR that is composed of a common -chain in combination with a certain number of 
-chains. After antigen recognition iNK T cells secrete high amounts of a large variety of 
cytokines and chemokines within minutes. Therefore, these cells exhibit rather an innate than 
an adaptive immune function. Several transcription factors were identified to be important for 
iNK T cell lineage choice. Among them, the transcription factor PLZF (promyelocytic leukemia 
zinc finger) is a key regulator for the development of this particular cell type (Kovalovsky et 
al., 2008; Savage et al., 2008), since in the thymus it is exclusively expressed by iNK T cells. In 
addition, several other transcription factors like NF-B (Sivakumar et al., 2003; Stanic et al., 
2004), Ets-1 (Lacorazza et al., 2002; Walunas et al., 2000), GATA-3 (Kim, P. J. et al., 2006), T-bet 
(Matsuda et al., 2006) and Runx proteins (Egawa et al., 2007) contribute to the development, 
differentiation and survival of iNK T cells. Because these transcription factors are also 
expressed in other thymic subpopulations they are not exclusively important for the iNK T cell 
lineage. However, PLZF-deficiency did not prevent iNK T cell development in general but 
severely interfered with iNK T cell effector differentiation and therefore with their 
functionality (Kovalovsky et al., 2008; Savage et al., 2008).  
In the thymus, a subpopulation of MHC-II-restricted CD4+ T cells further differentiates into 
CD25+ naturally occurring regulatory T cells (nTregs) characterized by the expression of the 
transcription factor FoxP3 (Fontenot et al., 2003; Hori et al., 2003). They comprise about 5 to 
10% of peripheral CD4+ T cell and play a crucial role for maintaining peripheral tolerance. 
nTregs are able to suppress the proliferation, cytokine secretion as well as activation of 
autoreactive effector T cells thereby preventing autoimmunity. FoxP3 plays an essential 
function for the regulation of nTregs suppressive activity, since the deficiency of a functional 
FoxP3 leads to a severe autoimmune pathology in mouse (Godfrey et al., 1991; Lyon et al., 
1990) and man (Bennett et al., 2001; Wildin et al., 2001). Several transcription factors are 
implicated in the FoxP3 gene regulation and therefore for the development and function of 
nTregs. After activation of PKCand/or CD28 engagement, Notch3 together with NF-B 
heterodimers composed of p50/p65 are able to bind and to trans-activate the FoxP3 
promoter in vivo (Barbarulo et al., 2011; Soligo et al., 2011). Also NF-B c-Rel was identified 
as a factor able to initiate FoxP3 transcription in thymic Treg precursors (Deenick et al., 2010; 
Isomura et al., 2009; Long et al., 2009; Ruan et al., 2009). Additionally, the FoxP3 promoter 
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contains several functional NFAT/AP-1 binding sites, which are occupied in vivo (Mantel et 
al., 2006). Moreover, the transcription factor Bcl11b is also able to promote directly FoxP3 as 
well as IL-10 expression. Deletion of Bcl11b at the DP stage of thymic T cell development or 
solely in Tregs causes inflammatory bowel disease – a severe autoimmune disorder - due to 
reduced Treg suppressor activity accompanied with reduced FoxP3 and IL-10 expression 
(Vanvalkenburgh et al., 2011).  
Conventional  T cells leave the thymus and settle peripheral lymphatic organs as naïve T 
cells. After activation by exposure to their cognate antigens naïve CD4+ cells differentiate 
into an appropriate T helper cell (TH) lineage that plays an essential role in acquired 
immunity. Depending on the cytokine milieu produced by antigen presenting cells naïve 
CD4+ cells undergo differentiation processes resulting in the expression of master 
transcription factors defining the ability to secrete a certain set of cytokines. Initially, two 
main TH subpopulations were described (Mosmann et al., 1986). The generation of TH1 
cells depends on the presence of IFN and/or IL-12 inducing the expression of the master 
transcription factor T-bet essential for the TH1 phenotype characterized by the production 
of large amounts of IFN, IL-2 and TNF. TH1 cells mediate the defense against infections 
by intracellular microbes and the isotype switching to IgG2a and IgG2b. In contrast, TH2 
cells are generated in the presence of IL-4 and also secrete, depending on the upregulation 
of the transcription factor GATA-3, IL-4 together with IL-5 and IL-13. Thereby, humoral 
responses against parasites and extracellular pathogens are supported and also the class 
switching to IgG1 and IgE (Mosmann et al., 1986; Mowen & Glimcher, 2004; Szabo et al., 2003). 
A third TH subpopulation was described, the TH17 cells that is characterized by the secretion 
mainly of IL-17A and IL17F, but also IL-21 and IL-22, protecting the host against bacterial and 
fungal infections. Their differentiation is induced by TGF together with IL-6 or IL-21, which 
prompts the expression of the master transcription factor essential for TH17-development – 
RORt (Ivanov et al., 2006). More recently, two additional TH subsets were described – TH9 
and TH22 expressing predominantly the cytokines IL-9 or IL-22, respectively. The 
development of TH9 cells is initiated upon antigen receptor stimulation in the presence of IL-4 
and TGF (Dardalhon et al., 2008; Veldhoen et al., 2008) and requires the upregulation of the 
transcription factor PU.1 (Chang et al., 2010). TH22, identified in the human skin, are 
characterized by the expression of the chemokine receptors CCR6, CCR4 and CCR10 as well as 
by the transcription factor aryl hydrocarbon receptor (AHR) that might be involved in the 
regulation of IL-22 gene expression (Duhen et al., 2009; Trifari et al., 2009). 
Another T helper subtype that differentiates in the periphery from naïve CD4+ cells is the 
follicular T helper (TFH) cell subpopulation, characterized by the expression of CXCR5, 
ICOS and PD-1 as surface markers. They synthesize large quantities of IL-21 and require the 
upregulation of the transcriptional repressor Bcl6 for their development and also for their 
function to promote germinal center B cell maturation (Johnston et al., 2009; Nurieva et al., 
2009; Yu et al., 2009). Bcl6 expression is regulated by IL-6 and IL-21 (Nurieva et al., 2009) 
and drives not only the TFH differentiation but also inhibits the development of other CD4+ 
differentiation pathways by blocking Blimp1 (Johnston et al., 2009). 
In the periphery, CD4+ effector T cells can be converted by exposure to TGF and IL-2 to 
inducible regulatory T cells (iTregs) expressing CD25 at the surface and, like nTregs, FoxP3 
as a master transcription factor necessary for Treg function (Davidson et al., 2007; Zheng et 
al., 2007) (Figure 7). 
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Fig. 7. Terminal Differentiation of CD4+ T cells. 
Differentiation of CD4+ T cells into different T helper cell subpopulations after antigen 
exposure is driven by the specific cytokine milieu and results in the expression of specific 
transcription factors (noted in white). Every T helper cell subset releases distinct cytokines, 
which modulate the immune response of the host. 
CD4+ T cell master transcription factors as well as lineage-specific cytokines characteristic for 
the appropriate TH subpopulations are able to block the differentiation of other TH subsets. 
For example, T-bet in cooperation with Runx3 suppresses the generation of TH2 cells by 
physical interaction with GATA-3 thereby inhibiting GATA-3 activity (Djuretic et al., 2007; 
Hwang et al., 2005). Additionally, T-bet also actively represses TH17 differentiation by 
preventing Runx1-mediated upregulation of RORt expression (Lazarevic et al., 2011). Also, as 
already noted, Bcl6 expressed by TFH antagonizes Blimp1 and thereby it inhibits the 
developmental program necessary for alternative TH cell differentiation (Johnston et al., 2009). 
However, several studies suggest certain plasticity in the expression of master transcription 
factors as well in the set of cytokines that differentiated T helper cells secrete. The conversion 
of peripheral effector CD4+ cells to iTregs expressing FoxP3 like nTregs that developed in the 
thymus was a first hint indicating plasticity of CD4+ TH cells (Jonuleit et al., 2001). Moreover, 
in the presence of TGF TH2 cells can acquire IL-9 producing capacity (Veldhoen et al., 2008). 
Additionally, several studies described the acquisition of IFN-producing potential by TH17 
cells in vivo in mouse and man (Kurschus et al., 2010; Wilson, N. J. et al., 2007) and even a 
complete conversion of TH17 cells into IFN-producers (Bending et al., 2009; Lee, Y. K. et al., 
2009; Shi et al., 2008). When stimulated with IL-4, TH17 cells can change into IL4-secreting TH2 
cells (Yi et al., 2009). Also, Tregs stimulated with IL-6 can express IL-17 and downregulate 
FoxP3 expression (Xu et al., 2007). Together, these data indicate the high flexibility of 
peripheral CD4+ cells in their potential to secrete a certain set of cytokines and therefore to 
modulate and/or influence the outcome of an ongoing immune response. However, the 
mechanism(s) underlying the plasticity of “committed” TH cells remain largely unclear. 
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1.4.3 Epigenetic mechanisms controlling hematopoiesis 
The highly coordinated program needed to pass through the diverse developmental stages 
that comprise hematopoiesis can only be achieved by tight regulation. In fact, every cellular 
transition and differentiation step is characterized by the activation of a new, lineage-
specific, genetic program and the extinction of the previous one. This is achieved by the 
action of well-defined networks of transcription factors at each developmental step as 
already described. However, transcription factors are not the only players in the complex 
differentiation process of hematopoiesis, since there is an increasing body of evidence 
demonstrating that the regulation of hematopoietic stemness and lineage commitment is 
dependent on epigenetic mechanisms. Chromatin, the higher order structure of DNA and 
nucleosomes, can adopt different structural conformations depending on epigenetic 
modifications, which influence the accessibility of DNA for the gene transcription 
machinery. Four types of epigenetic regulation can take place: DNA methylation, histone 
modification, chromatin remodeling and gene silencing via microRNAs.  
1.4.3.1 DNA methylation 
DNA methylation of cytosines at CpG dinucleotides, except for CpG islands, is established 
during early embryogenesis by DNA methyltransferases (Dnmt) and is maintained in 
somatic cells to repress transcription. The DNA methyltransferases Dnmt3a and Dnmt3b are 
supposed to convey de novo methylation, whereas Dnmt1 conserves previously installed 
methylation states during replication. First hints depicting the importance of DNA 
methylation for hematopoietic development arose from gene deletion studies in mice 
revealing the indispensable functions of Dnmt1 for HSC self-renewal and lineage-
commitment. The ablation or reduced expression of Dnmt1 in murine HSC led to 
diminished repopulating capacity of HSC and decreased production of lymphoid 
progenitors accompanied with retained myelo-erythroid progenitor development (Broske et 
al., 2009; Trowbridge et al., 2009). Additionally, the examination of genome-wide 
methylation profiles of the mouse hematopoietic system demonstrated methylation pattern 
changes during differentiation resulting in the activation of silent genes and the silencing of 
active genes. Moreover, the study could show that myeloid commitment involved less 
global DNA methylation than lymphoid commitment (Ji et al., 2010) in line with the 
findings from the Dnmt1 deletion studies. In contrast to Dnmt1, Dnmt3a/3b deficiency 
affected only the long-term reconstitution ability of HSC, but not their differentiation into 
committed progenitors (Tadokoro et al., 2007). Nevertheless, the molecular mechanisms 
mediating DNA methylation and demethylation during hematopoietic development have 
not been deciphered, although chromatin-remodeling factors as well as Polycomb 
group/Dnmt3a/3b complexes recruited by transcription factors were supposed to be 
involved (Gao et al., 2009; Kirillov et al., 1996; Vire et al., 2006). 
1.4.3.2 Histone modification 
Another crucial epigenetic mechanism is the posttranslational modification of histones, 
which embraces acetylation, methylation, phosphorylation and sumoylation among others. 
These modifications occur at the tails of histones and change the direct interactions between 
nucleosomes and DNA, thereby affecting gene expression (Campos & Reinberg, 2009). In 
terms of hematopoietic regulation the methylation of lysine 4 (K4) and 27 (K27) of histone 3 
(H3) particularly have to be stressed, since they can serve as repressing, activating and 
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poising marks dependent on the methylation pattern. The concomitant trimethylation of 
H3K27 (repressing mark) and H3K4 (activating mark) as well as the mono- and 
dimethylation of H3K4 introduce a bivalent epigenetic modification leading to poised 
chromatin that is primed for activation of gene transcription (Bernstein, B. E. et al., 2006; 
Heintzman et al., 2009; Orford et al., 2008). Several studies have demonstrated that a 
plethora of lineage-specific genes are poised at the beginning of hematopoiesis or achieve 
poising marks during hematopoietic differentiation. After commitment of the cell to a 
specific lineage, lineage-foreign genes lose their poising marks and repression of gene 
transcription occurs (Orford et al., 2008; Weishaupt et al., 2010). Moreover, genome-wide 
analysis of poised chromatin sites revealed a tight correlation of bivalent histone 
methylation sites with binding sites of lineage-determining transcription factors such as 
EBF1, E2A, GATA-1 or PU.1. These sites are independent of the transcription start site and 
are probably enhancer sites that are involved in the priming for transcriptional activation in 
later stages of hematopoietic development (Heintzman et al., 2009; Heinz et al., 2010; Lin, Y. 
C. et al., 2010; Treiber et al., 2010). Similar to DNA methylation, the molecular mechanisms 
underlying histone modifications have not yet been identified. 
1.4.3.3 Chromatin remodeling 
Additional epigenetic modifiers of DNA accessibility that were recruited through lineage-
specific transcription factors are chromatin-remodeling complexes. Such chromatin 
remodelers are multi-protein complexes that are able to change nucleosome location or 
conformation in an ATP-dependent manner, but they additionally contain interchangeable 
histone modifying enzymes such as deacetylase or acetylase to produce functionally distinct 
complexes (Bowen et al., 2004). For example, Ikaros, a lymphoid-specific transcription factor 
crucial for the commitment of LMPP into CLP can recruit Mi2/NuRD complexes in order to 
repress genes (Kim, J. et al., 1999; Koipally et al., 1999; Sridharan & Smale, 2007). Whereas, 
EBF1 and E2A are involved in the recruitment of the SWI/SNF complex to the upstream 
enhancer of the CD19 locus as well as to the CD79a promoter region facilitating the 
transcriptional activation of these B cell-specific genes (Gao et al., 2009; Walter et al., 2008). 
1.4.3.4 MicroRNAs 
Besides the already mentioned epigenetic mechanisms established at the level of DNA, the 
recent discovery of microRNAs (miRNAs) added a further layer of epigenetic regulation 
that guides the hematopoietic differentiation process. These mRNAs are small, single-
stranded, non-coding RNAs, which are able to repress mRNA transcription by the 
promotion of mRNA degradation due to direct binding to the 3’ untranslated regions (UTR) 
of specific target mRNAs. The first evidences for the importance of miRNAs during 
hematopoietic development revealed from the deletion of Dicer, an RNase-III-like enzyme 
that is indispensable for miRNA biogenesis, in mice. These gene ablation leads to embryonal 
lethality at day 7.5 due to a lack of detectable multipotent stem cells, whereas the 
conditional deletion in murine embryonic stem cells blocks the ability to differentiate 
(Bernstein, E. et al., 2003; Kanellopoulou et al., 2005) and the lineage-specific ablation of 
Dicer in lymphoid progenitors results in severe defects in the B as well as T cell 
development (Cobb et al., 2005; Koralov et al., 2008; Muljo et al., 2005). Moreover, analyses 
of miRNA expression in several subsets of human CD34+ HSC and progenitors cells as well 
as murine hematopoietic tissues have demonstrated the modulated transcription of different 
miRNA during hematopoiesis (Chen et al., 2004; Georgantas et al., 2007; Liao et al., 2008). With 
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regard to the relative young field of miRNA research, only limited data about the detailed role 
of single miRNAs in the different steps of HSC maintenance or hematopoietic differentiation 
are available, but some regulatory mechanisms are already described. At the level of HSC, 
where decision-making comprises self-renewal and differentiation into committed 
progenitors, miRNAs of the miR-196 and miR-10 family are highly expressed, which are able 
to modulate HSC homeostasis and lineage commitment through the regulation of certain HOX 
genes (Mansfield et al., 2004; Yekta et al., 2004), whereas miR-125a has been shown to mediate 
self-renewal of LT-HSC by targeting the pro-apoptotic protein Bak-1 (Guo, S. et al., 2010). In 
contrast, miR-126 conferring lineage commitment and progenitor production via down-
modulation of HOXA9 and the tumor suppressor polo-like kinase 2 that has to be 
downregulated during differentiation towards multipotent progenitors (Shen et al., 2008).  
Downstream of HSC, the introduction of lineage commitment is the most important task of 
a regulatory mechanism and several miRNAs are involved in these processes in the different 
progenitor populations. For example, during erythroid lineage differentiation starting from 
the MEP a progressive downregulation of miR-24, miR-221, miR-222 and miR-223 as well as 
a upregulation of miR-451 and miR-16 has been reported in differentiating human erythroid 
progenitors (Bruchova et al., 2007). The down-modulation of miR-221 and miR-222 is 
necessary for the expression of Kit that in turn allows the expansion of erythroblasts (Felli et 
al., 2005), whereas the repression of miR-24 permit the expression of activin type I receptor, 
which promotes erythropoiesis in cooperation with erythropoietin (Wang, Q. et al., 2008). A 
further activator of erythroid differentiation is the transcription factor and miR-223-target 
LIM-only protein 2 that along with GATA-1 and others constitutes a multi-protein complex 
(Felli et al., 2009). In contrast to these down-modulated miRNAs, miR-451 upregulation is 
indispensable for erythroid maturation and effective erythropoiesis in response to oxidative 
stress. Several studies have demonstrated that miR-451 targets 14-3-3, a chaperone protein 
modulating intracellular growth factor signals, and therefore regulating the expression of 
several genes associated with late erythropoiesis (Patrick et al., 2010; Rasmussen et al., 2010; 
Zhan et al., 2007). But also megakaryocyte differentiation occurs downstream of the MEP 
and several studies revealed the importance of miR-150 for lineage commitment during 
megakaryocyte-erythroid differentiation, since the ectopic expression of miR-150 in MEP 
drives the differentiation towards megakaryocytes at the expense of erythroid cells by 
targeting the transcription factor c-Myb (Lu et al., 2008). Further support for the lineage-
determining function of miR-150 has arose from a study demonstrating the regulation of 
miR-150 and c-Myb through the megakaryocyte-specific cytokine TPO (Barroga et al., 2008). 
Other miRNAs downregulated during megakaryopoiesis are miR-130 targeting MafB that in 
turn together with GATA-1 is needed for the induction of the GbIIb gene (Garzon et al., 
2006) as well as miR-155 that targets the transcription factors Ets-1 and Meis-1 (Romania et 
al., 2008).  
With respect to the role of miRNAs in myelopoiesis miR-223 has to be enumerated, which 
also functions as lineage-determining factor that is upregulated during granulopoiesis and 
downregulated during monopoiesis (Fazi et al., 2005; Johnnidis et al., 2008). Targets of 
miR-223 are the cell cycle regulator E2F1 and the monocyte lineage-promoting gene Mef2c 
leading to suppression of proliferation and induction of granulocyte differentiation (Johnnidis 
et al., 2008). Moreover, the transcription of miR-223 is activated by the master transcription 
factor for granulopoiesis C/EBP that replaces the transcriptional repressor NFI-A upon 
activation of granulocytic differentiation (Fazi et al., 2005). A similar mechanism has been 
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recently described for miR-34a that is also increased expressed during granulopoiesis by 
C/EBP-mediated transcription and targets the cell cycle regulator E2F3 (Pulikkan et al., 
2010). Another lineage-determining mechanism displays the repression of miR-21 and miR-
196b by the transcriptional repressor Gfi1 during granulopoiesis, since ectopic expression of 
both miRNAs in myeloid progenitors results in a complete block of G-CSF induced 
granulopoiesis (Velu et al., 2009). In favor of monocytic development acts the activation of 
miR-424 transcription via PU.1 that in turn targets the negative regulator of monopoiesis 
NFI-A (Forrest et al., 2010). Whereas the miR-17/miR-20/miR-106 cluster is repressed during 
monopoiesis in humans, probably to allow expression of the target AML-1 that consecutively 
promotes monocyte-macrophage differentiation and maturation (Fontana et al., 2007). 
Concerning the function of single miRNAs during lymphopoiesis only few data are 
available, despite the astonishing effects of Dicer deletion on lymphoid development. 
However, one study partially explains the phenotype of Dicer deletion by the defective 
expression of the miR17-92 cluster. This miRNA cluster that is highly expressed in 
progenitor cells targets the pro-apoptotic factors Bim and Pten. In line with these findings,  
 
Fig. 8. The regulatory network of miRNAs during hematopoiesis. 
Several miRNAs are involved in maintenance of HSC self-renewal, whereas other miRNAs 
are associated with lineage commitment and development towards differentiated progeny. 
HSC, hematopoietic stem cell; MPP, multipotent progenitor; LMPP, lymphoid-primed 
multipotent progenitor; CLP, common lymphoid progenitor; CMP, common myeloid 
progenitor; MEP, megakaryocyte-erythrocyte progenitor; GMP, granulocyte-macrophage 
progenitor; NP, neutrophil progenitor; MDP, monocyte-dendritic cell progenitor; TNK, T 
cell NK cell progenitor; EP, erythroid progenitor; MKP, megakaryocyte progenitor. 
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ablation of the miR17-92 cluster in mice results in a severe block of B cell development at the 
pro B to pre B transition due to increased apoptosis of pro B cells (Ventura et al., 2008). A 
similar block in B cell development at the pro B to pre B transition is caused by the ectopic 
expression of miR-150 in lymphoid progenitors due to the repression of the transcriptional 
repressor c-Myb (Xiao et al., 2007). The best-described miRNA involved in T lymphocyte 
development is miR-181, which promotes T cell differentiation through increasing signaling 
strength of the TCR signaling. In detail, miR-181 targets multiple phosphatases such as 
PTPN22 or DUSP5 and DUSP6, which are negative regulators of distinct steps of the TCR 
signaling pathway leading to an upregulation of ERK1/2 phosphorylation upon TCR 
engagement. This increased sensitivity of TCR signaling is needed during the positive 
selection of double-positive T cells in the thymus (Li, Q. J. et al., 2007) (Figure 8). 
1.4.4 Role of cytokines in guiding hematopoiesis 
Cytokines are a large family of extracellular ligands that stimulate several responses after 
binding to structurally and functionally conserved cytokine receptors. Biological responses 
provoked by cytokines cover a broad spectrum of different biological activities, for example 
survival, proliferation, differentiation, or maturation. In the case of the hematopoietic 
system, the most important cytokines are interleukins and colony-stimulating factors with 
supportive functions for several lineages as well as erythropoietin (EPO) and 
thrombopoietin (TPO) that act on single lineages (Metcalf, 2008). Besides the requirement of 
cytokines for regulation of basal hematopoiesis, they are also essential for controlling 
emergency hematopoiesis in response to infections or blood loss. This is reflected by the 
different origins of cytokines, secreted for example by activated immune cells or by stroma 
cells as well as by organs, like liver and kidney.  
In steady-state conditions, serum concentrations of cytokines are low, but they can be 
elevated up to 1000-fold by challenging the immune system and possess high picomolar 
affinities for their corresponding receptors (Metcalf, 2008). On the binding of cytokine 
molecules follows the activation of the receptor via homodimerization (G-CSFR), 
oligomerization with a common signaling subunit (GM-CSFR, IL-6R) or conformational 
changes in preformed receptor dimers (EPOR), which finally leads to activation of Janus 
kinases (JAK). Upon activation of the tyrosine kinases of JAK family, the cytokine receptors 
as well as the kinases themselves are phosphorylated to generate docking sites for SH2 
domain containing proteins. One example is the STAT protein family that promotes 
transcriptional activation of target genes after phosphorylation by JAK (Robb, 2007; 
Smithgall et al., 2000). Additionally, other signaling molecules can be recruited to the 
cytokine receptors, such as Src kinases, protein phosphatases or PI3K, which mediate the 
activation of numerous signaling pathways like MAPK-ERK, Ras or PI3K (Baker et al., 2007). 
To date, basically two hypotheses exist concerning the role of cytokines in hematopoiesis. 
The instructive model proposes that cytokines transmit specific signals to multipotent 
progenitors to direct their lineage commitment. In contrast, the permissive or stochastic 
model suggests that cytokines only provide permissive growth and survival signals to 
intrinsically determined and lineage-committed progenitors. Supportive data for the 
permissive as well as the instructive model of cytokine function originated from different 
studies, where cytokine receptors were ectopically expressed in lineage-committed 
progenitors. Studies in favor of the permissive model have demonstrated that viral 
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Fig. 8. The regulatory network of miRNAs during hematopoiesis. 
Several miRNAs are involved in maintenance of HSC self-renewal, whereas other miRNAs 
are associated with lineage commitment and development towards differentiated progeny. 
HSC, hematopoietic stem cell; MPP, multipotent progenitor; LMPP, lymphoid-primed 
multipotent progenitor; CLP, common lymphoid progenitor; CMP, common myeloid 
progenitor; MEP, megakaryocyte-erythrocyte progenitor; GMP, granulocyte-macrophage 
progenitor; NP, neutrophil progenitor; MDP, monocyte-dendritic cell progenitor; TNK, T 
cell NK cell progenitor; EP, erythroid progenitor; MKP, megakaryocyte progenitor. 
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transduction of fetal liver cells with the M-CSF receptor results in the generation of 
erythroid colonies upon M-CSF administration (McArthur et al., 1994). Similar results have 
been obtained by the restoration of definitive erythropoiesis in EPOR-deficient fetal liver 
cells via the expression of the human GM-CSFR plus GM-CSF treatment (Hisakawa et al., 
2001). Furthermore, replacement of the intracellular domain of the G-CSFR with the 
intracellular domain of EPOR induces no alterations in lineage commitment (Semerad et al., 
1999). Oppositional results emanated from the ectopic expression of IL-2R in CLP, which 
results in rapid generation of granulocytes and macrophages in the presence of IL-2 (Kondo 
et al., 2000). 
Additionally, ectopic expression of the human GM-CSFR in IL-7-deficient CLP was not able 
to restore lymphopoiesis upon GM-CSF administration (Iwasaki-Arai et al., 2003). 
Experiments with single GMP cultured in the presence of M-CSF or G-CSF have further 
supported the hypothesis of lineage instruction by cytokines due to the almost solely 
development of either macrophages or granulocytes, respectively (Rieger et al., 2009). 
Nevertheless, gene deletion studies for several cytokine receptors have shown the 
indispensable function of the most cytokines for hematopoiesis. For example, the knockout 
of EPO and EPOR in mice leads to embryonic death at E13.5 due to severe anemia, even if 
erythroid progenitor cells were present (Lin, C. S. et al., 1996; Wu, H. et al., 1995). Analysis 
of IL-7R-deficient mice revealed a lethal phenotype as a result of a severe hypoplasia of all 
lymphoid lineages, but retained development of the earliest unipotent T and B cell 
precursors (Peschon et al., 1994). In contrast, mice bearing deletions of colony-stimulating 
factor receptors demonstrated no lethal phenotypes. Disruption of the G-CSFR in mice 
results in ineffective granulopoiesis, with chronic neutropenia due to a decrease of mature 
myeloid cells in the bone marrow and a modest reduction of progenitor cells (Liu et al., 
1996), whereas deletion of the common -chain of IL-3, IL-5 and GM-CSF receptor in mice 
only lead to reduced numbers of eosinophils (Nishinakamura et al., 1996; Nishinakamura et 
al., 1996). 
Taken together, the present available data do not resolve the question if cytokines only have 
permissive functions in the guidance of hematopoiesis, especially with regard to 
differentiation from HSC to restricted progenitors or not. But the plasticity of the transition 
from multipotent progenitor cells to restricted progenitor cells, especially regarding 
adaption of hematopoiesis in emergency situations suggests that cytokines have to some 
extend instructive functions. Furthermore, almost nothing is known about potential 
functions of cytokines and cytokine signaling regarding gene expression or posttranslational 
regulation of lineage-determining transcription factors, which would provide a possible link 
between intrinsic and extrinsic regulation of hematopoiesis (Figure 9). 
1.5 Perspectives 
The unique property of the hematopoietic system to replenish permanently all 
hematopoietic cells together with the ongoing progress in the understanding of 
hematopoietic differentiation processes allows the development of new therapy approaches 
to treat hemic diseases such as hematologic malignancies, immunodeficiencies or 
autoimmune diseases. These new therapies are mainly based on the transplantation of 
hematopoietic stem cells (HSC). Two basic findings promoted the clinical use of HSC 
transplantation (HSCT) in the last twenty years. First, the definition of human HSC as  
 




Fig. 9. The role of cytokines in hematopoiesis. 
Cytokines act on both multipotent progenitors as well as committed progenitors and 
provide survival and proliferation signals. HSC, hematopoietic stem cell; CLP, common 
lymphoid progenitor; CMP, common myeloid progenitor; MEP, megakaryocyte-erythrocyte 
progenitor; GMP, granulocyte-macrophage progenitor; TNK, T cell NK cell progenitor; BCP, 
B cell progenitor. 
CD34+/CD38- cells that can be found in the bone marrow as well as in the umbilical cord 
blood (Weissman & Shizuru, 2008), and second, the discovery of the potent function of the 
cytokine G-CSF in mobilization of stem cells from the bone marrow into peripheral blood 
(Weaver et al., 1993). In most cases, this method provides several advantages in comparison 
to bone marrow transplantation, since the isolation of stem cells from peripheral blood via 
leukapheresis is less invasive for the donor and the recovery of the hematopoietic system 
occurs faster (Gertz, 2010).  
Currently, only two possibilities of HSCT for the treatment of life-threatening hemic 
diseases or immunodeficiencies are available: the autologous transplantation or the 
allogeneic transplantation of HSC from a healthy donor. Autologous transplantation of HSC 
is often used during the cure of hematologic malignancies like myeloma or some types of 
lymphoma to restore the hematopoietic system after aggressive chemotherapy (Gertz et al., 
2000; Linch et al., 1993; Moreau et al., 2011; Philip et al., 1995). In contrast, allogeneic HSC 
transplantation (HSCT) is the treatment of choice for many otherwise fatal hematologic 
malignancies (chronic myeloid leukemia, acute leukemia) and genetic disorders such as 
aplastic anemia, -thalassemia as well as primary immunodeficiencies (severe combined 
immunodeficiency, Wiskott-Aldrich syndrome) and requires an almost perfect human 
leukocyte antigen (HLA) match of donor and recipient (Roncarolo et al., 2011). Additionally, 
recent trails of allogeneic HSCT provided good results in the cure of autoimmune diseases 
like multiple sclerosis and rheumatoid arthritis (Sullivan et al., 2010). Nevertheless, the need 
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for an almost perfect HLA match to avoid graft-versus-host reactions, the restricted 
availability of donors as well as pre-transplant conditioning limits the application of 
allogeneic HSCT today (Roncarolo et al., 2011). 
One possible approach to circumvent the potential risks of allogeneic HSCT is the gene 
therapy, where defective genes are restored by the introduction of functional counterparts in 
autologous HSC. The first trails of gene therapy for primary immunodeficiencies employed 
the retroviral transduction of isolated HSC for gene delivery and afterwards the re-
transplantation into patients. But in some of this trails, a certain amount of patients 
developed hematologic malignancies due to random integration of the transgene into the 
genome that can lead to the trans-activation of proto-oncogenes when the virus sequence is 
integrated in their vicinity. Recent efforts for the improvement of viral vectors by the use of 
retro- and lentiviral vectors with cell-specific promoter sequences may provide gene therapy 
with a decreased incidence for undesired trans-activation of oncogenes. Another approach 
could be the development of robust methods for homologous recombination in HSC, which 
would not only avoid the cancer risk, but also allow the endogenous regulation of the 
corrected gene (Kohn, 2010). Additionally, new perspectives offered the groundbreaking 
findings of Takahashi and Yamanaka demonstrating the induction of pluripotent stem cells 
from mouse fibroblasts by the viral transduction of Oct3/4, Sox2, c-Myc and Klf4 (Takahashi 
& Yamanaka, 2006). Moreover, several recent improvements in induction of pluripotency in 
several cell types like dermal fibroblasts, keratinocytes and blood cells by the use of virus-
free and/or vector-free techniques render reprogrammed somatic cells to a possible future 
technology for stem cell plus gene therapy (Wu, S. M. & Hochedlinger, 2011). Some of the 
advantages of iPS (inducible pluripotent stem) cells are the independency of the cell source, 
the possibility of prolonged culturing ex vivo allowing genetic manipulation, and the 
differentiation into all cell types. A first proof of principle for use of iPS cells in gene therapy 
supplied the successful treatment of sickle cell anemia in a mouse model. In this study, 
autologous skin fibroblasts from humanized sickle cell anemia mice were reprogrammed 
into iPS cells and the genetic defect was repaired via homologous recombination, afterwards 
the iPS cells were differentiated into hematopoietic progenitors in vitro and finally 
transplanted into irradiated recipient mice (Hanna et al., 2007). Nevertheless, these types of 
therapies need a lot of extensive research before they can be applied in the clinic in future, 
but our increasing knowledge of the regulation of hematopoietic processes provides the 
basis for the individual treatment of patients with life-threatening hematologic disorders 
with autologous cells to abolish side effects associated with allogeneic HSCT, or to cure 
diseases currently not treatable with peripheral stem cell transplantation. 
2. Conclusion 
The process of differentiation and lineage commitment during hematopoietic development 
depends strongly on the defined activation of lineage-determining gene programs as well as 
the repression of lineage-foreign gene programs. This concerted regulation of genetic 
programs can only be achieved by the integration of several mechanisms such as activation 
of lineage-specific transcription factors, modulation of epigenetic marks and extrinsic 
signals that provide a supportive environment. Moreover, the described mechanisms of 
hematopoiesis illustrate the complex network involving the synergistic effects of a certain 
number of key transcription factors that not only induce transcription but also guide 
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epigenetic changes to allow or deny the access of the transcriptional machinery to the DNA 
or the repression of important genes via gene silencing. Additionally, some of these 
transcription factors are often involved in several lineage decisions were they induce quite 
different cell fates depending on the presence of other transcription factors co-expressed in 
the cell or on the level of protein expression. Therefore, the hematopoietic differentiation 
process clearly demonstrates the importance of regulatory networks that integrate several 
intrinsic and extrinsic signals for the outcome of differentiation and cell fate decisions. 
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1. Introduction 
Cytokine signalling is initiated through ligand interaction with specific members of the 
cytokine receptor superfamily. The subsequent receptor oligomerization and conformational 
change result in activation of either an intrinsic kinase domain or receptor associated 
kinases, notably the Janus (JAK) family of cytoplasmic tyrosine kinases. The activated JAKs 
phosphorylate tyrosine residues in the receptor and subsequently downstream substrates, 
such as the signal transducers and activators of transcription (STAT) proteins. Once 
recruited to the receptor complex, STAT proteins are themselves phosphorylated on 
tyrosine, dimerize and translocate into the nucleus, where they activate the transcription of 
genes mediating cytokine-induced responses (Ortmann et al., 2000). Cytokines also activate 
other signaling cascades, such as the Ras/Mitogen-Activated Protein Kinase (MAPK) and 
the Phosphoinositide 3-kinase (PI3K)/Akt pathways. These cascades have been implicated 
in the proliferation, survival, and differentiation of several cell types in the haematopoietic 
system (Geest and Coffer, 2009; Leevers et al., 1999. However, all these signalling pathways 
require precise cellular control and their deregulation has been implicated in haematopoietic 
disorders, autoimmune and chronic inflammatory diseases and cancer, making it important 
to understand the mechanisms by which these cytokine-mediated signalling pathways are 
controlled (Schade et al., 2006; Khwaja, 2006). 
It is therefore not surprising that multiple levels of control have evolved to finely 
modulate the threshold, magnitude and specific responses elicited by cytokine 
stimulation. This regulation is achieved through both positive and negative mechanisms. 
The aim of the present chapter is to review the current advances in the regulation of 
haematopoiesis, with special interest on inhibitory pathways. Understanding how 
haematopoiesis is modulated is essential to provide useful information on its 
physiological functioning, the pathological origin of many related haematological 
disorders and to yield potential therapeutic targets. 
2. Regulation of cytokine signalling pathways: Role of adaptor proteins 
Cytokine binding to their receptors results in tyrosine autophosphorylation of the associated 
tyrosine kinase and of the receptor cytoplasmic domain at sites where specific signalling 
molecules can bind. In this way, the cytoplasmic domain of these cytokine receptors serves 
 
Hematology – Science and Practice 
 
46
Wu, S.M. & Hochedlinger, K. (2011). Harnessing the potential of induced pluripotent stem 
cells for regenerative medicine. Nat Cell Biol, 13, 5, pp. 497-505. 
Xiao, C., Calado, D.P., Galler, G., Thai, T.H., Patterson, H.C., Wang, J., Rajewsky, N., Bender, 
T.P. & Rajewsky, K. (2007). MiR-150 controls B cell differentiation by targeting the 
transcription factor c-Myb. Cell, 131, 1, pp. 146-159. 
Xie, H., Ye, M., Feng, R. & Graf, T. (2004). Stepwise reprogramming of B cells into 
macrophages. Cell, 117, 5, pp. 663-676. 
Xu, L., Kitani, A., Fuss, I. & Strober, W. (2007). Cutting edge: regulatory T cells induce 
CD4+CD25-Foxp3- T cells or are self-induced to become Th17 cells in the absence 
of exogenous TGF-beta. J Immunol, 178, 11, pp. 6725-6729. 
Yamanaka, R., Barlow, C., Lekstrom-Himes, J., Castilla, L.H., Liu, P.P., Eckhaus, M., Decker, 
T., Wynshaw-Boris, A. & Xanthopoulos, K.G. (1997). Impaired granulopoiesis, 
myelodysplasia, and early lethality in CCAAT/enhancer binding protein epsilon-
deficient mice. Proc Natl Acad Sci U S A, 94, 24, pp. 13187-13192. 
Yekta, S., Shih, I.H. & Bartel, D.P. (2004). MicroRNA-directed cleavage of HOXB8 mRNA. 
Science, 304, 5670, pp. 594-596. 
Yi, T., Chen, Y., Wang, L., Du, G., Huang, D., Zhao, D., Johnston, H., Young, J., Todorov, I., 
Umetsu, D.T., Chen, L., Iwakura, Y., Kandeel, F., Forman, S. & Zeng, D. (2009). 
Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 
cells in graft-versus-host disease. Blood, 114, 14, pp. 3101-3112. 
Yu, D., Rao, S., Tsai, L.M., Lee, S.K., He, Y., Sutcliffe, E.L., Srivastava, M., Linterman, M., 
Zheng, L., Simpson, N., Ellyard, J.I., Parish, I.A., Ma, C.S., Li, Q.J., Parish, C.R., 
Mackay, C.R. & Vinuesa, C.G. (2009). The transcriptional repressor Bcl-6 directs T 
follicular helper cell lineage commitment. Immunity, 31, 3, pp. 457-468. 
Zandi, S., Mansson, R., Tsapogas, P., Zetterblad, J., Bryder, D. & Sigvardsson, M. (2008). 
EBF1 is essential for B-lineage priming and establishment of a transcription factor 
network in common lymphoid progenitors. J Immunol, 181, 5, pp. 3364-3372. 
Zarebski, A., Velu, C.S., Baktula, A.M., Bourdeau, T., Horman, S.R., Basu, S., Bertolone, S.J., 
Horwitz, M., Hildeman, D.A., Trent, J.O. & Grimes, H.L. (2008). Mutations in 
growth factor independent-1 associated with human neutropenia block murine 
granulopoiesis through colony stimulating factor-1. Immunity, 28, 3, pp. 370-380. 
Zhan, M., Miller, C.P., Papayannopoulou, T., Stamatoyannopoulos, G. & Song, C.Z. (2007). 
MicroRNA expression dynamics during murine and human erythroid 
differentiation. Exp Hematol, 35, 7, pp. 1015-1025. 
Zhang, P., Iwasaki-Arai, J., Iwasaki, H., Fenyus, M.L., Dayaram, T., Owens, B.M., 
Shigematsu, H., Levantini, E., Huettner, C.S., Lekstrom-Himes, J.A., Akashi, K. & 
Tenen, D.G. (2004). Enhancement of hematopoietic stem cell repopulating capacity 
and self-renewal in the absence of the transcription factor C/EBP alpha. Immunity, 
21, 6, pp. 853-863. 
Zheng, S.G., Wang, J., Wang, P., Gray, J.D. & Horwitz, D.A. (2007). IL-2 is essential for TGF-
beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for 
expansion of these cells. J Immunol, 178, 4, pp. 2018-2027. 
Zhuang, Y., Soriano, P. & Weintraub, H. (1994). The helix-loop-helix gene E2A is required 
for B cell formation. Cell, 79, 5, pp. 875-884. 
 
2 
Negative Regulation of Haematopoiesis:  
Role of Inhibitory Adaptors 
Laura Velazquez 
UMR U978 Inserm/Université Paris 13, UFR SMBH, Bobigny 
France 
1. Introduction 
Cytokine signalling is initiated through ligand interaction with specific members of the 
cytokine receptor superfamily. The subsequent receptor oligomerization and conformational 
change result in activation of either an intrinsic kinase domain or receptor associated 
kinases, notably the Janus (JAK) family of cytoplasmic tyrosine kinases. The activated JAKs 
phosphorylate tyrosine residues in the receptor and subsequently downstream substrates, 
such as the signal transducers and activators of transcription (STAT) proteins. Once 
recruited to the receptor complex, STAT proteins are themselves phosphorylated on 
tyrosine, dimerize and translocate into the nucleus, where they activate the transcription of 
genes mediating cytokine-induced responses (Ortmann et al., 2000). Cytokines also activate 
other signaling cascades, such as the Ras/Mitogen-Activated Protein Kinase (MAPK) and 
the Phosphoinositide 3-kinase (PI3K)/Akt pathways. These cascades have been implicated 
in the proliferation, survival, and differentiation of several cell types in the haematopoietic 
system (Geest and Coffer, 2009; Leevers et al., 1999. However, all these signalling pathways 
require precise cellular control and their deregulation has been implicated in haematopoietic 
disorders, autoimmune and chronic inflammatory diseases and cancer, making it important 
to understand the mechanisms by which these cytokine-mediated signalling pathways are 
controlled (Schade et al., 2006; Khwaja, 2006). 
It is therefore not surprising that multiple levels of control have evolved to finely 
modulate the threshold, magnitude and specific responses elicited by cytokine 
stimulation. This regulation is achieved through both positive and negative mechanisms. 
The aim of the present chapter is to review the current advances in the regulation of 
haematopoiesis, with special interest on inhibitory pathways. Understanding how 
haematopoiesis is modulated is essential to provide useful information on its 
physiological functioning, the pathological origin of many related haematological 
disorders and to yield potential therapeutic targets. 
2. Regulation of cytokine signalling pathways: Role of adaptor proteins 
Cytokine binding to their receptors results in tyrosine autophosphorylation of the associated 
tyrosine kinase and of the receptor cytoplasmic domain at sites where specific signalling 
molecules can bind. In this way, the cytoplasmic domain of these cytokine receptors serves 
 
Hematology – Science and Practice 
 
48
to initially localize the signalling response to the plasma membrane. It is the combination of 
the signalling proteins that are recruited to the receptor that then determines the quality of 
the response that is generated. Indeed, the location of the proteins inside the cell and the 
kinetics of their activation are important features of signal-transduction pathways. How the 
signalling molecules are localized in the cell and how the strength and quality of the signal 
is regulated is an area of intense research, and increasing attention has focused on the so-
called adaptor proteins as key molecules controlling these more complex aspects of signal 
transduction. 
Adaptor proteins lack enzymatic activity or other direct effector function. Adaptors can be 
transmembrane proteins, reside in the cytoplasm under resting conditions and be recruited 
to the membrane upon activation, or be localized by specific interactions in intracellular 
compartments. Regardless of their cellular localization, they possess an array of binding 
sites and modules that allow them to mediate specific protein-protein and protein-lipid 
interactions. Examples of binding domains in adaptors include Src-homology 2 (SH2) and 
Phosphotyrosine-binding (PTB) domains that bind to phosphotyrosine motifs, SH3 domains 
that bind to proline-rich sequences and Pleckstrin homology (PH) domain that recognizes 
phospholipids (Pawson and Scott, 1996). With an assemblage of modules and binding 
sequences, a single adaptor can serve as a scaffold protein for the binding of multiple 
proteins into complexes, bringing in this way effectors into close proximity to their targets. 
However, the general ability of adaptor proteins to amplify or inhibit signalling, highly 
depends on their cell-specific expression and level, as well as on that of their binding 
partners, their location in the cell, the stability of the interactions between the adaptor and 
its targets and in certain conditions, on the basal kinase/phosphatase activity in the cell.  
Lastly, it should be noted that the domains and motifs found in adaptors are also frequently 
present in enzymatically active molecules, such as tyrosine phosphatases of the SH2-
containing phosphatase (SHP) family and the ubiquitin ligases Casitas B-cell lineage 
lymphoma (c-Cbl) proteins, where they can mediate true adaptor-like functions and also 
orchestrate signalling complex formation. 
3. Inhibitory adaptors in cytokine signalling regulation  
New insights into the biology of adaptor protein function have been possible with the use of 
a variety of biochemical, cellular and imaging techniques, as well as in vivo genetic 
approaches. All these techniques have helped establish that adaptor proteins can affect the 
thresholds and the dynamics of signalling reactions by coordinating positive and negative 
feedback signals. Over the years, the majority of investigations on cytokine signalling 
pathways have mainly focused on the mechanisms of cytokine-receptor activation, whereas 
our knowledge of negative regulation has been less explored. However, the most recent 
research has placed increasing emphasis on the mechanisms by which cytokine signals are 
attenuated or terminated. Indeed, stringent mechanisms of signal attenuation are essential 
for ensuring an appropriate, controlled cellular response following cytokine stimulation. 
One could imagine how the aberrant assembly of macromolecular active signalling 
complexes could lead to disease: excess positive signalling or insufficient negative signalling 
may lead to autoimmunity, chronic inflammation or malignant transformation, while excess 
negative signalling or insufficient positive signalling may lead to immunodeficiency or 
certain haematological disorders. 
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A number of mechanisms have been proposed to regulate the initiation, duration, 
magnitude and specificity of cytokine signalling at multiple levels: 1) receptor 
internalization and inhibition mediated by soluble receptor antagonists and/or specific 
inhibitors (such as the Lnk and Dok adaptor proteins); 2) tyrosine dephosphorylation of the 
receptor and signalling intermediates mediated by tyrosine phosphatases; 3) proteosomal 
degradation of signalling molecules mediated by the suppressors of cytokine signalling 
(SOCS) proteins and the Cbl E3 ubiquitin ligases proteins; and lastly 4) transcriptional 
suppression mediated by specific inhibitors such as the protein inhibitors of activated 
STATs (PIAS) proteins. In this section, we review what is currently known about the 
function and regulation of four families of inhibitory adaptor proteins that are key players 
in some of the regulatory mechanisms mentioned above. These families are the DOK, the 
Lnk/SH2B3, the Cbl and the SOCS proteins. We first discuss the adaptors without catalytic 
activity (DOK and Lnk), followed by those possessing an enzymatic function (Cbl and 
SOCS). The latter ones are also known as scaffold proteins; however we will refer to them as 
adaptors in hopes that this distinction provides a clear picture on the different properties of 
each.  
 
Fig. 1. Schematic representation of the domain structure of inhibitory adaptors 
3.1 The DOK family 
3.1.1 Structure and cell expression 
The Dok (Downstream Of Tyrosine Kinases) family of adaptor proteins consists of seven 
members, Dok 1 to Dok-7, that differ in the length of their C-terminal region. They are all 
characterized by an N-terminal PH domain, a central PTB domain and multiple SH2 and 
SH3 binding motifs in the C-terminal region (Figure 1). Dok-1 (p62dok), Dok-2 (p56dok-2, also 
called Dok-R, or FRIP) and Dok-3 (also called DokL) are preferentially expressed in the 
haematopoietic compartment, as well as co-expressed in haematopoietic progenitors 
(Carpino et al., 1997; Yamanashi et al., 1997; Di Cristofano et al., 1998; Lemay et al., 2000). 
All three Dok proteins are expressed in myeloid cells, but differ in their lymphoid lineage 
expression. While Dok-1 and Dok-2 are highly expressed in T cells, Dok-3 is little or not 
detected at all. In contrast, Dok-1 and Dok-3 are expressed in B cells, while Dok-2 is not 
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expression. While Dok-1 and Dok-2 are highly expressed in T cells, Dok-3 is little or not 
detected at all. In contrast, Dok-1 and Dok-3 are expressed in B cells, while Dok-2 is not 
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normally detected in these cells. Moreover, several studies have demonstrated that Dok-1 
and Dok-2 expression was up or down-regulated, respectively, by different signalling 
pathways in immune cells. Dok-1 expression was upregulated in response to the 
glucocorticoid dexamethasone in RBL-2H3 mast cells (Hiragun et al., 2005). By contrast, its 
expression was downregulated in bone marrow-derived macrophages in response to 
lipopolysaccharide (LPS) [Shinohara et al., 2005]. As for Dok-2, its expression increased in 
response to cytokines such as M-CSF, granulocyte–macrophage colony stimulating factor 
(GM-CSF), and interleukin-3 (IL-3) in NFS-60 myeloid leukemia cells, suggesting its 
implication in a negative feedback loop for the regulation of these cytokine pathways (Suzu 
et al., 2000). The other Dok proteins, Dok-4 (IRS5), Dok-5 (IRS6), Dok-6 and Dok-7 are 
mainly expressed in non-haematopoietic cells, notably in neural cells. However, Dok-4 was 
reported to function as negative regulator in human T cells (Favre et al., 2003). 
 
Dok protein Binding domain Binding partner Signalling Receptor 
Dok-1 PTB Abl  BCR 
  SHIP-1 FcRIIB 
  Dok-1, Dok-2 CD2 
  TCR idem 
 pY CD3 idem 
  p120RasGap BCR, CD2+CD28, FcRI 
  Abl, Lyn BCR  
  Nck FcRI  
  SHIP-1 FcRIIB, FcRI 
Dok-2 PTB SHIP-1 FcRIIB 
  Dok-1, Dok-2 CD2 
  TCRCD3 idem 
 pY p120RasGAP,Abl BCR 
  Nck TCR 
Dok-3 PTB SHIP-1, Abl FcRIIB 
  Dok-3 BCR 
 pY Grb2 BCR 
  SHIP-1 FcRIIB 
Table 1. Signalling partners bound to the different domains and motifs of Dok proteins 
3.1.2 Signalling partners 
The biological functions of the Dok proteins have been defined with the identification and 
functional analysis of their binding partners, as well as of their subcellular localization. Dok-
1 was the first member of this family identified as a tyrosine-phosphorylated 62 kDa 
substrate of both v-ABL and BCR-ABL and associated with p120RasGap, a negative 
regulator of Ras. Several studies have later shown that Dok-1/2/3 can be tyrosine 
phosphorylated by a variety of growth factors, cytokines and immuno receptors, providing 
multiple docking sites for SH2 and PTB-containing proteins such as Nck, SHP-1, SHIP-1 and 
p120RasGap (Table 1). The interaction between p120RasGap and Dok-1/2 has been the most 
extensively studied and the one likely responsible for the negative regulation of the Ras/Erk 
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pathway mediated by the Dok adaptors. It involves the SH2 domain of p120RasGap and its 
binding motifs present in the C-terminal moiety of Dok-1/2 (Songyang et al., 2001). In 
contrast, Dok-3 protein has no YxxP motifs and therefore is unable to associate with p120 
RasGap. However, it can negatively regulate Erk activation through its binding with Grb2 
(Honma et al., 2006). Fewer signalling molecules have been reported to associate with the 
PTB domain of Dok-1/2/3 (Table 1). Interestingly, these Dok proteins show homotypic and 
heterotypic (for Dok-1/2) oligomerization that is dependent on their tyrosine 
phosphorylation and PTB domains. Moreover, this oligomerization appears crucial to their 
function, at least for Dok-1/2 (Boulay et al., 2005). Instead, the functional relevance of Dok-3 
oligomerization is not yet clear (Stork et al., 2007). The presence of a PH domain in the 
structure of Dok proteins suggests an important role for this domain in the localization or 
translocation of the Dok adaptors to cellular membranes. Indeed, it seems that Dok-1 and 
PI3K activity are required for the recruitment of the adaptor to the membrane and its 
negative effect on PDGF-mediated ERK activation. Furthermore, Dok-1/2 PH domain can 
bind tightly to PI(5)P and modulate the negative function and tyrosine phosphorylation of 
the adaptors in T-cells (Guittard et al., 2009). Conversely, the PH domain of Dok-3 is 
important for its localization to the membrane in B cells (Stork et al., 2007). 
3.1.3 Signalling pathways in immune cells 
Studies with Dok-1/2/3 deficient mice and/or cells have helped demonstrate the 
physiological importance of these inhibitory adaptors to the function and development of 
immune cells. Using Dok-1-deficient splenic B cells, Yamanashi et al. demonstrated a 
negative role of Dok-1 in antigen receptor-mediated signalling through suppression of 
MAPK activity and cell proliferation (Yamanashi et al., 2000). Moreover, co-cross-linking of 
the B-cell receptor (BCR) and FcRIIB receptor induces the tyrosine phosphorylation of Dok-
1 and its subsequent association with RasGap (Vuica et al., 1997). In FcRIIB signalling, Dok-
1 is recruited to the receptor complex at the membrane via SHIP, and in this way, 
contributes to the negative regulation of the Erk pathway [Figure 2.] (Tamir et al., 2000). On 
the other hand, Dok-3 is also expressed in B cells and therefore, one can expect a functional 
redundancy between Dok-1/3 in these cells. Indeed, it was reported that Dok-3 can function 
as a negative regulator of BCR-mediated responses (Ng et al., 2007). Furthermore, both Dok-
1 and Dok-3 were shown to be phosphorylated by Lyn kinase after stimulation of the BCR, 
suggesting that Lyn can activate these Dok proteins to then function as negative regulators 
in B cells (Yamanashi et al., 2000; Stork et al., 2007). However, B cells from Dok-3-deficient 
mice exhibited augmented proliferation and Ca2+ influx upon BCR stimulation (Ng et al., 
2007), while these responses are not observed in the absence of Dok-1 (Yamanashi et al., 
2000). These phenotypic differences could be attributed to Dok-1, but not Dok-3, recruiting 
p120RasGAP, which can inhibit Ras/Erk signalling; by contrast, Dok-3, but not Dok-1, can 
recruit Grb2, which can then inhibit Ca2+ signalling in B cells. 
Dok-1 and Dok-2 adaptor proteins have been also shown to play a role in the maintenance 
of T-cell homeostasis. In some cell line systems, Dok-1 is phosphorylated by Lck kinase and 
associates with RasGap upon CD2 and CD28 stimulation, but not CD3-TCR engagement, 
indicating a possible role of Dok-1 in T cell signalling (Nemorin & Duplay, 2000). 
Furthermore, overexpression of Dok-2 results in a dramatic reduction in both thymocytes 
and splenic T-cell numbers, suggesting a negative role of Dok-2 in T-cell development 
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normally detected in these cells. Moreover, several studies have demonstrated that Dok-1 
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pathway mediated by the Dok adaptors. It involves the SH2 domain of p120RasGap and its 
binding motifs present in the C-terminal moiety of Dok-1/2 (Songyang et al., 2001). In 
contrast, Dok-3 protein has no YxxP motifs and therefore is unable to associate with p120 
RasGap. However, it can negatively regulate Erk activation through its binding with Grb2 
(Honma et al., 2006). Fewer signalling molecules have been reported to associate with the 
PTB domain of Dok-1/2/3 (Table 1). Interestingly, these Dok proteins show homotypic and 
heterotypic (for Dok-1/2) oligomerization that is dependent on their tyrosine 
phosphorylation and PTB domains. Moreover, this oligomerization appears crucial to their 
function, at least for Dok-1/2 (Boulay et al., 2005). Instead, the functional relevance of Dok-3 
oligomerization is not yet clear (Stork et al., 2007). The presence of a PH domain in the 
structure of Dok proteins suggests an important role for this domain in the localization or 
translocation of the Dok adaptors to cellular membranes. Indeed, it seems that Dok-1 and 
PI3K activity are required for the recruitment of the adaptor to the membrane and its 
negative effect on PDGF-mediated ERK activation. Furthermore, Dok-1/2 PH domain can 
bind tightly to PI(5)P and modulate the negative function and tyrosine phosphorylation of 
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MAPK activity and cell proliferation (Yamanashi et al., 2000). Moreover, co-cross-linking of 
the B-cell receptor (BCR) and FcRIIB receptor induces the tyrosine phosphorylation of Dok-
1 and its subsequent association with RasGap (Vuica et al., 1997). In FcRIIB signalling, Dok-
1 is recruited to the receptor complex at the membrane via SHIP, and in this way, 
contributes to the negative regulation of the Erk pathway [Figure 2.] (Tamir et al., 2000). On 
the other hand, Dok-3 is also expressed in B cells and therefore, one can expect a functional 
redundancy between Dok-1/3 in these cells. Indeed, it was reported that Dok-3 can function 
as a negative regulator of BCR-mediated responses (Ng et al., 2007). Furthermore, both Dok-
1 and Dok-3 were shown to be phosphorylated by Lyn kinase after stimulation of the BCR, 
suggesting that Lyn can activate these Dok proteins to then function as negative regulators 
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mice exhibited augmented proliferation and Ca2+ influx upon BCR stimulation (Ng et al., 
2007), while these responses are not observed in the absence of Dok-1 (Yamanashi et al., 
2000). These phenotypic differences could be attributed to Dok-1, but not Dok-3, recruiting 
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recruit Grb2, which can then inhibit Ca2+ signalling in B cells. 
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(Gugasyan et al., 2002). Although the molecular mechanisms underlying the Dok-mediated 
inhibition are unclear, Dok proteins can bind to the ITAM motifs of TCR and CD3 through 
their PTB domain. As these ITAMs are essential for the binding and activation of ZAP-70, 
interference between the Dok proteins and ZAP-70 might occur through their binding to the 
ITAMs (Figure 2). Recently, Nunès and colleagues reported that the PH domain of Dok-1 
and Dok-2 is necessary for the tyrosine phosphorylation of these Dok proteins and their 
negative functions in T cells (Guittard et al., 2009). These results demonstrate the functional 
relevance of the membrane localization of the Dok adaptors. 
 
Fig. 2. Dok-mediated signalling pathways in immune cells 
Unlike lymphoid cells, myeloid cells express all the immune cell Dok proteins. However, the 
loss of Dok-1 and Dok-2 causes mainly neoplastic abnormalities in myeloid cells, suggesting 
an important role in immune and cytokine receptor signalling in these cells. Analysis of Dok-
1 and Dok-2 deficient myeloid cells showed enhanced proliferation and survival in response 
to Stem Cell Factor (SCF), IL-3, macrophage-colony stimulating factor (M-CSF), and 
granulocyte-monocyte-colony stimulating factor (GM-CSF), which are cytokines crucial for 
myelopoiesis. These findings indicate that Dok-1 and Dok-2 act as key negative regulators of 
signalling downstream of these cytokine receptors. Indeed, the activation of Erk and Akt in 
macrophages deficient for Dok-1 and Dok-2 was strongly augmented compared with that in 
wild type controls upon M-CSF receptor stimulation, confirming the role of Dok adaptors as 
negative regulators for these pathways. On the other hand, the role of Dok-1 and Dok-2 was 
examined in innate immune signalling in macrophages. Stimulation of macrophages by LPS 
induces rapid tyrosine phosphorylation of Dok-1 and Dok-2, suggesting the involvement of 
these adaptors in TLR4 signalling (Shinohara et al., 2005). In addition, the stimulation of 
Dok-1 or Dok-2-deficient macrophages promoted the activation of Erk and hyperproduction 
of TNF- and nitric oxide, two major signalling mediators of innate immunity, indicating 
that the Dok proteins are key negative regulators of TLR4 signalling in macrophages. The 
Dok adaptors are also expressed in mast cells where they have been shown to interact 
exclusively with negative regulators of FcεRI signalling. FcεRI stimulation leads to the 
tyrosine phosphorylation of only Dok-1 and Dok-2. Nevertheless, Dok-3 associates with 
tyrosine-phosphorylated proteins upon FcεRI stimulation, implicating a yet undefined 
function for this adaptor protein downstream of the receptor (Abramson et al., 2003). A 
complex of Dok-1, RasGAP, and SHIP-1, similar to the one described in B cells after co-
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aggregation of the BCR with FcγRIIB, was also described in mast cells after FcεRI and 
FcγRIIB co-aggregation (Ott et al., 2002). Moreover, Dok-1 has also been involved 
downstream of activating receptors, like FcεRI, by associating with and negatively 
regulating signals without the involvement of inhibitory receptors (Ott et al., 2002; 
Abramson et al., 2003). However, Dok-1-deficiency did not affect mast cell activation, 
suggesting a possible functional redundancy among the different isoforms expressed in 
these cells. 
Recently, two groups have reported the expression and function of the Dok proteins in 
human platelets.  Using a proteomic approach in these cells, it was shown that Dok proteins 
are tyrosine phosphorylated downstream of main platelet activation receptors (Garcia et al., 
2004; Hughan et al., 2007; Senis et al., 2009). Tyrosine phosphorylation of Dok-1 and Dok-3 
was primarily Src kinase-independent downstream of the integrin pathway, whereas it was 
Src-dependent downstream of glycoprotein VI (GPVI) pathway. Both proteins interact in an 
inducible-fashion with Grb-2 and SHIP-1 in fibrinogen-spread platelets, suggesting that the 
formation of a multi-molecular negative signalling complex may be a mechanism of down-
regulating IIb3 outside-in signalling. 
3.2 The Lnk/SH2B family 
3.2.1 Structure, origin and cell expression 
The Lnk (or SH2B) family of adaptor proteins is composed of 3 members, SH2-B [also 
known as PSM (proline-rich, PH and SH2 domain-containing signalling mediator) or 
SH2B1], APS (for Adaptor protein with PH and SH2 domain, also known as SH2B2) and 
Lnk (SH2B3). They all possess a dimerization (DD) domain and proline-rich motifs at the N-
terminus, followed by a PH and SH2 domains, and several potential tyrosine 
phosphorylation sites, notably a conserved tyrosine residue at the C-terminus [Figure 
1](Rudd, 2001). The SH2B1 gene encodes four isoforms (, , , ) resulting from alternative 
mRNA splicing at their 3’ terminus giving rise to proteins differing at their C-terminus 
(Nelms et al., 1999). SH2-B and  isoforms were originally cloned from yeast tribrid and 
two-hybrid systems screening, respectively, using different proteins as baits (Osborne et al., 
1995; Riedel et al, 1997; Rui et al., 1997). Despite its initial identification in immune cells, 
SH2-B isoforms are mainly expressed and functional, as shown by gene inactivation in mice, 
in non-haematopoietic tissues. The APS/SH2B2 gene encodes for two isoforms, SH2B2 and 
recently identified SH2B2 (Li et al., 2007). The APS protein was also identified in a two-
hybrid system screening of human B cells or adipocytes (Yokouchi et al., 1997; Moodie et al., 
1999). Like SH2-B, APS adaptor protein is also highly expressed in non-haematopoietic 
tissues. However, it is also expressed in haematopoietic cells, notably in mature B and mast 
cells. As for Lnk, it has only one form in mammalians and one invertebrate orthologue in 
Drosophila melanogaster (D-Lnk) to date (Werz et al., 2009). The Lnk adaptor protein was the 
first member of this family identified (Huang et al., 1995; Takaki et al., 1997). However, it 
was later found that the Lnk protein was much larger than initially reported (Li et al., 2000; 
Takaki et al., 2000; Velazquez et al., 2002). In contrast to SH2-B and APS, Lnk is mainly 
expressed in haematopoietic cells, notably in haematopoietic stem cells (HSC), and 
haematopoietic (lymphoid and myeloid) progenitors. Moreover, Lnk expression is up-
regulated by certain cytokines important for the development and function of these 
haematopoietic cells, such as SCF, thrombopoietin [TPO], and erythropoietin [EPO] (Kent et 
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al., 2008; Buza-Vidas et al., 2006; Gerry et al., 2009a, 2009b; Baran-Marszak et al., 2010). 
Interestingly, Lnk is also highly expressed in endothelial cells and its expression is also 
induced by Tumor Necrosis Factor (TNF)- (Fitau et al., 2006; Kwon et al., 2009). These 
findings suggest the implication of Lnk adaptor in a negative feedback loop for the 
regulation of these cytokine pathways. 
3.2.2 Signalling partners 
Over the last years, much effort has gone into understanding the role of the Lnk family as 
signalling regulators through the identification of the molecules binding to their different 
functional domains and motifs, as well as their signalling pathways (Table. 2). The SH2 
domain of the Lnk adaptor proteins is implicated in most of the key molecular interactions 
between the adaptors and their partners/effectors and their biological functions. The fist 
identified binding partner of the Lnk protein was the SCF receptor, Kit. The primary Kit-
binding site for Lnk SH2 domain has been identified as phosphotyrosine 567 (pTyr567), 
which resides in the juxtamembrane region of the receptor (Simon et al., 2008; Gueller et al., 
2008). Similarly, the SH2 domain of APS was reported to bind to Y568 and Y936 in the 
human c-Kit receptor (Wollberg et al., 2003). Interestingly, this region of Kit contains critical 
tyrosine (Y) residues (Y567/69) for the recruitment of different regulatory signalling 
molecules (Chan et al., 2003). In this system, a proposed mode of action of Lnk is that once 
bound to the juxtamembrane region of Kit, it will then block the association of activators 
with the receptor, resulting in down-regulation of SCF-mediated pathways. Indeed, 
expression of an SH2-inactive Lnk protein abolishes Lnk-mediated negative regulation of 
SCF-induced cell proliferation and migration (Simon et al., 2008). Lnk has been also reported 
to bind through its SH2 domain to other tyrosine kinase receptors, such as the PDGFR and 
the M-CSF receptor (c-Fms); however the physiological implication of these associations is 
not yet clear (Gueller et al., 2010, 2011). 
The JAK2 tyrosine kinase was the first characterized binding partner of SH2-B and APS, and 
subsequently of Lnk. This association results in activation of the kinase in the case of SH2-B 
and APS or in its inhibition when bound to Lnk. Different biochemical studies have shown 
that the interaction of the SH2 domains of SH2-B and APS occurs preferentially with kinase-
active, tyrosyl phosphorylated JAK2 (Rui et al., 1997). The primary JAK2-binding site for the 
SH2 domain of the Lnk family has been identified as pTyr813, which resides within the 
regulatory JH2 pseudokinase domain of JAK2 (Kurzer et al., 2004, 2006). Crystallographic 
studies have demonstrated that the SH2 domain of APS dimerizes when binding to the 
insulin receptor, whereas the SH2 domain of SH2-B, binds JAK2 as a monomer (Hu et al., 
2003; Hu & Hubbard, 2006). Less is known on how the Lnk SH2 domain binds JAK2. 
However, it has been shown that Lnk is capable of binding JAK2 wild-type form, as well as 
the constitutive active JAK2-V617F form present in myeloproliferative neoplasms (Bersenev 
et al., 2008; Gery et al., 2009; Baran-Marszak et al., 2010). In addition to the SH2-dependent 
interaction of the Lnk adaptor family with pTyr813 in JAK2, there appears to be one low-
affinity interaction involving amino acids outside the SH2 domain in the adaptors and 
inactive JAK2 that might prevent abnormal activation of the kinase. (Rui et al., 2000; Kurzer 
et al., 2006; Baran-Marzak et al., 2010).  
The N-terminal region of the Lnk adaptor family contains a dimerization domain whose 
crystal structure has revealed a “phenylalanine zipper” motif. This domain mediates SH2-B  
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Lnk proteins  Binding domain Binding partner Cells System  
Lnk N-term Lnk COS 
 Inter PH-SH2 ABP-280 COS, T cells (TCR) 
 SH2 Kit Mast (SCF) 
  JAK2 Myeloid (EPO, TPO) 
  c-Fms Myeloid (M-CSF) 
  PDGFR COS (PDGF) 
APS N-term APS, SH2B HEK293, CHO (In) 
 PH Vav3 NIH3T3 
 SH2 Kit Mast (SCF) 
  JAK2 Myeloid (GH) 
  IR Adipocyte (In) 
 pY618 Cbl Adipocyte (In) 
SH2B N-term SH2B, APS CHO (In), COS 
  Rac CHO, COS (GH) 
 SH2 JAK2 Myeloid (GH) 
  GHR, IR Adipocyte (GH, In) 
GHR, growth hormone receptor; IR, insulin receptor; In, insulin 
Table 2. Signalling partners bound to the different domains and motifs of Lnk proteins. 
and APS homo and heterodimerization that appears crucial to their function (Dhe-Paganon 
et al., 2004). Instead, Lnk homodimerization has only been shown in an over-expressed 
system (Takizawa et al., 2006) and therefore, its functional relevance is not yet clear.  
The presence of a PH domain in the structure of Lnk proteins suggests an important role for 
this domain in the localization or translocation of these adaptor proteins to cellular 
membranes. Indeed, previous reports showed that Lnk PH mutants (W191A or W270A) 
proteins moderately affected Lnk modulation of TPO-, EPO- or SCF-dependent biological 
responses (Tong & Lodish, 2004; Tong et al., 2005; Simon et al., 2008). Moreover, the Lnk PH 
domain seemed to display moderate affinity and little specificity to phosphoinositides in 
vitro. It is therefore possible that the Lnk PH domain may down-regulate membrane 
targeting of Lnk in the absence of docking site for the SH2 domain and increase binding 
stability to membrane receptors when the SH2 domain is engaged.  
Association of Lnk, APS and SH2-B with growth factor, cytokine receptors or the JAK2 
kinase allows phosphorylation of these adaptors and their proper localization at the 
signalling complex. The conserved C-terminal tyrosine residue present in all members of 
this family has been shown to be a main site for phosphorylation upon growth factor or 
cytokine stimulation. In Lnk, this residue, Y536, was suggested to be phosphorylated upon 
SCF stimulation in a mast cell line (Takaki et al., 2002). However, an Lnk form mutated at 
this tyrosine still gets phosphorylated upon Kit activation in primary mast cells (Simon et 
al., 2008). This result suggested that Lnk could be phosphorylated at sites other than Y536. 
Indeed, a similar result was reported with human Lnk mutated at this residue (Li et al., 
2000). On the other hand, the biological relevance of Lnk Y536 seems to depend on the 
signalling pathway analyzed. Lnk Y536 is dispensable for lymphoid development, TPO- or 
SCF-dependent signalling pathways, but it might play a regulatory role in IL3- and EPO-
mediated proliferation (Takaki et al., 2003; Tong & Lodish, 2004; Simon et al., 2008). 
 
Hematology – Science and Practice 
 
54
al., 2008; Buza-Vidas et al., 2006; Gerry et al., 2009a, 2009b; Baran-Marszak et al., 2010). 
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However, it has been shown that Lnk is capable of binding JAK2 wild-type form, as well as 
the constitutive active JAK2-V617F form present in myeloproliferative neoplasms (Bersenev 
et al., 2008; Gery et al., 2009; Baran-Marszak et al., 2010). In addition to the SH2-dependent 
interaction of the Lnk adaptor family with pTyr813 in JAK2, there appears to be one low-
affinity interaction involving amino acids outside the SH2 domain in the adaptors and 
inactive JAK2 that might prevent abnormal activation of the kinase. (Rui et al., 2000; Kurzer 
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targeting of Lnk in the absence of docking site for the SH2 domain and increase binding 
stability to membrane receptors when the SH2 domain is engaged.  
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al., 2008). This result suggested that Lnk could be phosphorylated at sites other than Y536. 
Indeed, a similar result was reported with human Lnk mutated at this residue (Li et al., 
2000). On the other hand, the biological relevance of Lnk Y536 seems to depend on the 
signalling pathway analyzed. Lnk Y536 is dispensable for lymphoid development, TPO- or 
SCF-dependent signalling pathways, but it might play a regulatory role in IL3- and EPO-
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However, no Lnk binding partners for this site has so far been identified. In contrast, APS C-
terminal tyrosine, Y618, has been shown to get phosphorylated by activated growth factor 
(IR), cytokine (EPO) and immune (BCR) receptors and then serve as binding site for the Cbl 
protein (Moodie et al., 1999; Yokouchi et al., 1997; Wakioka et al., 1999). The APS/Cbl 
association plays an important role in down-regulation of IR signalling (Kishi et al., 2007). 
Other binding proteins have been identified that associate with other regions of Lnk, APS 
and SH2-B that are involved in actin regulation. In particular, an amino acid sequence in the 
N-terminal region of SH2-B has been shown to bind to Rac, a mayor actin regulating 
protein, while a similar sequence in APS can associate with Vav3, a guanine nucleotide 
exchange factor for Rac (Diakonova et al., 2002; Yabana and Shibuya, 2002). Lnk was 
demonstrated to associate with the actin binding protein ABP-280 via a sequence between 
the PH and SH2 domains of human Lnk in Jurkat T cells (He et al., 2000).  These findings 
suggest a role for the Lnk family members in the regulation of actin cytoskeleton and cell 
motility. 
3.2.3 Signalling pathways in haematopoietic cells 
The initial in vitro biochemical analysis was done on SH2-B and APS and showed that these 
adaptors were phosphorylated and became positive mediators of receptor and protein 
tyrosine kinases cascades. However, APS can also function as negative regulator in the BCR 
and JAK2 signalling pathways (Yokouchi et al., 1997; Wakioka et al., 1999). Conversely, Lnk 
is considered as a negative regulator of growth factor and cytokine receptor-induced 
proliferation and migration (Takaki et al., 2000, 2002; Velazquez et al., 2002; Tong & Lodish, 
2004; Tong et al., 2005; Fitau et al., 2006; Simon et al., 2008; Gueller et al., 2010, 2011). 
Nonetheless, Lnk seems to play a positive role in mouse platelets for the stabilization of 
thrombus through the integrin IIb3 outside-in signalling and in human vascular 
endothelial cells via the PI3K/Akt pathway activated by TNF- (Takizawa et al., 2010; Fitau 
et al., 2006).  Together with data on in vivo ablation of these adaptors, these findings 
demonstrate that these adaptor proteins can function as positive and/or negative regulators 
depending on their cell expression and on the growth factor or cytokine receptor–mediated 
pathway. 
The generation of mice and cell lines deficient for members of this family has confirmed Lnk 
and APS, but not SH2-B, specific function in the haematopoietic system, while establishing 
SH2-B implication in other tissues. As stated before, Lnk is highly expressed in HSC, so as 
expected, Lnk-/--derived HSC show an increased capacity to proliferate and to self-renew 
together with an increase in the quiescent fraction. These effects on HSC homeostasis are due 
to abnormal TPO signalling in these cells, that results from an enhanced TPO hypersensibility, 
increased TPO-dependent activation of Akt, STAT5 and down-regulation of p38MAPK (Ema 
et al., 2005; Buza-Vidas et al., 2006; Seita et al., 2007; Bersenev et al., 2008). These findings 
therefore confirm that Lnk controls TPO-induced self-renewal, quiescence and proliferation of 
HSC. Moreover, Lnk deficiency enhances the ability of HSC and haematopoietic progenitors to 
reconstitute the haematopoietic system in irradiated hosts. Indeed, transient inhibition of 
endogenous Lnk significantly increased the repopulating capacity of the transduced cells and 
thereby, engraftment (Takizawa et al., 2006). Moreover, analysis of Lnk-/--derived 
haematopoietic progenitors show an hypersensibility to several cytokines resulting in 
sustained MAPK, JAK/STAT activation and cell proliferation (Takaki et al., 2000; Velazquez et 
al., 2002; Tong, 2005; Takizawa et al., 2008). 
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Lnk-deficient mice have also revealed an essential role for Lnk in B cell lymphopoiesis with 
the selective expansion of pro-/pre-B and immature B cells in bone marrow and spleen. This 
abnormal proliferation is partly due to hypersensitivity to SCF and IL-7 (Takaki et al., 2000; 
Velazquez et al., 2002). Alternatively, Lnk over-expression in transgenic mice show 
impaired B production in an Lnk dose-dependent manner confirming the negative control 
mediated by this adaptor in B-lineage cell production (Takaki et al., 2003). However, no 
evident effect on mature B cells was observed in the absence of Lnk, suggesting either a lack 
of role for Lnk in this population or a functional compensation by APS in these cells. APS 
has also been shown to play a role in B cell development and function. Ablation of APS in 
mice caused an increase in B-1 cell number and an enhanced humoral immune response 
against a thymus-independent type 2 antigen, suggesting a role for APS in mature B cell 
proliferation (Iseki et al., 2004). Accordingly, APS transgenic mice showed reduced numbers 
of peritoneal B-1 and splenic B cells and impaired BCR-induced proliferation of mature B 
cells (Iseki et al., 2005). In these cells, APS co-localized with pre-activated capped BCR 
complexes and filamentous actin, indicating a negative regulatory role for APS in BCR 
signalling and actin reorganization. 
Lnk has been also shown to control erythropoiesis and megakaryopoiesis. Studies on primary 
Lnk-/- erythrocytes and megakaryocytes indicate an abnormal proliferation due to the absence 
of negative regulation of EPO and TPO signalling pathways (Figure 3). Indeed, Lnk, through 
its SH2 domain, negatively modulates MPL, and EPO receptor (EPOR) signalling by 
attenuating three major signalling pathways: JAK2/STAT, MAPK and Akt (Tong et al., 2005; 
Tong & Lodish, 2004). Moreover, Lnk is capable of binding and regulating MPL-W515L and 
JAK2-V617F, the mutated forms expressed in Myeloproliferative Neoplasms [MPN] (Gery et 
al., 2007, 2009; Bersenev et al., 2008; Baran-Marszak et al., 2010). In addition, Lnk also regulates 
thrombopoiesis through control of crosstalk between integrin- and TPO-mediated pathways 
implicated in the megakaryocyte maturation and platelet release process (Takizawa et al., 
2008). Furthermore, Lnk plays an important role in stabilizing thrombus formation through 
positive regulation of integrin signalling pathways. In this way, it contributes to platelet 
cytoskeleton rearrangement and spreading (Takizawa et al., 2010). 
 
Fig. 3. Lnk family signalling pathways in haematopoietic cells  
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Studies on Lnk-/- and APS-/- mast cells demonstrated their physiological implication in mast-
cell functions. Lnk regulates SCF-mediated signalling pathways controlling proliferation 
(MAPK and JNK) and migration (Rac and p38MAPK) in these cells (Takizawa et al., 2006; 
Simon et al., 2008). These functions are mainly mediated by binding of its SH2 domain to 
specific effectors involved in actin rearrangement. On the other hand, APS controls actin 
cytoskeleton and magnitude of degranulation induced by FcRI receptor cross-linking 
(Kubo-Akashi et al., 2004). Besides its specific expression in the haematopoietic system, Lnk 
is also highly expressed in endothelial-like cells in the aorta-gonad-mesonephros (AGM) 
region and in endothelial progenitor (EPC) and mature cells [EC](Nobuhisa et al., 2003; 
Fitau et al., 2006; Kwon et al., 2009). Fitau et al. have shown that the pro-inflammatory 
cytokine TNF- rapidly evokes Lnk phosphorylation together with down-regulation of 
vascular cell adhesion molecule 1 (VCAM-1) expression in activated vascular ECs. These 
results implicate Lnk as an important negative regulator of TNF-α signalling pathway (Fitau 
et al., 2006). 
3.3 The Cbl family 
3.3.1 Origin, cell expression and structure  
The Cbl (for Casitas B-lineage Lymphoma) family comprises multidomain regulators with 
dual function, as E3 ubiquitin ligases and adaptor proteins. It consists of three mammalian 
homologues, c-Cbl, Cbl-b and Cbl-c/Cbl-3 (Blake et al., 1991; Keane et al., 1995, 1999), as 
well as invertebrate orthologues (Thien & Langdon, 2001). The first isoform of this family 
identified was the oncogenic protein v-Cbl, a Gag-fusion transforming protein of Cas NS-1 
retrovirus, which induces pre- and pro-B lymphomas and the transformation of rodent 
fibroblasts (Langdon et al., 1989). The cellular form, c-Cbl was subsequently cloned and 
revealed that v-Cbl was a result of a large truncation of its C-terminal portion and that 
overexpression of c-Cbl did not promote tumorigenesis. The 120 kDa c-Cbl protein is 
ubiquitously expressed, primarily cytoplasmic, with highest expression levels in 
haematopoietic organs (thymus) and testis. In contrast, Cbl-3 is expressed mainly in 
epithelial cells of the gastrointestinal system. 
All Cbl proteins share highly conserved N-terminal regions, but their C-terminal sequence 
differs and is less well-conserved (Figure 1).  The N-terminal half encompasses two 
important domains: a tyrosine kinase-binding (TKB) and a C3HC4 zinc-binding RING finger 
domains, both separated by a small linker sequence. The TKB domain contains three distinct 
subdomains comprising a four-helix bundle (4H), a calcium-binding EF hand and a 
modified SH2 domain, all necessary for its function as phosphotyrosine-binding (PTB) 
module. The second conserved domain in the N-terminal region is a zinc-binding RING 
finger domain responsible for the E3 ubiquitin ligase activity of c-Cbl (Joazeiro et al., 1999). 
The C-terminal sequences are less homologous among Cbl proteins; however, they all have 
proline-rich regions that are involved in numerous SH3-domain interactions (Keane et al., 
1995) and the major sites of tyrosine phosphorylation, which enable interactions of Cbl with 
SH2 domain containing proteins. The C-terminus of c-Cbl, Cbl-b contains a sequence 
homologous to both the leucine zipper (LZ) and the ubiquitin associated (UBA) domain. The 
LZ domain has been shown to mediate Cbl dimerization (Bartkiewicz et al., 1999; Liu et al., 
2003), while only Cbl-b and not c-Cbl can bind to ubiquitin through its UBA domain (Davies 
et al., 2004). 
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3.3.2 Signalling binding partners 
The TKB domain is unique to Cbl proteins and its feature role is to determine Cbl substrate 
specificity by engaging specific phosphorylated tyrosine residues on proteins that are to be 
ubiquitylated by Cbl. Some of Cbl TKB domain targets include: receptor tyrosine kinases 
(RTKs), non-receptor protein tyrosine kinases (PTKs) of the Syk family, several adaptors and 
regulatory proteins (Table 3). In contrast to SH2 binding motif, the TKB phosphotyrosine 
recognition consensus sequence displays an specificity conferred by amino acid residues C-
terminal to the tyrosine (Lupher et al., 1997). These findings argue that interaction of the 
TKB domain with RTKs may then primarily be to ensure the appropriate orientation of the 
receptor such that Cbl’s E3 ligase activity can promote the transfer of ubiquitin. TKB domain 
interactions may therefore determine the number of ubiquitin molecules transferred to the 
substrate and thus regulate the extent to which activated RTKs are ubiquitylated. Thus the 
TKB domain appears to have at least two important roles in regulating E3 ligase activity, 
and, as such, it is functionally more complex than classical SH2 or PTB domains. 
 
Binding domain Binding partner  Signalling receptor 
TKB Syk, Zap-70 AgR 
 c-Src AgR, GFR, CyR 
 APS HR 
 EGFR, PDGFR GFR 
RING E2s(Ub-conjugated enzyme) GFR, AgR, CyR 
Pro-rich Grb2 GFR 
 Nck GFR, AgR 
 Src kinases GFR, AgR, CyR 
pY Vav, CrkL, Src kinases AgR 
 p85 (only with c-Cbl) AgR, GFR 
UBA Ub (only with Cbl-b) GFR 
LZ c-Cbl, Cbl-b GFR, HR 
AgR, antigen receptor; GFR, growth factor receptor; CyR, cytokine receptor; HR, hormone receptor. 
Table 3. Signalling proteins bound to the different domains and motifs of c-Cbl/Cbl-b 
proteins. 
Separating the TKB and the RING domains, a short linker sequence extends which has been 
shown crucial for Cbl ubiquitin ligase activity (Thien et al., 2001). The TKB domain makes 
intramolecular contacts with the linker α-helix and these contacts are centred on conserved 
residues Y368 and Y371 in human c-Cbl (Zheng et al., 2000). Interestingly, deletion of these 
tyrosines causes c-Cbl to become oncogenic (Thien et al., 2001). Molecular modelling data 
predicted that this structural alteration, in addition to loss of E3 activity, is required to 
activate fully the oncogenic potential of Cbl proteins. The second highly conserved domain 
among all Cbl proteins is the RING finger. In vitro ubiquitylation assays proved that the 
highly conserved Cbl RING finger has intrinsic E3 ligase activity and can independently 
recruit E2s or ubiquitin-conjugating (Ubc) enzymes for the transfer of ubiquitin to substrates 
(Joazeiro et al., 1999). The structural integrity of the RING finger domain is an absolute 
requirement for Cbl proteins to function as E3 ligases. Moreover, the RING finger domain 
acts in concert with the TKB domain to facilitate ubiquitylation and degradation of activated 
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Studies on Lnk-/- and APS-/- mast cells demonstrated their physiological implication in mast-
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3.3.2 Signalling binding partners 
The TKB domain is unique to Cbl proteins and its feature role is to determine Cbl substrate 
specificity by engaging specific phosphorylated tyrosine residues on proteins that are to be 
ubiquitylated by Cbl. Some of Cbl TKB domain targets include: receptor tyrosine kinases 
(RTKs), non-receptor protein tyrosine kinases (PTKs) of the Syk family, several adaptors and 
regulatory proteins (Table 3). In contrast to SH2 binding motif, the TKB phosphotyrosine 
recognition consensus sequence displays an specificity conferred by amino acid residues C-
terminal to the tyrosine (Lupher et al., 1997). These findings argue that interaction of the 
TKB domain with RTKs may then primarily be to ensure the appropriate orientation of the 
receptor such that Cbl’s E3 ligase activity can promote the transfer of ubiquitin. TKB domain 
interactions may therefore determine the number of ubiquitin molecules transferred to the 
substrate and thus regulate the extent to which activated RTKs are ubiquitylated. Thus the 
TKB domain appears to have at least two important roles in regulating E3 ligase activity, 
and, as such, it is functionally more complex than classical SH2 or PTB domains. 
 
Binding domain Binding partner  Signalling receptor 
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LZ c-Cbl, Cbl-b GFR, HR 
AgR, antigen receptor; GFR, growth factor receptor; CyR, cytokine receptor; HR, hormone receptor. 
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PTKs, with the TKB domain conferring substrate specificity and the RING finger bringing in 
an E2 ubiquitin-conjugating enzyme. The carboxy-terminal half of c-Cbl is rich in proline 
residues, which contributes at least 15 and 17 potential SH3-domain-binding sites in c-Cbl 
and Cbl-b respectively, while Cbl-3 encodes five potential SH3-binding sites. Moreover, the 
proline-rich region in c-Cbl is also required for the ubiquitylation and proteasomal 
degradation of activated forms of Src (Yokouchi et al., 2001). In this case, the Cbl substrate is 
targeted by proline sequence interactions, rather than the TKB domain. 
c-Cbl and Cbl-b are prominent substrates of RTKs and PTKs following stimulation of 
diverse cell surface receptors, as they possess major sites of tyrosine phosphorylation at 
their C-terminal part that enable them to interact with different SH2 domain containing 
proteins. Indeed, several studies have demonstrated the important role of tyrosine 
phosphorylation of Cbl proteins for their adaptor function, as well as for their E3 activity. 
The best-characterized phosphorylation sites are Y700, Y731 and Y774 in human c-Cbl and 
Y709 and Y665 in Cbl-b (Tsygankov et al., 1996; Keane et al., 1995). These residues are 
efficiently phosphorylated by Syk and the Src-family kinases Fyn, Yes and Lyn, but not by 
Lck or ZAP-70. An important difference between c-Cbl and Cbl-b is the unique presence of 
Y731 in c-Cbl which binds the SH2 domain of the p85 regulatory subunit of PI3K. 
Surprisingly, this association enables c-Cbl to function as a positive regulator by recruiting 
PI3K to the cell membrane (Hunter et al., 1999). 
3.3.3 E3 ligase activity and adaptor function 
The multi-domain nature of Cbl allows it to interact, directly or indirectly, with a wide 
range of signalling molecules. In this way, activated Cbl proteins act essentially as 
attenuators of cellular signals by exerting their function as E3 ubiquitin ligases or as 
adaptors/inhibitors proteins towards PTK pathways.    
Cbl E3 ligase activity. Extensive biochemical studies have demonstrated Cbl-mediated 
ubiquitylation of its substrates (Figure 4). It is clear that ubiquitylation of a targeted receptor 
occurs in parallel to the onset of receptor internalization and continues to occur throughout 
the endosomal pathway. One of the best-studied examples of how Cbl-mediated 
ubiquitylation affects receptor trafficking, and helps terminate the signal from the activated 
receptor complex, is the EGF receptor (EGFR). This multistep process was initially described 
in C. elegans, where SLI-1 (the Cbl orthologue) was shown to negatively regulate signalling 
downstream of the LET-23 receptor [the EGFR orthologue] (reviewed in Thien and 
Langdon, 2001). This mechanism has become a model for the regulation of other RTKs by 
Cbl. 
Cbl as an adaptor/inhibitor protein. An alternative way for Cbl to ubiquitylate EGFR is 
indirect and utilises its adaptor/inhibitor function by binding to the adaptor protein growth 
factor- receptor bound-2 (Grb2). One of the first proteins to be recruited into the complex is 
Grb2, which can recruit Cbl proteins from the cytoplasm to the plasma membrane through 
interactions between the proline-rich region of Cbl proteins and the N-terminal SH3 domain 
of Grb2. In this way, Cbl competes with the guanine-nucleotide-exchange factor son-of-
sevenless (SOS) to bind Grb2, thereby blocking signalling through the Ras–mitogen-
activated protein kinase (MAPK) pathway and inhibiting proliferation. 
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3.3.4 Signalling pathways in the haematopoietic and immune systems 
Cbl gene deletions primarily affected the haematopoietic, immune and metabolic systems. A 
recent study on c-Cbl-/- HSC showed that the number and ability to reconstitute the 
haematopoietic system was increased in these cells compared to wild-type HSC. These 
results suggested that Cbl ubiquitin-mediated protein degradation is important for HSC 
homeostasis (Rathinam et al., 2008). Furthermore, it was shown that c-Cbl is capable of 
controlling HSC development and function through negative regulation of TPO-dependent 
STAT5 activation, an important pathway for HSC maintenance. Indeed, c-Cbl-deficient HSC 
displayed TPO hypersensibility, as well as increased levels of STAT5 and its activated form, 
phospho-STAT5. Thus, these findings underline the role of c-Cbl as important modulator of 
the TPO/Mpl/JAK/STAT5 signalling pathway in HSCs. 
The importance of c-Cbl and Cbl-b in immunity and immune receptor signalling pathways has 
been demonstrated clearly by the phenotypes of their respective gene knockout mice. Both c-
Cbl−/− and Cbl-b−/− mice display hyperactive signalling downstream of the TCR. Loss of either 
Cbl protein results in lower activation threshold for signalling through the TCR, 
hypersensitivity to low affinity/avidity engagement of the receptor, and activation of 
downstream signalling pathways without the normal requirement for co-receptor stimulation 
(Figure 4) (Murphy et al., 1998; Naramura et al., 1998; Bachmaier et al., 2000; Chiang et al., 
2007). Interestingly, these c-Cbl and Cbl-b phenotypes are restricted to thymocytes and T-cells, 
respectively, reflecting a difference in tissue distribution with c-Cbl more prominent in the 
thymus and Cbl-b highly expressed in peripheral T-cells. Loss of Cbl-b dramatically increases 
T-cell activation threshold and uncouples T-cell activation from the requirement for CD28 co-
stimulation, thus leading to spontaneous autoimmunity (Gronski et al., 2004). 
Cbl proteins have been also shown to differentially modulate BCR-dependent signalling. 
Loss of c-Cbl in primary B cells showed a significant inhibition of BCR-mediated signalling 
mainly caused, not by down-regulation of Syk, but instead by up-regulation of Lyn kinase 
(Shao et al., 2004). In contrast, Cbl-b negatively regulates BCR-mediated signalling, this 
time, by down-regulating Syk in primary B cells (Sohn et al., 2003). Furthermore, the activity 
of Cbl proteins as adaptors was also implicated in the effect of Cbl proteins on B-cell 
activation. In this case, it has been shown that c-Cbl negatively regulates the phospholipase 
C-2 (PLC-2) pathway in B cells, while Cbl-b was shown to positively regulate this same 
pathway (Yasuda et al., 2002). 
Studies carried out with cell lines have demonstrated that both c-Cbl and Cbl-b negatively 
regulated FcRI-mediated mast cell activation (Figure 4). However, experiments on primary 
mast cells derived from c-Cbl and Cbl-b-deficient mice revealed a more profound effect with the 
lack of Cbl-b than of c-Cbl (Zhang et al., 2004). Cbl-dependent FcRI down-regulation occurs 
mainly via Cbl E3 ubiquitin ligase activity that promotes receptor  and  multiubiquitination, 
providing signals for receptor internalization and sorting into lysosomal compartments for 
degradation. Interestingly, Syk activity is required for c-Cbl-dependent ubiquitylation of FcRI 
receptor (Paolini et al., 2002). On the other hand, Cbl proteins can also down-modulate engaged 
FcRI through its adaptor function by interacting with molecules involved in clathrin-mediated 
endocytosis (Molfetta et al., 2005). Remarkably, Cbl proteins also negatively regulate mast cell 
activation by selectively ubiquitinating and degrading the activated kinase form of Lyn and Syk 
proteins (Paolini et al., 2002; Kyo et al., 2003; Qu et al., 2004).   
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Fig. 4. A) Model of Cbl ligase activity. B) Schematic model of Cbl signalling pathways in T 
and mast cells 
c-Cbl also participates in the modulation of monocyte/macrophage signalling mediated by 
Fcand Colony Stimulating Factor (CSF)-1 receptors through its adaptor functions. c-Cbl is 
capable of attenuating CSF-1-mediated signalling by binding to a phosphotyrosine residue 
of this receptor and then ubiquitylating and targeting it for degradation. Lastly, c-Cbl also 
appears to play a negative regulatory role in platelets as well. This is not so surprising 
considering that Syk kinase has a biological function in these cells, a known substrate of c-
Cbl. The contribution of c-Cbl-dependent ubiquitylation of Syk to the negative effect of c-
Cbl on platelet functions is not yet understood, however, it is possible that the biological 
role of c-Cbl in platelets consists in preventing unwanted platelet activation in vivo by 
increasing the threshold of platelet activation.  
3.3.5 Regulation of Cbl function 
Cbl proteins are potent regulators of cell function and development through their adaptor 
function and ligase activity. It is therefore necessary that the Cbl proteins are at their turn, 
subject to complex and sophisticated regulatory mechanisms that fine-tune the effects that 
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these proteins have on signalling (Ryan et al., 2006). These include: cis-acting structural 
elements that prevent inappropriate E3 activity until the Cbl proteins interact with their 
substrate, degradation of the Cbl proteins, inhibition of Cbl protein function mediated by 
protein interactions, deubiquitination of the Cbl substrates, and negative regulation of 
trafficking of the ubiquitinated Cbl substrates. Therefore, abnormal Cbl regulation can lead 
to pathological conditions such as immunological and malignant diseases, thus 
underscoring the essential role of Cbl in normal homeostasis. 
3.4 The SOCS family 
3.4.1 Origin, structure and cellular expression 
The SOCS (for Suppressors Of Cytokine Signalling) proteins are a family of intracellular 
molecules that negatively regulate the strength and duration of cytokine receptor signalling 
cascades, notably the JAK/STAT pathway. This family consists of eight members, CIS and 
SOCS1-7 that share structural and functional homology. The first family member identified 
was CIS (for Cytokine-Inducible SH2-containing protein) cloned as an early gene 
differentially induced following IL-3 and EPO exposure (Yoshimura et al., 1995). The second 
member identified, SOCS1 (also known as JAB for JAK-Binding protein or SSI for STAT-
induced STAT Inhibitor) was identified simultaneously by three separate groups (Starr et 
al., 1997; Endo et al., 1997; Naka et al., 1997). SOCS-2 and SOCS-3 were cloned using 
distantly related expressed sequence tags [ESTs] and the rest of the members (SOCS4-7) 
were identified on the basis of a conserved C-terminal amino acid sequence using various 
DNA databases (Starr et al. 1997; Minamoto et al., 1997; Hilton et al., 1998). All members of 
the SOCS family have a similar tripartite domain organization composed of a variable N-
terminal region, followed by a central SH2 domain and a conserved C-terminal SOCS box 
domain (Fig. 1).  SOCS1 and SOCS3 differ from other family members in that they possess 
an extended SH2 domain at the N-terminus (for SOCS1 and SOCS3) or the C-terminus (for 
SOCS3) of this domain. Additionally, they also present at their N-terminal region and 
adjacent to their SH2 domain, a Kinase-Inhibitory Region (KIR) required for inhibition of 
JAK kinase activity (Yasukawa et al., 1999; Sasaki et al., 1999). Another exception is SOCS7 
which is unique in its possession of a proline-rich N-terminus and a nuclear localisation 
signal. 
SOCS molecules expression is controlled at the transcriptional, translational and post-
translational levels. Many SOCS genes contain STAT-binding sequences in their promoter 
region and their STAT-dependent transcription can be differentially regulated in a factor- 
and tissue specific manner. SOCS proteins are often low or undetectable at the basal level in 
unstimulated cells and their expression is rapidly induced to a variable extent in different 
cell types and tissues by immunoregulatory cytokines, colony stimulating factors, growth 
factors and hormones that signal via JAK-STAT pathway or via RTK [Table 4] (Starr et al., 
1997). Certain cytokines that do not signal via JAK kinases or RTKs, and a number of non-
cytokine ligands can also induce SOCS gene expression, such as TNF signalling and 
bacterial products such as LPS and CpG DNA which signal via Toll-like receptors (TLR). 
Because SOCS genes are induced by cytokines and the corresponding proteins inhibit 
further cytokine-induced signalling, SOCS proteins are believed to form part of a classical 
negative feedback loop mechanism. Northern blot analysis of murine tissues has shown that 
CIS and SOCS2 mRNA was ubiquitously expressed, with expression being particularly 
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which is unique in its possession of a proline-rich N-terminus and a nuclear localisation 
signal. 
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strong (CIS) or weak (SOCS2) in kidney, lung, liver, heart, testis and male spleen 
(Yoshimura et al., 1995; Starr et al., 1997). SOCS1 and SOCS3 mRNA was detected at 
different levels in adult haematopoietic organs such as the thymus and spleen and to some 
extent in other organs like lung, spleen and testis (Starr et al., 1997). However, SOCS3 show 
high expression in fetal liver (Marine et al., 1999). Although some of the SOCS members 
appear to be co-expressed in only a few organs, the in vivo expression of SOCS genes may be 
more pronounced than is detectable by Northern hybridisation, since most cell types seem 
to depend on cytokine stimuli for SOCS induction. 
3.4.2 Signalling targets 
The different domains in the SOCS proteins allow them to bind to the cytokine receptors, 
associated JAKs or other signalling molecules and to attenuate signal transduction directly 
or indirectly by targeting the receptor complex for ubiquitin-mediated degradation in 
proteosomes. The N-terminal region of the SOCS proteins is variable in length and 
sequence. In SOCS1 and SOCS3, there is a 12 amino acid sequence adjacent to the SH2 
domain that is essential for the inhibition of JAK2 kinase called KIR. This sequence is 
supposed to function via a conserved tyrosine residue as a pseudo-substrate, lodging in the 
catalytic cleft to block further JAK kinase activity. Removal of this tyrosine does not affect 
binding of the SOCS proteins to the kinase, but does abrogate its inhibition (Sasaki et al., 
1999).  Inded, a SOCS1-KIR mimetic peptide is sufficient to inhibit IFN-mediated JAK2 
activity in primary cells (Waiboci et al., 2007). The role of the remaining N-terminal region 
among the SOCS family members has yet to be elucidated. 
The central SH2 domain determines the target protein for degradation of each SOCS protein. 
It binds to distinct phosphorylated tyrosine motifs on SOCS target proteins (Table 4). Once 
the SH2 domain binds to its specific target, it brings other domains in proximity to the target 
protein, directing degradation of the appropriate protein. Mutagenesis studies allowed the 
identification of small regions at the N-termini of SOCS1 and SOCS3, and at the C-terminus 
of SOCS3 SH2 domains, critical for phosphotyrosine binding. These regions have been 
defined as an N- and C-extended SH2 domain (N-ESS and C-ESS, respectively). The solved 
structure of SOCS3 SH2 domain had shown that the N-ESS sequence directly contacts the 
phosphotyrosine-binding loop of the kinase and determines its orientation (Babon et al., 
2006). The C-ESS of SOCS3 forms part of the SH2 domain that is spatially displaced by a 35 
amino acid PEST [for Proline, Glutamic acid (E), Serine and Threonine rich sequence] 
insertion. This sequence is thought to signal for rapid proteolytic degradation. It is therefore 
not surprising that removal of this sequence lowers SOCS3 turnover without affecting the 
SH2 domain folding and function (Babon et al., 2006). Since other SOCS members contain 
putative PEST sequences, this may prove to be a common mechanism for regulation of 
SOCS protein levels. 
The SOCS proteins are substrate recognition factors for an E3 ligase that targets their specific 
cargo for ubiquitin-mediated degradation. They serve this function by binding to the E3 
complex via the highly conserved SOCS box domain at their C-terminus. The SOCS box is a 
40 amino acid motif found not only in the SOCS family members, but also in a vast number 
of proteins. The SOCS box consists of a three--helical structure bound to an E3 ubiquitin 
ligase complex that in turn covalently binds ubiqutin to lysines in the target protein. The N-
terminus of the SOCS box mediates interaction with Elongin C/B, while the C-terminus of  
 





SH2 partner Inducer system Signalling system 
inhibited 
CIS EPOR, PRLR, 
Leptin R 
EPO, IL-2/3/6, IFN, PRL, 
GH, Leptin 
EPO, PRL, IL-2/3, GH 
SOCS1 JAK2, IFNGRI EPO, TPO, GM-CSF, G-
CSF,M-CSF,IL-
2/4/6/7/9/10/13/15, 
PRL, LPS, TNF, GH, In, 
CpG DNA  
IL-2/4/6/7/12/15, 
IFN//, LIF, TNF, 
EPO, TPO, GH, PRL, In, 
Leptin 
SOCS2 GHR, Leptin R GH, IL-6, IFN/, LIF IL-6, GH, IGF-1 





2/6/9/10/13, GH, LPS, 
EGF, IFN/, LIF, EPO, 
GM-CSF, PRL, In, Leptin 
IL-2/4/6/9/11, 
IFN//, LIF, EPO, 
GH, PRL, In, Leptin 
SOCS4, 
SOCS5 
EGFR EGF, IL-6 EGF, IL-4/6 
SOCS6, 
SOCS7 
IRS2/4, IR In, IGF In, IGF 
In, insulin; PRL, prolacftin. 
Table 4. Signalling partners, transduction pathways and factors regulating SOCS protein 
expression and function. 
the SOCS box directs the SOCS/Elongin C/B association with Cullin 5 (Cul5) scaffold 
protein (Zhang et al., 1999). The latter one recruits the stabilizing RING finger protein Rbx 
and allows Cul5 to bind to an E2 ubiquitin-conjugating enzyme. The resulting complex 
SOCS/Elongin B/C/Cul5/Rbx/E2 forms a functional E3 ubiquitin ligase (Figure 5a). The 
SOCS1-SOCS box has been shown to be capable of driving the ubiquitination of specific 
proteins such as TEL-JAK2 fusion and Vav1, and only in very few cases the receptor 
complex for subsequent degradation through the proteosome (Frantsve et al., 2001; De 
Sepulveda et al., 2000; Irandoust et al., 2007; Verdier et al., 1998). The importance of the 
SOCS box has been further shown by in vivo targeted deletion of SOCS1 and SOCS3 in mice 
that resulted in partial loss of SOCS function with enhanced IFN and G-CSF signalling, 
respectively (Zhang et al., 2001).  
3.4.3 Regulation of cytokine receptor signalling pathways 
The structural analysis of the SOCS molecules revealed they can control cytokine receptor 
signalling by several mechanisms (Figure 5): 
(1) Direct inhibition of intrinsic kinase activity by binding to JAKs.  Immunoprecipitation 
assays revealed that both SOCS1 and SOCS3 were able to co-precipitate with JAK kinases 
upon cytokine stimulation, and that this association blocked JAK kinase activity, although 
with a different affinity and kinetics (Endo et al., 1997; Sasaki et al., 1999). Structure-function 
studies using truncated versions of SOCS1 identified the regions essential for SOCS-JAK 
association and for inhibition of JAK activity. SOCS1 inhibits tyrosine kinase activity upon 
interaction with phosphorylated tyrosine Y1007 located in the activation loop of JAK.  
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Fig. 5. A) Schematic representation of the SOCS box function, B) Mechanisms of suppression 
by the SOCS proteins. 
However, complete inhibition of the kinase activity requires not only the SH2 domain but 
also the KIR region (Narazaki et al., 1998; Nicholson et al., 1999). The critical amino acids for 
the KIR region’s function are conserved between SOCS1 and SOCS3, suggesting a common 
inhibitory mechanism for these two family members. 
(2) Indirect inhibition of JAKs by binding to the receptor. As with SOCS1, the SOCS3 SH2 
domain was initially shown to interact with Y1007 in JAK2, albeit with lower affinity than 
SOCS1. However, subsequent studies demonstrated that SOCS3 SH2 domain exhibited a 
higher affinity for phosphotyrosine residues located within the receptor subunits than for 
JAK2 (Sasaki et al., 1999). Accordingly, it was found that SOCS3 associated with higher 
affinity with phosphorylated residues in the IL-6 receptor subunit, gp130, notably Y759, 
than with the activation loop of JAKs (Nicholson et al., 2000). SOCS3, therefore, in contrast 
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to SOCS1, has to be recruited to the receptor complex in order to inhibit IL-6 signal 
transduction (Schmitz et al., 2000). Subsequently, SOCS3 might inhibit the kinase activity of 
JAKs through the pseudo-substrate, KIR, in the same way as SOCS1, but only after 
recruitment and binding to critical phosphotyrosine residues in the cytokine receptor. Given 
that SOCS1 and SOCS3 can interact with both receptor and JAK, a two-step interaction 
model has been proposed, whereby the SOCS1/3 SH2 domains are first recruited to the 
receptor and subsequent bi-modal binding to nearby JAK through the SH2 domain and KIR 
region results in a high affinity interaction, inhibition of JAK kinase activity and potential 
proteosomal degradation. 
(3) Blocking binding of downstream signalling molecules to the receptor. This mechanism 
has been shown for CIS and SOCS2 for EPO and GH signalling inhibition, respectively. 
Upon stimulation of the receptors, the SOCS proteins bind to tyrosine residues at the 
membrane distal region of receptor chains that are docking sites for downstream signalling 
molecules, such as STAT5 or SHP-2. By masking these phosphorylated residues, CIS/SOCS2 
competes with STAT thereby down-modulating the signalling (Yoshimura et al., 1995; Ram 
& Waxman, 1999). On the other hand, SOCS3-mediated inhibition of signalling via EpoR, 
gp130 and LeptinR could partially result from competitive inhibition of SHP-2 binding to 
gp130, LeptinR, and EpoR, resulting in the blockade of SHP-2-mediated ERK activation 
(Schmitz et al., 2000; Bjorbaek  et al., 2001; Sasaki et al., 2000). 
(4) Ubiquitination and subsequent proteasomal degradation of JAKs and receptor. Studies 
on EPO receptor using proteasome inhibitors showed that these compounds protected the 
EpoR and STAT5 from the normal reduction in phosphorylation upon CIS expression, 
indicating proteasome involvement of both EPO-receptor and STAT5 inactivation (Verdier 
et al., 1998). These results allow proposing a model where the phosphorylated target 
molecules may become a substrate of the proteolytic machinery by binding to SOCS. In this 
situation, the SOCS box acts as an adaptor molecule, bringing into this complex the Elongin 
B/C/E3 ligase for ubiquitination of the target protein. Subsequently, the substrate and the 
associated SOCS proteins may be destroyed, and the cell is ready to respond again to 
stimulation. Therefore, targeting the signalling proteins for degradation by the SOCS box 
seems to be another mechanism by which cytokine signalling might be inhibited under 
physiological levels of SOCS proteins. 
3.4.4 Regulation of SOCS proteins 
Besides elaborate transcriptional regulation, another control point of the expression of SOCS 
molecules is their protein stability. SOCS proteins exhibit a rapid turnover rate, and the half 
lives of SOCS1, SOCS2 and SOCS3 have been estimated to be less than 2 h (Siewert et al., 
1999). Several mechanisms have been proposed to regulate SOCS expression. The presence 
of a PEST sequence in SOCS3 appears to mediate non-proteosomal degradation, while SOCS 
box-dependent ubiquitination of SOCS3 on lysine 6, at least in vitro, contributes to 
proteosomal degradation of the SOCS3 protein (Sasaki et al., 2003). Furthermore, SOCS3 is 
uniquely phosphorylated within the SOCS box on Y204 and Y221 and this appears to have 
two consequences, interaction with the Elongin B/C complex is lost, destabilizing the 
SOCS3 protein, and signalling through the Ras/MAPK pathway can be potentiated (Haan et 
al., 2003; Cacalano et al., 2001). Nevertheless, the full implication of SOCS3 phosphorylation 
on its regulation remains to be explored. 
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4. Animal models of inhibitory adaptors: Definition of their physiological 
significance 
Central to understanding the physiological role of families of inhibitory adaptors in the 
haematopoietic and immune systems, has been the generation of mice deficient for these 
proteins when possible. This has also helped dissect regulatory and/or compensatory 
mechanisms through the functional, complete or partial, reconstitution in these mice, in 
particular for members of multi-gene families. These approaches have allowed 1) analyse 
changes in the expression level of the adaptor that can also affect its signalling pathway; 2) 
establish how deficiency of an adaptor can have dramatically different effects in different 
cell lineages; 3) understand the functional synergy between members of the same family of 
adaptors; 4) identify null mutations leading to the complete absence of some cell types, 
while leaving others with no discernable defect and 5) define how some deficiencies are 
selective within a cell type, disrupting only particular pathways while leaving others intact. 
Mice deficient for the different families of inhibitory adaptors discussed in this chapter have 
certainly provided important new insights into the biology and function of these adaptors. 
However, in some cases, these animal models have also raised important questions 
regarding the mechanisms of action of these regulators and their potential therapeutic 
application. 
4.1 Dok deficient mice 
Although Dok-1, Dok-2, and Dok-3 have been shown to act as negative regulators 
downstream of a wide range of immunoreceptors, cytokine, and LPS receptors mediated 
signalling, insights into their physiological importance in immune cells have and will 
continue to come from studies with mice or cells lacking individually or in combination 
Dok-1, Dok-2, and Dok-3. Dok-1 or Dok-2-deficient mice displayed normal steady-state 
haematopoiesis. By contrast, mice lacking both Dok-1 and Dok-2 succumbed to a 
myeloproliferative disease resembling human chronic myelogenous leukaemia (CML) and 
chronic myelomonocytic leukaemia (CMMoL) at around one year of age (Yasuda et al., 2004; 
Niki et al., 2004) [Table 5]. These animals displayed medullary and extramedullary 
hyperplasia of granulocyte/macrophage progenitors with leukemic potential, and their 
myeloid cells showed hyperproliferation and hypo-apoptosis upon treatment and 
deprivation of cytokines, respectively. Consistently, the mutant myeloid cells showed 
aberrant Ras/MAP kinase and Akt activation upon cytokine stimulation. Strikingly, ablation 
of Dok-1 and Dok-2 markedly accelerated leukaemia and blastic crisis onset in bcr-abl 
transgenic mice known to develop a CML-like disease. These results demonstrate the critical 
role of Dok-1 and Dok-2 in myeloid homeostasis and suppression of leukaemia. 
Interestingly, half of the double-deficient mice also developed histiocytic sarcoma (HS) of 
macrophage origin. These results suggest an involvement of additional genetic changes. 
Similar to Dok-1 and Dok-2 deficiency, Dok-3 inactivation did not result in development of 
aggressive tumors in haematopoietic cells (Ng et al., 2007). However, ablation of all three 
Dok proteins (Dok-1/2/3) in mice has recently shown drastic phenotypic consequences. 
These mice showed earlier mortality due to development of aggressive HS with multiple 
organ invasions, but no incidence of other types of tumors (Mashima et al., 2010). This 
disease is a haematological malignancy characterized by cells displaying a tissue 
macrophage-like (histiocytic) morphology (Grogan et al., 2008).  Indeed, loss of Dok-1/2/3 
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causes aberrant proliferation of macrophages in the lung, already detectable before the onset 
of morphologically recognizable HS. These cells displayed an exaggerated proliferative 
response to M-CSF or GM-CSF compared to wild type littermates. These results suggest that 
Dok proteins can mutually compensate and inhibit macrophage proliferation and therefore 
suppress the aggressive transformation of HS. 
4.2 Lnk/APS/SH2-B deficient mice 
Mice deficient for members of this family have demonstrated the positive (SH2-B) and 
negative (Lnk and APS) physiological role of these adaptors in growth factor, cytokine, and 
immune receptors signalling (Table 5). Deletion of the SH2B1 gene resulted in severe 
obesity, hyperphagia and both leptin and insulin resistance as well as infertility, which 
might be a consequence of resistance to IGF-1 (Ohtsuka et al., 2002; Ren et al., 2005). Thus, 
SH2-B-deficient mice support a role for this adaptor as a positive regulator of JAK2 
signalling pathways initiated by leptin, insulin and potentially, by IGF-1. 
Interestingly, APS-deficient mice also displayed an insulin-related phenotype. They showed 
a hypersensibility to insulin and enhanced glucose tolerance, a finding that is consistent 
with APS playing a negative role in insulin signalling (Minami et al., 2003). Moreover, these 
mice present also a haematopoietic phenotype with defects in degranulation of mast cells 
and cytoskeleton rearrangement in both mast and B-1 cells (Kubo-Akashi et al, 2004; Iseki et  
 
Gene Approach System Mouse phenotype/Human disease 
Dok-1 
Dok-2 
KO mu Impaired immunoreceptor signaling in lymphocytes, 
allergic responses in mast cells, enhanced ERK 
signaling, hyperresponsiveness to LPS 
Dok-1/2 KO mu MPN, Lupus Renal disease/CML, CMMoL 
Dok-
1/2/3 
KO mu HS 
    
Lnk KO mu MPN-like (ET/PMF), CML (aged mice) 
 Tg mu Impaired lymphopoiesis 
 Mu (SNP) hu MPN, autoimmune, cardiovascular and 
inflammatory diseases 
APS KO mu Insulin hypersensitivity, enhanced glucose tolerance, 
enhanced B1 cells proliferation 
 Tg mu Reduced B1 and B2 cell number, impaired B-cell 
development and BCR-dependent proliferation, 
reduced mast cell degranulation and actin assembly 
SH2B KO mu Severe obesity, hyperphagia, increased leptin and  
insulin resistance, infertility 
    
c-Cbl KO mu Enlarged thymus, splenomegaly, extramedullar 
haematopoiesis, enhanced thymocyte function/ 
myeloid malignancies 
 Mu mu Oncogenesis, mastocytosis, myeloid leukemia, 
tumourigenesis 
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4. Animal models of inhibitory adaptors: Definition of their physiological 
significance 
Central to understanding the physiological role of families of inhibitory adaptors in the 
haematopoietic and immune systems, has been the generation of mice deficient for these 
proteins when possible. This has also helped dissect regulatory and/or compensatory 
mechanisms through the functional, complete or partial, reconstitution in these mice, in 
particular for members of multi-gene families. These approaches have allowed 1) analyse 
changes in the expression level of the adaptor that can also affect its signalling pathway; 2) 
establish how deficiency of an adaptor can have dramatically different effects in different 
cell lineages; 3) understand the functional synergy between members of the same family of 
adaptors; 4) identify null mutations leading to the complete absence of some cell types, 
while leaving others with no discernable defect and 5) define how some deficiencies are 
selective within a cell type, disrupting only particular pathways while leaving others intact. 
Mice deficient for the different families of inhibitory adaptors discussed in this chapter have 
certainly provided important new insights into the biology and function of these adaptors. 
However, in some cases, these animal models have also raised important questions 
regarding the mechanisms of action of these regulators and their potential therapeutic 
application. 
4.1 Dok deficient mice 
Although Dok-1, Dok-2, and Dok-3 have been shown to act as negative regulators 
downstream of a wide range of immunoreceptors, cytokine, and LPS receptors mediated 
signalling, insights into their physiological importance in immune cells have and will 
continue to come from studies with mice or cells lacking individually or in combination 
Dok-1, Dok-2, and Dok-3. Dok-1 or Dok-2-deficient mice displayed normal steady-state 
haematopoiesis. By contrast, mice lacking both Dok-1 and Dok-2 succumbed to a 
myeloproliferative disease resembling human chronic myelogenous leukaemia (CML) and 
chronic myelomonocytic leukaemia (CMMoL) at around one year of age (Yasuda et al., 2004; 
Niki et al., 2004) [Table 5]. These animals displayed medullary and extramedullary 
hyperplasia of granulocyte/macrophage progenitors with leukemic potential, and their 
myeloid cells showed hyperproliferation and hypo-apoptosis upon treatment and 
deprivation of cytokines, respectively. Consistently, the mutant myeloid cells showed 
aberrant Ras/MAP kinase and Akt activation upon cytokine stimulation. Strikingly, ablation 
of Dok-1 and Dok-2 markedly accelerated leukaemia and blastic crisis onset in bcr-abl 
transgenic mice known to develop a CML-like disease. These results demonstrate the critical 
role of Dok-1 and Dok-2 in myeloid homeostasis and suppression of leukaemia. 
Interestingly, half of the double-deficient mice also developed histiocytic sarcoma (HS) of 
macrophage origin. These results suggest an involvement of additional genetic changes. 
Similar to Dok-1 and Dok-2 deficiency, Dok-3 inactivation did not result in development of 
aggressive tumors in haematopoietic cells (Ng et al., 2007). However, ablation of all three 
Dok proteins (Dok-1/2/3) in mice has recently shown drastic phenotypic consequences. 
These mice showed earlier mortality due to development of aggressive HS with multiple 
organ invasions, but no incidence of other types of tumors (Mashima et al., 2010). This 
disease is a haematological malignancy characterized by cells displaying a tissue 
macrophage-like (histiocytic) morphology (Grogan et al., 2008).  Indeed, loss of Dok-1/2/3 
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causes aberrant proliferation of macrophages in the lung, already detectable before the onset 
of morphologically recognizable HS. These cells displayed an exaggerated proliferative 
response to M-CSF or GM-CSF compared to wild type littermates. These results suggest that 
Dok proteins can mutually compensate and inhibit macrophage proliferation and therefore 
suppress the aggressive transformation of HS. 
4.2 Lnk/APS/SH2-B deficient mice 
Mice deficient for members of this family have demonstrated the positive (SH2-B) and 
negative (Lnk and APS) physiological role of these adaptors in growth factor, cytokine, and 
immune receptors signalling (Table 5). Deletion of the SH2B1 gene resulted in severe 
obesity, hyperphagia and both leptin and insulin resistance as well as infertility, which 
might be a consequence of resistance to IGF-1 (Ohtsuka et al., 2002; Ren et al., 2005). Thus, 
SH2-B-deficient mice support a role for this adaptor as a positive regulator of JAK2 
signalling pathways initiated by leptin, insulin and potentially, by IGF-1. 
Interestingly, APS-deficient mice also displayed an insulin-related phenotype. They showed 
a hypersensibility to insulin and enhanced glucose tolerance, a finding that is consistent 
with APS playing a negative role in insulin signalling (Minami et al., 2003). Moreover, these 
mice present also a haematopoietic phenotype with defects in degranulation of mast cells 
and cytoskeleton rearrangement in both mast and B-1 cells (Kubo-Akashi et al, 2004; Iseki et  
 
Gene Approach System Mouse phenotype/Human disease 
Dok-1 
Dok-2 
KO mu Impaired immunoreceptor signaling in lymphocytes, 
allergic responses in mast cells, enhanced ERK 
signaling, hyperresponsiveness to LPS 
Dok-1/2 KO mu MPN, Lupus Renal disease/CML, CMMoL 
Dok-
1/2/3 
KO mu HS 
    
Lnk KO mu MPN-like (ET/PMF), CML (aged mice) 
 Tg mu Impaired lymphopoiesis 
 Mu (SNP) hu MPN, autoimmune, cardiovascular and 
inflammatory diseases 
APS KO mu Insulin hypersensitivity, enhanced glucose tolerance, 
enhanced B1 cells proliferation 
 Tg mu Reduced B1 and B2 cell number, impaired B-cell 
development and BCR-dependent proliferation, 
reduced mast cell degranulation and actin assembly 
SH2B KO mu Severe obesity, hyperphagia, increased leptin and  
insulin resistance, infertility 
    
c-Cbl KO mu Enlarged thymus, splenomegaly, extramedullar 
haematopoiesis, enhanced thymocyte function/ 
myeloid malignancies 
 Mu mu Oncogenesis, mastocytosis, myeloid leukemia, 
tumourigenesis 
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Gene Approach System Mouse phenotype/Human disease 
c-Cbl Mu hu AML, MPD/MPN, aCML, JMML 
Cbl-b KO mu Impaired immunological tolerance, autoimmune 
diseases with inflammatory organ and tissue 
damage, enhanced peripheral T-cell function, 
rejection of certain tumours 
c-Cbl/ 
Cbl-b 
KO mu Embryonic lethal 
 T-cell KO mu Autoimmune-like vasculitis, SLE-like autoimmune 
disease 
    
CIS KO mu No specific phenotype 
 Tg mu Fewer T-cells, NK, and NK-T cells, lactation 
deficiency, similar phenotype to STAT5 KO 
SOCS1 KO mu perinatal lethality, enhanced IFN production and 
responsiveness, lymphopenia and inflammation 
with multi-organ infiltration 
 Tg(Tcell) mu Inhibited T-cell response to IFN, IL-6 and IL-7, 
increased CD4+T-cells, reduced peripheral T-cell 
activation  
  hu Increased expression in Th-driven inflammatory 
diseases (RA, UC, Crohn, dermatitis), decreased 
expression and/or hyper-methylation in certain 
cancers 
SOCS2 KO mu Gigantism, deregulated GH signalling 
 Tg mu Gigantism 
SOCS3 KO mu Embryonic lethality due to placental deficiency, 
erythrocytosis, deregulated LIF response 
 Tg mu Embryonic lethality due to anemia 
 Tg(Tcell) mu High TGF1 and IL-10 production 
 Mu (SNP) hu Allergic diseases  
  hu Increased expression in Th2-driven asthma patients 
and inflammatory diseases, hyper-phosphorylation 
in MPN 
SOCS5 KO mu No specific phenotype 
 Tg mu Reduced IL-4-mediated STAT6 activation, reduced 
Th2 development and cytokine production 
SOCS6 KO mu Mild growth retardation 
SOCS7 KO mu Growth retardation (strain-dependent), 
hypoglucemia, hydrocephalus, altered glucose 
homeostasis, enlarged pancreatic islets 
KO, knock out; Tg, transgenic; Mu, mutations; hu, human; mu, murine, RA, theumatoid arthritis; UC, 
ulcer colitis. 
Table 5. Mouse phenotype and human diseases related to deficiencies in inhibitory 
adaptors. 
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al., 2004). These results suggest a negative role for APS in controlling actin dynamics in 
these cells. Furthermore, APS-deficient mice display an increase in B-1 cells in the peritoneal 
cavity and humoral responses to type-2 antigen, indicating a negative regulatory role for 
APS in BCR-mediated cell proliferation and cytoskeletal regulation. 
By contrast, mice deficient for Lnk display a profound perturbation in haematopoiesis that 
confirmed its role as a key negative regulator of cytokine signalling in the haematopoietic 
system. Indeed, these mice exhibit splenomegaly together with fibrosis, expansion of HSC, B 
lymphoid and myeloid progenitors that confer an enhanced repopulating ability. Lnk-deficient 
mice have also revealed an important role for Lnk in B-cell lymphopoiesis, megakaryopoiesis 
and erythropoiesis, as a result of the absence of negative regulation of SCF, TPO and EPO 
signalling pathways. One important feature of the Lnk-/- mice phenotype is its resemblance to 
human myeloproliferative neoplasms (MPN): hypersensitivity to cytokines, increased number 
of haematopoietic progenitors, high platelet counts, splenomegaly together with fibrosis and 
extramedullary hematopoiesis (Velazquez et al., 2002; Campbell & Green, 2008). This has 
suggested an important role for Lnk in the development of these diseases. Indeed, loss of Lnk 
cooperates with oncogenes, such as JAK2 and BCR-ABL, to induce MPN in mice. These 
animals exhibit a disproportionate expansion of myeloid progenitors and immature precursors 
in vitro and in vivo (Bersenev et al., 2010). Moreover, aged Lnk-/- mice seem to spontaneously 
develop a Chronic Myeloid Leukemia (CML)-like MPN, suggesting a role for Lnk in myeloid 
expansion in vivo. However, this myeloid cell hyperproliferation fails to trigger blast crises, 
reflecting the need of Lnk-deficiency for additional oncogenic events to promote blast 
transformation. Lnk-deficient mice also exhibited an increase in endothelial progenitor cells 
(EPC) numbers that display an enhance capacity for colony formation. Different molecular, 
physiological and morphological approaches have shown that Lnk deficiency promotes 
vasculogenesis/angiogenesis and osteogenesis through the mobilization and recruitment of 
HSCs/EPCs via activation of the SCF/Kit signalling pathway in the ischemic and perifracture 
zone, respectively, thereby establishing an optimal environment for neovascularisation, bone 
healing and remodelling (Kwon et al., 2009, Matsumoto, et al., 2010). Taken together, these 
findings strongly suggest that Lnk regulates bone marrow EPC kinetics during vascular and 
bone regeneration. 
4.3 Cbl-deficient mice 
Mice deficient for c-Cbl and Cbl-b have been invaluable in demonstrating the important roles 
played by these proteins in fine-tuning signalling thresholds in immune cells. Despite close 
structural similarities, loss of c-Cbl and Cbl-b proteins evokes prominent phenotypic 
differences (Table 5). c-Cbl-null mice have an enlarged thymus, expanded hematopoietic 
progenitor pools with increased repopulating capacity, splenomegaly with extramedullary 
hematopoiesis, as well as changes in energy metabolism, and reduced fertility of male mice 
(Murphy et al., 1998; Naramura et al., 1998; Molero et al., 2004; El Chami et al., 2005, Rathinam 
et al., 2008).  However, the most marked alteration in c-Cbl and Cbl-b-deficient animals is being 
associated with thymocyte and peripheral T-cell activation, respectively. c-Cbl-/- mice exhibit 
strong effects on thymocytes, with increase cell numbers in the thymus of the young adult and 
enhanced signal strength following TCR engagement. Moreover, perturbed thymocyte 
signalling does not depend on the TKB domain of c-Cbl, as a TKB knock-in did not rescue the 
phenotype (Thien et al., 2003). In contrast, Cbl-b ablation results in an impaired immunological 
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Gene Approach System Mouse phenotype/Human disease 
c-Cbl Mu hu AML, MPD/MPN, aCML, JMML 
Cbl-b KO mu Impaired immunological tolerance, autoimmune 
diseases with inflammatory organ and tissue 
damage, enhanced peripheral T-cell function, 
rejection of certain tumours 
c-Cbl/ 
Cbl-b 
KO mu Embryonic lethal 
 T-cell KO mu Autoimmune-like vasculitis, SLE-like autoimmune 
disease 
    
CIS KO mu No specific phenotype 
 Tg mu Fewer T-cells, NK, and NK-T cells, lactation 
deficiency, similar phenotype to STAT5 KO 
SOCS1 KO mu perinatal lethality, enhanced IFN production and 
responsiveness, lymphopenia and inflammation 
with multi-organ infiltration 
 Tg(Tcell) mu Inhibited T-cell response to IFN, IL-6 and IL-7, 
increased CD4+T-cells, reduced peripheral T-cell 
activation  
  hu Increased expression in Th-driven inflammatory 
diseases (RA, UC, Crohn, dermatitis), decreased 
expression and/or hyper-methylation in certain 
cancers 
SOCS2 KO mu Gigantism, deregulated GH signalling 
 Tg mu Gigantism 
SOCS3 KO mu Embryonic lethality due to placental deficiency, 
erythrocytosis, deregulated LIF response 
 Tg mu Embryonic lethality due to anemia 
 Tg(Tcell) mu High TGF1 and IL-10 production 
 Mu (SNP) hu Allergic diseases  
  hu Increased expression in Th2-driven asthma patients 
and inflammatory diseases, hyper-phosphorylation 
in MPN 
SOCS5 KO mu No specific phenotype 
 Tg mu Reduced IL-4-mediated STAT6 activation, reduced 
Th2 development and cytokine production 
SOCS6 KO mu Mild growth retardation 
SOCS7 KO mu Growth retardation (strain-dependent), 
hypoglucemia, hydrocephalus, altered glucose 
homeostasis, enlarged pancreatic islets 
KO, knock out; Tg, transgenic; Mu, mutations; hu, human; mu, murine, RA, theumatoid arthritis; UC, 
ulcer colitis. 
Table 5. Mouse phenotype and human diseases related to deficiencies in inhibitory 
adaptors. 
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al., 2004). These results suggest a negative role for APS in controlling actin dynamics in 
these cells. Furthermore, APS-deficient mice display an increase in B-1 cells in the peritoneal 
cavity and humoral responses to type-2 antigen, indicating a negative regulatory role for 
APS in BCR-mediated cell proliferation and cytoskeletal regulation. 
By contrast, mice deficient for Lnk display a profound perturbation in haematopoiesis that 
confirmed its role as a key negative regulator of cytokine signalling in the haematopoietic 
system. Indeed, these mice exhibit splenomegaly together with fibrosis, expansion of HSC, B 
lymphoid and myeloid progenitors that confer an enhanced repopulating ability. Lnk-deficient 
mice have also revealed an important role for Lnk in B-cell lymphopoiesis, megakaryopoiesis 
and erythropoiesis, as a result of the absence of negative regulation of SCF, TPO and EPO 
signalling pathways. One important feature of the Lnk-/- mice phenotype is its resemblance to 
human myeloproliferative neoplasms (MPN): hypersensitivity to cytokines, increased number 
of haematopoietic progenitors, high platelet counts, splenomegaly together with fibrosis and 
extramedullary hematopoiesis (Velazquez et al., 2002; Campbell & Green, 2008). This has 
suggested an important role for Lnk in the development of these diseases. Indeed, loss of Lnk 
cooperates with oncogenes, such as JAK2 and BCR-ABL, to induce MPN in mice. These 
animals exhibit a disproportionate expansion of myeloid progenitors and immature precursors 
in vitro and in vivo (Bersenev et al., 2010). Moreover, aged Lnk-/- mice seem to spontaneously 
develop a Chronic Myeloid Leukemia (CML)-like MPN, suggesting a role for Lnk in myeloid 
expansion in vivo. However, this myeloid cell hyperproliferation fails to trigger blast crises, 
reflecting the need of Lnk-deficiency for additional oncogenic events to promote blast 
transformation. Lnk-deficient mice also exhibited an increase in endothelial progenitor cells 
(EPC) numbers that display an enhance capacity for colony formation. Different molecular, 
physiological and morphological approaches have shown that Lnk deficiency promotes 
vasculogenesis/angiogenesis and osteogenesis through the mobilization and recruitment of 
HSCs/EPCs via activation of the SCF/Kit signalling pathway in the ischemic and perifracture 
zone, respectively, thereby establishing an optimal environment for neovascularisation, bone 
healing and remodelling (Kwon et al., 2009, Matsumoto, et al., 2010). Taken together, these 
findings strongly suggest that Lnk regulates bone marrow EPC kinetics during vascular and 
bone regeneration. 
4.3 Cbl-deficient mice 
Mice deficient for c-Cbl and Cbl-b have been invaluable in demonstrating the important roles 
played by these proteins in fine-tuning signalling thresholds in immune cells. Despite close 
structural similarities, loss of c-Cbl and Cbl-b proteins evokes prominent phenotypic 
differences (Table 5). c-Cbl-null mice have an enlarged thymus, expanded hematopoietic 
progenitor pools with increased repopulating capacity, splenomegaly with extramedullary 
hematopoiesis, as well as changes in energy metabolism, and reduced fertility of male mice 
(Murphy et al., 1998; Naramura et al., 1998; Molero et al., 2004; El Chami et al., 2005, Rathinam 
et al., 2008).  However, the most marked alteration in c-Cbl and Cbl-b-deficient animals is being 
associated with thymocyte and peripheral T-cell activation, respectively. c-Cbl-/- mice exhibit 
strong effects on thymocytes, with increase cell numbers in the thymus of the young adult and 
enhanced signal strength following TCR engagement. Moreover, perturbed thymocyte 
signalling does not depend on the TKB domain of c-Cbl, as a TKB knock-in did not rescue the 
phenotype (Thien et al., 2003). In contrast, Cbl-b ablation results in an impaired immunological 
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tolerance induction and animals succumb to spontaneous and/or induced autoimmune 
diseases with widespread inflammatory organ (pancreas, lung) and tissue (adipose) damage 
(Bachmaier et al., 2000, 2007; Hirasaka et al., 2007). Importantly, Cbl-b-null mice are able to 
reject multiple types of tumours spontaneously (Chiang et al., 2007; Loeser et al., 2007). 
The redundant and overlapping functions of Cbl family proteins are more evident from the 
striking phenotypes of Cbl, Cbl-b double-deficient mice. Deletion of both proteins in the 
germline leads to early embryonic lethality (Naramura et al., 2002). In contrast, T-cell 
specific double knock-out mice are viable, however, their T-cells develop independent of 
MHC-restricted thymic selection and these mice eventually succumb to autoimmune-like 
vasculitis early in adult life (Huang et al., 2006; Naramura et al., 2002). Similarly, B-cell 
specific Cbl, Cbl-b double deficiency leads to a failure to acquire tolerance to self antigens 
and the animals developed Systemic Lupus Erythematosus (SLE)-like autoimmune diseases 
(Kitaura et al., 2007). At the molecular level, cells from these double knock-out mice display 
delayed down-modulation of cell surface antigen receptors and prolonged activation of 
downstream signalling pathways. 
Loss of c-Cbl, but not of Cbl-b, led to a significant expansion of HSC and haematopoietic 
progenitors. Strikingly, ablation of both proteins enhanced this phenotype and eventually all 
mice succumbed to aggressive myeloproliferative disease-like leukemia with peripheral organ 
involvement within two to three months after birth (Naramura et al., 2010). Moreover, blastic 
transformation of chronic myelogeneous leukemia in a bcr/abl-transgenic model is accelerated 
in the c-Cbl null background (Sanada et al., 2009). Combined, these observations support that 
c-Cbl can act as a tumor suppressor and that complete loss of Cbl functions is required to 
promote myeloid malignancy. In contrast to the tumor suppressor function of the wild-type c-
Cbl, c-Cbl mutants isolated from human and murine neoplasms, as well as v-Cbl, show clear 
transforming capacity in terms of anchorage-independent growth in soft agar in vitro and 
tumour generation in nude mice in vivo (Sanada et al., 2009; Thien et al., 2001). Bone marrow 
cells transduced with c-Cbl mutants in the linker (70Z) or in the RING finger domain (R420Q) 
generate generalized mastocytosis, a myeloproliferative disease, and myeloid leukemia in 
lethally irradiated mice with long latency but high penetrance (Bandi et al., 2009). The 
transforming activity of these mutant forms of c-Cbl seems to be mediated by alteration of the 
E3 ubiquitin ligase activity. Most c-Cbl mutations in myeloid neoplasms are missense changes 
at highly conserved amino acid positions within the linker and RING finger domains, or 
involve splice-site sequences, leading to amino acid deletions within them. Supporting these 
findings, the generation of knock-in mutants carrying single point mutations in the TKB, linker 
or RING domains of c-Cbl protein has further validated the importance of these domains in 
Cbl-mediated tumorigenesis. Interestingly, mice with an equivalent RING finger domain 
mutation in Cbl-b do not show comparable changes in the haematopoietic compartment, 
indicating that Cbl-b is not capable of inhibiting c-Cbl functions (Rathinam et al., 2010). Taken 
together, mouse models with Cbl family ablation or point mutations have convincingly 
established the role of these proteins as important E3 ubiquitin ligases for the homeostasis of 
the haematopoietic and immune systems and as tumour suppressors. 
4.4 SOCS-deficient mice 
Since the discovery of SOCS proteins, much attention has been drawn to their physiological 
roles and their involvement in human diseases. Many of their common inhibitory activities 
 
Negative Regulation of Haematopoiesis: Role of Inhibitory Adaptors 
 
73 
on cytokine signalling demonstrated in vitro, do not seem to be essential in vivo as genetic 
ablation of CIS, SOCS1, SOCS2 and SOCS3 genes has demonstrated remarkable cytokine 
specificity for different SOCS molecules (Table 5). 
SOCS1-deficient mice are growth retarded and died within 3 weeks of birth with a 
syndrome characterized by severe lymphopenia, activation of peripheral T cells, fatty 
degeneration and necrosis of the liver and multi-organ failure with rampant inflammation 
due to macrophage infiltration of major organs (Alexander et al., 1999; Marine et al., 1999a, 
Starr et al., 1998). The neonatal phenotypes appear primarily as the result of deregulated 
IFN signalling, because SOCS1-/- mice that are also deficient for IFN, do not die neonatally.  
Moreover, constitutive STAT1 activation and IFN-inducible genes were observed in SOCS1 
deficient mice, indicating that IFN signalling is regulated by SOCS1 and that its 
deregulation contributes to the lethal phenotype. However, the SOCS1, IFN double 
deficient mice ultimately died 6 months after birth with inflammation and polycystic 
kidneys, which suggests that SOCS1 regulation is not exclusive to IFN (Metcalf et al., 2002). 
The lethality in SOCS1-/- mice is also significantly delayed in the RAG2-/-, STAT1-/-, STAT6-/- 
and STAT4-/- backgrounds, thus implicating SOCS1 as a critical regulator of IFN, IL-4 and 
IL-12 signalling pathways (Alexander and Hilton, 2004). 
In recent years, it has become clear that some of the SOCS members play critical roles in 
regulating T-cell differentiation, maturation and function by controlling different signalling 
events, as shown by the phenotypes displayed by SOCS1 and SOCS3 deficient mice. In this 
sense, T-cell specific conditional deletion of SOCS1 showed that it is not sufficient to induce 
the lethal multi-organ disease; however it does cause T-cell specific abnormalities that 
include increased numbers of CD8+ T cells and increased sensitivity to cytokines with 
common -chain receptors. SOCS1 also plays an important role in the regulation of Tregs. 
Higher number of Tregs is observed in the thymus and spleen of T-cell-specific SOCS1-
deficient mice (Horino et al., 2008). This is probably due to higher IL-2 responses, because 
IL-2 enhances Tregs proliferation. Moreover, Lu and colleagues have recently showed that 
SOCS1-specific ablation in Tregs induced the development of spontaneous dermatitis, 
splenomegaly and lymphoadenopathy in these mice (Lu et al., 2009). These results point out 
SOCS1 as an important controller of Tregs. 
Analysis of mice bearing the deletion of the SOCS box of SOCS1 demonstrated the in vivo 
importance of the SOCS box for inhibition of IFN signalling by SOCS1. SOCS box deleted-
deficient mice also die prematurely and suffer from reduced body weight. Inflammatory 
lesions are observed in skeletal and heart muscle, cornea, pancreas and dermis.  
SOCS2 is thought to play a major role in the regulation of GH signalling. Indeed, mice 
deficient for SOCS2 develop gigantism with enlargement of visceral organs and 3 months 
after birth weight 30-40% more than control mice, elevated mRNA levels of insulin-like 
growth factor (IGF-1) and enhanced responses to exogenous GH (Metcalf et al., 2000; 
Greenhalgh et al., 2005). Interestingly, over-expression of SOCS2 increases GH signalling 
and SOCS2 transgenic mice develop mild gigantism (Favre et al., 1999). These results 
suggest a more complex role of SOCS2 in regulating GH signalling. To date, there are no 
evidences on the role of SOCS2 in the regulation of immune responses. 
Deletion of SOCS3 leads to embryonic lethality with embryos dying between 12 and 16 days 
of gestation (Marine et al., 1999b). Lethality was initially thought to result from excessive 
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tolerance induction and animals succumb to spontaneous and/or induced autoimmune 
diseases with widespread inflammatory organ (pancreas, lung) and tissue (adipose) damage 
(Bachmaier et al., 2000, 2007; Hirasaka et al., 2007). Importantly, Cbl-b-null mice are able to 
reject multiple types of tumours spontaneously (Chiang et al., 2007; Loeser et al., 2007). 
The redundant and overlapping functions of Cbl family proteins are more evident from the 
striking phenotypes of Cbl, Cbl-b double-deficient mice. Deletion of both proteins in the 
germline leads to early embryonic lethality (Naramura et al., 2002). In contrast, T-cell 
specific double knock-out mice are viable, however, their T-cells develop independent of 
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and the animals developed Systemic Lupus Erythematosus (SLE)-like autoimmune diseases 
(Kitaura et al., 2007). At the molecular level, cells from these double knock-out mice display 
delayed down-modulation of cell surface antigen receptors and prolonged activation of 
downstream signalling pathways. 
Loss of c-Cbl, but not of Cbl-b, led to a significant expansion of HSC and haematopoietic 
progenitors. Strikingly, ablation of both proteins enhanced this phenotype and eventually all 
mice succumbed to aggressive myeloproliferative disease-like leukemia with peripheral organ 
involvement within two to three months after birth (Naramura et al., 2010). Moreover, blastic 
transformation of chronic myelogeneous leukemia in a bcr/abl-transgenic model is accelerated 
in the c-Cbl null background (Sanada et al., 2009). Combined, these observations support that 
c-Cbl can act as a tumor suppressor and that complete loss of Cbl functions is required to 
promote myeloid malignancy. In contrast to the tumor suppressor function of the wild-type c-
Cbl, c-Cbl mutants isolated from human and murine neoplasms, as well as v-Cbl, show clear 
transforming capacity in terms of anchorage-independent growth in soft agar in vitro and 
tumour generation in nude mice in vivo (Sanada et al., 2009; Thien et al., 2001). Bone marrow 
cells transduced with c-Cbl mutants in the linker (70Z) or in the RING finger domain (R420Q) 
generate generalized mastocytosis, a myeloproliferative disease, and myeloid leukemia in 
lethally irradiated mice with long latency but high penetrance (Bandi et al., 2009). The 
transforming activity of these mutant forms of c-Cbl seems to be mediated by alteration of the 
E3 ubiquitin ligase activity. Most c-Cbl mutations in myeloid neoplasms are missense changes 
at highly conserved amino acid positions within the linker and RING finger domains, or 
involve splice-site sequences, leading to amino acid deletions within them. Supporting these 
findings, the generation of knock-in mutants carrying single point mutations in the TKB, linker 
or RING domains of c-Cbl protein has further validated the importance of these domains in 
Cbl-mediated tumorigenesis. Interestingly, mice with an equivalent RING finger domain 
mutation in Cbl-b do not show comparable changes in the haematopoietic compartment, 
indicating that Cbl-b is not capable of inhibiting c-Cbl functions (Rathinam et al., 2010). Taken 
together, mouse models with Cbl family ablation or point mutations have convincingly 
established the role of these proteins as important E3 ubiquitin ligases for the homeostasis of 
the haematopoietic and immune systems and as tumour suppressors. 
4.4 SOCS-deficient mice 
Since the discovery of SOCS proteins, much attention has been drawn to their physiological 
roles and their involvement in human diseases. Many of their common inhibitory activities 
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on cytokine signalling demonstrated in vitro, do not seem to be essential in vivo as genetic 
ablation of CIS, SOCS1, SOCS2 and SOCS3 genes has demonstrated remarkable cytokine 
specificity for different SOCS molecules (Table 5). 
SOCS1-deficient mice are growth retarded and died within 3 weeks of birth with a 
syndrome characterized by severe lymphopenia, activation of peripheral T cells, fatty 
degeneration and necrosis of the liver and multi-organ failure with rampant inflammation 
due to macrophage infiltration of major organs (Alexander et al., 1999; Marine et al., 1999a, 
Starr et al., 1998). The neonatal phenotypes appear primarily as the result of deregulated 
IFN signalling, because SOCS1-/- mice that are also deficient for IFN, do not die neonatally.  
Moreover, constitutive STAT1 activation and IFN-inducible genes were observed in SOCS1 
deficient mice, indicating that IFN signalling is regulated by SOCS1 and that its 
deregulation contributes to the lethal phenotype. However, the SOCS1, IFN double 
deficient mice ultimately died 6 months after birth with inflammation and polycystic 
kidneys, which suggests that SOCS1 regulation is not exclusive to IFN (Metcalf et al., 2002). 
The lethality in SOCS1-/- mice is also significantly delayed in the RAG2-/-, STAT1-/-, STAT6-/- 
and STAT4-/- backgrounds, thus implicating SOCS1 as a critical regulator of IFN, IL-4 and 
IL-12 signalling pathways (Alexander and Hilton, 2004). 
In recent years, it has become clear that some of the SOCS members play critical roles in 
regulating T-cell differentiation, maturation and function by controlling different signalling 
events, as shown by the phenotypes displayed by SOCS1 and SOCS3 deficient mice. In this 
sense, T-cell specific conditional deletion of SOCS1 showed that it is not sufficient to induce 
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suggest a more complex role of SOCS2 in regulating GH signalling. To date, there are no 
evidences on the role of SOCS2 in the regulation of immune responses. 
Deletion of SOCS3 leads to embryonic lethality with embryos dying between 12 and 16 days 
of gestation (Marine et al., 1999b). Lethality was initially thought to result from excessive 
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erythropoiesis due to enhanced EPO signalling. However, further studies showed that 
lethality was in fact due to placental insufficiency with poor development of embryonic 
vessels, spongiotrophoblasts, as well as increase in trophoblast giant cell differentiation 
(Roberts et al., 2001). Tetraploid aggregation assays resulting in SOCS3-deficient foetal 
components with SOCS3 sufficient placental tissues, generated live birth SOCS3-/- mice. 
These mice were smaller than littermates, exhibited cardiac hyperthrophy and finally 
succumbed by 25 days. Importantly, SOCS3 lethality could be rescued if mice were also 
deficient for Leukemia-Inhibitory factor (LIF) or its receptor (LIFR), indicating that SOCS3 is 
required for modulating LIF signalling in giant trophoblast cell differentiation (Takahashi et 
al., 2003, Robb et al., 2005). 
SOCS3 has also been shown to play an important role in Th1 and Th2 cell differentiation. 
Indeed, blocking SOCS3 either by a dominant-negative mutant or in heterozygous SOCS3 
mice diminishes the differentiation of Th2 cells, resulting in the skewing of T-cells towards 
the Th1 phenotype and reduced allergic responses (Seki et al., 2003; Kubo et al., 2006). 
Furthermore, over-expression of SOCS3 in T-cells provokes exacerbating Th2 cell-mediated 
eye-allergy, with inhibition of SOCS3 ameliorating the severity of the disease.  
The receptors to which SOCS3 binds mostly activate STAT3, therefore, SOCS3 has been 
considered as a negative regulator of inflammation and an inhibitor relatively specific to 
STAT3. Indeed, mice with a conditional deletion of SOCS3 in haematopoietic and 
endothelial cells die as young adults due to severe inflammatory lesions in the peritoneal 
and pleural cavities (Croker et al., 2004, Robb et al., 2005). If G-CSF is administered to these 
mice, mimicking emergency granulopoiesis during infection, they exhibit massive 
neutrophil infiltration and destruction of liver, lung, muscle and spinal tissue, resulting 
from increased intensity and duration of G-CSF-induced STAT3 activation.  These results 
thus indicate SOCS3 as a negative regulator of G-CSF and STAT3 in myeloid cells. Mice with 
SOCS3-deficient haematopoiesis display also high susceptibility to inflammatory joint 
disease in an IL-1-induced inflammatory model (Wong et al., 2006). Adenoviral gene 
transfer of SOCS3 or dominant negative STAT3 indeed reduced the proliferation of RA 
synovial fibroblasts and the severity of the disease in a mouse model that is also dependent 
on Th17 cells (Shouda et al., 2001). The generation of these same cells is enhanced in T-cell 
specific SOCS3-deficient mice and abrogation of SOCS3 binding site in gp130 knock-in 
mutant mice results in Th17-like arthritis (Taleb et al., 2009; Ogura et al., 2008). Together, 
these results show that the absence of SOCS3 has dramatic pro-inflammatory effects by 
promoting Th17 development and Th17-mediated disease. 
Mice lacking CIS did not display any specific phenotype (Marine et al., 1999a). However, 
CIS-over-expressing transgenic mice recreate a phenotype quite similar to STAT5-deficient 
mice with defects in growth and lactation, GH and prolactin signalling, as well as in natural 
killer, natural killer T-cell and T-cell development (Matsumoto et al., 1999). These results 
support its role in JAK/STAT5 pathway. 
The role of SOCS4 in vivo or in immune responses is to date unknown. However, in vivo 
studies on SOCS5 reveal its possible role in adaptive immunity, notably in Th1 and Th2 cell 
differentiation. SOCS5 transgenic mice show attenuation of IL-4-mediated STAT6 signalling, 
as well as reduced Th2 cell development and production of Th2-type-cytokines (Seki et al., 
2002). Interestingly, SOCS5 over-expression augmented eosinophilic airway inflammation 
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and septic peritonitis in mice (Ohshima et al., 2007; Watanabe et al., 2006). In contrast, 
SOCS5-deficent mice appear to have normal T-cell development and differentiation to both 
Th1 and Th2 cells (Brender et al., 2004). These contradictory phenotypes might be explained 
with the high homology between SOCS4 and SOCS5 denoting a redundant role of these 
proteins in vivo. 
SOCS6-deficient mice do not display overt abnormalities, but just mild growth retardation, 
suggesting its role in cell growth (Krebs et al., 2002). However, SOCS6 over-expression 
results in inhibited insulin signalling and improvement in glucose tolerance, similarly to 
p85-deficient mice (Li et al., 2004). SOCS7 ablation in vivo has mainly delineated its essential 
role in insulin signalling. SOCS7-deficient mice shows multiple defects at an early age with 
half of the homozygous progeny displaying severe hydrocephalus and growth retardation 
concomitant with hypoglycaemia and enhanced glucose metabolism that resulted in 
perinatal lethality (Banks et al., 2005; Krebs et al., 2004). On the other hand, SOCS7 seems to 
have a role in the regulation of allergic inflammatory disease. SOCS7-deficient mice have a 
propensity toward spontaneous development of cutaneous disease with infiltration of 
degranulated mast cells (Knisz et al., 2009). Thus, these studies suggest a role for SOCS7 in 
modulating the development of allergic diseases. 
5. Inhibitory adaptors in human haematological diseases 
As described in the previous section, animal models for the Dok, Lnk, Cbl and SOCS 
families have been invaluable in demonstrating the important roles played by these adaptor 
proteins in fine-tuning signalling thresholds in haematopoietic and immune cells. Some of 
these in vivo models recapitulate exactly or almost, essential features of different 
haematological and immune diseases, allowing us to identify new molecular players and 
mechanisms implicated in the initiation and progression of these malignancies. 
Dok proteins 
Studies on Dok-1 and Dok-2-deficient mice demonstrated that these adaptors are essential to 
suppress the blastic transformation of the Bcr-Abl–induced CML-like disease. However, it is 
of note that in case of patients with CML, blast crisis mostly results in myeloid or B cell 
leukemia/lymphoma, usually not in the T cell variety. That Bcr-Abl mice carrying a p53 
mutation also developed T cell lymphoma suggests involvement of genetic background 
(Honda et al., 2000). Moreover, as double Dok-1/2 knockout mice developed 
myeloproliferative disease in the absence of Bcr-Abl, Dok-1 and Dok-2 may oppose a wide 
range of myeloid leukemogenesis in humans. Consistently, undetectable or marginal levels 
of their expression was observed in about half of the leukemic cell lines established from 
patients with myeloid leukaemia, regardless of whether it is CML or not (Yasuda et al., 
2004). Further investigation of the tumour suppressive function of Dok-1 and Dok-2 in 
human malignancies, especially myeloid leukaemia including CML and CMMoL, might 
lead to an understanding of the molecular mechanisms of such diseases and contribute to 
designing effective therapies against them (Table 5). 
Histiocytic sarcoma (HS) is a malignant proliferation of cells showing morphological and 
immunophenotypic features of mature histiocytes, which represent tissue-resident 
macrophages. Until recently, HS, which was also known as malignant histiocytosis, was 
often confused with anaplastic large B-cell lymphoma or with other malignant lymphomas 
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(Weiss et al., 2009). As the molecular etiology of this disease is unknown, there remains a 
need for realistic animal models. Mouse models that have been reported for HS frequently 
show multiple lesions including lymphomas and severe renal failure. The syndrome elicited 
in mice lacking all the three proteins, Dok-1, Dok-2, and Dok-3, more specifically resembles 
the disease found in humans and hence may serve as a useful model for the study of HS. 
Although elucidation of the mechanisms by which the ablation of Dok proteins specifically 
causes HS and how the tumour gains its aggressive phenotype awaits further studies, such 
studies will help unveil the hidden etiology of this rare aggressive human malignancy. 
Lnk proteins 
Lnk-deficient mice display a phenotype reminiscent of BCR-ABL negative (Ph-) MPNs, 
notably Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF) that has 
suggested a role for Lnk in the development of these diseases (Table 5). All MPNs are clonal 
disorders of HSC characterized by excessive proliferation of haematopoietic cells due to 
hypersensibility to normal cytokine regulation and absence of negative feed back regulation. 
The recent discovery of the Val617Phe acquired mutation of the JAK2 gene (JAK2-V617F) 
represents the first reliable molecular marker of Ph- MPN (Campbell & Green, 2008). The 
pathogenic role of JAK2-V617F constitutive active kinase and more recently of mutated Mpl 
(MPLW-515L) most likely will go through abnormal activation of signalling molecules, 
among which Lnk likely plays an important negative regulatory role through its binding to 
JAK2-V617F and MPL-W515L forms. Indeed, recent work has demonstrated a modulation of 
Lnk level in megakaryocyte/platelets and CD34+ cells from MPNs patients (Baran-Marszak 
et al., 2010). Recently, the first LNK mutations in JAK2-V617F-negative MPN patients (ET 
and PMF) were identified (Oh et al., 2010).  Both mutations are on exon 2, one (E208Q) is a 
missense mutation in the PH domain (ET patient), while the second mutation lead to a 
premature stop codon resulting in the absence of the protein (PMF patient). The prevalence 
of such mutations is rare (5% or less). However, other LNK mutations  have been identified 
in leukemic transformation of MNP at a higher frequency [13%] (Pardani et al., 2010). 
Moreover, LNK exon 2 mutations were also found in pure erythrocytosis (Lasho et al., 2010). 
In this case, one mutation (A215V) was previously described in PMF blast crisis and another 
(E208X) results in absence of the protein. This finding suggests that the LNK mutations 
induce an MPN phenotype that may depend on different parameters, such as the presence 
of other mutations (Lasho et al., 2011).  
Genome-wide association studies (GWAS) have recently revealed that different diseases share 
susceptibility variants. The LNK/SH2B3 gene maps on chromosome 12q24 and a non-
synonymous single nucleotide polymorphisms (SNP) in this gene has been reported in exon 2 
resulting in a missense mutation at position 262 leading to a R262W amino acid substitution in 
the PH domain. Surprisingly, this nsSNP has recently been associated with inflammatory 
disorders, such as celiac disease (Hunt et al., 2008; Zhernakova et al., 2010), type 1 diabetes 
(Lavrikova et al., 2010), asthma (Gudbjartsson et al., 2009) multiple sclerosis (Alcina et al., 
2010), and also to eight clinically relevant haematological parameters (Soranzo et al., 2009; 
Ganesh et al., 2009) in different populations. Furthermore, the LNK R262W variant has also 
been associated to cardiovascular diseases such as myocardial infarction, coronary heart 
disease and hypertension (Gudbjartsson et al., 2009; Ikram et al., 2010). All these data suggests 
that Lnk nsSNP could be a risk variant for these diseases contributing to their pathogenesis, 
and in consequence, providing a useful diagnostic marker. 
 




Animal models have demonstrated the enhanced biological responses in the haematopoietic 
and immune system of Cbl family members when they are either genetically ablated or 
point mutated. It is in this context that the recent identification of mutations in CBL in 
patients with myeloid malignancies provides an important milestone (Table 5). Two groups 
simultaneously identified CBL mutations in Acute Myeloid Leukaemia (AML) patient 
samples (Sargin et al., 2007; Caligiuri et al., 2007). CBL mutations are most frequently 
observed in a distinct group of myeloid disorders named myelodysplastic 
syndromes/myeloproliferative neoplasms (MDS/MPN) that include: the Chronic 
Myelomonocytic Leukaemia (CMML), atypical Chronic Myeloid Leukaemia (aCML) and 
Juvenile Myelomonocytic Leukaemia (JMML). They originate from immature 
haematopoietic progenitors and are characterized by the production of dysplastic blood 
cells and myeloproliferative features. In most adult cases, mutations seem to be somatic, but 
germline mutations were reported in some JMML cases in children (Loh et al., 2009; 
Niemeyer et al., 2010; Martinelli et al., 2010). Genetic alterations in these haematological 
malignancies are strongly associated with hyperactivation of the Ras/MAPK signalling 
pathway due to activating mutations in signalling molecules involved in this pathway 
accounting for approximately 75%cases of JMML (Schubbert, et al., 2007). Strikingly, CBL 
mutations are found in 5% of aCML and up to 15% of JMML and CMML (Grand et al., 2009; 
Loh et al., 2009; Muramatsu et al., 2010; Shiba et al., 2010; Dunbar et al., 2008; Sanada et al., 
2009). Most CBL mutations associated with myeloid malignancies are clustered around the 
linker and the RING finger domains and in vitro studies with these mutants have shown 
their lack of E3 ubiquitin ligase activity (Sargin et al., 2007; Grand et al., 2009; Sanada et al., 
2009). Complete loss of CBL, deletions or mutations outside the linker/RING finger domains 
are rare, as well as mutations in CBLB. These findings suggest that expression of mutant Cbl 
proteins act as dominant negative inhibitor of wild-type Cbl or even of lost Cbl expression. 
A remarkable genetic feature of c-CBL mutations in these myeloid neoplasms is that 
mutations are homozygous in most cases, as a result of duplication of the mutated parental 
copy of 11q (where the CBL gene resides) and loss of the remaining wild-type allele, a 
genetic process called “acquired uniparental disomy” (aUPD) (Grand et al., 2009). This 
feature underlies the gain-of-function nature, rather than a loss-of-function, of the CBL 
mutations and may represent a defining oncogenic event.  Indeed, mutations involving 
RUNX1, JAK2, FLT3 and TP53 have been shown to coexist with CBL mutations in myeloid 
neoplasms (Sanada et al., 2009; Perez et al., 2010; Tefferi, 2010; Makishima et al., 2011) 
suggesting that additional oncogenic events may contribute to the mutant Cbl-driven 
leukemogenic process. 
SOCS proteins 
There is now emerging evidence that SOCS expression is differentially regulated during Th 
cell differentiation and in Th-driven inflammatory diseases (Table 5). In Th1 inflammatory 
diseases (rheumatoid arthritis, ulcerative colitis, Crohn disease, contact and atopic 
dermatitis), SOCS1 expression is observed in  lymphocytes and macrophages, as well as 
keratinocytes and stromal cells that are capable of antigen presentation, but granulocytes are 
negative (Egan et al., 2003; Federici et al., 2002). Importantly, SOCS3 expression levels seem 
to correlate with the severity of this type of inflammatory diseases (Seki et al., 2003; Shouda 
et al., 2001; Suzuki et al., 2001). The same is true for Th2-driven asthma that promotes 
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keratinocytes and stromal cells that are capable of antigen presentation, but granulocytes are 
negative (Egan et al., 2003; Federici et al., 2002). Importantly, SOCS3 expression levels seem 
to correlate with the severity of this type of inflammatory diseases (Seki et al., 2003; Shouda 
et al., 2001; Suzuki et al., 2001). The same is true for Th2-driven asthma that promotes 
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lymphocyte, basophile and mast cell infiltration, where SOCS3 expression in Th2 
lymphocytes is elevated. Furthermore, the association of the function of SOCS molecules in 
the allergic response has been supported by human studies analyzing the association of 
polymorphisms in SOCS genes with allergic disease in people. Interestingly, an association 
of a promoter polymorphism leads to a promoter with modified activity in vitro, suggesting 
that changes in SOCS1 expression can have considerable effects on disease manifestations in 
patients (Harada et al., 2007). SOCS1 expression has been found decreased in some human 
cancers including hepatocellular carcinoma and myeloproliferative neoplasms and this is 
frequently associated with hyper-methylation of one or more SOCS genes (Yoshikawa et al., 
2001; Watanabe et al., 2004; Quentmeier et al., 2008; Chaligné et al., 2009). In some cases, this 
methylation has been correlated to the degree of malignancy (Okochi et al., 2003; Yoshida et 
al., 2004). These observations strongly suggest that SOCS proteins may be tumour 
suppressors. Loss of SOCS expression may then contribute or favour tumour progression in 
synergy with other oncogenes. SOCS expression has also been implicated in the resistance to 
interferon in haematopoietic malignancies, such as leukaemia, lymphomas and multiple 
myeloma (Sakamoto et al., 2000, Sakai et al., 2002). Persistent expression of SOCS1 and/or 
SOCS3 has been detected in cutaneous T-cell lymphoma (CTCL), chronic myeloid leukaemia 
(CML), and some acute leukaemia (Brender et al., 2001b; Cho-Vega et al., 2004; Roman-
Gomez et al., 2004). In these circumstances, elevated expression of SOCS coincides with 
constitutive activation of JAK/STAT pathways. Moreover, in certain myeloproliferative 
neoplasm, SOCS3 has been found hyper-phosphorylated, which enhances the half-life of the 
protein but interferes with its regulatory function (Hookham et al., 2007; Elliott et al., 2009; 
Suessmuth et al., 2009). These data suggests that perturbed SOCS expression may contribute 
to the malignant phenotype and favour disease progression, rather than being an early 
event in the oncogenic process. 
6. Therapeutic application of inhibitory adaptors 
Given the central role played by inhibitory adaptors in the regulation of different aspects of 
haematopoietic and immune cell function, they are predicted to serve as excellent new 
targets in the development of anti-oncogenic, anti-inflammatory and immunosuppressor 
reagents. The advantage of these adaptors as targets is their restricted expression in cells of 
the haematopoietic and immune system, at least of some of the members in the different 
families discussed here. The disadvantage for some of them (Dok, Lnk) is their lack of 
enzymatic activity for drug targeting. However, this can be surpassed by utilizing strategies 
based in the direct inhibition or blockade of their specific protein-protein interactions for 
targeting a particular signalling pathway. This approach relies on the current information 
available on the molecular structure of the adaptor functional domains and the 
identification of specific sequences or residues involved in the adaptor/partner interaction. 
In some pathological contexts, the association of the inhibitory adaptor with mutated or 
oncogenic forms of its targets is modified from that engaged with its normal counterpart 
(Baran-Marszak et al., 2010). These findings open the possibility to use the binding sequence 
in the adaptor to exclusively inhibit the oncogenic protein and signalling pathway, while 
sparing the normal cell signalling cascades. Indeed, successful development of small 
molecule inhibitors of protein-protein interaction has begun to emerge, validating it as a 
practical approach (Azmi & Mohammad, 2009). The use of dominant negative forms of 
these inhibitory proteins has also proved to be advantageous, notably for adaptors that have 
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shown dual functions, as positive and negative regulators, as they allow modulate 
specifically their function depending on the cell type and biological response to be 
addressed. In the case of Lnk, its loss or inhibition causes the abnormal expansion and 
enhanced ability for engraftment of HSC (Takizawa et al., 2006); this feature can be used for 
bone marrow transplantation where the scarce number of these cells is always the limiting 
factor for the use of this therapy. 
On the other hand, adaptors with catalytic activity, like the Cbl and SOCS proteins, have the 
double advantage of being used as adaptors and as E3 ligase. In the case of Cbl, it is clear 
that its ligase activity is central to the regulation of many oncogenic proteins, so drugs that 
could enhance this activity may provide new therapeutic strategies for limiting their 
constitutive signalling. A potential strategy is the screening for molecules that could mimic 
the activation of its E3 activity while retaining its targets binding. This can be use in 
basophile and mast cells of allergic patients as a therapy to treat allergy diseases. In the case 
of SOCS, a strategy based in the delivery of the SOCS3 protein using a recombinant cell 
penetrating moiety has proved to increase the concentration and activity of SOCS3 in the 
cells and suppressed the effects of acute inflammation (Jo et al., 2005).  Moreover, 
therapeutic trials using SOCS antisense oligonucleotide, small hairpin RNA and peptide 
mimetics are currently investigated in animal models (Yoshimura et al., 2007). Importantly, 
a better understanding of the spectrum of signalling alterations provoked by mutant forms 
of the inhibitory adaptors identified in human pathologies is likely to reveal therapeutic 
strategies for patients with these mutations. In this context, the association of single 
nucleotide polymorphisms (SNP) in the genes of some of these adaptors (LNK, SOCS) with 
different inflammatory, myeloproliferative and vascular diseases suggests the implication of 
these molecules as risk factor and their potential use as biomarkers in these diseases. Lastly, 
future challenges in the study of inhibitory adaptors lie also in the development of 
performing techniques that will allow accurate monitoring of their signalling complexes at 
the molecular level. Indeed, precise regulation of protein interactions is of medical 
relevance, as modifications in the composition or localization of crucial components of these 
signalling networks can lead to the development of human diseases. 
7. Conclusions 
Over the past decade, it has become clear the pivotal role that cytokines play in the 
development and pathology of human diseases, including those of the haematopoietic and 
immune system. They perform their actions by regulating essential biological functions, 
such as cell proliferation, differentiation, cell morphology and migration. It is therefore not 
surprising that cytokine signal transduction pathways are tightly regulated. To achieve this, 
they have set up a variety of mechanisms and the rate at which the signal is turned off will 
be due to the net effect of all of these regulatory pathways. Although initially identified and 
best understood as mediators of positive signalling, adaptors have also shown an equally 
critical role in the negative control of signalling events. Inhibitory adaptors have been 
demonstrated important for maintaining homeostasis by preventing inappropriate cellular 
activation (Lnk, Cbl), by localizing enzymatically active regulatory molecules to specific 
subcellular compartments (Dok), and/or by terminating signalling cascades once they are 
initiated through targeting activated mediators to degradative pathways (Cbl, SOCS). In 
doing so, these molecules act upon three key signalling intermediates (the receptor, 
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lymphocyte, basophile and mast cell infiltration, where SOCS3 expression in Th2 
lymphocytes is elevated. Furthermore, the association of the function of SOCS molecules in 
the allergic response has been supported by human studies analyzing the association of 
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of a promoter polymorphism leads to a promoter with modified activity in vitro, suggesting 
that changes in SOCS1 expression can have considerable effects on disease manifestations in 
patients (Harada et al., 2007). SOCS1 expression has been found decreased in some human 
cancers including hepatocellular carcinoma and myeloproliferative neoplasms and this is 
frequently associated with hyper-methylation of one or more SOCS genes (Yoshikawa et al., 
2001; Watanabe et al., 2004; Quentmeier et al., 2008; Chaligné et al., 2009). In some cases, this 
methylation has been correlated to the degree of malignancy (Okochi et al., 2003; Yoshida et 
al., 2004). These observations strongly suggest that SOCS proteins may be tumour 
suppressors. Loss of SOCS expression may then contribute or favour tumour progression in 
synergy with other oncogenes. SOCS expression has also been implicated in the resistance to 
interferon in haematopoietic malignancies, such as leukaemia, lymphomas and multiple 
myeloma (Sakamoto et al., 2000, Sakai et al., 2002). Persistent expression of SOCS1 and/or 
SOCS3 has been detected in cutaneous T-cell lymphoma (CTCL), chronic myeloid leukaemia 
(CML), and some acute leukaemia (Brender et al., 2001b; Cho-Vega et al., 2004; Roman-
Gomez et al., 2004). In these circumstances, elevated expression of SOCS coincides with 
constitutive activation of JAK/STAT pathways. Moreover, in certain myeloproliferative 
neoplasm, SOCS3 has been found hyper-phosphorylated, which enhances the half-life of the 
protein but interferes with its regulatory function (Hookham et al., 2007; Elliott et al., 2009; 
Suessmuth et al., 2009). These data suggests that perturbed SOCS expression may contribute 
to the malignant phenotype and favour disease progression, rather than being an early 
event in the oncogenic process. 
6. Therapeutic application of inhibitory adaptors 
Given the central role played by inhibitory adaptors in the regulation of different aspects of 
haematopoietic and immune cell function, they are predicted to serve as excellent new 
targets in the development of anti-oncogenic, anti-inflammatory and immunosuppressor 
reagents. The advantage of these adaptors as targets is their restricted expression in cells of 
the haematopoietic and immune system, at least of some of the members in the different 
families discussed here. The disadvantage for some of them (Dok, Lnk) is their lack of 
enzymatic activity for drug targeting. However, this can be surpassed by utilizing strategies 
based in the direct inhibition or blockade of their specific protein-protein interactions for 
targeting a particular signalling pathway. This approach relies on the current information 
available on the molecular structure of the adaptor functional domains and the 
identification of specific sequences or residues involved in the adaptor/partner interaction. 
In some pathological contexts, the association of the inhibitory adaptor with mutated or 
oncogenic forms of its targets is modified from that engaged with its normal counterpart 
(Baran-Marszak et al., 2010). These findings open the possibility to use the binding sequence 
in the adaptor to exclusively inhibit the oncogenic protein and signalling pathway, while 
sparing the normal cell signalling cascades. Indeed, successful development of small 
molecule inhibitors of protein-protein interaction has begun to emerge, validating it as a 
practical approach (Azmi & Mohammad, 2009). The use of dominant negative forms of 
these inhibitory proteins has also proved to be advantageous, notably for adaptors that have 
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shown dual functions, as positive and negative regulators, as they allow modulate 
specifically their function depending on the cell type and biological response to be 
addressed. In the case of Lnk, its loss or inhibition causes the abnormal expansion and 
enhanced ability for engraftment of HSC (Takizawa et al., 2006); this feature can be used for 
bone marrow transplantation where the scarce number of these cells is always the limiting 
factor for the use of this therapy. 
On the other hand, adaptors with catalytic activity, like the Cbl and SOCS proteins, have the 
double advantage of being used as adaptors and as E3 ligase. In the case of Cbl, it is clear 
that its ligase activity is central to the regulation of many oncogenic proteins, so drugs that 
could enhance this activity may provide new therapeutic strategies for limiting their 
constitutive signalling. A potential strategy is the screening for molecules that could mimic 
the activation of its E3 activity while retaining its targets binding. This can be use in 
basophile and mast cells of allergic patients as a therapy to treat allergy diseases. In the case 
of SOCS, a strategy based in the delivery of the SOCS3 protein using a recombinant cell 
penetrating moiety has proved to increase the concentration and activity of SOCS3 in the 
cells and suppressed the effects of acute inflammation (Jo et al., 2005).  Moreover, 
therapeutic trials using SOCS antisense oligonucleotide, small hairpin RNA and peptide 
mimetics are currently investigated in animal models (Yoshimura et al., 2007). Importantly, 
a better understanding of the spectrum of signalling alterations provoked by mutant forms 
of the inhibitory adaptors identified in human pathologies is likely to reveal therapeutic 
strategies for patients with these mutations. In this context, the association of single 
nucleotide polymorphisms (SNP) in the genes of some of these adaptors (LNK, SOCS) with 
different inflammatory, myeloproliferative and vascular diseases suggests the implication of 
these molecules as risk factor and their potential use as biomarkers in these diseases. Lastly, 
future challenges in the study of inhibitory adaptors lie also in the development of 
performing techniques that will allow accurate monitoring of their signalling complexes at 
the molecular level. Indeed, precise regulation of protein interactions is of medical 
relevance, as modifications in the composition or localization of crucial components of these 
signalling networks can lead to the development of human diseases. 
7. Conclusions 
Over the past decade, it has become clear the pivotal role that cytokines play in the 
development and pathology of human diseases, including those of the haematopoietic and 
immune system. They perform their actions by regulating essential biological functions, 
such as cell proliferation, differentiation, cell morphology and migration. It is therefore not 
surprising that cytokine signal transduction pathways are tightly regulated. To achieve this, 
they have set up a variety of mechanisms and the rate at which the signal is turned off will 
be due to the net effect of all of these regulatory pathways. Although initially identified and 
best understood as mediators of positive signalling, adaptors have also shown an equally 
critical role in the negative control of signalling events. Inhibitory adaptors have been 
demonstrated important for maintaining homeostasis by preventing inappropriate cellular 
activation (Lnk, Cbl), by localizing enzymatically active regulatory molecules to specific 
subcellular compartments (Dok), and/or by terminating signalling cascades once they are 
initiated through targeting activated mediators to degradative pathways (Cbl, SOCS). In 
doing so, these molecules act upon three key signalling intermediates (the receptor, 
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JAK/other kinases, and STATs/downstream effectors) to completely switch off the signal. 
In contrast to SOCS and Lnk, which are induced in response to cytokines, Cbl and Dok (with 
the exception of Dok-2 in some cases) are constitutively present in the cell and may therefore 
function as more acute, early response regulators. The timing and specificity of each of these 
mechanisms, as well as how the inhibitors interact and cooperate with each other, is still an 
area for future investigation. Furthermore, the fact that the expression of these adaptors is 
itself regulated, points out further the complexity of the regulatory system. While gene-
targeting studies have highlighted critical roles for the inhibitory adaptors in immune 
function, haematological malignancy and inflammation, the complexity of the mouse 
models, particularly with regard to multi-gene families, suggests that these studies should 
be carefully interpreted, and certainly more work is required before we can predict the 
consequences of using these molecules or their agonists/antagonists in a clinical setting. 
Thus, one of the challenges for the future is sorting out the roles of negative regulators of 
cytokine signalling in all the existing pathways activated in response to cytokines. This 
knowledge is likely to yield both new and confirmatory findings, with the anticipation of a 
better understanding of how these adaptors orchestrate the functional activity and fate of 
many partners to produce the desired intensity of a signalling response. Although a great 
deal of research remains to be done to clarify the roles of these inhibitors and their mutant 
forms in human diseases such as cancer and inflammation, it can be foreseen that it will lead 
to the development of strategies based on the up- or down-regulation of their properties for 
therapeutic purposes. 
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1. Introduction  
Mature blood cells arise from hematopoietic stem cells (HSCs) capable of generating every 
hematopoietic cell type; including the various lymphoid and myeloid lineages. To maintain 
the steady state levels of hematopoietic cells in the circulation, each HSC has the capacity to 
generate large numbers of mature cells daily via various multi- and oligopotent lineage-
committed progenitors (Kondo et al., 2003; Orkin, 2000). Finely tuned self-renewal and 
differentiation programs, controlled by essential transcriptional regulatory networks 
(Miranda-Saavedra & Gottgens, 2008), determine the HSC and progenitor pool sizes in 
adults. These regulatory networks include both positive and negative transcriptional 
regulators that control lineage specific gene expression and ensure normal hematopoietic 
cell differentiation.  Deregulation of these transcriptional networks caused by aberrant 
upstream signalling, point mutations as well as chromosomal translocations of key 
transcriptional regulators particularly within the HSC compartment (Bonnet & Dick, 1997) 
can lead to various blood related disorders including anemia and hematological 
malignancies or leukemia.  
The origins of HSCs during the development of a mammalian embryo are only beginning to 
be understood. Tracing of the true stem cells via marker analysis is difficult and the ‘gold 
standard’ for identifying these cells is based on their ability to reconstitute lethally 
irradiated hosts over a long term. Various transplantation studies in the mouse (Dzierzak & 
Medvinsky, 2008)  have revealed that HSCs arise in a complex developmental process 
during which multipotent progenitors sequentially migrate to several anatomical sites 
(Dzierzak & Speck, 2008; Orkin & Zon, 2008), including the yolk sac, the aorta-
gonadomesonephros (AGM) region, placenta, fetal liver and finally the bone marrow in the 
adult (Palis et al., 2001). Lately, it is thought that the first definitive adult-type of HSCs are 
generated in the AGM region at embryonic day (E) 10.5 in the mouse (de Bruijn et al., 2002). 
It was demonstrated through fate mapping that the first HSCs arise as part of the 
hematopoietic progenitor clusters that emerge from the hemogenic endothelium and 
subendothelial layers at the ventral part of the dorsal aorta and in the vitelline artery 
(Rybtsov et al., 2011; Yokomizo et al., 2011). These small cell clusters of hematopoietic 
progenitors are closely associated with the endothelium and originate from vascular 
remodelling and extravascular budding (Boisset et al., 2010; Robin et al., 2011; Zovein et al., 
2010). This involves changes in endothelial cell shape and loss of cellular adhesion that have 
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been likened to the changes in cell adhesion that epithelial cells undergo during epithelial to 
mesenchymal transition (EMT). EMT encompasses a series of events in which well-
polarized epithelial cells round up in shape, lose their cell contacts and acquire the motile, 
migratory properties of mesenchymal cells (Greenburg & Hay, 1982). EMT is essential for 
many developmental processes including mesoderm formation during gastrulation and 
neural crest delamination and migration (Kalluri & Weinberg, 2009; Thiery et al., 2009). 
Similar EMT-like changes in cellular morphology can be observed during tumor progression 
and allow tumor cells to acquire the capacity to invade into the surrounding tissue and 
ultimately metastasize to a distant site (Berx et al., 2007). Subsequent tissue colonization 
occurs via a reverse transitional mechanism, called mesenchymal to epithelial transition 
(MET) (Kalluri, 2009). Significant cross talk and interactions between members of the Snai 
family and Zeb family of transcription factors have been documented to be involved in the 
regulation of these EMT/MET processes (Thiery & Sleeman, 2006). More recently, it has 
been suggested that the expression of the EMT regulators are also involved in the 
formation/acquisition of (cancer) stem cell properties (Gupta et al., 2009). In addition to 
their roles in epithelial/mesenchymal biology there is accumulating evidence that these 
EMT inducers may be involved in several aspects of hematopoietic differentiation and 
hematological malignancies that is the main focus of this chapter and are reviewed below.   
2. EMT regulators of the Snai family  
Members of Snai family encode for transcription factors with a common structural 
organization consisting of a highly conserved C-terminal region with four to six C2H2 zinc-
fingers (Knight & Shimeld, 2001) and a more divergent N-terminal region (Fig. 1). This zinc-
finger domain serves as a sequence-specific DNA binding domain that recognizes consensus 
E2-box type elements C/A(CAGGTG)  (Batlle et al., 2000; Cano et al., 2000; Mauhin et al., 
1993). All vertebrate Snai family members share as well an evolutionary conserved 7-9 AA 
N-terminus, the SNAG (Snail/Gfi) domain (Grimes et al., 1996). This domain was originally 
identified as a repressor domain in the zinc-finger protein Gfi1 that acts as a molecular hook 
to recruit co-regulators and/or demethylases and is essential for their Snai transcriptional 
repressive function (Lin et al., 2010). 
Snail (also known as Snai1, Sna, Snah, Slugh2, Snail1.) represents the founding member of 
the superfamily (Manzanares et al., 2001; Nieto, 2002) and was first described in Drosophila 
melanogaster (Grau et al., 1984). In mammals, besides Snail two other Snail family members 
were identified Slug (aka Snai2, Slugh1, Slugh, Snail2) and Smuc (aka Snai3, Zfp293, 
Znf293). Snail and Slug are the best characterized and have been implicated in the formation 
of the mesoderm (Boulay et al., 1987; Sefton et al., 1998) and neural crest cell migration  (del 
Barrio & Nieto, 2002; LaBonne & Bronner-Fraser, 2000) as well as with the loss of epithelial 
features associated with the acquisition of a fibroblast-like motile and invasive phenotype of 
tumor cells. Induced expression of Snail or Slug in various epithelial cancer cell lines either 
by FGF, Wnt, Notch or TGF administration (De Craene et al., 2005) or directly via ectopic 
expression of the repressors is sufficient to adopt a more mesenchymal morphology (Cano 
et al., 2000). This phenotypic switch is characterized by the downregulation of a number of 
epithelial marker genes (E-cadherin, desmoplakin, Muc-1, cytokeratin-18) (Batlle et al., 2000; 
Cano et al., 2000) and the induction of various mesenchymal marker genes (vimentin, 
fibronectin) (Cano et al., 2000), which can vary dependent on the cellular context. Several 
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lines of evidence indicated that Snail family members not only regulate cellular adhesion 
and motility or invasion but as well can bind and regulate genes that participate in other 
processes (Wu Y. & Zhou, 2010) like proliferation (CyclinD1) (Liu J. et al. 2010), cell 
survival/apoptosis (BID, caspase-6) (Kajita et al., 2004), inflammation (Lyons et al., 2008; 
Yang & Wolf, 2009) and angiogenesis (Gill et al. 2011). 
 
Fig. 1. Schematic diagram of conserved functional domains of the three members of the Snai 
family of transcription factors. All  members contain an N-terminal SNAG domain and a C-
terminal zinc-finger (ZF) domain. The central SLUG-domain is unique for Slug (Figure 
based on Cobaleda et al., 2007)   
Besides this, Snai gain-of-function is correlated with the acquisition of (cancer) stem cell 
properties (Gupta et al., 2009). Studies of various neoplastic tissues have demonstrated the 
existence of cancer stem cells (CSC) or tumor-initiating-cells with self-renewal capacity that 
exhibit an ability to induce new tumors when transplated into nude and/or syngeneic 
mouse strains (Schatton et al., 2009). The existence of CSCs was initially discovered in 
leukemia samples (Bonnet & Dick, 1997), but subsequently they have been identified in 
various solid tumor types as well (Al-Hajj et al., 2003; Ricci-Vitiani et al., 2007; Singh et al., 
2004). The origin of these stem cells is until now unclear but compelling results from Mani 
and colleagues (Mani et al., 2008) now link EMT processes with the formation of CSCs. 
Ectopic expression of Snail in an immortalized human mammary epithelial cell line resulted 
in the acquisition of mesenchymal traits, expression of stem cell markers and enhanced 
capacity to form mammospheres, a property previously and exclusively associated with 
mammary epithelial stem cells. For now it is unclear whether this is restricted to cancer stem 
cells of an epithelial origin or can be generalized to all (cancer) stem cells. Somewhat 
contradictory to this, is the recent findings that suppression of EMT inducers and the 
expression of E-cadherin  is one of the first essential steps during the reprogramming of 
fibroblasts for the generating induced pluripotent stem cells (Li et al., 2010; Redmer et al., 
2011; Wang et al., 2010). This may reflect the fact that stemness properties and totipotency 
are not equivalent and may be controlled by divergent molecular mechanisms.  
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Yang & Wolf, 2009) and angiogenesis (Gill et al. 2011). 
 
Fig. 1. Schematic diagram of conserved functional domains of the three members of the Snai 
family of transcription factors. All  members contain an N-terminal SNAG domain and a C-
terminal zinc-finger (ZF) domain. The central SLUG-domain is unique for Slug (Figure 
based on Cobaleda et al., 2007)   
Besides this, Snai gain-of-function is correlated with the acquisition of (cancer) stem cell 
properties (Gupta et al., 2009). Studies of various neoplastic tissues have demonstrated the 
existence of cancer stem cells (CSC) or tumor-initiating-cells with self-renewal capacity that 
exhibit an ability to induce new tumors when transplated into nude and/or syngeneic 
mouse strains (Schatton et al., 2009). The existence of CSCs was initially discovered in 
leukemia samples (Bonnet & Dick, 1997), but subsequently they have been identified in 
various solid tumor types as well (Al-Hajj et al., 2003; Ricci-Vitiani et al., 2007; Singh et al., 
2004). The origin of these stem cells is until now unclear but compelling results from Mani 
and colleagues (Mani et al., 2008) now link EMT processes with the formation of CSCs. 
Ectopic expression of Snail in an immortalized human mammary epithelial cell line resulted 
in the acquisition of mesenchymal traits, expression of stem cell markers and enhanced 
capacity to form mammospheres, a property previously and exclusively associated with 
mammary epithelial stem cells. For now it is unclear whether this is restricted to cancer stem 
cells of an epithelial origin or can be generalized to all (cancer) stem cells. Somewhat 
contradictory to this, is the recent findings that suppression of EMT inducers and the 
expression of E-cadherin  is one of the first essential steps during the reprogramming of 
fibroblasts for the generating induced pluripotent stem cells (Li et al., 2010; Redmer et al., 
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are not equivalent and may be controlled by divergent molecular mechanisms.  
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Recently, the in vivo functions of Snail and Slug could be further analyzed by the generation 
of novel gain/loss-of-function mouse models. Here we shall focus more on the 
hematopoietic phenotypes observed in these mouse models. 
2.1 Slug is an important downstream mediator of SCF/cKit signaling and plays pivotal 
roles in stress-induced hematopoietic stem/progenitor cell survival and self-renewal 
The first evidence of an important role for Slug in hematopoiesis and leukemia came from 
study by Inukai et al. (1999) in which Slug was identified as a downstream target of the 
E2A-HLF oncogene in leukemic B-cells. The E2A-HLF fusion gene transforms human pro-B 
lymphocytes by interfering with the apoptotic signaling pathway at an early step. Moreover, 
Slug expression in IL3-dependent Baf-3 cells prolonged the survival of these cells 
significantly after deprivation of the cytokine. These initial data suggested a pivotal role for 
Slug in the cell survival pathway of lymphocyte progenitor cells and possibly as well in 
other hematopoietic progenitors, based on its expression profile. Endogenous Slug is 
normally expressed in both long- and short-term repopulating HSCs and in committed 
progenitors of the myeloid lineage but not in differentiated myeloid cells or pro-B or pro-T 
cells.  Its role in other lineages was further investigated in vivo by the generation of Slug 
deficient mice. Mice lacking Slug survive and are fertile, but display postnatal growth 
retardation phenotypes (Inoue et al., 2002). Upon loss of Slug, normal circulating blood cell 
counts were observed but the number of hematopoietic colony-forming progenitors in the 
bone marrow and spleen were significantly (2-4-fold) increased. This suggested that in the 
absence of Slug, hematopoietic progenitor pools must expand to maintain normal levels of 
differentiated blood cells in the circulation. In addition, Slug deficient mice are more radio-
sensitive; these mice not only died earlier upon -irradiation, but as well showed 
accentuated decreases in peripheral blood cell counts and marked increases in apoptotic 
(TUNEL+) bone marrow progenitors cells compared to their control littermates. These data 
implicated an important role for Slug in protecting hematopoietic progenitor cells from 
apoptosis after DNA damage (Inoue et al., 2002). By crossing the Slug knockout mice with 
various other mouse models it was demonstrated that Slug directly represses the 
proapoptotic factor Puma and in this way is able to antagonize the p53-mediated 
upregulation of Puma in -irradiated myeloid progenitor cells, allowing them to survive 
(Wu W.S. et al., 2005). All together these data suggest that Slug governs a pivotal checkpoint 
that controls cell survival/apoptosis decisions upon exposure to genotoxic stress. 
The role of Slug in the regulation of the bone marrow stem cell compartment was further 
investigated under both normal steady-state and stress conditions via competitive 
repopulating assays and serial bone marrow transplants (Sun et al., 2010). Under normal 
conditions, Slug deficiency seems to have no effect on proliferation or differentiation of HSC 
or progenitors. However, if transplanted, Slug null HSCs demonstated increased 
repopulating potential that was not a result of altered differentiation nor homing ability, 
suggesting Slug deficiency alters HSC self-renewal. Indeed this was confirmed under the 
stress conditions of serial bone marrow transplantation. Consistently, 5-FU treatment of 
Slug knockout mice showed an expansion of the Lin-Sca1+ cell population, not by changing 
their cell survival capacity but by increasing their proliferation rates (Sun et al., 2010).    
More detailed analysis of Slug deficient mice revealed macrocytic anemia as well as 
pigmentation deficiency and gonadal defects (Perez-Losada et al., 2002). These phenotypes 
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are  very similar to the defects reported in the white-spotting (W) and Steel (Sl) mutant mice 
with mutations in the c-Kit receptor (Chabot et al., 1988; Geissler et al., 1988) and its Stem 
Cell Factor (SCF) ligand (Copeland et al., 1990; Huang et al., 1990; Zsebo et al., 1990). The 
SCF/c-Kit signaling pathway has pleiotrophic functions in hematopoiesis and beyond. The 
primary function of SCF/c-Kit in early hematopoiesis seems to induce the growth of 
quiescent progenitor/stem cells through synergistic interactions with other early-acting 
cytokines (Migliaccio et al., 1991; Williams N. et al., 1992). Ample evidence indicates that in 
the absence of other cytokines, SCF selectively promotes viability rather than proliferation of 
primitive murine progenitor cells (Fleming et al., 1993) and confirms previous findings of 
Slug playing a role in both cell cycle/proliferation and cell survival/apoptosis. Next to its 
role in hematopoiesis, SCF/c-Kit signaling has been implicated in the 
development/migration of melanocytes (Nishikawa et al., 1991). In human piebaldism 
patients, c-Kit signaling has been demonstrated to be involved in congenital depigmented 
patches and poliosis, (Giebel & Spritz, 1991). Interestingly in some piebaldism patients, also 
heterozygous SLUG deletions could be detected, providing further genetic evidence that 
Slug may play crucial roles in the SCF/c-Kit signaling pathway (Sanchez-Martin et al., 
2003). The importance of Slug as a putative downstream mediator of c-Kit signaling was 
further tested by means of a complementation study in which transduction with TAT-Slug 
protein was sufficient to rescue the radio-sensitivity of c-Kit deficient mice. Taken together 
these data clearly demonstrate that Slug is an important mediator downstream of c-Kit 
receptor activation (Perez-Losada et al., 2003).  
The observed macrocytic anemia observed in the Slug mutant mice resemble in some ways 
human congenital anemias such as Diamond-Blackfan anemia (Perez-Losada et al., 2002), 
however more research is necessary to explore the involvement of Slug in this disease. 
2.2 Snail and Smuc in normal hematopoiesis  
Mice deficient for Snail are embryonic lethal at E7.5-8.5 due to defects in mesoderm 
formation (Carver et al., 2001) as well as vascular defects (Lomeli et al., 2009). Consequently, 
due to the early embryonic lethality, the effects of Snail loss on hematopoiesis could not be 
further investigated in these mice. Although some evidence exists that Snail is expressed in 
the hematopoietic system, more detailed research is necessary and final proof of its potential 
role in hematpoiesis will come from breeding the conditional floxed Snail mice (Murray S.A. 
et al., 2006) to mice with hematopoietic-specific transgenic Cre lines.  
Based upon the fact that in vitro Snail binds similar E-box binding domains and in general 
shows more drastic phenotypes both in vitro as in vivo compared to Slug, Snail may also play 
crucial roles in hematopoiesis. Interestingly, Snail and Slug in most cases can complement 
each other and differences in phenotypes can be explained by differences in expression 
patterns as exemplified by the aggravated phenotypes of the Snail/Slug double knockouts 
(Murray S.A. et al., 2007). In addition, loss of one Snai family member often induces or 
increases the expression of the other(s). In this way hematopoietic-specific double knockouts 
may reveal even more functions for Snail and Slug in normal hematopoiesis.     
More recently a third family member of the Snail family was identified in vertebrates, Smuc. 
Until now, little is known about its functions but it is abundantly expressed in thymocytes 
(Zhuge et al., 2005), specifically in the early CD4-CD8- double negative (DN) and 
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counts were observed but the number of hematopoietic colony-forming progenitors in the 
bone marrow and spleen were significantly (2-4-fold) increased. This suggested that in the 
absence of Slug, hematopoietic progenitor pools must expand to maintain normal levels of 
differentiated blood cells in the circulation. In addition, Slug deficient mice are more radio-
sensitive; these mice not only died earlier upon -irradiation, but as well showed 
accentuated decreases in peripheral blood cell counts and marked increases in apoptotic 
(TUNEL+) bone marrow progenitors cells compared to their control littermates. These data 
implicated an important role for Slug in protecting hematopoietic progenitor cells from 
apoptosis after DNA damage (Inoue et al., 2002). By crossing the Slug knockout mice with 
various other mouse models it was demonstrated that Slug directly represses the 
proapoptotic factor Puma and in this way is able to antagonize the p53-mediated 
upregulation of Puma in -irradiated myeloid progenitor cells, allowing them to survive 
(Wu W.S. et al., 2005). All together these data suggest that Slug governs a pivotal checkpoint 
that controls cell survival/apoptosis decisions upon exposure to genotoxic stress. 
The role of Slug in the regulation of the bone marrow stem cell compartment was further 
investigated under both normal steady-state and stress conditions via competitive 
repopulating assays and serial bone marrow transplants (Sun et al., 2010). Under normal 
conditions, Slug deficiency seems to have no effect on proliferation or differentiation of HSC 
or progenitors. However, if transplanted, Slug null HSCs demonstated increased 
repopulating potential that was not a result of altered differentiation nor homing ability, 
suggesting Slug deficiency alters HSC self-renewal. Indeed this was confirmed under the 
stress conditions of serial bone marrow transplantation. Consistently, 5-FU treatment of 
Slug knockout mice showed an expansion of the Lin-Sca1+ cell population, not by changing 
their cell survival capacity but by increasing their proliferation rates (Sun et al., 2010).    
More detailed analysis of Slug deficient mice revealed macrocytic anemia as well as 
pigmentation deficiency and gonadal defects (Perez-Losada et al., 2002). These phenotypes 
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are  very similar to the defects reported in the white-spotting (W) and Steel (Sl) mutant mice 
with mutations in the c-Kit receptor (Chabot et al., 1988; Geissler et al., 1988) and its Stem 
Cell Factor (SCF) ligand (Copeland et al., 1990; Huang et al., 1990; Zsebo et al., 1990). The 
SCF/c-Kit signaling pathway has pleiotrophic functions in hematopoiesis and beyond. The 
primary function of SCF/c-Kit in early hematopoiesis seems to induce the growth of 
quiescent progenitor/stem cells through synergistic interactions with other early-acting 
cytokines (Migliaccio et al., 1991; Williams N. et al., 1992). Ample evidence indicates that in 
the absence of other cytokines, SCF selectively promotes viability rather than proliferation of 
primitive murine progenitor cells (Fleming et al., 1993) and confirms previous findings of 
Slug playing a role in both cell cycle/proliferation and cell survival/apoptosis. Next to its 
role in hematopoiesis, SCF/c-Kit signaling has been implicated in the 
development/migration of melanocytes (Nishikawa et al., 1991). In human piebaldism 
patients, c-Kit signaling has been demonstrated to be involved in congenital depigmented 
patches and poliosis, (Giebel & Spritz, 1991). Interestingly in some piebaldism patients, also 
heterozygous SLUG deletions could be detected, providing further genetic evidence that 
Slug may play crucial roles in the SCF/c-Kit signaling pathway (Sanchez-Martin et al., 
2003). The importance of Slug as a putative downstream mediator of c-Kit signaling was 
further tested by means of a complementation study in which transduction with TAT-Slug 
protein was sufficient to rescue the radio-sensitivity of c-Kit deficient mice. Taken together 
these data clearly demonstrate that Slug is an important mediator downstream of c-Kit 
receptor activation (Perez-Losada et al., 2003).  
The observed macrocytic anemia observed in the Slug mutant mice resemble in some ways 
human congenital anemias such as Diamond-Blackfan anemia (Perez-Losada et al., 2002), 
however more research is necessary to explore the involvement of Slug in this disease. 
2.2 Snail and Smuc in normal hematopoiesis  
Mice deficient for Snail are embryonic lethal at E7.5-8.5 due to defects in mesoderm 
formation (Carver et al., 2001) as well as vascular defects (Lomeli et al., 2009). Consequently, 
due to the early embryonic lethality, the effects of Snail loss on hematopoiesis could not be 
further investigated in these mice. Although some evidence exists that Snail is expressed in 
the hematopoietic system, more detailed research is necessary and final proof of its potential 
role in hematpoiesis will come from breeding the conditional floxed Snail mice (Murray S.A. 
et al., 2006) to mice with hematopoietic-specific transgenic Cre lines.  
Based upon the fact that in vitro Snail binds similar E-box binding domains and in general 
shows more drastic phenotypes both in vitro as in vivo compared to Slug, Snail may also play 
crucial roles in hematopoiesis. Interestingly, Snail and Slug in most cases can complement 
each other and differences in phenotypes can be explained by differences in expression 
patterns as exemplified by the aggravated phenotypes of the Snail/Slug double knockouts 
(Murray S.A. et al., 2007). In addition, loss of one Snai family member often induces or 
increases the expression of the other(s). In this way hematopoietic-specific double knockouts 
may reveal even more functions for Snail and Slug in normal hematopoiesis.     
More recently a third family member of the Snail family was identified in vertebrates, Smuc. 
Until now, little is known about its functions but it is abundantly expressed in thymocytes 
(Zhuge et al., 2005), specifically in the early CD4-CD8- double negative (DN) and 
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CD4+CD8+ double positive (DP) stages of thymocyte maturation and then solely expressed 
in the CD8+ T lymphocyte lineage both in the thymus and peripheral immune system. In 
macrophages, Smuc is able to interact with PU.1, a master regulator of myeloid 
differentiation, and binds the negative regulatory element within the Pactolus promoter. 
These data suggests that Smuc is modulating the PU.1 transcriptional activity and lack of 
Smuc leads to aberrant PU.1 transactivation (Hale et al., 2006). 
2.3 Overexpression of Snail or Slug induces leukemia  
Based on the prominent roles of Snail and Slug in stress-induced hematopoiesis, and their 
roles in the progression of solid tumours, as well as acquisition of cancer stem cell 
characteristics, it is therefore surprising that only a limited number of studies have 
addressed the roles of Snai family members in hematopoietic malignancies.   
Nevertheless, strong evidence that Snail and Slug are involved in leukemia formation 
and/or progression comes from the gain-of-function mouse models that were previously 
developed. CombiTA-Snail mice, carrying a hypermorphic tetracycline-repressible Snail 
transgene, showed increased Snail expression up to 20% above normal levels (Perez-
Mancera et al., 2005b). These mice survive and are fertile and although no morphological 
alterations were observed, their thymus were smaller and showed reduced differentiation 
towards CD4+CD8+ DP thymocytes. From 5-7 months onwards, CombiTA-Snail mice 
started to develop various types of epithelial and non-epithelial cancers especially 
lymphomas and acute leukemias (> 75% in two separate transgenic lines). Suppression of 
the Snail transgene expression by tetracycline administration did not ameliorate the 
malignant phenotype, suggesting that the effect of Snail overexpression is irreversible. As 
well, CombiTA-Snail transgene expression resulted in increased in vivo radioprotection, 
suggesting similar roles for Snail in hematopoietic cell survival upon genotoxic stress as was 
previously shown for Slug. 
Similar experiments were performed for in vivo overexpression of Slug. In a similar setup as 
described above for Snail, CombiTA-Slug mice were generated. To prove transgene 
functionality, these mice were crossed with Slug deficient mice, which rescued the null 
phenotype. Again these mice were born without overt morphological abnormalities (Perez-
Mancera et al., 2006). Only after 6-8 months 20% of the transgenic mice died as a 
consequence of congestive heart failure.  The surviving mice started to develop various 
tumors from 9 months of age with highest incidence of (90%) acute leukemias (Perez-
Mancera et al., 2005a). Similar as to the CombiTA-Snail mice this malignant phenotype was 
irreversible after tetracycline administration. As well, c-Kit signaling has been implicated 
both in solid tumors as well as leukemias, e.g. constitutive activating mutations of the 
receptor have been described in AML (Jung et al., 2011) Furthermore, the BCR–ABL 
oncogene did not induce leukaemia in Slug-deficient mice, implicating Slug in BCR–ABL 
leukemogenesis in vivo (Perez-Mancera et al., 2005a). As well, in an independent study it 
was shown that the increased Slug expression upon Bcr-Abl mutations is involved in the 
prolonged survival of chronic myeloid leukemia cells (Mancini et al., 2010). 
From the Slug knockout mice it appears that it is governing a pivotal role in cell survival 
upon DNA damage by repressing the pro-apoptotic factor Puma. These results may be 
highly relevant for cancer therapy. Analyzing or controlling Slug levels before or during 
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treatment may be useful as a prognostic marker for sensitivity to genotoxic agents and can 
be helpful for limiting therapeutic doses or increasing the efficiency of radiation or 
chemotherapy.  
3. EMT regulators of the Zeb family 
The Zinc finger E-Box binding (ZEB) family of DNA-binding transcriptional regulators 
consists of two structurally related proteins (Fortini et al., 1991)(Fig. 2): Zeb1 (also known as 
EF-1, TCF8, BZP, ZEB, AREB6, NIL-2-A, Zfhep, and Zfhx1a) and Zeb2 (also known as Sip1, 
KIAA0569 and Zfhx1b). Both genes have a very similar genomic structures (Fortini et al., 
1991; Vandewalle et al., 2009) and encode for large multi-domain proteins that possess N-
terminal and C-terminal zinc finger DNA binding domains along with more centrally 
located homeo (HD), Smad protein binding (SBD) and CtBP interaction (CID) domains; and 
in the case of Zeb2, an N-terminal NuRD interaction domain (Verstappen et al., 2008). ¶ 
 
Fig. 2. Schematic diagram of conserved functional domains of the two members of the Zeb 
family of transcription factors. Both possess 2 zinc-finger domains, a homeodomain (HD), 
Smad (SBD) and CtBP (CID) binding domain (Figure based on Vandewalle et al., 2009) 
Especially within the Zn-finger domains there exists a high degree of sequence 
similarity/identity between the two Zeb proteins, suggesting they bind similar target 
sequences (Verschueren et al., 1999). Each Zn-finger cluster independently can bind a 5’-
CACCT(G)-3’ sequence located in the target promotor region (Remacle et al., 1999). The 
domains outside the Zn-finger clusters seem less conserved and may be essential for the 
recruitment of various co-repressors, like CtBP (Grooteclaes & Frisch, 2000;Postigo & Dean, 
1999b; van Grunsven et al., 2007) or co-activators like p300 or P/CAF (van Grunsven et al., 
2006). Still a lot of controversy exists over whether Zeb proteins can only act as 
transcriptional repressors or as well as activators. The molecular mechanism underlying the 
choice between repression or activation are currently unknown and may include cell-type 
specific differences and/or posttranslational modifications (Costantino et al., 2002). 
Similarly, the roles of Zeb proteins in TGF/BMP signaling are not well understood; both 
Zebs have been shown to be able to bind receptor activated R-Smads (Postigo, 2003; 
Verschueren et al., 1999). Postigo et al. (Postigo, 2003) postulated Zeb proteins as putative 
important downstream mediators of this signaling pathway however with opposing effects. 
While Zeb1 would synergize with Smad proteins to activate transcription of TGF 
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well, CombiTA-Snail transgene expression resulted in increased in vivo radioprotection, 
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leukemogenesis in vivo (Perez-Mancera et al., 2005a). As well, in an independent study it 
was shown that the increased Slug expression upon Bcr-Abl mutations is involved in the 
prolonged survival of chronic myeloid leukemia cells (Mancini et al., 2010). 
From the Slug knockout mice it appears that it is governing a pivotal role in cell survival 
upon DNA damage by repressing the pro-apoptotic factor Puma. These results may be 
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Fig. 2. Schematic diagram of conserved functional domains of the two members of the Zeb 
family of transcription factors. Both possess 2 zinc-finger domains, a homeodomain (HD), 
Smad (SBD) and CtBP (CID) binding domain (Figure based on Vandewalle et al., 2009) 
Especially within the Zn-finger domains there exists a high degree of sequence 
similarity/identity between the two Zeb proteins, suggesting they bind similar target 
sequences (Verschueren et al., 1999). Each Zn-finger cluster independently can bind a 5’-
CACCT(G)-3’ sequence located in the target promotor region (Remacle et al., 1999). The 
domains outside the Zn-finger clusters seem less conserved and may be essential for the 
recruitment of various co-repressors, like CtBP (Grooteclaes & Frisch, 2000;Postigo & Dean, 
1999b; van Grunsven et al., 2007) or co-activators like p300 or P/CAF (van Grunsven et al., 
2006). Still a lot of controversy exists over whether Zeb proteins can only act as 
transcriptional repressors or as well as activators. The molecular mechanism underlying the 
choice between repression or activation are currently unknown and may include cell-type 
specific differences and/or posttranslational modifications (Costantino et al., 2002). 
Similarly, the roles of Zeb proteins in TGF/BMP signaling are not well understood; both 
Zebs have been shown to be able to bind receptor activated R-Smads (Postigo, 2003; 
Verschueren et al., 1999). Postigo et al. (Postigo, 2003) postulated Zeb proteins as putative 
important downstream mediators of this signaling pathway however with opposing effects. 
While Zeb1 would synergize with Smad proteins to activate transcription of TGF 
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responsive reporter constructs, the structurally very similar Zeb2 would inhibit 
transcriptional activation donwstream of TGF(Postigo, 2003). These antagonistic effects 
were hypothesized to result from differential recruitment of co-activators and co-repressors 
to the Smads by Zeb1 or Zeb2 respectively (Postigo et al., 2003). 
The Zeb family of zinc finger/homeodomain proteins genes was first idenfied in Drosphila 
melanogaster (Fortini et al., 1991) and shown to be essential for myogenesis (Postigo et al., 1999) 
and the organization of the central nervous system (Clark & Chiu, 2003).  As well in 
vertebrates a vast number of muscle master regulatory genes have been shown to be repressed 
directly by Zeb1/2 (7 integrin, crystalin enhancer, Mef2c) (Postigo & Dean, 1997, 1999a) as 
well as genes essential for cartilage and bone formation (Col21) (Murray D. et al., 2000). The 
first functional studies in Xenopus proved Zeb1 to be essential for the expression of XBra 
(Xenopus Brachyury) (Papin et al., 2002), a member of T-box family of transcription factor 
essential for mesoderm formation and notochord differentiation and previously been 
implicated in EMT processes. Subsequently various in vitro studies using multiple epithelial 
cancer cell lines, it was demonstrated that both Zeb1/2 are able to bind and downregulate E-
cadherin (Comijn et al., 2001; Eger et al., 2005) and other epithelial-specific marker genes via 
binding bipartite E-boxes in their promotor regions. Exogeneous Zeb1/2 overexpression 
results in EMT-like phenotypes similarly as described above for the Snai family members of 
EMT inducers (Comijn et al., 2001; Vandewalle et al., 2005). Increased in vivo Zeb1/2 
expression has been correlated in various tumor types with increased invasion, metastasis, 
dedifferentiation, cancer stem cell characteristics, recurrence and bad prognosis (Spaderna et 
al., 2006; Spoelstra et al., 2006; Wellner et al., 2009; Yoshihara et al., 2009).  
Besides their roles in suppression of epithelial marker genes more and more studies 
revealed their participation in other cellular processes like cell division (Mejlvang et al., 
2007), apoptosis and senescence (Liu Y. et al., 2008; Ozturk et al., 2006; Sayan et al., 2009) 
and inflammation (Chua et al., 2007). 
From expression analysis it was clear that both Zeb proteins are also expressed in the 
hematopoietic system.  Actually, Zeb1 has been demonstrated to be more expressed during T-
lymphocyte development, while Zeb2 expression has been seen more in splenic B cells (Postigo 
& Dean, 2000). Using various novel mouse models recent data clearly indicated that this family 
of EMT inducers also plays pivotal roles in various steps of hematopoietic differentiation and 
progression of hematopoietic malignancies, which are discussed in detail below.  
3.1 Role of Zeb2 in hematopoietic stem/progenitor differentiation and mobilization 
Moderate to high Zeb2 expression is reported in all hematopoietic cells with highest levels 
in stem (HSC) and progenitor (HPC) populations (Goossens et al., 2011) and lowest 
expression in mature T cells (Postigo & Dean, 2000). Through the use of a conditional Zeb2 
knockout mouse (Higashi et al., 2002) model we could show that it is not essential for the 
initial formation of HSCs in the embryo but it is crucial for HSC differentiation and 
mobilization/homing (Goossens et al., 2011). Hematopoietic-specific Zeb2 loss-of-function 
resulted in embryonic lethality resulting from bleedings occurring in the developing brain. 
The observed phenotype is very reminiscent of the phenotypes associated with ubiquitous 
loss of the hematopoietic transcriptional regulators AML/Runx1 (Okuda et al., 1996). Runx1 
knockout embryos are deficient in AGM HSCs and lack intra-arterial hematopoietic clusters, 
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suggesting that Zeb2 deletion may also affect hematopoietic cluster formation. However, no 
changes in the number of hematopoietic progenitor clusters was detected for the Zeb2 null 
AGM regions (Goossens et al., 2011) indicating that the formed stem cells are not functional 
at later stages of development. Zeb2 seems to be more involved in stem/progenitor 
differentiation properties as isolated progenitors from various developing hematopoietic 
organs were unable to differentiate in vitro. As well, significant decreases in fully 
differentiated hematopoietic cells were observed. Next to this differentiation block, an 
increased adhesion/clustering of hematopoietic cells in the fetal liver and less mobile 
progenitors in the peripheral blood were observed. It was hypothesized that the increased 
levels of Cxcr4 within the Zeb2 null progenitors lead to their retention in the fetal liver that 
resulted in less progenitors in the embryonic circulation. This decreased mobilization of 
hematopoietic progenitors likely contributed to the decreased levels of angiogenic factors 
(like Ang1) within the circulation, thereby resulting in less maturation and pericyte 
recruitment towards the newly formed vessels in the developing brain. Most probably this 
defect contributed to the observed cephalic bleeding phenotype. From this initial data it has 
become clear that Zeb2 is not only a crucial transcriptional regulator of hematopoietic 
differentiation but as well plays pivotal roles in the mobilization and homing of HSCs 
within the embryo (Goossens et al., 2011). More experiments need to be performed to 
analyze whether this also holds true in adult haematopoiesis.  
3.2 Role of Zeb1 in T cell development  
Neonatal Zeb1 total knockout mice die shortly after birth. Drastic skeletal abnormalities 
(Takagi et al., 1998) and serious thymic atrophy were observed. Through the use of a second 
Zeb1 loss-of-function mouse model, expressing a C-terminal zinc finger truncation allowed 
survival to adulthood, it was feasible to further investigate the in vivo role of Zeb1 in adult 
hematopoiesis (Higashi et al., 1997). In these C-fin mice no skeletal phenotypes were 
observed. On the other hand T lymphocyte differentiation was drastically impaired. This 
observation points towards the hypothesis that different domains of Zeb1 are responsible 
for alternative/synergistic functions, which as well was hypothesized previously by Postigo 
and colleagues via their in vitro approaches described above (Postigo & Dean, 1999a). More 
detailed FACS analysis of Zeb1 C-fin mutant thymocytes revealed a block at a very early 
stage in the cKit+ CD4-CD8-DN population, before rearrangements of the T cell receptor 
(TCR) locus (Higashi et al., 1997). Only a very small proportion of the intrathymic T cell 
precursors (<1%compared of the normal T cell development) was able to differentiate 
further and expressed differentiated T cell markers. These differentiated cells were skewed 
mainly towards CD4+CD8-SP cells, indicated that also at later stages of T cell development 
Zeb1 expression may play essential roles. More recently it was shown that Zeb1 binds the 5’ 
E-boxes in the proximal enhancer of the CD4 promoter and competes with the 
transcriptional activators E12 and HEB for DNA binding. Therefore it was concluded that 
overexpression of Zeb1 in T cells converts the CD4 proximal enhancer into a silencer 
element leading to a reduction of CD4 expression. This data shows that the CD4 gene is a 
direct target of the transcriptional repressor Zeb1 and can explain the increased proportion 
of CD4+CD8-SP mature T cells in Zeb1 mutant mice (Brabletz et al., 1999).   
Another known downstream target of Zeb1 during myogenesis is 4-integrin. Also in 
hematopoietic differentiation of various lineages 4-integrin is known to play crucial roles 
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responsive reporter constructs, the structurally very similar Zeb2 would inhibit 
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through its interaction with fibronectin and V-CAM in the stromal matrix and stromal cells 
of the bone marrow and fetal liver.  4-integrin is highly expressed in stem and progenitor 
cells and upon further differentiation its expression is restricted to lymphocytes and 
myeloid subpopulations. Zeb1 binds and directly represses 4-integrin expression (Postigo 
& Dean, 1999a). Previously it was shown that 4 integrin expression depends on C-Myb and 
Ets family of transcription factors. Based on in vitro 4-intregrin promotor analysis, Postigo 
(Postigo & Dean, 1997) concluded that Zeb1 blocks activity of c-Myb and Ets individually 
but together these synergize to overcome Zeb1 repression. Next to CD4 and 4 integrin, 
Zeb1 has been suggested to repress a number of other genes implicated in proper T cell 
differentiation like Gata3 (Gregoire & Romeo,  1999), immunoglobin heavy chain enhancer 
(Genetta et al.,1994) and interleukin-2 (Williams T.M. et al., 1991; Yasui et al., 1998).    
Within B-lymphocytes a functional cooperation between FoxO transcription factors and 
Zeb1 has been revealed. Zeb1 binds and activates two promotors of known FoxO target 
genes cyclin G2 and retinoblastoma-like 2. Both have been implicated in cell cycle arrest and 
Foxo-dependent quiescence in fibroblasts (Chen et al., 2006).   However a role of Zeb1 in B-
cell development has not been reported 
3.3 Role of Zeb1/2 in T and B cell acute lymphoblastic leukemia 
Using the same C-fin Zeb1 mutant mice described above it was demonstrated that 
expression of the truncated Zeb1 protein resulted in the development of spontaneous CD4+ 
T-cell lymphomas with a median onset at 30 weeks of age. This is consistent with the fact 
that ZEB1 expression is frequently lost in human adult T-cell leukemia/lymphoma (T-ALL) 
patients (Hidaka et al., 2008; Vermeer et al., 2008). In T-ALL cell lines it was demonstrated 
that the tumour cell’s resistance to TGF- mediated growth suppression is via up-regulation 
of the inhibitory Smad7 (Nakahata et al., 2010).  Here the role of Zeb proteins in the 
regulation of Smad7 remains needs to be better understood. Similarly the actual role of the 
other above described Zeb1 targets remains to be determined in T cell lymphomas.   
The role of Zeb1 in B-Cell leukemia has not been reported. However, in terms of 
hematological malignancy, some independent genome-wide retroviral insertional 
mutagenesis screens have identified Zeb2 and not Zeb1 as a possible gene involved in 
mouse B-cell lymphoma progression (Lund et al., 2002; Mikkers et al., 2002; Shin et al., 
2004). From these initial studies it was not clear if Zeb2 expression is lost due to retroviral 
integration and translocation events or enhanced during the transformation process.  More 
recently in CALM-AF10 transgenic mice, enhanced Zeb2 expression was found to correlate 
with increased leukemia progression (Caudell et al., 2010). Additionally, knockdown of 
Zeb2 in a B-ALL cell line resulted in decreased proliferation rates. However in vivo Zeb2 
overexpression studies are missing to be conclusive concerning the role of Zeb2 in 
leukemogenesis. Nevertheless, ZEB2 genomic locus rearrangements are commonly 
associated with aggressive B cell lymphomas in humans as well (Matteucci et al., 2008). 
4. Conclusions 
From the above literature survey it is clear that EMT inducers of the Snai and Zeb families 
play crucial and yet specific roles during various stages of hematopoiesis and leukemic 
transformation. These specific roles are in some way surprising given that they all bind 
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similar E box-containing DNA sequences and a significant overlap in target genes has been 
reported. This can in some ways be explained by differences in their expression patterns 
and/or the recruitment of other cell-specific co-repressors and/or activators.  
As well, the above reviewed data clearly indicate crucial roles for the EMT inducers of the 
Zeb and Snai family in different aspects of hematopoiesis: differentiation, proliferation, 
apoptosis/survival, mobilization, stemness, as well as quiescence. All of this suggests that 
these two family of proteins might be excellent targets for developing novel and improved 
cancer therapies not only as was suggested before for solid tumours but as well for blood-
borne cancers and other haematological defects associated with improper lineage 
differentiation. 
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1. Introduction 
Asymmetric division is a process by which stem cells asymmetrically segregate certain 
proteins, called “cell fate determinants”, in order to generate two functionally different cells.  
Normally, one of the daughter cells terminally differentiates while the other retains stem cell 
properties and continues proliferating.  Asymmetric division has been found in virtually all 
developing systems where stem cells need to simultaneously proliferate and generate 
differentiated cells: brain, skin, gut, mammary gland, hematopoiesis, also in plants and 
algae. As a consequence of these studies, it has been established that, by virtue of 
asymmetric division, both developing and adult organs maintain the delicate equilibrium 
between proliferation and differentiation. The recent discovery of links to cancer has added 
momentum to an already very dynamic research area.  This review article will discuss the 
latest developments in the asymmetric division field, with a focus on the immuno-
hematopoietic system.  
2. Historical perspective 
The hypothesis about the existence of asymmetric division was postulated in 1878 based on 
studies of leech development, where certain cytoplasmic domains of the egg are 
differentially segregated to the descendants (Whitman, 1878).   In the 1980s asymmetric 
division was described and analyzed in many other organisms, like yeasts, nematode, algae 
and Drosophila (see Horvitz and Herskowitz 1992 for a comprehensive review). At this stage, 
it was thought that each organism had a different means to undergo asymmetric division. 
Daughter cells acquired the differences that made them differentiate into various lineages 
either intrinsically (by differential inheritance of cytoplasmic or chromosomal factors) or 
extrinsically, by differential segregation of soluble factors. Intrinsic differences were 
described in expression of transcription factors, chromatin components, nucleases, 
receptors, cytoskeletal proteins and others; however, at this point it was not clear which of 
them were involved in generating asymmetry or were subject to asymmetric segregation 
themselves to influence differentiation. Extrinsic asymmetric cell division seemed to be the 
result of either direct cell-cell contact, or secretion of soluble factors. We will focus on 
intrinsic asymmetric division, which has been most widely studied. 
In the 1990s, Drosophila asymmetric division was analyzed in detail and visualized by 
confocal microscopy (Rhyu, Jan, and Jan 1994). Two proteins with antagonistic function, 
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Numb and Notch, were pointed out as the main characters in this complicated process.  This 
was followed by the description of asymmetric division in mammalian brain, with a similar 
mechanism and also involving asymmetric segregation of Numb (Zhong et al. 1996). At this 
point, Numb function was unknown, however it was discovered that it could bind (and 
antagonize) the transmembrane receptor Notch. During the following years, efforts in the 
two main invertebrate model systems, C. elegans and Drosophila, were focused on the 
mechanisms to set up cell polarity previous to division, spindle positioning and asymmetric 
localization of cell fate determinants (Betschinger and Knoblich 2004). Studies on vertebrates 
showed that many of the proteins involved were conserved, and that there may be a general 
mechanism for asymmetric division, conserved from the most ancient organisms up to our 
own brain and muscles. These discoveries resulted on a shift of research in the direction of 
vertebrates and, concretely, mammalians, and soon asymmetric division was first described 
in the hematopoietic system (Wu et al. 2007; Schroeder 2007). Studies in Drosophila were still 
ahead, thus the first link between cancer and asymmetric division was discovered in 
Drosophila earlier than in mammalians (Caussinus and Gonzalez 2005). In the following 
years, an important role for phosphorylation of cell fate determinants during mitosis was 
described (Wirtz-Peitz, Nishimura, and Knoblich 2008). Additionally, the mechanisms for 
asymmetric inheritance of centrioles (mediated by microtubules), DNA and vesicles were 
discovered [reviewed in (Neumuller and Knoblich 2009)].   It was realized that, although the 
proteins involved in asymmetric division are conserved, their roles are different in 
vertebrates. However, Drosophila studies were vey helpful in the case of the link to cancer, 
and a molecular mechanism involving Numb and p53 was discovered (Colaluca et al. 2008). 
The challenge for the next decade will be to integrate all this knowledge at the systems level 
to understand how asymmetric division works in health and disease, with enormous 
implications for stem cell research.  
3. Molecular mechanisms of asymmetric division 
Although the mechanism of asymmetric cell division has been intensively studied, there is 
no general model of how it occurs, because the data have been obtained studying different 
organisms that normally have their own specificity. Besides, different techniques, 
depending on the field, have been used to obtain the data, making it difficult to discern real 
differences from those arising as a result of using different techniques. Another problem, 
even when dealing with a single model system, is that there are data on asymmetric 
segregation of different proteins and organelles of the cell, but these data are not connected 
either temporally or mechanistically.  A considerable effort to unify this knowledge into a 
common model has been made by J. Knoblich, who has continually summarized the data 
from diverse model systems in a series of excellent reviews  [specifically (Knoblich 2010) 
(Neumuller and Knoblich 2009) are of great help in understanding the underlying 
mechanisms of asymmetric division]. We will first summarize the current knowledge on 
how different components of the cell are asymmetrically segregated.  
Membrane adaptors- The first stage of asymmetric division in Drosophila neuroblasts is 
polarization of the cell fate determinants Numb (an endocytic adaptor) and Miranda (an 
adaptor that recruits other proteins to the membrane), as a result of asymmetric 
phosphorylation by aPKC (Wirtz-Peitz, Nishimura, and Knoblich 2008).  If Numb and 
Miranda are phosphorylated by aPKC, they cannot localize to the membrane and exert their 
function (Wirtz-Peitz, Nishimura, and Knoblich 2008). During interphase, aPKC is bound to 
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PAR6 and Numb to L(2)GL, which allows Numb to be at the membrane. When the cell 
enters mitosis, Aurora A phosphorylates PAR6, resulting in L(2)GL phosphorylation and 
decoupling from Numb, allowing the adaptor PAR3 to bind simultaneously to both Numb 
and aPKC. Numb is then phosphorylated by aPKC and excluded from the membrane as a 
consequence (Smith et al. 2007; Wirtz-Peitz, Nishimura, and Knoblich 2008). Since aPKC is 
asymmetrically positioned in a constitutive fashion, this automatically results in asymmetric 
membrane distribution of Numb. This mechanism seems to be conserved in mammalians. 
Vesicular compartments- Both endocytic adaptors (like Numb) and vesicles have been 
described to segregate asymmetrically both in Drosophila and mammalians (Zhong et al. 
1996; Le Borgne and Schweisguth 2003). Most transmembrane receptors are subject to 
constant internalization, degradation and recycling, and the balance between these defines 
signaling levels at each moment. It is also known that receptors inside the endosomes do not 
only undergo degradation, but are also able to signal, sometimes even at a stronger level 
than on the membrane (Miaczynska and Bar-Sagi, 2010). This indicates that asymmetric 
segregation of vesicular compartments is a means to enhance signaling by certain receptors 
in one of the daughter cells at the expense of the other. Interestingly, such asymmetric 
segregation of vesicles or proteins involved in endocytosis has been shown to exist in the 
hematopoietic system (Aguado et al. 2010; Giebel and Beckmann 2007). 
Microtubules- During telophase, microtubules play a role in spindle orientation and 
maintenance of Numb and Miranda asymmetric segregation, although the mechanism is not 
completely understood (Knoblich 2010).  
Centrioles- It has been shown that centrioles are asymmetrically segregated in neuroblasts 
(the old centriole normally remains with the cell retaining progenitor potential) and this 
may play a role in cell fate determination (Yamashita et al. 2007). 
DNA- There is evidence in some model systems of asymmetric DNA segregation, where the 
“template” DNA strand is retained by the less differentiated cell. This seems to be true for 
intestinal epithelium (Potten et al. 1978), muscle (Shinin et al. 2006), and neural stem cells 
(Karpowicz et al. 2005) but not for hair follicle (Sotiropoulou, Candi, and Blanpain 2008) or 
hematopoietic (Kiel et al. 2007) stem cells. However, it is not clear whether these disparities 
arise from looking at cells with different specifics in terms of lag between divisions.  
Ribosomal components- In Drosophila, the cell that retains stem cell properties has been shown 
to present both increased size and enhanced protein synthesis. This seems to be related to 
asymmetric segregation of ribosomes (Neumuller et al. 2008) and other factors involved in 
protein synthesis (Fichelson et al. 2009). This has not yet been demonstrated in 
mammalians, but nevertheless is very intriguing and may be the mechanism by which the 
capacity to keep proliferating is asymmetrically inherited by just one of the precursors 
during development.  
At this point, the data indicate that the main mechanism of asymmetric division consists on 
asymmetric inheritance of diverse proteins and subcellular structures, which in its turn 
helps to enhance the difference between the two daughter cells, so that one can retain stem 
cell capabilities while the other terminally differentiates. In this way, asymmetric 
segregation of endocytic adaptors, vesicles and microtubules may contribute to differential 
signaling in the two daughter cells, while differential inheritance of centrioles, DNA and 
ribosomes may help preserve stem cell capabilities in just one of the cells.  
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Numb and Notch, were pointed out as the main characters in this complicated process.  This 
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PAR6 and Numb to L(2)GL, which allows Numb to be at the membrane. When the cell 
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segregation of endocytic adaptors, vesicles and microtubules may contribute to differential 
signaling in the two daughter cells, while differential inheritance of centrioles, DNA and 
ribosomes may help preserve stem cell capabilities in just one of the cells.  
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Two other important aspects that influence asymmetric division are polarization and 
spindle orientation during cell division. Polarization has been most extensively studied in 
C. elegans, where a complex formed by the proteins Par-3, Par-6 and aPKC are already 
polarized during interphase (Suzuki and Ohno 2006).  This mechanism is conserved in 
Drosophila and is involved in all processes that depend on cell polarity. The mentioned 
complex is located in the apical part of the cell and, in mammalian cells, is combined with 
Cadherin and mediates adhesion. Thus, when the spindle forms during cell division, its 
orientation is crucial to determine symmetry or asymmetry. If the spindle is positioned 
perpendicular to the Par complex, the cell divides asymmetrically, and the daughter cell that 
inherits the complex remains a stem cell (probably through adhesion to the stem cell niche), 
while the other daughter cell abandons the cell niche and differentiates. On the contrary, if 
the spindle axis parts the Par complex, both daughter cells inherit it and the division is 
symmetric (Knoblich 2010; Fig. 1). 
 
Fig. 1. Polarization and spindle orientation during symmetric or asymmetric division in  
C. elelgans. 
Undoubtedly, in the future all these facts will be unified in a single model explaining how 
and when things happen during asymmetric division, independently of individual 
differences among the various model systems used to obtain the data. 
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4. Asymmetric division during normal hematopoiesis 
Hematopoiesis is the process by which about 7x109  blood cells are replaced everyday and 
per kg to maintain the Hematopoietic Stem Cell (HSC) pool in an organism. On the other 
hand, a HSC can be defined as a clonogenic cell that has the capacity to self-renew and 
differentiate into the progenitors of mature blood cells through a symmetric or an 
asymmetric division, respectively. 
The hematopoietic system in mammalians shows a hierarchical structure. There is a wide 
range of distinct mature cells, such as erythrocytes, megacaryocytes, myeloid cells, mast 
cells, NK cells, monocytes, B and T cells, and others (Figure 2). All these different cells share 
a common progenitor cell, the Hematopoietic Stem Cell (HSC). HSCs can divide trough a 
symmetric process to self-renew or through an asymmetric division process to generate 
daughter cells with different fates: one daughter cell with the same fate as the progenitor 
cell, and the second one with Multipotent Progenitor cell fate (MPP). Later, MPPs go 
downstream through the hierarchy and can divide into three different Oligopotent 
Progeitors (OPPs). These three different OPPs are Common Lymphoid Progenitors (CLPs), 
megakaryocyte/erythrocyte progenitors (MEPs) and Common Myeloid Progenitors (CMPs). 
The last type of OPPs can generate other OPPs such as granulocyte/macrophage 
progenitors (GMPs) or MEPs. Then, these OPPs derive in a wide range of Lineage Restricted 
Progenitors, such as pro-B lymphoid cells, pro-T lymphoid cells, pro-NK cells, etc., to finally 
generate Mature Effector Cells (platelets, dendritic cells, macrophages, erytorocytes, NK, B 
& T cells, etc). It must be emphasized that multipotency is lost during this process, therefore, 
the potency to generate two daughter cells with different fates is reduced from HSCs to 
mature effector cells (Seita and Weissman 2010). 
 
Fig. 2. Schematic representation of precursor decisions during hematopoiesis. 
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In symmetric divisions, identical copies of the progenitor cell are generated, maintaining the 
pool of HSCs. On the other hand, asymmetric divisions contribute to generate diversity. 
Although it is accepted that the capacity to generate cells with different fates is an intrinsic 
property of HSCs, and studies with fluorescent proteins have shown that several 
determinant factors can be asymmetrically distributed during mitosis (Congdon and Reya 
2008), the environment has an important role in asymmetric division, as well. Thus, several 
studies have indicated that the stroma plays an important role in differentiation of HSCs 
into all blood cell types (Purton and Scadden 2008). In this study, different cell lineages with 
various fates were obtained culturing the HSCs in the presence of different stromas. Other 
studies indicate that osteoblasts and endothelial cells act as stem cell niches and may play an 
important role in progenitor diversity generation. Some experiments show that when HSCs 
are cultured in the presence of osteoblasts asymmetric division is induced, and symmetric 
division is more frequent when HSCs are cultured on stromal cells. In addition, experiments 
where HSCs were cultured in presence or not of Lnk, trombopoeitin (TPO) and several 
interleukins such as IL-3, IL-6 and IL-11 showed effects in self-renewal and differentiation 
processes. For instance, Lnk is considered a negative regulator of self-renewal while TPO is 
a negative regulator of differentiation. In addition, there are other cell types with a potential 
role as regulators of the HSC niche. One of them is the sympathetic nervous system 
(Katayama et al. 2006). Therefore, it seems that asymmetric division is an important process 
for hematopoiesis, although the molecular details remain to be elucidated. 
5. Role of cell fate determinants in hematopoietic malignant proliferation 
The plasma membrane receptor Notch in directly implicated in the proliferative/ 
differentiative balance of stem cells. Thus, deregulation in Notch signaling is related with 
several diseases, such as cancer. An increase in Notch signaling results in the development 
of adenocarcinomas in lung and mammary gland (Allen et al. 2010; Farnie and Clarke 2007). 
Notch1 can be found in many hematopoietic tissues, such as peripheral T and B cells, 
neutrophils and bone marrow precursors (Stier et al. 2002), and activation of Notch1 
increases self-renewal of HSCs while inhibiting the generation of mature cells. This supports 
previous in vitro studies where Notch activation produced immortalized clones of 
multipotent cells (Stier et al. 2002; Varnum-Finney et al. 2000), however Notch1 did not 
completely block the generation of mature cells.  
The first proof of the relationship between Notch signaling and cancer was found in acute T 
lymphoblastic leukemia (T-ALL), and afterwards Notch signaling was shown to be involved 
in generation of solid tumors, including melanoma, colorectal cancer, breast cancer, non-
small cell lung carcinoma and others (Ranganathan, P., et al. 2011). Currently, Notch 
signaling is receiving increased attention in the development of new therapies against 
cancer. Some studies have shown that its ligands (specifically Dll4, involved in angiogenesis 
and T cell fate specification) are overexpressed in different kinds of cancer (Stylianou S, et al. 
2006).  As a result, several ways of inhibiting Notch signaling are being tested at different 
levels:  
Synthetic inhibitors. The Notch pathway is inhibited by small compounds, which arrest the 
proteolysis of Notch receptors by the -secretases-presenilin complex or interfere with the 
activity of the Notch intracellular domain.  The most common -secretases (GSIs) are DAPT 
and DBZ (dibenzazepine). In addition, specific inhibitors for Dll4-Notch signaling have been 
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developed as well. Although different versions of these inhibitors can be found, all of them 
present the same disadvantage. Initially, these drugs were developed to arrest proteolysis of 
the amyloid precursor protein (APP) in Alzehimer’s disease and therefore, they are not 
specific and normally interfere with a wide range of different pathways. On the other hand, 
dnMAML1, a dominant negative of Mastermind-like 1 (MAML1) represents a more selective 
option. dnMAML1 blocks the transduction of the four known Notch receptors (Notch 1-4). 
Although dnMAML1 is a potent inhibitor, it shows low levels of cell permeability; for this 
reason, similar compounds with a better cell permeability have been developed. All these 
inhibitors down-regulate Notch signaling and have shown good results in treating T-ALL. 
Endogenous inhibitors. Endogenous inhibitors, such as Fwb (an E3 ligase), Cbl, Numb and 
Numblike can be used to regulate Notch signaling by targeting Notch receptors, however, 
an important disadvantage is their poor specifity. On the other hand, soluble inhibitors such 
as the extracellular domains of Jagged1, DLk1 and EGFL7 can offer a more specific 
alternative. However, it must be considered that the mechanism of these inhibitors is not 
well known and their role in Notch signaling must be studied in detail. 
Antibodies. Antibodies against Notch receptors can be used to regulate Notch signaling. 
Some antibodies have been already developed against Notch1 and Notch3 receptors (Asano 
N., et al. 2008, Elyaman W., et al 2007, Jurynczyk M., et al 2008, Maekawa Y., et al 2003, 
Schaller MA., et al. 2007 and Li K., et al. 2008). Antibodies can block specific Notch receptors 
with a high selectivity, leaving other Notch receptors activated.  For example, an anti-Dll4 
antibody has been developed against Dll4-Notch signaling and it is showing promising 
perspectives in anti-angiogenic cancer therapy because of its low toxicity (Ridgway J, et al. 
2006). A similar strategy uses molecules called decoys. Decoys are soluble extracellular 
domains of Notch receptors or ligands. They compete with Notch receptors, inhibiting 
Notch signaling by binding to endogenous molecules. These associations do not trigger 
Notch signaling because of lacking the transmembrane region. Notch signaling in 
endothelial cells has been inhibited using a decoy of Notch1, successfully reducing tumor 
growth. Other decoys of Dll1, Dll4 and Jagged1 have been successfully developed 
(Funahashi Y., et al. 2008, Varnum-Finney B., et al. 2000 and Small D., et al. 2001). However, 
decoys show an important disadvantage. It has been observed that they can be switched 
from inhibitors into activators easily. The association of decoys with extracellular matrix can 
produce an activator and trigger Notch proteolysis and activation. The process by which a 
decoy can be transformed into an activator is not yet fully understood, and this feature 
makes decoys unpredictable and not valid as therapeutics (Hicks C., et al. 2002). 
Notch is regulated by Numb, and loss of this regulation has been described in more than 
50% of human mammary carcinomas. When Numb is lost, Notch signaling is increased, and 
the balance between self-renewal and differentiation is affected, which results in 
uncontrolled proliferation.  Loss of Numb may be due to ubiquitylation and subsequent 
proteosomal degradation.  
Recent studies carried out by Colaluca et al. (Colaluca et al. 2008) showed that Numb plays 
an important role in the regulation of the protein p53, also called TP53, an important tumor 
suppressor involved in 50% of breast cancers and in 70% of colon cancers. Numb binds to 
p53 and the E3 ubiquitin ligase HDM2 (or MDMD2 ligase) to form a triple complex, 
inhibiting p53 ubiquitylation and, therefore, its degradation. As a consequence, p53 levels 
are higher and the apparition of breast cancer is diminished. When there is loss of Numb, 
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p53 degradation is higher, allowing higher expression of Notch, which results in 
chemoresistance to the drugs used to combat the disease and in uncontrolled cellular 
proliferation. Besides, p53 regulates the expression of genes implicated in cell-cycle arrest 
and apoptosis upon cellular stress. Additionally, it acts as transcriptional factor. Therefore, it 
seems clear that there is a relationship between Numb deregulation and uncontrolled 
cellular proliferation via the tumor suppressor p53. However, the mechanism by which 
Numb regulates p53 remains still unclear (Carter and Vousden 2008).  
In some cases, such as in breast cancers, deficiency in Numb expression is due to an increase 
in ubiquitylation resulting in higher proteasomal degradation. This may be related to 
increased levels or activity of E3-ligases such as LNK, Siah-1 and MDM2. Another 
explanation for Numb loss may be ubiquitylation after over-phosphorylation. Restoration of 
Numb normal levels could be achieved pharmacologically using substances with 
antiproteasomal activity such as PS-341 or enzymatic inhibitors of Numb degradation (Pece 
et al. 2004). These investigations have a clear practical application: hopefully, in the future 
some of the resulting knowledge will be applied to the clinic. 
6. Asymmetric division in the immune system 
During immune system development and function, progenitor cells undergo a series of 
proliferation and differentiation processes in order to generate the different mature cell 
populations that protect the body from foreign pathogens. T cells develop in the thymus 
from bone marrow precursors through a series of intermediate stages. Double negative cells 
(DN) undergo some division rounds before differentiating into double positive cells (DP), 
afterwards T cell progenitors do not divide again in the thymus: only after exiting the 
thymus and populating the periphery will mature T cells be able to proliferate again. During 
the immune response, naive T lymphocytes (T lymphocytes recently created that have not 
encountered antigen) are activated by antigen-presenting cells.  Naive T cell activation, 
through the T cell receptor (TCR), leads to proliferation and differentiation, triggering a 
massive expansion of differentiated effector cells, as well as a small number of memory cells 
(these will remain undifferentiated until subsequent antigen encounters). Thus, after T cell 
activation, a single naïve T cell is able to generate many different T cell types in order to 
orchestrate an effective immune response (Stemberger et al. 2007). How can a single cell 
generate all the T lymphocyte types that are required for immunity? This question has 
fascinated immunologists over the past years. Several models have been suggested to 
explain the generation of subset diversity during the immune response. Some studies 
suggest a progressive differentiation model (Sallusto, Geginat, and Lanzavecchia 2004), 
while others suggest an early bifurcation between effector and memory phenotypes, more 
consistent with asymmetric division, but the question remains controversial. Despite 
asymmetric division being the most widespread process that regulates the generation of a 
variety of cell types, this process has only started to be studied in the immune system in the 
last few years, and it still remains controversial.  
Nothing suggests, a priori, that the widespread principle of asymmetric division should not 
be applied to the thymus, where DN cell proliferation does regulate the total number of cells 
in the whole organ, and during this process, precursor cells resulting from such divisions 
must decide between differentiation and proliferation. In this respect, three different aspects 
should have been studied before making statements about the role of asymmetrically 
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segregated cell fate determinants in thymocytes. First, demonstration of the existence of 
asymmetric division itself (including an assessment of the effect of manipulating 
asymmetric division); second, identification of cell fate determinants that are asymmetrically 
segregated and their signaling pathways; finally, elucidation of the mechanisms that lead to 
asymmetric localization of these determinants, including external cues that regulate cell 
polarization, as well as intracellular processes that mediate asymmetric segregation of 
proteins and organelles (as has been described before for studies of both Drosophila and 
mammalian neural system).  
However, the first studies related to asymmetric division in the thymus used either 
transgenic or knockout mice to over-express or delete Numb (French et al. 2002; Anderson et 
al. 2005; Wilson et al. 2007).  In these studies, investigators used classical assessments of 
thymocyte differentiation in order to determine whether or not Numb played a role in 
thymocyte differentiation (they never examined asymmetric division). The conclusion 
drawn by the three studies was that Numb plays no role in thymus differentiation. 
However, there are three important considerations that were not taken into account. First, 
both Numb and its homologue Numblike are expressed in mammalians (the thymus 
included), and if their levels are reduced so that just 1% of endogenous levels of either 
Numb or Numblike remain in the cells, this is still enough to maintain normal asymmetric 
division (Petersen et al. 2002; Petersen et al. 2006). Second, four different isoforms of Numb 
are expressed in mammalians (Dho et al. 1999). Third, knockout studies in the immune 
system must be taken with caution, since there is accumulating evidence that the absence of 
phenotype does not necessarily mean that the protein does not have a function (Saveliev 
and Tybulewicz 2009). If Numb acts as a cell fate determinant during asymmetric division in 
the thymus, one would expect an effect in precursor proliferation rate and the total number 
of thymocytes, however none of these were examined in these first studies. Nevertheless, 
the existence of three studies claiming no role for Numb in the thymus predisposed the 
whole field against the notion of asymmetric division.  
Fortunately, over the past few years, the first studies on asymmetric division in the thymus 
and peripheral T lymphocytes performed following a more logical order (i.e., examining in 
the first place asymmetric segregation of determinants) have provided exciting data about 
asymmetric division in the immune system (Aguado et al. 2010; Chang et al. 2007).  In the 
first study, our group showed by confocal microscopy that Numb is segregated 
asymmetrically during thymocyte division. By inhibiting Numb (using a dominant 
negative), or overexpressing it, we showed that functional Numb levels determine DN 
thymocyte proliferation rate and, ultimately, thymus size. Furthermore, we showed that 
Numb can regulate pre-TCR localization and signaling, acting as an endocytic protein. As a 
result, a model was proposed where thymocytes divide by asymmetric division to generate 
one daughter cell that inherits Numb and keeps precursor properties and a second that does 
not inherit Numb and receives pre-TCR signaling as a consequence, which results in 
differentiation (Fig. 3). The second study showed that peripheral CD8+ T cells do indeed 
undergo asymmetric division, and this process regulates the choice between effector and 
memory differentiation (Chang et al. 2007). The authors showed that after the first naïve 
CD8+ T cell division, the proximal and distal daughter cells have different phenotypes. Thus, 
proximal daughter cells expressed low CD62L levels and higher CD69, CD43 and CD25 
levels. Furthermore, when these cells were transferred into naïve secondary recipients, they 
provided protection against acute infection, but poor long-term protection, a profile 
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consistent with the effector lineage. However, distal daughters expressed high levels of 
CD62L and lower levels of CD69, CD43, CD25 and CD44 and these cells provided a good 
long-term protection in vivo, a profile more consistent with the central memory cells. This is 
clear evidence that asymmetric division occurs, at least during the first division.  
As we have explained before, for asymmetric division to occur, the progenitor cell needs to 
receive an external cue to dictate the axis of polarity, recruit cell fate determinants and align 
the mitotic spindle with a correct position that ensures asymmetric segregation of the 
determinants. During mature T cell division, the axis of polarity and mitotic spindle 
alignment are established by the formation of the immunological synapse. The 
immunological synapse has been extensively studied as a site of clustered signaling 
molecules, and can be considered as a marker of the polarized T cell and a mechanism for 
asymmetric division regulation. Recent studies showed that asymmetric cell division is not 
observed either during non antigen–dependent activation or the second and subsequent cell 
divisions following antigen stimulation, and that the polarity cue for asymmetric cell 
division requires the contact with antigen-presenting cells (Chang et al. 2007; Oliaro et al. 
2010; Fig. 3). One problem with this model is that if it is just the first division that is  
 
Fig. 3. Schematic representation of the current models for asymmetric division in thymus 
and periphery. 
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asymmetric during the immune response, and all the subsequent divisions are symmetric, it 
is not clear how the final numbers of memory and effector cells are achieved. In any case, 
these data on thymus and peripheral T cells demonstrate that the immunological system is 
not a remarkable exception to the principle of asymmetric division as the universal 
mechanism to ensure a correct balance between expansion and differentiation during 
development. The mechanistic details on how asymmetric division is orchestrated in the 
immune system in order to achieve correct numbers of mature cells will surely be elucidated 
soon. 
7. Future directions of the field 
Asymmetric division has transitioned from being an intriguing but unexplained anomaly of 
neural development into a fertile field where scientists working on different developmental 
biology areas converge to exchange methods and ideas. The recently discovered link to 
cancer stresses out the importance of these studies in the immuno-hematopoietic system.  
An important current challenge for the field of asymmetric division is unification of 
knowledge. A general model for the functioning of asymmetric division that applies to all 
organisms and tissues needs to be postulated, even if it is very schematic at the beginning. 
Next, unification of methods should be achieved: the same phenomenon in different 
organisms should not be studied using different techniques simply because researchers of 
different areas feel more comfortable with a certain approach. To avoid this, more joint 
scientific meetings on asymmetric division must be organized, so that researchers can 
exchange views and knowledge, besides funding should be available for those willing to 
assume the risk of applying new techniques to old model systems.  If the field does not 
evolve in this way, it risks loosing its current novelty and drive.  Hopefully, new exciting 
discoveries will keep the area alive, and the many open questions about how organisms and 
tissues orchestrate growth and differentiation will be answered soon.  
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1.1. Hemoglobin synthesis 
The human hematopoiesis initiates in the second to third embryonic weeks with formation 
of mesoderm-derived blood islands in the extraembryonic mesoderm of the developing 
secondary yolk sac (Migliaccio et al., 1986). Erythropoiesis involves proliferation and 
differentiation of committed erythroid progenitors to mature red blood cells (erythrocytes). 
Although globins represents <0.1% of proteins at the proerythroblast level, it reaches 95% of 
all proteins at the level of reticulocytes (Nienhuis & Benz, 1977). Physiologically, the 
expression of the globin genes is generally regulated in such a way that at any point in 
development the output of the beta ()-globin-like chains equals the alpha (α)-globin chains 
(Lodish & Jacobsen, 1972). The α-globin gene cluster contains three genes and several 
pseudogenes arranged from the telomere toward the centromere in the following order: 5'-
ξ2-ξ1-α2-α1-α2-α1-1-3' (Higgs et al., 1998). The human -globin locus consists of five 
functional -like globin genes, that are arranged in the order of their expression during 
development (5’--G-G---3’), and an upstream regulatory element, the locus control 
region (LCR), that is physically composed of five DNase I-hypersensitive sites (HSs) 
(Grosveld et al., 1987). The most widely studied changes during red cell ontogeny are the 
shifts or “switches” in globin types. Embryonic erythroblasts are characterized by the 
synthesis of the unique hemoglobins Gower I (ζ2ε2), Gower II (α2ε2), and Hb Portland (ζ2γ2). 
The zeta (ζ)- and epsilon (ε)-globin chains are embryonic α-like and β-like chains, 
respectively. Thus, a switch from ζ- to α- and ε- to gamma (γ)-globin gene production begins 
during the embryonic phase of erythropoiesis but is not complete until fetal erythropoiesis 
is well established. During the transition from yolk sac to fetal liver erythropoiesis (5–8 
weeks), erythroid precursors within the fetal liver co-express embryonic (ζ- or ε-) and fetal 
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1.1. Hemoglobin synthesis 
The human hematopoiesis initiates in the second to third embryonic weeks with formation 
of mesoderm-derived blood islands in the extraembryonic mesoderm of the developing 
secondary yolk sac (Migliaccio et al., 1986). Erythropoiesis involves proliferation and 
differentiation of committed erythroid progenitors to mature red blood cells (erythrocytes). 
Although globins represents <0.1% of proteins at the proerythroblast level, it reaches 95% of 
all proteins at the level of reticulocytes (Nienhuis & Benz, 1977). Physiologically, the 
expression of the globin genes is generally regulated in such a way that at any point in 
development the output of the beta ()-globin-like chains equals the alpha (α)-globin chains 
(Lodish & Jacobsen, 1972). The α-globin gene cluster contains three genes and several 
pseudogenes arranged from the telomere toward the centromere in the following order: 5'-
ξ2-ξ1-α2-α1-α2-α1-1-3' (Higgs et al., 1998). The human -globin locus consists of five 
functional -like globin genes, that are arranged in the order of their expression during 
development (5’--G-G---3’), and an upstream regulatory element, the locus control 
region (LCR), that is physically composed of five DNase I-hypersensitive sites (HSs) 
(Grosveld et al., 1987). The most widely studied changes during red cell ontogeny are the 
shifts or “switches” in globin types. Embryonic erythroblasts are characterized by the 
synthesis of the unique hemoglobins Gower I (ζ2ε2), Gower II (α2ε2), and Hb Portland (ζ2γ2). 
The zeta (ζ)- and epsilon (ε)-globin chains are embryonic α-like and β-like chains, 
respectively. Thus, a switch from ζ- to α- and ε- to gamma (γ)-globin gene production begins 
during the embryonic phase of erythropoiesis but is not complete until fetal erythropoiesis 
is well established. During the transition from yolk sac to fetal liver erythropoiesis (5–8 
weeks), erythroid precursors within the fetal liver co-express embryonic (ζ- or ε-) and fetal 
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(α- or γ-) globins both in vivo and in vitro (Peschle et al., 1984). The predominant type of 
hemoglobin synthesized during fetal liver erythropoiesis is fetal hemoglobin (HbF, α2γ2). 
HbF is formed by γ-globin chain A or G according to the amino acid at the 136 position in 
the γ chain, i.e., alanine or glycine. The proportion of Gγ to Aγ is constant throughout fetal 
development: about 75% of Gγ and 25% of Aγ. However, in adult red cells, the small amount 
of HbF is composed mainly of Aγ (60% vs. 40% of Gγ) (Jensen et al., 1982). α- and β-globin 
chains combine as a tetramer of two α- and two β-globin polypeptides along with a heme 
moiety to form the adult hemoglobin molecule (HbA, α2β2). HbA, detectable at the earliest 
stages of fetal liver erythropoiesis, is also synthesized as a minor component throughout this 
period, but HbA2 (α2δ2), minor hemoglobin in the adult, is undetectable in these early 
stages. From about the 30th gestational week onward, β-globin synthesis steadily increases, 
so that by term 50%–55% of hemoglobin synthesized is HbA. By 4-5 weeks of postnatal age, 
75% of the hemoglobin is HbA, this percentage increasing to 95% by 4 months as the fetal-
to-adult hemoglobin switch is completed. HbF levels in circulating red cells are in a plateau 
for the first 2–3 weeks (as a result of the decline in total erythropoiesis that follows birth), 
but HbF gradually declines and normal levels (<1%) are achieved by 200 days after birth.  
1.2 The GATA-1/2 and Krüppel-like factors role in hemoglobin switching 
The regulation of globin gene switching is a very complex process requiring the 
coordination of different signaling pathways and molecular reactions. Many transcription 
factors controlling globin gene expression have been identified and characterized. These 
factors form a complex network of protein-protein and protein-DNA interactions with each 
other, globin gene promoters, LCR HSs, and other cis-acting intergenic regions 
(Stamatoyannopoulos, 2005). The GATA family of proteins (GATA1–6) comprises zinc 
finger transcription factors that both activate and repress target genes containing a 
consensus GATA binding motif (Orkin, 1992). Binding sites with this motif are present in 
many positions in the α- and β-globin loci, as well as many other erythroid-expressed genes. 
The founding member of this family, GATA1, was discovered as a β-globin locus-binding 
protein (Pruzina et al., 1991). GATA1 is essential for erythroid cell maturation in vivo 
(Pevny et al., 1989). In addition, GATA1 homodimerizes and interacts with other 
transcription factors, such as SP-1 and erythroid Krüppel-like factor (EKLF/KLF1), further 
contributing to the complex network of GATA factor interactions (Gregori et al., 1996). 
GATA2 is primarily expressed in primitive erythropoiesis, but later in development GATA1 
expression predominates (Leonard et al., 1993). Downregulation of GATA2 is important for 
progression of erythroid cell differentiation (Persons et al., 1999). The protein Friend of 
GATA1 (FOG) is co-expressed with GATA1 during embryonic development in erythroid 
cells (Tsang et al., 1997). GATA1 binds a region upstream of both the HBG1- and HBG2-
promoter, necessary for HbF silencing, in a FOG1 dependent manner leading to recruitment 
of the suppressive NuRD-complex (Harju-Baker et al., 2008). GATA-1, together with FOG-1, 
functions as an anchor in the formation of chromatin looping, and is required for physical 
interactions between the β LCR and β globin promoter (Vakoc et al., 2005). 
The Krüppel-like factors are a family of C2H2 zinc finger DNA binding proteins that are 
important in controlling developmental programs. KLF1 gene is an erythroid cell-specific 
zinc finger transcription factor, containing a DNA-binding domain located at its C-terminus, 
composed of three ‘Krüppel-like’ C2H2 zinc finger motifs, and a proline-rich transactivation 
domain at its N-terminus (Miller & Bieker, 1993). KLF1 preferentially activates the -globin 
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gene promoter by binding with high affinity to the CACCC element (Bieker & Southwood, 
1995). KLF1 is essential for adult β-globin gene transcription and binds to the βLCR and β-
globin promoters, required for direct interactions between the βLCR and the β-globin gene 
in humans (Donze et al., 1995, Scheme 1). Patients with hereditary persistence of HbF, with 
elevated levels of HbF, have mutations in the gene encoding erythroid transcription factor 
KLF1 (Borg et al., 2010). Recent findings demonstrate that KLF1, and the co-activator BRG1, 
are designated by short-chain fatty acid derivatives to activate the fetal globin genes. The 
SWI/SNF complex chromatin-modifying core ATPase BRG1 is required for γ-globin 
induction by short-chain fatty acid derivatives, and is actively recruited to the γ-globin 
promoter in the KLF1-dependent manner (Perrine et al., 2009). KLF1-GATA1 fusion proteins 
activated δ-, γ-, and β-globin promoters, and significantly up-regulated delta (δ)- and γ-
globin RNA transcript and protein expression in human erythroleukemic cells (Zhu et al., 
2011). DRED (direct repeat erythroid-definitive) was identified as a repressor of the -globin 
gene, it appears to prevent binding of KLF1 to the -globin gene promoter and silences -
globin expression during definitive erythropoiesis (Tanimoto et al., 2000). KLF2 also 
regulates the expression of the human embryonic ε-globin gene but not the adult β-globin 
gene (Basu et al., 2005). Another erythroid-specific transcription factor, called fetal Krüppel-
like factor (KLF11), activates - and -globin genes in human erythroleukemic cells (Asano et 
al., 1999, Scheme 1). KLF11 also activates -globin transcription via the CACCC element in 
the promoter (Asano et al., 2000). The protein encoded by this gene is a zinc finger 
transcription factor that binds to SP1-like sequences in - and -globin gene promoters.  
 
Sheme 1. Overview of globin genes control by examined transcription factors. 
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of the suppressive NuRD-complex (Harju-Baker et al., 2008). GATA-1, together with FOG-1, 
functions as an anchor in the formation of chromatin looping, and is required for physical 
interactions between the β LCR and β globin promoter (Vakoc et al., 2005). 
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important in controlling developmental programs. KLF1 gene is an erythroid cell-specific 
zinc finger transcription factor, containing a DNA-binding domain located at its C-terminus, 
composed of three ‘Krüppel-like’ C2H2 zinc finger motifs, and a proline-rich transactivation 
domain at its N-terminus (Miller & Bieker, 1993). KLF1 preferentially activates the -globin 
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gene promoter by binding with high affinity to the CACCC element (Bieker & Southwood, 
1995). KLF1 is essential for adult β-globin gene transcription and binds to the βLCR and β-
globin promoters, required for direct interactions between the βLCR and the β-globin gene 
in humans (Donze et al., 1995, Scheme 1). Patients with hereditary persistence of HbF, with 
elevated levels of HbF, have mutations in the gene encoding erythroid transcription factor 
KLF1 (Borg et al., 2010). Recent findings demonstrate that KLF1, and the co-activator BRG1, 
are designated by short-chain fatty acid derivatives to activate the fetal globin genes. The 
SWI/SNF complex chromatin-modifying core ATPase BRG1 is required for γ-globin 
induction by short-chain fatty acid derivatives, and is actively recruited to the γ-globin 
promoter in the KLF1-dependent manner (Perrine et al., 2009). KLF1-GATA1 fusion proteins 
activated δ-, γ-, and β-globin promoters, and significantly up-regulated delta (δ)- and γ-
globin RNA transcript and protein expression in human erythroleukemic cells (Zhu et al., 
2011). DRED (direct repeat erythroid-definitive) was identified as a repressor of the -globin 
gene, it appears to prevent binding of KLF1 to the -globin gene promoter and silences -
globin expression during definitive erythropoiesis (Tanimoto et al., 2000). KLF2 also 
regulates the expression of the human embryonic ε-globin gene but not the adult β-globin 
gene (Basu et al., 2005). Another erythroid-specific transcription factor, called fetal Krüppel-
like factor (KLF11), activates - and -globin genes in human erythroleukemic cells (Asano et 
al., 1999, Scheme 1). KLF11 also activates -globin transcription via the CACCC element in 
the promoter (Asano et al., 2000). The protein encoded by this gene is a zinc finger 
transcription factor that binds to SP1-like sequences in - and -globin gene promoters.  
 
Sheme 1. Overview of globin genes control by examined transcription factors. 
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1.3 Other factors that participate in hemoglobin switching 
A nuclear protein, special AT-rich binding protein 1 (SATB1), regulates genes through 
targeting chromatin remodeling and its overexpression increases -globin and decreases -
globin gene expression (Wen et al., 2005, Scheme 1). Global changes to chromatin, including 
acetylation, phosphorylation, and methylation play roles in LCR activation. Histone 
acetylation occurs during chromatin remodeling and hyperacetylation is associated with 
transcriptional activation of a locus (Pazin & Kadonaga, 1997). Similar to acetylation, 
phosphorylation of histone H3 disrupts DNA-nucleosome interaction and increases 
transcription factor accessibility to DNA. SATB1 overexpression increased ε-globin and 
decreased γ-globin gene expression accompanied by histone hyperacetylation and 
hypomethylation in chromatin from the ε-globin promoter and HS2, and histone 
hypoacetylation and hypermethylation associated with the γ-globin promoter (Wen et al., 
2005). Mitogen activated protein kinase (MAPK) pathways, as well as the stress activated 
p38 pathway, activate histone H3 phosphorylation (Cheung et al., 2000). Studies on p38 
knockout mice established a role for the p38 stress pathway in the switch from primitive to 
definitive erythropoiesis (Tamura et al., 2000). Mutations in the transcription factor alpha 
thalassemia/mental retardation syndrome X-linked (ATRX), nearly always downregulate α-
globin expression, provide potentially important insight into the trans-regulation of globin 
gene expression (Gibbons et al., 1995). Alpha hemoglobin stabilizing protein (AHSP) is an 
erythroid-specific protein that forms a stable complex with free alpha-hemoglobin (Kihm et 
al., 2002). It has been found that AHSP expression was highly dependent on the larger 
subunit of nuclear factor erythroid-derived 2 (NFE2) (Guo-wei et al., 2010). The transcription 
factor NFE2 activation of globin production was stimulated by cAMP-dependent protein 
kinase (PKA) in erythroid cells (Casteel et al., 1998).  
BCL11A gene (encoding the transcription factor B-cell lymphoma/leukemia 11A) maintains 
silencing of γ-globin expression in adult erythroid cells and functions as a direct 
transcriptional regulator of the fetal to adult hemoglobin switch in humans. BCL11A protein 
levels vary in erythroid progenitors over the course of human ontogeny. BCL11A is 
expressed as short variant proteins in primitive erythroid progenitors that largely express γ-
globin and as full-length forms at the adult stage with silenced γ-globin genes (Sankaran et 
al., 2008). In erythroid progenitors, BCL11A physically interacts with the NuRD chromatin 
remodelling complex, and the erythroid transcription factors, GATA1 and FOG1. In 
addition, KLF1, as a key activator of BCL11A, controls globin gene switching by directly 
activating β-globin and indirectly repressing γ-globin gene expression (Zhou et al., 2010). 
BCL11A binds the upstream LCR, ε-globin, and the intergenic regions between γ-globin and 
δ-globin genes. BCL11A and SOX6 co-occupy the human β-globin cluster along with 
GATA1, and cooperate in silencing γ-globin transcription in adult human erythroid 
progenitors (Xu et al., 2010, Scheme 1). SOX6 has also been suggested to enhance definitive 
erythropoiesis in mouse by stimulating erythroid cell survival, proliferation and terminal 
maturation (Dumitriu et al., 2006). A broad genome expression profile studies led to the 
identification of common genetic polymorphisms in the locus of the β-globin gene, a region 
between the HBS1-like gene HBS1L and the oncogene MYB, as well as within the gene 
BCL11A (Galarneau et al., 2010). HBS1L-MYB intergenic polymorphism on chromosome 
6q23 is associated with elevated HbF levels. MYB and HBS1L expression was significantly 
 
Nitric Oxide / Cyclic Nucleotide Regulation of Globin Genes in Erythropoiesis 
 
139 
reduced in erythroid cultures of individuals with high HbF levels, whereas overexpression 
of MYB in human erythroleukemic cells inhibited γ-globin expression supporting role of 
MYB in HbF regulation (Jiang et al., 2006). The human erythroid precursor cells from 
individuals with higher HbF and higher F cell levels have lower MYB expression associated 
with lower erythrocyte count but higher erythrocyte volume (Jiang et al., 2006). 
MicroRNAs (miRNAs or miRs) are small, 19 to 25 nucleotide long, non-coding RNAs, which 
target mRNAs in a sequence-specific manner, inducing translational repression or decay. 
Increased miRNA-210 levels elevated γ-globin levels in hereditary persistence of HbF 
(Bianchi et al., 2009), while the let-7 family has been associated with hemoglobin switching 
(Noh et al., 2009). Recently, two miRNAs, miR-221 and miR-222, have been identified to 
regulate HbF expression in erythropoietic cells via the kit receptor (Gabbianelli et al., 2010). 
miRNA-150 repression of MYB in hematopoietic progenitor cells, of human bone marrow 
origin, supported MYB's importance in erythroid and megakaryocytic differentiation (Lu et 
al., 2008). It has been reported that miRNA-96, miRNA-146a, let-7a, miR-888 and miR-330a-
3p are significantly more abundant in reticulocytes obtained from adults than from 
umbilical cord blood and therefore are potential inhibitors of γ-globin expression. The miR-
96 has been identified as a direct inhibitor of γ-globin expression (Azzouzi et al., 2011, 
Scheme 1). These findings demonstrate that miRNAs contribute to HbF regulation by the 
post-transcriptional inhibition of γ-globin expression during adult erythropoiesis. 
2. Microarray analysis of globin related genes during ontogenesis 
2.1 Introduction 
Several groups have examined the gene expression profile of human CD34+ hematopoietic 
progenitor cells from bone marrow (BM), peripheral blood (PB) and cord blood (CB) using 
microarray technology (He et al., 2005; Ng et al., 2004; Steidl et al., 2002). The modulation of 
gene expression during ontogeny, in fetal liver (FL)- and CB-derived CD34+CD38  
hematopoietic progenitor cells, appears to overlap broadly with early response genes of 
growth factor stimulated adult (BM) hematopoietic progenitor cells (Oh et al., 2000). Recent 
studies have begun to define a general gene expression profiling for human erythroid cells 
from different origins - adult BM and PB (Goh et al., 2007; Gubin et al., 1999; Fujishima et al., 
2004). In general, it has been hypothesized that globin gene switching may be mediated by 
proteins expressed during different stages of ontogeny.  
Following the same intention, we have performed serial gene expression profiling in human 
differentiating erythroid cells by oligonucleotide microarrays. The several expressed genes 
(GATA1, ALAS2, EPOR, globins, etc.) linked to known erythroid differentiation confirms 
the validity of our approach in establishing the appropriate in vitro cell culture conditions. 
To study the mechanism of globin gene switching, we have performed gene expression 
profiling of erythroid progenitor cells derived from hematopoietic tissues during ontogeny, 
using a large Gene Array to gain insight into the associated molecular pathways. Gene 
expression patterns of CD71+ erythroid progenitor cells, differentiated from human FL, CB, 
BM, PB and granulocyte colony-stimulating factor (G-CSF) mobilized PB (mPB), were 
compared to establish the expression patterns of representative genes.  
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1.3 Other factors that participate in hemoglobin switching 
A nuclear protein, special AT-rich binding protein 1 (SATB1), regulates genes through 
targeting chromatin remodeling and its overexpression increases -globin and decreases -
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transcriptional activation of a locus (Pazin & Kadonaga, 1997). Similar to acetylation, 
phosphorylation of histone H3 disrupts DNA-nucleosome interaction and increases 
transcription factor accessibility to DNA. SATB1 overexpression increased ε-globin and 
decreased γ-globin gene expression accompanied by histone hyperacetylation and 
hypomethylation in chromatin from the ε-globin promoter and HS2, and histone 
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2005). Mitogen activated protein kinase (MAPK) pathways, as well as the stress activated 
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thalassemia/mental retardation syndrome X-linked (ATRX), nearly always downregulate α-
globin expression, provide potentially important insight into the trans-regulation of globin 
gene expression (Gibbons et al., 1995). Alpha hemoglobin stabilizing protein (AHSP) is an 
erythroid-specific protein that forms a stable complex with free alpha-hemoglobin (Kihm et 
al., 2002). It has been found that AHSP expression was highly dependent on the larger 
subunit of nuclear factor erythroid-derived 2 (NFE2) (Guo-wei et al., 2010). The transcription 
factor NFE2 activation of globin production was stimulated by cAMP-dependent protein 
kinase (PKA) in erythroid cells (Casteel et al., 1998).  
BCL11A gene (encoding the transcription factor B-cell lymphoma/leukemia 11A) maintains 
silencing of γ-globin expression in adult erythroid cells and functions as a direct 
transcriptional regulator of the fetal to adult hemoglobin switch in humans. BCL11A protein 
levels vary in erythroid progenitors over the course of human ontogeny. BCL11A is 
expressed as short variant proteins in primitive erythroid progenitors that largely express γ-
globin and as full-length forms at the adult stage with silenced γ-globin genes (Sankaran et 
al., 2008). In erythroid progenitors, BCL11A physically interacts with the NuRD chromatin 
remodelling complex, and the erythroid transcription factors, GATA1 and FOG1. In 
addition, KLF1, as a key activator of BCL11A, controls globin gene switching by directly 
activating β-globin and indirectly repressing γ-globin gene expression (Zhou et al., 2010). 
BCL11A binds the upstream LCR, ε-globin, and the intergenic regions between γ-globin and 
δ-globin genes. BCL11A and SOX6 co-occupy the human β-globin cluster along with 
GATA1, and cooperate in silencing γ-globin transcription in adult human erythroid 
progenitors (Xu et al., 2010, Scheme 1). SOX6 has also been suggested to enhance definitive 
erythropoiesis in mouse by stimulating erythroid cell survival, proliferation and terminal 
maturation (Dumitriu et al., 2006). A broad genome expression profile studies led to the 
identification of common genetic polymorphisms in the locus of the β-globin gene, a region 
between the HBS1-like gene HBS1L and the oncogene MYB, as well as within the gene 
BCL11A (Galarneau et al., 2010). HBS1L-MYB intergenic polymorphism on chromosome 
6q23 is associated with elevated HbF levels. MYB and HBS1L expression was significantly 
 
Nitric Oxide / Cyclic Nucleotide Regulation of Globin Genes in Erythropoiesis 
 
139 
reduced in erythroid cultures of individuals with high HbF levels, whereas overexpression 
of MYB in human erythroleukemic cells inhibited γ-globin expression supporting role of 
MYB in HbF regulation (Jiang et al., 2006). The human erythroid precursor cells from 
individuals with higher HbF and higher F cell levels have lower MYB expression associated 
with lower erythrocyte count but higher erythrocyte volume (Jiang et al., 2006). 
MicroRNAs (miRNAs or miRs) are small, 19 to 25 nucleotide long, non-coding RNAs, which 
target mRNAs in a sequence-specific manner, inducing translational repression or decay. 
Increased miRNA-210 levels elevated γ-globin levels in hereditary persistence of HbF 
(Bianchi et al., 2009), while the let-7 family has been associated with hemoglobin switching 
(Noh et al., 2009). Recently, two miRNAs, miR-221 and miR-222, have been identified to 
regulate HbF expression in erythropoietic cells via the kit receptor (Gabbianelli et al., 2010). 
miRNA-150 repression of MYB in hematopoietic progenitor cells, of human bone marrow 
origin, supported MYB's importance in erythroid and megakaryocytic differentiation (Lu et 
al., 2008). It has been reported that miRNA-96, miRNA-146a, let-7a, miR-888 and miR-330a-
3p are significantly more abundant in reticulocytes obtained from adults than from 
umbilical cord blood and therefore are potential inhibitors of γ-globin expression. The miR-
96 has been identified as a direct inhibitor of γ-globin expression (Azzouzi et al., 2011, 
Scheme 1). These findings demonstrate that miRNAs contribute to HbF regulation by the 
post-transcriptional inhibition of γ-globin expression during adult erythropoiesis. 
2. Microarray analysis of globin related genes during ontogenesis 
2.1 Introduction 
Several groups have examined the gene expression profile of human CD34+ hematopoietic 
progenitor cells from bone marrow (BM), peripheral blood (PB) and cord blood (CB) using 
microarray technology (He et al., 2005; Ng et al., 2004; Steidl et al., 2002). The modulation of 
gene expression during ontogeny, in fetal liver (FL)- and CB-derived CD34+CD38  
hematopoietic progenitor cells, appears to overlap broadly with early response genes of 
growth factor stimulated adult (BM) hematopoietic progenitor cells (Oh et al., 2000). Recent 
studies have begun to define a general gene expression profiling for human erythroid cells 
from different origins - adult BM and PB (Goh et al., 2007; Gubin et al., 1999; Fujishima et al., 
2004). In general, it has been hypothesized that globin gene switching may be mediated by 
proteins expressed during different stages of ontogeny.  
Following the same intention, we have performed serial gene expression profiling in human 
differentiating erythroid cells by oligonucleotide microarrays. The several expressed genes 
(GATA1, ALAS2, EPOR, globins, etc.) linked to known erythroid differentiation confirms 
the validity of our approach in establishing the appropriate in vitro cell culture conditions. 
To study the mechanism of globin gene switching, we have performed gene expression 
profiling of erythroid progenitor cells derived from hematopoietic tissues during ontogeny, 
using a large Gene Array to gain insight into the associated molecular pathways. Gene 
expression patterns of CD71+ erythroid progenitor cells, differentiated from human FL, CB, 
BM, PB and granulocyte colony-stimulating factor (G-CSF) mobilized PB (mPB), were 
compared to establish the expression patterns of representative genes.  
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2.2 Material and methods 
2.2.1 Liquid erythroid cell cultures  
CD34+ hematopoietic progenitor cells were purified by positive immunomagnetic selection 
using the MACS cell isolation system (Miltenyi Biotec, Auburn, CA). Fresh BM, PB and G-
CSF stimulated mPB CD34+ cells were collected (AllCells LLC, Berkeley, CA) and proceeded 
with selection. CB CD34+ cells (AllCells LLC) and FL CD34+ cells (Cambrex Bio Science, Inc., 
Walkersville, MD) were collected and frozen. For analysis, CD34+ cells were resuspended in 
medium with erythropoietin (EPO), as already described (Cokic et al., 2003). After 6 days of 
EPO treatment, 5x105 cells were washed and incubated for 20 minutes in the presence of the 
monoclonal antibody anti-CD71 Tricolor for cell staining (Beckman-Coulter, Miami, FL). 
Cells were then washed, fixed and acquired on an LSRII flow cytometer (BD Biosciences, 
San Jose, CA). Data were analyzed with Flowjo software (Tree Star, San Carlos, CA). After 6 
days of erythropoietin treatment and incubation at 37°C (5% CO2, 95% humidity), we used 
the RNeasy protocol for isolation of total RNA from erythroid progenitor cells (Qiagen, 
Valencia, CA) according to the manufacturer's instructions. Concentration and integrity of 
total RNA was assessed using an 8453 UV/Visible Spectrophotometer (Hewlett-Packard 
GmbH, Waldbronn, Germany) and Agilent 2100 Bioanalyzer Software (Agilent 
Technologies, Waldbronn, Germany).     
2.2.2 Microarray studies 
In microarray studies, the numbers of total genes overexpressed in erythroid cells of CB, BM 
and PB origin were determined from three independent samples as biological repeats. FL 
and mPB-derived samples were analyzed in independent duplicate samples at day 6 of 
erythroid liquid culture. High quality oligonucleotide glass arrays were produced 
containing a total of 16,659 seventy-mer oligonucleotides (Operon Inc. Valencia, CA). The 
array includes probes for 2121 hypothetical proteins and 18-expressed sequence tags (ESTs) 
and spans approximately 50% of the human genome (Operon Inc.). The arrays were 
produced in house by spotting oligonucleotides on poly-L-lysine coated glass slides by Gene 
Machines robotics (Omnigrid, San Carlos, CA).  
Total human universal RNA (HuURNA) isolated from a collection of adult human tissues to 
represent a broad range of expressed genes from both male and female donors (BD 
Biosciences, Palo Alto, CA) served as a universal reference control in the competitive 
hybridization. Labeled cDNA probes were produced as described (Risinger et al., 2003). 
cDNA was purified by the MinElute column (Qiagen). Binding buffer PB was added to the 
coupled cDNA, and the mixture applied to the MinElute column and centrifuged. After 
discharging the flow-through, washing buffer PE was added to the column, and centrifuged. 
Then the columns were placed into a fresh eppendorf tube and elution buffer added to the 
membrane, incubated and centrifuged and probe collected. The probe was dried in speed-
vac. Finally, 5 l of 2X coupling buffer and 5 l Cy3 and Cy5 dye (GE Healthcare Bio-
Sciences Corp., Piscataway, NJ) were mixed into the control (HuURNA) and experimental 
cDNAs (huES cell-derived) respectively and incubated at room temperature in dark for 90 
minutes. After incubation, the volume was raised to 60 l by DEPC water and then cDNA 
was purified by the MinElute column and eluted with 13 l elution buffer by centrifugation. 
For hybridization, 36 l hybridization mixture was pre-heated at 100C for 2 minutes and 
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cooled for 1 minute. Total volume of probe was added on the array and covered with cover 
slip. Slides are placed in hybridization chamber and 20µl water was added to the slide, and 
incubated overnight at 65oC. Slides were then washed for 2 minutes each in 2X SSC, 1X SSC 
and 0.1X SSC and spin-dried. Microarray slides were scanned in both Cy3 (532nm) and Cy5 
(635nm) channels using Axon GenePix 4000B scanner (Axon Instruments, Inc., Foster City, 
CA) with a 10-micron resolution. Scanned microarray images were exported as TIFF files to 
GenePix Pro 3.0 software for image analysis. The average of the total Cy3 and Cy5 signal 
gave a ratio that was used to normalize the signals. Each microarray experiment was 
globally normalized to make the median value of the log2-ratio equal to zero. The Loess 
normalization process corrects for dye bias, photo multiplier tube voltage imbalance, and 
variations between channels in the amounts of the labeled cDNA probes hybridized. The 
data files representing the differentially expressed genes were then created. For  
advanced data analysis, gpr and jpeg files were imported into microarray database, and 
normalized by software tools provided by NIH Center for Information Technology 
(http://nciarray.nci.nih.gov/). Spots with confidence interval of 99 (≥ 2 fold) with at least 
150-fluorescence intensity for both channel and 30 μm spot size were considered as good 
quality spots for analysis. Paired t test was used in microarray analysis.  
2.3 Results 
2.3.1 Predominantly elevated genes expression in ontogenic tissues 
In the presence of EPO and other cytokines, CD34+ cells were differentiated in vitro into 
erythroid progenitor cells. Besides flow cytometry for analysis of in vitro erythroid 
differentiation, we already reported measurement of hemoglobin content by benzidine 
staining and high-performance liquid chromatography in erythroid progenitor cells during 
their in vitro differentiation in same culture conditions (Cokic et al., 2003, 2008). The 
transferrin receptor (CD71) is present on early erythroid cells but is lost as reticulocytes 
differentiate into mature erythrocytes (Cokic et al., 2003). At day 6 of erythroid cell culture, 
the erythroid progenitor cells were sorted as 100% CD71+, a well-known early marker of 
erythroid differentiation. In microarray studies, the quantities of tissue specific 
overexpressed genes were determined from two to four independent samples (biological 
repeats). During microarray analysis genes are upregulated or downregulated versus 
HuURNA, what we used as a control alongside each sample. We observed largely 
upregulated genes in all tissues (Table 1).  
Besides common highly expressed genes in erythroid progenitor cells: CD71, Rh-associated 
glycoprotein (RHAG), SERPINE1 mRNA binding protein 1 (SERBP1); the highly expressed 
genes in erythroid cells of FL origin are ribonuclease, RNase A family 2 and 3 (RNASE2/3) 
and serpin peptidase inhibitor, clade B (SERPINB1, Table 1). 
The highly expressed genes in erythroid cells of CB origin are hemoglobin gamma A 
(HBG1), NFE2 and eosinophil peroxidase (EPX). The greatly expressed genes in erythroid 
cells of BM origin are latexin (LXN), coproporphyrinogen oxidase (CPOX) and carbonic 
anhydrase II (CA2). The highly expressed genes in erythroid cells of mPB origin are KLF1, 
aminolevulinate, delta-, synthase 2 (ALAS2) and THO complex 2 (THOC2). The genes with 
reduced expressed in erythroid cells of PB origin are proteoglycan 2 (PRG2), Charcot-
Leyden crystal protein (CLC), EPX and v-myb myeloblastosis viral oncogene homolog  
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Biosciences, Palo Alto, CA) served as a universal reference control in the competitive 
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coupled cDNA, and the mixture applied to the MinElute column and centrifuged. After 
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cooled for 1 minute. Total volume of probe was added on the array and covered with cover 
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incubated overnight at 65oC. Slides were then washed for 2 minutes each in 2X SSC, 1X SSC 
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(635nm) channels using Axon GenePix 4000B scanner (Axon Instruments, Inc., Foster City, 
CA) with a 10-micron resolution. Scanned microarray images were exported as TIFF files to 
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gave a ratio that was used to normalize the signals. Each microarray experiment was 
globally normalized to make the median value of the log2-ratio equal to zero. The Loess 
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cells of BM origin are latexin (LXN), coproporphyrinogen oxidase (CPOX) and carbonic 
anhydrase II (CA2). The highly expressed genes in erythroid cells of mPB origin are KLF1, 
aminolevulinate, delta-, synthase 2 (ALAS2) and THO complex 2 (THOC2). The genes with 
reduced expressed in erythroid cells of PB origin are proteoglycan 2 (PRG2), Charcot-
Leyden crystal protein (CLC), EPX and v-myb myeloblastosis viral oncogene homolog  
 





Fold induction vs. HuURNA (±SD) 
FL CB BM mPB PB 
HBG1 hemoglobin, gamma A  4.2±0.7 4.5±0.9 4.1±1 4.3±0.2 4.7±0.6 
CLC Charcot-Leyden crystal protein  4.3±0.4 4.3±0.7 4.6±0.6 4.8±0.4 2.9±0.6 
PRG2 proteoglycan 2, bone marrow 5±0.3 4.2±0.9 4.7±0.5 4.1±0.7 2.9±0.4 
RNASE2 ribonuclease, RNase A family, 2  4.3±0.7 3.7±0.9 3.1±0.6 3.5±0.7 1.4±0.8 
HBD hemoglobin, delta  2±1.3 3.5±0.3 4.3±0.4 4.2±0.4 3.2±0.5 
EPX eosinophil peroxidase  4±0.2 3.4±0.8 2.9±0.7 2.6±1.1 0.9±0.5 
SRGN serglycin  4.3±1 2.8±1 4.4±1.3 4.6±0.4 2.1±0.5 
TFRC transferrin receptor (p90, CD71)  3.1±1 3.3±1.2 4.4±0.3 4.3±0.03 3±0.9 
HBE1 hemoglobin, epsilon 1  3±1.2 2.6±1.5 4.4±1.7 4.6±0.01 3.4±1.3 
RHAG Rh-associated glycoprotein  2.7±1.3 3.2±1.2 2.1±0.9 3.1±0.7 2.1±0.5 
MPO myeloperoxidase  3.8±0.2 3.2±0.6 3.4±0.1   
MYB v-myb myeloblastosis viral oncogene homolog  3±0.3 3.1±0.7 2.6±0.4 3.5±0.4 1.7±1 
RNASE3 ribonuclease, RNase A family, 3  3.6±1.2 2.7±1.5 2±1 3.1±0.7 0.6±0.2 
LXN latexin 1.5±0.4 1.9±0.7 4.7±1 4.1±0.5 2.7±0.2 
CD36 CD36 molecule (thrombospondin rec)  1.6±1.1 2.6±0.5 4±1 3.2±0.5 2.1±0.8 
CPOX coproporphyrinogen oxidase 2±0.8 2.7±0.6 3.5±0.7 2.9±0.4 1.8±0.6 
CA2 carbonic anhydrase II  0.15 1±0.3 3.3±0.6 1.8±0.2 1.7±0.5 
CYTL1 cytokine-like 1 1.4±0.8 1.7±0.4 2.8±0.4 3.7±0.3 2.4±0.3 
KLF1 Kruppel-like factor 1 (erythroid) 1±0.4 1.7±0.5 2.5±0.9 3.6±0.3 2.3±0.2 
ALAS2 aminolevulinate, delta-, synthase 2 1.5±0.4 1.4±0.3 2.5±0.9 3.5±0.7 2.7±0.3 
CPA3 carboxypeptidase A3 (mast cell)  1 0.9±0.3 1.9±0.7 3.2±0.4 1.2±0.5 
THOC2 THO complex 2 0.6±0.4 0.9±0.5 1.4±0.7 3.1±0.2 1.6±0.5 
GATA1 globin transcription factor 1 0.9 2.1±0.4 2.7±0.6 2.5±0.3 2.3±0.3 
NFE2 nuclear factor (erythroid-derived 2) 1.4±0.4 1.9±0.5 2.6  1.6±0.5 
SERPINB1 serpin peptidase inhibitor, clade B 2.5±0.2 1.8±0.3 1.7±0.4 0.9±0.3 0.7±0.3 
SERBP1 SERPINE1 mRNA binding protein 1  2.1±0.4 2.4±0.5 1.9±0.7 1.9±0.5 1.6±0.6 
Table 1. Largely up-regulated genes vs. HuURNA among different tissues: FL, CB, BM, 
mPB, PB. Bolded black values represent increased genes expression, whereas bolded gray 
values represent decreased genes expression in comparison to other tissues. 
(MYB). Presence of certain gene in the least two samples (66% filtering), in one group of 
tissues, reduced largely the total gene expression in all tissues. Using the range of 
microarray analysis and filtering reduction, the erythroid cells of FL tissue origin expressed 
1772 genes, CB-derived erythroid cells expressed 3846 genes, BM derived erythroid cells 
expressed 1827 genes, mPB derived erythroid cells expressed 4008 genes, and PB derived 
erythroid cells expressed 1320 genes. The observed gene expression is more than doubled in 
CB and mPB tissues in comparison to other tissues.  
2.3.2 A comparison in genes expression of erythroid cells during subsequent stages 
of development 
Using Venn diagrams we compared total gene expression, determined by microarray 
analysis, among all examined ontogenic tissues. By 66% filtering, we analyzed only genes  
 




Fig. 1. Venn diagram of genes expression in erythroid progenitor cells between FL and 
other developmental tissues. A: Comparison among FL, CB and BM tissues; B: Comparison 
among FL, CB and mPB tissues; C: Comparison among FL, CB and PB tissues; D: 
Comparison among FL, BM and mPB tissues. 
present in at least two donor samples per tissue. We compared gene expression of FL-
derived erythroid cell with other ontogenic derived tissues in Figure 1. Shared genes 
expression was more prominent between CB and FL/mPB derived erythroid cells, than 
between FL and BM/PB tissues (Figure 1A-C). Moreover, the FL- and CB-derived erythroid 
cells have the more common genes with mPB-derived erythroid cells than with BM and PB 
tissues (Figures 1D, 2C). The genes related to FL tissue shared the similar expression with 
BM- and PB-derived cells (Figure 2A). In addition, the genes expression in mPB-derived 
erythroid cells contains the majority of genes expressed in FL, BM and PB tissues (Figure 2B,  
 
Fig. 2. Venn diagram of genes expression in erythroid progenitor cells among ontogenic 
tissues. A: Comparison among FL, BM and PB tissues; B: Comparison among FL, mPB and 
PB tissues; C: Comparison among CB, BM and mPB tissues. 
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cells have the more common genes with mPB-derived erythroid cells than with BM and PB 
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erythroid cells contains the majority of genes expressed in FL, BM and PB tissues (Figure 2B,  
 
Fig. 2. Venn diagram of genes expression in erythroid progenitor cells among ontogenic 
tissues. A: Comparison among FL, BM and PB tissues; B: Comparison among FL, mPB and 
PB tissues; C: Comparison among CB, BM and mPB tissues. 
 




Fig. 3. Venn diagram of genes expression in erythroid progenitor cells between PB and 
other ontogenic tissues. A: Comparison among CB, BM and PB tissues; B: Comparison 
among CB, mPB and PB tissues; C: Comparison among BM, mPB and PB tissues. 
3C), but not in CB tissue (Figures 2C, 3B). Also, mPB-derived erythroid cells shared more 
genes with BM tissue than with PB tissue (Figure 3C). The genes expression in CB-derived 
erythroid cells overwhelmed the gene expression in BM tissues and almost completely in PB 
tissue (Figure 3A). 
Comparison in genes expression between FL- and CB-derived erythroid cells revealed 
couple statistically significant genes (p<0.01, Table 2): POLE3 and BRP44. Negative values in 
Tables represent downregulated genes expression in ontogenic tissues in contrast to 
HuURNA, whereas positive values represent upregulated genes.  
 







POLE3  polymerase epsilon 3 0.0022 0.4±0.22 0.8±0.4 FL, CB, mPB, PB 
SNRPD3  small nuclear ribonucleoprotein D3 0.0036 0.8±0.02 1.6±0.4 FL, CB, mPB 
ZFP36  zinc finger protein 36 0.0072 -1.6±0.07 -2.3±0.6 FL, CB, mPB 
BRP44  brain protein 44  0.0063 -0.14±0.09 0.5±0.1 All tissues 
Table 2. Comparison of statistically significant (p<0.01) genes between FL and CB tissues.  
Brain protein 44 (BRP44) gene expressions was highly significantly increased in CB-derived 
erythroid cells vs. FL-derived cells (Table 2), but was reduced in comparison to PB-derived 
cells (Table 8). BRP44 gene was stable expression in all examined ontogenic tissues, whereas 
POLE 3 gene expression was absent in BM tissue (Table 2). Comparison in genes expression 
between FL- and BM-derived erythroid cells exposed more statistically significant genes 
(Table 3): SBNO2, WDR1 and CTAG2 present in all tissues.  
WD repeat domain 1 (WDR1) gene expressions was significantly increased in BM- vs. PB-
derived erythroid cells (Table 10), but was reduced in comparison to FL-derived cells (Table 
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3). Evaluation in genes expression between FL- and mPB-derived erythroid cells exposed 
also statistically significant genes (Table 4): ME2 present just in FL and mPB tissues, highly 
upregulated EEF1B2 expressed in all tissues. IFI30 was downregulated in mPB-derived 
erythroid cells, but was upregulated in FL-derived cells (Table 4). 
 





SPRR2B small proline-rich protein 2B 0.0001 -0.8±0.03 -0.9±0.5 FL, CB, BM,mPB 
SRI  sorcin  0.0014 0.9±0.04 1.1±0.2 All tissues 
KPNA2 karyopherin alpha 2  0.002 0.5±0.005 1 ±0.2 All tissues 
SDHC  succinate dehydrogenase complex, subunit C 0.0021 0.1±0.05 0.2±0.2 All tissues 
NCOA4 nuclear receptor coactivator 4 0.0048 2±0.3 1.8±0.4 All tissues 
SBNO2  strawberry notch homolog 2 0.005 -1.5±0.02 -1.1±0.6 All tissues 
TTC3  tetratricopeptide repeat domain 3  0.0057 0.3±0.08 0.6±0.1 FL, CB, BM,mPB 
PTTG1  pituitary tumor-transforming1  0.0078 0.7±0.05 1±0.2 All tissues 
WDR1  WD repeat domain 1  0.0079 0.5±0.002 0.3±0.1 All tissues 
MINK1  Misshapen-like kinase 1  0.0089 -1.2±0.1 -0.9±0.5 All tissues 
CTAG2  cancer/testis antigen 2  0.0094 -0.1±0.25 -0.2±0.54 All tissues 
Table 3. Comparison of statistically significant (p<0.01) genes between FL and BM tissues. 
 





ME2  malic enzyme 2, NAD(+)-dependent, mitochondrial  0.0068 1.19±0.15 0.9±0.14 FL, mPB 
INSIG1 insulin induced gene 1  0.0073 -0.08±0.4 -0.01±0.4 FL, mPB 
EEF1B2 eukaryotic translation elongation factor 1 beta 2  0.0009 1.77±0.12 2.3±0.12 All tissues 
ZNF224  zinc finger protein 224  0.0015 -0.2±0.06 0.9±0.06 FL, CB, BM, mPB 
CSDE1  cold shock domain containing E1, RNA-binding 0.004 0.56±0.08 0.6± 0.02 All tissues 
IFI30  Interferon, gamma-inducible protein 30  0.0059 0.06±0.05 -2±0.07 FL, CB, BM, mPB 
PSMD11 proteasome 26S, non-ATPase,11  0.0091 0.67±0.17 0.18±0.16 All tissues 
PGAM1 phosphoglycerate mutase 1  0.0093 0.87±0.15 0.06±0.16 FL, CB, mPB, PB 
PTPRC protein tyrosine phosphatase, receptor type, C  0.0093 1.42±0.75 1.5±0.75 FL, CB, BM, mPB 
Table 4. Comparison of statistically significant (p<0.01) genes between FL and mPB tissues. 
Comparison between FL- and PB-derived erythroid cells revealed just two significant genes: 
TOP1 and CAT (Table 5). TOP1 and CAT genes have higher levels in FL tissue than in PB.  
 




Fig. 3. Venn diagram of genes expression in erythroid progenitor cells between PB and 
other ontogenic tissues. A: Comparison among CB, BM and PB tissues; B: Comparison 
among CB, mPB and PB tissues; C: Comparison among BM, mPB and PB tissues. 
3C), but not in CB tissue (Figures 2C, 3B). Also, mPB-derived erythroid cells shared more 
genes with BM tissue than with PB tissue (Figure 3C). The genes expression in CB-derived 
erythroid cells overwhelmed the gene expression in BM tissues and almost completely in PB 
tissue (Figure 3A). 
Comparison in genes expression between FL- and CB-derived erythroid cells revealed 
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Tables represent downregulated genes expression in ontogenic tissues in contrast to 
HuURNA, whereas positive values represent upregulated genes.  
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PTPRC protein tyrosine phosphatase, receptor type, C  0.0093 1.42±0.75 1.5±0.75 FL, CB, BM, mPB 
Table 4. Comparison of statistically significant (p<0.01) genes between FL and mPB tissues. 
Comparison between FL- and PB-derived erythroid cells revealed just two significant genes: 
TOP1 and CAT (Table 5). TOP1 and CAT genes have higher levels in FL tissue than in PB.  
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TOP1  topoisomerase I  0.0017 1.3±0.34 0.9±0.7 All tissues 
CAT  catalase  0.0042 1.8±0.18 1.3±0.26 FL, CB, mPB, PB 
Table 5. Comparison of statistically significant (p<0.01) genes between FL and PB tissues. 
Evaluation in genes expression between CB- and BM-derived erythroid cells exposed 
several genes: WAPAL, GRB2, GOLIM4, etc. (Table 6). CTDSP1 has the elevated expression 
in CB tissue, while TPST2 has the higher expression in BM tissue (Table 6).  
 







secretory carrier membrane 
protein 2  0.0022 0.4±0.22 0.8±0.4 CB, BM, PB 
ABCF2 ATP-binding cassette, sub-family F 0.0075 -0.2±0.17 0.22±0.08 CB, BM, PB 
ZNF16  zinc finger protein 16  0.0093 0.2±0.2 0.6±0.18 CB, BM, PB 
GRIPAP1 GRIP1 associated protein 1  0.0014 -0.6±0.45 -0.06±0.45 All tissues 
WAPAL wings apart-like homolog  0.0023 1.3±0.1 1.7±0.1 All tissues 
TPST2  tyrosylprotein sulfotransferase 2 0.0029 0.8±0.26 1.6±0.21 All tissues 
TPSB2  tryptase beta 2  0.0035 -0.7±0.43 1±0.33 All tissues 
CCNB2 cyclin B2  0.0037 1.3±0.21 1.7±0.19 All tissues 
RPS13  ribosomal protein S13  0.0041 1.9±0.23 1.5±0.21 All tissues 
GRB2  growth factor receptor-bound protein 2  0.0067 -0.06±0.4 0.4±0.38 All tissues 
GSK3A glycogen synthase kinase 3α 0.0071 -1±0.04 -0.8±0.06 All tissues 
CTDSP1 carboxy-terminal domain,  A polypeptide small phosphatas 1  0.0077 0.4±0.23 -0.05±0.01 All tissues 
ZNF43  zinc finger protein 43  0.0086 0.9±0.11 1.2±0.09 All tissues 
GOLIM4  golgi integral membrane protein 4 0.0094 0.4±0.04 0.85±0.07 All tissues 
Table 6. Comparison of statistically significant (p<0.01) genes between CB and BM tissues. 
Zinc finger protein 43 (ZNF43) has also significantly increased gene expressions in BM-
derived erythroid cells compared to CB- and PB-derived erythroid cells (Tables 6, 10). Golgi 
integral membrane protein 4 (GOLIM4) gene has also significantly increased expressions in 
BM-derived erythroid cells compared to CB- and mPB-derived erythroid cells (Tables 6, 9). 
Assessment in genes expression between CB- and mPB-derived erythroid cells uncovered 
several genes: ARF4, PHIP, ACIN1, etc. (Table 7). ARF4 has highly upregulated gene 
expression in CB-derived cells compared to mPB tissue.  
Measurement in genes expression profile between CB and PB tissues revealed the 
downregulated genes PPFIA4 and WIPI2, as well as upregulated genes FBL and BRP44 
(Table 8). WIPI2 was less downregulated in PB tissue than in CB tissue. 
Determination of statistical significance between BM and mPB tissues showed the prevalent 
quantity of genes: MYCL2, ADIPOR2 and POP7 present in CB, BM and mPB tissues; 
NFATC3, YY1, GCA present in all tissues except PB; YWHAZ, TACC3, UBE2D3 present in 
BM, mPB and PB tissues (Table 9). 
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GRN  granulin  0.0007 -1.1±0.35 -1.5±0.16 All tissues 
PHIP  pleckstrin homology domain interacting protein 0.0009 0.5±0.38 1.4±0.29 All tissues 
ARF4  ADP-ribosylation factor 4  0.0037 0.4±0.3 0.04±0.15 FL, CB, BM, mPB 
UBE2V1 ubiquitin-conjugating enzyme E2 variant 1  0.0044 0.7±0.06 0.4±0.04 All tissues 
ACIN1 apoptotic chromatin condensation inducer 1  0.0058 0.6±0.11 0.3±0.05 All tissues 
XRCC6 
X-ray repair complemen-
ting defective repair in 
Chinese hamster cells 6  
0.0067 1.2±0.13 0.8±0.11 All tissues 
F2R  coagulation factor II (thrombin) receptor  0.0072 -0.2±0.22 -0.9±0.21 FL, CB, BM, mPB 
SNRPA  small nuclear ribonucleo-protein polypeptide A  0.008 1.6±0.37 1.1±0.02 FL, CB, mPB 
LGALS1  lectin, galactoside-binding, soluble, 1  0.0093 -1.3±0.48 -0.5±0.57 FL, CB, mPB 
Table 7. Comparison of statistically significant (p<0.01) genes between CB and mPB tissues. 
 







phatase, f polypeptide, 
interacting protein α 4  
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interacting 2  
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FBL  fibrillarin 0.0056 1.5±0.29 0.9±0.36 All tissues 
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Table 8. Comparison of statistically significant (p<0.01) genes between CB and PB tissues. 
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mpp9  0.0012 -0.7±0.18 -1.3±0.19 CB, BM, mPB 
SLC25A39 solute carrier family 25, member 39 0.0013 1.5±0.13 0.9±0.07 CB, BM, mPB 
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TOP1  topoisomerase I  0.0017 1.3±0.34 0.9±0.7 All tissues 
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Table 5. Comparison of statistically significant (p<0.01) genes between FL and PB tissues. 
Evaluation in genes expression between CB- and BM-derived erythroid cells exposed 
several genes: WAPAL, GRB2, GOLIM4, etc. (Table 6). CTDSP1 has the elevated expression 
in CB tissue, while TPST2 has the higher expression in BM tissue (Table 6).  
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BM, mPB and PB tissues (Table 9). 
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GRN  granulin  0.0007 -1.1±0.35 -1.5±0.16 All tissues 
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UBE2V1 ubiquitin-conjugating enzyme E2 variant 1  0.0044 0.7±0.06 0.4±0.04 All tissues 
ACIN1 apoptotic chromatin condensation inducer 1  0.0058 0.6±0.11 0.3±0.05 All tissues 
XRCC6 
X-ray repair complemen-
ting defective repair in 
Chinese hamster cells 6  
0.0067 1.2±0.13 0.8±0.11 All tissues 
F2R  coagulation factor II (thrombin) receptor  0.0072 -0.2±0.22 -0.9±0.21 FL, CB, BM, mPB 
SNRPA  small nuclear ribonucleo-protein polypeptide A  0.008 1.6±0.37 1.1±0.02 FL, CB, mPB 
LGALS1  lectin, galactoside-binding, soluble, 1  0.0093 -1.3±0.48 -0.5±0.57 FL, CB, mPB 
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UBE2NL  ubiquitin-conjugating enzyme E2N-like  0.0015 0.9±0.17 0.6±0.17 CB, BM, mPB 
POP7  Processing of precursor 7, ribonuclease P/MRP subunit 0.0027 -0.4±0.21 0.28±0.12 CB, BM, mPB 
ANKH  ankylosis, progressive homolog  0.0031 -0.5±0.22 -1.2±0.21 CB, BM, mPB 
ADIPOR2 adiponectin receptor 2  0.0045 0.6±0.32 0.6±0.01 CB, BM, mPB 
ZBTB43  zinc finger and BTB domain containing 43  0.0041 -0.9±0.22 -1.4±0.21 CB, BM, mPB 
RBM8A  RNA binding motif protein 8A  0.0048 -0.9±0.45 -0.3±0.13 CB, BM, mPB 
ZYG11B  zyg-11 homolog B  0.0062 -0.2±0.28 -0.9±0.23 CB, BM, mPB 
APBB2  
amyloid beta precursor 
protein-binding, family B, 
member 2  
0.0074 -0.8±0.16 -1.1±0.17 CB, BM, mPB 
CEP97  centrosomal protein 97kDa  0.0082 -0.6±0.09 -1.4±0.1 CB, BM, mPB 
KLRD1  killer cell lectin-like receptor subfamily D 0.0011 -0.4±0.16 -1.3±0.16 FL, CB, BM, mPB 
TOMM34  translocase of outer mitochondrial membrane 34 0.0035 -0.5±0.21 -0.6±0.15 FL, CB, BM, mPB 
NFATC3  
nuclear factor of activated T-
cells, cytoplasmic, 
calcineurin-dependent 3  
0.0045 1.3±0.19 0.9±0.23 FL, CB, BM, mPB 
YY1  YY1 transcription factor  0.0047 1.4±0.18 0.8±0.22 FL, CB, BM, mPB 
SSB  Sjogren syndrome antigen B 0.0050 2.7±0.72 2.3±0.003 FL, CB, BM, mPB 
UBC  ubiquitin C  0.0069 -1±0.53 -1.3±0.08 FL, CB, BM, mPB 
UBA1  ubiquitin-like modifier activating enzyme 1  0.0083 -0.4±0.6 -0.6±0.17 FL, CB, BM, mPB 
LRRC59  leucine rich repeat containing59  0.0086 1.9±0.25 1.5±0.03 FL, CB, BM, mPB 
GCA  grancalcin, EF-hand calcium binding protein  0.0098 1.2±0.21 0.4±0.17 FL, CB, BM, mPB 
TACC3  transforming, acidic coiled-coil containing protein 3  0.0011 0.02±0.01 -0.3±0.03 BM, mPB, PB 
LMNB1 lamin B1 0.0014 1±0.1 -0.1±0.04 BM, mPB, PB 
SREBF2  sterol regulatory element binding  0.0019 -0.6±0.05 -2.1±0.18 BM, mPB, PB 





protein, zeta polypeptide  
0.0042 1.4±0.08 0.7±0.04 BM, mPB, PB 
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GOLIM4  golgi integral membrane protein 4  0.0044 0.8±0.02 0.29±0.05 BM, mPB, PB 
GLE1  GLE1 RNA export mediator homolog  0.0049 -0.4±0.02 0.29±0.12 BM, mPB, PB 
CORO1C  coronin actin binding protein 1C  0.0049 1.4±0.1 0.6±0.08 BM, mPB, PB 
ARHGDIB  Rho GDPdissociation inhibitorβ 0.0075 1.4±0.02 1.2±0.03 BM, mPB, PB 
TMEM187  transmembrane protein 187  0.0082 -0.4±0.08 -0.9±0.03 BM, mPB, PB 
TIMM23  
translocase of inner 
mitochon-drial membrane 23 
homolog  
0.0088 0.9±0.1 0.3±0.05 BM, mPB, PB 
PSMB5  proteasome subunit, β type, 5 0.0092 0.3±0.02 0.02±0.02 BM, mPB, PB 
Table 9. Comparison of statistically significant (p<0.01) genes between BM and mPB tissues. 
YY1 transcription factor has significantly increased gene expressions in BM-derived 
erythroid cells compared to PB- and mPB-derived erythroid cells (Tables 9, 10). 
Measurement of statistical significance between BM and PB tissues revealed the following 
significant genes: NUCKS1 and KDM3B prevalent in BM tissue, ATF5 and ATP5L prevalent 
in BM tissue (Table 10).  
 







nuclear casein kinase and cyclin-
dependent kinase substrate 1   0.0092  1.1±0.62  0.7±0.12   CB, BM,PB  
KDM3B  lysine (K)-specific demethylase 3B   0.0002  0.8±0.01  0.15±0.03  BM, mPB, PB 
WDR1  WD repeat domain 1   0.0018  0.3±0.1   -0.2±0.03  BM, mPB, PB 
YY1  YY1 transcription factor   0.0018  1.4±0.2   0.25±0.14  BM, mPB, PB 
FEN1  flap structure-specific endonuclease 1   0.004  2.7±0.1   1.13±0.2  BM, mPB, PB 
ATF5  activating transcription factor 5   0.0057  -0.8±0.1  -0.2±0.14  BM, mPB, PB 
ZNF43  zinc finger protein 43   0.0058  1.2±0.08  0.5±0.15   BM, mPB, PB 
ATP5L  
ATP synthase, H+ transporting, 
mitochondrial F0 complex, 
subunit G  
 0.0071  0.3±0.08  0.78±0.09  BM, mPB, PB 
HLA-C  MHC class I human leukocyte antigen  0.0046  -2.7±0.7  -2.1±0.88 CB,BM,PB  
Table 10. Comparison in statistically significant (p<0.01) gene between BM and PB tissues. 
Flap structure-specific endonuclease 1 (FEN1) gene has significantly decreased expressions 
in PB-derived erythroid cells compared to BM- and mPB-derived erythroid cells (Tables 10, 
11). Similarity in genes expression between mPB and PB tissues was limited on four 
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Measurement of statistical significance between BM and PB tissues revealed the following 
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in PB-derived erythroid cells compared to BM- and mPB-derived erythroid cells (Tables 10, 
11). Similarity in genes expression between mPB and PB tissues was limited on four 
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significant genes: TXNIP, EIF3E, FEN1 and FECH (Table 11). TXNIP was present and 
downregulated just in mPB and PB tissues, whereas EIF3E and FEN1 was highly 
upregulated in all tissues and predominantly in mPB-derived erythroid cells. FECH has 
more prominent expression in PB- than in mPB-derived cells. 
 





TXNIP Brain-expressed HHCPA78 homolog VDUP1 0.0063 -1.3±0.05 -0.14±0.18 mPB, PB 
EIF3E eukaryotic translation initiation factor 3, subunit E 0.0003 2.5±0.14 1.2±0.24 All tissues 
FEN1 flap structure-specific endonuclease 1 0.0028 2±0.21 1.13±0.21 All tissues 
FECH ferrochelatase  0.0074 1.6±0.7 2.5±0.59 FL, CB, mPB, PB 
Table 11. Comparison in statistically significant (p<0.01) gene between mPB and PB tissues. 
2.3.3 Signaling pathways related to globin genes expression 
It has been already reported that γ globin genes expression is regulated by nitric oxide (NO) 
and p38 MAPK signaling pathways (Cokic et al., 2003; Ramakrishnan & Pace, 2011). We 
examined the genes related to those pathways in erythroid progenitor cells during ontogeny 
in succeeding tissues (Figure 4). Protein kinase, cAMP-dependent, regulatory, type II, beta 
(PRKAR2B) has the highest expression in NO signaling pathways linked genes throughout 
the ontogeny reaching the top in PB-derived erythroid cells. Calmodulin 2 (CALM2) gene 
demonstrates decline in expression during ontogeny, as well as protein phosphatase 3 beta 
isoform (PPP3CB, Figure 4A). Downregulation in gene expression during ontogeny was 
shown for protein kinase, cAMP-dependent, regulatory, type I, alpha (PRKAR1A) and 
calmodulin 3 (CALM3). Regarding p38 MAPK signaling pathway, transforming growth 
factor, beta 1 (TGFB1) gene expression was predominant in FL- and BM-derived erythroid 
cells, while heat shock 27kDa protein 1 (HSPB1) was decreased in BM-derived erythroid 
cells (Figure 4B). Linked to p38 MAPK, v-myc myelocytomatosis viral oncogene homolog 
(MYC) has the most upregulated gene expression throughout the ontogeny (Figure 4B). 
2.3.4 Discussion 
To recognize sets of genes that reveal the essential mechanisms in hematopoiesis, as 
potential novel therapeutic targets, several groups have performed individual gene 
expression profiling in erythroid cells from certain tissues during ontogenesis. We extended 
those studies, of gene expression pattern of ontogenic tissues, to compare gene expression 
from fetal to adult hematopoiesis as a more reflective and comprehensive overview of 
erythropoiesis. Gene expression in normal human erythroid progenitor cells has been 
described and generally static expression analysis was performed on cultured human 
erythroid progenitor CD71+ cells derived from CD34+ cells in the presence of EPO and 
cocktail of cytokines. We presented the number of total genes overexpressed in evaluated 
tissues, the most dominant in CB and mPB tissues. Also, the highly expressed genes are 
SERPINE1, PRG2, CLC, HBG1, NFE2 and EPX. General genes expression was more present 
between CB and FL/mPB derived erythroid cells, than between FL and adult tissues.  
 







Fig. 4. Gene expression in signaling pathways related to globins stimulation determined 
by microarray analysis. A: Induction of Nitric oxide signaling pathway related genes in 
erythroid progenitor cells during human ontogeny. B: Induction of p38 MAPK signaling 
pathway related genes in erythroid progenitor cells during human ontogeny. 
Comparison between certain tissues revealed the statistically significant genes: TOP1, CAT, 
IFI30 in FL tissue, ARF4, CTDSP1 in CB tissue, WDR1, ATF5, YWHAZ in BM tissue, EIF3E 
and FEN1 in mPB tissue, FECH in PB tissue. PRKAR2B has the highest expression in NO 
signaling pathways, while MYC has the most upregulated gene expression in p38 MAPK 
signaling pathway in erythroid progenitor cells throughout ontogeny. 
3. Nitric oxide interaction with signaling pathways related to erythropoiesis  
It has been found that proliferation of erythropoietic cells is more related to activation of 
JAK-STAT and MAPK p42/44 signaling pathways, whereas the survival of erythropoietic 
cells correlated better with activation of PI-3K-AKT, JAK-STAT and MAPK p42/44 
pathways (Ratajczak et al., 2001). During erythroid maturation, the p38 MAPK regulates γ-
globin transcription through its downstream effector cAMP response element binding 
protein 1 (CREB1) which binds the Gγ-globin 3’,5’-cyclic adenosine monophosphate (cAMP) 
response element (Ramakrishnan & Pace, 2011). NO is a diffusible free radical that plays a 
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role as a chemical messenger involved in vasodilator, neurotransmitter, and anti-platelet 
aggregation. NO is produced and released from three different isoforms of NO synthase 
(NOS) that convert the l-arginine and molecular oxygen to citrulline and NO in cells: 
endothelial (eNOS), inducible (iNOS), and neuronal (nNOS) (Cokic & Schechter, 2008). NO 
readily diffuses across cell membranes into neighboring cells, or may produce effects distant 
from its site of production transported by vehicles such as low-molecular weight S-
nitrosotiols, S-nitrosylated proteins including hemoglobin and albumin, and nitrosyl-metal 
complexes which liberate NO spontaneously or after cleavage by ectoenzymes (Bogdan, 
2001). A significance of NO in erythroid differentiation has been founded on demonstration 
that NO donors inhibit growth of erythroid primary cells and colony cultures (Maciejewski 
et al., 1995). Besides observation that NO inhibited erythroid differentiation induced by 
butyric acid, antitumour drugs aclarubicin and doxorubicin, but not by hemin (Chénais et 
al., 1999), additional study demonstrated inhibitory effect of NO in the hemin-induced 
erythroid differentiation (Kucukkaya et al., 2006). NO decreased colony-forming unit-
erythrocytes (CFU-E) and CFU-granulocyte macrophage (CFU-GM) formation derived from 
human bone marrow mononuclear cells. Moreover, NO increased CFU-GM and decreased 
CFU-E formation derived from CD34+ hematopoietic progenitor cells (Shami & Weinberg, 
1996). Although NO increased intracellular levels of guanosine 3’,5’-cyclic monophosphate 
(cGMP) in bone marrow cells, addition of a membrane permeable cGMP analogue did not 
reproduce previously mentioned effects of NO in bone marrow derived colonies (Shami & 
Weinberg, 1996). We have previously shown that HbF stimulation is dependent on 
NO/cGMP signaling pathway in erythroid progenitor cells (Cokic et al., 2003). NO-releasing 
agents and cGMP analogues inhibit murine erythroleukemia cell differentiation and 
suppress erythroid-specific gene expression such as beta-globin and delta-aminolevulinate 
synthetase (Suhasini et al., 1995). Serum nitrate and nitrite (NOx) concentrations correlated 
inversely with hemoglobin levels (Choi et al., 2002).  
EPO increased the level of phosphorylated eNOS and stimulated NO production and cGMP 
activity during hypoxia (Beleslin-Cokic et al., 2004; Su et al., 2006). Phospho-eNOS and eNOS 
were significantly induced by hypoxia (Beleslin-Čokić et al., 2011). NO participates in stability 
control of hypoxia inducible factor (HIF)-1α and induces HIF-1α accumulation and HIF-1-
DNA binding (Kovacević-Filipović et al., 2007). Hypoxia and EPO increased erythropoietin 
receptor (EPOR) gene expression and protein level (Beleslin-Čokić et al., 2011). The 
physiologically low oxygenation of bone marrow is a regulator of hematopoiesis maintenance, 
and physiological levels of O2 should be considered as an important environmental factor that 
significantly influences cytokine activity (Brüne & Zhou, 2007; Krstic et al., 2009a). The 
proportion of γ–globin mRNA (the γ/(γ+β) mRNA ratio) increased with reduced oxygen, 
reaching a maximum value at 5% O2 of 1.5 to 4-fold higher than at 20% O2, and then decreased 
as the O2 dropped to 2%. In parallel, the proportion of HbF (the HbF/(HbF+HbA) ratio) also 
peaked at 5% O2. Reported increase in the HbF was generally lower than that of the γ-globin 
mRNA, suggesting that although globin mRNA accumulation is primarily under 
transcriptional regulation, additional post-transcriptional processing such as globin chain 
stability contribute to the amount of produced hemoglobins (Rogers et al., 2008). 
4. Nitric oxide influence on hematopoietic microenvironment in bone marrow  
Various growth factors, cytokines, and chemokines are secreted by human hematopoietic 
progenitor cells, myeloblasts, erythroblasts, and megakaryoblasts to regulate normal 
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hematopoiesis in an autocrine/paracrine manner. Furthermore, each stromal cell in the bone 
marrow may provide the preferable microenvironment for a rapid expansion of the lineage-
restricted progenitor cells (Kameoka et al., 1995; Majka et al., 2001). We showed that the 
human endothelial cells and macrophages contain NOS activity, representing the potential 
pool for NO production. The erythroid progenitor cell co-cultures with either macrophages 
or endothelial cells, stimulated by NO-inducers, demonstrated more elevated levels of γ-
globin gene expression than in the erythroid cells only (Čokić et al., 2009). This observation 
suggests that NO could come out of the bone marrow stromal cells and diffuse into the 
erythroid progenitor cells largely participating in γ-globin gene induction, linked to stromal 
cells augmented capability for NO production. This supplemented NO production, in the 
hematopoietic microenvironment, has the potential to enhance HbF synthesis in erythroid 
progenitor cells, which still have low hemoglobin levels and presumably low scavenging 
activity. Accumulating evidence emphasized the involvement and important role of NO in 
the regulation of hematopoiesis (Krstić et al., 2009, 2010). Spleen is also an active 
hematopoietic organ where response of hematopoietic cells to cytokines depends on the 
tissue microenvironment (Jovčić et al., 2007). Improper signaling inside bone marrow 
stromal cells can lead to their failure and inconsistent microenvironmental niche for 
hematopoietic stem cells. It has been recently shown that basal NO/cGMP/cGMP-
dependent protein kinase (PKG) activity is necessary for preserving bone marrow stromal 
cell survival and promoting cell proliferation and migration (Wong & Fiscus, 2011). Co-
culture studies of human macrophages, as well as human bone marrow endothelial cell line, 
with erythroid progenitor cells resulted in induction of γ-globin mRNA expression in the 
presence of cytostatic hydroxyurea. NOS-dependent stimulation of NO by 
lipopolysaccharide and interferon-γ has been observed in human macrophages. In addition, 
lipopolysaccharide and interferon-γ together increased γ-globin gene expression in human 
macrophage/erythroid cell co-cultures (Čokić et al., 2009). These observations are in accord 
to the intimate contact between erythroid and stromal cells, effects and associations in 
physiological hematopoietic microenvironment. The endothelial cells as well as 
macrophages, normal components of bone marrow stroma, play an active role in the 
modulation of human hematopoietic stem cell growth (Ascensao et al., 1984; Davis et al., 
1005; Hanspal & Hanspal, 2004). The murine endothelial cell lines also stimulate the 
proliferation and differentiation of erythroid precursors, where close cell contact is 
necessary for erythropoiesis (Ohneda & Bautch, 1997). Mice deficient in eNOS, expressed by 
bone marrow stromal cells, demonstrated a defect in progenitor cell mobilization (Aicher et 
al., 2003). Hemoglobin synthesis of erythroleukemia cells line was increased after co-culture 
with endothelial cells and monolayers of bone-marrow-derived macrophages, as well as 
with cell-free culture media conditioned by blood-monocyte-derived macrophages (Zuhrie 
et al., 1988). NO has also an important role in bone marrow angiogenesis, together with 
vascular endothelial growth factor (VEGF), with implications in patients with leukemic 
malignancies (Antic et al., 2010, 2011). NO-cGMP pathway stimulates the proliferation and 
osteoblastic differentiation of primary mouse bone marrow-derived mesenchymal stem cells 
and osteoblasts (Hikiji et al., 1997). NO donors, as well as proteasome inhibitors, inhibited 
cytokine induced intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion 
molecule 1 (VCAM-1) expression (Cobb et al., 1996; De Caterina et al., 1995). The 
proteasome inhibition also significantly enhanced endothelial-dependent vasorelaxation of 
rat aortic rings (Stangl et al., 2004), as well as NO production in endothelial cells (Cokic et 
al., 2007). 
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5. Cyclic nucleotides induction of globin genes expression  
5.1 NO/cGMP stimulation of γ-globin gene expression 
We demonstrated that NO increases γ-globin gene expression in erythroid cells during 
differentiation. Inhibition of soluble guanylate cyclase (sGC) prevents NO-induced increase 
in γ-globin gene expression (Cokic et al., 2003). In addition, we have shown that the well 
known γ-globin gene inducer hydroxyurea stimulated HbF by the NO-dependent activation 
of sGC in human erythroid progenitor cells (Cokic et al., 2003). It has been shown that both 
sGC activators and cGMP induce γ-globin gene expression in human erythroleukemic cell 
line and primary erythroblasts (Ikuta et al., 2001). Therefore, intracellular pathway including 
sGC and PKG induced expression of the γ-globin gene (Ikuta et al., 2001). Moreover, it has 
been reported that hydroxyurea increased NOx levels and NOS-dependent γ-globin 
transcription in erythroleukemic and primary erythroid cells. This γ-globin gene activation 
demonstrated cGMP-dependence (Lou et al., 2009). We found that during human erythroid 
differentiation in vitro, eNOS mRNA and protein levels were initially high but then declined 
steadily, as did the production of NO derivatives, in contrast with steady elevation of 
hemoglobin levels, a potent scavenger of NO (Cokic et al., 2008). According to our previous 
results, hydroxyurea dose- and time-dependently induced rapid but transient activation of 
eNOS in endothelial cells (Cokic et al., 2006). Hydroxyurea stimulated NO production in 
endothelial cells, both as short and long term effects (Cokic et al., 2006, 2007). Chronic 
hydroxyurea therapy significantly increased NO, cGMP, and HbF levels in patients with 
sickle cell anemia (Nahavandi et al., 2002). cGMP levels were found to be significantly 
higher in red blood cells (RBCs) of sickle cell patients than in RBCs of normal individuals, 
and were further increased in RBCs of sickle cell patients on hydroxyurea therapy (Conran 
et al., 2004). NOS activity was also higher in RBCs of sickle cell disease patients on 
hydroxyurea therapy than in untreated patients (Iyamu et al., 2005). It is in accordance with 
results that l-arginine alone does not increase serum NOx production in steady-state 
patients, however it does when given together with hydroxyurea (Morris et al., 2003). 
Neither l-arginine alone nor l-arginine in combination with NOS inhibitor effected 
hydroxyurea-mediated induction of HbF synthesis in erythroid progenitors (Haynes et al., 
2004). L-arginine did not change the suppression of burst forming unit-erythroid (BFU-E) 
colony growth and stimulation of HbF synthesis by hydroxyurea in erythroid progenitors 
(Baliga et al., 2010). Inhibition of NOS attenuated the hydroxyurea and l-arginine effects on 
BFU-E colony growth and HbF synthesis (Baliga et al., 2010), but did not decrease NOx 
production in RBCs during incubation with hydroxyurea (Nahavandi et al., 2006). 
5.2 Nitric oxide synthase levels in red blood cells 
It has been demonstrated that human RBCs contain iNOS and eNOS as well as calmodulin, 
suggesting that RBCs may synthesize its own NO (Jubelin & Gierman, 1996). This notion 
was supported by the observation that RBCs have an active eNOS protein (Chen & Mehta, 
1998). Addition of l-arginine to RBCs stimulated NO production (measured as plasma 
nitrite) in a dose-dependent manner (Nahavandi et al., 2006), whereas it did not significantly 
change NOx levels (Chen & Mehta, 1998). However, it was later reported that RBCs possess 
iNOS and eNOS, but the proteins are without catalytic activity (Kang et al., 2000). Recent 
studies, revealed eNOS protein activity in the cytosol and in the internal side of membrane 
RBCs, serving essential regulatory functions for RBCs deformability and platelet 
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aggregation (Kleinbongard et al., 2006). In vitro NOx production by RBCs (normal and 
sickle) is increased by treatment with hydroxyurea, but it’s not decreased by NOS inhibition 
(Nahavandi et al., 2006). In difference to this result, we showed that hydroxyurea increased 
NO production via induction of eNOS activity in endothelial cells (Cokic et al., 2006). Thus, 
hydroxyurea may increase the plasma concentration of NO by combining endothelial cell 
NOS activity and interaction with oxy/deoxy hemoglobin in RBCs. We found previously 
that hydroxyurea increased cAMP and cGMP levels in human endothelial cells (Cokic et al., 
2006), as well as NO levels via activation of eNOS and proteasome inhibition (Cokic et al., 
2007). Previous reports indicated that cAMP elevation activated the L-arginine/NO system 
and induced vasorelaxation in rabbit femoral artery in vivo and human umbilical vein in 
vitro (Xu et al., 2000). It is known that agents that increase cAMP stimulate eNOS activity in 
human umbilical vein endothelial cells (Ferro et al., 1999). A recent report revealed that a 
rapid increase in endothelial NO production by bradykinin is mediated exclusively by PKA 
signaling pathway (Bae et al., 2003). PKA signaling acts by increasing phosphorylation of 
Ser1177 and dephosphorylation of Thr495 to activate eNOS (Michell et al., 2001). Shear 
stress stimulates phosphorylation of bovine eNOS at the corresponding serine in a PKA-
dependent, but PKB/Akt-independent, manner, whereas NO production is regulated by the 
mechanisms dependent on both PKA and PKB/Akt (Boo et al., 2002). 
5.3 A role of cAMP-dependent pathway in γ-globin gene induction 
During erythroid differentiation adenylate cyclase and cAMP phosphodiesterase activity, as 
well as cellular cAMP concentrations, decline in a synchronized manner (Setchenska et al., 
1981). The cAMP-dependent pathway plays a negative role in a γ-globin gene expression in 
K562 erythroleukemic cell line, in contrast to a cGMP positive role (Inoue et al., 2004). It has 
been also found that, upon activation of the cAMP pathway, expression of the γ-globin gene 
is induced in adult erythroblasts (Kuroyanagi et al., 2006). The subsequent study found that 
the cAMP-dependent pathway efficiently induced γ-globin expression in adult erythroblasts 
of beta-thalassaemia (Bailey et al., 2007). In patients with beta-thalassaemia intermedia, 
cAMP levels were elevated in both RBCs and nucleated erythroblasts but no consistent 
elevation was found with cGMP levels. The transcription factor cAMP response element 
binding protein (CREB) was phosphorylated in nucleated erythroblasts and its 
phosphorylation levels correlated with γ-globin gene expression of the patients (Bailey et al., 
2007). According to previous study, guanylate cyclase inhibition minimally reduced HbF 
induction, whereas adenylate cyclase inhibition markedly decreased HbF induction by 
hydroxyurea in CD34+-derived erythroid cells. Activation of the adenylate cyclase modestly 
induced HbF production, while hydroxyurea failed to significantly stimulate adenylate 
cyclase activity on days 7 to 10 of erythroid cells liquid culture (Keefer et al., 2006). 
However, in our cultures we found that in early erythroid progenitor cell cultures (day 4), 
hydroxyurea stimulated cAMP production (Cokic et al., 2008). It has been also postulated 
that cJun activates the Gγ-globin promoter via an upstream cAMP response element in a way 
equivalent to CREB1 (Kodeboyina et al., 2010). 
5.4 Cyclic nucleotides interaction with phosphodiesterases 
It has been shown that nitrite increased blood flow in the human circulation as well as 
vasodilatation of rat aortic rings. Formation of both NO gas and NO-modified hemoglobin 
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resulted from the nitrite reductase activity of deoxyhemoglobin and deoxygenated 
erythrocytes levels (Cosby et al., 2003). Studies of nitrite activation of sGC demonstrated 
that nitrite alone activated sGC in solution (Jeffers et al., 2005). In our performed in vitro 
studies nitrite failed to induce cGMP, in purified form of sGC in solution, what confirmed a 
major role of NO molecule in hydroxyurea interaction with sGC (Cokic et al., 2008). It has 
been also demonstrated that eNOS is rapidly activated and phosphorylated on both Ser1177 
and Thr495 in the presence of cGMP-dependent protein kinase II and the catalytic subunit of 
PKA in endothelial cells. These processes are more prominent in the presence of 
Ca2+/calmodulin (Butt et al., 2000). The transient rises of cGMP levels induced by 
bradykinin and endothelin-1, which caused release of Ca2+ from internal stores, were 
similarly enhanced by activation of adenylate cyclase and increased cAMP levels. The cAMP 
seems to enhance NO formation, which depends on Ca2+ release from internal stores (Reiser, 
1992). An elevated cGMP level attenuated the store-operated Ca2+ entry in vascular 
endothelial cells (Kwan et al., 2000). The cGMP-mediated [Ca2+]i-reducing mechanisms may 
operate as a negative reaction to protect endothelial cells from the damaging effect of 
excessive [Ca2+]i. The main targets of cGMP are phosphodiesterases (PDEs), resulting in 
interference with the cAMP-signaling pathway (Vaandrager & de Jonge, 1996). cAMP 
hydrolyzing PDE isozymes in endothelial cells are represented by PDE2 and PDE4 as 
cGMP-stimulated and cGMP-insensitive PDE, respectively. In endothelial cells, PDE4 
inhibition may up-regulate basal production of NO, being supported by PDE2 inhibition 
(Lugnier et al., 1999). cGMP-inhibited PDE3 was expressed in K562 erythroleukemic cells at 
a high level (Inoue et al., 2004), while PDE3/4 inhibitor treatment reduced asymmetrical 
dimethylarginine, an endogenous NOS inhibitor, and elevated NO/cGMP levels 
(Pullamsetti et al., 2011). In addition, PDE9A gene expression is increased in CD34+-derived 
erythroid cells and K562 erythroleukemic cells. Inhibition of PDE9A enzyme significantly 
increased production of the γ-globin gene in K562 cells (Almeida et al., 2008). 
6. Nitric oxide-related therapy in hemoglobinopathies 
NO inhibits HbS polymer formation and has anti-sickling properties. NO may disrupt HbS 
polymers by abolishing the excess positive charge of HbS, resulting in increased oxygen 
affinity in patients with sickle cell disease (Ikuta et al., 2011). In sickle cell disease, HbS 
polymerization and intravascular sickling lead to reperfusion injury, hemolysis, decreased 
NO bioavailability and oxidative stress. Increased expression of HbF decreased 
intravascular sickling, accompanied by decreased hemolysis, oxidative stress and increased 
NO metabolites (NOx) levels (Dasgupta et al., 2010). Nitrite can react similarly with adult 
oxy- and deoxy-hemoglobin (HbA), resulting in oxidative denitrosylation of nitrosyl-
hemoglobin and rapid dissociation of NO. RBCs containing oxy-HbF (F-cells) had 
accelerated oxidative denitrosylation. So, induction of HbF present in sickle cell disease may 
enhance vasodilatation in addition to direct inhibition of polymerization of deoxy sickle 
hemoglobin (Salhany, 2008). The role of NO in erythrocyte function, sickle cell anemia, 
malaria, and damage to banked blood has been already reviewed, as well as the use of NO 
targeted therapies for erythrocyte disease (Maley et al., 2010). Pain from vaso-occlusive 
crisis is the major cause of hospitalization in patients with sickle cell disease, where 
beneficial therapeutic effects of inhaled NO have been demonstrated (Head et al., 2010).  
Decreased exhaled nitric oxide levels (FENO) have been described in patients with sickle cell 
disease, together with deficiency in plasma arginine. Additional study shows that sickle cell 
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disease patients, with and without a history of acute chest syndrome, have similar FENO at 
baseline when compared with healthy controls (Sullivan et al., 2010).  
The protecting effects of exogenous NO on murine cerebral malaria are associated with 
decreased brain vascular expression of inflammatory markers, ICAM-1 and P-selectin, 
resulting in attenuated endothelial damage and facilitating blood flow (Zanini et al., 2011). 
Previous reports demonstrated reduced NO levels in severe malaria related to impaired 
production of NO, reduced mononuclear cell iNOS expression and NOS substrate arginine 
(Anstey et al., 1996; Lopansri et al., 2003). Responsible factors for low NO levels in malaria 
include scavenging of NO by free hemoglobin and superoxide anion, and reduced levels of 
nitrate, a NO precursor molecule (Lopansri et al., 2003). Endothelial activation plays a 
central role in the pathogenesis of severe malaria with angiopoietin-2 as a key regulator. NO 
is a major inhibitor of angiopoietin-2 release from endothelium and has been shown to 
decrease endothelial inflammation and reduce the adhesion of parasitized RBCs. Low-flow 
inhaled NO is an attractive new candidate for the adjunctive treatment of severe malaria 
(Hawkes et al., 2011). Exhaled NO was also lower in severe malaria in comparison to 
moderately severe falciparum malaria and controls. Intravenous administration of l-arginine 
increased exhaled NO in moderately severe malaria (Yeo et al., 2007). 
7. Conclusion: Nitric oxide and soluble guanylate cyclase 
Besides direct stimulation of sGC in erythroid cells, NO is produced by stromal cells of bone 
marrow hematopoietic microenvironment. NOS enzymes in stromal cells are activated via 
PKA, supported by intracellular Ca2+ elevation. NO has been released into the intercellular 
space and then passed through the plasma membrane of erythroid cells, where it binds 
directly to ferrous-deoxy heme of sGC, activating the enzyme. Activation of NO-sGC 
increases conversion of GTP to cGMP, resulting in elevation of cGMP and subsequent 
activation of cGMP-dependent protein kinases (PKG) and cGMP-hydrolyzing PDEs. 
Activation of sGC and PKG increases expression of the γ-globin gene in erythroid cells. NO 
reduces cAMP levels in erythroid cells, whereas cAMP appears to enhance NO formation. 
The NO-mediated cAMP-reducing mechanisms may operate as a negative feedback in 
control of cAMP levels. In addition, cGMP enhances cAMP level and cAMP-signalling 
pathway by competing for the PDEs active site that has modest cyclic nucleotides selectivity 
(e.g., PDE3 isozymes). By this way, cGMP inhibits the activity of cAMP-specific PDE3, 
which results in the increase in intracellular cAMP levels and thereby leads to the activation 
of PKA. Activation of the cAMP-dependent pathway also induces expression of the γ-globin 
gene in erythroblasts. The phosphorylation levels of CREB correlated with elevated γ-globin 
gene expression. Moreover, inhibition of PDE9A enzyme significantly increases production 
of the γ-globin gene. Therefore, it appears that activation of the linked cGMP- and cAMP-
signalling pathways regulates γ-globin expression. 
Presented results contribute to the understanding of the significance of NO participation in 
γ-globin induction. These results should support future studies, with the emphasis focused 
on the hematopoietic microenvironment, in search of therapy of sickle cell disease. In 
addition to the possibility of NOS presence and activity in mature RBCs, our data show 
strong eNOS protein levels and function in more primitive human erythroid progenitor and 
precursor cells, where control of gene expression occurs. While mechanisms involved in 
globin gene expression have been recognized at different levels within the regulatory 
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resulted from the nitrite reductase activity of deoxyhemoglobin and deoxygenated 
erythrocytes levels (Cosby et al., 2003). Studies of nitrite activation of sGC demonstrated 
that nitrite alone activated sGC in solution (Jeffers et al., 2005). In our performed in vitro 
studies nitrite failed to induce cGMP, in purified form of sGC in solution, what confirmed a 
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and Thr495 in the presence of cGMP-dependent protein kinase II and the catalytic subunit of 
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similarly enhanced by activation of adenylate cyclase and increased cAMP levels. The cAMP 
seems to enhance NO formation, which depends on Ca2+ release from internal stores (Reiser, 
1992). An elevated cGMP level attenuated the store-operated Ca2+ entry in vascular 
endothelial cells (Kwan et al., 2000). The cGMP-mediated [Ca2+]i-reducing mechanisms may 
operate as a negative reaction to protect endothelial cells from the damaging effect of 
excessive [Ca2+]i. The main targets of cGMP are phosphodiesterases (PDEs), resulting in 
interference with the cAMP-signaling pathway (Vaandrager & de Jonge, 1996). cAMP 
hydrolyzing PDE isozymes in endothelial cells are represented by PDE2 and PDE4 as 
cGMP-stimulated and cGMP-insensitive PDE, respectively. In endothelial cells, PDE4 
inhibition may up-regulate basal production of NO, being supported by PDE2 inhibition 
(Lugnier et al., 1999). cGMP-inhibited PDE3 was expressed in K562 erythroleukemic cells at 
a high level (Inoue et al., 2004), while PDE3/4 inhibitor treatment reduced asymmetrical 
dimethylarginine, an endogenous NOS inhibitor, and elevated NO/cGMP levels 
(Pullamsetti et al., 2011). In addition, PDE9A gene expression is increased in CD34+-derived 
erythroid cells and K562 erythroleukemic cells. Inhibition of PDE9A enzyme significantly 
increased production of the γ-globin gene in K562 cells (Almeida et al., 2008). 
6. Nitric oxide-related therapy in hemoglobinopathies 
NO inhibits HbS polymer formation and has anti-sickling properties. NO may disrupt HbS 
polymers by abolishing the excess positive charge of HbS, resulting in increased oxygen 
affinity in patients with sickle cell disease (Ikuta et al., 2011). In sickle cell disease, HbS 
polymerization and intravascular sickling lead to reperfusion injury, hemolysis, decreased 
NO bioavailability and oxidative stress. Increased expression of HbF decreased 
intravascular sickling, accompanied by decreased hemolysis, oxidative stress and increased 
NO metabolites (NOx) levels (Dasgupta et al., 2010). Nitrite can react similarly with adult 
oxy- and deoxy-hemoglobin (HbA), resulting in oxidative denitrosylation of nitrosyl-
hemoglobin and rapid dissociation of NO. RBCs containing oxy-HbF (F-cells) had 
accelerated oxidative denitrosylation. So, induction of HbF present in sickle cell disease may 
enhance vasodilatation in addition to direct inhibition of polymerization of deoxy sickle 
hemoglobin (Salhany, 2008). The role of NO in erythrocyte function, sickle cell anemia, 
malaria, and damage to banked blood has been already reviewed, as well as the use of NO 
targeted therapies for erythrocyte disease (Maley et al., 2010). Pain from vaso-occlusive 
crisis is the major cause of hospitalization in patients with sickle cell disease, where 
beneficial therapeutic effects of inhaled NO have been demonstrated (Head et al., 2010).  
Decreased exhaled nitric oxide levels (FENO) have been described in patients with sickle cell 
disease, together with deficiency in plasma arginine. Additional study shows that sickle cell 
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disease patients, with and without a history of acute chest syndrome, have similar FENO at 
baseline when compared with healthy controls (Sullivan et al., 2010).  
The protecting effects of exogenous NO on murine cerebral malaria are associated with 
decreased brain vascular expression of inflammatory markers, ICAM-1 and P-selectin, 
resulting in attenuated endothelial damage and facilitating blood flow (Zanini et al., 2011). 
Previous reports demonstrated reduced NO levels in severe malaria related to impaired 
production of NO, reduced mononuclear cell iNOS expression and NOS substrate arginine 
(Anstey et al., 1996; Lopansri et al., 2003). Responsible factors for low NO levels in malaria 
include scavenging of NO by free hemoglobin and superoxide anion, and reduced levels of 
nitrate, a NO precursor molecule (Lopansri et al., 2003). Endothelial activation plays a 
central role in the pathogenesis of severe malaria with angiopoietin-2 as a key regulator. NO 
is a major inhibitor of angiopoietin-2 release from endothelium and has been shown to 
decrease endothelial inflammation and reduce the adhesion of parasitized RBCs. Low-flow 
inhaled NO is an attractive new candidate for the adjunctive treatment of severe malaria 
(Hawkes et al., 2011). Exhaled NO was also lower in severe malaria in comparison to 
moderately severe falciparum malaria and controls. Intravenous administration of l-arginine 
increased exhaled NO in moderately severe malaria (Yeo et al., 2007). 
7. Conclusion: Nitric oxide and soluble guanylate cyclase 
Besides direct stimulation of sGC in erythroid cells, NO is produced by stromal cells of bone 
marrow hematopoietic microenvironment. NOS enzymes in stromal cells are activated via 
PKA, supported by intracellular Ca2+ elevation. NO has been released into the intercellular 
space and then passed through the plasma membrane of erythroid cells, where it binds 
directly to ferrous-deoxy heme of sGC, activating the enzyme. Activation of NO-sGC 
increases conversion of GTP to cGMP, resulting in elevation of cGMP and subsequent 
activation of cGMP-dependent protein kinases (PKG) and cGMP-hydrolyzing PDEs. 
Activation of sGC and PKG increases expression of the γ-globin gene in erythroid cells. NO 
reduces cAMP levels in erythroid cells, whereas cAMP appears to enhance NO formation. 
The NO-mediated cAMP-reducing mechanisms may operate as a negative feedback in 
control of cAMP levels. In addition, cGMP enhances cAMP level and cAMP-signalling 
pathway by competing for the PDEs active site that has modest cyclic nucleotides selectivity 
(e.g., PDE3 isozymes). By this way, cGMP inhibits the activity of cAMP-specific PDE3, 
which results in the increase in intracellular cAMP levels and thereby leads to the activation 
of PKA. Activation of the cAMP-dependent pathway also induces expression of the γ-globin 
gene in erythroblasts. The phosphorylation levels of CREB correlated with elevated γ-globin 
gene expression. Moreover, inhibition of PDE9A enzyme significantly increases production 
of the γ-globin gene. Therefore, it appears that activation of the linked cGMP- and cAMP-
signalling pathways regulates γ-globin expression. 
Presented results contribute to the understanding of the significance of NO participation in 
γ-globin induction. These results should support future studies, with the emphasis focused 
on the hematopoietic microenvironment, in search of therapy of sickle cell disease. In 
addition to the possibility of NOS presence and activity in mature RBCs, our data show 
strong eNOS protein levels and function in more primitive human erythroid progenitor and 
precursor cells, where control of gene expression occurs. While mechanisms involved in 
globin gene expression have been recognized at different levels within the regulatory 
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hierarchy, relations between molecular pathways are only emerging. Our presented 
microarray results demonstrated the broad gene expression profile and related pathways 
linked to stimulation of globin genes during ontogeny. The presented genes and signaling 
pathways, involved in the mechanism of globin genes activation, might be targets for 
therapeutic agents that upregulate γ-globin gene expression and HbF levels in 
hemoglobinopathies. This ontogenic overview linked to specific genes and transcriptional 
programs in normal erythropoiesis may contribute to further understanding of erythroid 
progenitor cell development.  
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1. Introduction  
Platelets play a central role in hemostasis and thrombosis, initiating clot formation in 
response to vessel wall damage. Platelet aggregates are formed at sites of injury by the 
binding and crosslinking of the integrin IIb3 to fibrinogen, von Willebrand factor and 
other soluble ligands. Platelets also form pathological thrombi, and the resulting arterial 
occlusion can lead to myocardial infarction or stroke. Inhibition of IIb3 binding can 
decrease the formation of pathologic thrombi, and IIb3 has become an important 
pharmacological target. Anti-IIb3 therapies have been highly successful in preventing 
death following myocardial infarction and percutaneous arterial stent placement.(Topol, 
Lincoff et al. 2002; De Luca, Ucci et al. 2009) However, attempts to design novel, orally 
available anti-IIb3 agents have been hampered by what appears to be paradoxical 
activation of IIb3 by the drug, in some cases leading to an increased risk of mortality in 
patients who received the drug.(Quinn, Plow et al. 2002)  
A novel approach to manipulatingIIb3 would be to perturb its post-translational 
processing and trafficking within the megakaryocyte, prior to platelet formation. Like most 
membrane proteins, IIb3 is formed by concerted processes of protein sorting and 
trafficking. Some of the mechanisms underlying IIb3 biogenesis and expression in 
megakaryocytes have been described, such as the calnexin cycle of protein quality 
control.(King and Reed 2002; Tiwari, Italiano et al. 2003; El.Golli, Issertial et al. 2005; Lo, Li 
et al. 2005) Clues to the stringent protein quality control of IIb3 biogenesis come from the 
study of patients with defective or absent IIb3, who manifest the mucocutaneous bleeding 
disorder Glanzmann thrombasthenia. A subset of patients with mutations in the IIb gene 
produce full-length IIb that retains the ability to form a complex with 3 but is retained 
within the cell and degraded, resulting in disease. These patients demonstrate the existence 
of stringent quality control mechanisms acting post-translationally to control IIb3 
biogenesis and expression. A clearer understanding of these mechanisms may lead to new 
possibilities of anti-integrin therapy. 
Toward the goal of identifying proteins involved in IIb3 biogenesis we performed a 
proteomic analysis of proteins interacting with IIb in megakaryocytes cultured from 
human umbilical cord blood (UCB) and in HEK293 cells expressing IIb and 3. 
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Megakaryocyte proteins were captured by poly-histidine tagged IIb, or by photoreactive 
crosslinking followed by immunoprecipitation with anti-IIb mAbs, and analyzed by mass 
spectrometry.  
The IIb and b3 subunits are synthesized as a single-chain precursors in the chaperone-rich 
folding environment of the endoplasmic reticulum (ER) (Fig 1). The precursor IIb, pro-
IIb, is glycosylated under control of the calnexin cycle of protein folding. The 3 precursor 
is also glycosylated but does not appear to interact with the calnexin cycle. The two 
precursors heterodimerize to briefly form pro-IIb3, and then pro-IIb is cleaved by one or 
more members of the furin family of proteases in the Golgi. Cleavage of pro-IIb to mature 
IIb marks the exit of IIb from the ER, and this cleavage occurs only when pro-IIb is in 
complex with 3.(Bray, Rosa et al. 1986; Rosa and McEver 1989) Both IIb and 3 are 
synthesized in excess of what will finally be processed to mature IIb3. The calnexin cycle 
exerts stringent quality control over IIb production and up to one half of all pro-IIb is 
targeted to the proteasome for degradation in megakaryocytes. Excess 3 is degraded by a 
non-proteasomal mechanism. Inhibition of the proteasome in megakaryocytes resulted in a 
build-up of pro-IIb that was not being degraded, but had no apparent effect on the level of 
mature IIb in the IIb3 complex. Thus, the expression level of mature IIb3 is not simply 
a result of the stoichiometry of production vs. degradation. Rather there appears to be a 
concerted mechanism that controls how much pro-IIb3 will be converted into mature 
IIb3, and this mechanism is not grossly responsive to excessive levels of pro-IIb or 3.  
 
Fig. 1. Biogenesis of IIb3 
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We hypothesized that whatever proteins underlie this mechanism must be interacting with 
pro-IIb and/or pro-IIb3 complex, but not with the mature IIb3 complex. We chose a 
proteomics approach to identify these interacting proteins. In order to enrich our assay for 
proteins that preferentially bound pro-IIb or pro-IIb3, we used an IIb subunit 
harboring R858G and R859G mutations that eliminates furin cleavage and traps IIb in its 
pro-IIb form.(Kolodziej, Vilaire et al. 1991) This IIbR858G/R859G construct can form a 
complex with 3, but only in small amounts compared to normal IIb3. In addition, while 
some of the mutant IIb3 complexes reach the cell surface and can mediate adherence to 
immobilized fibrinogen, the proportion of IIbR858G/R859G reaching the surface is very 
small compared to normal IIb.(Kolodziej, Vilaire et al. 1991)  Thus, IIbR858G/R859G is a 
“nearly normal” mutant IIb subunit that is primarily retained within the cell, making it a 
useful bait to capture the proteins involved in that process.  
The hsp40 type chaperone protein, DNAJC10, was captured by both the normal IIb and 
IIbR858G/R859G subunits, and was evaluated as a putative IIb interacting protein.. We 
report that DNAJC10 interacted with pro-IIb and 3 in megakaryocytes, and appears to 
promote the degradation of pro-IIb. Notably, while IIb3-DNAJC10 interaction was 
evident in megakaryocytes, specific interaction was not detectable in HEK293 cells 
transfected with IIb cDNA, suggesting megakaryocyte specificity. Knockdown of 
DNAJC10 by siRNA increased IIb3 surface expression in UCB derived megakaryocytes, 
indicating that DNAJC10 negatively regulates IIb3 surface expression. Thus, DNAJC10-
IIb interaction represents a novel post-translational mechanism regulating IIb3 surface 
expression.  
2. Materials and methods 
2.1 Antibodies 
The antibodies used in this study were: 10E5 (anti-IIb3 complex); B1B5 (anti-IIb);7H2 
and B36 (anti-3) (all 4 generous gifts from Dr Barry Coller); CA3 (anti-IIb), anti-V5 
epitope, and anti-Myc epitope (all three Millipore, Temecula,CA); anti-DNAJC10 (Genetex, 
Irvine, CA); M148 (anti-IIb) (Santa Cruz Biotechnology, Santa Cruz, CA); mouse IgG, and 
rabbit IgG (both Jackson ImmunoResearch Inc, West Grove, PA). 
2.2 Human Umbilical Cord Blood culture 
This study used human UCB from the US National Cord Blood Bank that was deemed not 
suitable for clinical use due to low white blood cell number. Mothers who donate their UCB 
to the National Cord Blood Bank sign a consent giving permission to donate the UCB to 
research if it is inadequate for clinical use and will be discarded. Because the donated units 
are completely de-identified and are not collected prospectively specifically for research, the 
New York Blood Center Institutional Review Board (IRB), which oversees research ethics at 
the National Cord Blood Bank, considers their use exempt from IRB review. Human UCB 
was prepared as previously described.(Mitchell, Li et al. 2006) Briefly, leukocytes were 
separated from 1-3 units of human UCB judged to be inadequate for clinical purposes 
(generously provided by the New York Blood Center) by Dextran 70 sedimentation 
(Amersham Biosciences, Piscataway, NJ) for 1h, and then enriched for CD34+ progenitor 
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cells by negative selection using a combination of antibodies against maturation/lineage-
specific markers (RosetteSep, StemCell Technologies, Vancouver, BC) concomitant with 
density sedimentation using Ficoll-Paque Plus (Amersham Biosciences, Piscataway, NJ). 
These cells were cultured in serum-free medium (StemCell Technologies, Vancouver, BC) 
with 50 ng/ml thrombopoietin (TPO) plus 1 ng/ml SCF (both Millipore, Temecula,CA) for 3 
days in 10 cm dishes in a 37°C incubator. At this point a portion of the cells will have died. 
The remaining living population of larger cells was gently washed and replated in fresh 
media with the same cytokines in 10 cm dishes and left until use (Day 8 or 9). Fresh media 
was added on day 6. We have previously reported that under these conditions the UCB 
differentiate into a population of large cells with > 90% expressing IIb3, > 80% expressing 
GPIb, about 50% expressing 21.(Mitchell, Li et al. 2007) For experimental use the cells 
were gently harvested, pelleted at 300 rpm for 5 min, or let settle by gravity, and gently 
resuspended in the appropriate buffer. 
2.3 HEK293 cell culture 
HEK293  cell lines (American Type Culture Collection (ATCC), Manassas, VA) that stably 
expressed human IIb3 receptors were established as previously described.(Mitchell, Li et 
al. 2006) Transfections were performed using Lipofectamine 2000 (Gibco-BRL, Carlsbad, 
CA) according to the manufacturer’s instructions, followed by selection in media containing 
500 g/ml G418 for 2-4 weeks. To obtain a population of cells uniformly expressing high 
levels of IIb3, cells were labeled with the mAb 10E5 (anti-IIb3) and sorted using a 
MoFlo cell sorter (Beckman Coulter, Fullerton, CA).  
2.4 Immunoprecipitation and biosynthetic labeling 
Samples were prepared as previously described and all steps were performed on ice unless 
otherwise stated.(Mitchell, Li et al. 2006) Briefly, cells (either day 8 megakaryocytes derived 
from UCB cells or HEK293 cells) were lysed in 1% Brij 98 lysis buffer containing protease 
inhibitors and 20uM N-methylmaleimide (NEM). Lysates were precleared with protein-G 
Sepharose beads (Amersham Biosciences, Piscataway, NJ), and then equivalent amounts of 
protein, usually 400 g, were incubated one h at 4C with one or more of the antibodies 
listed above (4 g/reaction). Samples were incubated with protein-G Sepharose beads for 
one h at 4C, washed twice, and incubated with SDS sample buffer for 10 min at 100°C. 
Reduced samples contained 10% beta mercaptoethanol (Sigma, Thermo Scientific, Rockford, 
IL). Samples were subjected to SDS-PAGE on 7% gels, and the gels were either stained for 
mass spectrometry identification (described below) or transferred to PVDF membranes for 
immunoblotting. Non-specific binding was determined by performing parallel 
immunoprecipitation with mouse or rabbit IgG in each experiment. In preliminary 
experiments, the production of IIbR858G/R859G and 3 was confirmed in the transfected 
HEK293 cell line by immunoprecipitation with both anti-IIb and anti-3 mAbs followed by 
immunoblot. For biosynthetic labeling, cells were incubated for 30 min at 37°C in 
methionine/cysteine-free medium, followed by pulse-labeling for 15 min at 37ºC in medium 
containing 35S-methionine/cysteine (300 Ci/10 cm plate). The pulse was terminated by 
incubation in medium containing unlabeled methionine/cysteine (1 mg/ml each) and the 
cells were incubated at 37 °C until lysis in 1% Triton-X 100 lysis buffer. Following cell lysis, 
supernatants were prepared as above. Gels were dried and exposed to film. For inhibition of 
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the proteasome cells were incubated in the proteasome inhibitor MG132 (10 
M)(Sigma_Aldrich, St Louis, MO) in normal growth medium at 37C and then immediately 
lysed. 
2.5 Histidine-tag/Nickel bead pulldown assay  
HEK293 cells expressing poly-histidine tagged IIb cDNA (in vector pEF1/V5-His) and 3 
cDNA (in vector pcDNA3.1)(Mitchell, Li et al. 2007) were lysed in 1% Triton, 150 mM NaCl, 
10 mM imidazole buffer (lysis buffer) on ice for 30 m, centrifuged for 30m at 4C, and then 
the supernatant was reacted with 50 l of a 6:4 slurry of Ni beads:imidazole buffer (Qiagen, 
Inc. Valencia, CA) to bind the histidine-tagged subunits to the nickel beads. After incubating 
for 30 m the beads were washed four times with 10 mM imidazole lysis buffer by using a 
magnetic chamber to isolate the beads. Next, fresh whole cell lysates (1 mL) of UCB-derived 
megakaryocytes in 1% Triton, 150 mM NaCl, 10 mM imidazole buffer were incubated with 
the washed, Ni-bound IIb for 1 h, and then the beads were washed twice with 1 mL lysis 
buffer containing 20 mM imidazole. Ni-bound proteins were eluted with 250 mM imidazole 
and the entire eluate was subjected to SDS-PAGE on a 7% gel followed by staining with 
Imperial Stain (Pierce, Thermo Scientific, Rockford, IL). Control experiments were run in 
parallel in which no megakaryocyte lysate was added to the beads, but all other steps 
remained the same. These controls aimed to identify the remaining HEK293 cell proteins 
still bound to either the beads or to IIb after the washing steps, before incubation with 
megakaryocyte lysate. Experimental and control gels were run simultaneously, and the 
lanes were excised and analyzed by mass spectrometry.  
2.6 Photocrosslinking amino acids 
UCB cells were cultured as described above for eight days, then were washed and incubated 
for 24 hours in leucine- and methionine- free medium containing photoreactive methionine 
and leucine, dialyzed FBS (both Pierce, Thermo Scientific, Rockford, IL), and 50 ng/ml TPO 
(Millipore, Temecula,CA). The cells were exposed to 345 nm UV light for 15 minutes to 
crosslink the photoreactive amino acids, and harvested immediately, according to 
manufacturer’s instructions. Whole cell lysates were immunoprecipitated with antibodies 
specific for IIb or 3, and the proteins were separated by SDS-PAGE using the same 
protocol as for the histidine-tag affinity capture. Controls were simultaneously 
immunoprecipitated with non-immune IgG. Experimental and control lanes were excised 
and analyzed by mass spectrometry. 
2.7 RNAi  
HEK293 cells stably expressing high levels of IIb and 3 were transfected with 100 nM 
siRNA duplexes (Dharmacon, Thermo Scientific, Rockford, IL and Qiagen, Valencia, CA) 
using Dharmafect-1 reagent (Dharmacon, Thermo Scientific, Rockford, IL), then analyzed by 
flow cytometry using a FacsCanto (Becton Dickenson, ) at 48-96 h after transfection. 
Cultured UCB cells were transfected twice, on culture days 3 and 5, with 100 nM of siRNA 
duplexes or controls also using Dharmafect-1 reagent, and then analyzed 48 – 72 h later by 
flow cytometry. In order to identify individual transfected cells by FACS, cells were co-
transfected with 10 nM of fluorescent-labeled non-coding siRNA (Qiagen, Valencia, CA). In 
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cells by negative selection using a combination of antibodies against maturation/lineage-
specific markers (RosetteSep, StemCell Technologies, Vancouver, BC) concomitant with 
density sedimentation using Ficoll-Paque Plus (Amersham Biosciences, Piscataway, NJ). 
These cells were cultured in serum-free medium (StemCell Technologies, Vancouver, BC) 
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differentiate into a population of large cells with > 90% expressing IIb3, > 80% expressing 
GPIb, about 50% expressing 21.(Mitchell, Li et al. 2007) For experimental use the cells 
were gently harvested, pelleted at 300 rpm for 5 min, or let settle by gravity, and gently 
resuspended in the appropriate buffer. 
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al. 2006) Transfections were performed using Lipofectamine 2000 (Gibco-BRL, Carlsbad, 
CA) according to the manufacturer’s instructions, followed by selection in media containing 
500 g/ml G418 for 2-4 weeks. To obtain a population of cells uniformly expressing high 
levels of IIb3, cells were labeled with the mAb 10E5 (anti-IIb3) and sorted using a 
MoFlo cell sorter (Beckman Coulter, Fullerton, CA).  
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otherwise stated.(Mitchell, Li et al. 2006) Briefly, cells (either day 8 megakaryocytes derived 
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immunoprecipitation with mouse or rabbit IgG in each experiment. In preliminary 
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the proteasome cells were incubated in the proteasome inhibitor MG132 (10 
M)(Sigma_Aldrich, St Louis, MO) in normal growth medium at 37C and then immediately 
lysed. 
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the supernatant was reacted with 50 l of a 6:4 slurry of Ni beads:imidazole buffer (Qiagen, 
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the washed, Ni-bound IIb for 1 h, and then the beads were washed twice with 1 mL lysis 
buffer containing 20 mM imidazole. Ni-bound proteins were eluted with 250 mM imidazole 
and the entire eluate was subjected to SDS-PAGE on a 7% gel followed by staining with 
Imperial Stain (Pierce, Thermo Scientific, Rockford, IL). Control experiments were run in 
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remained the same. These controls aimed to identify the remaining HEK293 cell proteins 
still bound to either the beads or to IIb after the washing steps, before incubation with 
megakaryocyte lysate. Experimental and control gels were run simultaneously, and the 
lanes were excised and analyzed by mass spectrometry.  
2.6 Photocrosslinking amino acids 
UCB cells were cultured as described above for eight days, then were washed and incubated 
for 24 hours in leucine- and methionine- free medium containing photoreactive methionine 
and leucine, dialyzed FBS (both Pierce, Thermo Scientific, Rockford, IL), and 50 ng/ml TPO 
(Millipore, Temecula,CA). The cells were exposed to 345 nm UV light for 15 minutes to 
crosslink the photoreactive amino acids, and harvested immediately, according to 
manufacturer’s instructions. Whole cell lysates were immunoprecipitated with antibodies 
specific for IIb or 3, and the proteins were separated by SDS-PAGE using the same 
protocol as for the histidine-tag affinity capture. Controls were simultaneously 
immunoprecipitated with non-immune IgG. Experimental and control lanes were excised 
and analyzed by mass spectrometry. 
2.7 RNAi  
HEK293 cells stably expressing high levels of IIb and 3 were transfected with 100 nM 
siRNA duplexes (Dharmacon, Thermo Scientific, Rockford, IL and Qiagen, Valencia, CA) 
using Dharmafect-1 reagent (Dharmacon, Thermo Scientific, Rockford, IL), then analyzed by 
flow cytometry using a FacsCanto (Becton Dickenson, ) at 48-96 h after transfection. 
Cultured UCB cells were transfected twice, on culture days 3 and 5, with 100 nM of siRNA 
duplexes or controls also using Dharmafect-1 reagent, and then analyzed 48 – 72 h later by 
flow cytometry. In order to identify individual transfected cells by FACS, cells were co-
transfected with 10 nM of fluorescent-labeled non-coding siRNA (Qiagen, Valencia, CA). In 
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some experiments, Cy3-labeled siRNA duplexes were used (Dharmacon, Thermo Scientific, 
Rockford, IL). Controls were: no treatment, transfection reagent but no siRNA duplex, Cy3-
labeled negative control siRNA duplex only (Qiagen), siControl non targeting siRNA 
duplex, and siRNA duplex against cyclophillin B (positive control) (both Dharmacon). 
2.8 Quantitative RT-PCR 
For analysis of RNA content, cells were collected in RNAlater (Applied Biosystems, Foster 
City, CA) and RNA was purified using the RNEasy mini kit (Qiagen, Valencia, CA). For 
some analyses, siRNA transfected cells were sorted for expression of the fluorescent marker 
using a MoFlo sorter, and the sorted cells were subjected to QRT-PCR. Analysis was 
performed on an ABI 7900 or an ABI 7700 thermocycler/ fluorescence analyzer (Applied 
Biosystems, Foster City, CA) using the SYBR green probe (Qiagen or Invitrogen) and 
Quantitect primer assays (Qiagen). Relative mRNA levels were calculated using the Ct 
method that corrects for GAPDH expression in all samples. Fold-reduction was corrected for 
percent transfection in each experiment. 
2.9 Immunofluorescence analysis 
Mks were cytospun onto poly L-lysine-coated glass coverslips and fixed in methanol for 5 
minutes at RT. Cells were then washed with saponin buffer (PBS containing 0.02% BSA, 
0.005% saponin), then blocked with saponin buffer for 1 hour at RT. Cells were then 
incubated with the primary antibody diluted in saponin buffer for 1 hour at RT. After 
washing with PBS, cells were incubated with the appropriate conjugated secondary 
antibody in PBS for 1 hour at RT. Specimens were mounted with Prolong gold (Invitrogen). 
Images were acquired using a Zeiss LSM 510 META (Axiovert 200M Inverted Microscope 
Stand) confocal laser scanning microsope through a 100x objective. Each set of staining 
conditions was repeated 3 times. Background fluorescence was measured by incubating 
fixed cells with the secondary antibody only and then acquiring images with the exact 
settings used to obtain the experimental images. 
2.10 Mass spectrometry data analysis 
The protein gel bands were excised from the SDS-PAGE. The gel bands were reduced with 
10 mM of DTT and alkylated with 55 mM iodoacetamide, and then digested with Sequence 
Grade Modified Trypsin (Promega, Madison, Wisconsin) in ammonium bicarbonate buffer 
at 37 overnight.(Kumarathasan, Mohottalage et al. 2005) The digestion products were 
extracted twice with 0.1% trifluoroacetic acid and 50% Acetonitrile and 1.0% trifluoroacetic 
acid respectively. The extracted mixture was dried by Speed-Vac and redisolved in 10 L 
0.1% trifluoroacetic acid. Half of the extracts were injected by LC-MS/MS analysis. For LC-
MS/MS analysis, each digestion product was separated by a 60 min gradient elution with 
the Dionex U3000 capillary/nano-HPLC system (Dionex, Sunnyvale, California) at a flow 
rate of 0.250 L/min that is directly interfaced with the Thermo-Fisher LTQ-Obritrap mass 
spectrometer (Thermo Fisher, San Jose, California) operated in data-dependent scan mode. 
The analytical column was a home-made fused silica capillary column (75 m ID, 100 mm 
length; Upchurch, Oak Harbor, Washington) packed with C-18 resin (300 A, 5 m, Varian, 
Palo Alto, California). Mobile phase A consisted of 0.1% formic acid, and mobile phase B 
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consisted of 100% acetonitrile and 0.1% formic acid. The 60 min gradients with 250 nL/min 
flow rate for B solvent went from 0 to 55% in 34 minutes and then in 4 min to 80%. The B 
solvent stayed at 80% for another 8 min and then decreased to 5% in 8 min. Another 6 min 
was used for equilibration, loading and washing. The mass acquisition method was one FT-
MS scan followed by 6 subsequent MS/MS scan in the ion trap. The FT-MS scan was 
acquired at resolution 30,000 in the Orbi-trap. The six most intense peaks from the FT full 
scan were selected in the ion trap for MS/MS. The selected ions were excluded for further 
selection for 180 seconds. The following search parameters were used in all MASCOT 
searches: maximum of 1 missed trypsin cleavages, cysteine carbamidomethylation, 
methionine oxidation. The maximum error tolerance for MS scans was 10 ppm for MS and 
1.0 Da for MS/MS respectively. Proteins were designated as “hits” if they matched at least 2 
distinctive peptides with a MASCOT score of at least 40. For proteins matching the same 
sets of peptides, only the protein with the greater percentage of coverage was selected. In 
the one case where 2 isoforms could not be distinguished (HSP70A/B), both proteins are 
reported. Proteins identified in the control gels were considered “negative,” and these 
proteins were removed from further analysis. The interaction data were further analyzed 
using the Cytoscape(Cline, Smoot et al. 2007) software and publically available protein 
interaction databases (e.g. INTACT, NCBI, UniProt) to generate a network of first-degree 
interactions with IIb. The network was further expanded to include proteins that were 
previously reported to interact with IIb and known interactions between any of the 
proteins identified in our primary assays.  
2.11 Statistical analysis 
Flow cytometry data was summarized as the geographic mean fluorescence intensity (MFI) 
of antibody binding, and normalized to the MFI of control siRNA treated cells, so that the 
experimental MFI is expressed as a percentage of the control MFI. The overall percent 
change of the replicates was expressed as the average percent change +/- the confidence 
interval. The two-sided, paired t-test was used to determine whether there were differences 
in antibody binding between the different experimental groups. In the siRNA experiments, 
relative mRNA levels were calculated using the Ct method that corrects for GAPDH 
expression.  
3. Results 
3.1 The IIb interactome 
Proteins putatively interacting with IIb were isolated from UCB derived megakaryocytes 
and from HEK293 cells expressing IIb3, and these proteins were analyzed by mass 
spectrometry. Samples were processed by the two methods depicted in Figure 2. In the first 
method, recombinant IIb or IIbR858G/R859G subunits bearing a polyhistidine tag were 
expressed in HEK293 cells along with normal 3. The cells were lysed with 1% Triton buffer, 
and the lysates were reacted with Ni beads that bind polyhistidine. The Ni beads were 
washed using a magnetic separator to reduce non-specific binding to the Ni-bound IIb, 
and then incubated with fresh whole cell lysate of umbilical cord blood derived 
megakaryocyte. Since we are interested in the early process of IIb3 formation and 
intracellular trafficking we used megakaryocytes at day 8 or 9 of culture; at that point in our 
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some experiments, Cy3-labeled siRNA duplexes were used (Dharmacon, Thermo Scientific, 
Rockford, IL). Controls were: no treatment, transfection reagent but no siRNA duplex, Cy3-
labeled negative control siRNA duplex only (Qiagen), siControl non targeting siRNA 
duplex, and siRNA duplex against cyclophillin B (positive control) (both Dharmacon). 
2.8 Quantitative RT-PCR 
For analysis of RNA content, cells were collected in RNAlater (Applied Biosystems, Foster 
City, CA) and RNA was purified using the RNEasy mini kit (Qiagen, Valencia, CA). For 
some analyses, siRNA transfected cells were sorted for expression of the fluorescent marker 
using a MoFlo sorter, and the sorted cells were subjected to QRT-PCR. Analysis was 
performed on an ABI 7900 or an ABI 7700 thermocycler/ fluorescence analyzer (Applied 
Biosystems, Foster City, CA) using the SYBR green probe (Qiagen or Invitrogen) and 
Quantitect primer assays (Qiagen). Relative mRNA levels were calculated using the Ct 
method that corrects for GAPDH expression in all samples. Fold-reduction was corrected for 
percent transfection in each experiment. 
2.9 Immunofluorescence analysis 
Mks were cytospun onto poly L-lysine-coated glass coverslips and fixed in methanol for 5 
minutes at RT. Cells were then washed with saponin buffer (PBS containing 0.02% BSA, 
0.005% saponin), then blocked with saponin buffer for 1 hour at RT. Cells were then 
incubated with the primary antibody diluted in saponin buffer for 1 hour at RT. After 
washing with PBS, cells were incubated with the appropriate conjugated secondary 
antibody in PBS for 1 hour at RT. Specimens were mounted with Prolong gold (Invitrogen). 
Images were acquired using a Zeiss LSM 510 META (Axiovert 200M Inverted Microscope 
Stand) confocal laser scanning microsope through a 100x objective. Each set of staining 
conditions was repeated 3 times. Background fluorescence was measured by incubating 
fixed cells with the secondary antibody only and then acquiring images with the exact 
settings used to obtain the experimental images. 
2.10 Mass spectrometry data analysis 
The protein gel bands were excised from the SDS-PAGE. The gel bands were reduced with 
10 mM of DTT and alkylated with 55 mM iodoacetamide, and then digested with Sequence 
Grade Modified Trypsin (Promega, Madison, Wisconsin) in ammonium bicarbonate buffer 
at 37 overnight.(Kumarathasan, Mohottalage et al. 2005) The digestion products were 
extracted twice with 0.1% trifluoroacetic acid and 50% Acetonitrile and 1.0% trifluoroacetic 
acid respectively. The extracted mixture was dried by Speed-Vac and redisolved in 10 L 
0.1% trifluoroacetic acid. Half of the extracts were injected by LC-MS/MS analysis. For LC-
MS/MS analysis, each digestion product was separated by a 60 min gradient elution with 
the Dionex U3000 capillary/nano-HPLC system (Dionex, Sunnyvale, California) at a flow 
rate of 0.250 L/min that is directly interfaced with the Thermo-Fisher LTQ-Obritrap mass 
spectrometer (Thermo Fisher, San Jose, California) operated in data-dependent scan mode. 
The analytical column was a home-made fused silica capillary column (75 m ID, 100 mm 
length; Upchurch, Oak Harbor, Washington) packed with C-18 resin (300 A, 5 m, Varian, 
Palo Alto, California). Mobile phase A consisted of 0.1% formic acid, and mobile phase B 
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consisted of 100% acetonitrile and 0.1% formic acid. The 60 min gradients with 250 nL/min 
flow rate for B solvent went from 0 to 55% in 34 minutes and then in 4 min to 80%. The B 
solvent stayed at 80% for another 8 min and then decreased to 5% in 8 min. Another 6 min 
was used for equilibration, loading and washing. The mass acquisition method was one FT-
MS scan followed by 6 subsequent MS/MS scan in the ion trap. The FT-MS scan was 
acquired at resolution 30,000 in the Orbi-trap. The six most intense peaks from the FT full 
scan were selected in the ion trap for MS/MS. The selected ions were excluded for further 
selection for 180 seconds. The following search parameters were used in all MASCOT 
searches: maximum of 1 missed trypsin cleavages, cysteine carbamidomethylation, 
methionine oxidation. The maximum error tolerance for MS scans was 10 ppm for MS and 
1.0 Da for MS/MS respectively. Proteins were designated as “hits” if they matched at least 2 
distinctive peptides with a MASCOT score of at least 40. For proteins matching the same 
sets of peptides, only the protein with the greater percentage of coverage was selected. In 
the one case where 2 isoforms could not be distinguished (HSP70A/B), both proteins are 
reported. Proteins identified in the control gels were considered “negative,” and these 
proteins were removed from further analysis. The interaction data were further analyzed 
using the Cytoscape(Cline, Smoot et al. 2007) software and publically available protein 
interaction databases (e.g. INTACT, NCBI, UniProt) to generate a network of first-degree 
interactions with IIb. The network was further expanded to include proteins that were 
previously reported to interact with IIb and known interactions between any of the 
proteins identified in our primary assays.  
2.11 Statistical analysis 
Flow cytometry data was summarized as the geographic mean fluorescence intensity (MFI) 
of antibody binding, and normalized to the MFI of control siRNA treated cells, so that the 
experimental MFI is expressed as a percentage of the control MFI. The overall percent 
change of the replicates was expressed as the average percent change +/- the confidence 
interval. The two-sided, paired t-test was used to determine whether there were differences 
in antibody binding between the different experimental groups. In the siRNA experiments, 
relative mRNA levels were calculated using the Ct method that corrects for GAPDH 
expression.  
3. Results 
3.1 The IIb interactome 
Proteins putatively interacting with IIb were isolated from UCB derived megakaryocytes 
and from HEK293 cells expressing IIb3, and these proteins were analyzed by mass 
spectrometry. Samples were processed by the two methods depicted in Figure 2. In the first 
method, recombinant IIb or IIbR858G/R859G subunits bearing a polyhistidine tag were 
expressed in HEK293 cells along with normal 3. The cells were lysed with 1% Triton buffer, 
and the lysates were reacted with Ni beads that bind polyhistidine. The Ni beads were 
washed using a magnetic separator to reduce non-specific binding to the Ni-bound IIb, 
and then incubated with fresh whole cell lysate of umbilical cord blood derived 
megakaryocyte. Since we are interested in the early process of IIb3 formation and 
intracellular trafficking we used megakaryocytes at day 8 or 9 of culture; at that point in our 
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system IIb3 is highly expressed but there is not yet any proplatelet formation. The Ni-
bound histidine-tagged IIb and IIb-bound proteins were washed twice and then were 
eluted from the Ni beads with 250 mM imidazole in a 1% Triton buffer. Simultaneous 
control experiments were performed without megakaryocyte lysate in order to identify 
proteins non-specifically binding to either the Ni beads or the polyhistidine tag. The 
proteins thus collected were separated by one dimensional SDS-PAGE on a 7% gel. After 
staining, the experimental and control lanes were cut out and analyzed by mass 
spectrometry. This entire process was repeated in three separate experiments with normal 
IIb, and in four separate experiments with IIbR858G/R859G. 
 
Fig. 2. Methods used to isolate and identify IIb-interacting proteins. A): Polyhistidine-
tagged IIb subunits were captured on Ni beads and then incubated with whole cell lysate 
of day 8 UCB-derived megakaryocytes. Protein complexes thus captured were processed as 
described in the text, and then the proteins were identified by FT-MS and MS/MS. B) 
Crosslinking experiments were performed on day 8 UCB-derived megakaryocytes and 
transfected HEK293 cells. Cells were fed photoactivatable methionine and leucine, exposed 
to UV light and lysed immediately. Samples were processed for mass spectrometry as 
described. 
The second strategy used photo-activated amino acids to crosslink IIb to its binding 
partners (Figure 2B). UCB-derived megakaryocytes were starved for methionine and 
leucine, then fed photo-activatable methionine and leucine overnight, and then exposed to 
UV light to crosslink the amino acids of neighboring proteins. The megakaryocytes were 
immediately lysed and the IIb-bound proteins were immunoprecipitated by anti-IIb 
mAb. These proteins were separated by one dimensional SDS-PAGE and then the 
appropriate bands were cut out and analyzed by mass spectrometry. Because we were 
looking only for proteins crosslinked to IIb, only the portions of the bands with Mr > 120 
(Mr of the mature IIb subunit) were analyzed. Five separate crosslinking experiments were 
performed with UCB-derived megakaryocytes and two on HEK293 cells expressing 
IIbR858G/R859G and normal 3. 
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Minimum criteria for protein inclusion in data analysis were at least 2 distinctive peptides 
with a MASCOT score of at least 40, and absence of the protein in the control lanes. 
Importantly, since we were interested in proteins that are more abundant in the 
megakaryocyte than in HEK293 cells, even proteins known to interact with IIb3, such as 
talin, were removed from the final results because they were present in the control lanes. 
Proteins identified in the Ni bead extraction experiments that are known to harbor natural 
polyhistidine sequences (such as the DEAH boxes) that could independently bind to the Ni 
beads were also excluded. Combining the results of both methods, 98 proteins were 
identified as potentially interacting with the normal IIb subunit, and 79 proteins were 
identified as putatively interacting with the IIbR858G/R859G subunit (Table 1). These 163 
proteins putatively constitute a portion of the IIb interactome, a network of protein-protein 
interactions relevant to the trafficking and function of IIb in megakaryocytes (Figure 3).  
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system IIb3 is highly expressed but there is not yet any proplatelet formation. The Ni-
bound histidine-tagged IIb and IIb-bound proteins were washed twice and then were 
eluted from the Ni beads with 250 mM imidazole in a 1% Triton buffer. Simultaneous 
control experiments were performed without megakaryocyte lysate in order to identify 
proteins non-specifically binding to either the Ni beads or the polyhistidine tag. The 
proteins thus collected were separated by one dimensional SDS-PAGE on a 7% gel. After 
staining, the experimental and control lanes were cut out and analyzed by mass 
spectrometry. This entire process was repeated in three separate experiments with normal 
IIb, and in four separate experiments with IIbR858G/R859G. 
 
Fig. 2. Methods used to isolate and identify IIb-interacting proteins. A): Polyhistidine-
tagged IIb subunits were captured on Ni beads and then incubated with whole cell lysate 
of day 8 UCB-derived megakaryocytes. Protein complexes thus captured were processed as 
described in the text, and then the proteins were identified by FT-MS and MS/MS. B) 
Crosslinking experiments were performed on day 8 UCB-derived megakaryocytes and 
transfected HEK293 cells. Cells were fed photoactivatable methionine and leucine, exposed 
to UV light and lysed immediately. Samples were processed for mass spectrometry as 
described. 
The second strategy used photo-activated amino acids to crosslink IIb to its binding 
partners (Figure 2B). UCB-derived megakaryocytes were starved for methionine and 
leucine, then fed photo-activatable methionine and leucine overnight, and then exposed to 
UV light to crosslink the amino acids of neighboring proteins. The megakaryocytes were 
immediately lysed and the IIb-bound proteins were immunoprecipitated by anti-IIb 
mAb. These proteins were separated by one dimensional SDS-PAGE and then the 
appropriate bands were cut out and analyzed by mass spectrometry. Because we were 
looking only for proteins crosslinked to IIb, only the portions of the bands with Mr > 120 
(Mr of the mature IIb subunit) were analyzed. Five separate crosslinking experiments were 
performed with UCB-derived megakaryocytes and two on HEK293 cells expressing 
IIbR858G/R859G and normal 3. 
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Minimum criteria for protein inclusion in data analysis were at least 2 distinctive peptides 
with a MASCOT score of at least 40, and absence of the protein in the control lanes. 
Importantly, since we were interested in proteins that are more abundant in the 
megakaryocyte than in HEK293 cells, even proteins known to interact with IIb3, such as 
talin, were removed from the final results because they were present in the control lanes. 
Proteins identified in the Ni bead extraction experiments that are known to harbor natural 
polyhistidine sequences (such as the DEAH boxes) that could independently bind to the Ni 
beads were also excluded. Combining the results of both methods, 98 proteins were 
identified as potentially interacting with the normal IIb subunit, and 79 proteins were 
identified as putatively interacting with the IIbR858G/R859G subunit (Table 1). These 163 
proteins putatively constitute a portion of the IIb interactome, a network of protein-protein 
interactions relevant to the trafficking and function of IIb in megakaryocytes (Figure 3).  
 













Q60FE2   gi|12667788  
MYOSIN, HEAVY 
POLYPEPTIDE 9, NON-
MUSCLE 70 45 4 




Q6NTA2  gi|11527777 
HETEROGENEOUS 
NUCLEAR 
RIBONUCLEOPROTEIN L 33 53 4 
STIM1 6786 Q13586    gi|21070997  
STROMAL INTERACTION 
MOLECULE 1 28 46 2 
CKAP4 10970 Q07065    gi|19920317  
CYTOSKELETON-
ASSOCIATED PROTEIN 4 27 55 2 
HSP90AB1 3326 P08238    gi|154146191  
HEAT SHOCK PROTEIN 
90kDa ALPHA, CLASS A 
MEMBER 1 21 36 1 
SF3A1 10291 Q15459     gi|53831995  
SPLICING FACTOR 3A, 




A8K5I0  gi|5123454  
HEAT SHOCK 70kDa 
PROTEIN 1A 15 34 3 
ATXN2L* 11273 
Q8WWM7 




Q9BWG0  gi|41406064  
MYOSIN, HEAVY 
POLYPEPTIDE 10, NON-
MUSCLE 13 9 1 
DNAJC10* 54431 Q8IXB1    gi|24308127  
DNAJ (HSP40) HOMOLOG, 
SUBFAMILY C, MEMBER 10 13 21 3 
PSPC1 55269 Q8WXF1   gi|109240550  
PARASPECKLE 
COMPONENT 1 13 35 3 
SFPQ 6421 
P23246 




TRACT BINDING PROTEIN 
ASSOCIATED) 12 35 1 
SF1* 7536 Q14820 gi|42544123  SPLICING FACTOR 1 12 20 2 
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Q15637   
HSPA5* 3309 P11021    gi|119608027  
HEAT SHOCK 70kDa 
PROTEIN 5 (GLUCOSE-
REGULATED PROTEIN, 
78kDa) 11 37 4 





Q3MNF0 gi|119574312  
MYOSIN, HEAVY 
POLYPEPTIDE 11 11 9 1 
LTBP1 4052 
Q14766 
B7ZLY3   gi|46249414  
LATENT TRANSFORMING 
GROWTH FACTOR BETA 
BINDING PROTEIN 1 10 8 2 
PKM2* 5315 P14618    gi|127795697  
PYRUVATE KINASE, 
MUSCLE 10 28 1 
RAVER1* 125950 Q8IY67    gi|123173757  RAVER1 10 29 2 
XIRP2 129446 A4UGR9   gi|61696134 
CARDIOMYOPATHY 




A2BF75  gi|21759807  
ATP-BINDING CASSETTE, 
SUB-FAMILY F (GCN20), 
MEMBER 1 9 14 1 
POTEF 728378 A5A3E0    gi|153791352 
POTE ANKYRIN DOMAIN 
FAMILY, F 9 8 1 
HSP90AA1 3320 
P07900 
Q86SX1   gi|153792590  
HEAT SHOCK PROTEIN 
90kDa ALPHA, CLASS A 
MEMBER 1 8 13 3 
ITGA2B* 3674 P08514    gi|119571981  
INTEGRIN, ALPHA 2B 
(PLATELET GLYCOPROTEIN 
IIB OF IIB/IIIA COMPLEX, 
ANTIGEN CD41) 8 17 2 
TF* 7018 
Q06AH7 
P02787   gi|110590597  TRANSFERRIN 8 18 2 
SAP 62 8175 A0PJA6    gi|21361376  
SPLICING FACTOR 3A, 
SUBUNIT 2, 66kDa 8 19 1 
LYZ 4069 
Q05DF2 
Q15428   gi|4930023  
LYSOZYME (RENAL 




Q13485   gi|4885457  
SMAD, MOTHERS AGAINST 
DPP HOMOLOG 4 
(DROSOPHILA) 7 12 2 
HSP90B1 7184 P14625    gi|4507677  
HEAT SHOCK PROTEIN 
90kDa BETA (GRP94), 
MEMBER 1 7 12 2 




Q7Z5C0  gi|32816595 
LOW DENSITY 
LIPOPROTEIN-RELATED 




B3KX11   gi|14124984  
CHAPERONIN 
CONTAINING TCP1, 
SUBUNIT 3 (GAMMA) 6 21 2 
HSPA1L 3305 P34931    gi|21759781  
HEAT SHOCK 70kDa 
PROTEIN 1-LIKE 5 15 2 
NCL 4691 P19338 gi|189306  NUCLEOLIN 5 6 1 
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B3KM80   
PIP 5304 P12273    gi|4505821  
PROLACTIN-INDUCED 
PROTEIN 5 31 1 
SLPI 6590 P03973    gi|4507065  
SECRETORY LEUKOCYTE 




O15513  gi|854189  TROPOMYOSIN 1 (ALPHA) 5 10 1 
HECTD1 25831 Q9ULT8    gi|118498337  
HECT DOMAIN 
CONTAINING 1 5 5 3 
LACRT 90070 Q9GZZ8   gi|15187164  LACRITIN 5 30 1 
ACTG3 71 P63261    gi|178045   4 12 1 
DMBT1 1755 Q9UGM3   gi|169218264  
DELETED IN MALIGNANT 
BRAIN TUMORS 1 4 11 1 
FLG 2312 P20930    gi|62122917  FILAGGRIN 4 2 1 
HNRNPK 3190 
P61978 
Q6IBN1   gi|55958544  
HETEROGENEOUS 
NUCLEAR 
RIBONUCLEOPROTEIN K  4 11 2 
HSPA8* 3312 
B3KTV0 
P11142   gi|5729877  
HEAT SHOCK 70kDa 
PROTEIN 8 4 8 1 
KPNB1 3837 Q14974    gi|119615215  
KARYOPHERIN (IMPORTIN) 
BETA 1 4 8 1 
LCN1 3933 P31025    gi|4504963  LIPOCALIN 1 4 30 1 
LMAN1* 3998 P49257    gi|5031873  
LECTIN, MANNOSE-
BINDING, 1 4 15 1 
PRSS2 5645 
P07478 
Q5NV56   gi|74353564  
PROTEASE, SERINE, 2 
(TRYPSIN 2) 4 15 1 
ALDH18A1  5832 P54886    gi|76779856  
ALDEHYDE 
DEHYDROGENASE 18 
FAMILY, MEMBER A1 4 5 1 
NPM3 10360 O75607    gi|5801867 
NUCLEOPHOSMIN/NUCLE
OPLASMIN, 3 4 12 1 
WAC 51322 Q9BTA9    gi|55664165  
WW DOMAIN CONTAINING 
ADAPTOR WITH COILED-
COIL 4 5 1 
ANKRD24 170961 Q8TF*21   gi|16418357  
ANKYRIN REPEAT DOMAIN 




B4DJ51  gi|61680528 CALMODULIN 3 18 1 
COL7A1 1294 
Q02388 
Q59F16   gi|119585300  
COLLAGEN, TYPE VII, 
ALPHA 1 (EPIDERMOLYSIS 
BULLOSA, DYSTROPHIC, 
DOMINANT AND 
RECESSIVE) 3 1 1 
HSPD1 3329 P10809    gi|14326412  
HEAT SHOCK 60kDa 
PROTEIN 1 3 15 2 
ME2 4200 
P23368 
Q9BWL6   gi|5822326  
MALIC ENZYME 2, NAD(+)-
DEPENDENT 3 5 2 
PEX1 5189 O43933     gi|4505725 
PEROXISOMAL BIOGENESIS 
FACTOR 1 3 2 1 
PRKAA1 5562 Q13131    gi|29124503  
PROTEIN KINASE, AMP-
ACTIVATED, ALPHA 1 3 5 1 
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B4DJ51  gi|61680528 CALMODULIN 3 18 1 
COL7A1 1294 
Q02388 
Q59F16   gi|119585300  
COLLAGEN, TYPE VII, 
ALPHA 1 (EPIDERMOLYSIS 
BULLOSA, DYSTROPHIC, 
DOMINANT AND 
RECESSIVE) 3 1 1 
HSPD1 3329 P10809    gi|14326412  
HEAT SHOCK 60kDa 
PROTEIN 1 3 15 2 
ME2 4200 
P23368 
Q9BWL6   gi|5822326  
MALIC ENZYME 2, NAD(+)-
DEPENDENT 3 5 2 
PEX1 5189 O43933     gi|4505725 
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FACTOR 1 3 2 1 
PRKAA1 5562 Q13131    gi|29124503  
PROTEIN KINASE, AMP-
ACTIVATED, ALPHA 1 3 5 1 
 








DEHYDROGENASE) 3 3 2 
PDIA4 9601 
Q549T6 
P13667   gi|37182276  
PROTEIN DISULFIDE 
ISOMERASE FAMILY A, 
MEMBER 4 3 2 1 
COLEC10 10584 Q9Y6Z7    gi|5453619  
COLLECTIN SUB-FAMILY 
MEMBER 10 (C-TYPE 
LECTIN) 3 12 1 
FOXJ3 22887  gi|114555879  FORKHEAD BOX J3 3 4 1 
ARS2 51593 Q9BXP5    gi|33150698 ARS2 PROTEIN 3 5 1 
FOXJ2 55810 Q9P0K8    gi|8923842  FORKHEAD BOX J2 3 4 1 
UBAP2 55833 
Q5T6F2 
Q9P0H6   gi|22325364  
UBIQUITIN ASSOCIATED 
PROTEIN 2 3 3 1 
KIAA1529* 57653 Q9P1Z9    gi|7959325  KIAA1529 3 2 3 
LRRC8E 80131 B3KR78    gi|801893  
LEUCINE RICH REPEAT 
CONTAINING 8 FAMILY, 
MEMBER E 3 3 1 
QRICH2 84074 Q9H0J4    gi|14149793  GLUTAMINE RICH 2 3 3 1 
DPP9* 91039 
Q86TI2 
Q1ZZB8   gi|119589606  DIPEPTIDYL-PEPTIDASE 9 3 4 2 
LPLUNC1 92747 Q8TDL5     gi|40807482 
NASOPHARGYNEAL 
RELATED 3 6 1 
DOK7 285489 Q18PE1    gi|119602869  
HYPOTHETICAL PROTEIN 
FLJ33718 3 4 1 
SLFN14 342618 P0C7P3    gi|193788704 
ORTHOLOG OF MOUSE 
SCHLAFEN 10 3 5 1 
ENO1 2023 P06733    gi|4503571  ENOLASE 1 2 6 1 
XRCC5 7520 P13010    gi|119590969  
X-RAY REPAIR 
COMPLEMENTING 
DEFECTIVE REPAIR IN 
CHINESE HAMSTER CELLS 5 
(DOUBLE-STRAND-BREAK 
REJOINING; KU 
AUTOANTIGEN, 80kDa) 2 4 1 
WDR1 9948 O75083    gi|12652891  WD REPEAT DOMAIN 1 2 6 1 
NLRP1 22861 
Q9C000 
Q9H5Z7   gi|37927559  
NLR FAMILY, PYRIN 
DOMAIN CONTAINING 1 2 1 1 
PPA2 27068 
Q9H2U2 
A6NKL9   gi|119612395  
PYROPHOSPHATASE 
(INORGANIC) 2 2 1 1 
VPS35 55737 Q96QK1   gi|7022978 
VACUOLAR PROTEIN 
SORTING 35 2 2 1 
 
Proteins Captured with normal IIb 




No. Description # Pep % Cov # Exp 
ITGB3* 3690 P05106  gi|183531 
INTEGRIN, BETA 3 
(PLATELET 
GLYCOPROTEIN IIIA, 
ANTIGEN CD61) 25 42 7 
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TUBB2C 7284 P49411  gi|20809886  TUBULIN, BETA 2C 17 35 1 
DHTKD1 55526 Q96HY7 gi|119606733 
DEHYDROGENASE E1 AND 
TRANSKETOLASE 
DOMAIN CONTAINING 1 15 36 1 
GLUD1 2746 P00367  gi|183056 
GLUTAMATE 
DEHYDROGENASE 1 15 67 3 
DARS 1615 
P14868 
P78371  gi|45439306 
ASPARTYL-TRNA 
SYNTHETASE 14 60 3 
LMAN1* 3998 P49257  gi|5031873  
LECTIN, MANNOSE-
BINDING, 1 12 36 1 
PRKAB1 5564 Q9Y478  gi|4506061  
PROTEIN KINASE, AMP-
ACTIVATED, BETA 1 NON-
CATALYTIC SUBUNIT 12 38 1 
HSPA5* 3309 
P11021 
P08246  gi|16507237  
HEAT SHOCK 70kDa 
PROTEIN 5 (GLUCOSE-
REGULATED PROTEIN, 






VOLTAGE-GATED, TYPE X, 
ALPHA 11 5 1 
TUBB 10383 P68371  gi|7106439 TUBULIN, BETA 5 11 44 4 
TUBB4 23071 Q9BS26  gi|21361322  TUBULIN, BETA 4 10 26 1 
ALDH18A1 5832 P54886  gi|76779856  
ALDEHYDE 
DEHYDROGENASE 18 
FAMILY, MEMBER A1 9 18 2 
DNAJC10* 54431 Q8IXB1  gi|24308127  
DNAJ (HSP40) HOMOLOG, 
SUBFAMILY C, MEMBER 10 9 21 4 
EXOSC10 5394 
Q01780 
P05156  gi|50301239 
EXOSOME COMPONTENT 
10 9 8 1 
UGP1 10352 Q9UGM6  gi|48255966  
UDP-GLUCOSE 
PYROPHOSPHORYLASE 1 9 33 1 
ADPGK 83440 Q9BRR6  gi|31542509  
ADP-DEPENDENT 
GLUCOKINASE 8 22 1 
ALAD 210 P13716  gi|248839  
AMINOLEVULINATE, 
DELTA-, DEHYDRATASE 8 22 1 
CCT2 10576 P78371  gi|5453603  
CHAPERONIN 
CONTAINING TCP1, 
SUBUNIT 2 (BETA) 8 39 1 
CCT4 10575 P50991  gi|38455427  
CHAPERONIN 
CONTAINING TCP1, 
SUBUNIT 4 (DELTA) 8 28 1 
FARS2 10667 O95363  gi|62898407  
PHENYLALANINE-TRNA 
SYNTHETASE 2  8 24 1 
HSPA1A* 3303 B3KTT5 gi|5123454  
HEAT SHOCK 70kDa 
PROTEIN 1A 8 19 1 
HSPA1B 3304 P08107  gi|167466173 
HEAT SHOCK 70kDa 
PROTEIN 1B 8 21 1 
HSPA9 3313 P38646  gi|12653415  
HEAT SHOCK 70kDa 
PROTEIN 9B (MORTALIN-2) 8 17 2 
NUDT19 390916 A8MXV4 gi|157739940 
NUDIX (NUCLEOSIDE 
DIPHOSPHATE LINKED 
MOIETY X)-TYPE MOTIF 19 8 36 1 
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AKR7A2 8574 O43488  gi|41327764  
ALDO-KETO REDUCTASE 
FAMILY 7, MEMBER A2 
(AFLATOXIN ALDEHYDE 
REDUCTASE) 7 37 1 
CHD9 80205 Q3L8U1 gi|95147342 
CHROMODOMAIN 
HELICASE DNA BINDING 
PROTEIN 9 7 2 1 
FAM175B 23172  gi|148529023
UNKNOWN PROTEIN 
LOC23172 7 14 1 
KIF14 9928 Q15058  gi|7661878 
KINESIN FAMILY MEMBER 
14 7 4 1 
NT5DC2 22978 A8K6K2 gi|12597653  
5'-NUCLEOTIDASE 
DOMAIN CONTAINING 2 7 36 2 
P15RS 55197 Q96P16 gi|142385371
REGULATION OF 
NUCLEAR pre-mRNA 
DOMAIN CONTAINING 1A 7 20 1 
PDLIM1 9260 
Q9Y3C6 
Q9NR12  gi|13994151  
PDZ AND LIM DOMAIN 1 
(ENIGMA) 7 37 1 
PM20D2 135293 Q8IYS1  gi|58082085  AMINOACYLASE 1-LIKE 2 7 15 1 
POLDIP2 26073 
Q9Y2S7 
Q9BVV8  gi|7661672  
POLYMERASE (DNA-
DIRECTED), DELTA 
INTERACTING PROTEIN 2 7 26 1 
TF* 7018 P02787  gi|553788  TRANSFERRIN 7 12 1 
ACTN4 604638  gi|2804273  ACTININ, ALPHA 4 6 9 1 
ATXN2L* 11273 Q8WWM7 gi|119572372 ATAXIN 2-LIKE 6 9 1 
CCT7 10574 Q99832  gi|62896515  
CHAPERONIN 
CONTAINING TCP1, 
SUBUNIT 7 (ETA) 6 23 1 
CNDP2 55748 Q96KP4  gi|8922698 
CNDP DIPEPTIDASE 2 
(METALLOPEPTIDASE M20 
FAMILY) 6 11 1 
FLJ12529 79869 Q8N684  gi|24432016  
PRE-MRNA CLEAVAGE 
FACTOR I, 59 kDa SUBUNIT 6 12 1 
PBEF1 10135 P43490   gi|55960735 
PRE-B-CELL COLONY 
ENHANCING FACTOR 1 6 4 1 
PPP1R9A 55607 Q9ULJ8  gi|261244899
PROTEIN PHOSPHATASE 1, 
REGULATORY (INHIBITOR) 
SUBUNIT 9A, 5 isoforms 6 5 1 
RB1CC1 9821 Q8TDY2  gi|134304845
RB1-INDUCIBLE COILED-
COIL 1 6 3 1 
SERBP1 26135 
Q8NC51 
Q9H707  gi|66346679  
SERPINE1 MRNA BINDING 
PROTEIN 1 6 16 1 
TXNDC4 23352 
Q8WXW3 




RETICULUM) 6 35 3 
ACLY 47 
Q9NP58 
P53396  gi|38569423  ATP CITRATE LYASE 5 3 1 
ACTB 60 Q1KLZ0 gi|14250401 ACTIN, BETA 5 22 3 
CTTN 2017  gi|2498954  CORTACTIN 5 4 1 
CUL-5 8065 Q93034  gi|67514034 CULLIN 5 5 5 1 
FHL1 2273 Q13642  gi|3851650  FOUR AND A HALF LIM 5 3 1 
 




GPHN 10243 Q9NQX3  gi|10880983  GEPHYRIN ISOFORM 1 5 8 1 
HNRPH1 3187 P31943  gi|5031753  
HETEROGENEOUS 
NUCLEAR 
RIBONUCLEOPROTEIN H1 5 16 1 
HSPA8* 3312 P11142  gi|10880983  
HEAT SHOCK 70kDa 
PROTEIN 8 5 8 3 
IDH3A 3419 P50213  gi|5031777  
ISOCITRATE 
DEHYDROGENASE 3 
(NAD+) ALPHA 5 13 1 
PRKAG1 5571 P54619  gi|2230863  
PROTEIN KINASE, AMP-
ACTIVATED, GAMMA 1 
NON-CATALYTIC SUBUNIT 5 27 1 
RILPL1 353116 Q5EBL4 gi|30315660  
RAB INTERACTING 
LYSOSOMAL PROTEIN-
LIKE 1 5 12 1 
SAP130 79595 Q9H0E3  gi:25579126 
SIN3A-ASSOCIATED 
PROTEIN, 130kDa 5 3 1 
WARS2 80139 Q9H7S9  gi|7710154  
TRYPTOPHANYL TRNA 
SYNTHETASE 2 5 19 1 
ADCY6 112 O43306  gi|168480141 ADENYLATE CYCLASE 6 4 3 1 
C5orf25 375484 Q8NDZ2  gi|196259795 FLJ44216 PROTEIN 4 8 1 
CARS2 79587 Q9HA77 gi|119618821 
HYPOTHETICAL PROTEIN 
FLJ39378 4 10 1 




KINASE 21) 4 2 1 
EEF2K 29904 O00418  gi|9558749  
EUKARYOTIC 
ELONGATION FACTOR-2 
KINASE 4 4 1 
FLJ22184 80164 Q9H6K5 gi|239757129
HYPOTHETICAL PROTEIN 
FLJ22184 4 5 1 
FLNA 2316 P21333  gi|57284166  
FILAMIN A, ALPHA 
(ACTIN BINDING PROTEIN 
280) 4 2 2 
FRMPD1 22844 Q5SYB0 gi|239582740
FERM AND PDZ DOMAIN 
CONTAINING 1 4 3 1 
GOPC 57120 Q9HD26  gi|9966877  
GOLGI ASSOCIATED PDZ 
AND COILED-COIL MOTIF 
CONTAINING 4 12 1 
HMGCS1 3157 Q01581  gi|53734504  
3-HYDROXY-3-
METHYLGLUTARYL-
COENZYME A SYNTHASE 1 
(SOLUBLE) 4 14 1 
HNRNPL* 3191 P14866  gi|133274  
HETEROGENEOUS 
NUCLEAR 
RIBONUCLEOPROTEIN L 4 11 2 
HTRA2 27429 O43464  gi|21614538  HTRA SERINE PEPTIDASE 2 4 16 1 
NAGK 55577 Q9UJ70  gi|6491737  
N-ACETYLGLUCOSAMINE 
KINASE 4 10 1 
PKM2* 5315 P14618  gi|31416989  PYRUVATE KINASE, 4 16 1 
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AKR7A2 8574 O43488  gi|41327764  
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DOMAIN CONTAINING 1A 7 20 1 
PDLIM1 9260 
Q9Y3C6 
Q9NR12  gi|13994151  
PDZ AND LIM DOMAIN 1 
(ENIGMA) 7 37 1 
PM20D2 135293 Q8IYS1  gi|58082085  AMINOACYLASE 1-LIKE 2 7 15 1 
POLDIP2 26073 
Q9Y2S7 
Q9BVV8  gi|7661672  
POLYMERASE (DNA-
DIRECTED), DELTA 
INTERACTING PROTEIN 2 7 26 1 
TF* 7018 P02787  gi|553788  TRANSFERRIN 7 12 1 
ACTN4 604638  gi|2804273  ACTININ, ALPHA 4 6 9 1 
ATXN2L* 11273 Q8WWM7 gi|119572372 ATAXIN 2-LIKE 6 9 1 
CCT7 10574 Q99832  gi|62896515  
CHAPERONIN 
CONTAINING TCP1, 
SUBUNIT 7 (ETA) 6 23 1 
CNDP2 55748 Q96KP4  gi|8922698 
CNDP DIPEPTIDASE 2 
(METALLOPEPTIDASE M20 
FAMILY) 6 11 1 
FLJ12529 79869 Q8N684  gi|24432016  
PRE-MRNA CLEAVAGE 
FACTOR I, 59 kDa SUBUNIT 6 12 1 
PBEF1 10135 P43490   gi|55960735 
PRE-B-CELL COLONY 
ENHANCING FACTOR 1 6 4 1 
PPP1R9A 55607 Q9ULJ8  gi|261244899
PROTEIN PHOSPHATASE 1, 
REGULATORY (INHIBITOR) 
SUBUNIT 9A, 5 isoforms 6 5 1 
RB1CC1 9821 Q8TDY2  gi|134304845
RB1-INDUCIBLE COILED-
COIL 1 6 3 1 
SERBP1 26135 
Q8NC51 
Q9H707  gi|66346679  
SERPINE1 MRNA BINDING 
PROTEIN 1 6 16 1 
TXNDC4 23352 
Q8WXW3 




RETICULUM) 6 35 3 
ACLY 47 
Q9NP58 
P53396  gi|38569423  ATP CITRATE LYASE 5 3 1 
ACTB 60 Q1KLZ0 gi|14250401 ACTIN, BETA 5 22 3 
CTTN 2017  gi|2498954  CORTACTIN 5 4 1 
CUL-5 8065 Q93034  gi|67514034 CULLIN 5 5 5 1 
FHL1 2273 Q13642  gi|3851650  FOUR AND A HALF LIM 5 3 1 
 




GPHN 10243 Q9NQX3  gi|10880983  GEPHYRIN ISOFORM 1 5 8 1 
HNRPH1 3187 P31943  gi|5031753  
HETEROGENEOUS 
NUCLEAR 
RIBONUCLEOPROTEIN H1 5 16 1 
HSPA8* 3312 P11142  gi|10880983  
HEAT SHOCK 70kDa 
PROTEIN 8 5 8 3 
IDH3A 3419 P50213  gi|5031777  
ISOCITRATE 
DEHYDROGENASE 3 
(NAD+) ALPHA 5 13 1 
PRKAG1 5571 P54619  gi|2230863  
PROTEIN KINASE, AMP-
ACTIVATED, GAMMA 1 
NON-CATALYTIC SUBUNIT 5 27 1 
RILPL1 353116 Q5EBL4 gi|30315660  
RAB INTERACTING 
LYSOSOMAL PROTEIN-
LIKE 1 5 12 1 
SAP130 79595 Q9H0E3  gi:25579126 
SIN3A-ASSOCIATED 
PROTEIN, 130kDa 5 3 1 
WARS2 80139 Q9H7S9  gi|7710154  
TRYPTOPHANYL TRNA 
SYNTHETASE 2 5 19 1 
ADCY6 112 O43306  gi|168480141 ADENYLATE CYCLASE 6 4 3 1 
C5orf25 375484 Q8NDZ2  gi|196259795 FLJ44216 PROTEIN 4 8 1 
CARS2 79587 Q9HA77 gi|119618821 
HYPOTHETICAL PROTEIN 
FLJ39378 4 10 1 




KINASE 21) 4 2 1 
EEF2K 29904 O00418  gi|9558749  
EUKARYOTIC 
ELONGATION FACTOR-2 
KINASE 4 4 1 
FLJ22184 80164 Q9H6K5 gi|239757129
HYPOTHETICAL PROTEIN 
FLJ22184 4 5 1 
FLNA 2316 P21333  gi|57284166  
FILAMIN A, ALPHA 
(ACTIN BINDING PROTEIN 
280) 4 2 2 
FRMPD1 22844 Q5SYB0 gi|239582740
FERM AND PDZ DOMAIN 
CONTAINING 1 4 3 1 
GOPC 57120 Q9HD26  gi|9966877  
GOLGI ASSOCIATED PDZ 
AND COILED-COIL MOTIF 
CONTAINING 4 12 1 
HMGCS1 3157 Q01581  gi|53734504  
3-HYDROXY-3-
METHYLGLUTARYL-
COENZYME A SYNTHASE 1 
(SOLUBLE) 4 14 1 
HNRNPL* 3191 P14866  gi|133274  
HETEROGENEOUS 
NUCLEAR 
RIBONUCLEOPROTEIN L 4 11 2 
HTRA2 27429 O43464  gi|21614538  HTRA SERINE PEPTIDASE 2 4 16 1 
NAGK 55577 Q9UJ70  gi|6491737  
N-ACETYLGLUCOSAMINE 
KINASE 4 10 1 
PKM2* 5315 P14618  gi|31416989  PYRUVATE KINASE, 4 16 1 
 






P30048  gi|14250063  PEROXIREDOXIN 3 4 20 1 
SF1* 7536 Q15637  gi|46362557  SPLICING FACTOR 1 4 5 1 
TIMM50 92609 Q3ZCQ8  gi|48526509  
TRANSLOCASE OF INNER 
MITOCHONDRIAL 
MEMBRANE 50 HOMOLOG 4 6 1 
AER61 285203  gi|39930530 
GLUCOSYLTRANSFERASE 
AER61 C3orf64 3 6 1 
CSNK2A2 1459 Q14012  gi|4503097  
CASEIN KINASE 2, ALPHA 
PRIME POLYPEPTIDE 3 6 1 
DPP9* 91039 Q86TI2  gi|114657671 DIPEPTIDYL-PEPTIDASE 9 3 2 1 
DVL2 1856 O14641  gi|55665917  
DISHEVELLED, DSH 
HOMOLOG 2 
(DROSOPHILA) 3 2 1 
ELMO1 9844 O60895  gi|86788139 
ENGULFMENT AND CELL 
MOTILITY 1 3 5 1 
GAPDH 2597 
P04406 
Q16678  gi|31645  
GLYCERALDEHYDE-3-
PHOSPHATE 
DEHYDROGENASE 3 18 1 
KIAA0895 23366 Q8NCT3 gi|154426319 KIAA0895 PROTEIN 3 6 1 
LUC7L2 51631 Q9Y383  gi|4929587  CGI-59 PROTEIN 3 5 1 
MPO 4353 P05164  gi|88180  MYELOPEROXIDASE 3 5 2 
PEG10 23089 Q86TG7 gi|94421473  
PATERNALLY EXPRESSED 
10 3 11 1 
RPLP0 6175 
P05388 
Q9NQX7  gi|12654583  
RIBOSOMAL PROTEIN, 
LARGE, P0 3 12 1 
SEC13 6396 A8MV37 gi|119584482 
SEC13-LIKE 1 (S. 
CEREVISIAE) 3 11 1 
SEC23A 10484 
Q15436 
Q92736  gi|22477159  
SEC23 HOMOLOG A (S. 
CEREVISIAE) 3 3 1 
SHROOM3 57619 Q8TF72  gi|57284166  
SHROOM3 F-ACTIN 
BINDING PROTEIN 3 2 4 
UBR4 23352  gi|9367763  ZINC FINGER, UBR1 TYPE 1 3 3 1 
A2M 2 P01023  gi|177872  
ALPHA-2-
MACROGLOBULIN 2 1 1 
ABCA13 154664 Q86UQ4  gi|8928549  
ATP-BINDING CASSETTE, 
SUB-FAMILY A (ABC1), 
MEMBER 13 2 5 2 
CORO1A 11151 P31146  gi|5902134  
CORONIN, ACTIN 
BINDING PROTEIN, 1A 2 4 1 
KIAA1529* 57653 Q9P1Z9 gi|7959325 KIAA1529 2 2 4 
MAP3K7IP2 23118 Q9NYJ8  gi|14149669  
MITOGEN-ACTIVATED 
PROTEIN KINASE KINASE 
KINASE 7 INTERACTING 
PROTEIN 2 2 2 1 
RANBP10 57610 Q6VN20 gi|40538736  RAN BINDING PROTEIN 10 2 4 1 
RAVER1* 125950 Q8IY67  gi|123173757 RAVER1 2 4 1 
TUBA1A 203068 P07437  gi|340021 TUBULIN, ALPHA 2 2 3 
ZNF703 80139  gi|13376610 ZINC FINGER PROTEIN 703 2 3 1 
Table 1. Proteins captured with IIb in megakaryocytes and HEK293 cells. Results are 
separated according to the IIb subunit they were captured with. Column labels: Gene 
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Symbol, EntrezGene ID, Protein Accession Number and Description are from the NCBI 
database. SwissProt Accession Number is from the UniProt database. Number of Unique 
Peptides is cumulative from all experiments. Coverage percent is cumulative for all 
experiments. Tally is shown of the total number of experiments in which a protein was 
identified (No Expts), and whether captured by histidine tag/Ni affinity (Ni-His) or by 
crosslinking (X-link). Presence or absence in a recently published expression study 
(HaemAtlas) is indicated. * Proteins captured by both normal and mutant IIb subunits. 
3.2 Gene Ontology analysis 
Gene Ontology (GO) analysis using the DAVID Bioinformatics Resources(Dennis, Sherman 
et al. 2003; Huang, Sherman et al. 2008) revealed enrichment for protein functions related to 
processing and trafficking, and ER, Golgi or vesicle components (Figure 3). Comparison of 
the proteins isolated with the normal IIb subunits vs with the IIbR858G/R859G subunits 
showed similar distributions of their localization and molecular functions (Table 2). 
Notably, the IIbR858G/R859G subunits captured a greater percentage of these types of 
proteins, suggesting that a greater percentage of the IIbR858G/R859G subunits were 
associated with the ER, Golgi and vesicles. Comparison of our data set to a recently 
published analysis of gene expression in megakaryocytes(Watkins, Gusnanto et al. 2009) 
showed that approximately 70% of the proteins identified herein as potentially interacting 
with IIb were identified as expressed in the megakaryocyte transcriptome.  
 
GO function/location % of total proteins 
  IIb IIbR858G/R859G 
Protien transport 31 49 
Stress Caperone 21 34 
Vesicle part 6 14 
ER or Golgi part 19 21 
Organelle part 27 41 
Cytoskeleton 21 29 
ATP/GTP binding 31 45 
Table 2. Distribution of captured proteins into Gene Ontology categories. Some proteins 
appear in more than one category. 
Despite the similarity in distributions into GO categories pertaining to protein processing 
and localization, there were only 14 proteins in common between the normal IIb and 
IIbR858G/R859G captured proteins (Table 1). This may indicate a difference in the relative 
amount of time spent by the normal and mutant subunits in the protein processing 
environment. One protein, DNAJC10, was captured in all experiments by both IIb and 
IIbR858G/R859G. Like other DNAJ proteins, DNAJC10 contains a binding domain for the 
chaperone BiP, but is unique in that its second domain has four protein-disulfide-isomerase 
(PDI) consensus sequences. (Cunnea, Miranda-Vizuete et al. 2003; Dong, Bridges et al. 2008)  
Because disulfide bond rearrangement is important for both biogenesis and function of 
IIb3, we investigated the putative interaction between IIb and DNAJC10. To our 
knowledge, DNAJC10 has not previously been reported to interact with IIb or 3. 
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Symbol, EntrezGene ID, Protein Accession Number and Description are from the NCBI 
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3.3 DNAJC10 interacts with IIb3 during biogenesis 
DNAJC10 coimmunoprecipitated with IIb and 3 from UCB derived megakaryocytes 
using anti-IIb mAbs 10E5, B1B5, M148 and CA3, and the anti 3 mAb 7H2. DNAJC10 
either interacted with IIb and 3 directly or was part of a complex with them (Figure 3). 
Because DNAJC10 was captured by the IIbR858G/R859G subunit, we explored the 
possibility that DNAJC10 interacted with IIb prior to IIb3 complex formation and IIb 
cleavage to its mature form. We have previously shown that pro-IIb is degraded by the 
proteasome and that proteasome inhibition leads to an increase of pro-IIb within the cells. 
(Mitchell, Li et al. 2006) The undegraded pro-IIb is trapped in a “pre-degradation” state in 
which normally transient protein interactions, which usually lead to degradation, may 
become more long-lived and may be captured by co-immunoprecipitation. Incubation of 
megakaryocytes with MG132 resulted in increased DNAJC10 co-immunoprecipitation with 
IIb by all mAbs, but particularly M148 and CA3. Thus, DNAJC10 may associate with IIb 
early in biogenesis, before excess pro-IIb is targeted to the proteasome.  
 
Fig. 3. Network derived from Table 1 data. Proteins are represented as nodes (circles) 
labeled with their gene symbol, and putative protein interactions with IIb are indicated by 
thin green connecting lines. Thick blue lines and blues circles represent interactions or 
proteins, respectively, retrieved from online databases (Intact and NCBI) using the 
Cytoscape software. Arrow indicates DNAJC10. Figure prepared using Cytoscape. 
To test this possibility we used a panel of conformation-specific mAbs that we have 
previously used to track the conformational changes of IIb as it proceeds through 
biogenesis (Figure 3).(Mitchell, Li et al. 2007) Specifically: mAb10E5 binds to the IIb head 
region and recognizes both the pro-IIb3 and mature IIb3 complex; mAb 7E3 binds to 
the 3 head region and also recognizes both the pro- and mature complex; mAb B1B5 binds 
to the IIb tail and preferentially recognizes pro-IIb and pro-IIb3 complex, and mAb 
M148 preferentially recognizes mature IIb3 but its epitope is not known.(Mitchell, Li et al. 
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2007) To determine whether DNAJC10 interacts with IIb during a specific stage of 
biogenesis, IIb was immunoprecipitated from megakaryocytes in the presence of MG132 
using this panel of conformation-specific mAbs. DNAJC10 was most strongly 
coimmunoprecipitated by mAb B1B5, suggesting that DNAJC10 preferentially interacts with 
pro-IIb or the pro-IIb3 complex. In contrast, DNAJC10 coimmunoprecipitated less well 
with mAb M148, suggesting less interaction with mature IIb. DNAJC10 also interacted 
with the precursor and/or mature IIb3 complex, since it coimmunoprecipitated with the 
complex-specific mAb10E5. Since the ratio of pro-IIb3 to mature IIb3 is small in 
megakaryocytes,(Mitchell, Li et al. 2007) this binding pattern is consistent with DNAJC10 
having bound preferentially to the small amount of pro-IIb3 present in the cells. Together 
these findings suggest that DNAJC10 preferentially interacted with pro-IIb and the pro-




Fig. 4. Interaction of DNAJC10 with IIb3 during biogenesis. A) Schematic of changing 
conformations of IIb3 as it progresses through biogenesis. B) Changing specificity of 3 
mAbs against IIb as it progresses through distinct conformations during biogenesis. B1B5 
preferentially recognizes pro-IIb, while M148 shows preference for mature IIb, and 10E5 
recognizes the heterodimer complex.C) Immunoprecipitation and Western blot of proteins 
isolated from megakaryocytes, as described in text. DNAJC10 coimmunoprecipitated 
preferentially with IIb that was pulled down by 10E5 and B1B5, but not M148, suggesting 
that DNAJC10 preferentially interacts with pro-IIb and pro-IIb3. The last lane is an IgG 
control. D) siRNA mediated knockdown of DNAJC10 increased surface expression of IIb3 
as measured by flow cytometry using an Alexa647-labeled anti-IIb3 mAb (10E5). 
Expression was increased by 25 +\- 11% (p=0.02, n=4) in UCB-derived megakaryocytes 
(UCB) and by 35 +\- 12% (p=0.01, n=3) in HEK293 cells (HEK293) compared to control 
siRNA transfection (CTL).  
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3.3 DNAJC10 interacts with IIb3 during biogenesis 
DNAJC10 coimmunoprecipitated with IIb and 3 from UCB derived megakaryocytes 
using anti-IIb mAbs 10E5, B1B5, M148 and CA3, and the anti 3 mAb 7H2. DNAJC10 
either interacted with IIb and 3 directly or was part of a complex with them (Figure 3). 
Because DNAJC10 was captured by the IIbR858G/R859G subunit, we explored the 
possibility that DNAJC10 interacted with IIb prior to IIb3 complex formation and IIb 
cleavage to its mature form. We have previously shown that pro-IIb is degraded by the 
proteasome and that proteasome inhibition leads to an increase of pro-IIb within the cells. 
(Mitchell, Li et al. 2006) The undegraded pro-IIb is trapped in a “pre-degradation” state in 
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become more long-lived and may be captured by co-immunoprecipitation. Incubation of 
megakaryocytes with MG132 resulted in increased DNAJC10 co-immunoprecipitation with 
IIb by all mAbs, but particularly M148 and CA3. Thus, DNAJC10 may associate with IIb 
early in biogenesis, before excess pro-IIb is targeted to the proteasome.  
 
Fig. 3. Network derived from Table 1 data. Proteins are represented as nodes (circles) 
labeled with their gene symbol, and putative protein interactions with IIb are indicated by 
thin green connecting lines. Thick blue lines and blues circles represent interactions or 
proteins, respectively, retrieved from online databases (Intact and NCBI) using the 
Cytoscape software. Arrow indicates DNAJC10. Figure prepared using Cytoscape. 
To test this possibility we used a panel of conformation-specific mAbs that we have 
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2007) To determine whether DNAJC10 interacts with IIb during a specific stage of 
biogenesis, IIb was immunoprecipitated from megakaryocytes in the presence of MG132 
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with the precursor and/or mature IIb3 complex, since it coimmunoprecipitated with the 
complex-specific mAb10E5. Since the ratio of pro-IIb3 to mature IIb3 is small in 
megakaryocytes,(Mitchell, Li et al. 2007) this binding pattern is consistent with DNAJC10 
having bound preferentially to the small amount of pro-IIb3 present in the cells. Together 
these findings suggest that DNAJC10 preferentially interacted with pro-IIb and the pro-
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3.4 DNAJC10 depletion increases surface expression of IIb3  
To determine whether the IIb-DNAJC10 interaction had physiological relevance, we 
assessed its impact on the surface expression of IIb3 in megakaryocytes. siRNA mediated 
knockdown of DNAJC10 was performed on both human megakaryocytes derived from 
UCB and on HEK293 cells expressing normal IIb and 3. At least an 80% decrease in RNA 
level was achieved (data not shown). Knockdown of DNAJC10 increased IIb3 surface 
expression on megakaryocytes by 25% +/- 11% (n = 4, p = 0.02), and on HEK293 cells 
expressing IIb3 by 35% +/- 12% (n=4, p = 0.01) (Figure 3D). 
3.5 Intracellular localization of DNAJC10 in megakaryocytes 
DNAJC10 was localized within megakaryocytes by immunofluorescence microscopy 
(Figure 5). The distribution of DNAJC10 was compared to that of IIb, 3, and the ER and 
Golgi compartments. Both IIb and 3 were distributed throughout the ER as well as on the 
cell surface. DNAJC10 had a diffuse punctate distribution in the periphery of the cell, away 
from the nucleus, and colocalized with only a portion of aIIb and 3, consistent with their 
presumably transient interaction. There was partial overlap between the ER marker calnexin 
and DNAJC10, suggesting that part of the DNAJC10 distribution is outside the ER or at least  
 
Fig. 4. Intracellular localization of DNAJC10. Cultured megakaryocytes were fixed and 
immunostained as described in the text. DNAJC10 (Blue) exhibited a punctate staining in 
the periphery of the cells, away from the nucleus. There was partial overlap of DNAJC10 
with calnexin (Red) staining. IIb (Green) was distributed throughout the ER and cell 
surface. While IIb partially colocalized with the cis- and trans-Golgi, DNAJC10 did not.  
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separate from the distribution of calnexin in the ER. This finding was surprising since 
DNAJC10 has the ER-retention signal KDEL. DNAJC10 did not localize with markers for the 
cis- or trans-Golgi compartments.  
4. Discussion 
We have used a proteomics approach to identify novel proteins interacting with IIb in 
megakaryocytes. Two different constructs of IIb, representing normal IIb and pro-IIb 
subunits, were used to capture proteins interacting with both nascent and mature subunits. 
Megakaryocytes were derived from human UCB and used on day 8, which in our system 
yields high expression IIb3 on the surface but no proplatelet formation.(Mitchell, Li et al. 
2006) In all, 163 proteins were identified as potentially interacting with IIb subunits; 98 
were captured with normal IIb and 79 with aIIbR858/G859G, with 14 overlapping (Table 
1). Day 8 megakaryocytes express very high amounts of IIb, most of which is mature 
IIb3, resulting in a relatively small proportion of nascent IIb. However, a large 
proportion of the mutant aIIbR858/G859G subunits are retained within the cell and 
degraded. Thus the difference between the two protein lists could partly be due to their 
differences in localization within the cell. This may be reflected in the larger proportion of 
ER and Golgi related proteins that were captured with the mutant subunit (Table 2). Only a 
few intracellular proteins have been reported to interact with IIb and IIb3, most notably 
talin, calnexin, and calreticulin (Intact and NCBI). Our two-step protein capture method was 
designed to isolate proteins with low affinity binding to IIb, such as calnexin, while 
screening out higher affinity binding proteins, such as talin and 3. In accord with this 
expectation, both talin and 3 were identified in both the control and experimental lanes, 
and so were excluded from the final interaction list, while calnexin and calreticulin were 
identified only in the experimental lanes. Surprisingly, while DNAJC10 readily 
coimmunoprecipitates with IIb3 from megakaryocytes, we have been unable to replicate 
this finding in HEK293 cells transfected with IIb and 3, despite an abundance of 
DNAJC10 in HEK293 cells (data not shown). While this is in no way conclusive, it is 
suggestive of cell-specific interaction of IIb3 and DNAJC10 in megakaryocytes. 
Comparison of our experimental results with previously reported platelet proteomic data 
and IIb3 interaction data showed good correlation. About 70% of the proteins identified 
in our screens were reported as “present” in platelets in the Haem Atlas, a proteomic 
analysis of platelet protein content(Watkins, Gusnanto et al. 2009).  
Two protein capturing strategies were used, each with strengths and weaknesses. The two-
cell pull-down assay using Ni beads to capture poly-histidine-tagged IIb, allowed the use 
of mutant cDNA constructs, such as IIbR858G/R859G, as bait. However, by introducing a 
protein synthesized in HEK293 cells as bait, there was the potential for false positive 
identification of proteins that associated with IIb in the HEK293 cells but not in 
megakaryocytes. Since the interactions of chaperone proteins are typically of low affinity, 
these proteins were most likely cleared by the washing steps and did not appear in the 
control lanes. Another source of false positives was non-specific binding to the Ni beads. 
Proteins with poly-His sequences (such as DEAH boxes) or naturally occurring Ni binding 
activity (such as keratin) could have bound to the beads, constituting false positives. 
However, virtually all of these potential false positives appeared in the control lanes as well 
and were excluded from analysis. The photoreactive crosslinking assay was intended to 
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were captured with normal IIb and 79 with aIIbR858/G859G, with 14 overlapping (Table 
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capture proteins in situ with IIb in megakaryocytes. While crosslinking experiments 
typically produce high numbers of false positives, in our experiments we identified low 
numbers of proteins from both the experimental and control lanes. The low yield may be 
due in part to the short crosslinking time used. We found that more than 15 minutes of UV 
exposure caused excessive protein degradation, while shorter exposure resulted in low 
crosslinking activity.  
Of the proteins captured using both IIb and IIbR858G/R859G the Hsp40-type chaperone 
protein, DNAJC10 (ERdj5), was notable due to its disulfide isomerase activity, since both 
IIb and 3 require disulfide bond rearrangement for both biogenesis and function. (Shen, 
Meunier et al. 2002; Cunnea, Miranda-Vizuete et al. 2003; Dong, Bridges et al. 2008) Among 
its several functions, the ER chaperone protein BiP protects nearly-folded proteins against 
aggregation by binding to exposed hydrophobic patches.(Hendershot 2004) The Hsp40 
chaperones bind to BiP and increase its efficiency of ATP hydrolysis, which allows BiP to 
release its substrate. DNAJC10 has been shown to be induced during ER stress, and may 
assist in delivering misfolded ER proteins to the proteasome for degradation.(Shen, Meunier 
et al. 2002; Cunnea, Miranda-Vizuete et al. 2003; Dong, Bridges et al. 2008)  
DNAJC10 coimmunoprecipitated with both IIb and 3 subunits in megakaryocytes, 
suggesting that it may bind the IIb3 complex. The immunoprecipitation pattern obtained 
using a panel of conformation-specific mAbs(Mitchell, Li et al. 2007) indicated that 
DNAJC10 preferentially interacted with pro-IIb or pro-IIb3 rather than mature IIb3. 
Together these findings suggest that DNAJC10 interacted with pro-IIb up to the point of 
complex formation, but not after pro-IIb cleavage (Figure 2). Thus DNAJC10 appears to be 
present and interacting with IIb at a critical decision point during IIb3 biogenesis, i.e. 
when pro-IIb will either form the mature IIb3 complex or be targeted to degradation.  
Surprisingly, the distribution of DNAJC10, which has a KDEL ER-localization signal, was 
not confined to the ER, as judged by the distribution of calnexin. To determine if DNAJC10 
was cycling to the Golgi and back, as many ER packaging proteins do, we looked for 
colocalization of DNAJC10 with cis and trans Golgi markers, and found none. The identity 
of the organelle(s) where DNAJC10 resides remains to be determined. 
Depletion of DNAJC10 by siRNA resulted in an increase in surface expression of IIb3 on 
both human megakaryocytes and transfected HEK293 cells (Figure 2D) Since DNAJC10 
depletion led to an increase in IIb3 surface expression, it appears to be a negative 
regulator of IIb3 surface expression. These findings make DNAJC10 an interesting and 
potentially targetable protein for perturbing IIb3 biogenesis. 
5. Conclusion 
While the details of DNAJC10-IIb interaction remain to be investigated, the current 
findings provide proof of principle that manipulation of early events in IIb biogenesis can 
result in altered expression levels of the mature IIb3 receptor, thereby setting a precedent 
for a novel approach to integrin-related therapy. These studies also support the validity of 
the data set, although other putative interactions must be explored for greater validation. 
We hope that the data set created will be a useful tool for studying integrin and 
megakaryocyte biology.  
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By deciphering the IIb3 biogenesis pathway we hope to gain an inroad into controlling 
the level of IIb3 expression on platelets with the long-term goal of developing novel anti-
thrombotic therapies. These types of therapy would not just inactivate the circulating 
platelets, but would modulate the megakaryocytes to make less adhesive platelets. One can 
imagine a scenario where patients at high risk of heart attack or stroke could be maintained 
on a drug that decreases their platelet IIb3 expression. Below a certain level of expression, 
platelet activation and aggregation would be diminished but not completely eliminated, 
resulting in an overall decrease in platelet thrombus formation but not complete loss of 
platelet function. This type of therapy could potentially have a greater safety profile than 
current therapies that summarily inactivate circulating platelets. 
This study also assembles some of the wide range of research methods available to 
hematology research. No single technique could have discovered, validated and explored 
the function of DNAJC10 in megakaryocytes: rather, a broad range of methods was 
required. This wide variety is part of what makes research exciting and underscores the 
benefits of collaboration.  
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1. Introduction 
Vertebrates have evolved a lymphocyte based adaptive immune system which specifically 
recognises antigens (Pancer and Cooper, 2006). The lymphoid progenitor cells migrate to the 
thymus a primary lymphoid organ for the development of T cells (Yang et al., 2010; Zlotoff 
and Bhandoola, 2011). Progenitor cells undergo a stringent selection process which leads to 
the development of T cells which have a T cell receptor that specifically reacts with the 
foreign antigens and not with the self antigens. The pre-T cells further differentiate into 
many subpopulations in the thymus or the peripheral organs, which perform different 
functions and are responsible for the adaptive immune responses. The maturation and 
development of T cells is typically defined by the expression of specific cell surface 
receptors. The early immature thymocytes that do not express either CD4 or CD8 are called 
double negative (DN) thymocytes. At these stage the cells undergo the rearrangement of T 
cell receptor (TCR) β chain. Subsequently, these cells express both CD4+ CD8+ and are 
referred to as the double positive (DP) cells. During this stage, the rearrangement of the α 
chain of TCR happens and the cells express the complete T cell receptor (Kreslavsky et al., 
2010). The DP thymocytes undergo proliferation and depending on the strength of TCR 
signaling further develop into either CD4+ or CD8+ single positive (SP) T cells via repression 
of the gene encoding the other receptor. 
The mature T cells migrate to the periphery wherein they encounter the antigens and 
develop into effector cells. The differentiation of naïve cells into the effector cells depends on 
the signaling pathways, the pathogen or the cytokines secreted by the antigen presenting 
cells (APCs). Naïve CD4 T cells mature into various subpopulations which secrete 
characterisic effector cytokines that define the functions of T cells. Based on the cytokines 
produced the CD4 T cells are distinguished into multiple subtypes such as TH1, TH2, TH17, 
induced regulatory T cells (iTregs), Tfh and TH9 (Zhu et al., 2010). Table 1 provides general 
overview of various lineages of CD4+ T cells with their key factors and cytokines secreted. 
The first functionally distinct subpopulations of CD4+ T cells were identified and described 
as the TH1/TH2 paradigm by Mosmann and Coffman, (Mosmann et al., 1986; Mosmann & 
Coffman, 1987) followed by delineation of the roles of TH1 and TH2 cells in cell-mediated 
and humoral immunity respectively. IL-12 signaling via STAT-4 results in the development 
of TH1 cells. IL-4 signaling in conjunction with STAT-6 skews the cells towards TH2 
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phenotype. Another major subtype of CD4+ T cells that has gained considerable importance 
in recent years is TH17 which produce IL-6 and IL-17. The transcription factors STAT-3 and 
RORγt act as master regulators for TH17 differentiation (Park et al., 2005; Dong et al., 2008). 
Major function of TH cells is to help B cells to develop antigen-specific antibody response. A 
subset of TH cells enter into germinal center and interact with developing B cells and assist 
them for class-switching. This subset of cells is known as Follicular Helper T cells (Tfh). The 
Tfh cells secrete IL-4 or IFNγ depending upon their priming (King et al., 2008). Naïve 
peripheral CD4+ T cells can be induced to give rise to iTreg cells which require FOXP3 
transcription factor. These cells are shown to be involved in suppressor function of immune 
system and for maintainance of tolerance to self-antigens (DiPaolo et al., 2007). TH9 is 
another recently discovered type of CD4+ T cells which produce IL-9 and whose function is 
not clearly understood. However it is proposed that these cells might be involved in 










secreted by cells 
Function 
(Described in) 
TH1 STAT-4, T-bet  IFN-γ Cell mediated Immunity 
(Mosmann & Coffman, 1987) 
TH2 STAT-6, SATB1, 
GATA-3 
IL-5, IL-4, IL-13 Humoral Immunity 
(Mosmann & Coffman, 1987) 
Treg FOXP3   Maintainance of tolerance  
(Sakaguchi et al., 2008) 
TH17 STAT-3, ROR γt IL-17A, IL-17F Inflammation, autoimmunity 
(Hirota et al., 2011) 
Tfh Bcl-6 IL-21 Mediate help and class 
switching in B cells in germinal 
centers  
(Kitano et al., 2011) 
TH9 IRF-4 IL-9 Immunity against helminth 
infection, most important cell 
type responsible for the 
pathogenesis of Asthma  
(Staudt et al., 2010) 
Table 1. Functional subtypes of CD4+ T lineage. Various characterized subtypes of  CD4+ T 
cells are listed with their reported essential factors required for lineage determination, key 
cytokine secreted and function of these cells. For details see text. 
2. SATB1 and its role in transcriptional regulation of multiple genes 
The cell signaling pathways which initiate the differentiation process ultimately lead to 
expression of a specific transcription factor. The key transcription factors are important for 
the expression of specific cytokine gene and maintenance of the phenotype. SATB1 is a T cell 
enriched transcription factor that regulates large number of genes involved in T cell 
development and is also required for the maintainance of higher-order chromatin 
architecture (Alvarez et al., 2000; Kumar et al., 2006; Cai et al., 2003; Cai et al., 2006, Kumar 
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et al., 2007). Ablation of SATB1 causes dysregulation of genes required for the development 
of T cells and the development is stalled at the DP stage (Alvarez et al., 2000). Thymocytes 
from SATB1 knockout mice revealed ectopic expression of genes such as IL-2R and IL-7R. 
SATB1 is known to regulate genes by selectively tethering their regulatory regions and via 
formation of a characteristic cage-like structure around the heterochromatic regions in 
Thymocytes (Cai et al., 2004), presumably demarcating the active and inactive domains 
(Galande et al., 2007). SATB1 also acts as a docking site for chromatin 
remodeling/modifying factors such as ISWI, ASF1 and NURD complex containing HDAC1, 
leading to the repression of genes (Yasui et al., 2000). Post-translational modifications of 
SATB1 such as acetylation and phosphorylation act as molecular switches regulating its 
ability to govern gene expression. The PDZ-like domain of SATB1 undergoes 
phosphorylation by PKC and acetylation by PCAF acetyltransferase in signal-dependent 
manner (Kumar et al., 2006). Acetylation of SATB1 negatively influences the DNA binding 
activity of SATB1 whereas phosphorylated form of SATB1 is shown to bind tightly to the Il-
2 promoter and repress Il-2. Interaction of SATB1 with the CtBP1 corepressor via its N-
terminal PDZ-like domain represses transcription. Upon inhibition of Wnt signaling by LiCl 
treatment SATB1 is acetylated, loses its interaction with CtBP1 and thus leads to activation 
of Il-2 (Purbey et al., 2009). Further, SATB1 is also known to regulate chromatin loop domain 
organization (‘loopscape’) in a cell type-specific manner. In Jurkat T cells, SATB1 organizes 
the MHC class I locus into a ‘loopscape’ comprising six loops. However, CHO cells which 
express comparatively less SATB1 exhibit a different ‘loopscape’ of the MHC locus. 
Intersstingly, overexpression of SATB1 in CHO cells rendered the ‘loopscape’ similar to that 
in Jurkat cells underscoring the importantance of SATB1 in cell-type specific higher-order 
chromatin organization (Kumar et al., 2007; Galande et al., 2007). In TH2 cells, SATB1 
organizes the loop domain architecture of the TH2 cytokine locus and governs the 
coordinated expression of IL-4, IL-5 and IL-13 and thus regulate TH2 differentiation (Cai et 
al., 2006). Thus, SATB1 has emerged as an important factor orchestrating gene expression by 
modulating the higher-order chromatin architecture in a cell-type specific and signal-
dependent manner.  
Number of studies in the past few years have demonstrated the role of SATB1 in cancer. It 
has been shown that siRNA-mediated knockdown of SATB1 in higly aggressive breast 
cancer cells reversed the tumorogenic capability of cells and also inhibited the tumor growth 
(Han et al., 2008). Downregulation of SATB1 in cancerous cells resulted in alteration in the 
expression of about thousand genes. Furthermore, overexpression of SATB1 in a non-
aggressive tumor cell line resulted in augmenting the tumorigenic and metastatic capacity of 
these cells indicating its direct role in coordinated regulation of multiple genes. SATB1 
presumably reprogrammes gene expression by inducing specific epigenetic modifications at 
target gene loci, leading to upregulation of metastasis-associated genes and simultaneously 
causing downregulation of tumor suppressor genes (Han et al., 2008). These studies point to 
a coordinated mechanism of tumor progression.  
3. SATB1 in T cell development and differentiation 
3.1 Overview of T cell development 
T cells arise from the hematopoietic stem cell precursors that migrate to the thymus. Early 
stage T cell precursors (ETPs)  that migrate to the thymus lose the capability to give rise to B 
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stage T cell precursors (ETPs)  that migrate to the thymus lose the capability to give rise to B 
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cells, however they have the propensity to develop into  lineages other than T cells such as 
macrophages, dendritic cells and NKT cells (Yui et al., 2010). The ETPs also called DN1 
phenotypically are CD4-, CD8-, CD3-, CD25-, CD44+ cells. These cells undergo extensive 
proliferation and are not yet completely committed to T lineage (Rothenberg et al., 2010). 
The next stage of development is characterized by upregulation of CD25 and is called DN2 
stage at which cells are CD4-, CD8-, CD3-, CD25+, CD44+. Further, CD44 is downregulated 
and such cells are referred to as DN3 stage (CD4- , CD8-, CD3-, CD25+, CD44-) and at this stage 
they are committed to the T cell lineage. The DN3 cells stop dividing and undergo 
rearrangement of TCRβ chain. Successful assembly of the β chain facilitates the movement of 
cells and this process is known as β-selection (Michie & Zuniga-Pflucker, 2002). 
Subsequently, these cells downregulate both CD25 (IL-2R) and CD44, the stage is called 
DN4 and these are fully committed towards T lineage and start proliferation. Following the 
successful rearrangement of αβ TCR, thymocytes start expressing CD4 and CD8 coreceptors 
on the cell surface. The DP thymocytes undergo a stringent selection process, where the 
TCRs that cannot bind to self antigens undergo death by neglect, whereas those which bind 
to self MHC with intermediate affinity undergo positive selection (Marrack & Kappler, 
1997). Further, these thymocytes either develop into CD4+ or CD8+ SP thymocytes 
dependent on the TCR signals and the expression of specific transcription factor(s) (Singer et 
al., 2008). In the periphery, the mature T cells differentiate into effector T cells depending on 
the antigen encountered and cytokine signals.  
3.2 Role of SATB1 in thymocyte development 
SATB1 knockout mice exhibit a severe defect in T cell development. SATB1-null mice have 
disproportionately small thymi and spleens as compared to the wild-type mice. At the 
cellular level, these mice exhibit multiple defects in T-cell development. The population of 
immature CD3-,CD4-,CD8- triple negative (TN) thymocytes is greatly reduced. Most 
strikingly, the thymocyte development is blocked at the double positive stage and the CD4+ 
or CD8+ SP thymocytes fail to develop (Alvarez et al., 2000). Ablation of SATB1 also results 
in dysregulation of multiple genes such as Il-2R and Il-7R involved in T cell development 
and differentiation (Alvarez et al., 2000). Within the thymus majority of the DP thymocytes 
are eliminated via apoptosis during positive and negative selection process (Surh & Sprent, 
1994). Dexamethasone-induced apoptosis of thymocytes resulted in rapid dissociation of 
SATB1 from chromatin. Furthermore, SATB1 is specifically cleaved by caspase-6 after the 
aspartate residue at position 254 which led to the identification of the PDZ-like domain in 
the N-terminal region of SATB1. In vitro analysis revealed that caspase-6 cleavage also 
abolished the DNA-binding ability of SATB1 (Galande et al., 2001). The cleavage of SATB1 
during T cell apoptosis might be required for the initiation of DNA fragmentation. In 
SATB1- null mice peripheral CD4+ T cells fail to respond to activation stimulus and undergo 
apoptosis demonstrating indispensible role of SATB1 during proper T cell development 
(Alvarez et al., 2000). Comparison of the wild-type mice with the SATB1-/-  mice indicated 
that repression of Il-2R gene was caused specifically by recruitment of histone deacetylases 
by SATB1 (Yasui et al., 2002). Immunostaining of SATB1 in mouse thymocytes revealed that 
it forms a unique cage-like structure differentiating euchromatin from heterochromatin (Cai 
et al., 2003; Notani et al., 2010). In thymocytes, SATB1 is also known to cooperate with other 
regulatory factors such as β-catenin and CtBP-1 in signal-dependent manner and regulate 
gene expression (Purbey et al., 2009; Notani et al., 2010). SATB1-binding site-driven reporter 
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assays revealed that SATB1:β-catenin interaction regulates the expression of Wnt target 
genes in TCF-independent manner (Notani et al., 2010). The recruitment of β-catenin to 
SATB1 target genes is preceded by deacetylation of SATB1 upon Wnt/β-catenin signaling in 
thymocytes and CD4+ T cells. SATB1 directly binds to cis regulatory elements at the CD8 
enhancer and required for the CD8 SP thymocyte development from the DP thymocytes 
(Yao et al., 2010). Thus, SATB1 which is highly expressed in thymocytes acts as a global 
regulator in their development. 
3.3 Role of SATB1 in TH2 differentiation 
CD4+ SP thymocytes from the thymus migrate to peripheral lymphoid organs, where they 
encounter antigen presented by the antigens presenting cells (APCs) and further 
differentiate into T helper (TH) effector phenotypes. TH1 population is involved in cellular 
immunity wherein they assist macrophages and cytotoxic T cells (Tc) for clearance of 
infected cells while TH2 cells help B cells in generating humoral response by increasing 
production of neutralising antibodies against the pathogen (Zhu and Paul, 2008). TH2 
population is characterized by the effector cytokines it secretes viz., IL-5, IL-13 and IL-4. 
Strikingly, SATB1 which is known to have a important role during thymocyte development 
is upregulated during TH2 differentiation (Lund et al., 2005; Notani et al., 2010). SATB1 was 
shown to regulate the expression of TH2 cytokines by remodeling the chromatin in an 
actively transcribed loop form (Cai et al., 2006). T cell activation along with IL-4 cytokine 
stimulus showed that SATB1 forms higher-order chromatin structure of the 200 Kb TH2 
cytokine locus and regulates Il-5, Il-13 and Il-4. SATB1 induces expression of these cytokines 
by recruiting chromatin modifying enzyme Brg1 and RNA Pol II converting the locus into 
transcriptionally active region (Cai et al., 2006). Furthermore, induction of SATB1 expression 
in CD4+ cells during TH2 differentiation is STAT-6 dependent (Lund et al., 2005 and Ahlfors 
et al., 2010). Transcriptome profiling of differentiating CD4+ cells into TH1/ TH2 subtypes 
revealed that SATB1 is involved in regulation of over 300 genes indicating its crucial role 
during TH cell differentiation (Ahlfors et al., 2010).  
An important insight into the role of SATB1 in TH differentiation was obtained when the 
gene expression profiles of various subsets of TH cells were compared with the TCR-
activated CD4+ T cells, a condition referred to as TH0. To ascertain whether SATB1 regulated 
genes are involved in TH cell differentiation, Ahlfors et al., (2010) silenced expression of 
SATB1 using siRNAs in TH cells. Their studies revealed that expression of multiple genes 
was altered upon SATB1 knockdown in TH1, TH2 and TH0 population. The RNA expression 
profile revealed that in differentiating CD4+ T cells, expression of 319 genes was altered. Out 
of these, 70 genes were selectively affected in TH2 population while 43 genes had altered 
expression in TH1 population. Thus total of 40% (43+14+43=127) genes showed altered 
expression upon cytokine treatment suggesting SATB1 targets were partly specific to TH 
subsets. Notably, 48% of SATB1 target genes were regulated by IL-4. Furthermore, TCR 
stimulation alone regulated one third of SATB1 targets and only 18% of SATB1 target genes 
were not regulated by TCR or combination of TH1/TH2 polarizing cytokines. The gene 
expression profiling clearly indicated that SATB1 is likely to play an essential role in the 
development or function of various TH subtypes (Ahlfors et al., 2010). Another important 
contribution of this study was the finding that IL-5 which is predominantly secreted by TH2 
cells is repressed by SATB1 during early stages of polarization. The repression of Il-5 
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cells, however they have the propensity to develop into  lineages other than T cells such as 
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rearrangement of TCRβ chain. Successful assembly of the β chain facilitates the movement of 
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assays revealed that SATB1:β-catenin interaction regulates the expression of Wnt target 
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revealed that SATB1 is involved in regulation of over 300 genes indicating its crucial role 
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An important insight into the role of SATB1 in TH differentiation was obtained when the 
gene expression profiles of various subsets of TH cells were compared with the TCR-
activated CD4+ T cells, a condition referred to as TH0. To ascertain whether SATB1 regulated 
genes are involved in TH cell differentiation, Ahlfors et al., (2010) silenced expression of 
SATB1 using siRNAs in TH cells. Their studies revealed that expression of multiple genes 
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profile revealed that in differentiating CD4+ T cells, expression of 319 genes was altered. Out 
of these, 70 genes were selectively affected in TH2 population while 43 genes had altered 
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expression upon cytokine treatment suggesting SATB1 targets were partly specific to TH 
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stimulation alone regulated one third of SATB1 targets and only 18% of SATB1 target genes 
were not regulated by TCR or combination of TH1/TH2 polarizing cytokines. The gene 
expression profiling clearly indicated that SATB1 is likely to play an essential role in the 
development or function of various TH subtypes (Ahlfors et al., 2010). Another important 
contribution of this study was the finding that IL-5 which is predominantly secreted by TH2 
cells is repressed by SATB1 during early stages of polarization. The repression of Il-5 
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promoter by SATB1 was during brought about by recruiting HDAC1 corepressor to the Il-5 
locus (Figure 1). Later the course of differentiation, the competition between binding of 
SATB1 and GATA-3 results in binding of GATA-3 to the Il-5 promoter which derepresses  Il-
5 locus and IL-5 is produced (Ahlfors et al., 2010). IL-5 plays important role in differentiation 
and activation of eosinophils and dysregulation of Il-5 results into eosinophila (Mosmann & 
Coffman 1987; Campbell et al., 1988; Sanderson, 1988). Hence regulation of IL-5 is not only 
important in proper TH differentiation but also in understanding its role in diseases such as 
eosinophila. 
TH2 differentiation is also regulated by the downstream transcription factors like GATA-3 
and STAT-6. GATA-3 is a transcription factor predominantly expressed in T cells and brain 
(Oosterwegel et al., 1992). GATA-3 has been shown to play an important role in thymocyte 
development and also during TH2 differentiation (Ho et al., 2010). The essential role of 
GATA-3 was demonstrated by creating mice lacking GATA-3 expression. GATA-3-deficient 
CD4+ T cells cannot differentiate into TH2 phenotype and they produce IFNγ under TH2 
polarizing conditions (Zhu J et. al., 2004). IL-4-STAT6 signaling pathway is known to cause 
the upregulation of GATA-3 in TH2 differentiating cells. However, a recent report provided 
an alternative view by demonstrating that CD4+ T cells can differentiate to TH2 phenotype in 
absence of STAT6 via notch signaling although with a reduced efficiency (Amsen et al., 
2004). In this review we have focused on the newly dicovered mechanism for regulation of 
GATA-3 expression by SATB1 in Wnt-dependent manner. 
 
Fig. 1. SATB1 mediated regulation of Il-5 during TH2 differentiation. IL-5 is a late TH2 
cytokine. SATB1 directly binds to Il-5 promoter and inhibits its expression by recruiting 
HDAC repressor complex. During allergic conditions GATA-3 displaces SATB1 bound to 
the Il-5 promoter and upregulates IL-5 cytokine expression (Ahlfors et al., 2010). 
3.4 SATB1 as a mediator of Wnt signaling  
Recently, a new role for SATB1 has been discovered as a mediator of Wnt-signaling 
pathway during TH differentiation (Notani et al., 2010). Wnt signaling is one of the well 
studied and highly conserved pathways responsible for various developmental processes 
and cell fate decisions (Logan and Nusse, 2004). β-catenin is the key transducer of canonical 
Wnt signaling cascade which upon Wnt signaling is stabilized in the cytoplasm, then 
translocates to the nucleus and interacts with T cell factor (TCF) family transcriptional 
factors. Asociation of β-catenin with the TCF family proteins alters the expression of Wnt-
responsive genes (Logan and Nusse, 2004). SATB1 brings about TH2 cell differentiation via 
Wnt signaling by recruiting β-catenin to its genomic targets (Notani et al., 2010). This study 
demonstrated that SATB1 represses target genes in undifferentiated cells. Upon Wnt 
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signalling in the polarized cells, SATB1 interacts with β-catenin, recruits it to Gata-3 
promoter and derepresses it leading to TH2 commitment (Figure 2). Several SATB1 
regulated genes are activated by SATB1:β-catenin complex in Wnt-dependent manner. Post-
translational modifications of SATB1 act as molecular switches regulating its DNA-binding 
activity and ability to interact with multiple partner proteins (Kumar et al., 2006). Upon Wnt 
signaling SATB1 is deacetylated and directly interacts with β-catenin through its PDZ-like 
domain. The physical interaction between SATB1 and β-catenin is required for TH2 
differentiation. The two prominent factors TCF and SATB1 compete for β-catenin 
interaction. SATB1 competitively recruits β-catenin and hence also affects the transcription 
of TCF regulated genes. However, TCF and SATB1 do not interact with each other 
suggesting that they have non-overlapping effects (Notani et al., 2010). Thus, these two 
mediators of Wnt signaling presumably bind to their genomic targets independent of each 
other. LEF/TCF family proteins were the only known β-catenin partners for number of 
years. Another β-catenin partner known to be involved in pituitary gland development and 
lineage determination is the homeodomain protein Prop-1 (Olson et al., 2006). The report by 
Notani et al. (2010), demonstrated that homeodomain-containing transciption regulator 
SATB1 is also a β-catenin-binding factor and is involved in TH2 differentiation.  
 
Fig. 2. SATB1: β-catenin complex regulates Gata-3 expression during TH2 differentiation. 
Upon Wnt signaling β-catenin translocates into the nucleus. SATB1 interacts with β-catenin 
and regulates multiple genes. GATA-3 is known to be a master regulator of TH2 
differentiation. In differentiating TH2 cells, SATB1: β-catenin complex binds to the Gata-3 
promoter and upregulates  Gata-3 expression by recruiting the p300 activator complex. 
SATB1: β-catenin complex regulates Gata-3 expression in Wnt-dependent manner and thus 
regulates TH2 differentiation (Notani et al., 2010). 
Role of transcription factor GATA-3 in TH2 polarization by upregulating IL-4 secretion and 
inhibiting IFN-γ expression is very well established (Avni et al., 2002; Spilianakis et al., 2004). 
SATB1 positively regulates GATA-3 expression in TH2 cells by recruiting p300 
acetyltransferase and β-catenin to Gata-3 promoter upon Wnt signal (Figure 2). The role of Wnt 
signaling in TH2 cell differentiation was further demonstrated by using DKK1, an inhibitor of 
Wnt signaling. Upon DKK1 treatment in TH cells, GATA-3 expression was suppressed and 
also TH2 cytokines were downregulated. Quantitative transcript profiling revealed that 
expression of GATA-3 was suppressed upon Dkk1 treatment in TH2 subset, suggesting that 
Wnt signaling is necessary for the upregulation of GATA-3 during differentiation of TH2 cells. 
Overexpression and siRNA mediated silencing of SATB1 and -catenin provided the 
conclusive evidence for their direct roles in the differentiation of CD4+ cells. Upon siRNA-
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promoter by SATB1 was during brought about by recruiting HDAC1 corepressor to the Il-5 
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absence of STAT6 via notch signaling although with a reduced efficiency (Amsen et al., 
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studied and highly conserved pathways responsible for various developmental processes 
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Wnt signaling cascade which upon Wnt signaling is stabilized in the cytoplasm, then 
translocates to the nucleus and interacts with T cell factor (TCF) family transcriptional 
factors. Asociation of β-catenin with the TCF family proteins alters the expression of Wnt-
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demonstrated that SATB1 represses target genes in undifferentiated cells. Upon Wnt 
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signalling in the polarized cells, SATB1 interacts with β-catenin, recruits it to Gata-3 
promoter and derepresses it leading to TH2 commitment (Figure 2). Several SATB1 
regulated genes are activated by SATB1:β-catenin complex in Wnt-dependent manner. Post-
translational modifications of SATB1 act as molecular switches regulating its DNA-binding 
activity and ability to interact with multiple partner proteins (Kumar et al., 2006). Upon Wnt 
signaling SATB1 is deacetylated and directly interacts with β-catenin through its PDZ-like 
domain. The physical interaction between SATB1 and β-catenin is required for TH2 
differentiation. The two prominent factors TCF and SATB1 compete for β-catenin 
interaction. SATB1 competitively recruits β-catenin and hence also affects the transcription 
of TCF regulated genes. However, TCF and SATB1 do not interact with each other 
suggesting that they have non-overlapping effects (Notani et al., 2010). Thus, these two 
mediators of Wnt signaling presumably bind to their genomic targets independent of each 
other. LEF/TCF family proteins were the only known β-catenin partners for number of 
years. Another β-catenin partner known to be involved in pituitary gland development and 
lineage determination is the homeodomain protein Prop-1 (Olson et al., 2006). The report by 
Notani et al. (2010), demonstrated that homeodomain-containing transciption regulator 
SATB1 is also a β-catenin-binding factor and is involved in TH2 differentiation.  
 
Fig. 2. SATB1: β-catenin complex regulates Gata-3 expression during TH2 differentiation. 
Upon Wnt signaling β-catenin translocates into the nucleus. SATB1 interacts with β-catenin 
and regulates multiple genes. GATA-3 is known to be a master regulator of TH2 
differentiation. In differentiating TH2 cells, SATB1: β-catenin complex binds to the Gata-3 
promoter and upregulates  Gata-3 expression by recruiting the p300 activator complex. 
SATB1: β-catenin complex regulates Gata-3 expression in Wnt-dependent manner and thus 
regulates TH2 differentiation (Notani et al., 2010). 
Role of transcription factor GATA-3 in TH2 polarization by upregulating IL-4 secretion and 
inhibiting IFN-γ expression is very well established (Avni et al., 2002; Spilianakis et al., 2004). 
SATB1 positively regulates GATA-3 expression in TH2 cells by recruiting p300 
acetyltransferase and β-catenin to Gata-3 promoter upon Wnt signal (Figure 2). The role of Wnt 
signaling in TH2 cell differentiation was further demonstrated by using DKK1, an inhibitor of 
Wnt signaling. Upon DKK1 treatment in TH cells, GATA-3 expression was suppressed and 
also TH2 cytokines were downregulated. Quantitative transcript profiling revealed that 
expression of GATA-3 was suppressed upon Dkk1 treatment in TH2 subset, suggesting that 
Wnt signaling is necessary for the upregulation of GATA-3 during differentiation of TH2 cells. 
Overexpression and siRNA mediated silencing of SATB1 and -catenin provided the 
conclusive evidence for their direct roles in the differentiation of CD4+ cells. Upon siRNA-
 
Hematology – Science and Practice 
 
202 
mediated silencing of SATB1 the expression of GATA-3 was downregulated in TH2 cells. 
Overexpression of SATB1 led to a significant increase in the expression of GATA-3 in TH2, 
suggesting that SATB1 positively regulates GATA-3 expression (Notani et al., 2010). In 
summary, Wnt signaling is essential for TH2 differentiation whereby SATB1 upregulates 
GATA-3 expression which further enhances IL-4 secretion. CD4+ T cells are receptive to Wnt 
signals because they produce different Wnts themselves (Notani et al., 2010). The differential 
sensitivity of TH cell subtypes to Wnt signaling could be due to the fact that the downstream 
processes such as stabilization of -catenin occur prominently in the TH2 subtype and not TH1 
(Notani et al., 2010). Thus, these evidences clearly argue in favor of requirement of SATB1 and 
Wnt/-catenin signaling during TH cell differentiation.  
GATA3 facilitates chromatin remodeling of TH2 cytokine locus leading to conversion of the 
Il4–Il5–Il13 locus to an open conformation, allowing transcription of this locus by 
transcription factors involved in TH2-cell differentiation (Avni et al., 2002). The associated 
specific epigenetic changes include histone modifications upon binding of GATA-3 to its 
DNA targets were found to be mainly H3K4 and H3K27 methylation (Wei et al., 2011). 
Another chromatin protein CTCF binds to TH2 cytokine locus and assists GATA-3 and 
SATB1 mediated TH2 commitment (Almeida et al., 2009). Thus, collectively the three 
regulators namely SATB1, GATA-3 and CTCF could be responsible for orchestrating the 
coordinated regulation of TH cell differentiation. 
A model for regulation of TH2 differentiation by SATB1 is illustrated in Figure 3. TH0 cell is 
activated and polarized by TCR docking and IL-4 cytokine respectively. In the absence of  
 
 




Fig. 3. Model depicting the early events occurring upon Wnt signaling in polarized TH2 cell 
and role of SATB1 in this process. In the complex paradigm of TH2 polarization model there 
have been several studies suggesting role(s) of different mechanisms and it is now evident that 
SATB1 plays a major role during this process of TH2 commitment. A, In naïve cells when IL-4 
signalling is absent, expression of SATB1 is low and GATA-3 is not upregulated. B, Under TH2 
conditions, when a peptide antigen is presented by an antigen presenting cell (APC) to the 
TCR on T cell surface and IL-4 secreted by the APCs causes the activation of Jak Kinases which 
phosphorylate STAT-6,  which in turn upregulates  SATB1 and GATA-3. SATB1 interacts with 
β-catenin which is translocated to the nucleus in Wnt-dependent manner and this complex 
regulates Gata-3 expression. STAT-6, SATB1 and GATA-3 coordinatively regulate Il-4 
expression which is a characteristic cytokine of TH 2 differentiation. However, the role of 
STAT-6 in regulation of SATB1 as depicted here is speculative. 
Wnt signaling, β-catenin is phosporylated by destruction complex and targeted for 
degradation to proteosomal complex. SATB1 is acetylated and has low DNA-binding 
affinity in the absence of Wnt signal. Also, in the absence of nuclear β-catenin TCF does not 
regulate Wnt responsive genes and hence their transcription is suppressed (Figure 3A). 
Upon Wnt signaling, the destruction complex that sequesters -catenin does not form and β-
catenin is stabilized, which then translocates to nucleus. SATB1 is deacetylated upon Wnt 
signaling and it then competes with TCF for interaction with β-catenin. Deacetylated SATB1 
recruits β-catenin to genomic targets and regulates Wnt-responsive genes resulting into TH2 
differentiation (Notani et al., 2010). SATB1 also binds to TH2 cytokine locus and upregulates 
transcription of Il-4, Il-5 and Il-13 resulting into TH2 commitment (Figure 3B).  
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4. Regulation of SATB1 via STAT-6 
Signal transducer and activator of transcription (STATs) are important in various biological 
processes such as development, programed cell death, organogenesis, cell growth regulation 
and adaptive immunity (Horvath, 2000). Upon appropriate cytokine signaling STAT 
molecules are phosphorylated by Janus kinases and they form homodimers. The 
phosphorylated STATs translocate to the nucleus and affect the transcription of their target 
genes (Schindler and Darnell, 1995). Cytokine signaling mediates the activation of specific 
STAT molecules and plays an important role during T helper cell differentiation. During the 
TH differentiation STAT-4 and STAT-6 play seminal roles during TH1 and TH2 differentiation 
process respectively. IL-12 signaling initiates from binding of IL-12 to the IL-12 receptor, 
which further associates with protein tyrosine kinases and Jak2. The Jak2 kinase specifically 
causes the phosphorylation of STAT-4 (Waltford et al., 2004). STAT-4 causes the expression 
of Interferon  and transcription factor Tbet during TH1 differentiation (Thieu et al., 2008, 
Robertson et al., 2005). IL-4 secreted by the APCs engages to the IL-4 receptor on CD4+ T 
cells which then recruits Jak 3 kinases and causes the activation of STAT-6 (Witthuhn et al., 
1994). STAT-6 regulates the expression of IL-4 and GATA-3 during the TH2 differentiation 
(Zhu and Paul, 2008). The knockout models of STAT-4 and STAT-6 have revealed that T 
cells cannot differentiate into their respective effector phenotypes (Wuster et al., 2000). 
Genome-wide analysis of occupancy of STAT factors have shown that they preferentially 
bind to the promoters and intergenic regions in the genome. STAT proteins have a 
palindromic GAA consensus binding site. STAT molecules generally colocalize with the 
active histone marks, and it is shown that both proteins SAT4 and SAT6 colocalize with 
H3K4 trimethylation marks in the genome (Wei et al., 2010). Gene expression studies along 
with elucidation of the epigenetic marks at key loci using STAT knockout mice have 
revealed that STAT are important for the maintenance of epigenetic marks on such genes 
and thus regulation of gene expression. 
STAT-6 knockdown caused the downregulation of CRTH2 expression in cells polarised to 
TH2 phenotype (Elo et al., 2010). Another study also demonstrated that STAT-6 knockdown 
resulted in downregulation of SATB1 expression at both RNA and protein level (Ahlfors et 
al., 2010). Microarray-based gene expression profiling data from different groups using 
mouse and human models depicted similar results showing downregulation of SATB1 (Wei 
et al., 2010; Elo et al., 2010). Bsed on these finding, we hypothesize that STAT-6 may directly 
bind to the SATB1 promoter and mediate activating epigenetic histone modifications 
leading to the upregulation of SATB1 during TH2 differentiation. SATB1 in turn causes 
positive regulation of Il-4 expression.  
Interestingly, two recent studies have implicated Foxp3 in the regulation of SATB1 (Beyer et 
al. 2011; McInnes et al., 2011). Foxp3 tumor suppressor regulates SATB1 expression in breast 
epithelial cells and downregulates its expression in miRNA-dependent manner (McInnes et 
al., 2011). Repression of SATB1 has been also identified as a crucial mechanism for the 
phenotype and function of T(reg) cells. Foxp3 acts as a transcriptional repressor for the 
SATB1 locus and indirectly suppresses it through the induction of microRNAs that bound 
the SATB1 3' untranslated region (Beyer et al., 2011). Thus, elucidation of such regulatory 
loops will be important steps towards understanding the regulation and in vivo functions of 
SATB1.  
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5. Loss of SATB1 function: Sézary syndrome 
Adaptive immune response raised against pathogen includes clonal expansion of antigen-
specific T cells which are then cleared from the system mainly by activation-induced cell 
death (AICD), a type of apoptosis (Krammer et al., 2007). Sézary syndrome which is a 
variant of cutaneous T cell lymphoma results by clonal accumulation of mature T cells 
originating from skin (Willemze et al., 2005). This accumulation of cells occurs as a result of 
resistance of cells to AICD (Klemke et al., 2006). The pathogenesis of Sézary Syndrome (SS) 
is still not very clear. A recent study by Wang et al. (2011) revealed that the deficiency of 
SATB1 leads to SS. Sézary cells obtained from patients are CD4+ CD7- mature memory T 
cells and show a TH2 cytokine profile with loss of expression of CD7. Transcription profiling 
of the Sézary cells from patients and Hut78 (Sézary-derived cell line) revealed that SATB1 
was drastically downregulated in these cells as compared to non-Sézary control cells such as 
Jurkat T cells. Additionally, immunofluorescence staining showed a lowered nuclear 
localization of SATB1 in of primary Sézary cells as well as in Hut98 cells (Wang et al., 2011). 
Retroviral transduction mediated restoration of SATB1 in Hut98 cells increased apoptosis in 
these cells within 4 days without changing their proliferation rate. Subsequently, it was 
demonstrated that the SATB1 restored cells were sensitized to AICD. The transcriptome 
analysis of these SATB1 restored cells showed remarkable up-regulation of FASL/CD95L 
which is a death receptor ligand. Further, 32 out of total 153 (12%) dysregulated genes in 
Sézary cells were normalized upon SATB1 restoration in these cells (Wang et al., 2011). The 
increased AICD in SATB1 restored Sézary cells was shown to be induced by FASL via 
caspase 8-dependent pathway. These studies strongly suggested that SATB1 plays a very 
important role in pathogenesis of Sézary syndrome and it plays a vital role in regulation of 
homeostasis of T cells. Sézary cells are known not to respond to radiation therapy as these 
cells do not have increased proliferation but rather possess resistance to apoptosis. 
Currently the therapies for SS include upregulation of FASL to sensitize these cells for 
apoptosis. Restoration of SATB1 in Sézary cells could be a promising new strategy for the 
treatment of Sézary syndrome. The SS cells would also serve as a knockout model for 
studying role of SATB1 in human T cell functions. 
6. Conclusions 
In the field of T cell biology, TH differentiation is itself a complex phenomenon, one reason 
being that TH cell fate is not pre-decided during development in thymus, it is primarily 
executed upon the encounter of undifferentiated T cell with the antigen in the peripheral 
immune system. Hence TH cell polarization leading to final differentiation is a multi-cascade 
process with several epigenetic changes invoked in response to various signals. In this 
Chapter we focused on role of SATB1 which is an important global regulator involved in T 
cell development, maturation and differentiation. We elaborated on the role of SATB1 
during TH cell differentiation which is an important pool of cells for humoral as well as cell 
mediated immunity. To summarize the findings of various studies, it can be concluded that 
SATB1 plays an important role at the very early stages of TH cell differentiation. The studies 
discussed here suggest that SATB1 represses the chromatin in undifferentiated cells by 
recruiting repressors to the gene loci. Upon early events of cell polarization such as TCR 
signal and cytokine secretion by cells, SATB1 immediately responds to even lower level of 
cytokine signal such as IL-4 by changing the chromatin ‘loopscape’ of specific loci in TH2 
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cells which culminates into synthesis of downstream transcription factors required for 
further differentiation such as GATA-3. Wnt signaling acts as a booster for the 
differentiation signal in these cells which brings about changes in chromatin organization 
via SATB1 as a mediator of Wnt signaling and promotes GATA-3 transcription. In the later 
stages of differentiation, TH subtype specific factors such as GATA-3 take over and 
competitively overcome the SATB1 mediated repression of TH2 cytokines and  in turn 
upregulate the TH2 signature cytokines such as IL-5. Thus, SATB1 presumably acts as a 
regulatory switch at the very early stages of cell polarization and differentiation by 
repressing various cell type specific genes, however it specifically responds to polarization 
signal by changing its acetylation status. The indispensible role of SATB1 in TH cell 
differentiation is exemplified by diseases such as Eosinophila and Sézary syndrome, the 
later manifests as a result of SATB1 deficiency.  
7. Future perspectives 
The role of SATB1 in differentiation of CD4+ T cells has come into the limelight as described 
in this review. However, the role of SATB1 during earlier events such as thymocyte 
maturation are not studied in detail and requires further investigation. Since SATB1 is 
known to regulate genes such as Thpok which are important for the lineage commitment 
process, it is essential to evaluate whether SATB1 plays a direct role during the thymocyte 
lineage commitment. Findings from recent studies have highlighted the requirement for 
delineation of molecular mechanisms governing the expression of SATB1 during the process 
of thymocyte maturation. In the CD4+ T cells, it would be important to study the regulation 
of SATB1 which might be regulated by an IL-4:STAT6-dependent mechanism as seen during 
the differentiation of TH2 cells. It would be also interesting to investigate whether SATB1 
plays any role(s) in the differentiation of the other subtypes of CD4+ T cells. Studies 
elucidating role of miRNAs in the regulation of SATB1 in these various subtypes of T cells 
would also shed light on the signaling pathways and associated mechanisms regulating the 
development and differentiation of various subtypes of T cells. 
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1. Introduction 
Neutrophils (also known as polymorphonuclear leukocytes or PMN), the first line of 
defense against intruding microorganisms, are produced in the bone marrow from stem 
cells that in turn proliferate and differentiate into mature neutrophils. They play an 
important role in host defense and contribute to inflammation-related tissue injuries. During 
inflammation, neutrophils extravasate across the endothelium that lines the blood vessel 
wall through a multistep process [1, 2], which includes rolling on and subsequent firm 
adhesion to endothelial cells. 
Neutrophil migration through the vascular endothelial layer into lymphoid or inflamed 
tissues involves a dynamic regulation of cell adhesion in which new adhesions are formed at 
the cell’s leading edge, [3] while filipodia and lamellipodia are generated as exploratory and 
motile projections and, coordinately, adhesions are released from the trailing edge [4].  
For these events, the supply of adhesion molecules to the site of pseudopodial protrusion 
must be necessarily replenished in order to enable the cell to move forward. There is 
evidence that the membrane trafficking pathways that recycle adhesion receptors contribute 
to cell migration [5], which is crucial for polarization and migration in various cell types [6]. 
Preferential targeting of proteins to the leading or lagging edge of migrating cells is 
important for polarity and chemotaxis. Asymmetric distribution of proteins has implications 
beyond polarity and chemotaxis because these same proteins display characteristic 
localization patterns when cells undergo morphological changes in general. Several proteins 
have been identified as contributing to cell polarity organization and subsequent 
inflammatory-cell migration by regulating membrane trafficking. Ly49Q directs the 
organization of neutrophil polarization as well as neutrophil migration to inflammation sites 
by regulating membrane raft functions, reorganizing neutrophils in the presence of 
inflammatory signals, and maintaining neutrophil homeostasis in the absence of such 
signals [7]. In addition, regulated exocytosis plays a crucial role in conversion of inactive, 
circulating neutrophils into fully activated cells capable of chemotaxis, phagocytosis, and 
bacterial killing [8]. 
Polarity gives cells morphologically and functionally distinct spatial restriction to leading 
and/or lagging edges by relocating certain proteins or their activities selectively to the 
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Polarity gives cells morphologically and functionally distinct spatial restriction to leading 
and/or lagging edges by relocating certain proteins or their activities selectively to the 
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poles. Polarization provides cells with morphological, functional, and sensitivity differences 
to the chemoattractant, altering the way the cell responds to a gradient. Thus, polarization 
generates a bipolar mechanosensory state with a dynamic leading edge for acquiring new 
contacts and signals, a stiff mid-body, and a sticky uropod that is dragged along the 
substrate and stabilizes the cell position in complex environments [9, 10]. Hence, integration 
of signals generated in both cellular poles leads to a coordinated movement of the leukocyte. 
Chemotaxis is conceptually divided into motility, directional sensing, and polarity; 
however, chemotaxis typically incorporates these features. Many molecules involved in 
chemotaxis include both lipids and proteins and are localized on the membrane or in the 
cortex, specifically at either the leading or the lagging edge of polarized cells. 
Freely diffusing chemoattractant or soluble molecular cues, known as Damage-associated 
molecular patterns (DAMP), are liberated from damaged tissue in high abundance. DAMP 
include Adenosine triphosphate (ATP), bacterial peptides, heat-shock proteins, chromatin, 
and galectins [11], providing short-lived or pulsatile directional information, in addition to 
longer-lived cues provided by constitutive or induced tissue-bound chemoattractants [11]. 
Beyond adhesive migration arrest, local reduction of promigratory signals is achieved by 
down-modulation of chemoattractant receptors, receptor desensitization, and ligand 
competition, whereas termination of chemoattractant activity occurs through uptake by 
neutralizing chemoattractant receptors and/or proteolytic degradation. After ligation, 
chemoattractant receptors become internalized and are either recycled to the leading edge or 
stored in vesicles in the uropod, thus limiting the availability of both the chemoattractant 
and its receptor [12]. The end result is a cascade of activation and adhesion events designed 
to uptake  leukocytes along vessel walls, activate these for them to make stable adhesions, 
allow them to locomote along the endothelial surface, and to transmigrate across endothelial 
junctions and through the subendothelial basal lamina, guiding them onto the damage site  
(Figure 1) [13].  
 
Fig. 1. Type chemotaxis in neutrophils. A) Chemotaxis triggered by soluble diffusing 
compounds leading to formation of the leading edge. B) Directed-mediated migration 
toward chemoattractants trapped on tissue structures. 
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2. Trafficking requirements  
Trafficking leukocytes often reduce their migration speed, pause, and polarize toward the 
bound cell or the tissue structure to execute crucial functions including phagocytosis, cell-to-
cell signaling, activation, and the release of cytokines or toxic factors toward an encountered 
cell. 
At least three basic kinetic states govern leukocyte positioning in tissues, including fast 
migration (5 to 25 μm/min), slow and often locally confined movement (2 to 5 μm), and 
adhesive arrest, and these rapidly interconvert. Based on these kinetic states, leukocyte 
accumulation in tissues occurs by means of at least three distinct mechanisms: 1) local 
engagement of adhesion receptors causes individual leukocytes to stick and become 
immobilized at a specific spot; 2) degradation of promigratory signals causes cell 
populations to slow down or stop movement, and 3) loss of exit signals confines cells to a 
local microenvironment despite ongoing migration [14]. 
Complete migration arrest is mediated by activation of adhesion receptors on the moving 
cell followed by attachment to counter-receptors on other cells or on Endothelial cell 
migration (ECM) structures, leading to an immobilized cell. Within seconds, adhesion 
overrides ongoing promigratory signals; this is followed by cytoskeletal polarization toward 
the bound cell or the ECM structure [15].  
3. Ensuring tightened adhesion  
Endothelial cells (EC) are the critical substrate for leukocyte attachment and motility within 
the vascular lumen via adhesion molecules such as integrin, ligands whose expression is 
enhanced on activated ECs, which in turn react to molecules generated during infection and 
inflammation such as Tumor necrosis factor alpha (TNF-), interleukin 1 (IL-1), and 
interleukin 17 (IL-17). Expression of these molecules can be further regulated through the 
cross-talk between EC and leucocytes; binding of PSGL-1 to P-selectin and E-selectin 
establishes the initial contact between neutrophils and activated ECs. Interaction of EC 
adhesion molecules (ICAM-1 and VCAM-1) with leukocyte ligands triggers the formation of 
docking structures or transmigrating cups [16, 17], which embrace adherent leucocytes [18]. 
Additionally, formation of pro-adhesive sites termed “endothelial adhesive platforms” 
(EAP) is determined by the existence of pre-formed, tetraspanin-enriched microdomains 
such as CD9, CD151, and CD81 [19].  
Adherent leukocytes may transmigrate at the point of initial arrest, but sometimes rather 
locomote laterally to preferred sites of Transendothelial cell migration (TECM) [20, 21]; in 
vitro and in vivo luminal crawling is dependent on β2 integrins and its blockade appears to 
increase the incidence of trans- as opposed to paracellular cell migration [21]. The junctional 
adhesion molecule A (JAM-A), an adhesion molecule expressed on both EC and leukocytes 
[22], regulate integrin internalization and re-cycling [23]. 
There are other molecules and mechanisms that have been recently implicated in leukocyte 
motility; for example, it has been demonstrated both in vivo and in vitro that platelets 
enhance neutrophil TECM in inflammation, which is consistent with a mechanistic role for 
PSGL-1 for this response [24].  
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2. Trafficking requirements  
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[22], regulate integrin internalization and re-cycling [23]. 
There are other molecules and mechanisms that have been recently implicated in leukocyte 
motility; for example, it has been demonstrated both in vivo and in vitro that platelets 
enhance neutrophil TECM in inflammation, which is consistent with a mechanistic role for 
PSGL-1 for this response [24].  
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4. Neutrophil mobilization 
Leukocyte interactions with the endothelial surface trigger cellular and sub-cellular events 
that initiate and/or facilitate leukocyte passage through the endothelium by interaction of 
docking structures with cytoskeleton via adaptor proteins such as vinculin, paxilin, and 
Ezrin, radixin, and moesin (ERM) proteins [18, 25], although Guanosine triphosphate 
(GTP)ases (RhoG and RhoA) induce actin polymerization leading to the formation of small 
membrane protrusions called apical cups or docking structures. 
Once firm adhesion is established, two routes can be taken for transendothelial migration: 
the transcellular road, whereby neutrophils penetrate the individual EC, or the paracellular 
road, by which neutrophils squeeze between EC Figure 2.  
A number of molecules at EC junctions actively facilitate leukocyte transmigration via a 
paracellular route such as Platelet endothelial adhesion molecular-1 (PECAM-1), 
Intracellular adhesion molecule-2 (ICAM-2), CD99, Endothelial cell-selective adhesion 
molecules (ESAM), and junctional adhesion molecules (JAM) [22, 26] and, according to in 
vivo and in vitro evidence, a sequence of events has been suggested that regulate neutrophil 
transmigration to EC walls and that include the following: (i) ICAM-1 and ICAM-2 on the 
luminal surface of EC and within the junction may provide a haptotactic gradient to guide 
neutrophils to EC junctions via their 2 partners (LFA-1 and MAC-1) [27]; (ii) once within 
junctions, endothelial-cell JAM-A (through interaction, possibly with LFA-1) [28], facilitates 
completion of neutrophil passage through the EC layer, and (iii) within the EC junction, 
homophilic interactions between endothelial and leukocyte PECAM-1 stimulates 
neutrophils to express the key leukocyte laminin receptor, integrin α6β1, on their surface, 
which facilitates neutrophil passage through the vascular basement membrane [29-31]. It is 
also noteworthy that signals from ICAM-1 activate Src and Pyk-2 tyrosine kinases, which 
phosphorylate VE-Cadherin, destabilizing its bonds and loosening endothelial cell-cell 
junctions [32]. 
The transcellular route is taken by some 20% of neutrophils and has been observed in a 
broad range of tissues including bone marrow, thymus, lymph nodes, pancreas, and the 
blood brain barrier [33]. Apparently, there is clear evidence for the formation of a 
transcellular pore requiring membrane fusion and displacement of cytoplasmic organelles 
during transcellular migration. Vesicular vacuolar organelles (VVO) are enriched at pore-
formation sites, apparently providing additional membrane to the area and facilitating the 
fusion of apical and basal membranes in a process dependent on SNARE-containing 
membrane fusion complexes [34], and there is increasing evidence for a role for caveolin-1 in 
determining transendothelial migration route [35]. 
Carman et al. (2008) [34] have identified in vitro and in vivo the existence of protrusive 
podosomes on the basal side of crawling lymphocytes ; these protrusive podosomes appear 
to identify the cell’s thinner peripheral areas rather than the perinuclear region in order to 
identify a pore formation-permissive site. These dynamic investigatory podosomes can then 
extend to form invasive podosomes, resembling invadopodia of metastatic tumor cells, 
which extend down into the EC, bringing the apical and basal membranes into close 
apposition. U 
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5. Mobilization beyond the endothelium   
Beyond the endothelium, migrating cells face two further barriers; the pericyte sheath, and 
the tough venular Basement membrane (BM) [36, 37]. Neutrophils have the ability to 
migrate through the pericyte sheath via both para- [38] and transcellular pathways  
 
Fig. 2. Hypothetical sequence of events during neutrophil transmigration. Neutrophils are 
tethered by P- and E-selectin on endothelial cells and PSGL, L-selectin, and CD44 on 
neutrophils simultaneously participate in neutrophil rolling and activation. Endothelium 
activation by stimuli such as IL-1, IL17, TNF- promote transmigration dependent of 
molecules such as PECAM-1, ICAM-1, and JAM-A, thus unzipping the tight junctions and 
restoring themselves while TNF- promote transmigration via ESAM. Neutrophils take 
trans- or paracellular routes. Postendothelial cleavage of structural proteins occurs by means 
of secreted or membrane-anchored matrix metalloproteases (MMPs). Abbreviations: 
Basement membrane (BM), Endothelial cells (EC), Platelet endothelial cell adhesion 
molecule (PECAM-1), Intracellular adhesion molecule-1 (ICAM-1), Endothelial cell-selective 
adhesion molecule (ESAM), Tumor necrosis factor-  (TNF-) [39].  
On the other hand, leukocyte penetration of the vascular BM depends on the vascular bed. 
Additionally, it has recently been shown that the venular BM contains pre-formed regions 
with low expression of certain BM components, denominated Low expression regions 
(LER), which are preferentially utilized by transmigrating neutrophils and monocytes [29, 
40]. Alignment of these regions with gaps between adjacent pericytes suggests a key role for 
these cells in vascular BM generation in vivo. Vascular BM architecture depends on the 
migration of neutrophils, but not monocytes, through the LER remodeling these regions and 
increasing their size [41, 42], suggesting the involvement of proteases in this response.  
6. Neutrophil polarization and migration structures 
Neutrophils present in the blood are able to tissue-injury or infection signals by adhering to 
vascular endothelial cells, then transmigrating across the endothelium through the 
basement membrane and homing into sites of infection or inflammation.  
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The following four steps mediate the multiple cycles of attachment and detachment 
generating neutrophil forward movement during migration: the leading edge protrudes one 
or several pseudopods by actin flow; protruding membrane and surface receptors interact 
with the substrate; actomyosin-mediated contraction of the cell body occurs in mid-region, 
thus the rear of the cell moves forward. Neutrophil migration moves at up to 30 μm/min, 
lacks strong adhesive interactions to the tissue, and commonly preserves tissue integrity [9].  
Receptors such as β2 integrins in neutrophils show discrete relocation toward the tips of 
ruffles [43]. The mid-region of amoeboid cells contains the nucleus and a relatively 
immobile cell region that maintains the front-rear axis. The trailing edge contains the highly 
glycosylated surface receptors CD43 and CD44, adhesion receptors including Intercellular 
adhesion molecule (ICAM)-1, ICAM-3, β1 integrins, and Ezrin-radixin-moesin adaptor 
proteins (ERM), as well as GM-1-type cholesterol-rich microdomains [44]. The uropod 
mediates cell–matrix and cell–cell interactions during migration and has a putative 
anchoring function [45]. The uropod extends rearward from the nucleus and contains the 
microtubule-organizing center and rearward-polarized microtubules, the Golgi, and 
abundant actin-binding ERM proteins. In association with microtubules, mitochondria 
localize to the rear of the cell that, presumably, due to local ATP delivery to the region of 
ATP-dependent actomyosin contraction, is required for proper polarization, uropod 
retraction, and migration [10, 46].  
7. Polarization of cytoskeletal and signaling scaffolds 
In neutrophils, polarization and migration to chemoattractant gradients such as chemokines 
and cytokines, lipid mediators, bacterial factors, and Extracellular matrix (ECM) 
degradation products including collagen, fibronectin, and elastin fragments [47, 48], is 
known as chemotaxis. After chemokines and chemoattractants bind to the extracellular 
domains of their cognate G protein-coupled receptor (GPCRs) pseudo- and lamellipodia 
protrusion are induced. In leukocytes, the majority of GPCRs transmit through the α subunit 
of Giα. These GPCR include the following: the fMLP (N-formyl-Met-Leu-Phe) receptor and 
the C5a receptor; chemokine receptors including CCR7, CXCR4, CXCR5, and CCR3; the 
leukotriene B4 receptor BLT1; sphingosine-1-phosphate receptors 1–4 (S1P1–4), and 
Lysophosphatidic acid (LPA) receptors 1–3 [49]. All these GPCR mediate promigratory 
signals but also enhance cell activation. A key GPCR-mediated pathway is signaling 
through the Phosphatidylinositol-3-kinase (PI(3)K), which contains the p110γ catalytic 
subunit). PI(3)K-γ is recruited into the inner leaflet of the plasma membrane by the G 
protein βγ subunit, where it becomes activated and subsequently phosphorylates 
Phosphatidylinositol phosphates (PIP) and other effectors [50]. PIP serve as docking sites for 
pleckstrin-homology domain-containing proteins, notably Akt (also known as protein 
kinase B), which is implicated in inducing actin polymerization and pseudopod protrusion 
by phosphorylating downstream effectors [51] such as the actin-binding protein girdin [52]. 
A second pathway linked with PI(3)K activation is induced by ζ-chain-associated receptors, 
including T cell receptors (TCRs) and receptors FC (FcRs). These receptors signal through 
tyrosine kinases Lck and Zap-70 to class Ia PI(3)Ks (consisting of p110δ) and activate 
downstream Akt, as well as the GTPases Rac and Cdc42 [53]. A third, PI(3)K-independent 
pathway induced by the fMLP receptor in neutrophils leads to the activation of p38 
mitogen-associated protein kinase and downstream Rac activation [54, 55]. Ultimately, Rac 
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induces actin polymerization through WAVE (Scar) and Arp2/3. WAVE, a member of the 
WASP family of actin-binding proteins, mediates actin filament formation [56], while 
Arp2/3 causes sideward branching of actin filaments. Together, these activities generate 
interconnected, branched networks [57]. Thus, promigratory signals received at the leading 
edge generate local Rac activation and actin network protrusion, pushing the plasma 
membrane outward. Preferential receptor-sensitivity mechanisms at the leading edge are 
likely diverse and may include local signal- amplification mechanisms [58] and exclusion of 
counter-regulatory proteins. The mid-region generates actomyosin-based stiffness and 
contractility, limits lateral protrusions, and thereby maintains a stable, bipolar cortex. The 
cytoskeletal motor protein myosin II, located in the central and rear regions of leukocytes, 
promotes actin-filament contraction and limits lateral protrusions. Myosin II cross-links 
actin filaments in parallel, forming the contractile shell required to hold the extending cell 
together and propelling the cell nucleus, the most rigid part of the cell, forward [59].  
8. Leukocyte movement in different environments and initial migration 
Neutrophils are able to migrate along or through 2- or 3- dimensional (2-D or 3-D) surfaces. 
2-D Surfaces, such as inner vessel walls, peritoneum, and pleura, require integrin-mediated 
attachment known as haptokinesis and polarized adhesion through binding of integrins 
α4β1 and LFA-1 (L2) to their counterparts (VCAM-1 and ICAM-1)(Figure 3A). In contrast, 
migration in 3-D, ECM environments, which are composed mainly of cellular (lymph node) 
or fibrillar ECM components, is integrin-independent and cells use weakly adhesive-to-
nonadhesive interaction and traction mechanisms that are mediated by actin flow along the 
confining ECM scaffold structure, contributing to shape change and squeezing [9, 44, 60] 
(Figure 3B). It is likely that neutrophils adapt to tissue geometry and follow paths of least 
resistance, a process known as contact guidance (Figure 2). 
For passage, the first postendothelial tissue structure and barrier to cells undergoing 
diapedesis, locally confined cleavage of the structural proteins laminin-10 and type IV 
collagen, occurs by secreted or membrane-anchored Matrix metalloproteases (MMPs) and 
serine proteases [61, 62]. Cell-body deformation is coupled with cytoplasmic propulsion and 
streaming through preexisting or newly formed pores; the deformation and constriction 
capability of leukocytes is considerable, especially for neutrophils [63]. 
Interestingly, a recent study showed the existence of venule-wall regions in which laminin-
10, collagen IV, and nidogen-2 expression is considerably diminished; neutrophil 
transmigration enlarges the size of these regions, and their protein content is further 
reduced, an effect that appears to involve neutrophil-derived serine proteases [40]. Location 
of proteases at the leukocyte cell surface takes place through two different mechanisms: 
either by endogenous expression as transmembrane proteins or by binding of extracellular 
proteases to integral membrane receptors. Integrins are shown to act as anchoring receptors 
for several proteases including MMPs; such interactions have been detected in caveolae, 
invadopodia, and at the leading edge of migrating cells, where directed proteolytic activity 
is required [64]. In this regard, pro-MMP-2 and pro-MMP-9 are bound to L2 and M2 on 
the surface of activated leukemic cells, and inhibition of these complexes blocks 2 integrin-
dependent leukocyte migration [65]. Pro-MMP-9–M2 complexes are primarily localized 
into intracellular granules of resting neutrophils, but after cellular activation, they are 
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relocalized to the cell surface [66]. Neutrophils secrete laminin, suggesting that leukocyte-
derived matrix proteins might also contribute to the transmigration process [67].  
 
Fig. 3. Type-substrate interaction with neutrophils. A) Two-dimensional integrin-mediated 
neutrophil migration. In vivo 2-D haptokinetic migration is present during crawling on 
Endothelial cell (EC) or through Extracellular matrix (EM). B) Three-dimensional integrin-
independent neutrophil migration. In vivo, this occurs through organized tissue structures.  
9. Role of cytoskeleton in regulating integrin adhesiveness 
Integrins are a superfamily of heterodimeric cell-surface receptors that are found in a broad 
range of animal species [68]; their main role, as their name implies, is to integrate the cell 
cytoskeleton with adhesion points of extracellular matrix and cell-surface ligands in order to 
mediate essential cellular processes such as cell-cell and cell-extracellular matrix 
interactions, polarization in response to extracellular cues, cell migration, differentiation, 
survival, and cell-pathogen interactions [69].  
In vertebrates, 19 different integrin  subunits and eight different integrin β subunits have 
been reported, in combination forming about 25 β heterodimers [70]. The majority of /β-
subunit combinations can be organized into three fundamental groups based on subunit 
type (β1, β2, and β3, or v chains, on the extracellular matrix protein-type recognized, or on 
the specific adhesion motifs [71] (Table 1). 
β1 integrins form the first and largest group of integrins and are ubiquitously distributed in 
nucleated cells as well as in platelets. β1 Integrins are expressed in bone marrow-derived cells 
(except for neutrophils), in certain tumor cells, and in muscle development. A second major 
group of integrins shares either the β3 or the v subunit (Table 1) and recognizes different 
ligands from a broad gamma of cell and tissue sources. Integrins with the v subunit may 
form dimers with at least five different β chains, including the β1 chain. Subunits v and β3 
recognize Arg-Gly-Asp (RGD) domains present in extracellular matrix proteins. 
The third group of integrins shares the β2 integrin chain, whose expression is restricted to 
leukocytes [72] (Table 1). Receptors such as 4β2, also known as the LFA-1 integrin, determine 
the capability of leukocytes in endothelial epithelium transmigration and recognize members 
of the Intercellular adhesion molecule (ICAM) family of adhesion proteins. In contrast, 
expression of Mβ2 is restricted to monocytes, macrophages, and granulocytes; it recognizes  
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 Ligands Motifs Distribution 
integrin    
 Co1,Lm ND EC, SMC, TC, Monos 
 Col, Fn, Lm, Echovirus 1 DGEA Plt, EC, Fb, SMC, TC, EPC 
 Col, Epiligrin, Fn, Lm, Invasin RGD EC, TC, EPC, Fb 
 Fn, Invasin, VCAM-1 EILDV (Fn) TC, Monos, Eos, LC, ER 
  QIDSPL(VCAM-1)  
 Fn, Invasin RGD Fb, EC, Monos, TC, Plt 
 Lm, Invasin ND Plts, TC, EC, EPC 
 Lm ND Myocytes 
  ND SMC 
 Col, Lm, Tenascin RGD EPC, Myocytes 
 Fn,Vn RGD Fb 
v and 3 
integrins    
v Fn, Vn RGD Fb 
v Vn, HIV Tat, Adenovirus RGD EC, EPC, Fb, Tumors 
v Fn, Tenascin RGD  
v Vn RGD Melanoma 
v
Col, Fib, Fn, Lm Opn, Pn, 
TSP, Vn RGD EC, FB, Monos, SMC, OC 

vWf, HIV Tat, Tenascin, 
Adenovirus  Plt, Tumors 
IIb Col, Fib, Fn, TSP, Vn, vWf, Borrelia KQAGDV Plt, Mega 
R Fib, Fn, Vn, vWf RGD PMN 
2 integrin    
L2 ICAMs (1-3) ND TC, BC, LGL, Monos, PMN, Eos 

Fib, Fn, Factor X, ICAM-1, 
iC3b  
PMN, Monos, Macros, 
LGL 
 Fib, iC3b GPRP Monos, Macros, PMN 
  ND TC. Macros 
Other integrins    
 Lm ND EC, EPC, Schwann cells 
 Fn, MAdCAM, VCAM-1 EILDV (Fn) Gut homing, TC 
 E-Cadherin ND Epithelial TC 
Table 1. Classification of integrins according to ligand motifs and distribution. 
Abbreviations: BC = B cells; Col = Collagen; EC = Endothelial cells; Eos = Eosinophils; EPC 
= Epithelial cells; Fb = Fibroblasts; Fib = Fibrinogen; Fn = Fibronectin; iC3b = inactivated 
component of complement; Lm = Laminin; LGL = Large granular lymphocytes;  
Macros = Macrophages; Mega = Megakaryocytes; Monos = Monocytes; OPN = Osteopontin; 
Plt = Platelets; PMN = Neutrophils or Polymorphonuclear leukocytes; SMC = Smooth 
muscle cells; TC = T cells; TSP = Thrombospondin; Vn = Vitronectin; vWf = von Willebrand 
disease. (Modified from [71]).  
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fibrinogen and inactivated C3b, playing an important role in the phagocytosis of opsonized 
particles and bacteria [73]. The fourth group of integrins includes three integrins (6β4, 
4β7, and Eβ7); these integrins recognize extracellular matrix components as well as 
adhesion molecules of the Immunoglobulin superfamily (IgSF). Common integrins 
expressed on leukocytes and their counterparts are summarized in Table 1.  
Association of extended forms of integrins with the cortical cytoskeleton is required to 
integrate mechanical forces from shear flow and F-actin and to undergo ligand-induced 
strengthening at endothelial contacts. Key differences between 4 and 2 integrins 
regarding their increase in cytoskeleton-mediated avidity may occur. The 4 integrins can 
bind paxillin upon dephosphorylation of Ser988 in their cytoplasmic domain at the sides 
and rear pole of the cell, whereas PKA-mediated phosphorylation of these integrins is 
confined to the cell’s leading edge. Paxillin regulates 4 integrin function (tethering and 
firm adhesion) [74], enhancing their migration rate and reducing their spreading, and 
paxillin–4 interaction downregulates the formation of focal adhesions, stress fibers, and 
lamellipodia by triggering activation of different tyrosine kinases, such as Focal adhesion 
kinase (FAK), Pyk2, Src, and Abl [75, 76]. The 4–paxillin complex inhibits stable 
lamellipodia by recruiting an ADP-ribosylation factor (Arf)-GTPase-activating protein that 
decreases Arf activity, thereby inhibiting Rac, and limiting lamellipodia formation to the cell 
front [77]. Recently, it was discovered that integrins can induce PIP5K1C-90 polarization 
independently of chemoattractants. This integrin-induced PIP5K1C-90 polarization works 
together with chemoattractant signaling in regulating neutrophil polarization and 
directionality in vitro and infiltration in vivo [78]. 
It has been described that LFA-1 and Mac-1 may use adapter molecules talin, -actinin, 
filamin, and 14-3-3 to anchor to the actin cytoskeleton properly [79, 80]. Regarding 
subcellular localization, LFA-1 pattern ranges from low- in the lamellipodia to high 
expression in the uropod. However, it has been reported that high-affinity clustered LFA-1 
is restricted to a mid-cell zone, termed the “focal zone”, different from focal adhesions and 
focal contacts. In addition, talin, properly activated by phosphorylation or by 
phosphatidylinositol-4,5-bisphosphate (PIP2), is essential for formation and stability of the 
focal zone and for LFA-1-dependent migration [81]. 
Locomotion can be regulated by integrins because the signals involved in integrin-mediated 
leukocyte firm adhesion to endothelium are subsequently attenuated to allow leukocyte 
migration toward an appropriate transmigration site. 2 integrins appear to promote direct 
locomotion, success in correct positioning at the endothelial junction, and effective 
diapedesis [82, 83]. Upon interaction with their ligands, integrins activate distinct myosin-
contractility effectors, actin-remodeling GTPases, and molecules involved in microtubule-
network regulation at motile leukocyte leading and trailing edges [84]. During cell 
polarization, Cdc42, Myosin light chain kinase (MLCK), Rac, RapL, Rap1, mDia, myosin-IIA, 
and chemokine receptors are redistributed to the cellular front, participating in exploratory 
filopodia formation and in lamellipodia extension. In contrast, Rho- and Rho-associated 
kinase (ROCK) (both involved in trailing- edge retraction), the Microtubule-organizing 
center (MTOC), and adhesion receptors ICAM-1, ICAM-3, CD44, and CD43 move toward 
the rear pole [85].  
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Recently, dystrophin protein-adhesion complex proteins such as short dystrophins, 
utrophins, and the dystrophin-associated protein complex -dystroglycan,syntrophin 
and dystrobrevins) form part of actin-based structures such as lamellipodia and uropod, 
in which their polarized distribution is evident and their feasible role in chemotaxis and 
migration is strongly suggested [86].  
Other proteins with differential distribution appear in Figure 4 and the list is increasing.  
 
Fig. 4. Neutrophil regions observed after triggered activation and differential protein 
distribution. Adapted from [87].  
10. Conclusions 
For exiting the vasculature, leukocytes follow a consecutive sequence of events that starts 
with the first contact of free-flowing neutrophil to the vascular endothelium followed by 
leukocyte rolling along the vessel wall. Both events are mediated by specialized receptor 
ligand pairs consisting of a member of the selectin family of adhesion molecules and specific 
carbohydrate determinants on selectin ligands. During rolling, leukocytes are in intimate 
contact with the vascular endothelium, enabling endothelial-bound chemokines to interact 
with their respective chemokine receptors on the neutrophil surface. Upon binding to the 
receptor, chemokine receptor-mediated signaling events trigger the activation of β2 
integrins. Activated integrins subsequently interact with endothelium-expressed ligands, 
which lead to a reduction in leukocyte rolling velocity and eventually, to mediate stable 
adhesion and migration across the blood vessel wall. Following neutrophil spreading and 
intravascular crawling along the endothelium, tethered neutrophils reach the correct spot 
for exiting into tissue. Upon neutrophil stimulation, actin, which is one of the major 
components of the cytoskeleton in neutrophils, is reorganized through reversible cycles of 
polymerization and depolymerization, thereby comprising the driving motor for the 
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formation of lamellipodia and pseudopodia during migration and phagocytosis. Activated 
neutrophils become polarized with a contracted tail (uropod) in the rear and F-actin-rich 
protrusions at the front and start crawling. Actin and the proteins regulating actin 
polymerization are key players in the establishment of morphological and functional cell 
polarity. Actin polymerization and membrane ruffling comprise the first events leading to 
the establishment of chemoattractant-stimulated neutrophil polarization. 
Morphological changes imply cytoskeleton redistribution triggered by certain activated 
pathways which are spatiotemporally coordinated.  
Undesrtanding the molecular and cellular interactions that regulate neutrophil 
transmigration could be of great value to design novel therapeutic strategies directed to 
promote or suppress an inflammatory response, which may be of potential benefit under 
physiological or pathological circumstances.  
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formation of lamellipodia and pseudopodia during migration and phagocytosis. Activated 
neutrophils become polarized with a contracted tail (uropod) in the rear and F-actin-rich 
protrusions at the front and start crawling. Actin and the proteins regulating actin 
polymerization are key players in the establishment of morphological and functional cell 
polarity. Actin polymerization and membrane ruffling comprise the first events leading to 
the establishment of chemoattractant-stimulated neutrophil polarization. 
Morphological changes imply cytoskeleton redistribution triggered by certain activated 
pathways which are spatiotemporally coordinated.  
Undesrtanding the molecular and cellular interactions that regulate neutrophil 
transmigration could be of great value to design novel therapeutic strategies directed to 
promote or suppress an inflammatory response, which may be of potential benefit under 
physiological or pathological circumstances.  
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The security system of the body against pathogenic invaders includes leukocytes that 
efficiently scan the organism. Leukocytes within the vasculature utilize the comprehensive 
circulatory system to examine the blood vessels of the entire body for signs of e.g. bacteria 
displayed on vascular endothelial cells. Upon infection, a successful immune response is 
dependent on prompt recruitment of leukocytes from the bloodstream to the afflicted site 
where they exert their effector functions. A critical aspect of leukocyte recruitment out of 
vasculature is the chemotactic gradient that guides leukocytes over the blood vessel wall, and 
further through the extracellular matrix towards the affected site. Leukocyte recruitment is a 
strictly regulated cascade of events involving different molecular mechanisms. To rapidly and 
efficiently reach their target, specific interactions between circulating leukocytes and vascular 
endothelium orchestrates leukocyte activation and guides them already within blood vessels 
to optimal transmigration sites at endothelial loci close to the source of inflammation. 
Despite the obvious need for effective leukocyte recruitment to eradicate bacteria and to 
maintain tissue homeostasis, amplified and dysregulated recruitment of leukocytes is a key 
factor in diverse disorders including autoimmune diseases and sepsis. For many of these 
conditions, therapeutic options are limited and unspecific. Understanding the triggering 
signals, involved molecules and underlying mechanisms by which the body enhances, 
controls and limits immune responses is therefore critical for the development of novel 
therapeutic interventions. 
In this chapter we summarize leukocyte recruitment during inflammation, highlighting a 
recent finding, namely intravascular leukocyte chemotaxis. 
2. Leukocyte recruitment and chemotaxis  
Over the last years, research groups have been dedicating their efforts to delineate the 
cellular and molecular mechanisms behind leukocyte recruitment using a wide range of in 
vivo imaging techniques (e.g. fluorescence intravital microscopy, spinning disk confocal, as 
well as two-photon confocal microscopy). These techniques, together with genetically 
altered mice (transgenic or knockout) combined with fluorescently labeled proteins and 
antibodies, allow detailed examination of leukocyte-endothelial cell interactions, adhesion 
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molecule expression and chemokine distribution. Thereby, an expanded and more detailed 
version of the leukocyte recruitment cascade was established. 
Leukocyte recruitment can be described as a sequential process having at least five distinct 
events, as depicted in Figure 1, induced by upregulation of endothelial adhesion molecules 
and molecular guidance signals (chemotactic stimuli). 
 
 
Fig. 1. The leukocyte recruitment cascade. The vessels is stained red by monoclonal 
antibodies to CD31 conjugated to Alexa Fluor 555, and cartoon neutrophils are added to the 
phtograph. The white boxes contain involved adhesion molecules, where the ones expressed 
by neutrophils are written in italics. Illustration adapted with permission from Phillipson M, 
Kubes P, Nature Medicine, 2011.  
2.1 Leukocyte tethering and rolling 
In order to leave the vasculature at the site of infection, leukocytes have to become marginated, 
leave the center of the blood stream, and decelerate to come in contact with the vascular 
endothelium. However, due to the force of blood flow in postcapillary venules (shear rate 150 
to 1600 s-1, depending on flow rate and vessel diameter) collisional contact duration between 
leukocytes and unstimulated endothelium is brief (i.e. <25 ms) (Simon S. I., Goldsmith H. L., 
2002). Specific interaction mechanisms between leukocytes and activated endothelium under 
shear flow are therefore required for leukocyte recruitment to inflammatory foci. 
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In fact, during inflammation, locally released stimuli (e.g. bacterial peptides, complement 
fragments, chemokines, histamine, and damage-associated molecular patterns) activate 
endothelial cells in the nearby venules to upregulate adhesion molecules on the plasma 
membrane which will aid leukocyte tethering, slow rolling and adhesion to the 
endothelium, leading ultimately to leukocyte transmigration into the tissue. 
Selectins are a family of long adhesive molecules, extending from the plasma membrane, 
which facilitate attachment of circulating leukocytes to the endothelium (Patel K. D. et al., 
1995; Kansas G.S., 1996). Increased expression of P- and E-selectin (CD62P and CD62E, 
respectively) on activated venular endothelium induces leukocyte tethering (Kunkel E. J., 
Ley K., 1996; Petri B. et al., 2008). While P-selectin is stored in Weibel-Palade bodies within 
the endothelial cells, E-selectin requires de novo synthesis. Once tethered, leukocytes can 
rapidly release and reengage selectin ligand bonds, resulting in a slow rotational movement 
along the vessel wall termed rolling (Norman M. U., Kubes P., 2005; Kelly M. et al., 2007; Ley 
K. et al., 2007). Rolling dynamics is optimized by force-regulated transitions from catch 
bonds to slip bonds1, which explains the requirement for a shear threshold to support 
rolling (McEver R. P., Zhu C., 2010). L-selectin (CD62L), constitutively expressed on 
leukocytes, participates redundantly with P- and E-selecting, and supports both capture and 
rolling of leukocytes in blood vessels (Kunkel E. J., Ley K., 1996; Petri B. et al., 2008).  
Each of the three selectins binds with different affinity to sialylated and fucosylated 
oligosaccharides including sialyl LewisX (sLeX) moieties, which are present on multiple 
glycolipids and glycoproteins on leukocytes and endothelium (McEver R. P., 2001; Simon S. 
I., Green C. E., 2005; Kelly M. et al., 2007). The best characterized selectin ligand is PSGL-1 
(P-selectin glycoprotein ligand-1), a heavily sialylated mucin present on leukocytes and 
endothelial cells, which can serve as a ligand to P-, E- and L-selectins although it binds P-
selectin with the highest affinity (Kansas G. S., 1996). Besides PSGL-1, other ligands have 
been identified for E-selectin, e.g. sialophorin (leukosialin, CD43), hematopoietic cell E-
selectin ligand (HCELL, CD44), and E-selectin ligand-1 (ESL1) (Kelly M. et al., 2007; Ley K. et 
al., 2007). L-selectin can also bind other ligands e.g. glycosylation-dependent cell adhesion 
molecule-1 (GlyCAM-1), mucosal addresin cell adhesion molecule-1 (MAdCAM-1), 
podocalyxin (CD34), heparan sulfate (HS) and sulphated glycoprotein-200 (Sgp200) (Wang 
L. et al., 2005). 
Rolling along the endothelium provides leukocytes a great opportunity to interact with and 
be further activated by chemokines or other inflammatory mediators presented on the 
luminal endothelium. 
2.2 Intravascular chemokine presentation to rolling leukocytes 
To initiate activation and recruitment of circulating leukocytes to tissue, tissue-derived 
chemokines need to be presented to rolling leukocytes at the apical endothelium. Within 
blood vessels, immobilization of chemokines on the endothelium is essential to avoid that 
they are washed away from the site of inflammation by the blood flow. 
                                                 
1 Catch bond: a bond that prolongs its lifetime in response to tensile force; Slip bond: a bond that shortens 
its lifetime in response to tensile force (McEver R. P., Zhu C., 2010). 
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Heparan sulfate proteoglycans (HSPGs) are proteins bearing covalently attached complex 
polysaccharide chains that are negatively charged (heparan sulfate, HS), and are found on 
cell surfaces of most cell types as well as in the extracellular matrix (Bernfield M. et al., 1999, 
Parish C., 2005). Chemokines and a variety of positively charged proteins bind to HS 
through specific and/or electrostatic interactions (Lindhal U., Kjellén L., 1991; Lindhal U., 
2007). Indeed, interstitially released chemokines were shown to cross the endothelium and 
to be presented by luminal HSPGs to leukocytes both in vitro (Ihrcke N. S. et al., 1993; Parish 
C., 2005; Wang L. et al., 2005; Lindhal U., 2007) and in vivo (Massena S. et al., 2010). Binding 
of chemokines to endothelial HSPG may promote molecular encounters between rolling 
leukocytes and chemokines, and thereby further inducing leukocyte activation. Moreover, 
endothelial HS acts as a ligand for L-selectin aiding neutrophil slow rolling (Wang L. et al., 
2005), which increase the propensity for leukocyte-chemokine encounters. 
How chemokines originating from the afflicted site or released by tissue leukocytes reach 
the luminal side of the endothelium in order to be presented by HS to leukocytes is not 
completely established. However, electron microscopy studies suggested that chemokines 
bound to HS are transported through the endothelium by transcytosis (Middleton J. et al., 
1997) as endothelium exposed to interleukin-8 (IL-8, CXCL8) contained IL-8 within 
intracellular caveola, while no chemokines were found at endothelial cell junctions. 
Nevertheless, under the experimental conditions of this study, it is impossible to tell if the 
intracellular chemokines are being transported through endothelium towards the apical 
membrane or if they are on their way to lyzosomes for degradation. In addition, soluble 
chemokines passing through junctions cannot be detected using electron microscopy, as 
they would be lost during tissue preparation prior to examination. 
Edema formation is one of the cardinal signs of inflammation, and is caused by increased 
vascular permeability and consequent plasma leakage. The primary cause of increased 
vascular permeability is leakage of plasma through paracellular gaps (Curry F. E., Adamson 
R. H., 2010; Lindbom L., Kenne E., 2011), which is regulated by the interplay of adhesive 
forces between adjacent endothelial cells and counter adhesive forces generated by 
endothelial actomyosin contraction (Mehta D., Malik A. B., 2006). The physiological 
importance of this event for leukocyte recruitment is debated. It is well documented that 
increased vascular permeability in presence of inflammatory mediators is accompanied by 
increased leukocyte adhesion and diapedesis (Curry F.E., Adamson R. H., 1999; Michel C. 
C., Curry F. E., 1999). Nevertheless, temporal and spatial uncoupling between these two 
events has also been described. During inflammation, vascular permeability can increase at 
a faster rate than leukocyte transmigration (Kim M. H. et al., 2009), suggesting that increased 
vascular permeability precedes leukocyte recruitment. Further, in aseptic wounds, vascular 
permeability and leukocyte extravasation were shown to be uncoupled (Curry F.E., 
Adamson R. H., 1999; Kim M. H. et al., 2009). It is generally believed that increased 
permeability supports chemokine influx into the vessels and one hypothesis is that the 
increase in vascular permeability during inflammation grants the paracellular transport of 
chemokines for rapid presentation to intravascular leukocytes, guiding them out to the 
afflicted area in the tissue. A recent study using intravital spinning-disk confocal 
microscopy in anesthetized mice revealed that chemokines added extravascularly became 
accumulated intra-luminally at endothelial cell junctions (Massena S. et al., 2010). High 
junctional sequestration of chemokines suggests that chemokines are transported either 
paracellularly into blood vessels or longitudinally on the apical endothelial cell membrane 
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towards junctions after being transcytosed. Further, this observation might simply reflect 
high concentrations of HS in junctional regions. However, these findings suggest that 
increased vascular permeability during inflammation does not necessary account for 
amplified leukocyte extravasation per se, but instead might promote cytokine/chemokine 
transport and thereby induce leukocyte recruitment. 
Endothelial cells display extraordinary phenotypic and functional heterogeneity. 
Endothelial cell structural features such as shape, thickness, molecular characteristics of 
apical membrane and junctions, as well as the thickness of the luminal glycocalyx are some 
of the features, which vary across the vascular tree (Van Den Berg B. M. et al., 2003; Aird W. 
C., 2007). Heparan sulfate is known to display miscellaneous structural features in various 
tissues and on different cell types (Lindhal U., Li J. P., 2009), which accounts for binding of 
proteins in a selective fashion. Differences in proteoglycan composition (altered structure of 
HS epitopes or sequences, and/or expression pattern of different syndecans) might result in 
different chemokine binding properties, explaining the observed differences in leukocyte 
recruitment of different organs upon diverse inflammatory stimuli. 
2.3 Leukocyte activation and adhesion to the endothelium 
After being stimulated by chemokines sequestered on the endothelium, rolling leukocytes 
adhere to the endothelium by rapid formation of shear-resistant bindings mediated by 
specialized leukocyte integrins (Rose D. M. et al., 2007). Integrins are noncovalently 
associated heterodimeric cell surface adhesion molecules consisting of combinations of  
and -molecules. Leukocytes express at least 10 members of the integrin family belonging to 
the 1-, 2- and 7-subfamilies (Luo B. H. et al., 2007). Leukocyte adhesion molecules relevant 
for recruitment belong to the 1- and 2-integrin families (Ley K. et al., 2007), of which LFA-1 
(Lymphocyte function-associated antigen-1, ITGAL, CD11a/CD18, L2), Mac-1 
(Macrophage antigen-1, ITGAM, CD11b/CD18, M2) and VLA-4 (very late antigen-4, 
CD49d/CD29, 41) are the most studied. 
Members of the 1-subfamily (also called VLA integrins) contain the 1-subunit associated to 
one of at least six different  subunits (Hemler M. E., 1990). VLA-4 integrin is amply 
expressed on peripheral blood B-lymphocytes, T-lymphocytes and monocytes (Hemler M. 
E., 1990). Peripheral blood neutrophils are believed to generally be devoid of cell surface 1-
integrin structures (Hemler M. E., 1990), even though some reports claim that immature 
neutrophils expressing surface VLA-4 can also be found in circulation (Lund-Johansen F., 
Terstappen L. W., 1993; Pillay J. et al., 2010). 
Most circulating leukocytes express integrins in a low affinity state (Carman C. V., Springer 
T. A., 2003). Upon binding of chemokines to G-protein-coupled receptors (GPCRs) 
expressed on leukocytes, a complex intracellular signaling network is triggered within 
milliseconds (Shamri R. et al., 2005; Ley K. et al., 2007). This induces integrins to undergo an 
almost instantaneous change in avidity and ligand affinity (Von Andrian U. H. et. al., 1992; 
Shamri R. et al., 2005; Hyduk S. J., Cybulsky M. I., 2009). Thus, inside-out signaling after 
chemokine binding to GPCRs shifts the integrins from a resting to an active conformation 
(Simon S.I., Goldsmith H. L., 2002; Simon S. I., Green C. E., 2005), which is necessary for 
binding to its ligands expressed on activated endothelial cells (Ley K. et al., 2007). 
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2007). Indeed, interstitially released chemokines were shown to cross the endothelium and 
to be presented by luminal HSPGs to leukocytes both in vitro (Ihrcke N. S. et al., 1993; Parish 
C., 2005; Wang L. et al., 2005; Lindhal U., 2007) and in vivo (Massena S. et al., 2010). Binding 
of chemokines to endothelial HSPG may promote molecular encounters between rolling 
leukocytes and chemokines, and thereby further inducing leukocyte activation. Moreover, 
endothelial HS acts as a ligand for L-selectin aiding neutrophil slow rolling (Wang L. et al., 
2005), which increase the propensity for leukocyte-chemokine encounters. 
How chemokines originating from the afflicted site or released by tissue leukocytes reach 
the luminal side of the endothelium in order to be presented by HS to leukocytes is not 
completely established. However, electron microscopy studies suggested that chemokines 
bound to HS are transported through the endothelium by transcytosis (Middleton J. et al., 
1997) as endothelium exposed to interleukin-8 (IL-8, CXCL8) contained IL-8 within 
intracellular caveola, while no chemokines were found at endothelial cell junctions. 
Nevertheless, under the experimental conditions of this study, it is impossible to tell if the 
intracellular chemokines are being transported through endothelium towards the apical 
membrane or if they are on their way to lyzosomes for degradation. In addition, soluble 
chemokines passing through junctions cannot be detected using electron microscopy, as 
they would be lost during tissue preparation prior to examination. 
Edema formation is one of the cardinal signs of inflammation, and is caused by increased 
vascular permeability and consequent plasma leakage. The primary cause of increased 
vascular permeability is leakage of plasma through paracellular gaps (Curry F. E., Adamson 
R. H., 2010; Lindbom L., Kenne E., 2011), which is regulated by the interplay of adhesive 
forces between adjacent endothelial cells and counter adhesive forces generated by 
endothelial actomyosin contraction (Mehta D., Malik A. B., 2006). The physiological 
importance of this event for leukocyte recruitment is debated. It is well documented that 
increased vascular permeability in presence of inflammatory mediators is accompanied by 
increased leukocyte adhesion and diapedesis (Curry F.E., Adamson R. H., 1999; Michel C. 
C., Curry F. E., 1999). Nevertheless, temporal and spatial uncoupling between these two 
events has also been described. During inflammation, vascular permeability can increase at 
a faster rate than leukocyte transmigration (Kim M. H. et al., 2009), suggesting that increased 
vascular permeability precedes leukocyte recruitment. Further, in aseptic wounds, vascular 
permeability and leukocyte extravasation were shown to be uncoupled (Curry F.E., 
Adamson R. H., 1999; Kim M. H. et al., 2009). It is generally believed that increased 
permeability supports chemokine influx into the vessels and one hypothesis is that the 
increase in vascular permeability during inflammation grants the paracellular transport of 
chemokines for rapid presentation to intravascular leukocytes, guiding them out to the 
afflicted area in the tissue. A recent study using intravital spinning-disk confocal 
microscopy in anesthetized mice revealed that chemokines added extravascularly became 
accumulated intra-luminally at endothelial cell junctions (Massena S. et al., 2010). High 
junctional sequestration of chemokines suggests that chemokines are transported either 
paracellularly into blood vessels or longitudinally on the apical endothelial cell membrane 
 
Intravascular Leukocyte Chemotaxis: The Rules of Attraction 
 
233 
towards junctions after being transcytosed. Further, this observation might simply reflect 
high concentrations of HS in junctional regions. However, these findings suggest that 
increased vascular permeability during inflammation does not necessary account for 
amplified leukocyte extravasation per se, but instead might promote cytokine/chemokine 
transport and thereby induce leukocyte recruitment. 
Endothelial cells display extraordinary phenotypic and functional heterogeneity. 
Endothelial cell structural features such as shape, thickness, molecular characteristics of 
apical membrane and junctions, as well as the thickness of the luminal glycocalyx are some 
of the features, which vary across the vascular tree (Van Den Berg B. M. et al., 2003; Aird W. 
C., 2007). Heparan sulfate is known to display miscellaneous structural features in various 
tissues and on different cell types (Lindhal U., Li J. P., 2009), which accounts for binding of 
proteins in a selective fashion. Differences in proteoglycan composition (altered structure of 
HS epitopes or sequences, and/or expression pattern of different syndecans) might result in 
different chemokine binding properties, explaining the observed differences in leukocyte 
recruitment of different organs upon diverse inflammatory stimuli. 
2.3 Leukocyte activation and adhesion to the endothelium 
After being stimulated by chemokines sequestered on the endothelium, rolling leukocytes 
adhere to the endothelium by rapid formation of shear-resistant bindings mediated by 
specialized leukocyte integrins (Rose D. M. et al., 2007). Integrins are noncovalently 
associated heterodimeric cell surface adhesion molecules consisting of combinations of  
and -molecules. Leukocytes express at least 10 members of the integrin family belonging to 
the 1-, 2- and 7-subfamilies (Luo B. H. et al., 2007). Leukocyte adhesion molecules relevant 
for recruitment belong to the 1- and 2-integrin families (Ley K. et al., 2007), of which LFA-1 
(Lymphocyte function-associated antigen-1, ITGAL, CD11a/CD18, L2), Mac-1 
(Macrophage antigen-1, ITGAM, CD11b/CD18, M2) and VLA-4 (very late antigen-4, 
CD49d/CD29, 41) are the most studied. 
Members of the 1-subfamily (also called VLA integrins) contain the 1-subunit associated to 
one of at least six different  subunits (Hemler M. E., 1990). VLA-4 integrin is amply 
expressed on peripheral blood B-lymphocytes, T-lymphocytes and monocytes (Hemler M. 
E., 1990). Peripheral blood neutrophils are believed to generally be devoid of cell surface 1-
integrin structures (Hemler M. E., 1990), even though some reports claim that immature 
neutrophils expressing surface VLA-4 can also be found in circulation (Lund-Johansen F., 
Terstappen L. W., 1993; Pillay J. et al., 2010). 
Most circulating leukocytes express integrins in a low affinity state (Carman C. V., Springer 
T. A., 2003). Upon binding of chemokines to G-protein-coupled receptors (GPCRs) 
expressed on leukocytes, a complex intracellular signaling network is triggered within 
milliseconds (Shamri R. et al., 2005; Ley K. et al., 2007). This induces integrins to undergo an 
almost instantaneous change in avidity and ligand affinity (Von Andrian U. H. et. al., 1992; 
Shamri R. et al., 2005; Hyduk S. J., Cybulsky M. I., 2009). Thus, inside-out signaling after 
chemokine binding to GPCRs shifts the integrins from a resting to an active conformation 
(Simon S.I., Goldsmith H. L., 2002; Simon S. I., Green C. E., 2005), which is necessary for 
binding to its ligands expressed on activated endothelial cells (Ley K. et al., 2007). 
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Differential leukocyte expression levels of integrins and chemokine receptors as well as 
receptor affinity for chemokines might account for selective arrest and recruitment of 
leukocyte subtypes. Additionally, chemokine-triggered signaling networks can regulate 
distinct integrins in specific leukocyte subtypes, contributing for differential leukocyte 
recruitment. 
2.3.1 Neutrophil adhesion 
2-integrin dependent neutrophil adhesion is fundamental for effective bacterial clearance. 
In fact, the genetic disorder leukocyte adhesion deficiency I (LAD I) is characterized by a 
profound defect in leukocyte recruitment and therefore severe immunodeficiency, due to 
neutrophils failing to adhere to the activated endothelium since the surface levels of 2-
integrins are dramatically reduced or absent (Bunting M. et al., 2002). 
It was recently found that binding of the 2-integrin LFA-1 to intercellular adhesion 
molecule-1 (ICAM-1, CD54) expressed by endothelial cells, mediates neutrophil firm 
adhesion to the vascular endothelium under shear flow (Shamri R. et al., 2005; Phillipson M. 
et al., 2006; Ley K. et al., 2007; Petri B. et al., 2008). LFA-1 is also able to bind to other 
immunoglobulin superfamily members, ICAM-2 (CD102) and ICAM-3 (CD50), albeit with 
lower affinity relative to ICAM-1 (De Fougerolles A. R. et al., 1994), in addition to JAM-A 
(junction adhesion molecule-A). 
However, there is some evidence that neutrophils adhere via other adhesion molecules than 
LFA-1, or by non-adhesion processes such as physical trapping, described to occur in lung 
capillaries or liver sinusoids (Doerschuk C. M. et al., 1990; Wong J. et al., 1997; Norman M. 
U., Kubes P., 2005). Indeed, anti-CD18 treatment did not reduce leukocyte recruitment to the 
lung of rabbits (Doerschuk C. M. et al., 1990), or in the rat liver (Jaeschke H. et al., 1996). In 
the liver, neutrophils have been reported to adhere via CD44 interacting with sinusoidal 
hyaluronan (McDonald B. et al., 2008). Furthermore, under systemic inflammatory 
conditions, such as sepsis, neutrophils have been suggested to adhere to the endothelium 
via VLA-4 (Ibbotson G. C. et al., 2001). This integrin was also proposed to be involved in 
neutrophil adhesion in the lung microvasculature (Ibbotson G. C. et al., 2001). 
2.3.2 Monocyte adhesion 
In contrast to neutrophil adhesion, 2-integrins seem to play a moderate role in monocyte 
arrest, since monocytes both adhere and polarize after blockade of 2-integrins as well as 
after blockade of ICAM-1 or ICAM-2 in vitro (Schenkel A. R. et al., 2004). Instead, 1-
integrins seem to play a more substantial role in monocyte adhesion to the endothelium. In 
fact, recent mouse models showed that monocytes firmly adhered to endothelium by VLA-4 
binding to endothelial VCAM-1 (vascular cell adhesion molecule-1, CD106) (Luscinkas F. W. 
et al., 1994; Meerschaert J., Furie M. B., 1995; Lee T. D. et al., 2003; Ley K. et al., 2007; 
Soehnlein O. et al., 2009). 
2.3.3 Lymphocyte adhesion 
During lymphocyte recruitment to peripheral tissues, LFA-1 is the dominant integrin 
involved in firm adhesion (Dustin M., Springer T. A., 1989; Shamri R. et al., 2005) by binding 
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to its ligand ICAM-1 (Shamri R. et al., 2005). As described for neutrophils, LFA-1 prevails in 
a low affinity state on most circulating lymphocytes. Stimulation of lymphocyte-GPCRs 
rapidly shifts LFA-1 integrin to a high avidity state (Carman C. V., Springer T. A., 2003). 
This high avidity state of LFA-1 on T-lymphocytes is transient, peaking 5 to 10 minutes after 
receptor stimulation and returns to the low affinity state by 30 min to 2 hours (Dustin M., 
Springer T. A., 1989). 
T-lymphocytes are not only recruited to tissue, they also home to lymph nodes. In vitro 
studies of T-lymphocyte adhesion to the specialized lymph node endothelium (high 
endothelial venules, HEV), demonstrated that besides LFA-1, VLA-4 is involved in T-cell 
adhesion (Faveew C. et al., 2000). Adhesion was reduced by 40-50% upon treatment with 
inhibiting antibodies to either integrin. Interestingly, the effects of VLA-4 and LFA-1 
antibodies were additive, giving >90% inhibition of T-lymphocyte adhesion. 
2.4 Intravascular chemotactic gradients and leukocyte crawling 
Using time-lapse in vivo microscopy, adherent neutrophils and monocytes were recently 
observed to crawl significant distances within the vessels (Phillipson M. et al., 2006; Auffray 
C. et al., 2007; Phillipson M. et al., 2009). The crawling neutrophils were searching the 
endothelium for optimal sites for transmigration, since inhibition of crawling significantly 
delayed neutrophil transmigration (Phillipson M. et al., 2006; Sumagin R. et al., 2010). 
2.4.1 Neutrophil crawling 
Intravascular crawling of neutrophils is dependent on the leukocyte 2-integrin Mac-1 and 
its ligand ICAM-1 on endothelial cells (Phillipson M. et al., 2006; Sumagin R. et al., 2010). 
Compared to LFA-1, Mac-1 binds a wider spectrum of ligands, including complement 
fragment iC3b, fibrinogen, fibronectin, laminin, collagen, myeloperoxidase, elastase, JAM-B 
and –C to name just a few (Simon S. I., Green C. E., 2005; Kelly M. et al.,  2007; Luo B. H. et 
al., 2007) suggesting that this integrin might have other roles apart from intravascular 
crawling. 
Neutrophil crawling on the stimulated endothelium occurs in two distinct stages. In the 
initial phase directly following neutrophil adhesion, a mechanotactic signal provided by 
shear stress induces neutrophil crawling perpendicular to blood flow until an endothelial 
cell junction is encountered (Phillipson M. et al., 2009). This observation has also been made 
in vitro when adherent neutrophils crawled perpendicular to the direction of flow when 
shear was applied to the system (Phillipson M. et al., 2009). However, as soon as the 
crawling neutrophils meet the junction, the shear stress signal is ignored and neutrophils 
instead begin to follow the junction. Considering that endothelial cells are elongated in the 
direction of flow, perpendicular crawling generates the greatest probability for a neutrophil 
to find an endothelial junction in the shortest period of time. 
More recently, the existence of an intravascular gradient of chemokines (macrophage 
inflammatory protein-2, CXCL2 [MIP-2]; keratinocyte-derived chemokine, CXCL1 [KC]) 
originating from the infection or released by tissue leukocytes on endothelial cells has been 
described (Massena S. et al., 2010). Indeed, this chemotactic gradient is sequestered on 
endothelial HS and provides directional cues to crawling neutrophils, which follow this 
gradient to optimal transmigration sites close to the origin of the infection (Massena S. et al., 
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Differential leukocyte expression levels of integrins and chemokine receptors as well as 
receptor affinity for chemokines might account for selective arrest and recruitment of 
leukocyte subtypes. Additionally, chemokine-triggered signaling networks can regulate 
distinct integrins in specific leukocyte subtypes, contributing for differential leukocyte 
recruitment. 
2.3.1 Neutrophil adhesion 
2-integrin dependent neutrophil adhesion is fundamental for effective bacterial clearance. 
In fact, the genetic disorder leukocyte adhesion deficiency I (LAD I) is characterized by a 
profound defect in leukocyte recruitment and therefore severe immunodeficiency, due to 
neutrophils failing to adhere to the activated endothelium since the surface levels of 2-
integrins are dramatically reduced or absent (Bunting M. et al., 2002). 
It was recently found that binding of the 2-integrin LFA-1 to intercellular adhesion 
molecule-1 (ICAM-1, CD54) expressed by endothelial cells, mediates neutrophil firm 
adhesion to the vascular endothelium under shear flow (Shamri R. et al., 2005; Phillipson M. 
et al., 2006; Ley K. et al., 2007; Petri B. et al., 2008). LFA-1 is also able to bind to other 
immunoglobulin superfamily members, ICAM-2 (CD102) and ICAM-3 (CD50), albeit with 
lower affinity relative to ICAM-1 (De Fougerolles A. R. et al., 1994), in addition to JAM-A 
(junction adhesion molecule-A). 
However, there is some evidence that neutrophils adhere via other adhesion molecules than 
LFA-1, or by non-adhesion processes such as physical trapping, described to occur in lung 
capillaries or liver sinusoids (Doerschuk C. M. et al., 1990; Wong J. et al., 1997; Norman M. 
U., Kubes P., 2005). Indeed, anti-CD18 treatment did not reduce leukocyte recruitment to the 
lung of rabbits (Doerschuk C. M. et al., 1990), or in the rat liver (Jaeschke H. et al., 1996). In 
the liver, neutrophils have been reported to adhere via CD44 interacting with sinusoidal 
hyaluronan (McDonald B. et al., 2008). Furthermore, under systemic inflammatory 
conditions, such as sepsis, neutrophils have been suggested to adhere to the endothelium 
via VLA-4 (Ibbotson G. C. et al., 2001). This integrin was also proposed to be involved in 
neutrophil adhesion in the lung microvasculature (Ibbotson G. C. et al., 2001). 
2.3.2 Monocyte adhesion 
In contrast to neutrophil adhesion, 2-integrins seem to play a moderate role in monocyte 
arrest, since monocytes both adhere and polarize after blockade of 2-integrins as well as 
after blockade of ICAM-1 or ICAM-2 in vitro (Schenkel A. R. et al., 2004). Instead, 1-
integrins seem to play a more substantial role in monocyte adhesion to the endothelium. In 
fact, recent mouse models showed that monocytes firmly adhered to endothelium by VLA-4 
binding to endothelial VCAM-1 (vascular cell adhesion molecule-1, CD106) (Luscinkas F. W. 
et al., 1994; Meerschaert J., Furie M. B., 1995; Lee T. D. et al., 2003; Ley K. et al., 2007; 
Soehnlein O. et al., 2009). 
2.3.3 Lymphocyte adhesion 
During lymphocyte recruitment to peripheral tissues, LFA-1 is the dominant integrin 
involved in firm adhesion (Dustin M., Springer T. A., 1989; Shamri R. et al., 2005) by binding 
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to its ligand ICAM-1 (Shamri R. et al., 2005). As described for neutrophils, LFA-1 prevails in 
a low affinity state on most circulating lymphocytes. Stimulation of lymphocyte-GPCRs 
rapidly shifts LFA-1 integrin to a high avidity state (Carman C. V., Springer T. A., 2003). 
This high avidity state of LFA-1 on T-lymphocytes is transient, peaking 5 to 10 minutes after 
receptor stimulation and returns to the low affinity state by 30 min to 2 hours (Dustin M., 
Springer T. A., 1989). 
T-lymphocytes are not only recruited to tissue, they also home to lymph nodes. In vitro 
studies of T-lymphocyte adhesion to the specialized lymph node endothelium (high 
endothelial venules, HEV), demonstrated that besides LFA-1, VLA-4 is involved in T-cell 
adhesion (Faveew C. et al., 2000). Adhesion was reduced by 40-50% upon treatment with 
inhibiting antibodies to either integrin. Interestingly, the effects of VLA-4 and LFA-1 
antibodies were additive, giving >90% inhibition of T-lymphocyte adhesion. 
2.4 Intravascular chemotactic gradients and leukocyte crawling 
Using time-lapse in vivo microscopy, adherent neutrophils and monocytes were recently 
observed to crawl significant distances within the vessels (Phillipson M. et al., 2006; Auffray 
C. et al., 2007; Phillipson M. et al., 2009). The crawling neutrophils were searching the 
endothelium for optimal sites for transmigration, since inhibition of crawling significantly 
delayed neutrophil transmigration (Phillipson M. et al., 2006; Sumagin R. et al., 2010). 
2.4.1 Neutrophil crawling 
Intravascular crawling of neutrophils is dependent on the leukocyte 2-integrin Mac-1 and 
its ligand ICAM-1 on endothelial cells (Phillipson M. et al., 2006; Sumagin R. et al., 2010). 
Compared to LFA-1, Mac-1 binds a wider spectrum of ligands, including complement 
fragment iC3b, fibrinogen, fibronectin, laminin, collagen, myeloperoxidase, elastase, JAM-B 
and –C to name just a few (Simon S. I., Green C. E., 2005; Kelly M. et al.,  2007; Luo B. H. et 
al., 2007) suggesting that this integrin might have other roles apart from intravascular 
crawling. 
Neutrophil crawling on the stimulated endothelium occurs in two distinct stages. In the 
initial phase directly following neutrophil adhesion, a mechanotactic signal provided by 
shear stress induces neutrophil crawling perpendicular to blood flow until an endothelial 
cell junction is encountered (Phillipson M. et al., 2009). This observation has also been made 
in vitro when adherent neutrophils crawled perpendicular to the direction of flow when 
shear was applied to the system (Phillipson M. et al., 2009). However, as soon as the 
crawling neutrophils meet the junction, the shear stress signal is ignored and neutrophils 
instead begin to follow the junction. Considering that endothelial cells are elongated in the 
direction of flow, perpendicular crawling generates the greatest probability for a neutrophil 
to find an endothelial junction in the shortest period of time. 
More recently, the existence of an intravascular gradient of chemokines (macrophage 
inflammatory protein-2, CXCL2 [MIP-2]; keratinocyte-derived chemokine, CXCL1 [KC]) 
originating from the infection or released by tissue leukocytes on endothelial cells has been 
described (Massena S. et al., 2010). Indeed, this chemotactic gradient is sequestered on 
endothelial HS and provides directional cues to crawling neutrophils, which follow this 
gradient to optimal transmigration sites close to the origin of the infection (Massena S. et al., 
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2010). However, whether haptotactic gradients can be established by all chemokines 
remains unclear, since different chemokines have diverse affinity to HS (Lindhal U., Kjellén 
L., 1991; Lindhal U., 2007). 
Directional intravascular crawling along a chemotactic gradient expedites neutrophil 
recruitment, compared to when no chemokine gradient is formed due to homogenous 
extravascular chemokine concentrations (Massena S. et al., 2010). Disruption of the 
chemokine gradient is translated into random crawling and inefficient recruitment of 
neutrophils which ultimately leads to a decreased ability to clear infections, as seen in 
Staphylococcus aureus infected mice with truncated HS chains (overexpressing heparanase, 
Massena S. et al., 2010). 
2.4.2 Monocyte crawling 
Intravascular crawling monocytes have been reported in vivo (Auffray C. et al., 2007; 
Sumagin R. et al., 2010), and crawling on endothelium is critical to reach optimal 
transmigration sites, as demonstrated in vitro (Schenkel A. R. et al., 2004). 
Whereas the integrin Mac-1 alone is responsible for crawling of neutrophils, LFA-1 and 
Mac-1 integrins were in some studies reported to play a redundant role in monocyte 
crawling via binding to ICAM-1 and ICAM-2 (Schenkel A. R. et al., 2004; Sumagin R. et al., 
2010). Blockade of each of these molecules led to a pirouette behavior at the adhesion site 
(Schenkel A. R. et al., 2004). Nevertheless, monocytes were shown to be able to adhere and 
polarize. 
Recently, a distinct role for each of these integrins on monocyte crawling under different 
endothelial activation states has been described. Monocytes were shown to crawl long 
distances on resting endothelium in a patrolling behavior (i.e. monitoring healthy tissue) in a 
LFA-1-dependent manner (Auffray C. et al., 2007; Sumagin R. et al., 2010). However, upon 
inflammatory stimulation, monocyte crawling became Mac-1-dependent and assumed a 
neutrophil-like crawling pattern, i.e. similar crawling distance and confinement ratio 
(Sumagin R. et al., 2010). These results have been suggested to correspond to differences 
between two different monocyte populations rather than to a shift in integrin expression 
upon inflammatory stimulation. 
Two monocyte subsets distinguished by their expression levels of selectins, integrins and 
chemokine receptors have already been characterized in various mammals (Geissman F. et 
al., 2003; Gordon S., Taylor P. R., 2005). These phenotypic differences encompass distinct 
effector functions. A monocyte subset termed "resident" (CX3CR1hi CCR2- Ly6C- in mice; 
CD14lo CD16+ in humans) is involved in tissue remodeling and wound repair (Gordon S., 
Taylor P. R., 2005; Auffray C. et al., 2007; Soehnlein O. et al., 2009). In contrast, another 
monocyte subset denominated "inflammatory" (CX3CR1lo CCR2+ Ly6C+ in mice; CD14hi 
CD16- in humans) is specialized in pro-inflammatory activities such as bacterial 
phagocytosis, secretion of inflammation-promoting cytokines and reactive species as well as 
proteolytic activity (Gordon S., Taylor P. R., 2005; Auffray C. et al., 2007; Soehnlein O. et al., 
2009). Resident monocytes, express high amounts of LFA-1. In contrast, inflammatory 
monocytes do not express LFA-1, even though no differences were found for Mac-1 between 
the two monocyte subsets (Auffray C. et al., 2007). 
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It is possible that the two subsets of circulating monocytes might use different integrins and 
display different crawling patterns to achieve the different effector functions. 
2.4.3 Lymphocyte crawling 
In vitro, adherent T-lymphocytes have been reported to crawl over the luminal surface of the 
endothelium in a LFA-1-dependent manner (Shulman et al., 2009). LFA-1 is also responsible 
for T-lymphocyte adhesion, but the distribution of the membrane LFA-1 is altered 
correlating with changes in cell morphology as soon as the T-lymphocyte starts to migrate 
(Smith A. et al., 2005). LFA-1 turnover at numerous focal points ensures rapid crawling and 
resistance to detachment by shear forces (Shulman et al., 2009). Low expression levels of 
LFA-1 were detected at the leading edge of the cell and high expression level in the non-
attached uropod at the rear (Smith A. et al., 2005). Interestingly, LFA-1 in the leading edge 
was not in a high-affinity state, as detected by use of specific antibodies that recognize LFA-
1 in different conformational states (Smith A. et al., 2007). Instead LFA-1 in the leading edge 
was in an intermediate affinity conformation allowing crawling possibly by weaker 
interactions with ICAM-1. 
Published studies have identified intravascular natural killer T-lymphocytes (NKT cells) 
with possible sentinel functions for the detection of bacteria in the blood (Geissmann F. et al., 
2005; Lee T. D. et al., 2010; Thomas S. Y. et al., 2011). These cells are distinguished by their 
restricted repertoire of T-cell receptor (TCR) variants that recognize lipids and glycolipids 
presented by CD1d (Kawano T. et al., 1997; Brossay L. et al., 1998). NKT cells primarily 
reside and wander within the vasculature of the liver and spleen (Geissmann F. et al., 2005; 
Bendelac A. et al., 2007) but have also been suggested to accumulate in smaller amounts in 
the vascular compartment of the lung (Thomas S. Y. et al., 2011). The mechanisms 
underlying adhesion and crawling of NKT cells are still poorly understood. It has been 
reported that treatment of mice with blocking antibodies to LFA-1 and ICAM-1 induced 
rapid detachment of adherent NKT cells from sinusoidal endothelium (Thomas S. Y. et al., 
2011). In contrast, blocking VLA-4 or VCAM-1 had no effect. Integrin activation typically 
relies on inside–out signaling after chemokine binding to GPCRs (Ley K. et al., 2007). 
However, genetic ablation of CXCR6 (the major chemokine receptor expressed on NKT 
cells) or treatment with an inhibitor of GPCRs, did not induce detachment of NKT cells from 
liver microvasculature (Geissmann F. et al., 2005; Lee T. D. et al., 2010). Furthermore, 
previous studies on NKT cells transferred into CD1d-deficient mice suggested that TCR 
activation was not a prerequisite for NKT cells sinusoidal adhesion (McNab F. W. et al., 
2005; Wei D. G. et al., 2005). Crawling was also unimpeded in mice treated with anti-CD1d 
antibody (Lee T. D. et al., 2010). Interestingly, upon infection with the blood-borne  
pathogen Borrelia burgdorferi (a spirochete injected intravenously through tick bite), NKT 
cells were reported to slow their crawling and to accumulate in clusters on Kupffer cells in a 
GPCRs-dependent way (CXCR3, and CD1d) (Lee T. D. et al., 2010). Kupffer cells are 
specialized ramified macrophages, which line the walls of liver sinusoids and prevent the 
dissemination of pathogens via the blood by capturing and engulfing them. Kupffer cells 
can then present glycolipid antigens via CD1d (Lee T. D. et al., 2010). In the absence of 
Kupffer or NKT cells, dissemination of Borrelia burgdorferi occurred, suggesting a role for 
NKT cells in vascular surveillance for blood-borne pathogens captured by Kupffer cells (Lee 
T. D. et al., 2010).  
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2010). However, whether haptotactic gradients can be established by all chemokines 
remains unclear, since different chemokines have diverse affinity to HS (Lindhal U., Kjellén 
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neutrophils which ultimately leads to a decreased ability to clear infections, as seen in 
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Sumagin R. et al., 2010), and crawling on endothelium is critical to reach optimal 
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2010). Blockade of each of these molecules led to a pirouette behavior at the adhesion site 
(Schenkel A. R. et al., 2004). Nevertheless, monocytes were shown to be able to adhere and 
polarize. 
Recently, a distinct role for each of these integrins on monocyte crawling under different 
endothelial activation states has been described. Monocytes were shown to crawl long 
distances on resting endothelium in a patrolling behavior (i.e. monitoring healthy tissue) in a 
LFA-1-dependent manner (Auffray C. et al., 2007; Sumagin R. et al., 2010). However, upon 
inflammatory stimulation, monocyte crawling became Mac-1-dependent and assumed a 
neutrophil-like crawling pattern, i.e. similar crawling distance and confinement ratio 
(Sumagin R. et al., 2010). These results have been suggested to correspond to differences 
between two different monocyte populations rather than to a shift in integrin expression 
upon inflammatory stimulation. 
Two monocyte subsets distinguished by their expression levels of selectins, integrins and 
chemokine receptors have already been characterized in various mammals (Geissman F. et 
al., 2003; Gordon S., Taylor P. R., 2005). These phenotypic differences encompass distinct 
effector functions. A monocyte subset termed "resident" (CX3CR1hi CCR2- Ly6C- in mice; 
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2.5 Diapedesis: Trans- and paracellular routes 
Leukocyte diapedesis out of vasculature into affected tissue can occur both between 
neighboring endothelial cells (paracellularly through junctions) and directly through the 
endothelium (transcellularly) (Feng D. et al., 1998; Shaw S. K. et al., 2001; Carman C. V., 
Springer T. A., 2004; Engelhardt B., Wolburg H., 2004; Yang L. et al., 2005; Phillipson M. et 
al., 2006). The route employed most likely depends on inflammatory stimuli, as well as the 
type of leukocyte and vascular bed. 
Diapedesis has been reported to be mediated by numerous endothelial adhesion molecules 
expressed in high density at endothelial junctions, such as platelet-endothelial cell adhesion 
molecule 1 (PECAM-1, CD31), CD99, vascular endothelial-cadherins (VE-cadherins), 
endothelial cell-selective adhesion molecule (ESAM), ICAM-1 and -2 and JAMs (Luscinskas 
F. W. et al., 2002; Engelhardt B., Wolburg H., 2004; Yang L. et al., 2005; Ley K. et al., 2007; Lou 
O. et al., 2007; Petri B. et al., 2008; Woodfin A. et al., 2011). Other molecules involved in 
leukocyte transmigration are integrins expressed on leukocytes (e.g. LFA-1, Mac-1, VLA-4) 
(Ley K. et al., 2007; Petri B. et al., 2008; Woodfin A. et al., 2011). The specific molecules 
involved in either of the transmigration pathways remains to be identified. 
The different molecules appear to mediate leukocyte transmigration in either a stimulus-
specific or leukocyte-specific manner. For example PECAM-1, ICAM-2 and JAM-A mediate 
leukocyte transmigration in response to interleukin-1β (IL-1β) but not to tumor necrosis 
factor-alpha (TNF-) (Wang S. et al., 2006; Ley K. et al., 2007). Direct activation of leukocytes 
by TNF-, fMLP (N-formyl-methionyl-leucyl-phenylalanine) or leukotriene-B4 (LTB4) 
appears to bypass the need for these molecules. Studies of activated mouse cremaster 
muscle and intravital microscopy in mice knocked down for ESAM gene (Ley K. et al., 2007) 
have shown that ESAM does not show a stimulus-specific role but appears to mediate 
neutrophil rather than T-lymphocyte transmigration. 
Neutrophils have been found to transmigrate predominantly through the paracellular route, 
i.e. between adjacent endothelial cells (Phillipson M. et al., 2006; Woodfin A. et al., 2011). 
Paracellular transmigration was found to be dependent on the ability for leukocytes to crawl 
to optimal transmigration sites at the endothelial cell junctions. In Mac-1 deficient mice, due 
to inhibition of intravascular crawling, transcellular transmigration predominated 
(Phillipson M. et al., 2006). 
Using in vivo spinning disk or multi-photon confocal microscopy, profound anatomical 
changes of the endothelium that facilitated leukocyte extravasation without compromising 
vascular barrier integrity were observed (Phillipson M. et al., 2008; Petri B. et al., 2011). 
Docking cup-like structures were formed by endothelial cells (endothelial projections) at the 
base of the transmigrating neutrophil, which has also been described for T-lymphocytes in 
vitro (Carman C. V., Springer T. A., 2004). The endothelial projections extended towards the 
top of the neutrophil and eventually formed a dome that surrounded the entire neutrophil, 
prior to basolateral opening and neutrophil migration further into tissue. If the dome 
formations were prevented, neutrophil transmigration was delayed (Petri B. et al., 2011), 
further implicating an active role of endothelium during leukocyte diapedesis, while 
maintaining the barrier function and vascular permeability. 
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2.5.1 Migration through the subendothelial basement membrane and pericyte sheet 
To overcome the barrier of the blood vessel and finally reach the inflamed tissue, leukocytes 
also have to transmigrate across the subendothelial basement membrane (BM) surrounding 
the venular endothelium. This has been shown to occur in areas low in collagen IV, laminin-
10 and nidogen-2 (Wang S. et al., 2006). These areas were seen to be closely associated to 
gaps between pericytes (Wang S. et al., 2006). Interestingly, leukocytes have been observed 
to initiate transmigration through endothelium at sites superimposing these specific areas. 
How intravascular crawling leukocytes can detect these areas from the luminal side of the 
endothelium remains unknown.  
2.6 Extravascular crawling  
Following leukocyte diapedesis across the vessel wall, further movement in tissue is 
required in order for the leukocytes to reach the affected site to exert their effector functions. 
As within the vasculature, leukocyte movement in the tissue is guided by chemotactic 
gradients leading to the source (Foxman E. F. et al., 1997; Lindbom L., Werr J., 2002). Upon 
binding to GPCRs on leukocytes, chemoattractants trigger downstream signaling, which 
translates to cytoskeletal reorganization, polarization and directional locomotion (Friedl P. et 
al., 2001). Migrating leukocytes thereby adopt a polarized morphology consisting of a 
leading edge and a tail-like uropod (Friedl P. et al., 2001). 
In order to initiate movement, leukocytes have to establish adhesive contacts with the tissue 
stroma via interactions between the extracellular integrin domains and components of the 
extracellular matrix (ECM) (Friedl P. et al., 2001; Lindbom L., Werr J., 2002). Stimulation by 
encountered chemoattractants activates surface integrins and recruits additional integrins 
from cytoplasmic stores (Diamond M. S., Springer T. A., 1994; Friedl P. et al., 2001). Binding 
to ECM macromolecules triggers integrin-mediated signals, which regulate further integrin 
apposition, actin assembly, cell polarity, and migration (Friedl P. et al., 2001). 
Accumulating evidence suggests that leukocyte chemotaxis in the ECM is mostly associated 
with 1-integrins while a limited role for 2-integrins is described (Sixt M. et al., 2001). 
Members of the 1-family shown to be involved in leukocyte locomotion (Gao J. X., Issekutz 
A. C., 1997; Werr J. et al., 1998; Sixt M. et al., 2001) show high affinity interactions with 
proteins of the ECM, including fibronectin, vibronectin, collagen and laminin (Hemler M. E., 
1990). Circulating neutrophils are not believed to constitutively express 1-integrins. 
However, it has been suggested that upregulation of 2-integrins by chemotactic stimuli 
induced an outside-in signaling leading to mobilization of 1-integrins to the neutrophil 
surface, in order to prepare recruited neutrophils for subsequent interactions with ECM 
(Lindbom L., Werr J., 2002). There are also studies demonstrating upregulation of neutrophil 
surface expression of 1-integrins in association with emigration from the vasculature 
(Kubes P. et al., 1995; Werr J. et al., 1998). 
Another adhesion molecule involved in extravascular crawling is L-selectin. Indeed, studies 
using L-selectin-deficient mice revealed no role of L-selectin on leukocyte rolling or 
adhesion, but transmigration was significantly impaired (Hickey M. J. et al., 2000). 
Furthermore, leukocytes in L-selectin-deficient mice were unable to respond to directional 
cues (platelet activating factor [PAF]; KC) in the interstitium (Hickey M. J. et al., 2000). These 
findings provided strong evidence of an important L-selectin function in leukocyte 
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emigration and extravascular locomotion. Intriguingly, L-selectin expression on emigrated 
leukocytes is dramatically reduced in comparison to levels on circulating leukocytes (Hickey 
M. J. et al., 2000). Shedding of L-selectin upon transmigration has been reported both in vitro 
(Smith C. W. et al., 1991; Allport J. R. et al., 1997) and in vivo (Jutila M. A. et al., 1989). These 
results raise the possibility that L-selectin early in the recruitment cascade triggers 
downstream signals that modulate consecutive transmigration and migration in the 
interstitium (Hickey M. J. et al., 2000). 
Further, integrins bind different components of the tissue stroma and with diverse affinities 
(Lindbom L., Werr J., 2002). Leukocyte chemotaxis in the tissue is therefore influenced not 
only by the stimuli encountered but also by the matrix proteins in the tissue. 
2.6.1 Prioritazing chemotactic cues 
During bacterial infections, the chemotaxing leukocytes are exposed to a cacophony of 
different chemotactic gradients of diverse origins. Chemoattractants originate from the 
bacteria themselves (e.g. fMLP; lipopolysaccharide [LPS]) or complement fragments bound 
to bacteria (e.g. complement fragment C5a), but also from nearby activated leukocytes and 
endothelial cells (e.g. LTB4; IL-8) (Foxman E. F. et al., 1997; Heit B. et al., 2008; Muller W. A., 
2011). A microenvironment where numerous chemoattractants are encountered requires 
tightly regulated intracellular mechanisms for leukocytes to readily prioritize between the 
cues, in order for them to effectively reach the target. Thus, to fulfill their missions, 
leukocytes need to find the bacteria without being distracted by opposing gradients. A 
hierarchical relationship between chemotactic factors has developed, and “end-target” 
chemotactic factors like bacterial products versus the “intermediate” chemokines released by 
activated endothelium or tissue leukocytes have been shown to activate separate signaling 
pathways in neutrophils (p38-mitogen-activated protein kinase [p38MAPK] and 
phosphoinositide 3-kinase [PI3K], respectively [Campbell J. J. et al., 1997; Heit B. et al., 2002]). 
In this way, neutrophils are able to sort signals in the noisy environment of inflammation, 
and respond to chemotactic cues in a hierarchical manner, preferring “end-target” 
chemoattractant factors like fMLP and C5a over “intermediate” chemokines like IL-8 
(Foxman E. F. et al., 1997). This has been suggested to occur through the p38MAPK pathway 
inhibiting PI3K through relocalization of phosphatase and tensin homologue (PTEN) on the 
basolateral cell membrane of the polarized moving cell (Heit B. et al., 2008). However, 
additional parallel scenarios of how chemotacting leukocytes are directed to their goal have 
been described (PLA2, cGMP and DOCK2/phosphatic acid). Despite the mentioned 
advances in understanding how leukocytes find their way in tissue, many issues remain to 
be deciphered considering the very complex nature of the extravascular environment during 
infection. Leukocytes will not only encounter bacterial chemoattractants and chemokines, 
but also cytokines, lipids and complement fragments. Cytokines (IL-1β, TNF-) are released 
simultaneously during infection and induce chemokine production. Chemokines and 
cytokines have been shown to act in concert to direct leukocyte delivery and activation, and 
chemokines of different families have been demonstrated in vitro to synergistically enhance 
influx of both neutrophils and monocytes (Gouwy M. et al., 2008; Kuscher K. et al., 2009). 
Further, interplay between lipid chemoattractant LTB4, the cytokine IL-1β and the 
chemokine ligands to first CCR1 and later CXCR2 was shown in a model of arthritogenesis 
(Chou R. C. et al., 2010). This vividly demonstrates that leukocyte recruitment in vivo, in 
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contrast to during in vitro settings hardly is the result of release of a single chemokine, and 
that synergistic as well as opposing effects of involved signaling molecules are to be 
expected to enhance as well as steer the inflammatory response. This interplay needs to be 
further clarified and the importance of these observations has to be confirmed in vivo, to 
determine therapeutic targets during different inflammatory conditions. 
3. Additional stimuli for leukocyte recruitment 
Inflammation is closely linked to hypoxia, and numerous leukocytes are detected at sites of 
tissue ischemia (Eltzschig H. K., Carmeliet P., 2011). Severe hypoxia causes both apoptosis 
and necrosis of somatic cells, which results in release of various damage-associated danger 
signals, like DAMPs (danger associated molecular pattern molecules). DAMPs include 
molecules originating from the cytosol or the nucleus, such as adenosine triphosphate 
(ATP), formylated peptides from mitochondria, heat shock proteins, chromatin and 
galectins, that often undergo denaturation when leaving the intracellular milieu, where after 
they become pro-inflammatory (Kono H., Rock K. L., 2008). Even though most of them are 
not considered directly chemotactic, they induce leukocyte recruitment by activating tissue 
macrophages and nearby endothelial cells to secrete pro-inflammatory cytokines (e.g. IL-1) 
and chemokines (e.g. IL-8), in addition to upregulating expression of adhesion molecules on 
endothelial cells (Muller W. A., 2011). However, fomylated peptides originating from 
mitochondria were recently found to recruit neutrophils via activation of the fMLP receptor 
formyl-peptide receptor-1 (McDonald B. et al., 2010; Zhang Q. et al., 2010).  
During hypoxia and cell injury, recruited neutrophils are believed to contribute to wound 
healing processes by clearing the area of debris through phagocytosis. In addition to 
phagocytosis, leukocytes have recently been acknowledged for their role in angiogenesis 
and tissue remodeling both during health and disease. Neutrophils produce and store 
within their granules pro-angiogenic molecules such as VEGF-A (vascular endothelial 
growth factor-A, [Gaudry M. et al., 1997]) and MMP-9 (matrix metalloproteinase-9, [Ardi V. 
C. et al., 2007]). VEGF is a key player in blood vessel formation and has a direct chemotactic 
effect on endothelial cells, while the pro-angiogenic function of MMP-9 is attributed to its 
ability to digest extra cellular matrix (ECM), which pave way for new vessels as well as 
release and thereby activate ECM-bound VEGF and other growth factors. The neutrophils 
are in fact the only cells in the body that release MMP-9 free of its endogenous inhibitor 
TIMP (tissue inhibitor of metalloproteinase), and are therefore capable of deliver highly 
active MMP-9 to sites of angiogenesis (Ardi V. C. et al., 2007). The pro-angiogenic capacity of 
neutrophils has been demonstrated in a corneal injury model, where the number of 
infiltrated neutrophils positively correlated to angiogenesis and VEGF levels (Gong Y., Koh 
D. R., 2010). Neutrophil depletion significantly impaired tissue healing in this model, as well 
as the release of VEGF. Further, neutrophils recruited to islets of Langerhans transplanted to 
striated muscle were recently shown to be crucial for revascularization to occur, as 
transplantation of islets to neutropenic mice resulted in complete inhibition of islets 
revascularization (Christoffersson G. et al., 2010). Neutrophils were shown to accumulate at 
sites for islet engraftment and were specifically localized at the newly formed vessels, as 
demonstrated in Figure 2. 
Monocytes have also been shown to have pro-angiogenic properties. For instance, tissue 
healing following myocardial infarction requires sequential mobilization of the two 
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healing following myocardial infarction requires sequential mobilization of the two 
 




Fig. 2. Isolated pancreatic islets (blue) transplanted to muscle causes Gr1+ cell (green) 
accumulation (courtesy of G. Christoffersson). Blood vessels are stained with anti-CD31 
(red). Scale bar equals 100 µm. 
described monocyte subsets which exhibit opposing phenotypes (Nahrendorf M. et al., 
2007). Recruited “inflammatory” monocytes exhibit proteolytic activity and inflammatory 
functions, whereas monocytes of the “resident” subtype contribute to angiogenesis and 
have attenuated inflammatory properties (Nahrendorf M. et al., 2007).  
In the field of tumor biology, it is known that the ability of tumors to create an 
immunomodulating microenvironment to escape cytotoxic immune cells and to allow for 
angiogenesis is central for tumor growth. Different factors have been shown to skew tumor-
associated leukocytes including neutrophils and macrophages from a pro-inflammatory, 
anti-tumorigenic to a pro-tumorigenic, pro-angiogenic phenotype (Fridlender Z. G. et al., 
2009; Hanahan D., Weinberg R. A., 2011; Rolny C. et al., 2011). Indeed, the angiogenic switch 
in islet dysplasia and tumors in the RIP1-Tag2 transgenic mouse model of pancreatic cancer 
was mediated by tumor-infiltrated MMP-9 expressing neutrophils (Nozawa H. et al., 2006). 
The identity of these pro-angiogenic leukocytes is currently being investigated, and whether 
circulating subpopulations with pro-angiogenic and anti-inflammatory properties exist, or if 
they attain their phenotype giving the stimuli, are under debate. Myeloid-derived 
suppressor cells (MDSCs) are a heterogenic population that increases in numbers in the 
spleen and bone marrow of tumor bearing mice, and consists of monocyte and neutrophil 
subsets with potent ability of suppressing immune functions such as T-lymphocyte 
activation (Bronte V. et al., 2000). In mice, they express CD11b and Gr-1, where the GR-1hi 
CD11b+ corresponds to immature and mature neutrophil subpopulations while the Gr-1int 
CD11b+ to the monocyte subset (Peranzoni E. et al., 2010; Youn J. I., Gabrilovich D. I., 2010). 
How other surface markers differ from the classical pro-inflammatory neutrophils or 
monocytes are not completely established, but the roles of neutrophils during restitution 
and angiogenesis described above might indeed involve the neutrophil subset of MDSC. 
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Further characterization of the identities of leukocytes involved in tissue restitution and 
angiogenesis, and even more importantly their functions during these situations, is of great 
relevance. 
4. Therapeutic interventions 
A variety of disorders are associated with leukocyte activation and infiltration. Asthma 
(Fanta C. H., 2009; Broide D. H. et al., 2011; Minnicozzi M. et al., 2011); emphysema 
(Martinez F. J. et al., 2011); atherosclerosis (Ross R., 1999; Hansson G., 2005); inflammatory 
bowel disease (Khor B. et al., 2011); rheumatoid arthritis (Olsen N. J., Stein C. M., 2004; 
O’Dell J. R., 2004; Scott D. L., Kingsley G. H., 2006); multiple sclerosis (Frohman E. M. et al., 
2006); sepsis (Hotchkiss R. S., Karl I. E., 2003); and allograft rejection after transplantation 
(Savasta M., Lentini S., 2011; Arias M. et al., 2011), are just some examples of this broad 
spectrum. Although many details remain to be delineated, the consensus is that the over-
exuberant, maladaptive and/or uncontrolled inflammation is in the pathogenesis of these 
conditions and leads to tissue injury. 
Over the past few years, pharmacotherapeutic advances have been made, with most 
therapeutic options focusing on means to prevent leukocyte activation and recruitment. 
Anti-adhesion therapies directed against different adhesion molecules have been evaluated. 
However, despite positive data from animal studies, many of the integrin antagonists have 
failed in clinical trials or are associated with severe side effects (Rutgeerts P. et al., 2009; 
Fontoura P., 2010; Del Zoppo G. J., 2010). 
A new approach for reducing leukocyte recruitment to tissue was recently described in mice 
(Maiguel D. et al., 2011). This study was based upon a nearly 20-year-old observation for 
eosinophils, which, in response to activating antibodies trapping VLA-4-integrin in a high-
avidity state, were able to adhere but not migrate (Kuijpers T. W. et al., 1993). Accordingly, 
the recent study screened for selective small-molecule Mac-1 agonists, named leukadherins. 
These agonists caused increased intravascular adhesion, but not transmigration of 
neutrophils, resulting in reduced leukocyte recruitment in experimental models of acute 
peritonitis and nephritis. Integrin clustering or outside-in signaling were not induced by 
binding of the agonist, which might account for the lack of detectable vascular injury, even 
though the effects on tissue blood flow by the increased number of intravascular adherent 
neutrophils remains to be studied. These observations are all very intriguing, even though 
further experimental evaluation of this course of action is required. 
5. Conclusion 
Leukocyte recruitment is a hallmark event in acute and chronic inflammation. Tightly 
regulated activation of circulating leukocytes and intravascular leukocyte guidance by the 
establishment of chemokine gradients within blood vessels is fundamental for leukocytes to 
efficiently transmigrate to the inflamed tissue, where they finally exert their effector 
functions. Specific interactions between transmigrating leukocytes and the activated 
vascular endothelium orchestrate profound anatomical changes of the endothelium which 
facilitate leukocyte extravasation while maintaining the barrier function and vascular 
permeability. Targeting intravascular leukocyte chemotaxis and the gating property of the 
endothelium would limit leukocyte transmigration and/ or vascular permeability during 
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detrimental inflammation. Understanding the underlying mechanisms behind these 
processes might therefore contribute for the development of novel therapeutic interventions. 
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1. Introduction  
The formation of new blood vessels, or neovascularization, involves multiple processes, 
including cell proliferation and migration, cell-cell and cell-matrix adhesion, and tube 
morphogenesis. Neovascularization can occur through one of two events: vasculogenesis, 
the de novo formation of blood vessels from angioblasts; or angiogenesis, the extension of 
new vessels from a pre-existing vasculature. Among these, angiogenesis in particular is 
relevant throughout life; its dysregulation has been causally related to several disorders that 
involve malignancy, inflammation, and ischemia. Angiogenesis is thought to depend on a 
set of signaling proteins – including certain kinases, integrins and vascular endothelial 
growth factor receptor-2 (VEGFR2) – that are enriched in specific plasma membrane 
domains. Both physiological and pathological angiogenesis rely on intracellular trafficking, 
a process that governs signaling by such proteins, as well as cell motility.  
In this chapter, we discuss our current understanding of angiogenesis from the perspective 
of trafficking of the membrane components that are responsible for endothelial-cell (EC) 
dynamics. 
2. Angiogenesis: Mechanism and importance  
The vascular system carries out a variety of functions vital to vertebrates. It delivers oxygen 
and nutrients to tissues and organs. It is required for waste disposal, including the 
detoxification of toxic metabolites in the liver and their excretion through kidney. It is 
needed for the onset of immune responses against pathogens, since it transports immune 
cells to the site of infection and/or inflammation. Finally, its constituent vessels produce 
instructive signals for organogenesis. 
Blood vessels are the main component of the vascular system and comprise: an EC 
monolayer that lines the vessel lumen, vascular smooth muscle cells that surround the EC 
monolayer, and a basement membrane that covers the vascular tube (Figure 1). The larger 
vessels, arteries and veins are stabilized by a thick layer of vascular smooth muscle cells, 
whereas the medium-sized vessels are supported by mural cells, for example pericytes 
(Gerhardt and Betsholtz, 2003). 
The vascular system is among the earliest organ systems to develop in embryos; it first 
emerges when haemangioblast progenitors proliferate, migrate and differentiate into  
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ECs and form a primitive vascular plexus. The formation of new blood vessels, or 
neovascularization, then occurs either through vasculogenesis or angiogenesis, as mentioned 
above. 
 
Fig. 1. Schematic representation of a mature blood vessel. Endothelial cells at the luminal 
side line tubular blood vessel. The smooth muscle cells and the pericytes that remain in 
contact with the endothelial cell lining through the basement membrane strengthen this 
tubular structure. 
2.1 Vasculogenesis 
Vasculogenesis, defined as de novo formation of blood vessels from precursor cells, starts 
with differentiation of precursor cells (angioblasts) into ECs and a primitive vascular 
network. In the first phase of vasculogenesis (during gastrulation), the splanchnic 
mesoderm gives rise to hemangioblasts, which are presumed to be the common progenitors 
of ECs and blood cells (Baron, 2001; Choi, 2002), and subsequently the outer cells of the 
blood island differentiate into angioblasts. In the second phase, angioblasts differentiate into 
ECs. In the third and final phase, the ECs participate in tube formation, giving rise to the 
primitive vascular plexus (Figure 2). Growth factor, fibroblast growth factor 2 (FGF2) 
generates hemangioblasts from the mesoderm, whereas vascular endothelial growth factor 
(VEGF) and its receptor, VEGFR, cooperate in hemangioblast generation and tube 
formation, and Angiopoietin-1 (Ang-1) regulates the connection between ECs and pericytes 
(Hiratsuka, 2011). 
2.2 Angiogenesis 
Angiogenesis, the establishment of new vessels from a pre-existing vasculature, starts with 
stimulation of ECs that line the luminal surface of blood vessels. The process of angiogenesis 
can be classified into two types: “sprouting” and “nonsprouting” (Risau, 1997). Sprouting 
angiogenesis refers to a process that entails proteolytic degradation of the extracellular 
matrix, the migration and proliferation of cells, the formation of a lumen, and maturation of 
ECs into functional capillaries. Specifically, ECs in pre-existing vessels respond to activation 
by a stimulatory molecule supplied by neighboring cells (e.g. VEGF), by producing a 
protease that degrades the surrounding basement membrane, to facilitate EC migration 
towards stimulatory signal. The sprout is comprised of a growth-arrested leading tip cell 
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and proliferating stalk cells (Gerhardt et al., 2003). The tips cells are migratory and extend 
long filopodia that guide the sprouts towards the stimulus. Subsequently, the sprout 
anastomoses with other newly formed vessels to allow circulation. The basement membrane 
reassembles pericytes and gets recruited to newly formed vessels (Figure 2). Sprouting 
angiogenesis occurs during yolk sac and embryo development, and later during brain 
development (Scappaticci, 2002). Non-sprouting angiogenesis is a process that occurs by 
invagination involving EC proliferation within a vessel, and results in an enlarged lumen 
that can be split by transcapillary or by the fusion and splitting of capillaries. Non-sprouting 
angiogenesis occurs mainly during development of the lung and heart (Scappaticci, 2002).  
Both sprouting and non-sprouting angiogenesis contribute to vessel formation in the adult, 
via a process known as “adult vasculogenesis”. This process is thought to rely on 
endothelial progenitor cells (EPCs) that originate from the bone marrow. While circulating 
in the blood, EPCs are incorporated into vessels at the site of angiogenesis (Caplice and 
Doyle, 2005).  
 
Fig. 2. Schematic outline of vasculogenesis (above) and angiogenesis (below). Both 
sprouting and non-sprouting mechanism of angiogenesis are shown. 
2.3 Pathological angiogenesis 
The process of angiogenesis is highly regulated in healthy adults and occurs only rarely, for 
example during ovulation and the endometrial growth that is central to the menstrual cycle. 
Angiogenesis is also required for wound healing, and ceases once this process is completed. 
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protease that degrades the surrounding basement membrane, to facilitate EC migration 
towards stimulatory signal. The sprout is comprised of a growth-arrested leading tip cell 
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and proliferating stalk cells (Gerhardt et al., 2003). The tips cells are migratory and extend 
long filopodia that guide the sprouts towards the stimulus. Subsequently, the sprout 
anastomoses with other newly formed vessels to allow circulation. The basement membrane 
reassembles pericytes and gets recruited to newly formed vessels (Figure 2). Sprouting 
angiogenesis occurs during yolk sac and embryo development, and later during brain 
development (Scappaticci, 2002). Non-sprouting angiogenesis is a process that occurs by 
invagination involving EC proliferation within a vessel, and results in an enlarged lumen 
that can be split by transcapillary or by the fusion and splitting of capillaries. Non-sprouting 
angiogenesis occurs mainly during development of the lung and heart (Scappaticci, 2002).  
Both sprouting and non-sprouting angiogenesis contribute to vessel formation in the adult, 
via a process known as “adult vasculogenesis”. This process is thought to rely on 
endothelial progenitor cells (EPCs) that originate from the bone marrow. While circulating 
in the blood, EPCs are incorporated into vessels at the site of angiogenesis (Caplice and 
Doyle, 2005).  
 
Fig. 2. Schematic outline of vasculogenesis (above) and angiogenesis (below). Both 
sprouting and non-sprouting mechanism of angiogenesis are shown. 
2.3 Pathological angiogenesis 
The process of angiogenesis is highly regulated in healthy adults and occurs only rarely, for 
example during ovulation and the endometrial growth that is central to the menstrual cycle. 
Angiogenesis is also required for wound healing, and ceases once this process is completed. 
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Since vessels nourish nearly every organ of the body the strict limitation of angiogenesis to 
such contexts is essential; deviation from normal vessel growth – in either direction – leads 
to fatal disease. Excess angiogenesis is characteristic of conditions such as retinopathy, 
rheumatoid arthritis, psoriasis and tumor growth (Folkman, 1995), and insufficient 
angiogenesis is a feature of ischemic heart and limb disease, stroke and gastrointestinal 
ulcers (Carmeliet and Jain, 2000).  
The process of angiogenesis plays a crucial role in cancer metastasis – the major cause of 
mortality in cancer patients. In tumor diseases, angiogenesis is stimulated by the secretion of 
signaling molecules, e.g. VEGFA, by either the tumor cells themselves or tumor-infiltrating 
macrophages. In most cancers, tumor angiogenesis is crucial for disease progression, as it 
supplies the tumor cells with nutrients and oxygen, enabling them to survive and spread 
(Folkman, 2002). Notably, tumor-supporting vessels tend to be disorganized and leaky; thus 
vessel function is suboptimal and angiogenesis is further stimulated by hypoxia-driven 
expression of VEGFA in the tumor tissue. These findings have stimulated great interest in 
targeting tumor vessels as a means of developing novel cancer therapies. Indeed, intensive 
research efforts toward this end have revealed that, in patients with metastatic colorectal 
cancer, supplementing chemotherapy with a neutralizing antibody against VEGFA 
(Avastin/Bevacizumab) results in significantly improved survival (McCarthy, 2003). 
Angiogenesis can also be regulated by microRNA (miRNA) (Wang and Olson, 2009). 
MicroRNA is a class of highly conserved, single stranded, non-coding small RNAs 
influencing gene expression by inhibiting translation of protein from mRNA or by 
promoting the degradation of mRNA (Bartel, 2004; Kim, 2005). The direct evidence of 
miRNA importance in angiogenesis was provided by observation of defective vascular 
remodeling during developmental angiogenesis in hypomorphic mouse line with EC-
specific deletion of Dicer, one of key enzymes involved in miRNA generation (Otsuka et al., 
2008; Yang et al., 2005). Endothelial cell primarily express miRNA-221/222, miRNA-21, the 
Let-7 family, the miR-17-92 cluster, the miRNA-23-24 cluster, and miRNA-126 (Harris et al., 
2008; Kuehbacher et al., 2007; Suarez et al., 2007). miRNA-210 which gets activated upon 
hypoxia is an important regulator of EC survival, migration and differentiation during 
angiogenesis (Fasanaro et al., 2008). miRNA-210 overexpression under normoxic conditions 
stimulates angiogenesis and VEGF-induced cell migration whereas its blockade by anti-
mRNA inhibits tube formation stimulated by hypoxia (Fasanaro et al., 2008). miRNA-210 
may play an important role in pathological angiogenesis  since hypoxia is associated with 
tumor development and organ ischemia. miRNA-21 and miRNA-31 are the other pro-
angiogenic miRNAs which are upregulated in various various cancers to stimulate invasion 
and metastasis in cancer (Tsai et al., 2009). 
3. Ligands and receptors in angiogenesis 
At the molecular level, the initiation of vascular development is dependent on a number of 
cell-surface receptors and their respective ligands. Upon binding to a wide range of peptide 
growth factors, members of the receptor tyrosine kinase (RTK) family of transmembrane 
proteins transduce proliferative and morphogenic signals, thereby fine-tuning the 
orchestration of vascular remodeling and angiogenic processes. Although angiogenesis is 
controlled by a wide range of extracellular signals, the most potent pro-angiogenic signaling 
is initiated by binding of VEGF (vascular endothelial growth factor) to EC-resident VEGF 
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receptors (VEGFRs) like VEGFR1 [Flt (Fms-like tyrosine kinase)-1], VEGFR2 [Flk-1 (fetal 
liver kinase 1)/KDR (kinase insert domain receptor)] and VEGFR3 (Flt-4) (Zachary, 2003). 
Remodeling from existing vessels during angiogenesis is governed by VEGF-mediated EC 
proliferation, and their sprouting from points of loose contact between capillaries and the 
extracellular matrix. The nascent capillary network then matures through the actions of 
TGF-β and platelet-derived growth factor (PDGF). The arterial and venous ECs within the 
final primary capillary express Ephrin B2 and its receptor EphB4, respectively, in their cell 
membranes; this enables correct fusion between arterial and venous vessels. 
3.1 The VEGF-VEGFR system coordinates the process of angiogenesis 
3.1.1 VEGF 
The VEGF family is a branch of the PDGF/VEGF supergene family and its members have a 
homodimeric structure (Ferrara and Davis-Smyth, 1997). The VEGF family consists of five 
related growth factors: VEGFA, VEGFB, VEGFC, VEGFD and PlGF (placental growth 
factor). Although VEGFs are homodimeric polypeptides, naturally occurring heterodimers 
have also been reported (DiSalvo et al., 1995). VEGFA, which was also isolated as vascular 
permeability factor (VPF), is alternatively spliced to generate VEGFA121, VEGFA145, 
VEGFA165 and VEGFA189 (the numbers indicate final residue in each polypeptide in 
humans). Alternative splicing and processing regulates ligand binding to VEGF receptors, 
heparan sulfate and neuropilins (NRPs) (Grunewald et al., 2010). VEGFA165 and VEGFA189 
bind to both heparan sulfate and NRP1. VEGFA plays an important role in the proliferation 
and migration of ECs, and also acts on monocytes and macrophages, neurons, cancer cells, 
and kidney epithelial cells. VEGFA is known to be regulated by hypoxia-inducible factor 
(HIF) (Germain et al., 2010), an event that leads to increased expression during embryonic 
development and wound healing, and also in the context of cancer. VEGFA produced by 
most parenchymal cells, act in paracrine manner on adjacent ECs to regulate signaling by 
the VEGF receptors. Autocrine VEGFA is essential for EC survival (Lee et al., 2007), and is 
consistent with their requirement for complete development of the vasculature in mice; both 
homozygosity and heterozygosity for knockout of the VEGFA gene result in embryonic 
lethality characterized by incomplete development of the vasculature (Carmeliet et al., 1996; 
Ferrara et al., 1996). The biological activity of VEGF is manifested after it binds to VEGF 
receptors, which are of 3 different types in human, and bind VEGF with distinct affinities. 
3.2 VEGF receptors 
Orthologs of each of the VEGF receptor tyrosine kinases (VEGFRs) – namely VEGFR1, 
VEGFR2 and VEGFR3 – have been identified in humans, mice and other mammals. 
Structurally, the VEGFRs have a common organization consisting of: an extracellular, 
ligand-binding domain that features 7 immunoglobulin (Ig)–like loops, a transmembrane 
domain; a juxtamembrane domain; a split kinase domain and a C-terminal tail (Figure 3). 
Structurally, the VEGFRs are distantly related to the PDGFRs, which have five extracellular 
Ig-like domains (Matthews et al., 1991; Terman et al., 1991). All three VEGFRs undergo 
alternative splicing to generate more than one receptor form. The truncated form of 
VEGFR1, known as soluble VEGFR1 (sVEGR1, sFlt-1) (Kendall and Thomas, 1993), is 
implicated as causative agent in preeclampsia, a major disorder that can occur during 
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Since vessels nourish nearly every organ of the body the strict limitation of angiogenesis to 
such contexts is essential; deviation from normal vessel growth – in either direction – leads 
to fatal disease. Excess angiogenesis is characteristic of conditions such as retinopathy, 
rheumatoid arthritis, psoriasis and tumor growth (Folkman, 1995), and insufficient 
angiogenesis is a feature of ischemic heart and limb disease, stroke and gastrointestinal 
ulcers (Carmeliet and Jain, 2000).  
The process of angiogenesis plays a crucial role in cancer metastasis – the major cause of 
mortality in cancer patients. In tumor diseases, angiogenesis is stimulated by the secretion of 
signaling molecules, e.g. VEGFA, by either the tumor cells themselves or tumor-infiltrating 
macrophages. In most cancers, tumor angiogenesis is crucial for disease progression, as it 
supplies the tumor cells with nutrients and oxygen, enabling them to survive and spread 
(Folkman, 2002). Notably, tumor-supporting vessels tend to be disorganized and leaky; thus 
vessel function is suboptimal and angiogenesis is further stimulated by hypoxia-driven 
expression of VEGFA in the tumor tissue. These findings have stimulated great interest in 
targeting tumor vessels as a means of developing novel cancer therapies. Indeed, intensive 
research efforts toward this end have revealed that, in patients with metastatic colorectal 
cancer, supplementing chemotherapy with a neutralizing antibody against VEGFA 
(Avastin/Bevacizumab) results in significantly improved survival (McCarthy, 2003). 
Angiogenesis can also be regulated by microRNA (miRNA) (Wang and Olson, 2009). 
MicroRNA is a class of highly conserved, single stranded, non-coding small RNAs 
influencing gene expression by inhibiting translation of protein from mRNA or by 
promoting the degradation of mRNA (Bartel, 2004; Kim, 2005). The direct evidence of 
miRNA importance in angiogenesis was provided by observation of defective vascular 
remodeling during developmental angiogenesis in hypomorphic mouse line with EC-
specific deletion of Dicer, one of key enzymes involved in miRNA generation (Otsuka et al., 
2008; Yang et al., 2005). Endothelial cell primarily express miRNA-221/222, miRNA-21, the 
Let-7 family, the miR-17-92 cluster, the miRNA-23-24 cluster, and miRNA-126 (Harris et al., 
2008; Kuehbacher et al., 2007; Suarez et al., 2007). miRNA-210 which gets activated upon 
hypoxia is an important regulator of EC survival, migration and differentiation during 
angiogenesis (Fasanaro et al., 2008). miRNA-210 overexpression under normoxic conditions 
stimulates angiogenesis and VEGF-induced cell migration whereas its blockade by anti-
mRNA inhibits tube formation stimulated by hypoxia (Fasanaro et al., 2008). miRNA-210 
may play an important role in pathological angiogenesis  since hypoxia is associated with 
tumor development and organ ischemia. miRNA-21 and miRNA-31 are the other pro-
angiogenic miRNAs which are upregulated in various various cancers to stimulate invasion 
and metastasis in cancer (Tsai et al., 2009). 
3. Ligands and receptors in angiogenesis 
At the molecular level, the initiation of vascular development is dependent on a number of 
cell-surface receptors and their respective ligands. Upon binding to a wide range of peptide 
growth factors, members of the receptor tyrosine kinase (RTK) family of transmembrane 
proteins transduce proliferative and morphogenic signals, thereby fine-tuning the 
orchestration of vascular remodeling and angiogenic processes. Although angiogenesis is 
controlled by a wide range of extracellular signals, the most potent pro-angiogenic signaling 
is initiated by binding of VEGF (vascular endothelial growth factor) to EC-resident VEGF 
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receptors (VEGFRs) like VEGFR1 [Flt (Fms-like tyrosine kinase)-1], VEGFR2 [Flk-1 (fetal 
liver kinase 1)/KDR (kinase insert domain receptor)] and VEGFR3 (Flt-4) (Zachary, 2003). 
Remodeling from existing vessels during angiogenesis is governed by VEGF-mediated EC 
proliferation, and their sprouting from points of loose contact between capillaries and the 
extracellular matrix. The nascent capillary network then matures through the actions of 
TGF-β and platelet-derived growth factor (PDGF). The arterial and venous ECs within the 
final primary capillary express Ephrin B2 and its receptor EphB4, respectively, in their cell 
membranes; this enables correct fusion between arterial and venous vessels. 
3.1 The VEGF-VEGFR system coordinates the process of angiogenesis 
3.1.1 VEGF 
The VEGF family is a branch of the PDGF/VEGF supergene family and its members have a 
homodimeric structure (Ferrara and Davis-Smyth, 1997). The VEGF family consists of five 
related growth factors: VEGFA, VEGFB, VEGFC, VEGFD and PlGF (placental growth 
factor). Although VEGFs are homodimeric polypeptides, naturally occurring heterodimers 
have also been reported (DiSalvo et al., 1995). VEGFA, which was also isolated as vascular 
permeability factor (VPF), is alternatively spliced to generate VEGFA121, VEGFA145, 
VEGFA165 and VEGFA189 (the numbers indicate final residue in each polypeptide in 
humans). Alternative splicing and processing regulates ligand binding to VEGF receptors, 
heparan sulfate and neuropilins (NRPs) (Grunewald et al., 2010). VEGFA165 and VEGFA189 
bind to both heparan sulfate and NRP1. VEGFA plays an important role in the proliferation 
and migration of ECs, and also acts on monocytes and macrophages, neurons, cancer cells, 
and kidney epithelial cells. VEGFA is known to be regulated by hypoxia-inducible factor 
(HIF) (Germain et al., 2010), an event that leads to increased expression during embryonic 
development and wound healing, and also in the context of cancer. VEGFA produced by 
most parenchymal cells, act in paracrine manner on adjacent ECs to regulate signaling by 
the VEGF receptors. Autocrine VEGFA is essential for EC survival (Lee et al., 2007), and is 
consistent with their requirement for complete development of the vasculature in mice; both 
homozygosity and heterozygosity for knockout of the VEGFA gene result in embryonic 
lethality characterized by incomplete development of the vasculature (Carmeliet et al., 1996; 
Ferrara et al., 1996). The biological activity of VEGF is manifested after it binds to VEGF 
receptors, which are of 3 different types in human, and bind VEGF with distinct affinities. 
3.2 VEGF receptors 
Orthologs of each of the VEGF receptor tyrosine kinases (VEGFRs) – namely VEGFR1, 
VEGFR2 and VEGFR3 – have been identified in humans, mice and other mammals. 
Structurally, the VEGFRs have a common organization consisting of: an extracellular, 
ligand-binding domain that features 7 immunoglobulin (Ig)–like loops, a transmembrane 
domain; a juxtamembrane domain; a split kinase domain and a C-terminal tail (Figure 3). 
Structurally, the VEGFRs are distantly related to the PDGFRs, which have five extracellular 
Ig-like domains (Matthews et al., 1991; Terman et al., 1991). All three VEGFRs undergo 
alternative splicing to generate more than one receptor form. The truncated form of 
VEGFR1, known as soluble VEGFR1 (sVEGR1, sFlt-1) (Kendall and Thomas, 1993), is 
implicated as causative agent in preeclampsia, a major disorder that can occur during 
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pregnancy (Levine et al., 2004). A naturally occurring soluble form of VEGFR2 has also been 
described; it could potentially arise as a result of alternative splicing or through proteolytic 
processing (Ebos et al., 2004). In humans, alternative splicing of VEGFR3 generates two 
isoforms with distinct C-terminal tails (Hughes, 2001). 
 
Fig. 3. VEGF receptors and their ligands. Schematic presentation of VEGF receptors 
(VEGFR1, VEGFR2 and VEGFR3). The signaling domain of all three receptors is present 
within cytosol. The Ig-like domains of VEGFRs are involved in VEGF binding, shown in 
elliptical structures that are present extracellularly. More than one kind of VEGF can bind to 
one receptor with different affinities. 
3.2.1 VEGFR1 
VEGFR1  (also known as Flt1 in mouse) is a glycoprotein of 150-184 kDa (de Vries et al., 
1992; Shibuya et al., 1990) that gets activated upon binding of VEGFA, VEGFB and PLGF. 
VEGFR1 is expressed in vascular ECs at relatively high levels, throughout development and 
in the adult (Peters et al., 1993). It is also expressed in various other cell types such as 
monocytes, macrophages, human trophoblasts, renal mesangial cells, vascular smooth 
muscle cells, dendritic cells and a variety of human tumor-cell types (Barleon et al., 1996; 
Dikov et al., 2005; Sawano et al., 2001).  
Alternative splicing of VEGFR1 generates soluble VEGFR1 (sVEGFR1), which is abundantly 
expressed in the placenta. Although the affinity of VEGFR1 for VEGFA is greater than that 
of VEGFR2, VEGFR1 transduces only weak signals for EC and pericyte growth and survival, 
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as well as for macrophage migration (Barleon et al., 1996; Nomura et al., 1995). In response 
to ligand binding, VEGFR1 undergoes autophosphorylation at various tyrosines within the 
intracellular domain (TYRs1169, 1213, 1242, 1327, 1333) (Ito et al., 1998; Sawano et al., 1997). 
Phosphorylation of TYR1169 allows binding and activation of phospholipase C (PLC)1, 
which regulates EC proliferation via the mitogen-activated protein kinase (MAPK) pathway 
(Sawano et al., 1997). Tyr1213 binds a variety of SH2-containing proteins, including PLCγ, 
growth-factor-receptor bound protein (GRB) 2, non-catalytic region of tyrosine kinase 
adaptor protein (Nck) and SH2-domain-containing protein tyrosine phosphatase 2 (SHP-2) 
(Igarashi et al., 1998; Ito et al., 1998). Tyr1309 is however phosphorylated in response to 
PLGF but not VEGF (Autiero et al., 2003) (Figure 4).  Although the exact role of VEGFR1  
 
Fig. 4. VEGFR1 tyrosine phosphorylation and signaling. Schematic presentation of 
intracellular dimerized VEGFR1. VEGFA/VEGFB binding induces tyrosine phosphorylation 
of VEGFR1 at different tyrosine (TYR) positions shown in yellow ellipses. PLGF binding 
stimulates phosphorylation at TYR1309 shown in orange ellipse. Signaling molecules 
(shown within boxes) binds to certain phosphorylated tyrosine residues (circled P) and 
activates downstream signaling events leading to specific physiological outcome (shown in 
purple boxes) required for vascular permeability and endothelial cell regulation. PLCγ, 
phospholipase C-γ; MAPK, mitogen-activated protein; RACK1, receptor for activated C-
kinase 1; SHP2, SH2-domain-containing protein tyrosine phosphatase 2. 
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as well as for macrophage migration (Barleon et al., 1996; Nomura et al., 1995). In response 
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remains a subject of debate, studies using VEGFR1-neutralizing antibodies have implicated 
this receptor in actin reorganization within, and the migration of ECs (Kanno et al., 2000), 
and suggested that receptor for activated C-kinase 1 (RACK1) is its downstream effector in 
this context (Wang et al., 2011). VEGFR1-dependent activation of PI3K/Akt may play a role 
in EC differentiation and organization (Huang et al., 2001) (Figure 4). Under in vitro 
conditions, VEGFR1 and VEGFR2 are known to form heterodimers on cells co-expressing 
these receptors (Huang et al., 2001), so it is believed that VEGFR1 can regulate EC functions 
via cross-talk with VEGFR2, through dimerization as a result of VEGFA binding to both. 
Binding of PLGF can also lead to crosstalk between VEGFR2 and VEGFR1 through 
transphosphorylation, leading to sensitization of VEGFR2 subsequent to activation by 
VEGFA (Autiero et al., 2003). Soluble VEGFR1 (sVEGFR1, sFlt1) can negatively influence 
vascular development, either by sequestering VEGFA from signaling receptors or by 
forming non-functional heterodimers with VEGFR2 (Kendall et al., 1994). Although, 
VEGFR1 and sVEGFR1 are considered VEGF decoys that control signaling by VEGFR1 and 
the formation of angiogenic sprouts (Kappas et al., 2008), the importance of VEGFR1 in 
angiogenesis is demonstrated by the fact that the VEGR1 null (vegfr1-/-) mouse dies at 
embryonic day 9, due to increased proliferation of ECs, disorganization and dysfunction of 
the vascular system (Fong et al., 1995). 
3.2.2 VEGFR2 
VEGFR2 (also known as KDR or Flk-1) is generally accepted to be the main receptor tyrosine 
kinase responsible for transducing the angiogenic activities of VEGFA, a factor that stimulates 
vascular-cell survival/growth and promotes angiogenesis. VEGFR2 knockout results in 
embryonic lethality due to deficiencies in vasculogenesis and hematopoiesis (Shalaby et al., 
1995). VEGFR2 is highly expressed in vascular endothelial progenitors during early 
embryogenesis and generates a variety of angiogenic signals, not only for the proliferation of 
ECs but also their migration and morphogenesis, and as such has an important role in vascular 
tube formation. VEGFR2 expression is upregulated under conditions that trigger pathological 
angiogenesis, such as in tumors (reviewed in (Matsumoto and Claesson-Welsh, 2001). The 
binding of VEGF to VEGFR2 leads to receptor dimerization and promotes EC differentiation, 
proliferation, migration and vascular-tube formation. Both homo- and heterodimerization 
occurs following the trans-phosphorylation of tyrosine in the receptor intracellular domain. 
The major phosphorylation sites on VEGFR2 are TYR951 (in the kinase-insert domain), 
TYR1054 and TYR1059 (within the kinase domain), and TYR1175 and TYR1214 (in the C-
terminal domain) (Matsumoto et al., 2005; (Takahashi et al., 2001). Additional phosphorylation 
sites on VEGFR2 have been identified at postions 1223, 1305, 1309 and 1319, but their function 
remains to be established (Matsumoto et al., 2005). Although TYR801 within the 
juxtamembrane can be phosphorylated when the intracellular portion of VEGFR2 is tested in 
isolation (Solowiej et al., 2009), its phosphorylation in the context of the intact protein has not 
yet been demonstrated. Phosphorylation at TYR951, within the kinase-insert domain, leads to 
binding and tyrosine  phosphorylation of the SH2-domain–containing signaling molecule T-
cell specific adapter (TSAd)(Matsumoto et al., 2005). TSAd, which is equipped with Src 
Homology 2 (SH2) and protein tyrosine binding (PTB) domains, in turn associates with the 
cytoplasmic tyrosine kinase Src, thereby regulating actin stress fiber organization and the 
migratory responses of ECs to VEGFA (Figure 5). Phosphorylation at TYR1054 and TYR1059, 
both of which are located within the kinase domain activation loop (Kendall et al., 1999), is 
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preceded by autophosphorylation at TYR801 (Solowiej et al., 2009). Phosphorylation at 
TYR1059 induces Src binding, which in turn phosphorylates TYR1175 of VEGFR2, as well as 
residues within downstream signal transducers, such as the actin binding protein IQ-motif-
contaning GTPase-activating protein 1 (IQGAP1), which is implicated in the regulation of cell-
cell contacts, proliferation and migration (Meyer et al., 2008; Yamaoka-Tojo et al., 2006). 
 
Fig. 5. VEGFR2 tyrosine phosphorylation and signaling. Schematic presentation of 
dimerized VEGFR2. VEGFA/VEGFB/VEGFC binding induces tyrosine phosphorylation of 
VEGFR2 at different tyrosine (TYR) positions shown in ellipses. Signaling molecules (shown 
within boxes) binds to certain phosphorylated TYR residues (circled P) and activates 
network of downstream signaling events required for variety of physiological outcomes 
(shown in purple boxes) essential during vasculogenesis and angiogenesis. 
Phosphorylation at TYR1175 is required for the binding of PLC, which mediates activation 
of the mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinase-1/2 
(ERK1/2) cascade and the proliferation of ECs (Takahashi et al., 2001). Binding of PLC 
stimulates the protein kinase C (PKC) pathway, leading to inositol triphosphate generation 
and calcium mobilization. In addition to interacting with PLC, phosphorylated TYR1175 
binds to the SH2-domain–containing adaptor protein B (SHB) and Src homology and 
collagen homology (Sck/SHC) (Holmqvist et al., 2004; Warner et al., 2000). SHB binds to 
Tyrosine-phosphorylated focal adhesion kinase (FAK) in VEGF-treated cells (Abu-Ghazaleh 
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remains a subject of debate, studies using VEGFR1-neutralizing antibodies have implicated 
this receptor in actin reorganization within, and the migration of ECs (Kanno et al., 2000), 
and suggested that receptor for activated C-kinase 1 (RACK1) is its downstream effector in 
this context (Wang et al., 2011). VEGFR1-dependent activation of PI3K/Akt may play a role 
in EC differentiation and organization (Huang et al., 2001) (Figure 4). Under in vitro 
conditions, VEGFR1 and VEGFR2 are known to form heterodimers on cells co-expressing 
these receptors (Huang et al., 2001), so it is believed that VEGFR1 can regulate EC functions 
via cross-talk with VEGFR2, through dimerization as a result of VEGFA binding to both. 
Binding of PLGF can also lead to crosstalk between VEGFR2 and VEGFR1 through 
transphosphorylation, leading to sensitization of VEGFR2 subsequent to activation by 
VEGFA (Autiero et al., 2003). Soluble VEGFR1 (sVEGFR1, sFlt1) can negatively influence 
vascular development, either by sequestering VEGFA from signaling receptors or by 
forming non-functional heterodimers with VEGFR2 (Kendall et al., 1994). Although, 
VEGFR1 and sVEGFR1 are considered VEGF decoys that control signaling by VEGFR1 and 
the formation of angiogenic sprouts (Kappas et al., 2008), the importance of VEGFR1 in 
angiogenesis is demonstrated by the fact that the VEGR1 null (vegfr1-/-) mouse dies at 
embryonic day 9, due to increased proliferation of ECs, disorganization and dysfunction of 
the vascular system (Fong et al., 1995). 
3.2.2 VEGFR2 
VEGFR2 (also known as KDR or Flk-1) is generally accepted to be the main receptor tyrosine 
kinase responsible for transducing the angiogenic activities of VEGFA, a factor that stimulates 
vascular-cell survival/growth and promotes angiogenesis. VEGFR2 knockout results in 
embryonic lethality due to deficiencies in vasculogenesis and hematopoiesis (Shalaby et al., 
1995). VEGFR2 is highly expressed in vascular endothelial progenitors during early 
embryogenesis and generates a variety of angiogenic signals, not only for the proliferation of 
ECs but also their migration and morphogenesis, and as such has an important role in vascular 
tube formation. VEGFR2 expression is upregulated under conditions that trigger pathological 
angiogenesis, such as in tumors (reviewed in (Matsumoto and Claesson-Welsh, 2001). The 
binding of VEGF to VEGFR2 leads to receptor dimerization and promotes EC differentiation, 
proliferation, migration and vascular-tube formation. Both homo- and heterodimerization 
occurs following the trans-phosphorylation of tyrosine in the receptor intracellular domain. 
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yet been demonstrated. Phosphorylation at TYR951, within the kinase-insert domain, leads to 
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preceded by autophosphorylation at TYR801 (Solowiej et al., 2009). Phosphorylation at 
TYR1059 induces Src binding, which in turn phosphorylates TYR1175 of VEGFR2, as well as 
residues within downstream signal transducers, such as the actin binding protein IQ-motif-
contaning GTPase-activating protein 1 (IQGAP1), which is implicated in the regulation of cell-
cell contacts, proliferation and migration (Meyer et al., 2008; Yamaoka-Tojo et al., 2006). 
 
Fig. 5. VEGFR2 tyrosine phosphorylation and signaling. Schematic presentation of 
dimerized VEGFR2. VEGFA/VEGFB/VEGFC binding induces tyrosine phosphorylation of 
VEGFR2 at different tyrosine (TYR) positions shown in ellipses. Signaling molecules (shown 
within boxes) binds to certain phosphorylated TYR residues (circled P) and activates 
network of downstream signaling events required for variety of physiological outcomes 
(shown in purple boxes) essential during vasculogenesis and angiogenesis. 
Phosphorylation at TYR1175 is required for the binding of PLC, which mediates activation 
of the mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinase-1/2 
(ERK1/2) cascade and the proliferation of ECs (Takahashi et al., 2001). Binding of PLC 
stimulates the protein kinase C (PKC) pathway, leading to inositol triphosphate generation 
and calcium mobilization. In addition to interacting with PLC, phosphorylated TYR1175 
binds to the SH2-domain–containing adaptor protein B (SHB) and Src homology and 
collagen homology (Sck/SHC) (Holmqvist et al., 2004; Warner et al., 2000). SHB binds to 
Tyrosine-phosphorylated focal adhesion kinase (FAK) in VEGF-treated cells (Abu-Ghazaleh 
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et al., 2001) and thereby contributes to EC attachment and migration (Holmqvist et al., 2003). 
The binding of SHC to TYR1175-phosphorylated VEGFR2 is believed to control Ras 
activation and mitogenicity in response to VEGF (Meadows et al., 2001). 
3.2.3 VEGFR3  
VEGFR3, also denoted Flt4, is a protein with a molecular weight of around 195 kDa, and 
becomes activated when bound to VEGFC or VEGFD. VEGFR3 is an essential protein; its 
inactivation results in embryonic death at E9.5, due to abnormal remodeling of the primary 
vascular plexus (Dumont et al., 1998). Although VEGFR3 plays a role in vascular 
development in the early embryo, its expression is later largely confined to ECs of the 
lymphatic system (Kaipainen et al., 1995). The exception is when its expression is induced in 
vascular ECs during active phases of angiogenesis, for example in the tumor vasculature or 
the endothelial tip cells of angiogenic sprouts in the retina (Tammela et al., 2008). VEGFR3 
has five tyrosine phosphorylation sites – at positions 1230, 1231, 1265, 1337 and 1363 in the 
C-terminal tail (Dixelius et al., 2003) – that are activated and phosphorylated upon binding 
of VEGFC or VEGFD. TYR1337 when phosphorylated is known to bind to Shc and Grb2 to 
initiate signaling by the MAPK pathway. Both TYR1063 and TYR1068, which are located 
within the kinase activation domain, are crucial for kinase activity. Phosphorylation of 
TYR1230 and TYR1231 creates a docking site for SHC–GBR2, which promotes signaling by 
the ERK1/2 and PI3K/Akt pathways (Figure 6). Phosphorylated TYR1063 has been shown 
to interact with adaptor protein C10 regulator of kinase (CRK I/II), which activates the c-Jun 
N-terminal kinase (JNK) pathway to promote cell survival (Salameh et al., 2005). 
3.2.4 Neuropilins (NRP) 
The cell-surface glycoprotein neuropilin is a transmembrane protein with a small 
cytoplasmic tail that lacks intrinsic catalytic function (Fujisawa et al., 1997). The neuropilin 
homolog NRP1 is expressed in arteries, whereas NRP2, is expressed in the venous and 
lymphatic vessels (Yuan et al., 2002). NRP1 was originally identified as a receptor for the 
collapsin/semaphorin family of neuronal guidance molecule (Chen et al., 1997). Later it was 
reported to also be expressed in ECs, where it acts as a coreceptor for VEGFA164 and 
VEGFA165 in mice and humans, respectively (Miao et al., 1999; Soker et al., 1998). NRP1 
modulates VEGFR signaling, leading to enhanced survival and migration of ECs in vitro 
(Favier et al., 2006). NRP1 has also been implicated in VEGFR2-mediated vascular 
permeability (Becker et al., 2005) and VEGFA-induced vessel sprouting and branching 
(Kawamura et al., 2008). Although the exact influence of NRP1 on VEGFA mediated 
VEGFR2 signaling remains to be deciphered, the importance of NRP1 in angiogenesis was 
established by the fact that overexpression or deletion of NRP1 in mice leads to embryonic 
lethality and vascular abnormalities (Kawasaki et al., 1999). Neuropilin is also expressed in 
tumors and is believed to enhance tumor angiogenesis (Miao et al., 2000); it probably does 
so by stabilizing VEGF/VEGFR signaling on adjacent cell in trans. 
3.3 Role of the extracellular matrix (ECM) in endothelial-cell interactions during 
angiogenesis 
The angiogenic process is influenced not only by ligand/receptor systems, but also overall 
composition of extracellular matrix (ECM) surrounding the vasculature. Indeed, the ECM 
 




Fig. 6. VEGFR3 tyrosine phosphorylation and signaling. Schematic presentation of 
intracellular dimerized VEGFR3. VEGFC/VEGFD binding induces tyrosine 
phosphorylation of VEGFR3 at different tyrosine (TYR) positions shown in green ellipses. 
Signaling molecules (shown within boxes) binds to certain phosphorylated tyrosine residues 
(circled P) and activates network of downstream signaling events required for variety of 
physiological outcomes (shown in purple boxes) essential during vasculogenesis and 
angiogenesis 
provides an essential connection between ECs and the surrounding tissues and affect 
angiogenesis either positively or negatively (Nyberg et al., 2005). ECs are attached to a 
basement membrane (BM), which forms a continuous coat around the vessels. The main 
components of the vascular BM are type IV collagen, laminins, fibronectin, heparan-
sulphate proteoglycans and nidogens. The BM provides structural support to the ECs 
(Kalluri, 2003), and interaction of ECs with components in the BM is important for 
maintaining integrity of the vessel wall (Hallmann et al., 2005). When ECs are exposed to 
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angiogenic growth factors such as VEGFA, several kind of matrix-degrading enzymes, such 
as matrix metalloproteinases, dissolve the BM. Matrix-degrading enzymes are produced by 
ECs and stromal cells, as well as by tumor and inflammatory cells (Egeblad and Werb, 2002). 
Endothelial sprouting is activated not only by growth factors, but also signals from the 
matrix proteins. Degradation of the BM reveals so-called cryptic sites that can activate the 
angiogenic properties of ECs. As the BM is degraded and vascular permeability increases, 
the blood-clotting protein fibrinogen leaks out of the vessels and polymerizes into a fibrin 
gel (Iivanainen et al., 2003). Constituents of the degraded BM, fibrin, and EC-produced 
extracellular matrix (ECM) components then form a provisional matrix that ECs invade with 
guidance from both growth factors and matrix proteins. Once through the provisional 
matrix, the endothelial sprout further invades the interstitial matrix, which is composed of 
many proteins including fibrillar collagens (such as collagen I) and fibronectin. These 
proteins may also promote angiogenesis, collagen I for example, has pro-angoigenic effects 
(Davis and Senger, 2005; Senger et al., 2002). The signals from the ECM are transmitted by 
cell-surface expressed adhesion receptors called integrins, which bind to different ECM 
proteins in a specific manner (Stupack and Cheresh, 2004). In conjunction with the fusion of 
newly formed vessel sprouts to allow perfusion, the BM reassembles and pericytes are 
recruited to the vessel. ECs recruit pericytes by secreting PDGF, which binds to the PDGF-
receptor expressed on pericytes; this process is crucial for vessel stabilization, and lack of 
pericyte engagement causes remodelling defects and leaky vessels (Uemura et al., 2002) 
3.4 Role of Integrin in endothelial-cell dynamics during angiogenesis 
Integrins are heterodimeric transmembrane glycoproteins consisting of non-covalently 
associated  and  subunits, and they promote cell-matrix adhesion and migration on the 
surrounding ECM. Integrins have no intrinsic enzymatic or kinase activity, but activate 
signaling pathways by co-clustering with kinases and adaptor proteins in a focal adhesion 
complex comprising: protein kinases such as FAK and Src; adaptor proteins such as Shc; 
signaling intermediates such as GTPases of the Rho family; and actin-binding cytoskeletal 
proteins such as talin, -actinin, paxillin, tensin and vinculin (Mitra et al., 2005; Mitra and 
Schlaepfer, 2006). Integrin signaling promotes cell migration, proliferation and survival 
(Avraamides et al., 2008). Eighteen α and eight β subunits can associate to form 24 unique 
integrin heterodimers. EC integrins that regulate cell growth, survival and migration 
during angiogenesis include heterodimers α1β1, α2β1, α4β1, α5β1, α6β1, α6β4, α9β1, αvβ3 
and αvβ5 (Avraamides et al., 2008). Integrin αvβ3 (a receptor for RGD-containing ECM 
proteins such as vitronectin, fibronectin, fibrinogen and osteopontin) was the first αv 
integrin shown to regulate EC survival and migration during angiogenesis. The 
expresssion of αvβ3 integrin on resting ECs is negligible, but is upregulated by the 
presence of angiogenic growth factors such as bFGF, TNFα and IL8 (Brooks et al., 1994). 
Integrin αvβ3 also regulate pathological angiogenesis during processes such as wound 
healing. The VEGFR2–αvβ3-integrin association is important for full VEGFR2 signaling 
activity, for activation of p38MAPK and FAK, and for the recruitment of actin-binding 
vinculin as needed to initiate EC migration (Mahabeleshwar et al., 2008). The ligation of 
endothelial αvβ3 integrin has also been shown to activate FAK, Src, and other kinases, 
resulting in cell proliferation, differentiation and migration (Eliceiri et al., 2002). Whereas 
αvβ3 dimers initiate angiogenesis in response to bFGF and TNFα, the related integrin 
αvβ5 is required for TNFα- and VEGF-mediated angiogenesis (Friedlander et al., 1995). β1 
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integrin, which pairs with variety of  integrin subunits, plays an important role in 
angiogenesis. Mice with EC-specific deletion of β1 integrin die during embryonic stages 
due to severe vascular defects (Tanjore et al., 2008). Matrix-bound VEGF induces the 
formation of a complex between VEGFR2 and β1 integrin, which leads to prolonged 
phosphorylation of VEGFR2 at TYR 1214 and association of β1 integrin with focal 
adhesions (Chen et al., 2010). 
Fibronectin secreted by ECs is a key ECM component. It is deposited by ECs during 
normal and tumor angiogenesis (Clark et al., 1982; Kim et al., 2000). Fibronectin interacts 
with integrins such as α5β1, αvβ5 and αvβ3 (Plow et al., 2000). During embryonic 
vascular development, as well as during tumor angiogenesis, the ECM protein fibronectin 
serves as an adhesive support and signals through α5β1 integrin to regulate the 
spreading, migration and contractility of ECs (Francis et al., 2002). Although the 
expression of α5β1 in quiescent endothelium is low, it is upregulated by exposure to a 
subset of angiogenic stimuli including bFGF, IL8 and the ECM protein (Kim et al., 2000). 
Integrin α5β1 promotes EC migration and survival in in vivo and in vitro models of 
angiogenesis by suppressing the activity of protein kinase A (PKA) (Kim et al., 2000b(Kim 
et al., 2002). Further, our recent study has demonstrated that integrin α5β1 recycling is 
essential for EC adhesion and migration on fibronectin (Tiwari et al., 2011), a process 
required during angiogenesis. Integrin α5β1 promotes the formation of focal adhesions 
and signaling through FAK (Schlaepfer and Hunter, 1998), which is required for EC 
migration (Mitra et al., 2005). The reduction in EC surface associated adhesion through 
integrin α5β1 in the context of impaired recycling leads to further reduction in total and 
activated FAK (Tiwari et al., 2011). During embryogenesis, integrin α5 is required for the 
development of early blood vessels and other tissues, as revealed by the fact that α5 
integrin-deficient mice exhibit a mesodermal defect and are embryonic lethal (Yang et al., 
1993). Integrin α4β1, another fibronectin receptor, affects the adhesion and extravasation 
of lymphocytes by binding to VCAM1, a member of the immunoglobulin superfamily, 
that is expressed on inflamed ECs. Deletion of integrin α4 in a mouse model leads to 
defects in plancentation, heart development and coronary artery development, and thus 
to embryonic lethality (Yang et al., 1995). Integrin α4β1 promotes adhesion of the 
endothelium to VCAM1-expressing vascular smooth muscle cells during blood vessel 
formation (Garmy-Susini et al., 2005). Integrin α4β1–VCAM1 facilitates cell-cell 
attachment between ECs expressing the pericyte chemoattractant PDGF and pericytes 
expressing VEGF, in response to growth and survival signals that emanate from each cell 
type during angiogenesis (Garmy-Susini et al., 2005). Integrin α9β1 is another fibronectin-
binding integrin known to have role in angiogenesis (Vlahakis et al., 2007). Although 
structurally similar to integrin α4β1, integrin α9β1 can bind to a number of ECM proteins 
and cell-surface receptors including tenascin C, thrombospondin, osteopontin, fibronectin, 
VCAM1 and other ligands (Liao et al., 2002; Marcinkiewicz et al., 2000; Staniszewska et 
al., 2007). α4β1 binds only to VEGF, and promotes VEGFA-induced angiogenesis. β1 
integrin, which pairs with variety of alpha integrin subunits, plays a key role in 
angiogenesis.  Mice with an EC-specific deletion of β1 integrin die at embryonic stages 
due to a severe vascular defect (Tanjore et al., 2008). Matrix-bound VEGF induces the 
formation of complex between VEGFR2 and β1 integrin, which leads to prolonged 
phosphorylation of VEGFR2 at TYR 1214 and to an association of β1 integrin with focal 
adhesions (Chen et al., 2010). 
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4. Membrane trafficking 
Membrane trafficking is an active process that relocates proteins from one region of a cell to 
another, and contributes to the regulation of cell migration (Ulrich and Heisenberg, 2009). 
Signaling by the membrane-resident proteins/receptors is regulated by their availability at 
the cell surface or correct locations that are controlled by membrane trafficking events. The 
trafficking of membrane receptors and their signaling are intertwined: trafficking itself 
affects signal transduction, and signaling by RTKs regulates the trafficking machinery 
(Sorkin and von Zastrow, 2009). The secretory and endocytic pathways, which are made up 
of a network of membrane-bound compartments, modify newly synthesized proteins, 
deliver them to their appropriate locations, and regulate the uptake and turnover of those 
that are targeted to the cell surface. Trafficking accomplishes the specific and regulated 
transfer of molecules between distinct membrane-enclosed organelles. The transport process 
involves the budding of vesicular or tubular carriers from donor membranes, followed by 
their delivery to specific acceptor membranes. Budding requires the formation of cargo-
laden vesicles or tubules at a donor compartment, and also the involvement of (i) specific 
coat proteins like COPI or COPII; (ii) adaptor proteins such as clathrin, AP-1, 2, 3; and (iii) 
membrane-deforming proteins like Bar-family proteins (Doherty and McMahon, 2009). The 
cargo-containing donor vesicle then docks to the acceptor compartment with the help of rab 
GTPases and a tether. Finally, fusion of the donor and acceptor membranes for the delivery 
of the cargo is accomplished with the help of N-ethylmaleimide-sensitive factor (NSF)-
attachment protein receptor (SNARE) protein complexes (Jahn and Scheller, 2006; Sudhof 
and Rothman, 2009).  
4.1 Biosynthetic/secretory pathway 
After being synthesized in the cytoplasm, new proteins are translocated to the endoplasmic 
reticulum (ER) (Lee et al., 2004) and then move to Golgi via membranous vesicles. After 
moving through the cis and medial cisternae of the Golgi, the ER-derived cargoes move to 
trans-Golgi cisternae, where the proteins destined for secretion or presentation on the PM 
are packed into secretory vesicle that subsequently fuse with the PM (Emr et al., 2009). The 
Golgi apparatus is the major sorting compartment of the cell; its cargo is sorted not only to 
the PM for presentation or secretion, but also to endosomes and lysosomes, or back to the 
ER (Emr et al., 2009). 
4.2 Endocytic and exocytic pathways 
The endocytic pathway regulates internalization and recycling of proteins internalized from 
the PM, through a variety of mechanisms, to early and/or late endosomes. Depending on 
the receptor type and the particular requirements of a particular cell, protein from the 
endosomes are either sorted to the lysosome, a major degradation site for both internalized 
and cellular proteins, or recycled back to the PM (Doherty and McMahon, 2009).  
Efficient protein trafficking within endomembrane system is further regulated by cross-talk 
between the two pathways. Endosomal and lysosomal proteins that maintain their integrity 
and functionality shuttle from the ER, via the Golgi, to endosomes and lysosomes (Ghosh et 
al., 2003). In polarized cells, movement of the proteins from one side of the cell to the other, 
via the transcytotic pathway, involves both the biosynthetic/secretory and the 
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endo/exocytic routes (Tuma and Hubbard, 2003). Thus, the membrane trafficking events 
control the cell communication network connected with signaling events, determining not 
only the intensity and duration, but also the final biological outcome.  
The membrane trafficking process is also important for the signaling activities required 
for cell survival and migration during the normal physiological response, as well as for 
those that take place during angiogenesis. In ECs, modulation of receptor tyrosine activity 
through endocytosis and vesicle trafficking affects downstream targets such as 
endothelial nitric oxide synthase (eNOS) and VE-cadherin. Further, activation of RTKs 
results in the dissolution of EC–specific adhesion through endocytosis of VE-cadherin, 
thereby promoting cell migration and vascular permeability (Mukherjee et al., 2006). 
Directional cell migration requires the trafficking of adhesion and growth factor receptors 
including VEGFR2, which is involved with angiogenesis (Lanahan et al., 2010). The 
angiogenic signals generated in response to VEGFR2 receptor activation are highly 
regulated by sorting pathways during intracellular trafficking (Manickam et al., 2011). 
VEGFR2 signaling is regulated by a broad range of angiogenic regulators that in turn 
regulates receptor trafficking through the endosomal system (Manickam et al., 2011; Scott 
and Mellor, 2009). Rab GTPases regulate key events in VEGFR2 trafficking between the 
PM, early endosomes and late endosomes (Bruns et al., 2009). In addition, the Golgi 
(which is the central hub for membrane trafficking across the mammalian cell) 
coordinates the cell-surface expression of VEGFR2 by regulating the secretory transport of 
newly synthesized VEGFR2 (Manickam et al., 2011). 
4.3 Endocytic trafficking of VEGFR2 
Resting ECs have two pools of VEGFR2: a stable cell-surface pool that can form a complex 
with VE-cadherin at cell-cell junctions and does not undergo rapid internalization 
(Lampugnani et al., 2006), and a pool that continuously cycles between the surface and 
sorting endosomes and is independent of VEGF binding (Gampel et al., 2006). The VEGFR2 
is associated with the caveolin-containing and cholesterol-enriched membrane microdomain 
(Labrecque et al., 2003). Binding of VEGF to extracellular domain of VEGFR2 triggers 
internalization of receptor subsequent to its dimerization and phosphorylation at TYR1054 
and TYR1059. Upon activation, VEGFR2 dissociates from caveolin and transported to 
endosomes (Salikhova et al., 2008). Multiple modes of VEGFR2 internalization exist, since 
VEGF-stimulated endocytosis of VEGFR2 is clathrin-dependent (Lampugnani et al., 2006), 
and VEGFR2 is known to be translocated to perinuclear caveosomes through caveolar 
endocytosis (Bauer et al., 2005; Labrecque et al., 2003). Thus, the intracellular distribution of 
VEGFR2 depends on VEGF stimulation. Endosomal trafficking and the signaling of VEGFR2 
is dependent on the Rab5a protein, a Ras-related small GTPase associated with early 
endosomes (Jopling et al., 2009). Depletion of Rab5a enhances VEGFR2 tyrosine 
phosphorylation and MAPK signaling, whereas overexpression of a Rab5a GTPase-deficient 
(constitutively active mutant, Q79L) causes VEGFR2 accumulation within endosomes 
(Jopling et al., 2009). Rab7a GTPase regulates VEGFR2 trafficking from early to late 
endosomes. Rab7a depletion is inhibitory whereas Rab5a depletion is stimulatory for EC 
migration (Jopling et al., 2009). VEGF stimulation also can increase the rate of VEGFR2 
recycling from sorting endosomes. The vesicles containing VEGFR2 /Src complex traffic to a 
late endosomal compartment after a longer duration (30 mins) of VEGF stimulation (Gampel 
et al., 2006). Since Src is an important downstream target of VEGFR2 in an angiogenesis and 
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vascular permeability pathway (Zachary, 2003), it is believed that recycling of VEGFR2/Src 
to the PM would sensitize pro-angiogenic signals. VEGF stimulation direct VEGFR2 from 
sorting endosomes to late endosomes finally directs it toward lysosomes for degradation 
(Gampel et al., 2006). 
Regulation of VEGFR2 degradation is important for angiogenesis since VEGFR2 down-
regulation controls the sensitivity of ECs to VEGF stimulation. Reports of VEGFR2 
degradation upon VEGF stimulation are varied. One study suggests that VEGFR2 
degradation is complete upon VEGF A stimulation (Ewan et al., 2006), whereas another 
study revealed degradation of only 30-40% of the total  receptor population (Gampel et al., 
2006). Degradation of activated VEGFR2 is promoted by its ubiquitination by c-Cbl, a 
protein that forms a complex with phospholipase Cγ1 (PLCγ1), a mediator of VEGFR2 
signaling (Singh et al., 2007). VEGFR2 trafficking can also be regulated by the co-receptors 
such as VEGFR1 and NRP1, which can interact with VEGFR2. VEGFR1 is ubiquitylated 
upon VEGF stimulation and recruits Cbl (Kobayashi et al., 2004). As discussed above, 
VEGFR1 forms a heterodimer with VEGFR2 upon VEGF binding, so that the decision for 
sorting of VEGFR2 along a degradative pathway could be influenced by VEGFR1. NRP1, 
one of the other VEGFR2 co-receptors, which forms a complex with VEGFR2 upon VEGF 
binding, could stabilize VEGFR2 on the EC surface since loss of NRP1 increases the 
degradation of VEGFR2 upon VEGF stimulation (Holmes and Zachary, 2008).  
4.4 Secretory transport of VEGFR2 
Although the endocytic transport of VEGFR2 has been characterized in detail, the reports on 
secretory transport, i.e transport of newly synthesized VEGFR2, are scant. The Golgi 
apparatus regulates the trafficking of newly synthesized VEGFR2, since the Golgi receives 
newly synthesized proteins and lipids from the endoplasmic reticulum (ER), the central 
organelle in which trafficking-route decisions are made. Recently, studies from our group 
demonstrated that a significant amount of VEGFR2 is present in the Golgi apparatus, and 
that VEGF mobilizes this pool from the Golgi compartment (Manickam et al., 2011). The 
post-Golgi trafficking of cargo occurs in vesicular fashion, where the cargo-loaded vesicles 
bud from Golgi, delivering the cargoes to their target destinations by membrane fusion 
events. Membrane fusion steps in eukaryotic cells require SNAREs (Chen and Scheller, 2001; 
Hong, 2005). The SNAREs are classified into 2 major groups based on the presence of a 
glutamine (Q SNAREs or t-SNAREs) or an arginine (R SNAREs or v-SNAREs) in the center 
of the SNARE motif. The trans-Golgi network- and endosome-localized t-SNARE syntaxin 6 
(STX6), but not syntaxin 10 and syntaxin 16, regulates secretory transport of VEGFR2 as well 
as VEGF-induced angiogenic processes (Manickam et al., 2011). Earlier studies 
demonstrated that STX6 participates in post-Golgi transport of components of membrane 
microdomains to the PM (Choudhury et al., 2006). Inhibition of STX6 either by loss-of-
function approaches, applying an siRNAs against STX6 or by expressing the inhibitory, 
cytosolic domains of STX6 interferes with trafficking of Golgi-resident pool of VEGFR2 and 
targets it to lysosomes for degradation in human ECs, as described in model (Figure 7). 
Further, inhibition of STX6 in cell culture reduced VEGF-induced cell proliferation, cell 
migration, and vascular tube formation (Manickam et al., 2011). Thus, the t-SNARE STX6 
plays a crucial role in maintaining cellular VEGFR2 levels and, subsequently, in 
physiological processes associated with VEGF-mediated angiogenesis. 
 




Fig. 7. Schematic summary of VEGFR2 trafficking. In endothelial cells, VEGFR2 is enriched 
in the plasma membrane, endosomes and Golgi apparatus. These VEGFR2 pools are 
maintained by endocytic and secretory transport pathways. The subcellular localization of 
VEGFR2 is essential for VEGF mediated signaling and angiogenesis, and is regulated by 
syntaxin 6, which colocalizes with VEGFR2 at the Golgi apparatus and endosomes. When 
syntaxin 6 function is inhibited, the cellular pool of VEGFR2 is depleted as a consequence of 
enhanced degradation in lysosomes. Syntaxin 6 contributes to trafficking of VEGFR2 from 
the Golgi and/or endosomes and the maintenance of proper levels of this receptor in 
different subcellular compartments required for efficient receptor signaling and 
angiogenesis. (Modified from Manickam et al., 2011. Blood 117, 1425-1435. © the American 
Society of Hematology.) 
4.5 VEGFR2 trafficking and angiogenesis 
The process of angiogenesis is regulated by the response of VEGFR2 to VEGF binding. The 
availability of VEGFR2 at the PM may directly control the signaling response of ECs to 
VEGF for the onset of pro-angiogenic events. Thus, the trafficking mechanisms, such as 
secretory transport, recycling or degradation that affects the surface level VEGFR2, would 
determine the response of ECs to VEGF during angiogenesis.  The EC-surface proteins that 
stabilize VEGFR2 at the plasma membrane contribute to the VEGF-driven cellular response 
during angiogenesis. A reduction in the engagement of VE-cadherin with ECs present in the 
stable vasculature leads to a reduction in surface levels of VEGFR2, thus reducing the 
sensitivity of ECs to VEGF (Lampugnani et al., 2006). The trafficking of VEGF receptors 
becomes more important under pathological conditions such as wound healing or ischemic 
heart disease, which may require rapid recycling and/or secretory transport of VEGF 
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receptors to the surface, ensuring continuous activation of the VEGF/VEGFR pathway to 
guide angiogenic events. 
As discussed above, a study by our group (Manickam et al., 2011) demonstrated that 
enhanced VEGFR2 degradation due to reduced secretory transport of VEGFR2 from the 
Golgi to PM (due to lack of functional STX6) leads to reductions in VEGF-induced 
proliferation, migration, and tube formation. Such in vitro effects may be responsible for 
reduced VEGFA-induced angiogenesis in the context of interference with STX6 function via 
adenoviral gene transfer of cytosolic domain of STX6 (STX6-cyto, inhibitory form) in ear 
angiogenesis assay in nude mice (Figure 8). This ear angiogenesis model demonstrated that 
trafficking of VEGFR2 is essential for angiogenesis. Also, in our most recent study, we 
demonstrated that STX6 is essential for maintenance of EC surface-localized integrin α5β1, 
which plays a crucial role in angiogenesis (Tiwari et al., 2011). The finding that expressing a 
cytosolic form of STX6 significantly blocks VEGF-induced angiogenesis raises the prospect 
that pharmacologic manipulation of STX6 function in the setting of vascular disorders may 
be an effective therapeutic tool.  
 
Fig. 8. Mice Ear Angiogenesis Assay: Representative images showing gross appearance of 
angiogenesis in mock, syntaxin 6-cyto– or syntaxin 16-cyto–injected mouse ears, 5 days 
before adenovirus expressing VEGF164 (Ad-VEGF164) administration. Nude mice (Nu/Nu 
strain) were given 2 injections under anesthesia. The first set of injections (1st) was PBS, 
syntaxin 6-cyto, or syntaxin 16-cyto. The second (2nd) was PBS or Ad-VEGF164, and given 2 
days later at the site of first injection. At 7 days after the first set of injections, animals were 
euthanized and the ears were photographed. (from Manickam et al., 2011. Blood 117, 1425-
1435. © the American Society of Hematology). 
 




Angiogenesis is regulated by VEGF-stimulated sensitization of the VEGF receptor and 
subsequent signaling events that are required during this process. Intracellular trafficking of 
VEGFR2 controls the VEGF signals that govern angiogenesis. Deciphering the mechanism 
underlying this trafficking and the roles of mediators in the transport of other VEGF 
receptors, as well as identifying other angiogenic components that play a role in the 
formation of new vessels, may provide better insight into angiogenesis. Syntaxin 6-
regulated membrane trafficking events control outside-in signaling via the haptotactic and 
chemotactic mechanisms that regulate integrin 51-mediated EC movement on fibronectin 
and VEGF-mediated VEGFR2 signaling– important components of the angiogenic process 
(Manickam et al., 2011; Tiwari et al., 2011). A great deal has been deciphered about 
angiogenesis-related signaling pathways, but a detailed investigation of the intracellular and 
membrane trafficking of molecules associated directly or indirectly with angiogenesis 
would add to our knowledge of the angiogenic process, as well as help us to design 
therapeutic strategies for pathological angiogenesis therapeutic strategies for pathological 
angiogenesis. 
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1. Introduction 
Over the years a wealth of information on the role played by transcription factors in 
myeloid biology has contributed to our understanding of both normal and abnormal 
myeloid development. However, the regulation of mRNA translation in myeloid cell 
maturation has, in comparison, been a neglected area of study. A better understanding of 
the translational control of myeloid gene expression will undoubtedly provide important 
insights into both normal and abnormal myeloid maturation. This chapter summarizes our 
current understanding of the regulation of myeloid gene expression at the mRNA 
translational level and delineates levels of disruption in myeloid disease, with an emphasis 
on leukemias. 
2. Myeloid differentiation and neutrophil development 
During hematopoiesis, granulocytes and monocytes arise from a common progenitor cell in 
the bone marrow and differentiate in response to cytokines and transcription factors 
ultimately giving rise to mature neutrophils and monocytes in the circulation. The 
granulocyte progenitor cells pass through several identifiable maturational stages, during 
which they acquire the morphologic appearance and granule contents that characterize the 
mature granulocyte(Rev in(Berliner, 1998)). The earliest identifiable granulocyte precursor is 
the myeloblast, which is characterized by very few granules, little cytoplasm and a 
prominent nucleolus. Transition to the promyelocyte stage is associated with the acquisition 
of primary granules. Primary granules are found in both granulocytes and monocytes and 
contain many of the proteins necessary for intracellular microbicidal activity (Bainton, 1975). 
The transition to the myelocyte stage is associated with the acquisition of secondary or 
“specific” granules(Bainton, 1971). Myelocytes further mature to give rise to bands and 
mature neutrophils. The appearance of secondary granules and their content proteins, 
provides a unique marker of commitment to terminal neutrophil differentiation (reviewed 
in (Borregaard et al., 2001)). Several lines of evidence from our laboratory have established 
that the expression of the secondary granule protein (SGP) genes, which are functionally 
diverse and physically unlinked, is coordinately regulated at the level of mRNA 
transcription (reviewed in(Berliner, 1998)). Absence of SGP gene expression is a consistent 
abnormality in Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).  
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2.1 Transcriptional control of myeloid maturation 
Maturation of myeloid progenitor cells into specialized blood cells that play a vital role in 
innate immunity, is regulated by a well-orchestrated interplay of transcription factors 
(Tenen, 2003). Recent studies have delineated transcription factors that contribute to the 
process of maturation. These include a  category of factors termed “master regulators” of 
lineage development and include PU.1, and CCAAT enhancer-binding protein- 
(C/EBP) (Tenen, 2003). These factors not only promote lineage-specific gene expression 
but also suppress alternative lineage pathways. For example, Laslo et al (Laslo et al., 2006) 
elegantly demonstrated that cell fate determination is dependent upon subtle changes in 
expression levels of transcription factors, which regulate differential lineage maturation. 
Levels of PU.1 expression are increased by Egr-1/Nab-2 in developing 
monocytes/macrophages; while Egr-1 simultaneously represses the expression of the 
neutrophil specific Gfi-1 transcription factor (see below), thereby repressing the 
neutrophil development program. 
2.1.1 C/EBP 
C/EBP has been recognized to be a master regulator of the granulopoietic developmental 
program. It is expressed at high levels throughout myeloid differentiation (Tsukada et al., 
2011). C/EBP binds to the promoters of multiple myeloid-specific genes, thereby 
regulating gene expression at many different stages of myeloid maturation. C/EBP mice 
die perinatally due to defects in gluconeogenesis that result in fatal hypoglycemia, and 
demonstrate an early block in the differentiation of granulocytes without affecting either 
monocyte/macrophage maturation or the differentiation of other hematopoietic lineages. 
The expression of C/EBP is associated with growth arrest and differentiation of 
granulocyte precursor cells. This block in proliferation is thought to occur via the interaction 
of C/EBP with cyclin-dependent protein kinases (cdk2 and cdk4), resulting in a block in 
cell proliferation. In addition, C/EBP inhibits E2F-dependent transcription, which also 
contributes to inhibition of cell proliferation and induction of differentiation associated with 
C/EBP-induced granulopoiesis (Timchenko et al., 1997; Timchenko et al., 1999) 
2.1.2 PU.1 
A second master myeloid regulator  PU.1, is a member of the Ets family of transcription 
factors and is expressed  in both B cells and monocyte/macrophages (Chen et al., 1995). PU.1 
is also expressed at lower levels in granulocytes and eosinophils as well as in CD34 
hematopoietic progenitor cells. High levels of PU.1 expression in fetal livers of mice 
preferentially directs monocyte/macrophage development, whereas low levels of PU.1 
result in B-cell development (DeKoter and Singh, 2000). Studies have revealed that 
downregulation of c-Jun, a coactivator of PU.1, by C/EBP is necessary for granulocytic 
maturation and is the mechanism through which C/EBP blocks macrophage development 
(Rangatia  et al., 2002). Gene knockout studies of PU.1 in mice resulted in perinatal lethality 
accompanied by the absence of mature monocytes/macrophages, B cells as well as and 
delayed and reduced granulopoiesis (Scott et al., 1994). Following in vitro differentiation, 
embryonic stem (ES) cells derived from PU.1 blastocysts fail to express mature myeloid 
cell markers, suggesting that PU.1 is not essential for the initial events associated with 
myeloid lineage commitment but is necessary for the later stages of development. 
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2.1.3 Growth Factor Independence-1 (Gfi-1) 
Gfi-1 is a highly conserved transcriptional repressor that encodes a 55kD nuclear proto-
oncogene that is composed of six zinc finger domains at the carboxy terminus and a N-
terminal SNAG  or repression domain (rev in (van der Meer et al., 2010). Gfi-1 is expressed at 
high levels in the thymus and bone marrow, while its paralog Gfi1B, is expressed in the bone 
marrow and spleen. An essential role of Gfi-1 in neutrophil differentiation became apparent 
following reports of gene disruption in mice (Hock et al., 2003). Gfi1-null mice are severely 
neutropenic and eventually succumb to bacterial infections. These mice lack mature 
neutrophils and their granulocyte precursors are unable to differentiate into mature 
neutrophils and also lack expression of specific granule proteins (SGPs). In addition, Gfi-1 
bone marrow expresses atypical Gr1Mac1 myeloid precursor cells that appear to have 
characteristics of both granulocyte and macrophage precursors. These observations confirm a 
critical role for Gfi-1 in the neutrophil maturation program. Work from our laboratory has 
shown that Gfi-1 synergizes with another member of the CCAAT enhancer binding protein 
family of transcription factors, C/EBP to transactivate the promoters of late myeloid genes. 
This synergy is lost in a patient with specific granule deficiency (SGD), who has a 
heterozygous substitution mutation in the C/EBP gene as well as decreased levels of Gfi-1 in 
the bone marrow (Khanna-Gupta et al., 2007). Heterozygous dominant negative mutations in 
the Gfi-1 gene have been described in two patients with severe congenital neutropenia (SCN) 
(Person et al., 2003), thus emphasizing the role of Gfi-1 in the neutrophil maturation pathway.  
Over the years a great deal of information pertaining to the transcriptional regulation of 
myeloid development has become available and has aided in our understanding of the 
process of granulopoiesis and how it goes awry in myeloid leukemias. In contrast, as 
outlined below, the role of mRNA translation in the process of normal  myeloid 
development is only just beginning to be understood (rev in (Khanna-Gupta, 2011)) 
3. An overview of the process of mRNA translation in eukaryotic cells 
Eukaryotic protein synthesis involves the coordinated interplay of hundreds of 
macromolecules such as mRNAs, tRNAs, activating enzymes, protein factors and 
ribosomes. Ribosomes are the protein synthetic factories upon which protein synthesis 
proceeds and are composed of a large (60S) and a small (40S) subunit. Each of these subunits 
is composed of two-thirds RNA and one-third protein. Protein synthesis occurs on the 
ribosome in three phases: translation initiation, elongation and termination. Regulation of 
gene expression takes place primarily at the initiation stage which therefore is the rate-
limiting step in protein synthesis. The delicate balance of events leading to protein 
expression is critical for cellular growth, proliferation, differentiation and apoptosis (Rev in 
(Van Der Kelen et al., 2009)). In eukaryotes, translation  initiation factors (eIFs) play a crucial 
role in the dissociation of 40S and 60S ribosomal subunits thus  enabling  recruitment of 
mRNA and initiator tRNAs to the 40S subunit followed by interaction with the 60S subunit 
resulting in the reformation of the 80S ribosome allowing for  elongation and termination of 
the polypeptide chain to ensue (rev in (Van Der Kelen et al., 2009)). 
3.1 Control of translation initiation 
The first step in the translation of mRNA in eukaryotic cells begins with the binding of the 
40S small ribosomal subunit to the 5’ end of the mRNA to be translated in the process of 5’ 
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cap-dependent translation. Cap-binding protein eukaryotic initiation factor 4E (eIF4E) 
recognizes and binds to the m7GpppN cap (where m is a methyl group and N any 
nucleotide) structure at the 5’end of the mRNA to be translated. Under normal physiologic 
conditions, eIF4E strongly associates with 4E-binding proteins (4E-BPs) thus preventing 
eIF4E from initiating protein synthesis, this represents the first rate limiting step in the 
process of protein synthesis. This inhibition is overcome by the phosphorylation of 4E-BPs 
via signal transduction pathways (involving PI3K and mTOR among others, see below) that 
are regulated by growth factors and nutrient status of the cell, thus causing 4E-BPs to be 
phosphorylated and to dissociate from eIF4E (Figure 1). This enables a competing adapter 
molecule eIF4G, to bind to eIF4E. eIF4G  then recruits the ATP-dependent RNA helicase 
eIF4A (eIF4E, 4G and 4A are collectively referred to as eIF4F in the literature), the 
ubiquitously expressed cofactor eIF4B as well as eIF3, a multisubunit initiation factor, all of 
which bind to the 5’ cap region of the mRNA, thus setting the stage for mRNA translation to 
begin (rev in(Sonenberg and AG., 2009)).  
 
Fig. 1. Under basal conditions eIF4E is tightly bound to 4E-BPs. When cells are under stress 
or nutrient deprived, Phosphorylation of 4E-BPs is triggered by P13K (Phospho-inositol 
Kinase) and mTOR, which causes the 4E-BPs to be phosphorylated and/or to have reduced 
affinity for eIF4E. eIF4E is now free to bind eIF4G to initiate mRNA translation. 
Translation initiation however requires the small ribosomal subunit 40S to be complexed 
with the so called ternary complex before it associates with the mRNA (Figure 2). The 
assembly of the ternary complex, consisting of the G protein eIF2B, eIF2, the initiator tRNA, 
tRNAi met and GTP, is the second rate-limiting step in mRNA translation. Recognition of the 
first AUG codon in the mRNA to be translated followed by initiation of protein synthesis is 
dependent on this process. Upon recognition of the first in-frame AUG, eIF2-GTP is 
hydrolyzed and the resulting eIF2-GDP is restored to eIF2-GTP by the guanine-nucleotide-
exchange factor known as eIF2B to continue another round of translation initiation (Figure 
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2). This process is inbibited when the  subunit (S51 residue) of eIF2 is phosphorylated. This 
is brought about by the activation of a number of eIF2 kinases which are activated under 
conditions of cellular stress and aid in the reduction of protein synthesis until the stressful 
circumstance has passed (Figure 2). If stress remains unabated, apoptosis ensues. EIF2 
kinases include the Heme-regulated inhibitor kinase (HRI), RNA-dependent protein kinase 
(PKR), PKR-like endoplasmic-reticulum kinase (PERK) and mGCN2(mammalian general 
control non-derepressing) (rev in (Raven and AE., 2008) and (Chen, 2007) and references 
therein). Since phosphorylated eIF2 has a higher affinity for eIF2B than eIF2, 
phosphorylation of even a small percentage of eIF2 can lead to a reduction in protein 
synthesis. Phosphorylation of eIF2 can be reversed upon removal of the phosphate group 
by specific phosphatases thus restoring the cell to homeostasis (Harding et al., 2009). 
 
Fig. 2. During initiation, a GTP molecule is hydrolyzed to GDP which is then recycled by 
eIF2B, making eIF2-GTP available for the continuation of the synthesis cycle. However, 
under cellular stress conditions, alterations in nutrient status, growth factors, mitogens and 
inducers of differentiation a variety of a eIF2 kinases are activated which causes the 
phosphorylation of eIF2 which has an increased affinity towards eIF2B. This traps 
available eIF2 and eIF2B resulting in a block in protein synthesis. 
Formation of the 43S preinitiation complex occurs once the ternary complex binds to the  
40S subunit complexed with eIF3 and eIF1A. The pre-initiation complex further associates 
with the mRNA through eIF3 and eIF4G, thus forming the 48S initiation complex. mRNA 
scanning begins when the 40S subunit moves along the mRNA in a 5’ to 3’ direction. Upon 
encountering the first in-frame translation initiation codon AUG, a codon (mRNA) – 
anticodon (tRNA) recognition is established resulting in the dissociation of initiation factors 
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from the 40S subunit. This enables the binding of the 60S subunit resulting in the assembly 
of the functional ribosome (80S) and for peptide elongation to proceed.  
The 3’ end of the mRNA together with a number of the initiation factors ensure the 
stabilization of ribosome-mRNA interaction. Poly (A) tail and polyA binding protein (PABP) 
interact with eIF4G to form a pseudo-circular mRNA. This structure is thought to reduce the 
translational error rate as translation from intact RNAs alone would be permitted. This 
mRNA configuration also gives the initiation factors the necessary spatial proximity that 
ensures efficient dissociation and re-association capabilities to permit another round of 
protein synthesis to occur. 
3.2 The mTOR pathway 
mTOR (mammalian/mechanistic target of rapamycin) is involved in an evolutionarily 
conserved pathway that is critical for cellular responses to environmental cues. mTOR  is a 
serine/threonine protein  kinase belonging to the phospho inositide 3-kinase (PI3K)-related 
protein kinases (PIKK) family of protein kinases, which consists of a protein complex that 
enable organisms to cope with metabolic, environmental and genetic stresses (rev in (Sengupta 
et al., 2010)). Mammalian TOR forms two structurally and functionally distinct  multiprotein 
complexes, mTORC1: in which mTOR is complexed with Raptor (the regulatory protein of 
mTOR), LST8 (also called GL) and PRAS40 (proline-rich Akt/PKB substrate 40kDa), and 
mTORC2, harboring both LST8 and Rictor (rapamycin-insensitive companion of mTOR). Only 
mTORC1 is responsive to the inhibitory effects of the antibiotic rapamycin (Figure 3) 
(Wullschieger et al., 2006). When activated, mTORC1 functions to regulate protein synthetic 
pathways in response to nutritional, environmental and growth factor mediated signals. The 
TCS1 and TCS2 (tuberous sclerosis 1 and 2) proteins form a tumor suppressor complex that 
transmits signals to mTORC1 by regulating the activation of Rheb (Ras homolog enriched in 
brain; a GTP-GDP exchange protein). The TCS1 and TSC2 complex regulates the GTP-loading 
state of Rheb. GTP-bound Rheb interacts with mTORC1 and renders it active. The two major 
targets of mTOR are the 4E-BPs (see Figure 1) and the 40S ribosomal protein S6 kinase (S6K1), 
both important components of the translational machinery (Figure 3). 
Upon activation, mTORC1 regulates the phosphorylation/activation of p70 S6 kinase  
(S6K1) and the phosphorylation/deactivation of 4E-BP1(Platanias, 2005). Activation of S6 
kinase modulates ribosome biogenesis through the activation of ribosomal protein S6 
(rpS6)(Lee-Fruman et al., 1999) (Figure 3). S6K1 also phosphorylates eIF2B, SKAR (S6K1 
Aly/REF-like target) and eukaryotic elongation factor 2 kinase, thus affecting both the 
initiation and elongation stages of mRNA translation. 
As described above, hypo-phosphorylation of the 4E-BPs increases their affinity for eIF4E, 
thus blocking the interaction of eIF4G and eIF4A thereby hampering translation initiation of 
mRNA from proceeding (Figure 1). However,  phosphorylation of the 4E-BPs by activation 
of  the mTORC1 signaling pathway (Figure 3) results in  lowered affinity of these proteins 
for eIF4E, thus allowing for the formation of the competing eIF4E-eIF4G-eIF4A (eIF4F)- 
mRNA  complex  that permits mRNA translation to proceed(Gingras et al., 2001). Thus 
inhibition of mTORC1 activity results in the down regulation of the activity of several 
components of the translational machinery resulting in a block in cell proliferation and 
eventually to cell death. 
 




Fig. 3. mTOR pathway. See text for details 
4. Translation control in Myeloid cells 
While the general principles of mRNA translation hold in myeloid cells,  it has been shown 
that when 4E-BP1 and 4E-BP2 genes were knocked out in mice an impairment of 
myelopoiesis was observed with no obvious effect on thymocyte maturation(Olson et al., 
2008). An increase in the number of immature granulocytic precursors and a decrease in the 
numbers of mature granulocytes was observed in these mice compared to their wild type 
littermates. Other studies have shown that expression of the 4E-BPs is significantly 
increased during granulopoiesis(Grolleau et al., 1999). It was thus concluded that 4E-BP1 
and 4E-BP2 play an important role in the early phases of granulo-monocytic differentiation 
thereby highlighting a critical role for translation initiation during granulopoiesis. It should 
be noted that 4E-BP1 has been shown to be constitutively phosphorylated in both chronic 
myeloid leukemia  (CML) and in acute myeloid leukemia (AML) due to the constitutive 
activation of mTOR and Bcr-Abl in CML(Ly et al., 2003) and PI3K-Akt in AML(Xu et al., 
2003). 
4.1 Translational defects in myeloid leukemias 
Activation of aberrant transcriptional and signaling pathways leading to enhanced survival 
and proliferation of leukemic progenitors is a hallmark of acute myeloid leukemia (AML) 
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(Scholl et al., 2008; Tenen, 2003). The recent past has seen marked changes for the better in 
our understanding of the biology underlying AML. Based on these advances, targeting 
overactive signaling pathways in transformed cells has become an active area of research 
with the ultimate goal of finding molecules that specifically target only the transformed cell.  
4.1.1 mTOR 
The mTOR pathway has been shown to be activated in a number of cancers including AML 
(rev in (Tamburini et al., 2009a)). In fact, mTORC1 has been shown to be activated in over 
90% of primary AML samples (Tamburini et al., 2009b). There has thus been a great effort to 
demonstrate the efficacy and use of Rapalogs, a class of drugs that include the mTORC1 
inhibitor Rapamycin (see Figure 3) and RAD001, as anti-cancer agents. However, despite the 
anticipated cell death that blocking the mTORC1 pathway should result in, it has been 
demonstrated that the anti-leukemic effects of rapalogs are merely cytostatic. This is likely 
due to the fact that mTORC1 inhibition by rapalogs results in the activation of a number of 
feedback loops involving leukemogenic kinases such as P13K and ERK, thus limiting the 
anti-leukemic effects of this class of drugs.(Wang et al., 2008) 
4.1.2 Oncogenic mRNAs  
The translation efficiencies of different mRNAs are dependent partly on the structural 
complexity of their 5’UTR (untranslated region). mRNAs with simple or short 5’UTRs,  such 
as in the actin mRNA, are translated with high efficiency even in untransformed cells. 
However, mRNAs harboring long and complex 5’UTRs are generally translated with low 
efficiency and are referred to as “weak” mRNAs because of weak interactions with the eIF4F 
translation initiation complex (see above). In transformed cells on the other hand, this 
interaction improves due to the increased activity of eIF4F leading to increased translation 
of the weak mRNAs. It is noteworthy that a number of these weak mRNAs have oncogenic 
potential because they encode proteins involved in cell cycle regulation (e.g. cyclin D1) DNA 
replication (ornithine decarboxylase) and other pathways (c-myc, VEGF, Bcl-2, survin),  all of 
which contribute to cell survival and proliferation. Expression of such mRNAs is regulated at 
the translational level and their overexpression likely contributes to the transformation process 
in AML ((Tamburini et al., 2009a) and references therein). Since these “oncogenic” mRNAs 
have been found to be more sensitive to translation inhibition, there has been an effort to 
identify compounds that block mRNA translation. An example of such a compound is 4EGI-1 
which is a 4E-BP1 mimetic and potently blocks the interaction of eIF4E and eIF4G during 
translation initiation (see above). 4EGI-1 has been shown to abrogate the expression of c-Myc 
and Bcl-xL, both proteins with oncogenic potential. Additionally, this compound has shown 
therapeutic potential as it induces selective apoptosis in AML blast while allowing normal 
CD34+ hematopoietic progenitors to survive (Tamburini et al., 2009b). 
Overexpression of the initiation factor eIF4E has been described in primary cells derived 
from M4/M5 AML  compared to bone marrow mononuclear cells (Topisirovic et al., 2003). 
EIF4E expression has been known to increase protein synthesis and to transform cells 
(Wendel et al., 2007). It should be noted that the antiviral compound ribavarin has been 
shown to inhibit the activity of eIF4E (Kentsis et al., 2004). In a small study involving 11 
M4/M5 AML patients who were given ribavarin, three patients responded with one in 
complete remission and two in partial remission (Assouline et al., 2009). This study 
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demonstrates that blocking the translational engine could prove to be a very important tool 
in the development of future AML therapeutics. 
5. Translational control of the myeloid master regulator C/EBP 
C/EBP is the founding member of a family of basic region/leucine zipper (bzip) 
transcription factors many of which contribute to granulopoiesis and are regulated at the 
translation level. (Rev in(Fuchs, 2007; Koschmieder et al., 2009; Muller and Pabst, 2006; 
Schuster and Porse, 2006) ). For the sake of simplicity only the translational control of the 
master myeloid regulator C/EBP will be discussed here.  
 
Fig. 4. Structure of the C/EBP mRNA. TE I, II and III are activation domains. bZip is the 
basic leucine-zipper DNA binding domain. 
Profound hematopoietic abnormalities have been reported for mice in which C/EBP is 
ablated(Zhang et al., 1997). The C/EBP gene is intronless and generates two isoforms as a 
result of the differential utilization of alternate translation start codons. The resultant p42kD 
(full length) and p30kD (truncated) C/EBP proteins differ from each other at the N-
terminus, which is shorter in the p30kD protein (Figure 4). Translational control of C/EBP-
isoform  expression occurs via a conserved cis-regulatory uORF (upstream open reading 
frame) in the 5’UTR (untranslated  region) that is out of frame with the coding region of 
C/EBP and is thought to be responsive to the activities of the translation initiation factors  
eIF4E and  eIF2 (Figure 4 and see above). Thus, an increase in the activity of eIF2 or eIF4E, 
results in the increase in expression of the shorter p30 isoform (rev in(Calkhoven et al., 
2000)). An uORF monitors the site of translation initiation by sensing the activity of the eIF2 
and eIF4E. When levels of these factors are high, the out-of-frame uORF (Figure 4, red AUG) 
is translated, but termination of its translation very close to the translational start site (black 
AUG) for p42 is thought to prevent reinitiation at the p42 AUG. Instead, ribosomes continue 
to scan and reinitiate at a downstream AUG (Figure 4, green AUG), resulting in the 
expression of C/EBP p30. In contrast, under basal conditions, when levels of the initiation 
factors are relatively low, most ribosomes do not initiate translation at the uORF but instead 
initiate translation at the p42 AUG by a process involving “leaky ribosome scanning”, 
resulting in translation of the full length  C/EBP p42 isoform(Calkhoven et al., 2000). This 
mechanism of translational control appears to be conserved among key regulatory proteins 
which govern differentiation and proliferation (rev in (Khanna-Gupta, 2011)). 
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High levels of expression of the p30 C/EBP protein  have been shown to  interfere with the 
DNA binding ability of the full length p42 C/EBP, thus  inhibiting transactivation of key 
granulocytic target genes in a dominant-negative manner (Pabst et al., 2001), In addition, p30 
transactivates the expression of a distinct subset of  target genes different from that of the 
full length p42 C/EBP thereby altering their expression (Geletu et al., 2007). Mice 
engineered to express only the p30 C/EBP isoform  resulted in the development of AML 
with complete penetrance (Kirstetter et al., 2008). Thus changes in the ratio of p42:p30 
isoforms of C/EBP play a critical role in contributing to AML(Fu et al., 2010). 
Suppression of C/EBP translation has also been observed in the leukemic blasts of patients 
with CML (chronic myelogenous leukemia). This occurs via an RNA binding protein, 
hnRNP-E2, which binds to the uORF of the C/EBP mRNA, thereby inhibiting translation. 
Expression of hnRNP-E2 is thought to be upregulated by the activity of the oncogenic BCR-
ABL fusion protein in CML patients, and downregulation of hnRNP-E2 by the BCR-ABL 
inhibitor Imatinib results in restoration of C/EBP protein expression and granulocytic 
differentiation of the CML blasts(Perrotti et al., 2002). 
6. Role of microRNAs in translation control 
6.1 General principles 
MicroRNAs (miRNAs) are 18-24 nucleotides long non-coding RNAs that regulate eukaryotic 
gene expression influencing cellular functions as diverse as cell proliferation, differentiation 
and apoptosis. miRNAs are non-coding RNAs which silence target genes post-
transcriptionally  by binding to complementary sequences in the 3’UTR (untranslated region) 
of the target mRNA  resulting in either  mRNA degradation  or translation repression (rev in 
(Ambros, 2004)). More than 100 miRNAs are expressed in the hematopoieteic compartment 
(rev in (Gazzar and McCall, 2011)). MiRNAs are encoded in the genome and are initially 
transcribed by RNA polymerase II as long primary transcripts referred to as primary miRNAs 
(pri-miRNAs). These hairpin transcripts are recognized and processed by RNase III enzymes 
called Drosha and DGCR8 into 60-80 nucleotide intermediates called precursor miRNAs (pre-
miRNAs) which are then exported to the cytoplasm by Exportin 5 where a second 
ribonuclease termed Dicer cleaves the pre-miRNAs to generate double stranded 18-24 
nucleotide long miRNAs. One strand of the miRNA is next destroyed and the remaining 
strand, the guide strand, is then incorporated into the RNA-induced silencing complex or 
RISC, a large protein complex that also contains the Argonaute 2 or mRNA cleaving proteins. 
The miRNA guides the RISC complex to target complementary regions in the 3’UTRs of 
mRNAs, leading to repression of translation or destabilization of the mRNA by deadenylation. 
(rev in (Manikandan et al., 2008)). In mammalian cells,  6-8 nucleotides of the miRNA (known 
as the seed region) base pair with the cognate recognition sequence in the 3’UTR of the target 
mRNA. In general, a perfectly matched sequence between the seed region and mRNA target 
results in degradation of the mRNA target. An imperfect match however, results in translation 
repression (rev in (Gazzar and McCall, 2011)). MiRNAs are thought to repress translation by 
blocking translation initiation of the target mRNA (Filipowicz et al., 2008). 
6.2 miRNAs in myeloid biology 
An increasing body of evidence implicates miRNA activity in mediating both normal and 
abmormal myelopoiesis (rev in (Pelosi et al., 2009) and (Gazzar and McCall, 2011)). 
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Granulocytes arise from the GMPs (granulocyte monocyte progenitors) which are capable of 
developing into granulocytes or monocytes as a result of cytokines  and thus transcription 
factor activation (Dahl R et al., 2003). MiRNAs have been shown to activate or be activated 
by myeloid specific transcription factors such as PU.1, C/EBP and Gfi-1. Mir-223, for 
example, is thought to be a direct target of C/EBP and its expression increases during 
granulopoiesis. C/EBP is a master regulator of  granulopoiesis (Tenen, 2003). Complete 
loss of  mir-223 in mice results in the expansion of granulocyte precursor cells resulting from 
a cell autonomous increase in the number of granulocytic progenitors (Johnnidis et al., 2008). 
In contrast, overexpression of mir-223 in acute promyelocytic leukemia (APL) cells results in 
an enhanced capacity for granulocytic differentiation (Fazi et al., 2005). Mir-223 is thus 
thought to be a positive regulator of granulopoietic differentiation. It has also been shown 
that mir-223 targets E2F1, a master cell cycle regulator, by inhibiting translation of its 
mRNA. Thus, granulopoiesis  appears to be regulated by a C/EBP–miR-223–E2F1 axis, 
where  miR-223 functions as a key regulator of myeloid cell proliferation associated with 
E2F1 in a negative feedback loop(Pulikkan et al., 2010).  
 In a recent study, Eiring et al demonstrated a new “decoy” role for miRNAs involving the 
master reugator C/EBP. They showed that mir-328 is down regulated in myeloid cells of 
chronic myelogenous leukemia (CML) patients in blast crisis. Restoration of mir-328 
expression however rekindles differentiation in the CML blast cells by  a mechanism 
involving the simultaneous interaction of mir-328 with the C/EBP translational inhibitor 
hnRNP-E2 (see above), as well as with the mRNA for PIM1, a survival factor. Since, the 
interaction with hnRNP-E2 occurs independently of mir-328’s seed sequence, this miRNA 
acts as a “sink” for hnRNA-E2 binding allowing for the  release of C/EBPmRNA from the 
negative effects of hnRNA-E2-mediated translational inhibition. Thus mir-328 appears to 
control cell fate by its ability to base pair with the 3’UTR of target mRNAs  (PIM1) as well as 
by acting as a decoy for hnRNP binding resulting in the release of C/EBP from 
translational inhibition, thereby altering cell fate(Eiring et al., 2010). 
Gfi-1 (growth factor independence-1), a transcriptional repressor that promotes granulocytic 
differention, has been shown to regulate the expression of mir-196b (Velu et al., 2009). The 
expression of mir-196b is high in the common myeloid progenitors (CMPs) which can 
differentiate either along the granulocytic or monocytic lineages. Gfi-1 has been shown to 
bind to the promoter of mir-196b thereby repressing its expression and promoting 
granulopoiesis. Additionally, overexpression of mir-196b was shown to block granulopoieis, 
confirming the importance of low level expression of this miRNA in contributing to 
granulopoietic maturation (Hock et al., 2003) . 
PU.1, a master transcriptional regulator of  monocyte/macrophage differentiation, regulates 
the expression of mir-424, which in turn inhibits the expression of the transcription factor 
NFI-A. Mir-424 expression has been shown to promote monocyte/macrophage 
differentiation. Thus the two primary transcriptional determinants of myeloid 
differentiation, PU.1 and C/EBP, both involve the activity of microRNAs for lineage 
maturation (Rosa et al., 2007). Thus, miRNAs and myeloid specific transcription factors play 
a critical role in lineage maturation pathways by forming lineage-specific regulatory loops 
(rev in (Gazzar and McCall, 2011)), which if disrupted can lead to the development of 
leukemias. 
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Numerous studies have analyzed the expression of miRNAs in acute myeloid leukemias 
and the resulting miR signatures generated have proved to be helpful in classifying sub-
types of AML and hence the choice of treatment options to be used, as well as in 
determining the efficacy of targeted therapies against AML. For example, Pelosi et al 
analyzed the expression of 12 selected granulocytic signature miRNAs and the impact of all 
trans-retinoic acid  (ATRA)-based therapy in a cohort of acute promyelocytic leukemia 
(APL) patients (Pelosi et al., 2009). APL is a subtype of acute leukemia and is characterized 
by the accumulation of promyelocytes as a result of a chromosomal translocation, most 
commonly involving the retinoic acid alpha receptor and the PML gene in a t(15;17) 
configuration. APL patients respond well to treatment with retinoic acid, a vitamin A 
derivative. The authors  demonstrated using a quantitative real time PCR approach, that 9 
miRNAs were overexpressed while three (mir-107, -342 and Let-7c) were downregulated in 
the blasts of APL patients, compared to normal promyelocytes. They showed in addition, 
that patients successfully treated with ATRA showed down regulation of mir-181b and 
upregulation of mir-15b, -16,-107, -223, -342 and let-7c. Thus, a small subset of miRNAs 
appeared to be differentially regulated in APL  and could be modulated by treatment with 
ATRA. This approach is fast becoming a paradigm in diagnosing and determining the 
efficacy of treatment regimens used in acute myeloid leukemias. 
7. Concluding remarks and perspectives 
Inspite of the fact that there has been a surge of interest in the role of mRNA translational 
regulation in mediating gene expression in myeloid cells in recent times, a great deal of 
work has yet to be done. A general interest in this subject derives its source from the fact 
that cellular pathways commonly deregulated in AML including cell cycle progression, 
proliferation and differentiation are mechanistically tied to mRNA translation. For example, 
several upstream (AKT, TSC1/2) and downstream (eIF4E) mediators of the mTORC1 
pathway are either mutated or activated in AML. Although there has been an intense search 
for therapeutic strategies targeting the mTOR pathway in myeloid cells, much work is yet to 
be done to gain a fundamental understanding of the role of the key players that contribute 
to translation initiation and control in normal and abnormal myeloid cells.   
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The myeloproliferative neoplasia (MPNs) are a spectrum of clonal disorders of the 
hematopoietic system. The distinct clinical manifestations are dictated by the primary cell 
type affected, and thus chronic myeloid leukemia (CML) is a proliferation of mature 
granulocytes, polycythemia vera (PV) is an expansion or red blood cells, essential 
thrombocythemia (ET) results in an increase of platelets, etc.. The natural history of MPNs is 
generally chronic in nature, and patients come to medical attention either by coincidence 
(abnormal blood findings during routine exam) or by signs and symptoms related to the 
expansion of the hematopoetic system (e.g., an enlarged spleen). Common to most MPNs is 
a small but finite risk of disease evolution to an acute leukemia, where hematopoetic 
development is blocked at an early stage of differentiation, leading to the accumulation of 
poorly functioning myeloid blasts at an expensive of critical depletion of normal white 
blood cells and platelets, leading to morbidity and mortality from infections and bleeding 
complications. If they do not progress to an acute leukemia, the natural history of MPNs 
often results in fibrosis of the bone marrow, migration of hematopoesis to other organs 
(spleen and liver), and eventual complications of this secondary organ involvement, as well 
as from decreased normal blood counts from marrow fibrosis. A unifying theme in the 
pathogenesis of MPNs is the activation of tyrosine kinases. The ‘‘poster child’’ is CML, 
where the BCR-ABL translocation is found in all cases; the fusion BCR-ABL activates 
proliferative and antiapoptotic pathways; and most importantly, inhibition by tyrosine 
kinase inhibitors (TKIs) can markedly reverse the natural history of the disease. The 
molecular lesions responsible for PV, ET, and myelofibrosis (MF) were unknown until 
relatively recently. From 2005, a flurry of reports found that a point mutation in JAK2, 
resulting in a valine for phenylalanine substitution at codon 617 (JAK2V617F), occurred at a 
high prevalence in these disorders. The mutation was found in roughly half of MF and ET 
cases and nearly all PV cases. Constitutive activation of JAK2 activates STAT and MAPK 
proliferative signaling pathways, leading to transformation of hematopoetic progenitors. 
Curiously, not all hematopoetic stem cells in cases with the JAK2V617F harbor the mutation. 
Moreover, the data suggested a differential dosage effect in the different diseases. Whereas 
in most cases the JAK2V617F is heterozygous with a normal JAK2 allele, in many cases of  
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relatively recently. From 2005, a flurry of reports found that a point mutation in JAK2, 
resulting in a valine for phenylalanine substitution at codon 617 (JAK2V617F), occurred at a 
high prevalence in these disorders. The mutation was found in roughly half of MF and ET 
cases and nearly all PV cases. Constitutive activation of JAK2 activates STAT and MAPK 
proliferative signaling pathways, leading to transformation of hematopoetic progenitors. 
Curiously, not all hematopoetic stem cells in cases with the JAK2V617F harbor the mutation. 
Moreover, the data suggested a differential dosage effect in the different diseases. Whereas 
in most cases the JAK2V617F is heterozygous with a normal JAK2 allele, in many cases of  
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PV the mutation is homozygous through the process of acquired uniparental disomy. 
Curiously, in vitro cultures of PV cases will often show homozygous JAK2V617F erythroid 
colonies, whereas similar colonies from ET patients are heterozygous for the mutation. 
There has been a substantial body of work attempting to study the effects of the JAK2V617F 
in mouse models. Early reports focused on a bone marrow transplantation model, where 
mouse bone marrow cells harboring exogenous JAK2-V617F were transplanted into 
irradiated mice. These models produced a syndrome of what appeared mostly like PV, but 
most failed to completely recapitulate the spectrum of leukocytosis, thrombocytosis, and 
myelofibrosis found in human disease. Transgeneic models followed, which again produced 
a spectrum of MPN disorders, with a suggestion of phenotype relating to the JAK2V617F 
expression levels. Very recently, several groups have created knockin systems placing a 
conditionally inducible JAK2V617F allele under control of the endogenous JAK2 promoter. 
This allows for control of the JAK2V617F expression in only hematopoetic tissues, getting 
one closer to replicating the disease experience of the human patient. Marty et al. found that 
the heterozygous expression of JAK2V617F produced a PV-like syndrome, not like human 
where heterozygousity is more often associated with ET. However, Akada et al. 
demonstrated that both heterozygous and homozygous JAK2V617F caused a PV syndrome, 
with a demonstration of a dose effect, as indicated by the fact that homozygous expressors 
had a greater manifestation of elevated blood counts and spleen size, compared to those 
mice with lower levels of JAK2V617F. In addition, Li et al. have produced a very 
provocative study in which a human JAK2V617F knockin was created. This model 
produced a transplantable disease with some features of both ET and PV. Of interest is the 
finding that affected mice had reduced numbers of primitive hematopoetic cells that had 
evidence of impaired normal function (cell cycling, apoptosis, and DNA damage). Moreover, 
competitive marrow transplantation showed impaired hematopoetic stem cell function. 
Recently, Mullally and colleagues used a conditional JAK2V617F expression model to yield 
physiological levels of the mutated allele. The phenotype in the mice resembled much of the 
cellular biology and clinical features of human PV, and it was serially transplantable with 
great efficiency. Separation of the bone marrow into immature Lineage– SCA-1+ c-Kit+ (LSK) 
and more mature myeloid erythroid progenitor (MEP) and granulocytic monocytic 
progenitor (GMP) subpopulations demonstrated that the ‘‘MPN-initiating’’ JAK2V617F cell 
capable of transplantation resided in the LSK population, but not in the committed myeloid 
MEP or GMP progenitors. Surprisingly, several studies showed that mutant cells in the LSK 
compartment were quite similar to wildtype cells in regard to cell cycle status, STAT 
signaling, and gene expression (though JAK2V617F cells showed enrichment of the 
erthyroid, myeloid, and megakaryocytic differentiation pathways). Similar to the Li et al. 
paper, competitive transplantation experiments showed that mutant cells had at best a 
minor competitive edge compared to wild-type, and a small number of mutated cells 
nonetheless causes a PV phenotype. Lastly, the authors demonstrated that the MPN 
initiating cell was not killed by JAK2 inhibition. Mice treated with the inhibitor had a 
dramatic decrease in spleen size and a reduction of erthyroid precursors in the marrow, but 
LSK cells from treated mice were able to cause the PV phenotype in subsequently 
transplanted mice. These studies in total offer an increased understanding of the MPN that 
may usher in a new era of therapy, much like what occurred in the study of CML. Similar to 
CML, these studies suggest the initiating cell resides in the primitive compartment but is  
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genetically and phenotypically quite similar to its normal complement. Like CML, mutated 
cells in the stem cell compartment appear resistant to kinase inhibition. However, as we 
move toward better therapies for MPN, these findings have implications in the feasibility of 
‘‘stem cell’’ therapy, because there may not be a large therapeutic window to selectively kill 
MPN ‘‘stem cells.’’ In addition, a limitation of murine systems is that however eloquent, 
they are still only models of human disease. For example, human MPN may well have 
additional genetic lesions contributing to initiation and progression, and mouse models 
cannot easily recapitulate this complexity. In this regard it is interesting that several other 
mutations have recently been discovered in MPN (e.g., TET2, ASXL1, IDH1, and IDH2); 
TET2 mutations have been found in JAK2V617F-positive and -negative clones from the 
same patient, suggesting that TET2 mutations may be a relatively early event in MPN. 
Moreover, if tumor initiation and progression is influenced by interactions with a host’s 
innate immunological system, then disease in the mouse model might be expected to be 
very different than in humans. Nonetheless, the work presented by Mullally and others are 
quite significant, and provide us with powerful tools to better understand disease and test 
new agents of therapy.However, it should be noted that some mutations might possess 
more than one mechanism of action, for example, JAK2V617F results in dysregulation of 
kinase signaling but might also have an epigenetic effect. Recently, Dawson et al.identified a 
novel nuclear role of JAK2 in the phosphorylation of Tyr 41 of histone H3 leading to 
chromatin displacement of HP1a. The authors suggested that the inability of HP1a to 
regulate chromatin could reduce the potential tumor suppressive functions of HP1a 
resulting in erratic mitotic recombination and transcription deregulation of several JAK2-
regulated genes such as LMO2. These results were confirmed in hematopoietic cell lines and 
in the CD34+ cells collected from the peripheral blood of one PMF patient with JAK2V617F 
mutation. Our group defined the subcellular localization of JAK2 in total BM cells and in 
sorted cell populations collected from MPN (ET, PV, PMF) patients with the JAK2V617F 
mutation or from MPN patients with wild type (wt) JAK2. We find that in contrast to cells 
with normal JAK2 in which the protein is detected predominantly in the cytoplasm, JAK2 is 
mostly nuclear in V617F-positive CD34+ cells. However, this nuclear localization is no 
longer observed in V617F-positive differentiated cells. After expressing JAK2V617F in K562 
cells, we observe a similar preferential accumulation of JAK2 in the nucleus in contrast to 
untrasfected- and wt JAK2-expressing cells in which the protein is found in the cytoplasm. 
The mutated-JAK2 nuclear translocation is mainly reverted by the addiction of the JAK2 
inhibitor AG490.  
1.1 Functional hallmarks of myeloid progenitors in myeloproliferative neoplasms 
The BCR-ABL-negative myeloproliferative diseases, which include polycythemia vera (PV), 
essential thrombocythemia (ET) and primary myelofibrosis (PMF), were recently renamed 
myeloproliferative neoplasms (MPNs).1 PV, ET and PMF are disorders of hematopoietic 
stem cells (HSCs) and early myeloid progenitors,2, 3 where myeloid progenitors are 
hypersensitive and/or independent of cytokines for survival, proliferation and 
differentiation. For instance, the majority of PV patients harbor erythropoietin (Epo)-
independent erythroid colonies.4 Several intracellular anti-apoptotic pathways and 
molecules, such as STAT3, Akt or BclXL, are activated/induced constitutively in such MPN 
myeloid progenitors,5, 6, 7 along with hypersensitivity to insulin-like growth factor 1 (IGF-1), 
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genetically and phenotypically quite similar to its normal complement. Like CML, mutated 
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1.1 Functional hallmarks of myeloid progenitors in myeloproliferative neoplasms 
The BCR-ABL-negative myeloproliferative diseases, which include polycythemia vera (PV), 
essential thrombocythemia (ET) and primary myelofibrosis (PMF), were recently renamed 
myeloproliferative neoplasms (MPNs).1 PV, ET and PMF are disorders of hematopoietic 
stem cells (HSCs) and early myeloid progenitors,2, 3 where myeloid progenitors are 
hypersensitive and/or independent of cytokines for survival, proliferation and 
differentiation. For instance, the majority of PV patients harbor erythropoietin (Epo)-
independent erythroid colonies.4 Several intracellular anti-apoptotic pathways and 
molecules, such as STAT3, Akt or BclXL, are activated/induced constitutively in such MPN 
myeloid progenitors,5, 6, 7 along with hypersensitivity to insulin-like growth factor 1 (IGF-1), 
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granulocyte macrophage colony-stimulating factor, interleukin 3 (IL-3), granulocyte colony-
stimulating factor (G-CSF) or thrombopoietin (Tpo).8,9, 10, 11 Unlike many malignancies, 
where the INK4a locus is inactivated, erythroid progenitors from PV patients exhibit 
increased expression of the INK4a/ARF locus.12 
1.2 Mutations involved in PV, ET and PMF 
The acquired somatic JAK2 V617F mutation is harbored by the majority of PV patients and 
by more than 50% of ET and PMF patients.13, 14, 15, 16, 17Subsequent identification of exon 12 
mutants of JAK2 in a minority of PV patients gave a molecular lesion to virtually all PV 
cases.18 Sequencing of the gene coding for the Tpo receptor (TpoR/c-Mpl) identified 
mutations in the juxtamembrane tryptophan residue W515 (W515L and W515K) in a low 
percentage of PMF and ET patients, the majority of which are JAK2 V617F-negative.19, 20 The 
W515 residue of TpoR is required to maintain the receptor inactive in the absence of 
ligand.21 All these mutations lead to constitutively active JAK–STAT pathway, especially 
JAK2, STAT5, STAT3, MAP kinase ERK1,2 and Akt.13, 16, 21Advancement over the past 3 
years in the MPN research field has raised several major questions, such as: (i) What are the 
molecular bases for the significant differences in the in vivo phenotypes induced by JAK2 
V617F and TpoR W515L? (ii) How can a unique somatic mutation, JAK2 V617F, be involved 
in the induction of three different diseases ET, PV or PMF? (iii) What mechanisms are 
responsible for the evolution of MPNs toward acute myeloid leukemia? (iv) What are the 
effects of JAK2 V617F and of the other JAK2 and TpoR mutants at the level of HSC? and (v) 
What preceding and subsequent (to JAK2 V617F) genetic events contribute to 
myeloproliferative diseases?Answers to these questions have begun to emerge. Gene 
dosage, as initially suggested by genotype/phenotype studies in patient cells,22 by retroviral 
bone marrow reconstitution studies23 and most recently probed in transgenic mice,24could 
be critically involved in inducing one or the other of the MPN phenotypes. It is fascinating 
that progenitors homozygous for the JAK2 V617F mutation occur in almost all PV patients, 
but very rarely in ET patients.25, 26 Although this can be seen as an argument in favor of the 
gene dosage hypothesis, other preceding or subsequent genetic changes might have an 
important function. Interestingly, host-modifying influences might have a major part in 
establishing the disease phenotype.27 A screen for genetic variation within the genes coding 
for EpoR, TpoR, G-CSF receptor (G-CSFR) and JAK2 led to the discovery of three JAK2 
single nucleotide polymorphisms that were significantly but reciprocally associated with PV 
and ET, but not with PMF. Three additional JAK2 single nucleotide polymorphisms were 
uniquely associated with PV. Such single nucleotide polymorphisms, although not in the 
coding region of the genes, might affect the levels of gene transcription, regulation by other 
factors or possibly expression of other genes. 
1.3 Unknown effects of JAK2 V617F signaling in HSCs 
JAK2 V617F mutation was detected at the HSC and the common myeloid/lymphoid 
progenitor levels, it skews the HSC differential potential toward the erythroid lineage and 
gives a selective proliferative advantage to myeloid lineages.28, 29 The HSC compartment of 
PV and PMF patients was found to contain JAK2 V617F-positive long-term, multipotent and 
self-renewing cells, with a much higher proportion of mutated HSCs in PMF than in PV.30 It 
is not clear at this moment whether JAK2 V617F profoundly affects the biology of HSCs30 or 
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whether it only gives a strong selection advantage past the HSC stage. A certain degree of 
heterogeneity exists between HSC subsets.31 HSCs exist in niches, some near osteoblasts and 
others near endothelial cells. Exactly where and in which HSC subset the JAK2 V617F 
mutation initially occurs might have a major impact on the subsequent disease 
phenotype.The JAK2 V617F mutation was present in 30–40% of splanchnic venous 
thrombosis patients (Budd–Chiari syndrome and portal vein thrombosis).32, 33,34, 35 A 
'special' stem cell with hematopoietic/endothelial potential was suggested to be at the origin 
of splanchnic venous thrombosis, and it might harbor JAK2V617F.36 A recent case report 
described a human allogeneic transplantation withJAK2 V617F-positive cells from such a 
splanchnic venous thrombosis donor (with one episode of JAK2 V617F-positive splanchnic 
venous thrombosis), but no MPN, to her HLA-matched sister with high-risk 
myelodysplastic syndrome (RAEB2).37The recipient exhibited a JAK2 V617F burden similar 
to the donor immediately after transplant, but this burden decreased over time, and 7 years 
later, the recipient continues to be in remission and to exhibit low levels of JAK2 V617F 
positivity.37 These data suggest that, indeed, the JAK2 V617F mutation can occur in an HSC, 
but at least in the transplantation setting, this HSC has no proliferative advantage. A 
considerable amount of data suggests that in addition to the presence of theJAK2 V617F 
mutation, preceding or subsequent genetic events might be necessary for developing the 
MPN disease. First, in certain MPN patients, the clonality of expanded myeloid progenitors 
is found to be larger than the JAK2 V617F clone, with the acquisition of JAK2 V617F being a 
late genetic event.38 Second, acute myeloid leukemia cases developed inJAK2 V617F-positive 
patients can occur with leukemic blasts not harboring JAK2V617F.39 Third, Epo-independent 
colonies might not always harbor the JAK2mutation in patients with the JAK2 V617F 
mutation.40 Such preceding or subsequent events could be associated differently with the 
three diseases, namely ET, PV and PMF. 
1.4 The signaling space 
Molecular cell biology textbooks list eight major signaling pathways that control gene 
expression that are linked to eight classes of cell surface receptors: cytokine receptors, 
receptor tyrosine kinases, receptors for transforming growth factor (TGF)-β, Wnt, 
Hedgehog, tumor necrosis factor (TNF)-, Notch (Delta) and G-protein-coupled receptors.41  
Nuclear and corticoid receptor pathways, as well as integrin signaling, complete the picture 
of intracellular cell signaling. In several paperit has been well described that aberrant 
signaling occurs in MPNs through some of the listed pathways, such as cytokine receptors, 
receptor tyrosine kinases, TGF-β and TNF-. It is not clear whether aberrant signaling in 
MPNs is simply due to the constitutive nature of signaling induced by mutated JAK2 or 
TpoR, or whether specific cross-talk events occur to other pathways that might confer 
specificity to JAK2 V617F versus JAK2 signaling. It is important to recognize from the outset 
that the experimental systems used by signal transduction research, such as 
phosphorylation studies, co-immunoprecipitation, gene expression and determination of 
protein localization, may not be able to identify subtle relative changes, such as kinetics and 
amplitude differences, between signals engaging generic pathways that are redundantly 
triggered by many stimuli. Such subtle quantitative differences might, however, be crucial 
for the disease phenotypes in vivo. That is the reason why genetics, in vivo models, results 
obtained with inhibitors and data derived from primary cells, must be taken into account to 
draw a picture describing aberrant signaling in MPNs. 
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1.5 Constitutive signaling and kinase activity of JAK2 V617F 
The mammalian genome codes for four Janus kinases (JAKs), JAK1, JAK2, JAK3 and Tyk2. 
On the basis of homology, JAKs share seven JAK homology domains (JH), denoted as JH1–
JH7. From the C to the N terminus, JH1 represents the kinase domain, JH2 the pseudokinase 
domain, JH3 and JH4 contain an SH2-like domain and linker regions, whereas JH5–JH7 





Fig. 1. Schematic illustration of Janus kinase (JAK)2 and the different JAK homology (JH) 
domains. The V617F mutation occurs in the pseudokinase domain rendering the kinase 
domain constitutively active. Exon 12 mutations, such as K539L, occur in the linker region 
between the JH3 and JH2 domains. Tyrosine residues that can be phosphorylated are 
depicted by their single letter. See text for details. 
JAKs have been proposed to have a bipartite structure and the N terminus is required for 
binding to receptors, chaperoning and stabilizing them at the surface,44, 45, 46, 47 whereas the 
kinase domain is absolutely crucial for signaling. The pseudokinase domain precedes the 
kinase domain, and because of sequence differences at key residues required for catalysis, it 
cannot transfer phosphate and thus is catalytically inactive.42Nevertheless, the pseudokinase 
domain is structurally required for the response of JAKs to cytokine receptor activation and 
for inhibiting the basal activity of the kinase domain.48, 49 The V617F mutation occurs in the 
pseudokinase domain, leading to constitutive activation of the kinase domain (Figure 1). 
Although no X-ray crystal structure of full-length JAK2 exists, modeling has suggested that 
the pseudokinase domain of JAK2 maintains the kinase domain inactive in the basal state.50 
Thus, the V617F mutation is expected to relieve the inhibitory effect of JH2 on JH1 and to 
lead to basal kinase activity. The homologous V617F mutations in JAK1 and Tyk2 also lead 
to constitutive activation,51 which strongly supports this model. Activating mutations in the 
pseudokinase domain of JAK1 at the homologous V658 position or at neighboring residues 
have been reported in 20% of patients with T-acute lymphoblastic leukemia.52, 53 In 
transiently transfected JAK2-deficient cells, such as the -2A human fibrosarcoma cell line,54 
JAK2 V617F expression leads to constitutive activation of STAT5 and STAT3 signaling. In 
such transient transfection experiments, JAK2 V617F is constitutively tyrosine 
phosphorylated at the activation loop Y1007. Co-transfection of wild-type JAK2 reduces 
signaling by JAK2 V617F, presumably due to competition for an interaction partner, such as 
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a cytokine receptor,13 but does not prevent constitutive phosphorylation of JAK2 V617F.16To 
investigate the catalytic activity of JAK2 V617F mutation, kinase assays have been 
performed on GST fusion proteins. In COS7 overexpression conditions, when compared 
with wild-type JAK2, the JAK2 V617F mutated protein exhibits enhanced basal kinase 
activity on a reporter GST fusion protein containing the sequence of the activation loop of 
JAK2 containing tyrosine (Y) 1007.17, 55 The kinase activity was clearly increased, but it 
appeared to be weak. In stably transfected Ba/F3 cells, JAK2 V617F also exhibits enhanced 
kinase activity on the same Y1007-containing GST fusion protein, but the levels of activation 
were also small (C Pecquet et al., unpublished results). This is very different from BCR-ABL 
or other fusion proteins such as TEL-JAK2, where the kinase domain alone is oligomerized 
and activated by a fused exogenous oligomeric domain. In contrast, the kinase domain of 
JAK2 V617F is expected to maintain most of the negative regulatory intramolecular 
interactions that normally limit kinase domain activation. 
1.6 JAK2 V617F and cytokine receptors 
The FERM domain of JAKs is responsible for appending JAKs to cytokine receptors. 
Cytokine receptors contain in the cytosolic juxtamembrane region a proline-rich sequence, 
usually PxxPxP, denoted as Box 1, located 10–15 amino acid residues downstream of the TM 
domain, and further down 50–60 amino acid residues downstream of the TM domain, a 
sequence composed of hydrophobic and charged residues denoted as Box 2.56JAK2 binds to 
the region of EpoR that encompasses cytosolic residues of Box 1, Box 2 and also most of the 
residues between these boxes.44, 56Interaction between JAK2 and EpoR or TpoR is disrupted 
by a point mutation (Y114A) in the FERM domain.47 Expression of the double-mutant JAK2 
V617F Y114A in Ba/F3-EpoR cells did not lead to constitutive signaling through STAT5 or 
to autonomous growth,57 suggesting that the V617F mutation does not suffice for activation 
in the absence of the assembly between the JAK2 V617F and a cytokine receptor. It can be 
noted that members of the JAK family are localized to membranes through recruitment by 
cytokine receptors, whereas mutations such as Y114A lead to cytosolic localization.58 
Furthermore, a mutation in the pseudokinase domain of JAK2 was identified (Y613 to 
glutamic acid, Y613E), which promotes constitutive activation only when JAK2 is in 
complex with the EpoR.59 This result suggests that in the absence of an association with a 
cytokine receptor, JAK2 is locked into an inactive state and that receptor binding through 
the FERM domain is important for activation.59Another argument supporting the notion 
that binding to a cytokine receptor is important for the activity of the V617F mutant arises 
from the lack of activation of JH2–JH1 fusion proteins where the V617F mutation was 
introduced in the JH2 sequence.60 The low basal activity of JH1 was shown to be suppressed 
by fusion with JH2.49, 61 However, the presence of the FERM–SH2 domains is required for 
the activation effect exerted by the V617F mutation. JAK2 is crucial for signaling by EpoR62 
and TpoR,63, 64 participates in signaling by G-CSFR65, 66 (Figure 2) and also mediates 
signaling by the IL-3/IL-5/granulocyte macrophage colony-stimulating factor family of 
cytokines, as well as by several type-II cytokine receptors, such as interferon- receptor 267. 
Given that MPNs mainly affect the erythroid, the megakaryocytic and the granulocyte 
lineages, as stated before, complexes between JAK2 V617F and EpoR, TpoR and G-CSFR 
may explain cytokine hypersensitivity and independence in these diseases (Figure 2). 
 
Hematology – Science and Practice 
 
304 
1.5 Constitutive signaling and kinase activity of JAK2 V617F 
The mammalian genome codes for four Janus kinases (JAKs), JAK1, JAK2, JAK3 and Tyk2. 
On the basis of homology, JAKs share seven JAK homology domains (JH), denoted as JH1–
JH7. From the C to the N terminus, JH1 represents the kinase domain, JH2 the pseudokinase 
domain, JH3 and JH4 contain an SH2-like domain and linker regions, whereas JH5–JH7 





Fig. 1. Schematic illustration of Janus kinase (JAK)2 and the different JAK homology (JH) 
domains. The V617F mutation occurs in the pseudokinase domain rendering the kinase 
domain constitutively active. Exon 12 mutations, such as K539L, occur in the linker region 
between the JH3 and JH2 domains. Tyrosine residues that can be phosphorylated are 
depicted by their single letter. See text for details. 
JAKs have been proposed to have a bipartite structure and the N terminus is required for 
binding to receptors, chaperoning and stabilizing them at the surface,44, 45, 46, 47 whereas the 
kinase domain is absolutely crucial for signaling. The pseudokinase domain precedes the 
kinase domain, and because of sequence differences at key residues required for catalysis, it 
cannot transfer phosphate and thus is catalytically inactive.42Nevertheless, the pseudokinase 
domain is structurally required for the response of JAKs to cytokine receptor activation and 
for inhibiting the basal activity of the kinase domain.48, 49 The V617F mutation occurs in the 
pseudokinase domain, leading to constitutive activation of the kinase domain (Figure 1). 
Although no X-ray crystal structure of full-length JAK2 exists, modeling has suggested that 
the pseudokinase domain of JAK2 maintains the kinase domain inactive in the basal state.50 
Thus, the V617F mutation is expected to relieve the inhibitory effect of JH2 on JH1 and to 
lead to basal kinase activity. The homologous V617F mutations in JAK1 and Tyk2 also lead 
to constitutive activation,51 which strongly supports this model. Activating mutations in the 
pseudokinase domain of JAK1 at the homologous V658 position or at neighboring residues 
have been reported in 20% of patients with T-acute lymphoblastic leukemia.52, 53 In 
transiently transfected JAK2-deficient cells, such as the -2A human fibrosarcoma cell line,54 
JAK2 V617F expression leads to constitutive activation of STAT5 and STAT3 signaling. In 
such transient transfection experiments, JAK2 V617F is constitutively tyrosine 
phosphorylated at the activation loop Y1007. Co-transfection of wild-type JAK2 reduces 
signaling by JAK2 V617F, presumably due to competition for an interaction partner, such as 
 
Molecular Mechanisms in Philadelphia Negative Myeloproliferative Neoplasia 
 
305 
a cytokine receptor,13 but does not prevent constitutive phosphorylation of JAK2 V617F.16To 
investigate the catalytic activity of JAK2 V617F mutation, kinase assays have been 
performed on GST fusion proteins. In COS7 overexpression conditions, when compared 
with wild-type JAK2, the JAK2 V617F mutated protein exhibits enhanced basal kinase 
activity on a reporter GST fusion protein containing the sequence of the activation loop of 
JAK2 containing tyrosine (Y) 1007.17, 55 The kinase activity was clearly increased, but it 
appeared to be weak. In stably transfected Ba/F3 cells, JAK2 V617F also exhibits enhanced 
kinase activity on the same Y1007-containing GST fusion protein, but the levels of activation 
were also small (C Pecquet et al., unpublished results). This is very different from BCR-ABL 
or other fusion proteins such as TEL-JAK2, where the kinase domain alone is oligomerized 
and activated by a fused exogenous oligomeric domain. In contrast, the kinase domain of 
JAK2 V617F is expected to maintain most of the negative regulatory intramolecular 
interactions that normally limit kinase domain activation. 
1.6 JAK2 V617F and cytokine receptors 
The FERM domain of JAKs is responsible for appending JAKs to cytokine receptors. 
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may explain cytokine hypersensitivity and independence in these diseases (Figure 2). 
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colony-stimulating factor receptor (G-CSFR). (i) Janus kinase 2 (JAK2) is the main JAK used 
by EpoR and TpoR, but JAK1 is also used physiologically by G-CSFR. Primarily, EpoR and 
TpoR are expected to be bound by JAK2 V617F, whereas G-CSFR is expected to be in 
complex with JAK2 V617F at high JAK2 V617F levels, i.e., in homozygous JAK2 V617F 
situations. Scaffolding of JAK2 V617F on the cytosolic tails of cytokine receptors leads to the 
enhanced activation of JAK2 V617F and downstream signaling through STATs, MAP kinase, 
PI-3-kinase (PI3K) and Akt. SOCS proteins are expected to engage both EpoR and activated 
wild-type JAK2, leading and down-modulation of JAK2 activity; the EpoR–JAK2 V617F 
complex appears to escape the down-modulation activity of SOCS3. (ii) Cytokine receptors 
that are in complex with JAK2 V617F are hypersensitive to their ligands for signaling. 
Cytokine binding to receptors coupled to wild-type JAK2 induce transient physiologic 
signals, leading to survival, proliferation and differentiation of myeloid progenitors. In 
contrast, receptors coupled to JAK2 V617F respond to lower levels of ligand, and are 
constitutively signaling after ligand withdrawal. It is not known whether dimeric receptor 
complexes, where one monomer is coupled to JAK2 V617F and the other to wild-type JAK2, 
are also hypersensitive to ligand or constitutively active. 
1.7 EpoR and MPNs 
EpoR functions as a preformed dimer on the cell surface, which upon cytokine binding 
undergoes a conformational change that triggers the activation of the receptor pre-bound 
JAK2.68, 69 This involves a rotation of the receptor monomers within the dimer,70 which is 
transmitted to JAK2 by switch residues, that is W258 in the juxtamembrane domain of 
EpoR.69 Current data suggest that JAK2 V617F can scaffold on the cytosolic domain of EpoR 
and induce Epo-independent signaling, possibly by phosphorylating key cytosolic tyrosine 
residues on EpoR, which leads to strong STAT5 activation.71Early on after the identification 
of JAK2 V617F, the need for a co-expressed type I dimeric cytokine receptor for constitutive 
signaling by JAK2 V617F provoked a controversy, which in the end led to a model of how 
dimeric receptors might actually promote JAK2 V617F activation. One study by Levine et 
al.16 reported that JAK2 V617F readily induced autonomous growth in Ba/F3 cells 
engineered to express the EpoR (Ba/F3 EpoR cells), but not in parental Ba/F3 cells. In 
contrast, the study by James et al.13 had shown that JAK2 V617F could induce autonomous 
growth in both Ba/F3 EpoR and parental Ba/F3 cells. This controversy (also described in 
Ihle and Gilliland72) was solved by carefully assaying the levels of JAK2 V617F transduction: 
at low levels, co-expression of a type I cytokine receptor was necessary for autonomous 
growth, whereas at higher levels JAK2 V617F alone induced autonomous growth, most 
likely by binding to an endogenous cytokine receptor, such as the IL-3-receptor β-subunit.60 
It is not clear whether other receptors—besides dimeric type I—could also promote 
signaling by low levels of transduced JAK2 V617F (Figure 2(ii)). Nevertheless, given that 
EpoR is a dimer in the absence of ligand, an insightful model was proposed by Harvey 
Lodish. In it, dimerization of JAK2 V617F by such a receptor is considered necessary for the 
activation of JAK2 V617F signaling, and the subtle V617F mutation promotes kinase 
activation when JAK2 is scaffolded on an inactive receptor dimer (Figure 2(i)).71 Given that 
in MPNs the three lineages affected are controlled by the three type I dimeric cytokine 
receptors, EpoR, TpoR and G-CSFR, the model that JAK2 V617F mainly functions as a 
transforming kinase in association with these receptors is very plausible. EpoR signals 
mainly by JAK2–STAT5 and PI-3–kinase/Akt (Figure 2(i)) pathways. It is a weak activator 
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situations. Scaffolding of JAK2 V617F on the cytosolic tails of cytokine receptors leads to the 
enhanced activation of JAK2 V617F and downstream signaling through STATs, MAP kinase, 
PI-3-kinase (PI3K) and Akt. SOCS proteins are expected to engage both EpoR and activated 
wild-type JAK2, leading and down-modulation of JAK2 activity; the EpoR–JAK2 V617F 
complex appears to escape the down-modulation activity of SOCS3. (ii) Cytokine receptors 
that are in complex with JAK2 V617F are hypersensitive to their ligands for signaling. 
Cytokine binding to receptors coupled to wild-type JAK2 induce transient physiologic 
signals, leading to survival, proliferation and differentiation of myeloid progenitors. In 
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transmitted to JAK2 by switch residues, that is W258 in the juxtamembrane domain of 
EpoR.69 Current data suggest that JAK2 V617F can scaffold on the cytosolic domain of EpoR 
and induce Epo-independent signaling, possibly by phosphorylating key cytosolic tyrosine 
residues on EpoR, which leads to strong STAT5 activation.71Early on after the identification 
of JAK2 V617F, the need for a co-expressed type I dimeric cytokine receptor for constitutive 
signaling by JAK2 V617F provoked a controversy, which in the end led to a model of how 
dimeric receptors might actually promote JAK2 V617F activation. One study by Levine et 
al.16 reported that JAK2 V617F readily induced autonomous growth in Ba/F3 cells 
engineered to express the EpoR (Ba/F3 EpoR cells), but not in parental Ba/F3 cells. In 
contrast, the study by James et al.13 had shown that JAK2 V617F could induce autonomous 
growth in both Ba/F3 EpoR and parental Ba/F3 cells. This controversy (also described in 
Ihle and Gilliland72) was solved by carefully assaying the levels of JAK2 V617F transduction: 
at low levels, co-expression of a type I cytokine receptor was necessary for autonomous 
growth, whereas at higher levels JAK2 V617F alone induced autonomous growth, most 
likely by binding to an endogenous cytokine receptor, such as the IL-3-receptor β-subunit.60 
It is not clear whether other receptors—besides dimeric type I—could also promote 
signaling by low levels of transduced JAK2 V617F (Figure 2(ii)). Nevertheless, given that 
EpoR is a dimer in the absence of ligand, an insightful model was proposed by Harvey 
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activation of JAK2 V617F signaling, and the subtle V617F mutation promotes kinase 
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in MPNs the three lineages affected are controlled by the three type I dimeric cytokine 
receptors, EpoR, TpoR and G-CSFR, the model that JAK2 V617F mainly functions as a 
transforming kinase in association with these receptors is very plausible. EpoR signals 
mainly by JAK2–STAT5 and PI-3–kinase/Akt (Figure 2(i)) pathways. It is a weak activator 
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of MAP kinase and of STAT3,73 as it does not contain a consensus site for STAT3 binding, 
whereas several phosphorylated tyrosine residues (Y343, Y401, Y429 and Y431) can bind 
STAT5 and are required for maximal STAT5 activation.74, 75 A consequence of STAT5 
activation is induction of the anti-apoptotic BclXL protein expression,76 which is 
constitutively expressed in PV erythroid progenitors.7 The connection of EpoR with the PI-
3–kinase pathway is accomplished by specific tyrosine residues, that is Y479, which appears 
to bind the regulatory subunit p85.77, 78 PI-3–kinase and Akt activations are critically 
involved in erythroid differentiation,79 possibly by the involvement of the transcription 
factor Forkhead family, FKHRL1.80 Another mechanism appears to be the phosphorylation 
of S310 of GATA1.81 Thus, scaffolding of an activated JAK2 to EpoR is predicted to activate 
the JAK2–STAT5 and PI-3–kinase/Akt pathways and stimulate proliferation and 
differentiation of erythroid progenitors. 
1.8 EpoR and exon 12 JAK2 mutations 
Patients with exon 12 JAK2 mutations, such as JAK2 K539L, exhibit an erythrocytosis 
phenotype, without pathology changes to megakaryocytes typical for MPNs.18 Unlike the 
uniqueness of the point mutation that generates JAK2 V617F, several deletions and insertions 
were noted in the case of exon 12 mutations.18, 82 An attractive hypothesis is that exon 12 
mutants of JAK2 favor interaction with EpoR over TpoR or G-CSFR, although a mechanistic 
basis for such a preference has yet to be found. Modeling of JAK2 suggests that the K539L falls 
in a loop in the linker region between the SH2 and the JH2 domain (Figure 1), which would be 
placed in space quite close to the loop represented by β4–β5 where V617 is located. 
1.9 TpoR and MPNs 
TpoR is coupled to and activates both JAK2 and Tyk2,64, 83, 84 which appear to have 
comparable affinities for the receptor juxtamembrane domain and to promote cell surface 
traffic of the receptor to a similar extent.47 However, JAK2 is much more effective than Tyk2 
in transmitting the signals of the receptor.47,64 TpoR activates JAK2, STAT5 and PI-3–
kinase/Akt,85 but in contrast to EpoR, it is a very strong activator of Shc, of the MAP kinase 
pathway and of STAT3 (Figure 2(i)).83, 86, 87, 88, 89, 90 It is interesting that the first consequence 
of expressing the JAK2 V617F (at lower than physiologic levels in the transgenic model) 
mutation is to promote platelet formation.24 Bipotential megakaryocyte–erythroid 
progenitors appear to be stimulated to engage on the platelet formation by STAT3 
activation, whereas STAT5 activation favors erythroid differentiation programs.91 STAT5 
emerged as a critical factor for lineage commitment between erythroid and megakaryocytic 
cell fates. Depletion of STAT5 from CD34(+) cells in the presence of Tpo and stem cell factor 
favors megakaryocytic differentiation at the expense of erythroid differentiation.91 
Overexpression of an activated form of STAT5 impaired megakaryocyte development 
favoring erythroid differentiation at the expense of megakaryocyte differentiation.91 Thus, at 
low levels of expression, JAK2 V617F might only activate STAT3, which might suffice for 
platelet formation. At higher expression levels, coupling to both TpoR and EpoR will lead to 
STAT5 activation, and this would favor the erythroid program. It is not clear at this point 
whether the PV phenotype is exclusively the result of EpoR activation or whether the 
pathologic activation of TpoR might also contribute to the PV phenotype. It is interesting to 
note that overexpression of TpoR in certain animal models led to an expansion of the 
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erythroid compartment.92The SH2 and PH (pleckstrin homology domain) adapter protein 
Lnk was shown to not only bind to phosphorylated tyrosine residues of both TpoR and 
EpoR but also to exert a negative role on signaling by these receptors.93, 94 It is not known 
whether the defects in this negative regulatory mechanism are operating in MPNs. Co-
expression of JAK2 V617F and TpoR in Ba/F3 cells leads to down-modulation of TpoR, most 
likely due to internalization and down-modulation seen after excessive activation of 
cytokine receptors (J Staerk, C Pecquet, C Diaconu and SN Constantinescu, unpublished 
observations). This is consistent with early studies that have identified a maturation defect 
and down-modulation of cell surface TpoR in platelets and megakaryocytes from MPN 
patients.95 More recently, an inverse correlation was reported between the burden of JAK2 
V617F and the levels of cell surface TpoR on platelets.96 Although these results suggest that 
JAK2 V617F may contribute to the down-modulation of TpoR, several patients with MPNs 
in the absence of JAK2 V617F also exhibited down-modulated TpoR. Such down-
modulation is not seen for EpoR. TpoR is a long-lived receptor at the cell surface47 and 
recycles,97 which is not the case for EpoR. Further experiments are necessary to follow up on 
the original observation of TpoR down-modulation in MPNs, which may be due to traffic 
alterations, excessive internalization and degradation or decreased protein synthesis. Several 
mutations in Mpl induce myeloid malignancies. A mutation in the transmembrane domain of 
Mpl, S505N, constitutively activates the receptor98and has been discovered in familial ET.99 
The S505N mutation in the transmembrane domain is expected to promote constitutive 
activation due to polar interactions between the asparagines that replace the natural serine. As 
stated earlier, mutations in Mpl at W515 induce severe MPNs with myeloprofibrosis.19, 20 
W515 mutations activate constitutive signaling by the receptor because W515 belongs to an 
amphipathic juxtamembrane helix (RWQFP in the human receptor), which is required for 
maintaining the un-liganded receptor in the inactive state. Another activating mutation was 
recently described for TpoR, where a threonine residue in the extracellular juxtamembrane 
region (located symmetrically from the W515 mutation on the N-terminal side of the 
transmembrane domain) is mutated to alanine (T487A) in a non-Down's syndrome childhood 
acute megakaryocytic leukemia.100 In bone marrow transplantation assays, this Mpl T487A 
also induces a severe myeloproliferative disease, close to the phenotype induced by TpoR 
W515L.100 Juxtamembrane mutations such as W515L/K or T487A may not only promote active 
dimeric conformations, but they could also induce receptor conformational changes by 
changing crossing angles between receptor monomers, whereas the S505N highly polar 
mutation in the transmembrane domain is predicted to stabilize an active dimeric 
conformation of the receptor. It will be interesting to test side by side in bone marrow 
transplantation experiments the effects of S505N, W515L and T487A mutations and to assess 
whether indeed the phenotype of the TpoR S505N mutation would be milder. 
1.10 G-CSFR and MPNs 
Bone marrow transplanted mice with HSCs expressing JAK2 V617F present not only an 
MPN phenotype, with low Epo, as predicted, but also with low G-CSF serum levels, 
suggesting that constitutive activation of G-CSFR occurs in these mice.101G-CSFR uses both 
JAK1 and JAK2 for signaling.65, 66 JAK2 V617F may affect G-CSFR signaling with less 
efficiency than for EpoR and TpoR, as JAK1 may be the key JAK for G-CSFR. This is perhaps 
the reason why the granulocytic lineage is affected to a lower extent in MPNs, when 
compared with the erythroid and megakaryocytic lineages, especially at low levels of JAK2 
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of MAP kinase and of STAT3,73 as it does not contain a consensus site for STAT3 binding, 
whereas several phosphorylated tyrosine residues (Y343, Y401, Y429 and Y431) can bind 
STAT5 and are required for maximal STAT5 activation.74, 75 A consequence of STAT5 
activation is induction of the anti-apoptotic BclXL protein expression,76 which is 
constitutively expressed in PV erythroid progenitors.7 The connection of EpoR with the PI-
3–kinase pathway is accomplished by specific tyrosine residues, that is Y479, which appears 
to bind the regulatory subunit p85.77, 78 PI-3–kinase and Akt activations are critically 
involved in erythroid differentiation,79 possibly by the involvement of the transcription 
factor Forkhead family, FKHRL1.80 Another mechanism appears to be the phosphorylation 
of S310 of GATA1.81 Thus, scaffolding of an activated JAK2 to EpoR is predicted to activate 
the JAK2–STAT5 and PI-3–kinase/Akt pathways and stimulate proliferation and 
differentiation of erythroid progenitors. 
1.8 EpoR and exon 12 JAK2 mutations 
Patients with exon 12 JAK2 mutations, such as JAK2 K539L, exhibit an erythrocytosis 
phenotype, without pathology changes to megakaryocytes typical for MPNs.18 Unlike the 
uniqueness of the point mutation that generates JAK2 V617F, several deletions and insertions 
were noted in the case of exon 12 mutations.18, 82 An attractive hypothesis is that exon 12 
mutants of JAK2 favor interaction with EpoR over TpoR or G-CSFR, although a mechanistic 
basis for such a preference has yet to be found. Modeling of JAK2 suggests that the K539L falls 
in a loop in the linker region between the SH2 and the JH2 domain (Figure 1), which would be 
placed in space quite close to the loop represented by β4–β5 where V617 is located. 
1.9 TpoR and MPNs 
TpoR is coupled to and activates both JAK2 and Tyk2,64, 83, 84 which appear to have 
comparable affinities for the receptor juxtamembrane domain and to promote cell surface 
traffic of the receptor to a similar extent.47 However, JAK2 is much more effective than Tyk2 
in transmitting the signals of the receptor.47,64 TpoR activates JAK2, STAT5 and PI-3–
kinase/Akt,85 but in contrast to EpoR, it is a very strong activator of Shc, of the MAP kinase 
pathway and of STAT3 (Figure 2(i)).83, 86, 87, 88, 89, 90 It is interesting that the first consequence 
of expressing the JAK2 V617F (at lower than physiologic levels in the transgenic model) 
mutation is to promote platelet formation.24 Bipotential megakaryocyte–erythroid 
progenitors appear to be stimulated to engage on the platelet formation by STAT3 
activation, whereas STAT5 activation favors erythroid differentiation programs.91 STAT5 
emerged as a critical factor for lineage commitment between erythroid and megakaryocytic 
cell fates. Depletion of STAT5 from CD34(+) cells in the presence of Tpo and stem cell factor 
favors megakaryocytic differentiation at the expense of erythroid differentiation.91 
Overexpression of an activated form of STAT5 impaired megakaryocyte development 
favoring erythroid differentiation at the expense of megakaryocyte differentiation.91 Thus, at 
low levels of expression, JAK2 V617F might only activate STAT3, which might suffice for 
platelet formation. At higher expression levels, coupling to both TpoR and EpoR will lead to 
STAT5 activation, and this would favor the erythroid program. It is not clear at this point 
whether the PV phenotype is exclusively the result of EpoR activation or whether the 
pathologic activation of TpoR might also contribute to the PV phenotype. It is interesting to 
note that overexpression of TpoR in certain animal models led to an expansion of the 
 
Molecular Mechanisms in Philadelphia Negative Myeloproliferative Neoplasia 
 
309 
erythroid compartment.92The SH2 and PH (pleckstrin homology domain) adapter protein 
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whether the defects in this negative regulatory mechanism are operating in MPNs. Co-
expression of JAK2 V617F and TpoR in Ba/F3 cells leads to down-modulation of TpoR, most 
likely due to internalization and down-modulation seen after excessive activation of 
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patients.95 More recently, an inverse correlation was reported between the burden of JAK2 
V617F and the levels of cell surface TpoR on platelets.96 Although these results suggest that 
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in the absence of JAK2 V617F also exhibited down-modulated TpoR. Such down-
modulation is not seen for EpoR. TpoR is a long-lived receptor at the cell surface47 and 
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the original observation of TpoR down-modulation in MPNs, which may be due to traffic 
alterations, excessive internalization and degradation or decreased protein synthesis. Several 
mutations in Mpl induce myeloid malignancies. A mutation in the transmembrane domain of 
Mpl, S505N, constitutively activates the receptor98and has been discovered in familial ET.99 
The S505N mutation in the transmembrane domain is expected to promote constitutive 
activation due to polar interactions between the asparagines that replace the natural serine. As 
stated earlier, mutations in Mpl at W515 induce severe MPNs with myeloprofibrosis.19, 20 
W515 mutations activate constitutive signaling by the receptor because W515 belongs to an 
amphipathic juxtamembrane helix (RWQFP in the human receptor), which is required for 
maintaining the un-liganded receptor in the inactive state. Another activating mutation was 
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region (located symmetrically from the W515 mutation on the N-terminal side of the 
transmembrane domain) is mutated to alanine (T487A) in a non-Down's syndrome childhood 
acute megakaryocytic leukemia.100 In bone marrow transplantation assays, this Mpl T487A 
also induces a severe myeloproliferative disease, close to the phenotype induced by TpoR 
W515L.100 Juxtamembrane mutations such as W515L/K or T487A may not only promote active 
dimeric conformations, but they could also induce receptor conformational changes by 
changing crossing angles between receptor monomers, whereas the S505N highly polar 
mutation in the transmembrane domain is predicted to stabilize an active dimeric 
conformation of the receptor. It will be interesting to test side by side in bone marrow 
transplantation experiments the effects of S505N, W515L and T487A mutations and to assess 
whether indeed the phenotype of the TpoR S505N mutation would be milder. 
1.10 G-CSFR and MPNs 
Bone marrow transplanted mice with HSCs expressing JAK2 V617F present not only an 
MPN phenotype, with low Epo, as predicted, but also with low G-CSF serum levels, 
suggesting that constitutive activation of G-CSFR occurs in these mice.101G-CSFR uses both 
JAK1 and JAK2 for signaling.65, 66 JAK2 V617F may affect G-CSFR signaling with less 
efficiency than for EpoR and TpoR, as JAK1 may be the key JAK for G-CSFR. This is perhaps 
the reason why the granulocytic lineage is affected to a lower extent in MPNs, when 
compared with the erythroid and megakaryocytic lineages, especially at low levels of JAK2 
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V617F. Activation of the G-CSFR JAK2 V617F complexes may lead to enhanced numbers of 
granulocytes, constitutive activation of granulocytes (with release of enzymes) as well as 
interactions with platelets, which would contribute to thrombotic complications. It is not 
clear whether leukocytosis, which is seen in certain MPN patients and which appears to be 
associated with certain complications or evolution toward leukemia,102 may be due to the 
pathologic activation of G-CSFR by JAK2 V617F. Granulocytes from patients with MPNs 
presented altered gene expression promoted by JAK2 V617F expression and confirmed a 
recapitulation of cytokine receptor signaling, resembling profiles of granulocytes activated 
by G-CSF.103Similar to TpoR, G-CSFR activates STAT3 and MAP kinase pathways, in 
addition to the JAK2–STAT5 and PI-3–kinase/Akt pathways. It can be noted that for this 
receptor, a very delicate balance has been identified between the activation of STAT3, 
required for differentiation and inducing a stop in cell growth (necessary for 
differentiation), and STAT5, which promotes proliferation.102 Binding of SOCS3 through its 
SH2 domain to a phosphorylated tyrosine residue in the receptor's cytosolic end specifically 
downregulates STAT5 signaling. Deletion of the cytosolic region, which contains the 
binding site for SOCS3, leads to enhanced STAT5-to-STAT3 signaling ratio,102 and this is 
associated with evolution toward acute myeloid leukemia of patients with severe congenital 
neutropenia. G-CSFR activation might synergize with other mechanisms and promote the 
mobilization of CD34(+) stem cells and progenitors from the bone marrow to the periphery. 
Interestingly, an increased number of circulating CD34(+) cells in MPN patients has been 
observed, and they exhibit granulocyte activation patterns similar to those induced by the 
administration of G-CSF.104 The release of CD34(+) cells is generally due to a combination of 
increased levels of proteases105 and especially due to the downregulation of the CXCR4 
receptor on CD34(+) cells.106 An altered SDF-1/CXCR4 axis was demonstrated in PMF 
patients with CD34(+) cells in the periphery.107 These findings are supported by the rapid 
mobilization of CD34(+) cells with AMD3100, a CXCR4 antagonist.108 
1.11 Tyrosine phosphorylation pattern of JAK2 V617F 
JAK2 V617F is constitutively tyrosine phosphorylated. However, besides Y1007 in the 
activation loop, which is crucial for activation,109 it is not known whether other 
phosphorylated tyrosines overlap with those phosphorylated in the wild-type JAK2. It can 
be noted that, JAK2 contains multiple tyrosine residues, of which at least 14 can be 
phosphorylated110 (Figure 1). Some of these tyrosine residues exert positive (Y221) and other 
negative (Y119, Y570) effects on signaling by JAK2.111, 112, 113 Y813 is a recruitment site for 
SH2-containing proteins,114 such as SH2B, which can promote homodimerization of JAK2.115 
In theory, the constitutive activation of JAK2 V617F might promote a different pattern of 
phosphorylated tyrosines from that of wild-type JAK2. 
1.12 STAT activation and MPNs 
A hallmark of MPNs is constitutive or hypersensitive activation of the STAT family of 
transcription factors in myeloid precursors. As mentioned, the expressions of JAK2 V617F, 
TpoR mutants or exon 12 JAK2 mutants lead to constitutive STAT5 and STAT3 activation in 
various systems.18, 116 As a function of the MPN disease type, one or the other of the STATs 
was suggested to be predominantly activated by JAK2 V617F. For example, in myelofibrosis, 
JAK2 V617F expression in neutrophils is associated with the activation of STAT3 but 
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apparently not with that of STAT5.117 In another study, in bone marrow biopsies and 
irrespective of JAK2 V617F, PV patients exhibited high STAT5 and STAT3 phosphorylation 
and ET patients exhibited high STAT3, but low STAT5 phosphorylation, whereas 
myelofibrosis patients exhibited low STAT5 and STAT3 phosphorylation.118 Thus, constitutive 
activation of the STAT5/STAT3 signaling appears to be a major determinant of MPNs, 
irrespective of the particular JAK2 or receptor mutation. Furthermore, STAT3 activation by IL-
6 has been shown in a murine model system to hold the potential to experimentally induce 
MPN. Mice homozygous for a knockin mutation in the IL-6 receptor gp130 
(gp130(Y757F/Y757F)), which leads to gp130-dependent hyperactivation of STAT1 and STAT3 
develop myeloproliferative diseases with splenomegaly, lymphadenopathy and 
thrombocytosis. gp130(Y757F/Y757F) is hyperactive owing to impaired recruitment of 
negative regulators such as SOCS3 and the SHP2 phosphatase.119,120 The hematological 
phenotype disappeared when the knockin mice were crossed with heterozygous Stat3(+/-) 
mice.121 Thus, the threshold of STAT3 signaling elicited by IL-6 family cytokines may have an 
important function in the myeloid lineage and may contribute to the development of MPN. 
1.13 SOCS3 and JAK2 V617F 
Suppressors of cytokine signaling (SOCS) proteins negatively regulate cytokine receptors and 
JAK–STAT signaling. There are eight members of the SOCS/CIS (cytokine-inducible SH2-
domain-containing protein) family, namely SOCS1–SOCS7 and CIS. Each SOCS molecule 
contains a divergent N-terminal domain, a central SH2 domain, and a C-terminal 40 amino 
acid domain known as the SOCS box.122 CIS/SOCS proteins are supposed to function as E3 
ubiquitin ligases and target proteins bound to the SOCS N terminus, such as active JAKs, as 
well as themselves for proteasome-mediated degradation.122 SOCS1 and SOCS3 can also 
inhibit the catalytic activity of JAK proteins directly, as they contain a kinase inhibitory region 
(KIR) that targets the activation loop of JAK proteins. SOCS proteins bind receptors and then 
target the activation loop of JAKs for inhibition by KIR and SH2 interactions.122SOCS3 is 
known to strongly down-modulate EpoR signaling.123 JAK2 V617F appears not to be 
downregulated by SOCS3, possibly due to continuous phosphorylation of SOCS3, which can 
impair its E3 ligase activity.124 Constitutive tyrosine phosphorylation of SOCS3 was also 
reported in peripheral blood mononuclear cells derived from patients homozygous for the 
JAK2 V617F mutant.124 Taken together, a model was proposed in which JAK2 V617F may 
escape physiologic SOCS regulation by hyperphosphorylating SOCS3. It would be important 
to also determine whether exon 12 mutants of JAK2 are able to overcome down-modulation by 
SOCS3.Furthermore, one of the two tyrosine residues in the C terminus of SOCS3 that become 
phosphorylated upon ligand-activated cytokine receptors interacts with the Ras inhibitor p120 
RasGAP.125 This leads, in the case of IL-2 signaling, to sustained ERK activation, whereas the 
JAK–STAT pathway is down-modulated.125Whether part of the sustained ERK activation 
detected in cells transformed by JAK2 V617F may involve complexes of degradation-resistant 
SOCS3 and p120 RasGAP is yet to be determined. 
1.14 Other JAK2 mutations activate JAK2 
Substitution of pseudokinase domain residue V617 by large non-polar amino acids causes 
activation of JAK2.126 Saturation mutagenesis at position 617 of JAK2 showed that, in 
addition to V617F, four other JAK2 mutants, V617W, V617M, V617I and V617L, were able to 
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V617F. Activation of the G-CSFR JAK2 V617F complexes may lead to enhanced numbers of 
granulocytes, constitutive activation of granulocytes (with release of enzymes) as well as 
interactions with platelets, which would contribute to thrombotic complications. It is not 
clear whether leukocytosis, which is seen in certain MPN patients and which appears to be 
associated with certain complications or evolution toward leukemia,102 may be due to the 
pathologic activation of G-CSFR by JAK2 V617F. Granulocytes from patients with MPNs 
presented altered gene expression promoted by JAK2 V617F expression and confirmed a 
recapitulation of cytokine receptor signaling, resembling profiles of granulocytes activated 
by G-CSF.103Similar to TpoR, G-CSFR activates STAT3 and MAP kinase pathways, in 
addition to the JAK2–STAT5 and PI-3–kinase/Akt pathways. It can be noted that for this 
receptor, a very delicate balance has been identified between the activation of STAT3, 
required for differentiation and inducing a stop in cell growth (necessary for 
differentiation), and STAT5, which promotes proliferation.102 Binding of SOCS3 through its 
SH2 domain to a phosphorylated tyrosine residue in the receptor's cytosolic end specifically 
downregulates STAT5 signaling. Deletion of the cytosolic region, which contains the 
binding site for SOCS3, leads to enhanced STAT5-to-STAT3 signaling ratio,102 and this is 
associated with evolution toward acute myeloid leukemia of patients with severe congenital 
neutropenia. G-CSFR activation might synergize with other mechanisms and promote the 
mobilization of CD34(+) stem cells and progenitors from the bone marrow to the periphery. 
Interestingly, an increased number of circulating CD34(+) cells in MPN patients has been 
observed, and they exhibit granulocyte activation patterns similar to those induced by the 
administration of G-CSF.104 The release of CD34(+) cells is generally due to a combination of 
increased levels of proteases105 and especially due to the downregulation of the CXCR4 
receptor on CD34(+) cells.106 An altered SDF-1/CXCR4 axis was demonstrated in PMF 
patients with CD34(+) cells in the periphery.107 These findings are supported by the rapid 
mobilization of CD34(+) cells with AMD3100, a CXCR4 antagonist.108 
1.11 Tyrosine phosphorylation pattern of JAK2 V617F 
JAK2 V617F is constitutively tyrosine phosphorylated. However, besides Y1007 in the 
activation loop, which is crucial for activation,109 it is not known whether other 
phosphorylated tyrosines overlap with those phosphorylated in the wild-type JAK2. It can 
be noted that, JAK2 contains multiple tyrosine residues, of which at least 14 can be 
phosphorylated110 (Figure 1). Some of these tyrosine residues exert positive (Y221) and other 
negative (Y119, Y570) effects on signaling by JAK2.111, 112, 113 Y813 is a recruitment site for 
SH2-containing proteins,114 such as SH2B, which can promote homodimerization of JAK2.115 
In theory, the constitutive activation of JAK2 V617F might promote a different pattern of 
phosphorylated tyrosines from that of wild-type JAK2. 
1.12 STAT activation and MPNs 
A hallmark of MPNs is constitutive or hypersensitive activation of the STAT family of 
transcription factors in myeloid precursors. As mentioned, the expressions of JAK2 V617F, 
TpoR mutants or exon 12 JAK2 mutants lead to constitutive STAT5 and STAT3 activation in 
various systems.18, 116 As a function of the MPN disease type, one or the other of the STATs 
was suggested to be predominantly activated by JAK2 V617F. For example, in myelofibrosis, 
JAK2 V617F expression in neutrophils is associated with the activation of STAT3 but 
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apparently not with that of STAT5.117 In another study, in bone marrow biopsies and 
irrespective of JAK2 V617F, PV patients exhibited high STAT5 and STAT3 phosphorylation 
and ET patients exhibited high STAT3, but low STAT5 phosphorylation, whereas 
myelofibrosis patients exhibited low STAT5 and STAT3 phosphorylation.118 Thus, constitutive 
activation of the STAT5/STAT3 signaling appears to be a major determinant of MPNs, 
irrespective of the particular JAK2 or receptor mutation. Furthermore, STAT3 activation by IL-
6 has been shown in a murine model system to hold the potential to experimentally induce 
MPN. Mice homozygous for a knockin mutation in the IL-6 receptor gp130 
(gp130(Y757F/Y757F)), which leads to gp130-dependent hyperactivation of STAT1 and STAT3 
develop myeloproliferative diseases with splenomegaly, lymphadenopathy and 
thrombocytosis. gp130(Y757F/Y757F) is hyperactive owing to impaired recruitment of 
negative regulators such as SOCS3 and the SHP2 phosphatase.119,120 The hematological 
phenotype disappeared when the knockin mice were crossed with heterozygous Stat3(+/-) 
mice.121 Thus, the threshold of STAT3 signaling elicited by IL-6 family cytokines may have an 
important function in the myeloid lineage and may contribute to the development of MPN. 
1.13 SOCS3 and JAK2 V617F 
Suppressors of cytokine signaling (SOCS) proteins negatively regulate cytokine receptors and 
JAK–STAT signaling. There are eight members of the SOCS/CIS (cytokine-inducible SH2-
domain-containing protein) family, namely SOCS1–SOCS7 and CIS. Each SOCS molecule 
contains a divergent N-terminal domain, a central SH2 domain, and a C-terminal 40 amino 
acid domain known as the SOCS box.122 CIS/SOCS proteins are supposed to function as E3 
ubiquitin ligases and target proteins bound to the SOCS N terminus, such as active JAKs, as 
well as themselves for proteasome-mediated degradation.122 SOCS1 and SOCS3 can also 
inhibit the catalytic activity of JAK proteins directly, as they contain a kinase inhibitory region 
(KIR) that targets the activation loop of JAK proteins. SOCS proteins bind receptors and then 
target the activation loop of JAKs for inhibition by KIR and SH2 interactions.122SOCS3 is 
known to strongly down-modulate EpoR signaling.123 JAK2 V617F appears not to be 
downregulated by SOCS3, possibly due to continuous phosphorylation of SOCS3, which can 
impair its E3 ligase activity.124 Constitutive tyrosine phosphorylation of SOCS3 was also 
reported in peripheral blood mononuclear cells derived from patients homozygous for the 
JAK2 V617F mutant.124 Taken together, a model was proposed in which JAK2 V617F may 
escape physiologic SOCS regulation by hyperphosphorylating SOCS3. It would be important 
to also determine whether exon 12 mutants of JAK2 are able to overcome down-modulation by 
SOCS3.Furthermore, one of the two tyrosine residues in the C terminus of SOCS3 that become 
phosphorylated upon ligand-activated cytokine receptors interacts with the Ras inhibitor p120 
RasGAP.125 This leads, in the case of IL-2 signaling, to sustained ERK activation, whereas the 
JAK–STAT pathway is down-modulated.125Whether part of the sustained ERK activation 
detected in cells transformed by JAK2 V617F may involve complexes of degradation-resistant 
SOCS3 and p120 RasGAP is yet to be determined. 
1.14 Other JAK2 mutations activate JAK2 
Substitution of pseudokinase domain residue V617 by large non-polar amino acids causes 
activation of JAK2.126 Saturation mutagenesis at position 617 of JAK2 showed that, in 
addition to V617F, four other JAK2 mutants, V617W, V617M, V617I and V617L, were able to 
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induce cytokine independence and constitutive downstream signaling. However, only 
V617W induced a level of constitutive activation comparable with V617F, and like V617F it 
was able to stabilize tyrosine-phosphorylated SOCS3.126 Also, the V617W mutant induced a 
myeloproliferative disease in bone-marrow-reconstituted mice, mainly characterized by 
erythrocytosis and megakaryocytic proliferation. Although JAK2 V617W would predictably 
be pathogenic in humans, the substitution of the Val codon, GTC, by TTG, the codon for 
Trp, would require three base pair changes, which makes it unlikely to occur. Therefore, 
codon usage and resistance to SOCS3-induced down-modulation are two mechanisms that 
might explain the uniqueness of JAK2 V617F in MPNs. 
2. Animal models of MPNs 
2.1 JAK2 mutants 
Mouse bone marrow reconstitution experiments with HSCs retrovirally transduced with 
JAK2 V617F resulted in strain-dependent myeloproliferative disease phenotypes. In these 
models, JAK2 V617F is expressed at ~10-fold higher than endogenous levels. In C57Bl6 
mice, JAK2 V617F induces erythrocytosis, and in some animals myelofibrosis, although 
most reconstituted mice remain alive several months, and in some the erythrocytosis 
regresses; in Balb/c mice, the phenotype is more severe with erythrocytosis being followed 
by myelofibrosis.13, 23, 127 Only very rarely, at low transduction levels, was a thrombocytosis 
phenotype observed, which, together with initial studies on primary patient cells,22 led to 
the suggestion that gene dosage may be important for a particular phenotype to develop.23 
This hypothesis has been supported by studies in transgenic mice in which the expression of 
the JAK2 V617F was carefully regulated.24 When JAK2 V617F levels were lower than 
endogenous JAK2 levels, an ET phenotype was obtained. When levels of JAK2 V617F were 
similar to those of endogenous wild-type JAK2, a PV-like phenotype was developed. 
Interestingly, upon development of the PV phenotype, a selection for higher levels of JAK2 
V617F occurs, up to 5- to 6-fold higher than the endogenous JAK2 levels, which is not the 
case for the ET phenotype.24 This indicates positive selection for JAK2 V617F expression in 
PV progenitors, a phenomenon that can be detected in stably transfected Ba/F3 cells.51 In 
addition overexpression of several non-mutated JAK proteins, including JAK2, was shown 
to promote hematopoietic transformation to cytokine independence.128The phenotype 
induced by exon 12 mutants of JAK2 is more restricted to erythrocytosis, without the 
abnormal megakaryocyte clusters seen in the classical MPNs.18 These in vivo data indicate 
that a difference must exist between signaling by JAK2 V617F and exon 12 JAK2 mutants. 
2.2 Mpl (TpoR) mutants 
The phenotype induced by TpoR W515L is different than that induced by JAK2 mutants, in 
that it is much more severe, with initial myeloproliferation, marked thrombocytosis, 
splenomegaly and myelofibrosis, and is established within 20–30 days after reconstitution.19 At 
least one other mutation at W515 was identified in patients with PMF and ET, that is W515K.20 
W515 is located in an amphipathic motif (RWQFP) at the junction between the transmembrane 
and cytosolic domains. This motif is required to maintain the un-liganded TpoR in an inactive 
state. Given that a W515A mutation is also active,21 it is not surprising that such different 
residues (Leu and Lys) are found in active TpoR mutants. We predict that other W515 
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mutations will be found in patients, as the loss of a Trp (W) residue is responsible for 
activation. The striking difference in severity and histopathology between the phenotypes 
induced by JAK2 V617F and Mpl 515 mutants is hard to understand when standard 
phosphorylation studies are performed on cell lines, such as Ba/F3 cells, where the same 
redundant pathways are activated by both JAK2 V617F and Mpl 515 mutants. Interestingly, 
deletion of the amphipathic motif (5TpoR) that contains W515 or the mutation of either the 
lysine K514 (R514 in the human receptor) or the W515 in this motif to alanine leads to 
constitutive JAK2 and STAT activation and colony formation in primary cells and 
hypersensitivity to Tpo.21 In hematopoietic cells transformed by 5TpoR (amphipathic motif 
deleted) or TpoR W515A, we noted enhanced STAT5 and MAP kinase activation in the 
absence of Tpo, and high levels of activation of STAT5, STAT3 and MAP kinase pathways on 
Tpo treatment.21 Such TpoR mutants do not down-modulate cell surface levels of TpoR,21 
unlike TpoR in complex with JAK2 V617F, which is down-modulated (J Staerk et al., 
unpublished observations). It is therefore tempting to speculate that prolonged activation of 
MAP kinase and STAT3 might be a distinct feature of TpoR W515 mutants, whereas JAK2 
V617F, which couples not only to TpoR but also to other cytokine receptors expressed in 
myeloid progenitors, would generate a weaker or different signal. Taken together, these data 
suggest that some level of signaling specificity must exist, which would make the excessive 
activation of TpoR through JAK2 V617F qualitatively different from that induced by W515 
mutations. Understanding this difference at the signaling level will be of utmost importance. 
2.3 JAK2 inhibitors 
Since 2005, mutations that directly or indirectly led to deregulated activation of non-receptor 
tyrosine kinase (TK) Janus activated kinase 2 (JAK2) have been implicated in the 
pathogenesis of MPN. These mutations activate the JAK2–signal transducer and activator of 
transcription (STAT) intracellular signaling pathways, which lead to increased cellular 
proliferation and resistance to apoptosis. These discoveries spurred the development of 
molecularly targeted agents (JAK2 inhibitors) as therapy for MPNs.  
In clinical development, JAK2 inhibitors exhibit differential inhibitory activity against the 
JAK family members, and some exhibit effects on other receptor kinases and therefore are 
not selective forJAK2 TK. For example, INCB018424 inhibits JAK1, whereas CEP-701 and 
TG101348 inhibit FLT3. JAK2 inhibitors are small molecules that act by competing with 
adenosine triphosphate for the adenosine triphosphate–binding catalytic site in the TK 
domain. The V617F mutation locates outside the TK domain of JAK2. Therefore, the current 
JAK2 inhibitors target both wild-type and mutated JAK2 indiscriminately. This could 
explain why these drugs are active in patients with both wild-type and mutated JAK2. 
However, targeting the wild-type JAK2 is expected to lead to myelosuppression as a result 
of the exquisite signalling through JAK2 of thrombopoietin and erythropoietin receptors in 
normal hematopoiesis. This probably explains the reported therapy-related anaemia and 
thrombocytopenia observed with JAK2 inhibitors in clinical trials. 
Previous research demonstrated that JAK2-deficiency is embryonically fatal in mice due to a 
lack of erythropoiesis. As a consequence, no in vivo JAK2 knock out animal model exists, 
which makes the biological characterization of JAK2 more difficult. siRNA knock down 
models may be useful for this purpose, but for the time being, they cannot be considered as 
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induce cytokine independence and constitutive downstream signaling. However, only 
V617W induced a level of constitutive activation comparable with V617F, and like V617F it 
was able to stabilize tyrosine-phosphorylated SOCS3.126 Also, the V617W mutant induced a 
myeloproliferative disease in bone-marrow-reconstituted mice, mainly characterized by 
erythrocytosis and megakaryocytic proliferation. Although JAK2 V617W would predictably 
be pathogenic in humans, the substitution of the Val codon, GTC, by TTG, the codon for 
Trp, would require three base pair changes, which makes it unlikely to occur. Therefore, 
codon usage and resistance to SOCS3-induced down-modulation are two mechanisms that 
might explain the uniqueness of JAK2 V617F in MPNs. 
2. Animal models of MPNs 
2.1 JAK2 mutants 
Mouse bone marrow reconstitution experiments with HSCs retrovirally transduced with 
JAK2 V617F resulted in strain-dependent myeloproliferative disease phenotypes. In these 
models, JAK2 V617F is expressed at ~10-fold higher than endogenous levels. In C57Bl6 
mice, JAK2 V617F induces erythrocytosis, and in some animals myelofibrosis, although 
most reconstituted mice remain alive several months, and in some the erythrocytosis 
regresses; in Balb/c mice, the phenotype is more severe with erythrocytosis being followed 
by myelofibrosis.13, 23, 127 Only very rarely, at low transduction levels, was a thrombocytosis 
phenotype observed, which, together with initial studies on primary patient cells,22 led to 
the suggestion that gene dosage may be important for a particular phenotype to develop.23 
This hypothesis has been supported by studies in transgenic mice in which the expression of 
the JAK2 V617F was carefully regulated.24 When JAK2 V617F levels were lower than 
endogenous JAK2 levels, an ET phenotype was obtained. When levels of JAK2 V617F were 
similar to those of endogenous wild-type JAK2, a PV-like phenotype was developed. 
Interestingly, upon development of the PV phenotype, a selection for higher levels of JAK2 
V617F occurs, up to 5- to 6-fold higher than the endogenous JAK2 levels, which is not the 
case for the ET phenotype.24 This indicates positive selection for JAK2 V617F expression in 
PV progenitors, a phenomenon that can be detected in stably transfected Ba/F3 cells.51 In 
addition overexpression of several non-mutated JAK proteins, including JAK2, was shown 
to promote hematopoietic transformation to cytokine independence.128The phenotype 
induced by exon 12 mutants of JAK2 is more restricted to erythrocytosis, without the 
abnormal megakaryocyte clusters seen in the classical MPNs.18 These in vivo data indicate 
that a difference must exist between signaling by JAK2 V617F and exon 12 JAK2 mutants. 
2.2 Mpl (TpoR) mutants 
The phenotype induced by TpoR W515L is different than that induced by JAK2 mutants, in 
that it is much more severe, with initial myeloproliferation, marked thrombocytosis, 
splenomegaly and myelofibrosis, and is established within 20–30 days after reconstitution.19 At 
least one other mutation at W515 was identified in patients with PMF and ET, that is W515K.20 
W515 is located in an amphipathic motif (RWQFP) at the junction between the transmembrane 
and cytosolic domains. This motif is required to maintain the un-liganded TpoR in an inactive 
state. Given that a W515A mutation is also active,21 it is not surprising that such different 
residues (Leu and Lys) are found in active TpoR mutants. We predict that other W515 
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mutations will be found in patients, as the loss of a Trp (W) residue is responsible for 
activation. The striking difference in severity and histopathology between the phenotypes 
induced by JAK2 V617F and Mpl 515 mutants is hard to understand when standard 
phosphorylation studies are performed on cell lines, such as Ba/F3 cells, where the same 
redundant pathways are activated by both JAK2 V617F and Mpl 515 mutants. Interestingly, 
deletion of the amphipathic motif (5TpoR) that contains W515 or the mutation of either the 
lysine K514 (R514 in the human receptor) or the W515 in this motif to alanine leads to 
constitutive JAK2 and STAT activation and colony formation in primary cells and 
hypersensitivity to Tpo.21 In hematopoietic cells transformed by 5TpoR (amphipathic motif 
deleted) or TpoR W515A, we noted enhanced STAT5 and MAP kinase activation in the 
absence of Tpo, and high levels of activation of STAT5, STAT3 and MAP kinase pathways on 
Tpo treatment.21 Such TpoR mutants do not down-modulate cell surface levels of TpoR,21 
unlike TpoR in complex with JAK2 V617F, which is down-modulated (J Staerk et al., 
unpublished observations). It is therefore tempting to speculate that prolonged activation of 
MAP kinase and STAT3 might be a distinct feature of TpoR W515 mutants, whereas JAK2 
V617F, which couples not only to TpoR but also to other cytokine receptors expressed in 
myeloid progenitors, would generate a weaker or different signal. Taken together, these data 
suggest that some level of signaling specificity must exist, which would make the excessive 
activation of TpoR through JAK2 V617F qualitatively different from that induced by W515 
mutations. Understanding this difference at the signaling level will be of utmost importance. 
2.3 JAK2 inhibitors 
Since 2005, mutations that directly or indirectly led to deregulated activation of non-receptor 
tyrosine kinase (TK) Janus activated kinase 2 (JAK2) have been implicated in the 
pathogenesis of MPN. These mutations activate the JAK2–signal transducer and activator of 
transcription (STAT) intracellular signaling pathways, which lead to increased cellular 
proliferation and resistance to apoptosis. These discoveries spurred the development of 
molecularly targeted agents (JAK2 inhibitors) as therapy for MPNs.  
In clinical development, JAK2 inhibitors exhibit differential inhibitory activity against the 
JAK family members, and some exhibit effects on other receptor kinases and therefore are 
not selective forJAK2 TK. For example, INCB018424 inhibits JAK1, whereas CEP-701 and 
TG101348 inhibit FLT3. JAK2 inhibitors are small molecules that act by competing with 
adenosine triphosphate for the adenosine triphosphate–binding catalytic site in the TK 
domain. The V617F mutation locates outside the TK domain of JAK2. Therefore, the current 
JAK2 inhibitors target both wild-type and mutated JAK2 indiscriminately. This could 
explain why these drugs are active in patients with both wild-type and mutated JAK2. 
However, targeting the wild-type JAK2 is expected to lead to myelosuppression as a result 
of the exquisite signalling through JAK2 of thrombopoietin and erythropoietin receptors in 
normal hematopoiesis. This probably explains the reported therapy-related anaemia and 
thrombocytopenia observed with JAK2 inhibitors in clinical trials. 
Previous research demonstrated that JAK2-deficiency is embryonically fatal in mice due to a 
lack of erythropoiesis. As a consequence, no in vivo JAK2 knock out animal model exists, 
which makes the biological characterization of JAK2 more difficult. siRNA knock down 
models may be useful for this purpose, but for the time being, they cannot be considered as 
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therapeutic agents. JAK2 antagonists, however, could be used efficiently for analyzing the 
possible therapeutic benefit of JAK2 inhibition in hematologic malignancies and 
myeloproliferative disorders. 
On the other hand, only a small number of JAK2 inhibitors have been reported in the 
literature so far. AG490 possesses significant JAK2 inhibition, for that reason it has been 
used extensively as a research tool. AG490 blocks leukemic cell growth significantly both in 
vitro and in vivo.16 On the other hand, this compound lacks sufficient target specificity, 
therefore the interpretation of results obtained with AG490 may not be limited to JAK2 
inhibition. Several other non-specific JAK2 inhibitors have already been reported in the 
literature (LFM-A13,21 INCB20,22 WP106623 and SD-100824). Since off-target effects may 
cause serious immune-modulative or proliferative side effects, specific JAK2 inhibition is 
highly desirable. 
One molecule, TG101209, was able to inhibit proliferation of both JAK2 V617F- and TpoR 
W515L/K-expressing hematopoietic cells.130 It may be recalled that TpoR W515-mutated 
proteins are expected to constitutively activate the wild-type JAK2. 
TG101348, a nano-molar JAK2 inhibitor, was highly specific for JAK2 as evidenced by a 300-
fold selectivity over JAK3. TG101348, was effective in a murine model of MPN induced by 
JAK2 V617F131 and inhibited the engraftment of JAK2 V617F-positive HSCs and myeloid 
progenitors in a bioluminescent xenogeneic transplantation assay.132 Importantly, the 
inhibitor decreased GATA1 expression and phosphorylation of GATA1 at S310 and, as 
expected, STAT5 activation. These signaling events might be associated with erythroid-
skewing of JAK2 V617F-positive progenitor differentiation, as phosphorylation at GATA1 
S310 was shown to be important for erythroid differentiation.81 GATA1 is absolutely 
required for erythroid and megakaryocyte formation.133, 134 Although both EpoR and 
GATA1 are crucial for erythroid differentiation, this phosphorylation event, which depends 
on PI-3-kinase and Akt,81 appears to be the only one described where a direct EpoR 
downstream signal affects GATA1. 
An experimental JAK2 inhibitor has been shown to be well tolerated and to produce a 
significant reduction in disease burden and durable clinical benefit in patients with 
myelofibrosis reports a study. 161 Currently there are no FDA approved treatments for 
myelofibrosis. Common treatments of the malignancy, which is associated with anaemia 
and splenomegaly, are palliative and do not alter the natural course of the disease. Median 
survival ranges from less than two years to greater than 15 years. Patients with 
myelofibrosis frequently harbour JAK-STAT activating mutations that are sensitive to 
TG101348, a selective small-molecule JAK2 inhibitor. It is estimated that JAK2 mutations 
occur in approximately 50 % of patients. Last September researchers reported positive 
results from a trial testing the experimental agent INCBO18424, (which inhibits JAK1 as well 
as JAK2) in patients with advanced myelofibrosis. In the current phase 1 study, Ayalew 
Tefferi and colleagues from the Mayo Clinic enrolled 59 patients, including 28 who took part 
in the dose-escalating phase. A substantial portion of patients experienced improvements in 
primary symptoms including splenomegaly, leukocytosis, thrombocytosis, and 
constitutional symptoms. There was also evidence for significant reductions in genomic 
disease burden, indicating the potential for disease-modifying activity. Although the drug 
was generally well tolerated, it caused anaemia in some patients, especially at higher doses. 
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A follow-up study is planned to see whether adjusting the dose will allow patients to 
achieve the benefits without the anaemia. In an accompanying editorial Srdan Verstovsek 
from the University of Texas MD Anderson Cancer Center wrote, "The development of 
JAK2 inhibitors has ushered in a new era of targeted therapies for Philadelphia-negative 
MPNs. These drugs do not eradicate the malignant clone, but they provide significant 
clinical benefit. Given that the current clinical management of patients with MF is largely 
palliative and minimally effective, significant improvements in two of the three most 
important clinical manifestations of MF (splenomegaly and systemic symptoms) seen with 
JAK2 inhibitors is significant therapeutic progress." Long term results, he added, are 
required to determine the full potential of JAK2 inhibitors in myelofibrosis and to determine 
whether they will have an impact on survival. 
3. Cross-talk: JAK2 V617F and other pathways 
3.1 JAK2 V617F and other tyrosine kinases 
Tyrosine kinase receptors have been suggested to contribute to the pathogenesis of PV. In 
patients with PV, circulating erythroid progenitor cells are hypersensitive to IGF-1 and this 
effect requires the IGF-1 receptor.10, 135Expression of JAK2 V617F in Ba/F3 cells renders the 
cells responsive to IGF-1 at doses where parental Ba/F3 cells are unresponsive.51 After 
selection for autonomous growth, these Ba/F3 JAK2 V617F cells acquire the ability to 
respond to IGF-1 by further tyrosine phosphorylation of the mutant JAK2 and of STAT5 and 
STAT3. Which adaptor/signaling protein mediates this cross-talk is not clear, but it might 
be relevant for the hypersensitivity of PV erythroid progenitors to IGF-1. 
Treatment with imatinib, an inhibitor of the Abl, c-KIT and PDGF receptor kinase, leads to 
minimal responses in PV, but nevertheless some rare patients achieve remission and a 
decrease in the JAK2 V617F allele burden.136 Imatinib exerts a dose-dependent growth 
inhibitory effect on factor dependent cell paterson (FDCP) cells expressing JAK2 V617F, 
most likely by interrupting the cross-talk between JAK2 V617F and c-KIT.137 Thus, this study 
predicts that in PV patients where imatinib exerts benefic effects, pathologic signaling 
occurs through c-KIT.Src tyrosine kinases have also been suggested to contribute to 
signaling by EpoR.138 However, Src kinases were dispensable for the polycythemia 
phenotype induced by JAK2 V617F, as shown by bone marrow reconstitution studies in 
mice deficient for Lyn, Fyn or Fgr kinases.139 
3.2 JAK2 V617F and TNF- 
In BALB/c mice reconstituted with HSCs transduced for the expression of JAK2 V617F, the 
PV-like phenotype is associated with increased serum levels of TNF-.101 TNF- might be 
required for suppressing normal hematopoiesis, and in this manner it might favor the 
mutated clone. Reconstitution experiments in TNF- knockout mice supported the notion 
that TNF- might be required for the establishment of the MPN phenotype and for clonal 
dominance (Bumm TGP, VanDyke J, Loriaux M, Gendron C, Wood LG, Druker BJ, 
Deininger MW. TNF- plays a crucial role in the JAK2-V617F-induced myeloproliferative 
disorder. Blood2007; 110. American Society of Hematology 2007 Abstract 675). Further 
studies will be required to firmly establish whether TNF signaling may contribute to clonal 
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therapeutic agents. JAK2 antagonists, however, could be used efficiently for analyzing the 
possible therapeutic benefit of JAK2 inhibition in hematologic malignancies and 
myeloproliferative disorders. 
On the other hand, only a small number of JAK2 inhibitors have been reported in the 
literature so far. AG490 possesses significant JAK2 inhibition, for that reason it has been 
used extensively as a research tool. AG490 blocks leukemic cell growth significantly both in 
vitro and in vivo.16 On the other hand, this compound lacks sufficient target specificity, 
therefore the interpretation of results obtained with AG490 may not be limited to JAK2 
inhibition. Several other non-specific JAK2 inhibitors have already been reported in the 
literature (LFM-A13,21 INCB20,22 WP106623 and SD-100824). Since off-target effects may 
cause serious immune-modulative or proliferative side effects, specific JAK2 inhibition is 
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One molecule, TG101209, was able to inhibit proliferation of both JAK2 V617F- and TpoR 
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skewing of JAK2 V617F-positive progenitor differentiation, as phosphorylation at GATA1 
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required for erythroid and megakaryocyte formation.133, 134 Although both EpoR and 
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An experimental JAK2 inhibitor has been shown to be well tolerated and to produce a 
significant reduction in disease burden and durable clinical benefit in patients with 
myelofibrosis reports a study. 161 Currently there are no FDA approved treatments for 
myelofibrosis. Common treatments of the malignancy, which is associated with anaemia 
and splenomegaly, are palliative and do not alter the natural course of the disease. Median 
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primary symptoms including splenomegaly, leukocytosis, thrombocytosis, and 
constitutional symptoms. There was also evidence for significant reductions in genomic 
disease burden, indicating the potential for disease-modifying activity. Although the drug 
was generally well tolerated, it caused anaemia in some patients, especially at higher doses. 
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A follow-up study is planned to see whether adjusting the dose will allow patients to 
achieve the benefits without the anaemia. In an accompanying editorial Srdan Verstovsek 
from the University of Texas MD Anderson Cancer Center wrote, "The development of 
JAK2 inhibitors has ushered in a new era of targeted therapies for Philadelphia-negative 
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clinical benefit. Given that the current clinical management of patients with MF is largely 
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important clinical manifestations of MF (splenomegaly and systemic symptoms) seen with 
JAK2 inhibitors is significant therapeutic progress." Long term results, he added, are 
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whether they will have an impact on survival. 
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most likely by interrupting the cross-talk between JAK2 V617F and c-KIT.137 Thus, this study 
predicts that in PV patients where imatinib exerts benefic effects, pathologic signaling 
occurs through c-KIT.Src tyrosine kinases have also been suggested to contribute to 
signaling by EpoR.138 However, Src kinases were dispensable for the polycythemia 
phenotype induced by JAK2 V617F, as shown by bone marrow reconstitution studies in 
mice deficient for Lyn, Fyn or Fgr kinases.139 
3.2 JAK2 V617F and TNF- 
In BALB/c mice reconstituted with HSCs transduced for the expression of JAK2 V617F, the 
PV-like phenotype is associated with increased serum levels of TNF-.101 TNF- might be 
required for suppressing normal hematopoiesis, and in this manner it might favor the 
mutated clone. Reconstitution experiments in TNF- knockout mice supported the notion 
that TNF- might be required for the establishment of the MPN phenotype and for clonal 
dominance (Bumm TGP, VanDyke J, Loriaux M, Gendron C, Wood LG, Druker BJ, 
Deininger MW. TNF- plays a crucial role in the JAK2-V617F-induced myeloproliferative 
disorder. Blood2007; 110. American Society of Hematology 2007 Abstract 675). Further 
studies will be required to firmly establish whether TNF signaling may contribute to clonal 
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dominance. Erythroblasts from JAK2 V617F-positive PV patients show increased death 
receptor resistance, which may give them a proliferative advantage over the non-mutated 
erythroblasts.101, 140 This effect was mediated by incomplete caspase-mediated cleavage of 
the erythroid transcription factor GATA-1, which in normal erythroblasts is completely 
degraded on CD95 stimulation. 
3.3 MPNs and TGF-β 
An increase of TGF-β expression in circulating megakaryocytic cells and platelets was 
demonstrated in PMF.141 Fibroblasts participating in myelofibrosis were shown to be 
polyclonal, as opposed to the hematopoietic progenitors, thus suggesting that myelofibrosis 
is a reactive process.141In myelofibrosis induced by excessive levels of Tpo,142 severe spleen 
fibrosis was seen only in wild-type mice but not in homozygous TGF-β1 null (TGF-β1 (-/-)) 
mice.143 Studies using peripheral CD34(+) cells cultured in medium with Tpo and stem cell 
factor concluded that PMF is a consequence of an increased ability of PMF CD34(+) 
progenitor cells to generate megakaryocytes and a decreased rate of megakaryocyte 
apoptosis, which lead to high levels of megakaryocyte-produced TGF-β.144 In other models 
with hyperactive JAK–STAT signaling, such as knock-in with a mutant hyperactive gp130 
receptor, the activation of the JAK–STAT pathway led to the expression of the inhibitory 
Smad7, which prevents the anti-proliferative effect of TGF-β.145 A pathway linking Tpo, 
GATA-1 and TGF-βin the development of myelofibrosis was invoked, given that mice 
expressing low levels of the transcription factor GATA-1 also develop myelofibrosis.146 
3.4 JAK2 V617F and chromatin 
Studies in Drosophila melanogaster show that persistent activation of D-STAT by mutated D-
JAK leads to chromatin effects and gene induction other than the normal targets of D-STAT, 
with counteracting heterochromatic gene silencing.147A genome-wide survey of genes 
required for JAK/STAT activity identified a WD40/bromodomain protein Drosophila 
homolog of BRWD3,148 a gene that is disrupted in human B-cell leukemia patients. Whether 
any histone acetylase, deacetylase, methyl-transferase or other proteins containing bromo-, 
chromo- or chromoshadow domains are direct targets of JAK2 V617F is not clear. Recently, 
encouraging results were obtained with an HDAC (histone deacetylase) inhibitor, which 
seems to target only JAK2 V617F-positive cells among primary myeloid progenitors from PV 
patients.149 Thus, like other cancers,150 MPNs might also show restriction of fate options 
through hypermethylation. This notion is supported by the different effects of sequential 
treatment with the DNA methyltransferase inhibitor, decitabine, followed by the histone 
deacetylase inhibitor, trichostatin A (TSA), on normal CD34(+) versus PMF CD34(+) cells. In 
the former, the treatment led to the expansion of cells, whereas in the latter the total number 
of CD34(+) cells and hematopoietic cells was reduced.151Furthermore, promoter de-
methylation appears to be at least partially at the basis of the dysregulated expression of the 
polycythemia rubra vera-1 (PRV-1) protein,152 which is a key marker of PV.153 Finally, 
hypermethylation of the SOCS1 promoter was reported approximately in 15% of MPN 
patients irrespective of JAK2 V617F positivity.154 SOCS1 promoter methylation may 
contribute to growth factor hypersensitivity, as SOCS1 appears to maintain the ability to 
down-modulate JAK2 V617F signaling.124 Recently, Dawson et al.155identified a novel 
nuclear role of JAK2 in the phosphorylation of Tyr 41 of histone H3 leading to chromatin 
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displacement of HP1a. The authors suggested that the inability of HP1a to regulate 
chromatin could reduce the potential tumor suppressive functions of HP1a resulting in 
erratic mitotic recombination and transcription deregulation of several JAK2-regulated 
genes such as LMO2155,156. These results were confirmed in hematopoietic cell lines and in 
the CD34+ cells collected from the peripheral blood of one PMF patient with JAK2V617F 
mutation. In this work we define the subcellular localization of JAK2 in total BM cells and in 
sorted cell populations collected from MPN (ET, PV, PMF) patients with the JAK2V617F 
mutation or from MPN patients with wild type (wt) JAK2. We find that in contrast to cells 
with normal JAK2 in which the protein is detected predominantly in the cytoplasm, JAK2 is 
mostly nuclear in V617F-positive CD34+ cells. However, this nuclear localization is no 
longer observed in V617F-positive differentiated cells. After expressing JAK2V617F in K562 
cells, we observe a similar preferential accumulation of JAK2 in the nucleus in contrast to 
untrasfected- and wt JAK2-expressing cells in which the protein is found in the cytoplasm. 
The mutated-JAK2 nuclear translocation is mainly reverted by the addiction of the JAK2 
inhibitor AG490.  
4. Methods 
4.1 Cell cultures 
K562 were grown in RPMI 1640 medium (Sigma-Aldrich), supplemented with 10% fetal 
bovine serum (FBS), 1% penicillin/streptomycin, and 1% glutamine. The cells were 
maintained at 37 C and 5% CO2. Transfection was performed by AMAXA electroporation in 
accordance with the manufacturer’s instructions. Stable cell lines were obtained by 
puromycin selection (3g/ml). Leptomycine B was added to a final concentration of 1 uM 
and the cells were harvested after 24 h of incubation. The differentiation of K562 cells was 
obtained by culturing the cells with 10 nMol PMA.  
4.2 Plasmids 
pMSCV-puro-JAK2 and pMSCV-puro-JAK2V617F were kindly provided by Dr. J. Cools.  
4.3 Confocal immunofluorescence (CFI) microscopy 
The BM fractions of CD34+, CD15+, CD41+, CD71+ cells and the K562 cells were washed 
once in PBS before cytocentrifugation onto polylysine-coated microscope slides. The cells 
were fixed for 5 min in methanol at room temperature and 5 min in acetone at -20 C. After 
stepwise incubation with a primary antibody and a secondary fluorescent antibody, the cells 
were stained with DAPI and mounted with glycerol. Confocal laser images were captured 
with a laser scanning microscope LSM 510 META microscope equipped with a 403 oil-
immersion lens.  
4.4 Patients 
BM aspirates and PB samples were obtained from 15 patients newly diagnosed with MPN 
according to the WHO criteria. Ten of the patients (ET n=4, PV n=3, PMF n=3) had the 
V617F mutation. The remaining 5 patients (PMF n= 2, ET n=3) had a normal JAK2. Informed 
consent for the study was obtained from all patients in accordance with the Declaration of 
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dominance. Erythroblasts from JAK2 V617F-positive PV patients show increased death 
receptor resistance, which may give them a proliferative advantage over the non-mutated 
erythroblasts.101, 140 This effect was mediated by incomplete caspase-mediated cleavage of 
the erythroid transcription factor GATA-1, which in normal erythroblasts is completely 
degraded on CD95 stimulation. 
3.3 MPNs and TGF-β 
An increase of TGF-β expression in circulating megakaryocytic cells and platelets was 
demonstrated in PMF.141 Fibroblasts participating in myelofibrosis were shown to be 
polyclonal, as opposed to the hematopoietic progenitors, thus suggesting that myelofibrosis 
is a reactive process.141In myelofibrosis induced by excessive levels of Tpo,142 severe spleen 
fibrosis was seen only in wild-type mice but not in homozygous TGF-β1 null (TGF-β1 (-/-)) 
mice.143 Studies using peripheral CD34(+) cells cultured in medium with Tpo and stem cell 
factor concluded that PMF is a consequence of an increased ability of PMF CD34(+) 
progenitor cells to generate megakaryocytes and a decreased rate of megakaryocyte 
apoptosis, which lead to high levels of megakaryocyte-produced TGF-β.144 In other models 
with hyperactive JAK–STAT signaling, such as knock-in with a mutant hyperactive gp130 
receptor, the activation of the JAK–STAT pathway led to the expression of the inhibitory 
Smad7, which prevents the anti-proliferative effect of TGF-β.145 A pathway linking Tpo, 
GATA-1 and TGF-βin the development of myelofibrosis was invoked, given that mice 
expressing low levels of the transcription factor GATA-1 also develop myelofibrosis.146 
3.4 JAK2 V617F and chromatin 
Studies in Drosophila melanogaster show that persistent activation of D-STAT by mutated D-
JAK leads to chromatin effects and gene induction other than the normal targets of D-STAT, 
with counteracting heterochromatic gene silencing.147A genome-wide survey of genes 
required for JAK/STAT activity identified a WD40/bromodomain protein Drosophila 
homolog of BRWD3,148 a gene that is disrupted in human B-cell leukemia patients. Whether 
any histone acetylase, deacetylase, methyl-transferase or other proteins containing bromo-, 
chromo- or chromoshadow domains are direct targets of JAK2 V617F is not clear. Recently, 
encouraging results were obtained with an HDAC (histone deacetylase) inhibitor, which 
seems to target only JAK2 V617F-positive cells among primary myeloid progenitors from PV 
patients.149 Thus, like other cancers,150 MPNs might also show restriction of fate options 
through hypermethylation. This notion is supported by the different effects of sequential 
treatment with the DNA methyltransferase inhibitor, decitabine, followed by the histone 
deacetylase inhibitor, trichostatin A (TSA), on normal CD34(+) versus PMF CD34(+) cells. In 
the former, the treatment led to the expansion of cells, whereas in the latter the total number 
of CD34(+) cells and hematopoietic cells was reduced.151Furthermore, promoter de-
methylation appears to be at least partially at the basis of the dysregulated expression of the 
polycythemia rubra vera-1 (PRV-1) protein,152 which is a key marker of PV.153 Finally, 
hypermethylation of the SOCS1 promoter was reported approximately in 15% of MPN 
patients irrespective of JAK2 V617F positivity.154 SOCS1 promoter methylation may 
contribute to growth factor hypersensitivity, as SOCS1 appears to maintain the ability to 
down-modulate JAK2 V617F signaling.124 Recently, Dawson et al.155identified a novel 
nuclear role of JAK2 in the phosphorylation of Tyr 41 of histone H3 leading to chromatin 
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displacement of HP1a. The authors suggested that the inability of HP1a to regulate 
chromatin could reduce the potential tumor suppressive functions of HP1a resulting in 
erratic mitotic recombination and transcription deregulation of several JAK2-regulated 
genes such as LMO2155,156. These results were confirmed in hematopoietic cell lines and in 
the CD34+ cells collected from the peripheral blood of one PMF patient with JAK2V617F 
mutation. In this work we define the subcellular localization of JAK2 in total BM cells and in 
sorted cell populations collected from MPN (ET, PV, PMF) patients with the JAK2V617F 
mutation or from MPN patients with wild type (wt) JAK2. We find that in contrast to cells 
with normal JAK2 in which the protein is detected predominantly in the cytoplasm, JAK2 is 
mostly nuclear in V617F-positive CD34+ cells. However, this nuclear localization is no 
longer observed in V617F-positive differentiated cells. After expressing JAK2V617F in K562 
cells, we observe a similar preferential accumulation of JAK2 in the nucleus in contrast to 
untrasfected- and wt JAK2-expressing cells in which the protein is found in the cytoplasm. 
The mutated-JAK2 nuclear translocation is mainly reverted by the addiction of the JAK2 
inhibitor AG490.  
4. Methods 
4.1 Cell cultures 
K562 were grown in RPMI 1640 medium (Sigma-Aldrich), supplemented with 10% fetal 
bovine serum (FBS), 1% penicillin/streptomycin, and 1% glutamine. The cells were 
maintained at 37 C and 5% CO2. Transfection was performed by AMAXA electroporation in 
accordance with the manufacturer’s instructions. Stable cell lines were obtained by 
puromycin selection (3g/ml). Leptomycine B was added to a final concentration of 1 uM 
and the cells were harvested after 24 h of incubation. The differentiation of K562 cells was 
obtained by culturing the cells with 10 nMol PMA.  
4.2 Plasmids 
pMSCV-puro-JAK2 and pMSCV-puro-JAK2V617F were kindly provided by Dr. J. Cools.  
4.3 Confocal immunofluorescence (CFI) microscopy 
The BM fractions of CD34+, CD15+, CD41+, CD71+ cells and the K562 cells were washed 
once in PBS before cytocentrifugation onto polylysine-coated microscope slides. The cells 
were fixed for 5 min in methanol at room temperature and 5 min in acetone at -20 C. After 
stepwise incubation with a primary antibody and a secondary fluorescent antibody, the cells 
were stained with DAPI and mounted with glycerol. Confocal laser images were captured 
with a laser scanning microscope LSM 510 META microscope equipped with a 403 oil-
immersion lens.  
4.4 Patients 
BM aspirates and PB samples were obtained from 15 patients newly diagnosed with MPN 
according to the WHO criteria. Ten of the patients (ET n=4, PV n=3, PMF n=3) had the 
V617F mutation. The remaining 5 patients (PMF n= 2, ET n=3) had a normal JAK2. Informed 
consent for the study was obtained from all patients in accordance with the Declaration of 
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Helsinki. The study was conducted according to the guidelines of the Italian ethics 
committee. 
4.5 Cell sorting 
Mononucleated cells were isolated by Ficoll centrifugation. After erythrocyte lyses, 10 
million BM (or PB) cells were labelled by incubation with the antibodies CD15-APC, CD41-
FITC, CD71-PerCP, CD34-Pe (BD Biosciences, San Jose, CA), analyzed, and sorted with a 
fluorescence-activated cell sorter FACSAria (BD Biosciences) using FACS Diva software (BD 
Biosciences) according to the manufacturer’s recommendations.  
4.6 ASO-PCR and RT-PCR 
The JAK2V617F mutation was identified by ASO-PCR as previously described13-15. Briefly, 
total RNA was isolated with the TRIzol reagent (Invitrogen) and cDNA was synthesised 
with the First Strand cDNA Synthesis kit (MBI Fermentas). Syber Green RQ-PCR was 
performed as previously described155. Quantitative values were obtained from the threshold 
cycle number (Ct) by subtracting the average Ct of the target gene from that of GAPDH and 
expressed as 2–ΔCt. 
4.7 Cell fractionation and immunoblotting 
Cytoplasmic and nuclear fractions were prepared using nuclei isolation KIT by Sigma-
Aldrich according to the manufacturer’s instructions. Equal amounts of cytoplasmic or 
nuclear fractions or total cell extracts were separated by SDS–PAGE, transferred to 
nitrocellulose and probed with relevant antibodies. 
4.8 JAK2 inhibitor and antibodies 
AG490 was provided by Invivogen. To establish the best experimental condition, the cells 
were cultured for 3 hours with 2 different concentrations of the inhibitor (12.5 uM and 25 
uM). The following antibodies were used at the stated dilutions: anti-JAK2 antibodies 
(D2E12 no. 3230; Cell Signaling Technology), p-JAK2 (tyr1007/tyr1008)-R and p-JAK2 
(tyr1007/tyr1008) (Santa Cruz), anti-b-tubulin (T5201; Sigma-Aldrich), anti-laminin A 
(Sigma-Aldrich); western blot 1:1000. Alex Fluor-488-conjugated IgG (Invitrogen) 
immunofluorescence 1:250. 
4.9 Apoptotic rate 
K562 cells were stained with propidium iodide and annexin V before and after 3 h 
incubation with AG490. Cell cycle parameters were assessed by FACS analysis using 
FACSCanto II flow cytometer (Becton Dickinson, San Jose, CA, USA). 
4.10 Statistical analysis 
Student t test was used to evaluate individual differences between means. P≤0.05 was 
considered significant. 
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5. Results and discussion  
5.1 V617FJAK2 goes into the nucleus of JAK2 mutated K562 
To determine whether the V617F mutation affects the sub-cellular localization of JAK2, we 
used CIF microscopy to analyze K562 cells stably transfected with pMSCV-puroJAK2V617F 
or pMSCV-puroJAK2. The results (Figure 3A) confirm the nuclear and cytoplasmic 
localization of JAK2 in K562 as reported by Dawson et al155. However, we consistently 
observed a much stronger nuclear signal in the cells expressing JAK2V617F than in those 
carrying wt JAK2, suggesting that the mutation leads to a nuclear accumulation of 
JAK2V617F. By CIF, this accumulation can be seen as a diffused nuclear pattern (Figure 3A 
top, upper and middle panels) or as nuclear spots (Figure 3A top, lower panel). This altered 
sub-cellular distribution was not affected by the addition of the nuclear export inhibitor 
leptomycin B (data not shown) and was confirmed by Western blot analysis of K562 cells 
(Figure 3A, bottom panels).  
5.2 Preferential nuclear JAK2 in V617FJAK2 positive CD34+ but not in differentiated 
erythroid, granulocytic or megakaryocytic cells 
To determine whether there is a preferential nuclear translocation of JAK2V617F in vivo, we 
analyzed by CIF microscopy the BM cells of 10 JAK2V617F-positive MPN patients (ET n=4, 
PV n=3, PMF n=3, allele burden median: 56%, 70%, 72% respectively) and of 5 MPN patients 
with wt JAK2 (PMF n= 2, ET n=3). We did not observe a significant signal in the nucleus of 
cells with wt JAK2 (Figure 3B). In contrast, we found a strong nuclear signal in 3%-5% of 
total BM mononucleated cells in 10 of 10 JAK2V617F-positive patients, suggesting that, 
unlike the wt JAK2, JAK2V617F has a predominantly nuclear homing. To identify the 
phenotype of these cells, we used fluorescence activated cell sorting (FACS) to isolate 
CD34+, CD15+, CD41+ and CD71+ fractions from the BM of three JAK2V617F-positive 
MPN patients (1 ET, 1 PV, 1 early PMF). We found nuclear JAK2 only in the fraction 
containing the CD34+ positive cells (Figure 3C, left panels). It should be noted that in these 
patients the CD34+ cells correspond to approximately 3% to 5% of total BM mononucleated 
cells. The nuclear localization of JAK2V617F was confirmed by WB analysis (Figure 3C, right 
panels). However, no predominant nuclear signal was detected in differentiated 
granulocytic, megakaryocytic and erythroid cells obtained from the patients (n=15) (Figure 
3D). Similar results were obtained with PB cells (data not shown). The relocation of the 
mutated JAK2 to the cytoplasm was confirmed in K562 cells after their differentiation with 
PMA (Figure 4A). However, the relocation was not complete as observed for the primary 
BM cells and nuclear JAK2 was still observed. We believe that this is due to the nature of 
K562 cells, which are BCR-ABL-positive CML cells, and to the difficulty to obtain their 
terminal differentiation in vitro.  
5.3 The JAK2 inhibitor AG490 relocate JAK2 in cytoplasm 
To determine whether an alteration of JAK2 activity could interfere with the nuclear 
localization of JAK2, we incubated K562 cells expressing JAK2V617F or JAK2 with the 
selective JAK2 inhibitor AG490158-160. After 3 h of incubation at the IC50 dose of 25 uM, CIF 
images showed a relocalization of JAK2V617F to the cytoplasm in the vast majority of K562 
cells (Figure 4B). Analyses with annexin V and propidium iodide did not reveal any 
significant change in the apoptotic rate of V617F-positive and wt-K562 cells.  
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Helsinki. The study was conducted according to the guidelines of the Italian ethics 
committee. 
4.5 Cell sorting 
Mononucleated cells were isolated by Ficoll centrifugation. After erythrocyte lyses, 10 
million BM (or PB) cells were labelled by incubation with the antibodies CD15-APC, CD41-
FITC, CD71-PerCP, CD34-Pe (BD Biosciences, San Jose, CA), analyzed, and sorted with a 
fluorescence-activated cell sorter FACSAria (BD Biosciences) using FACS Diva software (BD 
Biosciences) according to the manufacturer’s recommendations.  
4.6 ASO-PCR and RT-PCR 
The JAK2V617F mutation was identified by ASO-PCR as previously described13-15. Briefly, 
total RNA was isolated with the TRIzol reagent (Invitrogen) and cDNA was synthesised 
with the First Strand cDNA Synthesis kit (MBI Fermentas). Syber Green RQ-PCR was 
performed as previously described155. Quantitative values were obtained from the threshold 
cycle number (Ct) by subtracting the average Ct of the target gene from that of GAPDH and 
expressed as 2–ΔCt. 
4.7 Cell fractionation and immunoblotting 
Cytoplasmic and nuclear fractions were prepared using nuclei isolation KIT by Sigma-
Aldrich according to the manufacturer’s instructions. Equal amounts of cytoplasmic or 
nuclear fractions or total cell extracts were separated by SDS–PAGE, transferred to 
nitrocellulose and probed with relevant antibodies. 
4.8 JAK2 inhibitor and antibodies 
AG490 was provided by Invivogen. To establish the best experimental condition, the cells 
were cultured for 3 hours with 2 different concentrations of the inhibitor (12.5 uM and 25 
uM). The following antibodies were used at the stated dilutions: anti-JAK2 antibodies 
(D2E12 no. 3230; Cell Signaling Technology), p-JAK2 (tyr1007/tyr1008)-R and p-JAK2 
(tyr1007/tyr1008) (Santa Cruz), anti-b-tubulin (T5201; Sigma-Aldrich), anti-laminin A 
(Sigma-Aldrich); western blot 1:1000. Alex Fluor-488-conjugated IgG (Invitrogen) 
immunofluorescence 1:250. 
4.9 Apoptotic rate 
K562 cells were stained with propidium iodide and annexin V before and after 3 h 
incubation with AG490. Cell cycle parameters were assessed by FACS analysis using 
FACSCanto II flow cytometer (Becton Dickinson, San Jose, CA, USA). 
4.10 Statistical analysis 
Student t test was used to evaluate individual differences between means. P≤0.05 was 
considered significant. 
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5. Results and discussion  
5.1 V617FJAK2 goes into the nucleus of JAK2 mutated K562 
To determine whether the V617F mutation affects the sub-cellular localization of JAK2, we 
used CIF microscopy to analyze K562 cells stably transfected with pMSCV-puroJAK2V617F 
or pMSCV-puroJAK2. The results (Figure 3A) confirm the nuclear and cytoplasmic 
localization of JAK2 in K562 as reported by Dawson et al155. However, we consistently 
observed a much stronger nuclear signal in the cells expressing JAK2V617F than in those 
carrying wt JAK2, suggesting that the mutation leads to a nuclear accumulation of 
JAK2V617F. By CIF, this accumulation can be seen as a diffused nuclear pattern (Figure 3A 
top, upper and middle panels) or as nuclear spots (Figure 3A top, lower panel). This altered 
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significant change in the apoptotic rate of V617F-positive and wt-K562 cells.  
 







Fig. 3. V617F mutation favors nuclear translocation of JAK2 in K562 and early CD34+ 
progenitors isolated from BM of MPN patients. This translocation is not observed in 
differentiated cells.(A) CIF microscopy images of K562 cells stably transfected with pMSCV-
JAK2 (upper panels) or pMSCV-JAK2V617F (middle and lower panels) and Western 
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blotting of cytoplasmic (C) and nuclear (N) fractions confirm that JAK2V617F is more 
abundant than JAK2 in K562 nuclei. (B)CIF images of BM cells from an MPN patient with wt 
JAK2 (upper panels) and an MPN patient with JAK2V617F (lower panels) confirm a nuclear 
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Western blotting of cytoplasmic (C) and nuclear (N) extracts (right panel) confirm the data. 
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(D) Confocal IF images  of CD15+, CD41+, CD71+ cells isolated from a JAK2V617F–positive 
MPN patient (PV, JAK2 allele burden 71%) and Western blotting of cytoplasmic (C) and 
nuclear (N) extracts (right panel). DAPI, 4,6-diamidino-2-phenylindole; Anti-JAK2, Cell 
Signaling monoclonal antibody; Anti-Tubulin and Anti-Laminin A, Sigma-Aldrich 
monoclonal antibodies. 
5.4 V617F JAK2 up-regulates LMO2 and AG490 restores its level.  
By QRT-PCR we show that the V617F mutation strongly up-regulates the expression of 
LMO2 in K562 and in CD34+ cells (Figure 4C, left panels). The link between LMO2 
expression and JAK2 inhibition has been reported previously156,157. In our assay, the 
addition of AG490 progressively and completely restoreLMO2 levels in V617F expressing 






















Fig. 4. V617F mutation causes up-regulation of LMO2. The JAK2 inhibitor AG490 replaces 
JAK2 into cytoplasm and restores LMO2 levels.(A) Confocal IF images show the 
redistribution of JAK2 and the replacement in the cytoplasm in V617F expressing K562 after 
PMA differentiation (B) Confocal IF images show the redistribution of JAK2 and the 
replacement in the cytoplasm in the vast majority of  V617F expressing K562 (bottom panels)  
but not in wt cells (top panels) after AG490 incubation. (C) Quantitative RT-PCR revels that 
V617F mutation strongly up-regulates LMO2 expression in K562 and in CD34+ cells (left 
panels). The addiction of AG490 progressively and completely restoreLMO2 levels in V617F 
expressing K562 (right panels). DAPI, 4,6-diamidino-2-phenylindole; Anti-JAK2, Cell 
Signaling monoclonal antibody. 
6. Conclusions 
Where do the major advances towards understanding the precise molecular bases of MPNs 
lead us? One striking observation is the key role played by various tyrosine kinases, 
constitutively activated either by balanced translocations or deletions generating fusion 
oncoproteins, or by activating point mutations. These mechanisms seem to be the molecular 
hallmark of MPNs, although there are probably alternative mechanisms directly involving 
cytokine receptors, adaptor proteins or transcription factors. All the molecular defects 
identified in MPNs to date confer proliferation and survival advantages on transformed 
cells, which retain the capacity to differentiate into mature cells. Differentiation may be 
disrupted by additional events, such as transcription factor deregulation, as frequently 
observed in acute myeloid leukaemia. KIT mutations and FLT3 abnormalities are frequently 
found in cases of acute myeloid leukaemia. However, these molecular defects are now 
considered to be secondary events.  
Strikingly, the diverse mutants and fusion proteins with constitutive tyrosine kinase activity 
each appear to stimulate a specific lineage. For example, PDGFR fusion proteins induce 
eosinophil differentiation, FGFR fusion proteins induce lymphoid malignancies, and 
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JAK2V617F mostly expands the erythroid compartment, whereas translocations involving 
the JAK2 kinase domain promote lymphoid proliferation as well. Thus, constitutive 
signalling via these different kinases is likely to result in effects on specific differentiation 
programs. Uncovering the molecular details of this specificity remains a major challenge, 
particularly as similar signalling molecules (i.e. STAT5, STAT3, RAS/MAPK, PI3K/AKT 
and others) are constitutively activated by all oncogenic fusion proteins. 
Although the discovery of the JAK2V617F allele and the subsequent discovery of JAK2 exon 
12 mutations and MPLW515L/K alleles have provided crucial insights into the genetic basis 
of PV, ET and PMF, many questions remain regarding the molecular pathogenesis of these 
MPNs. The activating mutations that cause JAK2 and MPL-negative MPN are not known, 
and the inherited and acquired alleles that can cooperate with JAK2V617F remain to be 
identified. In addition, the predominance of the JAK2V617F allele is surprising given that 
JAK2 exon 12 mutations, as well as activating JAK2 alleles identified in AML (JAK2T875N 
and JAK2ΔIREED), have similar in vitro and in vivo effects as JAK2V617F. The different 
JAK2 alleles might differentially interact with different cytokine receptor scaffolds, activate 
different signalling pathways, and/or be differentially affected by negative-feedback 
mechanisms; structural insight and additional in vitro and in vivo studies are needed to 
elucidate differences between JAK2V617F and the other activating JAK2 alleles. Another 
important question relates to the effects of JAK2V617F gene dosage on signalling and on 
phenotype. In vitro studies do not conclusively show whether the co-expression of wildtype 
JAK2 with JAK2V617F alters the signalling and/or transforming properties of the 
JAK2V617F kinase, and although retroviral models allow for an assessment of the in vivo 
effects of JAK2V617F expression, they do not provide the appropriate genetic context to 
investigate the importance of JAK2V617F gene dosage. Subsequent studies using more 
accurate genetic models will enable the delineation of the differential effects of JAK2V617F 
heterozygosity and homozygosity on signalling and on phenotype. Moreover, the role of the 
JAK2V617F allele in three distinct disorders of the myeloid lineage is not known, and the 
ability of different activated tyrosine kinases (for example, BCR-ABL and FIP1L1–PDGFRA) 
to cause distinct MPN remains to be delineated.  
Dawson et al. identified a previously unrecognized nuclear role for JAK2 in the 
phosphorylation of the tyrosine 41 of the histone H3 with the exclusion of HP1a from 
chromatin and resulting in a disregulation of several JAK2-regulated genes such as LMO2 in 
haematopoietic cell lines and in one case on peripheral CD34+ cells from a JAK2V617F 
mutated PMF patient. 
Our data corroborate recently published results of a nuclear localization of JAK2 in 
hematopoietic cells and they also extend these findings by showing that in all subtypes of 
MPN patients JAK2V617F accumulates in the nucleus of progenitor CD34+ cells while it 
remains mostly in the cytoplasm of their differentiated progeny. The chromatin alterations 
due to the preferential accumulation of JAK2V617F in the nucleus correlates with a 
significant increase in LMO2 expression in cell lines and in sorted CD34+ cells. The selective 
JAK2 inhibitor AG490 is able to revert nuclear JAK2 and normalize LMO2 levels in vitro, 
suggesting how the block in JAK2 nuclear translocation could be a new treatment strategy 
for JAK2 mutated patients. A question that remains to be answered is why mutated JAK2 is 
found only in the cytoplasm of the differentiated cells. MPN are clonal disorders arising in a 
pluripotent hematopoietic stem cell and it is well known that the constitutive activation of 
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JAK2 provides a sustained growth and survival advantage to the hematopoietic mutated 
stem cell clones. Signaling by the mutated kinase utilizes normal pathways, and normal or 
mutated JAK2 regulate EPO, TPO, and GCS-F response during differentiation, though they 
are probably not necessary to the differentiated cell. The signals that are required for the 
translocation of normal and mutated JAK2 to the nucleus are unknown. It is possible that 
the activation of the kinase by phosphorylation could be the first one of a number of 
modifications that control nuclear translocation, similarly to what happens to the STAT 
proteins. If this is true, then it is also possible that as the cell undergoes differentiaition these 
modifications are shut off, leaving mutated JAK2 predominantly in the cytoplasm.  
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1. Introduction 
Natural Killer (NK) cells were first defined, more than 30 years ago, on the basis of their 
unique capability of killing spontaneously different targets including tumor and virus-
infected cells. Thus, since their first discovery, NK cells came across as a potential attractive 
tool for the implementation of immuno-therapeutic strategies for different diseases. 
Accordingly, besides the plethora of studies aimed at investigating their functional and 
phenotypic properties, considerable efforts have also been spent in the past several years to 
understand how these cells could be generated and how their functions could be regulated 
and/or manipulated. At the same time further attention has been paid on their alteration in 
vivo and their potential role in the occurrence of NK cell-based hematological malignancies. 
2. NK cells: From a function to a multifaceted population 
2.1 The discovery of NK cells 
NK cells were originally identified on a functional basis. In the middle ‘70s, it was discovered 
that healthy individuals could display selective cytotoxic activity against tumor or virally 
infected cells and that this activity was hidden within the circulating lymphocyte population 
(West et al., 1977; Santoli et al., 1978). This implied the presence in the Peripheral Blood (PB) of a 
lymphocyte subset capable of killing different targets without previous sensitization. These 
cells, that for their functional properties were termed ‘Natural Killer’, were then characterized 
morphologically as Large Granular Lymphocytes (LGL) by virtue of their size and cytolytic 
granule content. Finally, in the late ‘80s, NK cells were more precisely defined with the CD3-
CD56+CD16+ surface immuno-phenotype. This also allowed the identification of the 
CD16/FcRIII as the receptor responsible for the Antibody-Dependent Cell Cytotoxicity 
(ADCC) function shown by NK cells (Lanier et al., 1986; Trinchieri, 1989). In the same period, 
the circulating NK cell population, which represented approximately 10-15% of PB 
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lymphocytes, was further split into CD56brightCD16dim/neg and CD56dimCD16bright cell subsets, 
expressing respectively low and high cytolytic properties. In the following 10 years great efforts 
were done to widen the list of NK cell markers and to define the surface receptors responsible 
for the regulation of NK cell cytotoxicity. Finally, in the last decade it was discovered that NK 
cells could exert different regulatory functions, and many studies were oriented to the 
definition of novel NK cell subsets involved in such unexpected functional features. 
2.2 The regulation of NK cell function: Activating and inhibitory receptors 
Once NK cells could be physically identified and isolated, the goal was to understand how 
these cells could work; and the first questions were: “How can a single NK cell kill different 
targets?” and “how do NK cells recognize and spare self normal cells?” The answer to these 
questions was indicated by Karre in his “missing self hypothesis”. He postulated that NK 
cells could sense the absence (or reduction) of self MHC class I molecules (MHC-I) during 
cell-to-cell interaction: the missing recognition of self would allow NK cells to kill the 
targets, while recognition of self MHC-I would inhibit their cytolytic activity  (Ljunggren & 
Karre, 1990). This would explain how NK cells could kill tumor or virus infected cells, which 
frequently undergo surface MHC-I down-regulation, and spare self non-pathogenic cells, 
equipped with appropriate levels MHC-I. The hypothesis was then confirmed, and the 
inhibitory MHC-I-specific receptors responsible for the recognition of Self were identified. 
In humans, major HLA-I-specific inhibitory receptors are represented by the C-type lectin 
CD94/NKG2A dimer that recognizes the non-classical HLA-E alleles, and the Killer Ig-like 
Receptors (KIR). The CD94/NKG2A encoding genes are located in the NK Receptor 
complex on chromosome 12, while the KIR locus is located in the Leukocyte Receptor 
Complex in Chromosome 19. The KIRs constitute a family of strictly homologous proteins 
characterized by the presence of two or three extracytoplasmic Ig-like domains (KIR2D or 
KIR3D) and a long cytoplasmic tail (KIR2DL or KIR3DL) containing Immuno Tyrosine-
based Inhibitory Motifs (ITIMs) for the inhibitory signal transduction. Each KIR recognizes a 
specific epitope common to a defined group of HLA-I alleles. In particular, KIR2DL1 
recognizes the Lys80 containing C2 epitope, that is shared by a group of HLA-C alleles; 
KIR2DL2/L3 recognize the Asn80 containing C1 epitope, that is shared by the remaining 
alleles of the locus HLA-C; KIR3DL1 recognizes the Ile/Thr80 containing HLA-Bw4 epitope, 
that is common to certain HLA-A and HLA-B alleles, while KIR3DL2 recognizes certain 
HLA-A alleles (Biassoni et al., 2001; Parham, 2005). Interestingly, KIR3DL2 has also been 
recently shown to bind microbial nucleic acids at the cell surface and to shuttle them to 
TLR9 in the endosome, suggesting for certain KIR a novel (or rather an ancient) function as 
pathogen sensors (Sivori et al., 2010). The HLA-I-specific inhibitory receptors are clonally 
distributed within the NK cell population of each individual. Most NK cells express one or 
more receptors and at least one that recognize an autologous HLA-I allele. Recently, a KIR-
NKG2A- NK cell subset has been described in different donors. These cells, however, 
appeared to be poorly functional. This suggested that the expression and the engagement of 
inhibitory receptors during maturation of NK cells could dictate the acquisition of their 
cytolytic potential (Licensing theory) (Anfossi et al., 2006). The KIR family also includes 
activating KIRs. These are homologous to their inhibitory counterparts, but display a short 
cytoplasmic tail (KIR2DS or KIR3DS), lack ITIMs and associate an ITAM-bearing molecule 
(DAP12) to transduce activating signals. Similarly, also for NKG2A, does exist a short-tailed 
activating counterpart, termed NKG2C. The meaning of these receptors is poorly known. It 
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has been hypothesized that they may recognize HLA-I molecules loaded with viral or tumor 
peptides, or, with low affinity, normal HLA-I molecules. In this latter case, when target cells 
selectively down-regulate HLA alleles, recognized by inhibitory KIR, the engagement of 
activating KIR may result in NK cell activation. The simultaneous expression of activating 
and inhibitory KIRs may therefore represent a strategy whereby NK cells can recognize and 
kill pathologic cells uniquely by detecting changes in their HLA alleles repertoire. At 
present, however, binding to HLA-I molecules has been formally demonstrated only for 
KIR2DS1 and NKG2C. 
NK cells are also equipped with a large array of non-HLA-specific triggering receptors and 
co-receptors, whose engagement by specific Ligands expressed on target cells induces NK 
cell cytotoxicity and cytokine release (Moretta A. et al., 2001; Vivier et al., 2011). The group 
of NK-triggering receptors is largely heterogeneous: it encompasses molecules either 
structurally unrelated or belonging to different molecular families. At variance with KIRs, 
triggering receptors are expressed by virtually all NK cells and, in most cases, by different 
lymphocyte subsets or monocytes. The activating receptor Ligands till now identified, 
appear to be over-expressed in one or more of the following cases: tumor transformation, 
viral infection, cell stress or activation. Consistently, most of the activating receptors have 
been shown to be variably involved in the recognition and killing of virus infected and/or 
tumor cells. Two members of CD2 family: 2B4 (CD244) and NTBA, which recognize CD48 
and NTBA respectively, have been involved in the clearance of EBV-infected cells. NKp80 
and NKG2D, two Killer cell Lectin Receptors (KLR) encoded in the NK gene Complex on 
human chromosome 12, recognize molecules that can be expressed on tumor and/or virus 
infected cells. NKp80 recognizes AICL (encoded in the same NK gene complex) that is 
expressed on activated monocytes, but it can be also expressed on malignant myeloid cells 
(Welte et al., 2006). NKG2D recognizes MHC-I-related stress-inducible molecules of the MIC 
and ULBP families, that can be up-regulated on virus infected or tumor cells. Three 
receptors, that are expressed on cytotoxic lymphocytes (both NK and T cells), DNAM-1 
(CD226), TACTILE (CD96) and CRTAM, recognize members of the Nectin/Nectin-Like 
(NecL) family (Fuchs & Colonna, 2006). In particular DNAM-1, that is the most highly 
espressed on NK cells, recognizes Nectin2 (CD112) and NecL5 (CD155 - poliovirus receptor) 
(Bottino et al., 2003). Nectin/NecL molecules are involved in the formation of various types 
of cell-to-cell junctions, especially in epithelial cells, neurons or fibroblasts. Nectins 1 and 2, 
and NecL5 can also serve as viral entry receptors. These molecules, however, are frequently 
up-regulated in tumor cells of different histotypes. In addition, CMV infection can alter 
NecL5-Nectin3 intercellular interaction: in this case NecL5 would be exposed outside the 
cellular junction and allow DNAM-1 recognition. 
While all the above-mentioned activating receptors are expressed by different leukocyte 
subsets, NKp30, NKp46 and NKp44 triggering receptors are restricted to NK cells. NKp44 
and NKp46 are involved in the recognition of both viral antigens (as the influenza virus HA) 
(Mandelboim et al., 2001) and ligands expressed by tumor cells. NKp30 recognizes B7H6 
and BAT-3 (Brandt et al., 2009; Pogge von Strandmann et al., 2007). B7H6 is a member of the 
B7 family (which includes ligands for stimulatory/inhibitory T cell co-receptors 
CD28/CTLA4). B7H6 is poorly expressed on normal cells, while it is up-regulated in 
different tumor cell lines. BAT-3 is a nuclear factor released in exosomes by tumor cells and 
Dendritic Cells (DC) in response to stress/activation stimuli. The tumor ligands for NKp46 
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2.2 The regulation of NK cell function: Activating and inhibitory receptors 
Once NK cells could be physically identified and isolated, the goal was to understand how 
these cells could work; and the first questions were: “How can a single NK cell kill different 
targets?” and “how do NK cells recognize and spare self normal cells?” The answer to these 
questions was indicated by Karre in his “missing self hypothesis”. He postulated that NK 
cells could sense the absence (or reduction) of self MHC class I molecules (MHC-I) during 
cell-to-cell interaction: the missing recognition of self would allow NK cells to kill the 
targets, while recognition of self MHC-I would inhibit their cytolytic activity  (Ljunggren & 
Karre, 1990). This would explain how NK cells could kill tumor or virus infected cells, which 
frequently undergo surface MHC-I down-regulation, and spare self non-pathogenic cells, 
equipped with appropriate levels MHC-I. The hypothesis was then confirmed, and the 
inhibitory MHC-I-specific receptors responsible for the recognition of Self were identified. 
In humans, major HLA-I-specific inhibitory receptors are represented by the C-type lectin 
CD94/NKG2A dimer that recognizes the non-classical HLA-E alleles, and the Killer Ig-like 
Receptors (KIR). The CD94/NKG2A encoding genes are located in the NK Receptor 
complex on chromosome 12, while the KIR locus is located in the Leukocyte Receptor 
Complex in Chromosome 19. The KIRs constitute a family of strictly homologous proteins 
characterized by the presence of two or three extracytoplasmic Ig-like domains (KIR2D or 
KIR3D) and a long cytoplasmic tail (KIR2DL or KIR3DL) containing Immuno Tyrosine-
based Inhibitory Motifs (ITIMs) for the inhibitory signal transduction. Each KIR recognizes a 
specific epitope common to a defined group of HLA-I alleles. In particular, KIR2DL1 
recognizes the Lys80 containing C2 epitope, that is shared by a group of HLA-C alleles; 
KIR2DL2/L3 recognize the Asn80 containing C1 epitope, that is shared by the remaining 
alleles of the locus HLA-C; KIR3DL1 recognizes the Ile/Thr80 containing HLA-Bw4 epitope, 
that is common to certain HLA-A and HLA-B alleles, while KIR3DL2 recognizes certain 
HLA-A alleles (Biassoni et al., 2001; Parham, 2005). Interestingly, KIR3DL2 has also been 
recently shown to bind microbial nucleic acids at the cell surface and to shuttle them to 
TLR9 in the endosome, suggesting for certain KIR a novel (or rather an ancient) function as 
pathogen sensors (Sivori et al., 2010). The HLA-I-specific inhibitory receptors are clonally 
distributed within the NK cell population of each individual. Most NK cells express one or 
more receptors and at least one that recognize an autologous HLA-I allele. Recently, a KIR-
NKG2A- NK cell subset has been described in different donors. These cells, however, 
appeared to be poorly functional. This suggested that the expression and the engagement of 
inhibitory receptors during maturation of NK cells could dictate the acquisition of their 
cytolytic potential (Licensing theory) (Anfossi et al., 2006). The KIR family also includes 
activating KIRs. These are homologous to their inhibitory counterparts, but display a short 
cytoplasmic tail (KIR2DS or KIR3DS), lack ITIMs and associate an ITAM-bearing molecule 
(DAP12) to transduce activating signals. Similarly, also for NKG2A, does exist a short-tailed 
activating counterpart, termed NKG2C. The meaning of these receptors is poorly known. It 
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has been hypothesized that they may recognize HLA-I molecules loaded with viral or tumor 
peptides, or, with low affinity, normal HLA-I molecules. In this latter case, when target cells 
selectively down-regulate HLA alleles, recognized by inhibitory KIR, the engagement of 
activating KIR may result in NK cell activation. The simultaneous expression of activating 
and inhibitory KIRs may therefore represent a strategy whereby NK cells can recognize and 
kill pathologic cells uniquely by detecting changes in their HLA alleles repertoire. At 
present, however, binding to HLA-I molecules has been formally demonstrated only for 
KIR2DS1 and NKG2C. 
NK cells are also equipped with a large array of non-HLA-specific triggering receptors and 
co-receptors, whose engagement by specific Ligands expressed on target cells induces NK 
cell cytotoxicity and cytokine release (Moretta A. et al., 2001; Vivier et al., 2011). The group 
of NK-triggering receptors is largely heterogeneous: it encompasses molecules either 
structurally unrelated or belonging to different molecular families. At variance with KIRs, 
triggering receptors are expressed by virtually all NK cells and, in most cases, by different 
lymphocyte subsets or monocytes. The activating receptor Ligands till now identified, 
appear to be over-expressed in one or more of the following cases: tumor transformation, 
viral infection, cell stress or activation. Consistently, most of the activating receptors have 
been shown to be variably involved in the recognition and killing of virus infected and/or 
tumor cells. Two members of CD2 family: 2B4 (CD244) and NTBA, which recognize CD48 
and NTBA respectively, have been involved in the clearance of EBV-infected cells. NKp80 
and NKG2D, two Killer cell Lectin Receptors (KLR) encoded in the NK gene Complex on 
human chromosome 12, recognize molecules that can be expressed on tumor and/or virus 
infected cells. NKp80 recognizes AICL (encoded in the same NK gene complex) that is 
expressed on activated monocytes, but it can be also expressed on malignant myeloid cells 
(Welte et al., 2006). NKG2D recognizes MHC-I-related stress-inducible molecules of the MIC 
and ULBP families, that can be up-regulated on virus infected or tumor cells. Three 
receptors, that are expressed on cytotoxic lymphocytes (both NK and T cells), DNAM-1 
(CD226), TACTILE (CD96) and CRTAM, recognize members of the Nectin/Nectin-Like 
(NecL) family (Fuchs & Colonna, 2006). In particular DNAM-1, that is the most highly 
espressed on NK cells, recognizes Nectin2 (CD112) and NecL5 (CD155 - poliovirus receptor) 
(Bottino et al., 2003). Nectin/NecL molecules are involved in the formation of various types 
of cell-to-cell junctions, especially in epithelial cells, neurons or fibroblasts. Nectins 1 and 2, 
and NecL5 can also serve as viral entry receptors. These molecules, however, are frequently 
up-regulated in tumor cells of different histotypes. In addition, CMV infection can alter 
NecL5-Nectin3 intercellular interaction: in this case NecL5 would be exposed outside the 
cellular junction and allow DNAM-1 recognition. 
While all the above-mentioned activating receptors are expressed by different leukocyte 
subsets, NKp30, NKp46 and NKp44 triggering receptors are restricted to NK cells. NKp44 
and NKp46 are involved in the recognition of both viral antigens (as the influenza virus HA) 
(Mandelboim et al., 2001) and ligands expressed by tumor cells. NKp30 recognizes B7H6 
and BAT-3 (Brandt et al., 2009; Pogge von Strandmann et al., 2007). B7H6 is a member of the 
B7 family (which includes ligands for stimulatory/inhibitory T cell co-receptors 
CD28/CTLA4). B7H6 is poorly expressed on normal cells, while it is up-regulated in 
different tumor cell lines. BAT-3 is a nuclear factor released in exosomes by tumor cells and 
Dendritic Cells (DC) in response to stress/activation stimuli. The tumor ligands for NKp46 
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and NKp44 remain still undefined. The NKp30, NKp46 and NKp44 receptors are 
structurally and genetically unrelated. NKp46 encoding gene is located within the 
Leukocyte Receptor Complex in Chromosome 19, while the NKp30 and NKp44 encoding 
genes are located in separated regions in chromosome 6. However, for their expression 
pattern, restricted to NK cells, and their impressive capability of triggering NK cell 
cytotoxicity against an extremely wide range of tumor cell lines, they were grouped and 
collectively termed Natural Cytotoxicity Receptors (NCRs). 
Among the triggering receptors, NKp30, NKp46, NKp44, NKG2D and DNAM-1 are 
indispensable for the NK-mediated recognition and killing of tumor cells. Different studies 
have demonstrated how their blockade, impairment of function, or expression failure, 
heavily compromise the efficacy of NK cells in killing tumor cells in vitro, or in containing 
tumor growth in animal models (Bottino et al., 2004; Iguchi-Manaka et al., 2008; Guerra et 
al., 2008; Halfteck et al., 2009). Notably, NK cells can significantly improve their functional 
capabilities in response to various cytokines including type I IFN, IL-2, IL-15, IL-12 and IL-
18. In this context, exposure to IL-2, IL-15 and IL-12 can indeed induce up-regulation of 
NCRs, NKG2D and DNAM-1. In particular major effect is exerted on NKp44 that is not 
expressed at all on resting NK cells (Biron et al., 1999; Moretta A. et al., 2001; Della Chiesa et 
al., 2006; Balsamo et al., 2009; Vivier et al., 2011). 
Thus, NK cells by their inhibitory and activating receptors can sense the altered expression 
of both protective self HLA-I molecules and a large array of pathogenic markers, and on this 
basis can discriminate which cells have to be killed. 
The fact that, at variance with activating receptors, the inhibitory HLA-specific receptors are 
clonally distributed, allows the generation of a repertoire of NK cell subsets capable of 
sensing alteration of even single HLA-alleles. Importantly, this phenomenon is the basis for 
the exploitation of alloreactive NK cell subsets in aplo-identical Hematopoietic Stem Cell 
Transplanation ( HSCT) in hematological malignancies (see section 2.4). 
2.3 Multiple NK cell subsets and functions 
Besides their involvement in direct pathogen clearance, NK cells are also implied in the 
regulation of the immune responses. Indeed they can produce and respond to various 
cytokines, functionally interact with different immune cell types and participate at 
regulation of T cell functions, in particular at Th1/Th2 polarization (Cooper et al., 2001; 
Moretta A. et al., 2005; Scordamaglia et al., 2008). 
Up today several NK cell types, with distinct phenotype, function and anatomical location 
have been described (Table 1).  
The CD56brightCD16dim/negKIR-NKG2A+ NK cells are characterized by low granule content 
and low cytolytic activity but produce large amounts of cytokines, in particular IFN-. These 
cells cover 5-10% of circulating NK cells but represent the large majority of NK cells in 
Lymph Nodes (L.N.). At these sites, upon interaction with maturing DC, CD56bright NK cells 
can proliferate and produce IFN- thus favoring Th1 response (Fehniger et al., 2003; 
Ferlazzo & Munz 2004). 
The classical CD56dimCD16bright NK cells (approx. 90% of circulating NK cells) are highly 
cytotoxic, and also produce cytokines, in particular IFN- and TNF-and, to a lesser extent, 
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chemokines, such as MIP-1. These cells may migrate to peripheral tissues driven by 
chemokines and type I IFNs. Indeed, CD56dimCD16bright NK cells express receptors (CXCR1 
ChemR23 and CX3CR1) specific for chemokines (CXCL8, Chemerin and CX3CL1 
respectively) that are usually produced during inflammatory events by Macrophages, 
Neutrophils, DC and Endothelial cells (Moretta A. et al., 2005; Della Chiesa et al., 2006b; 
Parolini et al., 2007). In addition they also express GPR56, a molecule that would function as 
receptor for Extra Cellular Matrix components (Della Chiesa et al., 2010). In inflamed tissues, 
different viral or bacterial products (i.e. PAMPs - Pathogen Associated Molecular Patterns) 
may either directly activate NK cells (which express TLR6 and TLR9 PAMP receptors) or 
induce DC, plasmacytoid DC (pDC), M1 type Macrophages, to produce cytokines capable of 
activating NK cells. At these sites, CD56dimCD16bright NK cells  can physically interact with 
immature DC (iDC) and, by the engagement of NKp30 and DNAM-1, they can release TNF-
and HMGB1 and promote DC maturation. Once activated, NK cells, by using the same 
receptors (NKp30 and DNAM-1), can also kill iDCs (and spare mature DC - mDC). As 
compared to mDC, iDC express lower HLA-I levels, and are not “protected” from activated 
NK cells. This phenomenon may represent either a mechanism to eliminate those DC that 
have not properly undergone maturation or a signal to terminate the response and avoid 
chronic inflammation (Zitvogel et al., 2002; Moretta A. et al., 2005). 
Recently, a novel CD56+NKp44+ NK cell type was described in MALT (tonsils and Peyer 
patches), and was called NK22, by virtue of its ability to produce IL-22 in response to IL-23 
(Colonna, 2009). IL-22 is a IL-10 family cytokine with anti-bacterial effects, as it maintains 
epithelial-cell barrier function in the gut thus contrasting bacterial dissemination. The 
meaning of NK22 cells, as well as their ontogenesis, are not fully understood, nevertheless 
these cells may play an important role in constraining inflammation and in defense against 
bacterial infection in the mucosa. 
A unique NK cell subset expressing the phenotype CD56brightCD16dim/negKIR+NKG2A+, 
populates decidua in the first trimester of pregnancy (Moffet-King, 2002; Hanna et al., 2006). 
These cells display peculiar functional features: they express the NCRs but are poorly 
cytolytic; rather, the engagement of NKp30 and NKp44 would induce them to produce a 
defined pattern of chemokines and pro-angiogenic factors (see Table 1). These factors would 
favor trophoblast migration and decidua vascularization, ensuring an appropriate placenta 
and fetus development. Decidual NK (dNK) cells may also have a role in the induction of 
tolerance at the maternal/fetal interface. dNK cells, by producing IFN-, would induce 
expression of IDO in decidual myelomonocytic cells. In turn IDO, together with TGF-, 
would favor induction and proliferation of Tregs. Interestingly, unlike PB NK cells (see 
section 2.4), dNK cells are resistant to the inhibition of the IDO-induced Trp-catabolite, L-
kynurenine. This resistance implies that dNK cells can maintain production of IFN- and 
sustain the tolerogenic pathway over time (Vacca et al., 2010). 
It has been recently proposed that the CD56brightCD16dim/negKIR-NKG2A++ cells could 
undergo further differentiation through different stages (Bjorkstrom et al., 2010; Lopez-
Verges et al., 2010). The relatively immature and poorly cytotoxic CD56brightCD16dim/negKIR-
NKG2A++ cells, would progressively increase the expression of cytolytic granules, CD16, 
KIRs and CD57, down-regulate NKG2A, and modify the kinetics of IFN- release. In line 
with this hypothesis, four phenotypically distinct NK cell populations, possibly representing 
sequential stages of this differentiation process, have been identified within circulating pool:  
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and NKp44 remain still undefined. The NKp30, NKp46 and NKp44 receptors are 
structurally and genetically unrelated. NKp46 encoding gene is located within the 
Leukocyte Receptor Complex in Chromosome 19, while the NKp30 and NKp44 encoding 
genes are located in separated regions in chromosome 6. However, for their expression 
pattern, restricted to NK cells, and their impressive capability of triggering NK cell 
cytotoxicity against an extremely wide range of tumor cell lines, they were grouped and 
collectively termed Natural Cytotoxicity Receptors (NCRs). 
Among the triggering receptors, NKp30, NKp46, NKp44, NKG2D and DNAM-1 are 
indispensable for the NK-mediated recognition and killing of tumor cells. Different studies 
have demonstrated how their blockade, impairment of function, or expression failure, 
heavily compromise the efficacy of NK cells in killing tumor cells in vitro, or in containing 
tumor growth in animal models (Bottino et al., 2004; Iguchi-Manaka et al., 2008; Guerra et 
al., 2008; Halfteck et al., 2009). Notably, NK cells can significantly improve their functional 
capabilities in response to various cytokines including type I IFN, IL-2, IL-15, IL-12 and IL-
18. In this context, exposure to IL-2, IL-15 and IL-12 can indeed induce up-regulation of 
NCRs, NKG2D and DNAM-1. In particular major effect is exerted on NKp44 that is not 
expressed at all on resting NK cells (Biron et al., 1999; Moretta A. et al., 2001; Della Chiesa et 
al., 2006; Balsamo et al., 2009; Vivier et al., 2011). 
Thus, NK cells by their inhibitory and activating receptors can sense the altered expression 
of both protective self HLA-I molecules and a large array of pathogenic markers, and on this 
basis can discriminate which cells have to be killed. 
The fact that, at variance with activating receptors, the inhibitory HLA-specific receptors are 
clonally distributed, allows the generation of a repertoire of NK cell subsets capable of 
sensing alteration of even single HLA-alleles. Importantly, this phenomenon is the basis for 
the exploitation of alloreactive NK cell subsets in aplo-identical Hematopoietic Stem Cell 
Transplanation ( HSCT) in hematological malignancies (see section 2.4). 
2.3 Multiple NK cell subsets and functions 
Besides their involvement in direct pathogen clearance, NK cells are also implied in the 
regulation of the immune responses. Indeed they can produce and respond to various 
cytokines, functionally interact with different immune cell types and participate at 
regulation of T cell functions, in particular at Th1/Th2 polarization (Cooper et al., 2001; 
Moretta A. et al., 2005; Scordamaglia et al., 2008). 
Up today several NK cell types, with distinct phenotype, function and anatomical location 
have been described (Table 1).  
The CD56brightCD16dim/negKIR-NKG2A+ NK cells are characterized by low granule content 
and low cytolytic activity but produce large amounts of cytokines, in particular IFN-. These 
cells cover 5-10% of circulating NK cells but represent the large majority of NK cells in 
Lymph Nodes (L.N.). At these sites, upon interaction with maturing DC, CD56bright NK cells 
can proliferate and produce IFN- thus favoring Th1 response (Fehniger et al., 2003; 
Ferlazzo & Munz 2004). 
The classical CD56dimCD16bright NK cells (approx. 90% of circulating NK cells) are highly 
cytotoxic, and also produce cytokines, in particular IFN- and TNF-and, to a lesser extent, 
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chemokines, such as MIP-1. These cells may migrate to peripheral tissues driven by 
chemokines and type I IFNs. Indeed, CD56dimCD16bright NK cells express receptors (CXCR1 
ChemR23 and CX3CR1) specific for chemokines (CXCL8, Chemerin and CX3CL1 
respectively) that are usually produced during inflammatory events by Macrophages, 
Neutrophils, DC and Endothelial cells (Moretta A. et al., 2005; Della Chiesa et al., 2006b; 
Parolini et al., 2007). In addition they also express GPR56, a molecule that would function as 
receptor for Extra Cellular Matrix components (Della Chiesa et al., 2010). In inflamed tissues, 
different viral or bacterial products (i.e. PAMPs - Pathogen Associated Molecular Patterns) 
may either directly activate NK cells (which express TLR6 and TLR9 PAMP receptors) or 
induce DC, plasmacytoid DC (pDC), M1 type Macrophages, to produce cytokines capable of 
activating NK cells. At these sites, CD56dimCD16bright NK cells  can physically interact with 
immature DC (iDC) and, by the engagement of NKp30 and DNAM-1, they can release TNF-
and HMGB1 and promote DC maturation. Once activated, NK cells, by using the same 
receptors (NKp30 and DNAM-1), can also kill iDCs (and spare mature DC - mDC). As 
compared to mDC, iDC express lower HLA-I levels, and are not “protected” from activated 
NK cells. This phenomenon may represent either a mechanism to eliminate those DC that 
have not properly undergone maturation or a signal to terminate the response and avoid 
chronic inflammation (Zitvogel et al., 2002; Moretta A. et al., 2005). 
Recently, a novel CD56+NKp44+ NK cell type was described in MALT (tonsils and Peyer 
patches), and was called NK22, by virtue of its ability to produce IL-22 in response to IL-23 
(Colonna, 2009). IL-22 is a IL-10 family cytokine with anti-bacterial effects, as it maintains 
epithelial-cell barrier function in the gut thus contrasting bacterial dissemination. The 
meaning of NK22 cells, as well as their ontogenesis, are not fully understood, nevertheless 
these cells may play an important role in constraining inflammation and in defense against 
bacterial infection in the mucosa. 
A unique NK cell subset expressing the phenotype CD56brightCD16dim/negKIR+NKG2A+, 
populates decidua in the first trimester of pregnancy (Moffet-King, 2002; Hanna et al., 2006). 
These cells display peculiar functional features: they express the NCRs but are poorly 
cytolytic; rather, the engagement of NKp30 and NKp44 would induce them to produce a 
defined pattern of chemokines and pro-angiogenic factors (see Table 1). These factors would 
favor trophoblast migration and decidua vascularization, ensuring an appropriate placenta 
and fetus development. Decidual NK (dNK) cells may also have a role in the induction of 
tolerance at the maternal/fetal interface. dNK cells, by producing IFN-, would induce 
expression of IDO in decidual myelomonocytic cells. In turn IDO, together with TGF-, 
would favor induction and proliferation of Tregs. Interestingly, unlike PB NK cells (see 
section 2.4), dNK cells are resistant to the inhibition of the IDO-induced Trp-catabolite, L-
kynurenine. This resistance implies that dNK cells can maintain production of IFN- and 
sustain the tolerogenic pathway over time (Vacca et al., 2010). 
It has been recently proposed that the CD56brightCD16dim/negKIR-NKG2A++ cells could 
undergo further differentiation through different stages (Bjorkstrom et al., 2010; Lopez-
Verges et al., 2010). The relatively immature and poorly cytotoxic CD56brightCD16dim/negKIR-
NKG2A++ cells, would progressively increase the expression of cytolytic granules, CD16, 
KIRs and CD57, down-regulate NKG2A, and modify the kinetics of IFN- release. In line 
with this hypothesis, four phenotypically distinct NK cell populations, possibly representing 
sequential stages of this differentiation process, have been identified within circulating pool:  
 






Interestingly, along these putative differentiation steps NK cells would also progressively 
lose CCR7 and CD62L expression and acquire the fraktalkine receptor CX3CR1, thus 
skewing their initial homing capabilities to L.N., towards inflamed Peripheral Tissues 
(Juelke et al., 2010; Hamann et al., 2011). This latter point should not be disregarded, 
especially in view of the future perspective of selecting appropriate NK cell subsets for 
cancer immunotherapy. 
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CD3-CD56+NKp44+ MALT IL-22+ / mucosal immunity 
CD3-CD56+CD16+/-
KIR+ Liver Cytotoxicity 
Table 1. Surface phenotype, anatomical localization and function of different NK cell subsets 
2.4 Role of NK cells in the control of tumors 
The impressive advances obtained in the last 15-20 years in the knowledge of the 
mechanism of action of NK cells and of their regulation, have been fuelled by the evident 
therapeutic potential that these cells have shown since their first discovery. However, 
although the efficacy of NK cells in containing tumors in vivo has been demonstrated in 
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different animal models (Kim et al., 2000; Smyth et al., 2000; Guerra et al., 2008; Halftech et 
al., 2009), the way to develop effective NK-based immunotherapy has been elusive for many 
years and only very recently it yielded promising results. 
After the initial attempts by Rosenberg’s group (Rosenberg et al., 1985), several trials had 
been done to set protocols for the adoptive transfer of ex-vivo activated autologous NK cell 
populations or for the use of different cytokines to elicit NK cell responses in vivo (Sutlu & 
Alici, 2009). The advantages of these approaches, however, appeared minimal: both because 
of the technical limits in expanding ex vivo large bulk populations (as repeated infusions 
were necessary to overcome the short life-span of transferred mature NK cells), and because 
of the putative adverse effects induced by IL-2 in vivo (such as the possible expansion of 
CD25+ Tregs or the induction the AICD) (Ghiringhelli et al., 2005; Rodella et al., 2001). In 
addition, another possible limitation could be that tumor cells could retain sufficient HLA-I 
expression to protect themselves from autologous NK cell attack. A turning point in the 
definition of efficient NK-based immunotherapeutic strategies against cancer, was 
represented by the study by Velardi and co-workers, primarily aimed at the evaluation of 
the clinical outcome of aplo-identical HSCT in Acute Myeloid Leukemia (AML) (Ruggeri et 
al., 2002). In this study the authors suggested that, in the presence of HLA/KIR mismatch 
(i.e. recipient and donor expressing different HLA-I alleles that are recognized by different 
KIRs), NK cells that developed from donor’s progenitors could play an active role in 
reducing both the risk of leukemia relapse and even the Graft versus Host Disease (GvHD). 
This implied that heterologous NK cells could develop in the conditioned host, and kill 
Leukemic blasts more efficiently than autologous NK cells could do. Further studies by 
different groups have led to the current hypothesis that in the host, heterologous NK cell 
population expressing KIRs specific for donor’s and not for recipient’s HLA-I alleles can 
develop and be educated (licensed) by the donor’s bone marrow cells, thus acquiring 
efficient killing capabilities towards host (allogeneic) malignant cells or activated leukocytes 
(Pende et al., 2009; Cooley et al., 2010; Haas et al., 2011; L. Moretta et al., 2011). The 
functional capabilities of allogeneic NK cells would also explain the reduction of GvHD 
observed in patients undergoing HLA/KIR mismatched HSCT, as, besides the elimination 
of heterologous Leukemic blasts (Graft-versus-Leukemia - GvL - effect), donor’s NK cells 
would also be involved in the killing of those host’s DC capable of priming donor’s T cells. 
Interestingly, this alloreactive NK cell population may persist (and exert the its beneficial 
effect) for years (Pende et al., 2009; Haas et al., 2011) without causing apparent detrimental 
clinical signs ascribable to NK cell activity. 
The above studies open new perspectives for the exploitation of NK cells in 
immunotherapy. In this context, different trials have been designed for the treatment of 
hematological malignancies, and in some cases also for solid tumors (Miller et al., 2005; 
Terme et al., 2008; Sutlu & Alici, 2009). Several problems, however, still remain to be solved. 
For example the fact that immature, not fully competent, NK cells may predominate (and 
persist) in circulation during (and after) the recipient immunological reconstitution (Nguyen 
et al., 2005) with negative effects on the anti-tumor activity and surveillance against viruses. 
Another problem regards a general negative effect that malignancies may exert on NK cell 
functions. In this context, different studies have reported a down-regulation of activating 
receptors in circulating NK cells from tumor patients (Sanchez et al., 2010; Le Maux-Chansac 
et al., 2005; Fregni et al., 2011). Moreover , in solid tumors, the tumor microenvironment 
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different animal models (Kim et al., 2000; Smyth et al., 2000; Guerra et al., 2008; Halftech et 
al., 2009), the way to develop effective NK-based immunotherapy has been elusive for many 
years and only very recently it yielded promising results. 
After the initial attempts by Rosenberg’s group (Rosenberg et al., 1985), several trials had 
been done to set protocols for the adoptive transfer of ex-vivo activated autologous NK cell 
populations or for the use of different cytokines to elicit NK cell responses in vivo (Sutlu & 
Alici, 2009). The advantages of these approaches, however, appeared minimal: both because 
of the technical limits in expanding ex vivo large bulk populations (as repeated infusions 
were necessary to overcome the short life-span of transferred mature NK cells), and because 
of the putative adverse effects induced by IL-2 in vivo (such as the possible expansion of 
CD25+ Tregs or the induction the AICD) (Ghiringhelli et al., 2005; Rodella et al., 2001). In 
addition, another possible limitation could be that tumor cells could retain sufficient HLA-I 
expression to protect themselves from autologous NK cell attack. A turning point in the 
definition of efficient NK-based immunotherapeutic strategies against cancer, was 
represented by the study by Velardi and co-workers, primarily aimed at the evaluation of 
the clinical outcome of aplo-identical HSCT in Acute Myeloid Leukemia (AML) (Ruggeri et 
al., 2002). In this study the authors suggested that, in the presence of HLA/KIR mismatch 
(i.e. recipient and donor expressing different HLA-I alleles that are recognized by different 
KIRs), NK cells that developed from donor’s progenitors could play an active role in 
reducing both the risk of leukemia relapse and even the Graft versus Host Disease (GvHD). 
This implied that heterologous NK cells could develop in the conditioned host, and kill 
Leukemic blasts more efficiently than autologous NK cells could do. Further studies by 
different groups have led to the current hypothesis that in the host, heterologous NK cell 
population expressing KIRs specific for donor’s and not for recipient’s HLA-I alleles can 
develop and be educated (licensed) by the donor’s bone marrow cells, thus acquiring 
efficient killing capabilities towards host (allogeneic) malignant cells or activated leukocytes 
(Pende et al., 2009; Cooley et al., 2010; Haas et al., 2011; L. Moretta et al., 2011). The 
functional capabilities of allogeneic NK cells would also explain the reduction of GvHD 
observed in patients undergoing HLA/KIR mismatched HSCT, as, besides the elimination 
of heterologous Leukemic blasts (Graft-versus-Leukemia - GvL - effect), donor’s NK cells 
would also be involved in the killing of those host’s DC capable of priming donor’s T cells. 
Interestingly, this alloreactive NK cell population may persist (and exert the its beneficial 
effect) for years (Pende et al., 2009; Haas et al., 2011) without causing apparent detrimental 
clinical signs ascribable to NK cell activity. 
The above studies open new perspectives for the exploitation of NK cells in 
immunotherapy. In this context, different trials have been designed for the treatment of 
hematological malignancies, and in some cases also for solid tumors (Miller et al., 2005; 
Terme et al., 2008; Sutlu & Alici, 2009). Several problems, however, still remain to be solved. 
For example the fact that immature, not fully competent, NK cells may predominate (and 
persist) in circulation during (and after) the recipient immunological reconstitution (Nguyen 
et al., 2005) with negative effects on the anti-tumor activity and surveillance against viruses. 
Another problem regards a general negative effect that malignancies may exert on NK cell 
functions. In this context, different studies have reported a down-regulation of activating 
receptors in circulating NK cells from tumor patients (Sanchez et al., 2010; Le Maux-Chansac 
et al., 2005; Fregni et al., 2011). Moreover , in solid tumors, the tumor microenvironment 
 
Hematology – Science and Practice 
 
344 
may play an additional negative role by contrasting both the responses and the infiltration 
capabilities of the immune effector cells (Albertsson et al., 2003). In this context, different 
studies have indicated that in some tumors, infiltrating NK cells may be rare or poorly 
functional (Albertsson et al., 2003; Carrega et al., 2009; Platonova et al., 2011). At the tumor site 
several stromal components, induced by aberrant tumor-driven inflammation, can contribute 
to NK cell down-regulation (Mantovani et al., 2008). Tregs, by the release of TGF-, may 
suppress NK cell functions (Zimmer et al., 2008). The induction of M2 macrophages may 
reduce the macrophage-mediated NK cell activation (as this effect is prominently sustained by 
M1 macrophages) (Bellora et al., 2010). Also the Tumor Associated Fibroblasts (TAF) may 
contrast NK cells in their anti-tumor activity. Indeed, fibroblasts derived from melanoma 
lesions were found to inhibit, by mean of cell-to-cell contact and PGE2 release, the IL-2-driven 
up-regulation of NKp44, DNAM-1 and NKp30 on NK cells (Balsamo et al., 2009). Finally, even 
the tumor cells can induce down-modulation of activating NK receptors. Several tumor cell 
lines constitutively express IDO, an enzyme involved in the Trp catabolism. The IDO-induced 
Trp catabolite Kynurenine has been shown to down-regulate NKp46 and NKG2D (Della 
Chiesa et al., 2006). In addition, tumor cells can also induce down-regulation of NKG2D or 
DNAM-1 on NK cells by the release of soluble NKG2D-Ligands (Doubrovina et al., 2003) or by 
the prolonged engagement of DNAM-1 in cell-to-cell contact (Carlsten et al., 2009) 
3. Human Natural Killer cell development 
3.1 In vitro NK cell development  
3.1.1 Acquisition of NK cell receptors and function  
Most of information available on human NK cell development came from in vitro studies of 
NK cell differentiation from CD34+ Hematopoietic Stem Cells (HSC) or CD34+/-CD45RA+ 
early lymphoid precursors. These cells can be isolated from different sources such as fetal 
liver, Bone Marrow (BM), Thymus, PB and Umbilical Cord Blood (UCB) and stimulated 
with IL-2 or IL-15, in the presence or in the absence of feeder cells,  to obtain NK cell 
differentiation (Freud & Caligiuri , 2006). In the 90s’ it was shown that it was possible to 
obtain CD3-CD56+ CD94/NKG2A+ cytolytic NK cells from either CD34-CD45RA+CD7+CD1a- 
early thymic precursors (Mingari et al., a1991,b1997; Lanier et al., 1992; Sanchez et al., 1994) 
or CD34+HSC isolated from BM or UCB (Miller et al., 1994; Lotzova et al., 1993).  
Currently, optimal culturing conditions require the simultaneous presence of different 
cytokines: Stem Cell Factor (SCF), FMS-Like Tyrosine Kynase Ligand (Flt3-L), IL-7, IL-15 
and IL-21.  
During in vitro differentiation the development of NK cells proceeds through a step-by-step 
process (figure 1) (Freud& Caligiuri, 2006). Freshly isolated HSC precursors already express 
CD117 and Flt3, which are the SCF and Flt3-L receptors, respectively, and play an important 
role for their proliferation and survival before any cell lineage commitment takes place . The 
first cell markers that would suggest a NK-lymphoid commitment are the IL-2/IL-15 
receptors CD122, CD132 and the IL-7 -chain receptor (CD127). These receptors play an 
important role in transducing proliferation and differentiation signals upon interaction with 
the appropriate cytokines (IL-15 and IL-7 respectively). However, in humans, these markers 
are rarely detectable on ex-vivo isolated CD34+CD45RA+ precursors, while  they can be 
detected on small fractions of precursor after first days of culture (Freud& Caligiuri, 2006).   
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The first surface cell marker that clearly identify NK cell precursors is CD161 (Bennet et al., 
1996). It can be detected on small percentages of CD3-CD56-CD117+cells, which already 
express CD244 co-receptor: the acquisition of NKp44 activating receptor and CD56 
represents the following differentiation step. Next, the expression of the NKp46, NKG2D 
and DNAM-1 activating receptors and of CD94/NKG2A inhibitory receptor occurs. The 
acquisition of CD16 and KIRs can be hardly observed in vitro (Mingari et al., 1997; Miller et 
al., 2001; Sivori et al., 2002). These receptors are typical of functionally differentiated 
circulating NK cells: their acquisition by small percentages of cell precursors undergoing 
differentiation, appears after long term cultures in the presence of IL-21, a pro-inflammatory 
cytokine (Sivori et al., 2003). On the other hand, the early expression of NKp44 may be 
related to the fact that recombinant IL-15, present in the culture, rapidly activates NKp44 
gene transcription. Hence, NKp44 transcription could be differently regulated from that of 
the other activating receptors.  
This sequential process of cell marker acquisition identifies NK cell precursor intermediates 
with different functional properties (Freud & Caligiuri, 2006; Grzywacz et al., 2006). Early 
NK cell precursors CD117+CD161+CD244+CD56+/- NKp44+/- are not cytolytic but can secrete 
cytokines such as GM-CSF and IL-13. These cells lack the expression of all the other 
activating receptors and inhibitory receptors. The next stage of in vitro NK cell 
differentiation correlates with the definitive acquisition of CD56 and of NKp44 
(CD117+CD161+ CD244+CD56+NKp44+): these precursors can be defined as immature NK 
cells (iNK). Immature NK cells secrete large amounts of CXCL8 and low amounts of IL-22 
while they do not produce IFN-Freud & Caligiuri, 2006;Vitale et al., 2008; Tang et al., 
2011). The production of CXCL8 could have a role in the modulation of hematopoietic cell 
lineage commitment. In particular, CXCL8 inhibits myelopoiesis (Youn et al., 2000) and, 
thus, might favour NK cell differentiation. On the other hand, iNK cells are not cytotoxic. 
Indeed they have not acquired yet cytolytic granules in their cytoplasm, important NK 
activating receptors (i.e. NKp46), and the adhesion molecule LFA-1, that strongly contribute 
to the activation of cytolytic machinery (Bryceson et al., 2006).  
The acquisition of a weak cytolytic activity correlates with the expression of NKp46 
activating receptor and LFA-1; however, at this stage of development, the NKp46-mediated 
cytotoxicity against susceptible cell targets may be inhibited by the CD244 co-receptor, that 
acts as inhibitory receptor on these iNK cells. CD244 works as an activating co-receptor on 
mature NK cells thanks to the recruitment of an intra-cytoplasmic adaptor molecule SAP. 
However, on CD117+/-CD161+ CD244+CD56+NKp46+/-CD94/NKG2A-LFA-1+/- iNK cells 
SAP it is not synthetized yet, leading to inhibitory rather than activating function of CD244 
(Moretta et al., 2001; Sivori et al., a2002, b2003; Vitale et al., 2008). 
The full acquisition of cell functions typical of mature NK cells, such as IFN- secretion and 
cytolytic activity, correlates with the surface bright expression of NKp46, the expression of 
NKG2D and DNAM-1 activating receptors, CD94/NKG2A inhibitory receptor and of LFA-1 
molecule. At this stage, SAP starts to be synthesized, and CD244 acquires a co-stimulatory 
activity. These cells are defined as CD56bright NK cells since they are very similar to CD56bright 
CD94/NKG2A+CD16-KIR- NK cells present in the PB. Notably, differentiation is a 
continuous process and cells may not be synchronized in their maturation status: hence, a 
certain heterogeneity of the different cell subsets may be observed.  
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Altogether these experimental evidences indicate that NK cell development is tightly 
regulated and that evolution had particularly tuned the acquisition of cytolytic activity. NK 
cells, to become cytotoxic, must express at least the NKp46 activating receptor and the LFA-
1 adhesion molecule. Simultaneously, they have to loose the inhibitory activity of CD244 co-
receptor. The ability to control NK cytotoxicity by inhibitory CD244 could be a “safe” 
mechanism, important in the interactions between NK cell precursors and other 
hematopoietic cells. CD244 ligand is the CD48 molecule, which is expressed by different 
types of leucocytes and hematopoietic precursors (Cannons et al., 2011). On the other hand, 
iNK cells secrete a peculiar pattern of cytokines, such as IL-22 and CXCL8, involved in 
inflammatory process, defence against bacteria, neo-angiogenesis and modulation of 
haematopoiesis. Hence, iNK cells might exert important crosstalk with other cells present in 
microenvironment where their differentiation takes place.  
3.2 Factors that modulate NK cell differentiation 
Hematopoietic cell lineage commitment depends on a wide variety of factors. Genetic 
components dictate the initial commitment but the milieu that surrounds lineage precursors 
may have a key role in the fate of these cells. The balance between specific transcription 
factors and the appropriate cytokines and hormones can change the commitment of 
intermediate lymphoid precursors, inducing their switch towards alternative lineages 
(Laiosa et al., 2006; Doulatov et al., 2010). In this context, in vitro analysis have shown that 
NK cells can share intermediate precursors not only among lymphoid cells but also with 
dendritic cells and myeloid cells (Miller et al., 1999; Marquez et al., 1998; Perez et al., 2003; 
Vitale et al., 2008; Grzywacz et al., 2011). 
3.2.1 Cytokines 
Cytokines are important factors that modulate NK cell differentiation. SCF and Flt3-L have a 
role in the first days of in vitro development because they induce HSC to enter into the cell 
cycle, and sustain precursor proliferation and survival (Yu et al., 1998). Then, IL-7 supports 
the lymphoid lineage commitment, since this cytokine is involved in T cell homeostasis and 
lymphoid differentiation (Ma A. et al., 2006). However, it is IL-15 that plays a key role in NK 
cell differentiation, through the interaction with IL-2/IL-15 common  and  chains 
receptors (CD122 and CD132, respectively). Indeed, IL-15 has been shown to be critical in 
the terminal differentiation of CD117+/-CD161+CD56+ iNK towards mature NK cells 
(Mrozek et al., 1995; Freud & Caligiuri, 2006). In murine models, NK cell deficiencies are 
more pronounced in mice lacking IL-15 or its receptors, than in mice lacking IL-2 or IL-7 
related products (Di Santo et al., 1990; Giliani et al., 2005; Kennedy et al., 2000). In vitro 
assays revealed that high dose soluble IL-15 binds to its receptors and promote NK cell 
differentiation but, in vivo, IL-15 is primarily detectable complexed to its IL-15 Receptor 
(IL15-R) present on accessory (stromal) cells (Dubois et al., 2002). IL-15/IL15-R complex 
would then present the cytokine in trans to CD122+CD132+ cells, meaning that also stromal 
cells could exert an important role in the terminal differentiation of iNK cells (Miller et al., 
1994; Briard et al., 2002; Vacca et al., 2011). Finally, IL-21 have been shown to increase the 
proportions of CD56+KIR+ cells undergoing in vitro differentiation (Sivori et al., 2003).  
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3.2.2 Transcription factors 
In vitro and in vivo studies using mice with loss-of-function mutation helped to clarify the 
role of many transcription factors (TFs) involved in NK cell commitment, proliferation and 
maturation. Some of them, like the E proteins, orchestrate a lymphoid-biased cellular 
context versus myeloid compartment (de Pooter et al., 2010) but must be down-regulated to 
allow NK cell differentiation (Boos et al., 2007). Other TFs are important both in the NK cell 
and T cell commitment, such as Notch-1 or Id2 (Benne et al., 2009; Boos et al., 2007). Id2 is an 
helix loop helix TF, able to modulate the activation the E protein E2A, and have been shown 
to exert a prominent role in NK cell commitment. Recently, other two TF have been suggested 
to induce definitive early NK cell commitment:  a High Mobility Group protein, called TOX, 
and a basic leucin zipper, E4PB4 (also known as NFIL3)(Aliahmad et al., 2010; Gascoyne et al., 
2009; Kamizono et al., 2009). It has been shown that IL-15 activates E4PB4 that, in turn, would 
activate Id2 transcription, leading to a definitive NK cell commitment and expansion of NK 
cell precursors. In humans, E4BP4 and Id2 expression can be observed either in ex-vivo-
isolated early committed CD34+/-CD122+CD127+ NK cell precursors either in in vitro-derived 
CD117+/-CD161+CD56+LFA-1-NKG2A- iNK cells (Hughes et al., 2010; Vacca at al., 2011). On 
the other hand, TOX would influence the activation of T-bet,  a TF that correlates with the 
acquisition of cytolytic activity and the ability to produce IFN- by more differentiated 
CD161+CD56+LFA-1+ NKp46+ CD94/NKG2A+ NK cells (Yun et al., 2011).  
Expression of others TFs appears to correlate with the different stages of NK cell 
differentiation. RORC correlates with the secretion of IL-22 by iNK cells (Tang et al., 2011) 
while the expression of EOMES (a T-box TF), similar to T-bet, correlates with IFN- 
production by more differentiated NK cells (Glimcher et al., 2004). 
3.2.3 Corticosteroids 
In the last years the studies on in vitro NK cell development offered new important clues on 
NK cell lineage commitment and on the factors that may modulate this process. 
The attempt to improve models of in vitro NK cell differentiation, induced many groups to 
test additional factors, besides cytokines, that could favour in vitro NK cell differentiation: 
in particular, stromal cells and/or corticosteroids. These new protocols revealed an 
unexpected function for glucocorticoids, which were already known to exert a modulatory 
effect on T cell development (Jondal et al., 2004). Studies with Hydrocortisone (HC) showed 
that it was possible to obtain NK cells from the in vitro culture of CD33+CD14+/- myeloid 
progenitors isolated from UCB (Perez et al., 2003). These results suggested that, in cord 
blood, it was possible to switch the differentiation of monocyte precursors towards NK cells. 
We obtained similar results with Methylprednisolone (MePDN). This corticosteroid is 
commonly used as first line of treatment for acute GvHD after allogeneic HSCT. Our 
hypothesis was that MePDN could inhibit not only mature NK cell proliferation and 
functions but also the in vitro NK cell differentiation. Surprisingly, our results showed that 
pharmacological concentrations of MePDN accelerated NK cell differentiation and were able 
to induce myeloid precursors to switch their differentiation towards CD161+CD56+NKp44+ 
iNK cells (Vitale et al., 2008). More recently, Grwaycz et al., with an elegant in vitro 
experiment, provided evidence that HC, in combination with a stromal cell line, induce 
differentiation of CD33+CD13+CD115+/- myelomonocytic precursors into cytolytic 
CD56+NKp46+CD94/NKG2A+KIR+/-CD16+/- NK cells (Grwaycz et al., 2011). 
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These results offer important clues to better clarify some major issues that have been 
discussed in the last years.  
The first one is related to the hematopoietic cell lineage commitment. Current models of 
haematopoiesis suggest that HSC may commit early to the erythroid/platelet lineages or to 
leukocyte lineages. However, once committed to the leukocyte lineage, hematopoietic 
precursors would retain a high plasticity. Thus, the choice to terminally differentiate 
towards myeloid or lymphoid lineages would then depend on the role of lineage-specific 
transcription factors and on a permissive milieu (Doulatov et al., 2010). This would be of 
particular interest for NK cells, which are the only lymphocytes assigned to natural 
immunity compartment and that appear to be the connection ring with acquired immunity.  
The second issue regards the role of NK cells after HSCT and their use in immunotherapy to 
obtain GvL reaction. The possibility that myeloid precursors, in the presence of 
corticosteroids, could generate more rapidly functional NK cells offers important clues also 
in the clinical settings (Vitale et al., 2008; Grwaycz et al., 2011). It is conceivable that NK  
 
Fig. 1. Acquisition kinetic of receptors and  functions by NK cells undergoing in vitro cell 
development. 
Three main precursor subsets may be identified along different time intervals of culture: 
NK cell precursors, immature NK cells and more differentiated CD56bright NK cells. The 
appearance of CD56dim CD16+KIR+ NK cells (red cell) is a late and rare event and is more 
achievable in the presence of IL-21. Stages of differentiation are endowed with a peculiar 
surface phenotype and functions. In particular the acquisition of cytolytic activity correlates 
with the expression of LFA-1, activating receptors and the production of IFN-while high 
secretion of IL-8 correlates with the immature NK cell stage. 
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cells, present in high percentages in peripheral blood of patients at the earliest time intervals 
after HCST, may derive, at least in part, from myeloid precursors. Importantly, this 
maturation could not occur wholly in BM but also in PB and other sites. This is the third 
important issue that have been matter of debate of the last years: the site of in vivo human 
NK cell development and maturation. 
3.3 In vivo NK cell development and maturation 
NK cells were generally believed to differentiate into the BM from CD34+ hematopoietic 
stem cells (Freud & Caligiuri, 2006). However, NK cell developmental intermediates were 
detectable in vivo neither in the BM nor in thymus. The possibility to observe in vivo any 
different NK cell developmental stages detectable in vitro, came from analysis of 
lymphocyte recovery in patients undergoing allogeneic HSCT. Analysis of PB of these 
patients revealed that,  in some of them, the first waves of lymphocytes recovering at early 
time after transplant (2-3 weeks) are mostly NK cells. These lymphocytes are characterized 
by the CD56bright CD16- CD94/NKG2A+KIR- phenotype and a dull expression of NCRs, 
while CD56dimCD16+CD94/NKG2A+KIR+ NK cells can be detected later, (4-8 weeks after 
transplant). (Vitale et al., 2000; Shilling et al., 2003; Vitale et al., 2004).  
3.3.1 Sites of in vivo NK cell development: Stages of NK cell differentiation 
The finding that in vitro models of NK cell differentiation led to the generation of CD56bright 
CD16- NK cells, supported the hypothesis that, in vivo, this subset could be a precursor 
reservoir, able to promptly differentiate towards more cytotoxic CD56dimCD16+ upon 
specific stimuli. However, experimental evidences that support this hypothesis have been 
acquired only recently. Freud and co-workers discovered that CD45RA+CD117- and 
CD34+CD45+CD117+CD161+/- cells were enriched in Secondary Lymphoid Tissue (SLT), 
particularly in lymphnodes and tonsils. Importantly, these precursors were able to generate 
selectively NK cells upon culture in the presence of appropriate cytokines. They defined 
these cells as pro-NK and pre-NK cells respectively. Further analysis revealed that in SLT, it 
was possible to detect and isolate four different subsets of NK cell precursors representing 
different stages of NK cell differentiation (Freud et al., a2005, b2006).  
Stage 1: CD34+CD45RA+CD117-CD161- pro-NK cells; stage 2: 
CD34+CD45RA+CD117+CD161+/- pre-NK cells; stage 3: CD34-CD117+CD161+CD56+/-
NKp46-CD94/NKG2A-KIR-CD16- immature NK cells; stage 4: CD117+/- 
CD161+CD56+NKp46+CD94/NKG2A+KIR+/-CD16-, defined as CD56bright NK cells. Further 
analysis suggested that also the expression of CD122 and CD127 could help to identify 
stage 1/2 of pre-NK cell precursors. These discoveries confirmed for the first time that in 
vitro models of NK cell differentiation may have in vivo similar counterpart. Indeed, the  
above stages 2, 3 and 4  remind the differentiation steps observed in vitro (Freud & 
Caligiuri et al., 2006; Caligiuri, 2008). This discovery suggests that hematopoietic 
precursors could migrate from BM to SLT and generate NK cells in organs far from the 
BM. It is possible that at least a fraction of CD56bright NK cells present in SLT could 
differentiate from these precursors upon interaction with DC and other cells capable of 
presenting membrane-bound IL-15.  
As mentioned above a particular subset of NK cells has been found to be enriched in tonsils 
and gut-mucosa associated tissue: these cells are CD56+/-NKp46+/-NKp44+NKG2A- and 
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CD34+CD45+CD117+CD161+/- cells were enriched in Secondary Lymphoid Tissue (SLT), 
particularly in lymphnodes and tonsils. Importantly, these precursors were able to generate 
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these cells as pro-NK and pre-NK cells respectively. Further analysis revealed that in SLT, it 
was possible to detect and isolate four different subsets of NK cell precursors representing 
different stages of NK cell differentiation (Freud et al., a2005, b2006).  
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produce IL-22. Their development appears to be independent from IL-15. However, whether 
these cells may represent a new subset of NK cells (called NK22 cells) or simply immature 
NK cells with peculiar in vivo functions is still a matter of debate (Colonna, 2009).  
In conclusion, BM microenvironment may provide a fundamental support for the early 
stages of NK cell differentiation but peripheral tissues, in particular SLT, could provide a 















CD34 + + - - - 
CD45RA +/- +/- (+)/- +/(-) +/(-) 
CD117 - + + +/- - 
CD122 - - - +/- + 
CD127 dull dull + +/- - 
CD161 - +/- + + + 
CD244 + + + + + 
CD56 - (+)/- +/- + + 
NKp44 - - +/(-) (+)/- (+)/- 
NKp46 - - - + + 
NKG2A - - - + +/- 
KIR - - - (+)/- +/- 
CD16 - - - - - 
Table 2. Expression of surface markers by NK cell precursor intermediates isolated in SLT, 
according to model proposed by Freud and co. Legend: +/- variable expression; (+)/- 
majority of cells negative; +/(-) majority of cells positive; dull= weak expression 
3.3.2 Other sites of in vivo NK cell development 
The next step was to verify the possibility that NK-committed cell precursors could be 
isolated in other peripheral tissues, where peculiar NK cell subsets were enriched. Indeed 
NK–committed precursors were found in gut, endometrium and placenta (Chinen at al., 
2007; Male et al., 2010; Vacca et al., 2011). In all these districts there is a high concentration of 
CD56bright NK cells characterized by immune-regulatory activity. In particular, NK cells 
present in human decidua (dNK) during the first trimester of pregnancy display a peculiar 
phenotype (CD56brightCD16-NKG2A+KIR-/+) and exert peculiar functions. For long time dNK 
cells were supposed to derive from PB NK cells undergone phenotypic and functional 
modifications upon interaction with decidual microenvironment. Recently, different 
experimental evidences suggested that dNK cells could derive from NK precursors already 
present in endometrium or in decidua, able to promptly differentiate upon stimuli given by 
the onset of pregnancy (Male et al., 2010; Vacca et al., 2011). In particular, it has been shown 
that NK cell lineage-committed CD34+CD127+CD122+ cells expressing E4BP4 and Id2 TFs 
are present in human decidua (dCD34+) during the first trimester of pregnancy. They can 
undergo in vitro differentiation into functional CD56brightCD16- NK cells in the presence of 
suitable cytokines. More importantly, they could also differentiate without exogenous 
cytokines when co-cultured with decidual stromal cells (dSC), able to express endogenous 
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membrane-bound IL-15. These results suggest that interaction between CD34+ cell and 
decidual stromal cells would be sufficient to promote in situ NK cell differentiation. 
3.3.3 The stage five of human NK cell differentiation: CD56dim CD16+CD94/NKG2A+/-
KIR+ NK cells 
As already discussed, several evidences suggest that CD56dim NK cells may derive from 
CD56bright NK cells. After HSCT the first wave of NK cells is represented by 
CD56brightCD16CD94/NKG2A+KIR- cells while CD56dimCD16+CD94/NKG2A+/-KIR+ cells 
appear later. Importantly, CD56bright display longer telomeres than CD56dim NK cells. 
Moreover, different phenotypically defined NK cell subsets have been recently proposed as 
functional intermediates between the CD56bright and CD56dim cell types (see section 2.3) 
(Romagnani et al., 2007; Juelke et al., 2010).  
However, in in vitro assay, it is almost impossible to observe significant expansions of KIR+ NK 
cells from any type CD34+ cell precursors. Similar problems must be related to our inability to 
fully recreate the in vivo milieu in in vitro assay. CD56dim may acquire their surface phenotype 
and functional properties upon peripheral tissues/blood microenvironment stimuli. However, 
signals that drive the differentiation of CD56dim NK cells, both during normal homeostasis and 
infections, remain still elusive. Recent studies provided evidence that CD56dim cells change their 
phenotypic properties and continue to differentiate throughout their lifespan. The loss of 
expression of NKG2A, the acquisition of KIRs and CD57 would allow the identification of 
sequential steps of cell maturation accompanied by a progressive decline of cell proliferation 
and of responsiveness to cytokine stimulation. In particular, CD16 and KIR would be acquired 
at late stages of peripheral blood NK cell maturation (Björkström et al., 2010; Lopez-Vergès et 
al., 2010). Since the acquisition of KIR repertoire in each single NK cell is a stochastic process, 
related to the KIR genotype and polymorphism, it is important to understand how NK cells 
may be educated to avoid auto-reactivity. They should acquire appropriate KIR able to prevent 
them from killing healthy self-cells. However, in PB of normal donors, it is possible to detect 
NK cells expressing KIR mismatched for self HLA-I ligands or not expressing any HLA-I 
inhibitory receptor at all. These cells could represent a danger as they would not recognize self 
HLA-I on self normal cells. As above mentioned, however, it has been recently proposed that 
during their development only those NK cells expressing inhibitory receptors specific for self 
HLA-I ligands would acquire full functional competence, while cells that fail to express such 
receptors (i.e. potentially autoreactive NK cells) would retain a state of hypo-responsiveness. It 
has to be noted, however, that the question on how such licensing/educational process could 
actually occur in vivo is still matter of debate (Parham, 2006; Vivier et al., 2011).  
The interest for NK cells and their clinical application for the control of leukemic relapse 
after allogeneic HSCT is enormously increased in the last years: hence, it is mandatory 
trying to clarify the epigenetic factors that regulate KIR acquisition and functions, because 
their expression pattern on allogeneic donor NK cells play a crucial role in the eradication of 
recipient’s leukemia (Moretta et al., 2011). 
4. Classification of NK cell disorders 
The World Health Organization (WHO) classification of tumors of hematopoietic and 
lymphoid  tissues encompasses four distinct entities, two of which are provisional: 1) NK 
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cell lymphoblastic leukemia/lymphoma (provisional) (Borowitz  et al., 2008); 2) Chronic 
Lymphoproliferative Disorder of NK cells (provisional) (Villamor et al., 2008); 3) Aggressive 
NK cell leukemia (Chan et al., 2008a);  and 4) Extranodal NK/T-cell lymphoma, nasal type 
(Chan et al., 2008b). In addition, on the basis of morphology, immuno-phenotype, functional 
NK cell activity, and expression of cytotoxic molecules, NK cell neoplasms can be divided 
into immature and mature categories (Jaffe, 1996).  
In recent years rare cases of lymphoblastic lymphomas/leukemia arising from immature 
NK cells has been reported, although the lack of suitable markers for immature NK cells 
mentioned above makes it difficult to distinguish NK-cell lymphoblastic lymphoma (LBL) 
from precursor T-cell LBL. It is also worth mentioning that the plasticity of hematopoietic-
cell lineage seems greater than previously thought, and relations between phenotypically 
dissimilar neoplastic disorders are being reassessed. In contrast, it is believed that chronic 
lymphoproliferative disorder of NK cells, aggressive NK cell leukemia and extranodal NK 
cell lymphoma, nasal type, originate from mature NK cells (Chan et al., 2008a and b). 
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association No Yes Yes No 
Clinical 
course Aggressive Aggressive Very Aggressive Indolent 
Prognosis Poor Poor Poor Good 
Table 3. Clinical and Biological features of NK cell neoplasms 
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4.1 Immature NK cell neoplasms  
4.1.1 NK cell lymphoblastic leukemia/lymphoma, provisional 
A considerable confusion has been generated in the literature concerning this type of 
disorder, mostly due to the definition of NK cell leukemia on the basis of expression of 
CD56 antigen. This is indeed the most important and sensitive NK marker; unfortunately, 
CD56 is not specific for NK cells and can be also expressed in AML and ALL and blastic 
plasmacytoid dendritic cell neoplasms (BPDCN). On the other hand it may not be expressed 
by immature NK cells. NK cell lymphoblastic leukemia/lymphoma can be considered in 
cases showing blastic morphology, expressing CD56, TdT, immature T associated markers 
such as CD7 and CD2, and cytoplasmic CD3, but lacking the expression of surface CD3, 
CD19, CD20, CD13, CD33, and MPO (Liang & Graam, 2008). These patients frequently 
presented with leukemia and lymphadenopathy without skin involvement and were 
negative for EBV. TCR and/or Ig genes were in germline configuration in all cases in which 
the tests were performed. Outcomes of these patients were absolutely unfavourable. The 
immature morphology with NK cell-associated phenotype and genotype suggests that these 
tumours represent the true precursor NK cell neoplasms.  
Some well characterized cases of NK precursor tumours with lymphomatous presentation 
that expressed CD94 1A transcripts have been reported (Lin et al., 2005). CD94 1A, a distal 
promoter of the CD94 molecule, is activated only by IL-15 (Lopez-Botet et al., 1997). Lin et 
al., recently reported that CD94 1A is the predominant form found in immature NK cells 
and it is expressed in TCR- lymphoblastic leukemia (NK lineage LBL) but not in TCR+ LBL 
(T lineage LBL) (Lin et al., 2005). By studying 21 patients with LBL and, on the basis of the 
expression of CD94 1A transcripts and the lack of TCR, the above investigators identified 7 
patients with LBL of immature NK cell origin (CD94 1A+, TCR-). It is noteworthy that those 
NK-LBLs occurred in young patients and had better outcomes as compared with patients 
who had T-LBL (CD94 1A-, TCR+); none of the tumours was positive for CD56 (Lin et al., 
2005). Thus, the use of CD94 1A associated with TCR appears to be more suitable than CD56 
for identifying an immature NK cell neoplasm. 
A standard treatment protocol for immature NK cell neoplasms has not been established 
mainly because of the rarity of these cases. Current chemotherapy strategies for non-
Hodgkin’s lymphoma or acute lymphoblastic leukemia (ALL) were the most commonly 
used. However, the overall outcomes were dismal and HSCT  represents the only effective 
therapy to achieve a complete remission  (Lin et al., 2005).  
4.2 Mature NK cell neoplasms 
4.2.1 Extranodal NK/T cell lymphoma, nasal type 
The WHO classification encompasses both nasal NK/T cell lymphoma and extra-nasal 
NK/T cell lymphoma in the same category (Chan et al., 2008a). They share the same 
histology, even though these lymphomas may have different clinical manifestations, 
treatment approaches, and prognoses (Oshimi, 2007). Although most cases are genuine NK 
cell neoplasms, the term “NK/T” rather than “NK” is used because this entity also includes 
cytotoxic T cell neoplasms (Sozumiya et al., 1994). Nasal and extra-nasal NK/T cell 
lymphoma are invariably associated with EBV and have a ethnic predisposition, being more 
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cell lymphoblastic leukemia/lymphoma (provisional) (Borowitz  et al., 2008); 2) Chronic 
Lymphoproliferative Disorder of NK cells (provisional) (Villamor et al., 2008); 3) Aggressive 
NK cell leukemia (Chan et al., 2008a);  and 4) Extranodal NK/T-cell lymphoma, nasal type 
(Chan et al., 2008b). In addition, on the basis of morphology, immuno-phenotype, functional 
NK cell activity, and expression of cytotoxic molecules, NK cell neoplasms can be divided 
into immature and mature categories (Jaffe, 1996).  
In recent years rare cases of lymphoblastic lymphomas/leukemia arising from immature 
NK cells has been reported, although the lack of suitable markers for immature NK cells 
mentioned above makes it difficult to distinguish NK-cell lymphoblastic lymphoma (LBL) 
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Prognosis Poor Poor Poor Good 
Table 3. Clinical and Biological features of NK cell neoplasms 
 
Physiological and Pathological Aspects of Human NK Cells 
 
353 
4.1 Immature NK cell neoplasms  
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such as CD7 and CD2, and cytoplasmic CD3, but lacking the expression of surface CD3, 
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negative for EBV. TCR and/or Ig genes were in germline configuration in all cases in which 
the tests were performed. Outcomes of these patients were absolutely unfavourable. The 
immature morphology with NK cell-associated phenotype and genotype suggests that these 
tumours represent the true precursor NK cell neoplasms.  
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that expressed CD94 1A transcripts have been reported (Lin et al., 2005). CD94 1A, a distal 
promoter of the CD94 molecule, is activated only by IL-15 (Lopez-Botet et al., 1997). Lin et 
al., recently reported that CD94 1A is the predominant form found in immature NK cells 
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(T lineage LBL) (Lin et al., 2005). By studying 21 patients with LBL and, on the basis of the 
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histology, even though these lymphomas may have different clinical manifestations, 
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cell neoplasms, the term “NK/T” rather than “NK” is used because this entity also includes 
cytotoxic T cell neoplasms (Sozumiya et al., 1994). Nasal and extra-nasal NK/T cell 
lymphoma are invariably associated with EBV and have a ethnic predisposition, being more 
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prevalent in Asia, Mexico, and Central and South America (Chan et al., 2008b; Kwong, 2005) 
and rare in Western Countries, the Middle East and Africa. 
Nasal NK/T cell lymphomas refer to tumours that occur in the nose and the upper aero 
digestive tract (Oshimi, 2007; Cheung et al., 1998). They are the most common type among 
primary lymphomas of the nasal cavity (Cheung et al., 1998). The site of disease is primarily 
in the midline and includes the nasal cavity in more than 80% of cases. The tumour is locally 
invasive and might infiltrate surrounding tissues and organs, such as oropharynx, palate, 
orbits, till the appearance of the characteristic mid-facial destructive lesions, the so called 
“lethal midline granuloma” (Cheung et al., 1998). Common symptoms include nasal 
discharge, nasal obstruction, purulent rhinorrhea, epitasis and local swelling of the nasal 
bridge. The tumours may be destructive, leading to the highly characteristic midline 
perforation.  
Extra-nasal NK/T cell lymphomas represent the counterpart of nasal NK/T cell lymphomas 
and involve any other part of the body. Males are predominantly affected, and the median 
age of presentation is the fifth decade. Primary sites of involvement include the skin, 
gastrointestinal tract, salivary glands, spleen, and testis (Chan et al., 1997). Patients with 
extra-nasal NK/T cell lymphoma more likely exhibit an advanced stage of disease with 
significantly higher general involvement, high levels of lactate dehydrogenise and a 
significantly decrease of haemoglobin and platelet count as compared with patients who 
have nasal NK/T cell lymphoma (Chan et al., 1997). The histological features are similar, 
regardless of the involved sites. Mucosal sites often show ulceration. A diffuse infiltrate of 
lymphoid cells is found in association with tissue necrosis and coagulation, although in 
some cases infiltrating cells lack atypical morphology, resulting in misdiagnosis as chronic 
inflammation. An angiocentric and angiodestructive growth pattern with associated 
fibrinoid changes in the blood vessels is frequently observed. In most patients, the 
neoplastic cells are characterized by the CD45+ surface (s)CD3- cytoplasm (c)CD3ε+ CD56+ 
phenotype and lack myeloid and B lymphoid markers. Proliferating cells are also positive 
for cytotoxic granules, granzyme B, perforin, TIA. Rarely cells express CD30 and CD7, while 
CD56 negative cases have also been reported. Association with EBV can be demonstrated in 
nearly all patients (Harabuchi et al., 1990). Using in situ hybridization technique, EBV-
encoded RNA can be found in neoplastic cells and Southern Blot analysis can detect 
monoclonal proliferation of EBV. Analyses of the terminal repeat region of the EBV genome 
indicates that the virus is in a clonal episomal form. Other than providing an indirect proof 
of the clonal nature of the lymphoid proliferation, this finding suggests that the EBV might 
play an etiologic role in mature NK cell neoplasms (Minarovitz, 1994). A defect in immune 
surveillance for EBV infection is demonstrated by the high frequency of 30-base pair 
deletions of the LMP1 gene in EBV-infected Asians. In addition, amino acid changes in the 
sequence coding HLA-A2- restricted CTL epitopes of the LMP1 and LMP2 genes, and low 
frequency of HLA-A*0201 in NK/T cell lymphoma patients have been reported (Kanno et 
al., 2000;  Harabuchi et al., 2009). Genetic alterations have been detected in the tumour 
suppression genes and several oncogenes enabling tumour cells to proliferate and resist 
apoptosis. Mutations of p53 have been demonstrated, with variable frequencies (24 to 60%). 
Mutation of c-kit can also be frequently demonstrated, as far as Fas gene mutations (Hoshida 
et al., 2003; Shen et al., 2002). The most common cytogenetic aberration is deletion of 6q. A 
recent microarray study showed that several genes associated with vascular biology, EBV 
induced genes, and PDGFRa gene are over-expressed, pointing to the deregulation of the 
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tumor suppressor HACE1 in the frequently deleted 6q21 region (Huang et al., 2010). 
Moreover, in NK/T cell lymphoma, gene signatures related to angiogenesis, genotoxic stress 
and proliferation, and signaling pathways (TGF-, Notch and Wnt), were significantly 
enriched as compared to IL2-activated normal NK cells. Interestingly, NK/T lymphoma 
cells of NK lineage have a very similar molecular profile to that of NK/T-cell or peripheral 
T-cell lymphoma of -T cell lineage (Iqbal et al., 2010). 
The clinical outcome of patients with nasal NK cell lymphoma is variable. Most 
observational studies have consistently demonstrated that radiotherapy is superior to 
chemotherapy alone in patients with stage I/II disease (Sakata et al., 1997). Some patients 
with early-stage disease are cured by radiation therapy. It has been demonstrated that 
radiotherapy, either as initial treatment or as part of the chemotherapy regimen, is the single 
most important key to a successful outcome (Ribrag et al., 2001). However, some patients 
with early-stage disease have early local or systemic recurrences and die of disease. For 
patients with stage III/IV disease, chemotherapy is the treatment of choice (Kwong, 2005). 
In several published series, the median survival of patients with advanced-stage disease was 
approximately 12 months. Extra-nasal NK cell lymphomas are clinically aggressive, the 
response to therapy is poor, and most patients die within 6 months after diagnosis. The 
long-term remission rate with allogeneic HSCT is less than 10% (Cheung et al., 1998).  
4.2.2 Aggressive NK cell leukemia 
First described by Fernandez et al., (Fernandez et al., 1986), aggressive NK cell leukemia  
(ANKL) is a systemic disease, more common in Asians than in Caucasians (Chan et al., 2008a), 
which is characterized by the presence of neoplastic NK cells in the peripheral blood, bone 
marrow, liver and spleen and by a rapidly progressive clinical course with poor prognosis. 
There is an equal sex incidence in men and women. The disease typically affects young to 
middle-aged adults with a median age in the third decade. At presentation, patients usually 
are very compromised with systemic symptoms, liver dysfunction, and hepato-splenomegaly 
sometimes accompanied by systemic lymphoadenopathy. In contrast to extra-nodal NK cell 
lymphoma, skin lesions are uncommon. The clinical progression is devastating despite 
treatment, and most patients survive for only days to weeks. Disseminated intravascular 
coagulation and hemophagocytic syndrome are often seen during the course of disease 
(Oshimi, 2007). In tissue sections, the neoplastic infiltrate is diffuse and destructive with 
lymphoid cell population usually appearing monomorphous (Siu, Chan & Kwong, 2002). 
Morphologically, leukemic cells are slightly larger than normal LGLs (Oshimi,  2007). There is 
an ample amount of pale or slightly basophilic cytoplasm that contains fine or coarse 
azurophilic granules. These cells are sCD3-cCD3ε+CD56+CD16+ (75% of cases), CD57- CD94+ 
with a germ line configuration of  and  genes of TCR. The chemokine system plays a critical 
role in the tumor cell diffusion, leading to the fulminant clinical courses. Serum levels of 
soluble FasL, IL-8, MIP-1, and MIP-1 are significantly elevated in ANKL patients and 
proliferating cells are highly positive for Fas, IL-8, RANTES, MIP-1, and MIP-1 (Makishima 
et al., 2007). Although clonal EBV is found in tumour cells in most patients and EBV is 
considered to be the etiological agent (Oshimi, 2007), little is known about the mechanisms 
through which EBV infection triggers clonal proliferation of NK cells. A defective T cell and 
NK cell response to EBV infection may play a role in the development of this disorder. 
However up to 10% of cases have been shown to be EBV-negative (Suzuki et al., 2004). 
 
Hematology – Science and Practice 
 
354 
prevalent in Asia, Mexico, and Central and South America (Chan et al., 2008b; Kwong, 2005) 
and rare in Western Countries, the Middle East and Africa. 
Nasal NK/T cell lymphomas refer to tumours that occur in the nose and the upper aero 
digestive tract (Oshimi, 2007; Cheung et al., 1998). They are the most common type among 
primary lymphomas of the nasal cavity (Cheung et al., 1998). The site of disease is primarily 
in the midline and includes the nasal cavity in more than 80% of cases. The tumour is locally 
invasive and might infiltrate surrounding tissues and organs, such as oropharynx, palate, 
orbits, till the appearance of the characteristic mid-facial destructive lesions, the so called 
“lethal midline granuloma” (Cheung et al., 1998). Common symptoms include nasal 
discharge, nasal obstruction, purulent rhinorrhea, epitasis and local swelling of the nasal 
bridge. The tumours may be destructive, leading to the highly characteristic midline 
perforation.  
Extra-nasal NK/T cell lymphomas represent the counterpart of nasal NK/T cell lymphomas 
and involve any other part of the body. Males are predominantly affected, and the median 
age of presentation is the fifth decade. Primary sites of involvement include the skin, 
gastrointestinal tract, salivary glands, spleen, and testis (Chan et al., 1997). Patients with 
extra-nasal NK/T cell lymphoma more likely exhibit an advanced stage of disease with 
significantly higher general involvement, high levels of lactate dehydrogenise and a 
significantly decrease of haemoglobin and platelet count as compared with patients who 
have nasal NK/T cell lymphoma (Chan et al., 1997). The histological features are similar, 
regardless of the involved sites. Mucosal sites often show ulceration. A diffuse infiltrate of 
lymphoid cells is found in association with tissue necrosis and coagulation, although in 
some cases infiltrating cells lack atypical morphology, resulting in misdiagnosis as chronic 
inflammation. An angiocentric and angiodestructive growth pattern with associated 
fibrinoid changes in the blood vessels is frequently observed. In most patients, the 
neoplastic cells are characterized by the CD45+ surface (s)CD3- cytoplasm (c)CD3ε+ CD56+ 
phenotype and lack myeloid and B lymphoid markers. Proliferating cells are also positive 
for cytotoxic granules, granzyme B, perforin, TIA. Rarely cells express CD30 and CD7, while 
CD56 negative cases have also been reported. Association with EBV can be demonstrated in 
nearly all patients (Harabuchi et al., 1990). Using in situ hybridization technique, EBV-
encoded RNA can be found in neoplastic cells and Southern Blot analysis can detect 
monoclonal proliferation of EBV. Analyses of the terminal repeat region of the EBV genome 
indicates that the virus is in a clonal episomal form. Other than providing an indirect proof 
of the clonal nature of the lymphoid proliferation, this finding suggests that the EBV might 
play an etiologic role in mature NK cell neoplasms (Minarovitz, 1994). A defect in immune 
surveillance for EBV infection is demonstrated by the high frequency of 30-base pair 
deletions of the LMP1 gene in EBV-infected Asians. In addition, amino acid changes in the 
sequence coding HLA-A2- restricted CTL epitopes of the LMP1 and LMP2 genes, and low 
frequency of HLA-A*0201 in NK/T cell lymphoma patients have been reported (Kanno et 
al., 2000;  Harabuchi et al., 2009). Genetic alterations have been detected in the tumour 
suppression genes and several oncogenes enabling tumour cells to proliferate and resist 
apoptosis. Mutations of p53 have been demonstrated, with variable frequencies (24 to 60%). 
Mutation of c-kit can also be frequently demonstrated, as far as Fas gene mutations (Hoshida 
et al., 2003; Shen et al., 2002). The most common cytogenetic aberration is deletion of 6q. A 
recent microarray study showed that several genes associated with vascular biology, EBV 
induced genes, and PDGFRa gene are over-expressed, pointing to the deregulation of the 
 
Physiological and Pathological Aspects of Human NK Cells 
 
355 
tumor suppressor HACE1 in the frequently deleted 6q21 region (Huang et al., 2010). 
Moreover, in NK/T cell lymphoma, gene signatures related to angiogenesis, genotoxic stress 
and proliferation, and signaling pathways (TGF-, Notch and Wnt), were significantly 
enriched as compared to IL2-activated normal NK cells. Interestingly, NK/T lymphoma 
cells of NK lineage have a very similar molecular profile to that of NK/T-cell or peripheral 
T-cell lymphoma of -T cell lineage (Iqbal et al., 2010). 
The clinical outcome of patients with nasal NK cell lymphoma is variable. Most 
observational studies have consistently demonstrated that radiotherapy is superior to 
chemotherapy alone in patients with stage I/II disease (Sakata et al., 1997). Some patients 
with early-stage disease are cured by radiation therapy. It has been demonstrated that 
radiotherapy, either as initial treatment or as part of the chemotherapy regimen, is the single 
most important key to a successful outcome (Ribrag et al., 2001). However, some patients 
with early-stage disease have early local or systemic recurrences and die of disease. For 
patients with stage III/IV disease, chemotherapy is the treatment of choice (Kwong, 2005). 
In several published series, the median survival of patients with advanced-stage disease was 
approximately 12 months. Extra-nasal NK cell lymphomas are clinically aggressive, the 
response to therapy is poor, and most patients die within 6 months after diagnosis. The 
long-term remission rate with allogeneic HSCT is less than 10% (Cheung et al., 1998).  
4.2.2 Aggressive NK cell leukemia 
First described by Fernandez et al., (Fernandez et al., 1986), aggressive NK cell leukemia  
(ANKL) is a systemic disease, more common in Asians than in Caucasians (Chan et al., 2008a), 
which is characterized by the presence of neoplastic NK cells in the peripheral blood, bone 
marrow, liver and spleen and by a rapidly progressive clinical course with poor prognosis. 
There is an equal sex incidence in men and women. The disease typically affects young to 
middle-aged adults with a median age in the third decade. At presentation, patients usually 
are very compromised with systemic symptoms, liver dysfunction, and hepato-splenomegaly 
sometimes accompanied by systemic lymphoadenopathy. In contrast to extra-nodal NK cell 
lymphoma, skin lesions are uncommon. The clinical progression is devastating despite 
treatment, and most patients survive for only days to weeks. Disseminated intravascular 
coagulation and hemophagocytic syndrome are often seen during the course of disease 
(Oshimi, 2007). In tissue sections, the neoplastic infiltrate is diffuse and destructive with 
lymphoid cell population usually appearing monomorphous (Siu, Chan & Kwong, 2002). 
Morphologically, leukemic cells are slightly larger than normal LGLs (Oshimi,  2007). There is 
an ample amount of pale or slightly basophilic cytoplasm that contains fine or coarse 
azurophilic granules. These cells are sCD3-cCD3ε+CD56+CD16+ (75% of cases), CD57- CD94+ 
with a germ line configuration of  and  genes of TCR. The chemokine system plays a critical 
role in the tumor cell diffusion, leading to the fulminant clinical courses. Serum levels of 
soluble FasL, IL-8, MIP-1, and MIP-1 are significantly elevated in ANKL patients and 
proliferating cells are highly positive for Fas, IL-8, RANTES, MIP-1, and MIP-1 (Makishima 
et al., 2007). Although clonal EBV is found in tumour cells in most patients and EBV is 
considered to be the etiological agent (Oshimi, 2007), little is known about the mechanisms 
through which EBV infection triggers clonal proliferation of NK cells. A defective T cell and 
NK cell response to EBV infection may play a role in the development of this disorder. 
However up to 10% of cases have been shown to be EBV-negative (Suzuki et al., 2004). 
 
Hematology – Science and Practice 
 
356 
Several chromosomal abnormalities have been reported. In particular, the finding of 
abnormalities involving del(6q) in aggressive NK cell leukemia and in extranodal NK/T 
lymphoma provides a biological link between these two diseases (Wong, Chan  & Kwong, 
1997). A recent array-based comparative genomic hybridization study on 27 NK cell 
lymphoma/leukemia cases, classified into two disease groups based on the World Health 
Organization Classification (10 ANKL cases and 17 extranodal NK/T lymphomas, nasal 
type), showed recurrent gain of 1q and loss of 7p15.1–p22.3 and 17p13.1 in ANKL 
(Nakashima et al., 2005). The same study also demonstrated clear genetic differences 
between aggressive NK cell leukemia and extranodal NK/T cell lymphoma, suggesting that 
these are two separate entities (Nakashima et al., 2005).  
Aggressive NK cell leukemia is a catastrophic disease with an almost uniform mortality. A 
few patients have a clinical response with conventional chemotherapy (Kwong, 2005), 
although the response is typically transient and survival is measured in days to weeks. 
Allogeneic HSCT results in short-term remission in a few patients (Kwong, 2005). Taking 
together, big efforts for the recognition of new therapeutical targets and for development of 
new experimental protocols are urgently required to address the issue of ANKL therapy. As 
a matter of fact, recent data in a murine model have reported impressive response by 
targeting of survivin by nanoliposomal ceramide (Liu et al., 2010). 
4.2.3 Chronic lymphoproliferative disorder of NK cells (provisional) 
The chronic lymphoproliferative disorders of NK cells (CLPD-NK) are included among the 
novelties of the current WHO classification (Villamor et al., 2008). These rare and 
heterogeneous disorders are characterized by a chronic expansion of mature appearing NK 
cells (usually more than 2,000/l) in peripheral blood for more than 6 months (Loughran, 
1993; Semenzato et al., 1987; Tefferi et al., 1994; Semenzato et al., 1997; Oshimi, 1996), 
without a clearly identified cause (Figure 2). Patients are usually adults with a mean age of 
60 years without gender and racial predisposition (Pandolfi et al., 1990). In recent years 
several studies have been published focusing on the pathogenetic mechanisms of this 
disease (Zambello & Semenzato, 2009; Loughran et al., 1997; Zambello et al., 2003; Hodge et 
al., 2009; Gattazzo et al., 2010; Epling-Burnette et al., 2008). NK cell activation in response to 
an unknown stimulus, likely of viral origin, is postulated to play a role in the initial steps of 
CLPD-NK by selecting NK clones (Zambello & Semenzato, 2009). No prototypical HTLV 
infection was demonstrated in these patients. However, the evidence that sera from a series 
of patients from Europe and USA reacted with the recombinant HTLV env protein p21E, 
suggests that exposure to a protein containing homology to BA21 may be important in the 
pathogenesis of this lymphoproliferative disorder (Loughran et al., 1997). In contrast with 
other mature NK cell neoplasms, EBV is not usually detected within affected lymphocytes 
(Zambello & Semenzato, 2009). It is believed that BM, which is frequently involved in 
CLPD-NK patients, represents the setting where the putative inciting antigen could reside. 
In this compartment, DCs may represent the target of infection (Zambello et al., 2005). Bone 
marrow biopsies demonstrated a topographic distribution of DCs and NK cells that 
indicates a close contact between the two cell types (Zambello et al., 2005). Patients' NK cells 
also showed a reduced capability of promoting Mo-DC maturation and of killing iDC  
(Balsamo et al., 2009). These findings could be explained, at least in part, by the low 
expression levels of NKp30 activating receptor, usually involved in the molecular 
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interactions occurring between NK cells and DC. It is suggested that impairment of DC 
killing capabilities detected in patients' NK-GLs may allow an accumulation of DC that, at 
certain sites, may sustain the chronic proliferation of NK cells themselves. DCs are also 
likely to represent the source of IL-15 that is crucial in the mechanisms sustaining the 
maintenance of NK proliferation. IL-15 has been found to mediate its activity by interfering 
with Bcl-2 family members, and more specifically by modulating  Bid expression (Hodge et 
al., 2009). Hodge et al., demonstrated that CLPD-NK cells express low levels of Bid, that are 
reversed by blockade of IL-15 signaling (Hodge et al., 2009). Bid is also increased following 
bortezomib (Velcade/PS341) treatment and this effect is coordinate with increased 
susceptibility to Fas- or TRAIL- independent apoptosis. In fact, bortezomib increased cell 
surface expression of DR4, a TRAIL death receptor decoy. The inability of death receptors to 
account for the apoptosis may be explained by the putative role of Bid in DNA damage and 
repair. It is possible that elevation of Bid expression in CLPD-NK cells promotes S phase cell 
cycle block and death (Hodge et al., 2009).  
A genetic susceptibility for this disease has been suggested and has been related to the 
detection of type B KIR gene repertoire which is characterized by a high number of activating 
genes (Zambello & Semenzato, 2009). In fact, a restricted pattern of KIR expression has 
usually been reported in these patients. A typical feature is the preferential expression of the 
KIR activating receptor isoforms and this pattern correlates with a reduced expression of 
other activating receptors, such as NCRs (Zambello et al., 2003). Together with a bias 
towards activating KIR expression, a deep silencing of inhibitory KIR through increased 
gene methylation has been recently demonstrated by our group (Gattazzo et al., 2010). More 
specifically, we showed the complete lack of KIR3DL1 expression in most analyzed patients, 
being the receptor expressed in 13% of patients as compared to 90% of controls (p<0.01). 
Interestingly, the results of methylation patterns of KIR3DL1 promoter showed a 
significantly higher methylation status (0.76 ± 0.12 SD) in the patients with respect to the 
healthy subjects (0.49 ± 0.10 SD, p<0.01). These data suggest that together with the increased 
expression of activating receptors, the lack of the inhibitory signal could also play a role in 
the pathogenesis of disease (Gattazzo et al., 2010). Recent data on the pathogenesis of CLPD-
NK are summarized in Figure 2. 
Biochemical studies on the mechanisms sustaining the growth of NK cells in these patients 
have demonstrated a role of RAS farnesil transferase (Epling-Burnette et al., 2008), with 
clinical implications (see below). Pathological NK cells express CD16 and usually low levels 
of CD56 and CD57. As expected, cells express TIA1, granzyme and perforins, which 
correlate with the cytotoxic potential of these cells. CD94 is expressed at high density on 
patients’ NK cells, frequently associated with the inhibitory subunit NKG2A, although, in a 
relevant number of cases, the dimer CD94/NKG2C has been reported (Zambello & 
Semenzato, 2003). Patients’ NK cells express functional  and  chains of IL-2/IL-15 
receptor, which are strictly related to the role of these cytokines in the pathogenesis of 
disease (Zambello & Semenzato, 2009).  
Most patients are asymptomatic, and the disease has a chronic indolent clinical course, 
similar to that reported for patients with T-LGL leukemia (Loughran, 1993; Semenzato et al., 
1987; Tefferi et al., 1994; Semenzato et al., 1997; Oshimi 1996). In some cases this disorder is 
associated with other conditions, including pure red cell aplasia, vasculitic syndromes, solid 
and hematologic tumors, splenectomy, neuropathy and autoimmune disorders (Loughran, 
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maintenance of NK proliferation. IL-15 has been found to mediate its activity by interfering 
with Bcl-2 family members, and more specifically by modulating  Bid expression (Hodge et 
al., 2009). Hodge et al., demonstrated that CLPD-NK cells express low levels of Bid, that are 
reversed by blockade of IL-15 signaling (Hodge et al., 2009). Bid is also increased following 
bortezomib (Velcade/PS341) treatment and this effect is coordinate with increased 
susceptibility to Fas- or TRAIL- independent apoptosis. In fact, bortezomib increased cell 
surface expression of DR4, a TRAIL death receptor decoy. The inability of death receptors to 
account for the apoptosis may be explained by the putative role of Bid in DNA damage and 
repair. It is possible that elevation of Bid expression in CLPD-NK cells promotes S phase cell 
cycle block and death (Hodge et al., 2009).  
A genetic susceptibility for this disease has been suggested and has been related to the 
detection of type B KIR gene repertoire which is characterized by a high number of activating 
genes (Zambello & Semenzato, 2009). In fact, a restricted pattern of KIR expression has 
usually been reported in these patients. A typical feature is the preferential expression of the 
KIR activating receptor isoforms and this pattern correlates with a reduced expression of 
other activating receptors, such as NCRs (Zambello et al., 2003). Together with a bias 
towards activating KIR expression, a deep silencing of inhibitory KIR through increased 
gene methylation has been recently demonstrated by our group (Gattazzo et al., 2010). More 
specifically, we showed the complete lack of KIR3DL1 expression in most analyzed patients, 
being the receptor expressed in 13% of patients as compared to 90% of controls (p<0.01). 
Interestingly, the results of methylation patterns of KIR3DL1 promoter showed a 
significantly higher methylation status (0.76 ± 0.12 SD) in the patients with respect to the 
healthy subjects (0.49 ± 0.10 SD, p<0.01). These data suggest that together with the increased 
expression of activating receptors, the lack of the inhibitory signal could also play a role in 
the pathogenesis of disease (Gattazzo et al., 2010). Recent data on the pathogenesis of CLPD-
NK are summarized in Figure 2. 
Biochemical studies on the mechanisms sustaining the growth of NK cells in these patients 
have demonstrated a role of RAS farnesil transferase (Epling-Burnette et al., 2008), with 
clinical implications (see below). Pathological NK cells express CD16 and usually low levels 
of CD56 and CD57. As expected, cells express TIA1, granzyme and perforins, which 
correlate with the cytotoxic potential of these cells. CD94 is expressed at high density on 
patients’ NK cells, frequently associated with the inhibitory subunit NKG2A, although, in a 
relevant number of cases, the dimer CD94/NKG2C has been reported (Zambello & 
Semenzato, 2003). Patients’ NK cells express functional  and  chains of IL-2/IL-15 
receptor, which are strictly related to the role of these cytokines in the pathogenesis of 
disease (Zambello & Semenzato, 2009).  
Most patients are asymptomatic, and the disease has a chronic indolent clinical course, 
similar to that reported for patients with T-LGL leukemia (Loughran, 1993; Semenzato et al., 
1987; Tefferi et al., 1994; Semenzato et al., 1997; Oshimi 1996). In some cases this disorder is 
associated with other conditions, including pure red cell aplasia, vasculitic syndromes, solid 
and hematologic tumors, splenectomy, neuropathy and autoimmune disorders (Loughran, 
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1993; Semenzato et al., 1987; Tefferi et al., 1994; Semenzato et al., 1997; Oshimi, 1996). 
Recently, in patients with chronic myelogenous leukaemia, the association has been 
reported between treatment with dasatinib and the development of CLPD-NK. It has been 
suggested that the development of CLPD-NK might contribute on the control of Ph positive 
leukemic cells proliferation (Kim et al., 2009). Systemic symptoms, such as cytopenia (mostly 
neutropenia and anemia), are rare. Lymphoadenopathy, hepatomegaly, splenomegaly and 
cutaneous lesions are uncommon. Occasionally, patients present a slow progressive increase 
of peripheral blood NK cells and organ involvement. Several cases with a spontaneous 
complete remission have been reported (Zambello & Semenzato, 2009). Cytologically, the 
circulating cells show typical granular lymphocyte  morphology, with moderate amount of 
pale cytoplasm that contains > 3 azurophilic granules. Bone marrow biopsy is characterized 
by interstitial infiltration of cells with small nuclei and pale cytoplasm, which are difficult to 
recognize without the help of immunohistochemical techniques. Cytogenetic is normal in 
most cases (Zambello & Semenzato, 2009) and the germ line configuration of TCR is 
demonstrated, as expected for normal NK cells. Since clonality of proliferating cells is 
difficult to detect in these patients, the analysis of restriction fragment length polymorphism 
(RLFP) has been used as an indirect marker to demonstrate the clonality in some but not all 
patients. In rare case, in which EBV can be demonstrated in plasmid form within NK cells, 
the clonality of cells might be easily examined by Southern Blot analysis using probes 
recognizing the EBV terminal repeats (Kawa-Ha et al., 1989). Patients with CLPD-NK 
usually have an indolent clinical course and respond to immunosuppressive therapy with 
low doses of methotrexate (usually 10 mg/m2/week) or of cyclophosphamide (50 or 100 
mg/day) or cyclosporin (3-5 mg/kg/day) with or without inclusion of  low doses of 
steroids (Lamy & Loughran, 2011). 
 
 
Fig. 2. Possible mechanisms of CLPD-NK pathogenesis. 
 




NK cells are bone marrow–derived granular lymphocytes that have a key role in the 
recognition and in the killing of tumor- or virus-infected cells. The identification of a large 
array of surface NK receptors capable of transducing inhibitory or activating signals, let to 
explain how their effector functions could be regulated.  
In recent years, it has also been shown that NK cells may play a role in the regulation of the 
immune response. This has been based on the finding that NK cells were able to functionally 
interact with different cells of the innate immune system including DCs, pDCs and 
macrophages. Besides the well known CD56dimCD16+ cytotoxic PB NK cells, different NK 
cell subsets located in specific tissue/organ compartments have been shown to exert 
various, alternative, regulatory functions. NK cells homing in SLT promote Th1 
polarization. Conversely, decidual NK cells favour Treg expansion and play an important 
role in tissue remodelling and neo-angiogenesis process. In MALT, NK22 cells may support 
immune defence against bacteria invasion by their peculiar cytokine and chemokine 
secreting profile.  
Whether the above described different NK cell subsets may derive from the same lineage or 
from different ones, is still a matter of debate. Studies on NK cell development may help to 
clarify the possible lineage relationship between the different NK cell subsets. In vitro 
models of NK cell development helped to define phenotypically and functionally different 
maturation stages that were, at least in part, confirmed by in vivo analysis. For example, the 
CD56brightCD16-CD94/NKG2A+KIR- subset, that is largely represented at the end on in vitro 
development, represents the first wave of lymphocytes appearing in PB at early time 
intervals after HSCT. NK cells originate from CD34+ hematopoietic precursors but several 
experimental evidences suggest that the NK cell development and terminal maturation does 
not occur wholly in the BM. Other  secondary lymphoid organs, including L.N. and MALT, 
as well as decidua, may represent sites where  NK cell development occurs. This suggest 
how defined subsets of NK cells may differentiate in peculiar tissues and point the attention 
on the role of the microenvironment in such a process. The full characterization of the 
genetic and epigenetic factors that may contribute to determine the type of NK cell that will 
develop is still in process and it will be important also to better define mechanisms leading 
to NK cell malignant transformation. 
It is hopeful that investigation on NK cell neoplasm pathogenesis could lead to identify 
molecular targets and discovery of more efficient and less toxic treatments. The elucidation 
of pathways by which EBV transform NK cells might help to identify new molecular targets. 
Furthermore, the mechanisms of resistance to therapy, including alteration of apoptosis 
pathways should be deeply characterized. Thus, the definition the NK neoplasm patho-
physiology and the identification of possible biological targets may help to improve 
therapeutical approaches. 
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1. Introduction 
Follicular lymphoma (FL) is an indolent lymphoid neoplasm that is derived from mutated 
germinal center B cells and exhibits a nodular or follicular histologic pattern. It is typically 
composed of a mixture of small, cleaved follicle center cells referred to as centrocytes and 
large noncleaved follicular center cells referred to as centroblasts. FL  accounts for about 20 
% of all lymphomas with the highest incidence in the USA and Western Europe. In Asia and 
in the developing countries the incidence is much lower [1].  
2. The cell of origin of follicular lymphoma 
The current theory that tumors are derived from mutated stem cells called cancer stem cells 
was suggested because stem cells and some cancer cells share self-renewal and 
differentiation capacities [2-4]. Although this hypothesis was postulated in early reports [5-
7],definite proof of their existence came from recent studies in leukemia, where among the 
complete tumor cell population only a small subset of cells could initiate, regenerate and 
maintain the leukemia after transplantation into immunocompromised mice [8,9].Using 
similar functional approaches, a variety of cancer stem cells have been identified in an 
increasing number of epithelial tumors, including breast, prostate, pancreatic and head and 
neck carcinomas [10].Despite these outstanding discoveries in leukemias and solid tumors, 
the existence of lymphoma-originating cells with stem cell properties that may similarly 
generate lymphoma upon mutation remains a controversial and largely unexplored issue 
[11]. Recently, it has been proposed that commited lymphoid progenitors/precursor cells 
with an active V-D-J recombination program are the initiating cells of follicular lymphoma 
when targeted by immunoglobulin-gene translocations in the bone marrow. However, these 
pre-malignant lymphoma initiating cells cannot drive complete malignant transformation, 
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requiring additional cooperating mutations in specific stem cell programs to be converted 
into the lymphoma originating cells able to generate and sustain lymphoma development 
[12]. 
3. Clinical aspects of follicular lymphoma 
Signs and Symptom 
Follicular lymphoma mainly affects older adults. The average age at diagnosis is about 55. 
Men and women are nearly equally affected. Follicular lymphoma is a slow-growing disease 
with minor warning signs that often go unnoticed for a long time  before it is diagnosed.  
The disease is often advanced before a diagnosis is made. Most individuals are diagnosed in 
stage III or IV. However, even in advanced stages there is no immediate threat to life. The 
disease has a "waxing and waning" course, meaning that it flares up and regresses a number 
of times over years. 
The first sign of the condition is often a painless swelling in the neck, armpit or groin that is 
caused by enlarged lymph nodes. However the majority of patients initially present with 
disseminated disease that follows a relatively indolent clinical course. Patients with 
follicular lymphoma typically present with superficial lymph nodes of small to medium 
size. All common superficial territories can be involved by the disease. 
In some patients, the first symptoms are more insidious and related to the slow growth of 
lymph nodes in deep areas, usually in the infradiaphragmatic territories such as the 
retroperitoneum, the mesenteric, or the iliac areas. In those cases, patients may complain of 
atypical symptoms while the tumor bulk can be important, with single or confluent lymph 
nodes. Primary mediastinal involvement is uncommon, as well as isolated splenic 
enlargement[13]. Other symptoms may include loss of appetite and tiredness. The general 
status of the patient is usually preserved, Some people have night sweats, unexplained high 
temperatures and weight loss. These are known as B symptoms. Others have an altered 
performance status. 
Primary involvement of extranodal areas is also very uncommon[14]. The bone marrow is 
involved in 50% to 60% of the cases. Follicular lymphoma can arise in the gastrointestinal 
(GI) tract, predominantly in the duodenum or the small intestine, [15,16]. where it can 
eventually represent the unique site of disease. Lymphoma infiltration may be unifocal or 
multifocal[13]. The new World Health Organization–European Organization for Research on 
Treatment of Cancer (WHO-EORTC) cutaneous lymphoma classification recognizes an 
entity called "primary cutaneous follicle center cell lymphoma" that includes what was 
previously known as "cutaneous follicular lymphoma variant" in the WHO classification. 
[17]. Other follicular lymphomas that may be considered as peculiar entities with a distinct 
behavior are those involving the testis  [18]  and the rare cases of follicular lymphoma 
encountered in children [19]. 
Follicular lymphoma is characterised by response to treatment with disease-free or 
asymptomatic disease intervals, alternating with recurrence/progression and may 
transform to aggressive lymphoma at a rate of around 3% per year [13]. This feature is 
usually—but not systematically—associated with a poor outcome [20].The clinical factors 
associated with the risk of transformation (as well as the biology underlying this 
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phenomenon) are not fully characterized. Some reports indicated that early treatment and 
achievement of a complete response after the first-line therapy were associated with a lower 
risk of transformation in patients with follicular lymphoma [21]. 
4. Clinical prognostic factors  
Several prognostic parameters for follicular lymphomas were identified in the last two 
decades, that led to the development of some prognostic indexes. The International 
Prognostic Index developed for aggressive lymphomas was also found to be able of 
predicting the outcome for patients with follicular lymphoma, but the proportion of patients 
in the higher-risk categories was usually limited. [13] 
The first prognostic system specific to follicular lymphoma was developed by the Italian 
Lymphoma Intergroup (ILI) in the late 1990s [22]. Currently, the Follicular Lymphoma 
International Prognostic Index (FLIPI) [23] is deemed to be more applicable across a range of 
clinical settings . Both systems were developed prior to the introduction of monoclonal 
antibody therapy, which has profoundly changed the treatment and outcome of follicular 
lymphoma [24]. Hence, the FLIPI-2 was recently developed, in a prospective series of 
patients needing treatment, using parameters which were not previously amenable to 
retrospective analysis, and may represent a promising new tool for the identification of 
follicular lymphoma patients with different risk profiles in the era of immunochemotherapy 
[25].  
The description of the Follicular Lymphoma International Prognostic Index (FLIPI) 
represents an important step in identifying patient subgroups with predictable outcome and 
comparing the results of clinical trials. Analyses of gene expression profiles or constitutive 
gene variations may also provide additional insights for prognostication in the near future. 
Furthermore, these data underline the complex interactions between the tumor cells and 
their microenvironment; recent attempts to translate these findings with 
immunohistochemical studies remain unable to robustly predict patient outcome. The 
therapeutic strategies in follicular lymphoma have been transformed by monoclonal 
antibodies, used alone or in combination with chemotherapy. Treatment options should be 
adapted to the clinical features at diagnosis and appear to be able to modify the overall 
survival of some subgroups of patients. Further efforts may focus on strategies that can alter 
the natural history of this disease [13].   
5. Treatment 
There is a general consensus that the natural history of advanced stages of low-grade or 
indolent lymphoma has not changed for the last 30 years. Patients with advanced stages of 
indolent non-Hodgkin's lymphoma have been treated for many years with various 
approaches, including deferred initial therapy (watch and wait), single-agent alkylating 
agents, radiation therapy, combination chemotherapy, and autologous stem-cell 
transplantation. Unfortunately, it has been impossible to demonstrate that the long-term 
prognosis for these patients has significantly changed with any these treatment options [26]. 
The decision to start first-line treatment depends not only on the stage but also on the 
symptoms of the disease [27].According to The Swiss Group for Clinical Cancer Research 
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entity called "primary cutaneous follicle center cell lymphoma" that includes what was 
previously known as "cutaneous follicular lymphoma variant" in the WHO classification. 
[17]. Other follicular lymphomas that may be considered as peculiar entities with a distinct 
behavior are those involving the testis  [18]  and the rare cases of follicular lymphoma 
encountered in children [19]. 
Follicular lymphoma is characterised by response to treatment with disease-free or 
asymptomatic disease intervals, alternating with recurrence/progression and may 
transform to aggressive lymphoma at a rate of around 3% per year [13]. This feature is 
usually—but not systematically—associated with a poor outcome [20].The clinical factors 
associated with the risk of transformation (as well as the biology underlying this 
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phenomenon) are not fully characterized. Some reports indicated that early treatment and 
achievement of a complete response after the first-line therapy were associated with a lower 
risk of transformation in patients with follicular lymphoma [21]. 
4. Clinical prognostic factors  
Several prognostic parameters for follicular lymphomas were identified in the last two 
decades, that led to the development of some prognostic indexes. The International 
Prognostic Index developed for aggressive lymphomas was also found to be able of 
predicting the outcome for patients with follicular lymphoma, but the proportion of patients 
in the higher-risk categories was usually limited. [13] 
The first prognostic system specific to follicular lymphoma was developed by the Italian 
Lymphoma Intergroup (ILI) in the late 1990s [22]. Currently, the Follicular Lymphoma 
International Prognostic Index (FLIPI) [23] is deemed to be more applicable across a range of 
clinical settings . Both systems were developed prior to the introduction of monoclonal 
antibody therapy, which has profoundly changed the treatment and outcome of follicular 
lymphoma [24]. Hence, the FLIPI-2 was recently developed, in a prospective series of 
patients needing treatment, using parameters which were not previously amenable to 
retrospective analysis, and may represent a promising new tool for the identification of 
follicular lymphoma patients with different risk profiles in the era of immunochemotherapy 
[25].  
The description of the Follicular Lymphoma International Prognostic Index (FLIPI) 
represents an important step in identifying patient subgroups with predictable outcome and 
comparing the results of clinical trials. Analyses of gene expression profiles or constitutive 
gene variations may also provide additional insights for prognostication in the near future. 
Furthermore, these data underline the complex interactions between the tumor cells and 
their microenvironment; recent attempts to translate these findings with 
immunohistochemical studies remain unable to robustly predict patient outcome. The 
therapeutic strategies in follicular lymphoma have been transformed by monoclonal 
antibodies, used alone or in combination with chemotherapy. Treatment options should be 
adapted to the clinical features at diagnosis and appear to be able to modify the overall 
survival of some subgroups of patients. Further efforts may focus on strategies that can alter 
the natural history of this disease [13].   
5. Treatment 
There is a general consensus that the natural history of advanced stages of low-grade or 
indolent lymphoma has not changed for the last 30 years. Patients with advanced stages of 
indolent non-Hodgkin's lymphoma have been treated for many years with various 
approaches, including deferred initial therapy (watch and wait), single-agent alkylating 
agents, radiation therapy, combination chemotherapy, and autologous stem-cell 
transplantation. Unfortunately, it has been impossible to demonstrate that the long-term 
prognosis for these patients has significantly changed with any these treatment options [26]. 
The decision to start first-line treatment depends not only on the stage but also on the 
symptoms of the disease [27].According to The Swiss Group for Clinical Cancer Research 
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(SAKK) trials  at least one of the following signs is present in order to start treatment: B 
symptoms; symptomatic enlarged lymph nodes or spleen; steady, clinically significant 
progression of lymphadenopathy, splenomegaly or other follicular lymphoma lesions 
documented by a 50% increase in size over a period of at least 6 months; involvement of at 
least 3 nodal sites (>3 cm), bulky disease (>7 cm), haemoglobin <10g/dL, and platelets <100 
x 109/L due to bone marrow infiltration or splenomegaly [28]. 
Inspite of encouraging early results [29],there is still no solid data to confirm that early 
treatment with rituximab significantly delays the need for new therapy,and  whether this 
approach may alter the natural history of the disease and there is also conflicting results 
Whether early treatment of follicular lymphoma is associated with a decreased risk of 
transformation [27]. 
Horning [30],reported the results of sequential treatment studies conducted at Stanford 
University from 1960 to 1991. Median survival times have ranged from 7 to 10 years, and the 
OS for each group of studies was overlapping. Indolent lymphoma is generally considered 
incurable because no plateau in the survival curve has been demonstrable. However, the 
development of monoclonal antibodies (MoAbs) has revolutionized the treatment of 
patients with follicular lymphoma [26]. 
Many trials utilizing different protocols of combination chemotherapy plus rituximab,eg. 
CVP [31],  CHOP [32,33]   concluded that OS for patients with follicular lymphoma has 
improved over time and that the choice of initial therapy may matter. Sacchi et al 
[34],concluded that  FFS and OS have significantly improved in advanced-stage follicular 
lymphoma patients treated on GISL(  Gruppo Italiano Studio Linfomi) protocols during the 
last 18 years. These improvements are related to evolving front-line and salvage therapies, 
particularly the introduction of rituximab in combination with chemotherapy  
For patients needing therapy, most patients are treated with chemotherapy plus rituximab, 
which has improved response rates, duration of response, and overall survival. Randomized 
studies have shown additional benefit for maintenance rituximab both following 
chemotherapy-rituximab and single agent rituximab [35]. Rituximab maintenance for up to 
2 years has a favorable side effect profile and, based on a systematic meta-analysis, 
substantially prolongs PFS and OS in relapsed disease even after antibody-containing 
induction in patients who have not received antibody as first-line therapy [36]. 
Stem cell transplantation (SCT) including both autologous and allogeneic SCT or 
experimental agent therapy is considered for recurrent disease [35]. 
In the small proportion of patients with limited non-bulky stages I–II, radiotherapy 
(involved or extended field, 30–36 Gy) is the preferred treatment having a curative potential 
[37]. However, In selected cases a watchful waiting may be discussed to avoid the side 
effects of radiation [38]. Radioimmunotherapy or chlorambucil plus rituximab remains an 
alternative in patients with low risk profile or contraindications for a more intensive 
chemoimmunotherapy [39,40]. 
Therfore, the therapeutic strategies in follicular lymphoma have been transformed by 
monoclonal antibodies, used alone or in combination with chemotherapy. Treatment 
options should be adapted to the clinical features at diagnosis and appear to be able to 
modify the overall survival of some subgroups of patients. Further efforts may focus on 
strategies that can alter the natural history of this disease [13]. 
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6. Cytomorphology of follicular lymphoma 
Follicular NHLs are characterized by a follicular growth pattern , but a diffuse area may also 
be present. The follicles of follicular lymphoma were more closely packed together, more 
monotonous in size and shape, and frequently lacked an obvious mantle zone [41].  
These follicles contained a comparatively monomorphic cellular phenotype, mostly of 
centrocytes (small cells with cleaved nuclei) and occasional centroblasts (large cells with 
multilobated nuclei and multiple nucleoli). Mitotic figures were fewer than in reactive 
follicular hyperplasia (RFH) and tingible body macrophages were sparse or absent. 
Polykaryocytes were not observed in RFH or follicular lymphoma and sclerosis was only 
focally present to a minimal degree [42].  
The distinction of FL from RFH is essential, as the latter represents a benign condition [43].A 
number of morphological features are of value in making this distinction; in particular, a 
low density of follicles per unit area, The follicles are separated by wide interfollicular areas 
with prominent mantle zones. The variably sized follicles were composed of a polymorphic 
population of lymphocytes, dendritic cells, and tingible body macrophages that imparted 
a“starry sky” pattern. Mitotic figures were conspicuous. The presence of polarity within 
follicles and the lack of a monomorphic appearance within the follicles all favor RFH [42].  
7. Immunophenotype 
Being  a  mature  B-cell  lymphoma,  FL  express  a  large spectrum  of  B-cell  markers,  such  
as  CD20,  CD19,  CD22,  CD79a, and Pax51 [44].  
FL cells express antigens of the germinal center including CD10 and Bcl-6. Most cases of FL 
express Bcl-2 protein which is highly correlated with the presence of the t(14;18) but may be 
expressed in cases with a clonal karyotype lacking the t(14;18) [45].  
The follicles of RFH and follicular lymphoma stained positively for the B cell marker CD20 
which highlight the difference in the width of the interfollicular region between the follicles. 
In RFH, T cells were predominantly located in the interfollicular zones but also lightly 
percolated throughout the center of the follicles, demonstrated by T cell marker CD3. CD5 
stained T cells are in a nearly identical pattern. T cells stained positively for CD3 and CD5 in 
follicular lymphoma located within the interfollicular zones. The latter also displaying a 
more prominent spillover of CD20-positive cells than in RFH [42].  
Follicles in both RFH and follicular lymphoma were positive for BCL-6. BCL-2 staining 
revealed that the follicular centers in RFH were negative and those in follicular lymphoma 
were positive. CD10 staining was positive for both RFH and follicular lymphoma but 
showed a greater interfollicular staining in follicular lymphoma [41].  
Some cases of both RFH and follicular lymphoma manifested a vague follicular architecture 
that is difficult to detect. In these cases, CD23, a dendritic cell marker, outlined the follicles 
of RFH more clearly by disclosing a scaffolding or a cluster of interconnecting cells with 
elongated cytoplasmic processes. Follicular lymphoma manifested the same pattern of CD23 
staining. Ki-67, a marker for cellular proliferation, showed dense positivity that was 
polarized (unevenly distributed or centered at one edge of the follicle) within RFH follicles. 
In contrast, follicular lymphoma demonstrated a more diffuse, evenly distributed staining 
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pattern within the follicular centers. Polyclonality was evident in RFH, with in situ 
hybridization revealing roughly equal populations of both kappa and lambda light chains. 




Fig. 1. Histopathological and immunohistochemical characterization of reactive lymphoid 
hyperplasia and follicular lymphoma.(Top left) Hematoxylin-eosin staining demonstrates 
follicles in reactive lymphoid hyperplasia (RLH) (inset). The follicles are composed of small 
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cells with mitotic figures and tingible body macrophages (arrow). (Top right) Hematoxylin-
eosin-stainedsection of follicular lymphoma shows mostly small centrocytes with cleaved 
nuclei and an occasional centroblast (arrow) with a large nucleus and peripheral nucleoli. 
Inset shows the closer, less well-defined arrangement of several follicles. (Middle left) CD20 
stains B cells within the follicles of RLH. The inset indicates the substantial width of the 
interfollicular zones. (Middle right) CD20 also stains the B cells in the follicles of follicular 
lymphoma; the close arrangement of the follicles can again be appreciated in the 
inset.(Bottom left) CD3 stains T cells in the interfollicular zones (inset); the T cells can also be 
seen percolating throughout the folliclesof RLH. (Bottom right) Follicular lymphoma 
manifests nearly identical CD3 staining, with CD3_ cells prominent in the interfollicular 
zones (inset) as well as scattered within the follicles. (Top left and top right, hematoxylin-
eosin, 400, insets, 25;Middle left through Bottom right, immunoperoxidase reactions, 
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Fig. 2. Immunohistochemical characterization of reactive lymphoid hyperplasia and 
follicular lymphoma. (Top left) BCL-6stains B cells within follicles of reactive lymphoid 
hyperplasia (RLH). (Top right) Follicles of follicular lymphoma are also positivefor BCL-6. 
(Middle left) The follicles of RLH are negative for BCL-2. (Middle right) Follicles of follicular 
lymphoma are positivefor BCL-2. (Bottom left) Follicles in RLH are positive for CD10. 
(Bottom right) Follicles (F) of follicular lymphoma are also positive for CD10 but with more 
interfollicular staining than RLH. (Immunoperoxidase reactions, diaminobenzidine 
chromogen,200) [42].   
8. Follicular lymphoma—How many grades?  
The grading of FL was the subject of spirited discussion, both among the authors and the 
participants in the Clinical Advisory Committee. FL has traditionally been graded according 
to the proportion of centroblasts and into three Grades, 1-3 as detailed:  
World Health Organization classification of follicular lymphoma (FL).  
Follicular Lymphoma: Grading & Variants  
Grade 1: 0–5 centroblasts/HPF  
Grade 2: 6–15 centroblasts/HPF  
Grade 3: > 15 centroblasts/HPF  
3a: > 15 centroblasts, but centrocytes are still present  
3b: centroblasts form solid sheets with no residual centrocytes [46].  
Variants:  
Primary cutaneous follicle center lymphoma  
Pediatric follicle center lymphoma  
Intestinal follicle center lymphoma  
Diffuse follicle center lymphoma  
Grade 1, 0–5 centroblasts/HPF  
Grade 2, 6–15centroblasts/HPF[43]  
Pediatric FL lacking an association with the t(14;18). Primary cutaneous follicle center 
lymphoma (PCFCL) may contain a high proportion of large B-cells including large  
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Fig. 3. Further immunohistochemical characterization of reactive lymphoid hyperplasia 
(RLH) and follicular lymphoma. (Topleft) CD20 densely stains this region of RLH without 
obvious follicular architecture. (Top right) CD23 highlights the dendritic cell scaffolding of 
the follicles in an adjacent section. The inset shows a similar dendritic architecture 
broughtout by CD23 in follicular lymphoma. (Bottom left) Ki-67 stains cells within follicles 
of RLH in an uneven distribution; staining is crescentic and more dense at the bottom of the 
follicle. (Bottom right) Follicular cells in follicular lymphoma are more evenly and diffusely 
positive for Ki-67.(Immunoperoxidase reactions, diaminobenzidine chromogen, 200, inset, 
25) [42].   
centrocytes and centroblasts. Evidence of the t(14;18) is uncommon and most cases are BCL2 
negative. Dissemination beyond the skin is rare, and the prognosis is usually excellent [47].  
However, most studies have shown poor interobserver and intraobserver reproducibility. 
Moreover, the clinical significance of the separation of Grades 1 and 2 has been questioned, 
with minimal differences seen in long term outcome. Thus, the 2008 WHO classification 
lumps cases with few centroblasts as “FL Grade 1-2 (low grade)” and does not require or 
recommend further separation. FL Grade 3 is divided into Grades 3A and 3B, based on the 
absence of centrocytes in the latter category. Several studies have identified biological 
differences between these two subtypes, with most cases of FL Grade 3B being more closely 
related to DLBCL at the molecular level [47].  
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related to DLBCL at the molecular level [47].  
 
Hematology – Science and Practice 380 
However, in clinical practice the separation of Grades 3A and 3B can be challenging. Diffuse 
areas in any Grade 3 FL should be designated as DLBCL (with FL) and are more commonly 
observed in Grade 3B. Further studies are likely to lead to more precise delineation of the 
Grade 3 cases truly belonging within FL and those representing an intrafollicular variant of 
the GCB (germinal center B cell) type of DLBCL.  
The presence of diffuse areas within a FL appears to confer more aggressive clinical 
behavior. In addition, unusual cytological variants can be encountered that are not included 
in the World Health Organization classification, including cases with large centrocytes and 
others with small centroblasts; in some cases the latter may resemble the cytomorphology of 
Burkitt lymphoma and may be associated with MYC oncogene translocations [43].  
A truly diffuse form of FL may be rarely encountered, but on closer inspection, most cases 
demonstrate vaguely follicular architecture that is underappreciated without the routine use 
of immunostains for follicular dendritic cells. When a diagnosis of true diffuse follicle center 
lymphoma is considered, the pathologist is encouraged to demonstrate co-expression of 
CD10 and Bcl-6 as well as presumptive evidence of the t(14;18). Approximately 10% of FL 
cases reveal the presence of a zone of cells resembling marginal zone B cells, immediately 
surrounding neoplastic follicles. Importantly, a residual benign mantle zone is not seen, 
helping to distinguish FL from a marginal zone lymphoma. The area of marginal zone 
differentiation within a FL takes on a distinct morphology with cells having moderate 
amount of pale cytoplasm; moreover, the immunophenotype is also different, with 
downregulation of CD10 and Bcl-6 expression by cells within the marginal zone 
compartment [48].  
Unresolved issues in FL pathology remain and to some extent contribute to problems with 
reproducibility. Diffuse areas in FL are often not identified, due to underutilization of 
follicular dendritic cell stains. Similarly, follicular areas in suspected de novo DLBCL are 
underappreciated. Variability in the cytology of cells within follicles contributes to 
inconsistent reporting of FL grade. Follicular dendritic are commonly misidentified as 
centroblasts, resulting in higher grade and, in general, there is poor interobserver 
reproducibility for the counting of centroblasts. All of these factors lead to inconsistencies in 
the diagnosis and grading of FL biopsies, and to some extent raise questions regarding the 
validity of grading and clinical decision making based on grade [43].  
Finally, a rare form of FL may be seen referred to as “in-situ” FL. In these uncommon cases, 
scattered malignant follicles are identified within lymph nodes revealing mostly benign 
features. The malignant follicles show typically more monomorphic germinal centres (GCs). 
GCs involved in intrafollicular neoplasia/in situ follicular lymphoma are composed mainly 
of centrocytes with no evident atypia. A feature of these centres is the relative absence of 
macrophages with tingible bodies and the absence of polarization into light and dark zones. 
The paucity of large centroblasts reflects their low proliferation rate in insitu FLs. 
Intrafollicular neoplasia/in situ follicular lymphoma is characterized by strong co-
expression of Bcl-2 and CD10 in the involved GCs [49].  
9. Fine needle aspiration cytology  
FNA is a useful tool for staging as well as evaluating recurrences in lymph nodes and extra 
nodal sites without subjecting patients to multiple excisional biopsies. Transformation can 
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occur in some lymph nodes while low-grade lymphoma persists in others. An advantage of 
FNA is the ability to sample multiple lymph nodes, whereas open biopsy of different 
anatomic sites is not feasible  
Grading FL is based on the proportion of centroblasts in neoplastic follicles; therefore, the 
ability to identify the various cellular components in a fine-needle aspirate is the first 
essential step to the grading process. In Papanicolaou stained preparations, centrocytes or 
cleaved follicular center cells are small to medium-sized cells with angulated, elongated, 
twisted, or cleaved nuclei with inconspicuous nucleoli and scant, pale cytoplasm.  
Centroblasts are at least two times larger than a lymphocyte and usually are round or oval 
but occasionally have indented, irregular, or even lobulated nuclei. There is a narrow rim of 
cytoplasm, often basophilic to amphophilic. A large and central nucleolus with chromatin 
clearing around it is characteristic of immunoblasts. In more typical centroblasts, the 
chromatin generally is vesicular with one to three prominent, often peripherally located 
nucleoli. The cells also may be hyperchromatic. Centroblasts tend to be more fragile and, in 
some preparations, may not be preserved well [50].  
It is important not to confuse centroblasts with follicular dendritic reticulum cells, which 
tend to aggregate within the center of the neoplastic follicles. Although dendritic cells have 
nuclei that are similar in size to centroblasts, the nuclei of dendritic cells are somewhat 
coffee bean-shaped with one side typically flattened and with fine, smooth nuclear 
membranes. The cytoplasm is indistinct, not basophilic, in contrast to that of centroblasts. In 
Papanicolaou-stained preparations, the chromatin is pale gray and finely granular with 
small, central, eosinophilic nucleoli. The cytoplasm of dendritic cells form long, dendritic 
processes that can be appreciated in cell blocks by IHC staining for CD21. Large cleaved 
cells also must be distinguished from centroblasts. Although there is an overlap in size with 
centroblasts, large centrocytes are more irregular in shape and lack the prominent nucleoli 
and chromatin pattern of centroblasts [50]  
When it comes to differentiating individual cells, cytologic preparations are superior to 
hematoxylin and eosin-stained histologic sections, although cytologic preparations typically 
are less informative about architecture.  
Cell blocks are complimentary to smears and provide additional architectural clues. The 
FNA process often aspirates intact follicular structures that can be appreciated in the cell 
block. The presence of intact follicles may be proven by special stains on sections of the cell 
block [50].  
10. Grade versus pattern  
All three grades of lymphoma can have varying proportions of follicular and diffuse areas. 
Grade 1 and 2 FL generally have a predominantly follicular pattern. Because they are better 
differentiated, they have retained the ability to recapitulate follicles [ 51].  
Grade 3 FL occurs less frequently than Grade 1 and 2 FL, and a pure follicular pattern in 
Grade 3 FL is even more unusual. In Grade 3 FL, the presence of diffuse areas is more 
common, and most (but not all) studies show that this finding is associated with a worse 
prognosis.  
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In Grade 1 and 2 FL, there is conflicting evidence regarding whether the presence of large, 
diffuse areas or the degree of nodularity may alter prognosis significantly.  
SO the WHO classification system recommends estimating the proportion of follicular and 
diffuse components in the pathology report  
- Follicular (75% follicular),  
- Follicular and diffuse (25–75% follicular),  
- Minimally follicular (25% follicular).  
Note, however, that the proportion of centroblasts within the neoplastic follicles is what 
determines the grade of a FL, not the degree of nodularity. Furthermore, the grade of FL, in 
combination with other clinical factors,ultimately is what influences treatment decisions 
[50].  
11. Cytogenetics of follicular lymphoma  
The t(14;18)(q32;q21) chromosome translocation represents the defining cytogenetic 
hallmark of FL and is encountered in 80%-90% of cases. Its molecular consequence is the 
juxtaposition of the B-cell lymphoma/leukemia 2 (BCL2) proto-oncogene with enhancer 
sequences of the immunoglobulin heavy chain gene (IGH) promoter region, thereby 
deregulating its expression and resulting in an overexpression of the BCL2 protein in the 
neoplastic follicles [52,53]. However, 10–15% of cases do not harbor the t(14;18)(q32;q21) and 
in these t(14;18)-negative cases, other mechanisms are thought to be involved in the 
pathogenesis [54]. Moreover, t(14;18)- positive B cells can be identified in the blood and 
lymphoid tissues of healthy individuals, and the number of t(14;18)-positive cells is 
influenced by gender, personal lifestyle and exposure to toxic substances [55].  
The BCL2 proto oncogene, a potent anti-apoptotic molecule, is expressed in resting B cells in 
the perifollicular mantle zone and in post-follicular B cells, thereby promoting long-lived 
follicular precursor and memory B cells. Germinal center B cells, however, physiologically 
lack BCL2 expression and undergo apoptosis unless they are selected by specific antigens 
that drive them into processes termed somatic hypermutation and class switching. Due to 
the lack of BCL2 expression, amongst other factors, the large bulk of B-cells entering the GC 
microenvironment will be removed by apoptosis. The constitutive overexpression of BCL2 
in germinal center B cells inferred by the t(14;18)(q32;q21) leads to an accumulation of 
inappropriately rescued B cells with a prolonged life span, allowing for the development of 
additional genetic hits to occur, that are required for the establishment of overt FL . Variant 
translocations of the t(14;18), such as the t(2;18) or t(18;22), juxtapose BCL2 to the loci of the 
immunoglobulin light chains (k,l) and, likewise, result in inappropriate and sustained BCL2 
expression in GC B cells [56].  
The occurrence of the t(14;18) in a pre-FL B cell can be viewed as a first hit in a multistep 
process that results in the clonal dysregulation of cell cycle control and apoptosis of the 
tumor cells. During process of lymphomagenesis, a number of additional genetic or 
epigenetic events occur in a non-random fashion that lead to overt FL .For example, 
constitutive expression of activation-induced cytidine deaminase (AID) in the GC 
environment in B cells overexpressing BCL2 may propagate continuous somatic 
hypermutation and class switch recombination activity that results in increased genomic 
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instability. This may, in turn, foster the occurrence of secondary oncogenic hits and, finally, 
result in the malignant transformation to overt FL [57].  
Cong and co-workers[58],described the phenomenon of what they termed follicular 
lymphoma in situ in otherwise reactive, hyperplastic lymph nodes possibly representing the 
morphological equivalent of early, pre-invasive FL.  
12. Secondary chromosomal aberrations in follicular lymphoma  
A number of secondary chromosomal alterations have been described in FL including: 
structural and numerical changes. The complexity of the secondary alterations correlates 
with the grade – the higher the grade, the more complex aberrations are usually 
encountered [59].  
It has long been recognized that these alterations occur in a non-random fashion. Partial 
trisomies of chromosomes 1q, 7, 8 and 18q, and deletions in 1p and 6q have been described 
as the most common secondary alterations, and deletions in the long arm of chromosomes 1 
and 6 and in the short arm of chromosome 17 have been associated with a worse prognosis 
[60]. Some of these alterations may occur early in the course of the disease, whereas others 
might represent late genetic events. In addition, some of the alterations are mutually 
exclusive, while alterations of other chromosomal regions frequently appear together 
possibly leading to a coordinated deregulation of genetic pathways [61].  
Some of the secondary chromosomal alterations may cancel the effect of the t(14;18) that 
initially forms a low-grade neoplasia with a follicular growth pattern and subsequently 
enable the transformation to highgrade lymphoma. This process has been associated with 
three distinct secondary genetic alterations in FL that have a profound impact on the 
biological program and the clinical course in FL. These include an additional introduction of 
a t(8;14)/MYC rearrangement in the tumor cells [62], the inactivation of TP53 by mutation 
and deletion and, finally, the inactivation of p16, frequently occurring by biallelic deletion 
[63].  
The occurrence of a secondary MYC rearrangement in FL deserves particular attention, 
because these cases frequently demonstrate a Burkitt-like appearance and may be detectable 
by virtue of this specific morphology in combination with an overexpression of the BCL2 
protein caused by the t(14;18) that is usually not encountered in classical Burkitt’s 
lymphomas. Some studies suggest that the detection of TP53 mutations in primary 
diagnostic specimens of FL without signs of transformation also characterizes a patient 
subgroup with worse prognosis [64].  
13. BCL2-negative follicular lymphoma  
From recent studies t(14;18)-negative FLs belong to the biologic spectrum of FL, but show 
distinct genetic features as well as gene expression and immunohistochemical profiles that 
differ from their t(14;18)-positive counterparts [65]. The t(14;18)-negative FL appears to 
harbor genetic rearrangements of the BCL6 gene in 3q27[66] or trisomy 3 [67] whereas 
others show BCL2 expression on the immunohistochemical level despite the lack of the 
t(14;18)[68]. Moreover, increased expression of IRF4/MUM1, a protein associated with 
plasma cell differentiation has been described in FL without BCL2 rearrangement [69].  
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12. Secondary chromosomal aberrations in follicular lymphoma  
A number of secondary chromosomal alterations have been described in FL including: 
structural and numerical changes. The complexity of the secondary alterations correlates 
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plasma cell differentiation has been described in FL without BCL2 rearrangement [69].  
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14. Molecular genetics of follicular lymphoma 
Immunoglobulin heavy and light chains are rearranged in FL with the variable region genes 
showing extensive and ongoing somatic hypermutation [70, 71]. As a result of these 
mutations in the CDR-regions, PCR primer annealing may be hampered and depending on 
the primers used, immunoglobulin-PCR may not yield monoclonal products in a proportion 
of FL cases (10-40%). Multiplex PCR reactions using BIOMED-2 expanded primer sets detect 
closer to 90% of complete IGH (VH-JH) gene rearrangements, and clonality detection ap-
proximates 100% when primers detecting incomplete IGH (DH-JH) and light chain gene 
rearrangements are included [72]. 
For amplification of complete IGH (VH-JH) gene rearrangement, BIOMED-2 developed 
three sets of VH primers corresponding to the three VH FR regions (FR1, FR2, and FR3). 
Each set of primers consisted of six or seven oligonucleotides capable of annealing to their 
corresponding VH segments (VH1–VH7) with no mismatches for most VH segments. These 
VH primer sets were used in conjunction with a single JH consensus primer. The JH primer 
is fluorescently labeled to allow the detection of  PCR products by Gene Scanning [73].  
For incomplete IGH (DH-JH) rearrangements, seven family-specific DH primers were 
designed based on the high degree of homology within each DH family in combination with 
the consensus JH primer. Primers were designed such that crossannealing to other DH 
family segments would be minimal or preferably absent [73]. 
Six family-specific Vk primers were designed by van Dongen et al [73], to recognize the 
various Vk gene segments of the seven Vk families. The family-specific Vk primers were 
designed to be used in combination with either a set of two Jk primers or a Kde primer.A 
single consensus primer recognizing both Vλ1 and Vλ2 gene segments, as well as a Vλ3 
primer, were designed by van Dongen et al [73], in combination to a single consensus 
primer for the Jλ1, Jλ2, and Jλ3 gene segments.  
The t(14;18) and BCL2 gene rearrangements is one of the best characterized recurrent 
cytogenetic abnormalities in peripheral B-cell lymphoproliferative disease[74]  . FL is 
genetically characterized by this translocation which is present in up to 90% of the grade 1-2 
FL cases [75,76] but the proportion depends on the technique used [77, 78, 79]. BCL2 
rearrangements are much less frequent in grade 3B FL [80]. As a consequence of the 
translocation, the BCL2 gene (anti-apoptotic) from 18q21 is placed under the control of the 
strong enhancers of the IGH locus resulting in the deregulation of its normal pattern of 
expression [81,82]. The BCL2/IGH rearrangement is found in the PB of 25-75% of healthy 
donors, and also in reactive nodes, particularly if using sensitive nested or RT-PCR assays 
[83,84,85]. A recent study suggests that rather than being naive B-cells, these BCL2-re-
arranged cells are memory B-cells [86].  
There is no single gold standard detection strategy for the t(14;18), and a combination of 
cytogenetics and southern blotting have been generally used [87,88]. Interphase FISH 
detection strategies offer an applicable alternative that have the potential to pick up more 
translocations [89]. For molecular diagnostic laboratories PCR-based detection strategies 
offer rapid results, are generally applicable, and can be used for residual disease monitoring. 
However, the primers commonly used have not been designed to take into account recent 
information on the molecular anatomy of the breakpoints. As a consequence when 
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compared to gold standard approaches, PCR-based techniques only detect up to 60% of 
translocations, which seriously impairs the diagnostic capability of PCR. However, 
BIOMED-2 primers have been developed using three multiplex tubes for detection of MBR-
JH, 3'MBR- JH, and mcr-JH to maximize the detection of t(14;18) [73]. ). These data are 
supported by previous report  from our molecular hematology laboratory. We found that 
FISH was superior to PCR in the detection of t(14'18) (q32'q21)-IGH-BCL-2 in formalin-fixed, 
paraffin-embedded tissue samples. Moreover,  strong correlations between the FLIPI score 
and each of interphase FISH and  CD10 expression were demonstrated [90].   
Molecular profiling of many types of lymphoma using RQ-PCR and cDNA microarray has 
been used to predict survival by many researchers [91-94]. Genes involved in cell cycle 
control and DNA synthesis and metabolism (e.g. CXCL12, which is involved in signaling 
transduction and NEK2, which is involved in mitotic regulation, and MAPK1) are 
significantly up-regulated in the aggressive phase of FL[3]. MYC, as a known oncogene, and 
MYC-target genes (SFRS7, LDHA, MTHFD1, NME1, MSH2, and CKS2) are upregulated on 
transformation and may be implicated as a direct transforming factor [95-102].On the other 
hand, there is higher density of the T-cell infiltrate in low-grade FL as compared to high-
grade disease and this is reflected by several T cell–related genes (CD3, CD2, CD69). 
However, genes related to T-cell and macrophage activation including several chemokine 
receptors (CCR1, CCL3, CCL5, CCL8, AKAP12, ILF3, GEM) are significantly upregulated on 
transformation, suggesting an important biologic role. Notably, specific antagonists to 
several of the above-mentioned chemokine receptors are available and offer an attractive 
possibility for therapeutic interventions [103].  
15. Proposed algorithm for stratification of follicular lymphoma 
The National Comprehensive Cancer Network( NCCN)  has recently launched an algorithm  
for stratification of follicular lymphoma (Figure 4). 
 
Fig. 4. Proposed algorithm for stratification of follicular lymphoma (NCCN)  
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15. Proposed algorithm for stratification of follicular lymphoma 
The National Comprehensive Cancer Network( NCCN)  has recently launched an algorithm  
for stratification of follicular lymphoma (Figure 4). 
 
Fig. 4. Proposed algorithm for stratification of follicular lymphoma (NCCN)  
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1. Introduction  
Lymphoma is the fifth most common cancer type in the Western world, accounting for 
approximately 12,000 cases per annum in the UK alone. Moreover the occurrence of this 
type of cancer has been increasing. The age-adjusted incidence of non-Hodgkin’s lymphoma 
(NHL) in the US for example has increased 74% between 1976 and 2001 (SEER 2005). 
Follicular lymphoma (FL) is the most common form of low grade B-cell lymphoma (75-80% 
of all cases) representing about a third of all NHL cases in the US, and a quarter of all cases 
in Europe (Anderson et al. 1998). FL is characterised by the presence of the t(14;18) 
translocation in 90% of patients associated with up-regulation of the anti-apoptotic protein 
BCL2. Whilst FL tumours are chemo-sensitive, the disease is essentially incurable, with 
patients following a relapsing-remitting clinical course, typically experiencing several 
episodes of disease before eventually becoming refractory to treatment.  
Although indolent, with a median overall survival (OS) of ~10 years, about 30% of FL 
patients undergo high-grade transformation to an aggressive lymphoma that is 
histologically indistinguishable from diffuse large B-cell lympohoma (DLBCL). Transformed 
FL (tFL) patients have a particularly poor outcome with a median survival of <14 months 
(Wrench et al. 2010). The molecular basis of FL transformation is only poorly understood 
and importantly to date there are no reliable biomarkers that can identify FL patients at risk 
of transformation. In this chapter we will review the experimental evidence for the 
involvement of microRNAs in the pathology of FL with particular focus on the 
transformation process.  
2. Follicular lymphoma 
FL is a neoplasm of follicle center B cells (centrocytes) characterized by a (partially) follicular 
growth pattern. FL tumor cells are believed to arise from normal germinal centre–associated 
(GC) B cells as they express the same antigen profile as GC B cells (i.e. CD19, CD20, CD10, 
BCL6, and membrane-bound IgM or IgG), share many morphological features of normal GC 
cells, and are found within a follicular architecture embedded in a network of T cells and 
follicular dendritic cells. In contrast to normal GC cells however, FL tumour cells are 
characterised by the presence of t(14:18) translocation resulting in expression of the anti-
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episodes of disease before eventually becoming refractory to treatment.  
Although indolent, with a median overall survival (OS) of ~10 years, about 30% of FL 
patients undergo high-grade transformation to an aggressive lymphoma that is 
histologically indistinguishable from diffuse large B-cell lympohoma (DLBCL). Transformed 
FL (tFL) patients have a particularly poor outcome with a median survival of <14 months 
(Wrench et al. 2010). The molecular basis of FL transformation is only poorly understood 
and importantly to date there are no reliable biomarkers that can identify FL patients at risk 
of transformation. In this chapter we will review the experimental evidence for the 
involvement of microRNAs in the pathology of FL with particular focus on the 
transformation process.  
2. Follicular lymphoma 
FL is a neoplasm of follicle center B cells (centrocytes) characterized by a (partially) follicular 
growth pattern. FL tumor cells are believed to arise from normal germinal centre–associated 
(GC) B cells as they express the same antigen profile as GC B cells (i.e. CD19, CD20, CD10, 
BCL6, and membrane-bound IgM or IgG), share many morphological features of normal GC 
cells, and are found within a follicular architecture embedded in a network of T cells and 
follicular dendritic cells. In contrast to normal GC cells however, FL tumour cells are 
characterised by the presence of t(14:18) translocation resulting in expression of the anti-
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apoptotic molecule BCL2. This translocation is detectable in approximately 75% of cases by 
traditional karyotyping techniques but in over 90% of cases measured by polymerase chain 
reaction (PCR) (Tsujimoto et al. 1985). Although considered to be an essential feature of FL 
pathology, this genetic insult appears not to be in itself sufficient to cause FL as BCL2 
transgenic mice do not readily develop lymphoma (McDonnell & Korsmeyer 1991; Strasser 
et al. 1993). Furthermore, the t(14;18) translocation is not an uncommon finding in normal B 
cells, being detectable in over 50% of  healthy individuals (Roulland et al. 2006). Therefore, 
whilst the presence of t(14:18) is highly suggestive of FL, it is by no means diagnostic, and 
indeed may be found in other apparently unrelated cases of NHL including 15-30% of 
DLBCL cases (Iqbal et al. 2004). Furthermore about 5% of FL cases lack the t(14:18) 
translocation instead being characterised by a BCL6 translocation t(3;14) and displaying an 
almost exclusive centroblastic morphology (Jaffe et al. 2001).  
FL predominantly affects adults with a median age of 59 years and a male:female ratio of 
1:1.7 (Anderson et al. 1998). Most FL patients already have widespread disease at time of 
presentation, predominantly in the lymph nodes, but FL may also involve the spleen, bone 
marrow, and peripheral blood and occasionally extra-nodal sites such as the gastro-
intestinal tract or skin. Patients may be asymptomatic with slowly progressive 
lymphadenopathy or present with symptomatic complications of advancing tumour growth 
that require treatment. In nearly all survival studies, despite initial responsiveness to 
treatment, most patients relapse, and will eventually die of their disease.  
2.1 Histological transformation of FL tumors 
A percentage of FL patients (10-60% depending on the study) will eventually undergo high 
grade transformation from indolent FL to a much more aggressive tumor that is 
histologically indistinguishable from DLBCL, and is associated with a much poorer 
prognostic outcome. A recent study of 325 patients (median follow-up 15 years) found the 
risk of transformation to be 28% (Montoto et al. 2007). Despite the use of high dose therapy 
for transformed FL (tFL) cases, response rates are still lower than histologically equivalent de 
novo cases of DLBCL with a median survival of just 1.2 years. The molecular mechanisms 
behind this phenomenon, however, are very poorly understood and consequently the 
identification of at-risk patients, who might benefit from up-front high dose treatment 
modalities, remains one of the greatest challenges facing onco-hematologists today. 
Lossos et al identified 671 genes that were aberrantly expressed in at least three of twelve 
paired biopsy samples which fell into two distinct groups; those that had c-myc and its 
target genes up-regulated and those where these genes were down-regulated (Lossos et al. 
2002). Another study of five paired samples identified 36 up-regulated and 66 down-
regulated genes, seven of which were common with the study of Lossos et al (de Vos et al. 
2003). Sixty-seven and 46 genes were found to be up-regulated and down-regulated 
respectively in a series of eleven paired samples analyzed by Elenitoba-Johnson et al 
(Elenitoba-Johnson et al. 2003). Up-regulation of p38BMAPK was confirmed 
immunohistochemically as it was detected in DLBCL cases but not FL or normal GC cells. 
Davies et al examined the gene expression profile of twenty paired lymphoma samples 
taken pre- and post-transformation (Davies et al. 2007). They found that transformation 
proceeded by at least two molecular pathways; one characterized by a cell proliferation 
signature that was associated with recurrent oncogenic abnormalities and a decrease in T 
cell and follicular dendritic cell genes, while the other group showed no increase in 
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proliferation genes and followed an as yet undetermined route. In contrast a gene 
expression study of non-paired patients (24 FL patients who underwent transformation, 22 
FL patients without transformation (after 7 years) and 24 DLBCL patients who had 
previously transformed from FL) found that gene expression was too heterogeneous to 
reliably predict transformation (Glas et al. 2007). They did however report a correlation by 
immunohistochemistry with the spatial distribution to neoplastic follicles and the activation 
of CD4+ T cells and specifically T-helper 1 cells (P>0.05). They did not find any correlation 
with other infiltrating cell populations including CD68+ macrophages or regulatory T cells.  
Additionally, genomic alterations have been demonstrated to be associated with transformation 
of FL. The acquisition of novel mutations in PIM-1, PAX-5, RhoH/TTF and c-MYC genes, due 
to aberrant somatic hypermutation, was found in 5/9 cases that had undergone transformation 
(Rossi et al. 2006). Genomic aberrations were found to be more common in transformed cases of 
DLBCL than non-transformed FL and the alterations -6q16-21 and +7pter-q22 were only found 
in transformed DLBCL but not in follicular lymphoma whereas -4q13-21 was more common in 
transformed than de novo DLBCL (Berglund et al. 2007).  
However, despite intensive research the molecular basis for transformation in FL patients 
remains largely unknown. Recently, ourselves and others, have raised the possibility that 
microRNAs may be important factors in both FL transformation and antecedent FL 
lymphogenesis (Roehle et al. 2008; Lawrie et al. 2009). 
3. MicroRNAs 
MicroRNAs are a recently discovered class of naturally occurring short non-coding RNA 
molecules that regulate eukaryotic gene expression post-transcriptionally. There are now more 
than 900 human microRNAs that have been identified through cloning and/or sequence 
analysis (miRBase- (Griffiths-Jones et al. 2006)), and it is believed some 60% of all human genes 
are a target for microRNA regulation (Friedman et al. 2009). MicroRNAs have been shown to 
play key regulatory roles in virtually every aspect of biology including developmental timing, 
cell differentiation, apoptosis, cell proliferation, metabolism organ development, and 
hematopoiesis (Kim 2005). The potential importance of microRNAs in cancer is implied by the 
finding that the majority of human microRNAs are located at cancer-associated genomic 
regions (Calin et al. 2004), and there is now overwhelming evidence that dysfunctional 
expression of microRNAs is a common, if not ubiquitous, feature of cancer in general and 
lymphoid malignancy in particular (Lawrie 2008; Iorio & Croce 2009).  
Despite the fundamental role that microRNAs appear to play in biology, these molecules 
were unknown to the scientific world until 1993 when lin-4, a C. elegans developmental 
regulator was identified (Lee et al. 1993; Wightman et al. 1993). The significance of this 
finding was not however realised until seven years later when another worm microRNA, 
let-7 was discovered (Reinhart et al. 2000). Unlike lin-4, the sequence of let-7 was found to be 
highly conserved in almost all organisms (Pasquinelli et al. 2000). It was soon realised that 
similar sequences were scattered throughout eukaryotic genomes that were first called 
microRNAs in 2001 (Lee & Ambros 2001).  
3.1 MicroRNA biosynthesis and function 
The majority of human microRNAs are encoded within introns of coding or non-coding 
mRNAs whilst others are located exgenically, within the exons of non-coding mRNAs or 
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modalities, remains one of the greatest challenges facing onco-hematologists today. 
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respectively in a series of eleven paired samples analyzed by Elenitoba-Johnson et al 
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proceeded by at least two molecular pathways; one characterized by a cell proliferation 
signature that was associated with recurrent oncogenic abnormalities and a decrease in T 
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proliferation genes and followed an as yet undetermined route. In contrast a gene 
expression study of non-paired patients (24 FL patients who underwent transformation, 22 
FL patients without transformation (after 7 years) and 24 DLBCL patients who had 
previously transformed from FL) found that gene expression was too heterogeneous to 
reliably predict transformation (Glas et al. 2007). They did however report a correlation by 
immunohistochemistry with the spatial distribution to neoplastic follicles and the activation 
of CD4+ T cells and specifically T-helper 1 cells (P>0.05). They did not find any correlation 
with other infiltrating cell populations including CD68+ macrophages or regulatory T cells.  
Additionally, genomic alterations have been demonstrated to be associated with transformation 
of FL. The acquisition of novel mutations in PIM-1, PAX-5, RhoH/TTF and c-MYC genes, due 
to aberrant somatic hypermutation, was found in 5/9 cases that had undergone transformation 
(Rossi et al. 2006). Genomic aberrations were found to be more common in transformed cases of 
DLBCL than non-transformed FL and the alterations -6q16-21 and +7pter-q22 were only found 
in transformed DLBCL but not in follicular lymphoma whereas -4q13-21 was more common in 
transformed than de novo DLBCL (Berglund et al. 2007).  
However, despite intensive research the molecular basis for transformation in FL patients 
remains largely unknown. Recently, ourselves and others, have raised the possibility that 
microRNAs may be important factors in both FL transformation and antecedent FL 
lymphogenesis (Roehle et al. 2008; Lawrie et al. 2009). 
3. MicroRNAs 
MicroRNAs are a recently discovered class of naturally occurring short non-coding RNA 
molecules that regulate eukaryotic gene expression post-transcriptionally. There are now more 
than 900 human microRNAs that have been identified through cloning and/or sequence 
analysis (miRBase- (Griffiths-Jones et al. 2006)), and it is believed some 60% of all human genes 
are a target for microRNA regulation (Friedman et al. 2009). MicroRNAs have been shown to 
play key regulatory roles in virtually every aspect of biology including developmental timing, 
cell differentiation, apoptosis, cell proliferation, metabolism organ development, and 
hematopoiesis (Kim 2005). The potential importance of microRNAs in cancer is implied by the 
finding that the majority of human microRNAs are located at cancer-associated genomic 
regions (Calin et al. 2004), and there is now overwhelming evidence that dysfunctional 
expression of microRNAs is a common, if not ubiquitous, feature of cancer in general and 
lymphoid malignancy in particular (Lawrie 2008; Iorio & Croce 2009).  
Despite the fundamental role that microRNAs appear to play in biology, these molecules 
were unknown to the scientific world until 1993 when lin-4, a C. elegans developmental 
regulator was identified (Lee et al. 1993; Wightman et al. 1993). The significance of this 
finding was not however realised until seven years later when another worm microRNA, 
let-7 was discovered (Reinhart et al. 2000). Unlike lin-4, the sequence of let-7 was found to be 
highly conserved in almost all organisms (Pasquinelli et al. 2000). It was soon realised that 
similar sequences were scattered throughout eukaryotic genomes that were first called 
microRNAs in 2001 (Lee & Ambros 2001).  
3.1 MicroRNA biosynthesis and function 
The majority of human microRNAs are encoded within introns of coding or non-coding 
mRNAs whilst others are located exgenically, within the exons of non-coding mRNAs or 
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within the 3’UTR sequence of mRNA (Rodriguez et al. 2004). MicroRNAs are transcribed as 
5’-capped large polyadenylated transcripts (pri-microRNA) primarily in a Pol II-dependent 
manner (Figure 1), although the involvement of Pol-III transcription has also been 
postulated for microRNAs encoded within Alu repeat sequences (Borchert et al. 2006). 
Approximately 40% of human microRNAs are co-transcribed as clusters encoding up to 
eight distinct microRNA sequences in a single pri-microRNA transcript (Altuvia et al. 2005; 
Hertel et al. 2006). Pri-microRNAs are cleaved within the nucleus by Drosha, an RNaseIII-
type nuclease, to form 60-70 nucleotide hairpin structures (pre-microRNA). Drosha by itself 
possesses little enzymatic activity and requires the cofactor DiGeorge syndrome critical 
region 8 gene (DGCR8) in humans (Pasha in Drosophila) to form the so-called 
microprocessor complex (Yeom et al. 2006). Once produced, the pre-microRNAs are 
 
Fig. 1. Schematic diagram of microRNA biosynthesis and function in animal cells. Pri-
microRNA precursor is transcribed in Pol-II dependent manner and then cleaved by 
microprocessor complex (Drosha/DGCR8) to form hairpin-structure pre-microRNA. Pre-
microRNAs are exported from the nucleus by exportin-5 in a RAN-GTP dependent manner 
where they are cleaved into an asymmetric duplex by action of Dicer and accessory proteins. 
The mature microRNA is loaded into the miRISC complex which binds to cognate 3’UTR 
sequence of target mRNA resulting in either degradation of mRNA, or to blockage of 
translation without mRNA degradation. 
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exported from the nucleus to the cytoplasm by Exportin5 in a Ran-GTP dependent manner 
(Zeng 2006). The cytoplasmic pre-microRNA is further cleaved to form an asymmetric 
duplex intermediate (microRNA: microRNA*) by Dicer, another RNaseIII-type enzyme. 
Similar to Drosha, cofactors such as TRBP and PACT (in humans) are necessary for Dicer 
activity (Lee et al. 2006). The microRNA: microRNA* duplex is in turn loaded into the 
miRISC complex in which Argonaut (Ago) proteins appear to be the key effector molecules. 
The strand that becomes the active mature microRNA appears to be dependent upon which 
has the lowest free energy 5’ end and is retained by the miRISC complex whilst the other 
strand is usually degraded by an unknown nuclease (Khvorova et al. 2003; Schwarz et al. 
2003).  
The loaded miRISC is guided by the mature microRNA sequence (19-24 nucleotide) to 
partially complementary sequences within the 3’UTR (and probably coding sequences and 
5’UTR as well) of the target mRNA, leading to inhibition of translation, transcript 
degradation, or both (Lawrie 2007; Lytle et al. 2007). Although repression of translation 
without mRNA degradation was originally believed to be the modus operandi of animal 
microRNAs, the situation appears to be more complex than previously thought, as there is 
now compelling evidence that microRNAs also effect transcriptional levels through de-
adenylation and/or degradation (Giraldez et al. 2006) and may even positively affect 
translation in some instances (Vasudevan et al. 2007). How translational repression occurs 
remains unclear. It has been suggested that mRNA bound to the microRNA-miRISC 
complex may be sequestered away from the translational machinery in P-bodies that 
additionally act in concert with enzymes to remove the 5’-cap hence preventing translation 
(Liu et al. 2005; Sen & Blau 2005). Alternatively it has been suggested that microRNAs may 
prevent recognition of the 5’cap by translation factors (Pillai et al. 2005).  
4. MicroRNA expression in FL 
The following experimental details were taken in part from previously published research 
(Lawrie, CH et al., 2009). The only other study, as far we are aware, that considers 
microRNA expression in FL, was by Roehle et al which although it included 46 FL samples, 
only measured levels of 153 microRNA probes (compared with 464 microRNA probes in 
this study), and did not consider FL transformation (Roehle et al. 2008). 
4.1 Materials and methods 
4.1.1 Patient material 
Formalin-fixed paraffin-embedded (FFPE) biopsy samples from 98 patients were obtained 
from the Pathology Department of the John Radcliffe Hospital, Oxford, UK. Eighty 
patients were diagnosed histologically and clinically as having DLBCL; 64 de novo 
(DLBCL-de novo) and 16 transformed cases with previously diagnosed FL (DLBCL-t). Of 
the 18 cases of FL used in this study, seven subsequently underwent high grade 
transformation (FL-t) with a median time to transformation of 24 months (range 10-96 
months) from initial diagnosis. The remaining 11 FL cases (FL-nt) had no recorded 
transformation events (median follow-up time 60 months; range 52-132 months). The FL-t 
and DLBCL-t samples were not paired. All FL cases were grade 1 or 2 at time of original 
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activity (Lee et al. 2006). The microRNA: microRNA* duplex is in turn loaded into the 
miRISC complex in which Argonaut (Ago) proteins appear to be the key effector molecules. 
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(Lawrie, CH et al., 2009). The only other study, as far we are aware, that considers 
microRNA expression in FL, was by Roehle et al which although it included 46 FL samples, 
only measured levels of 153 microRNA probes (compared with 464 microRNA probes in 
this study), and did not consider FL transformation (Roehle et al. 2008). 
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4.1.1 Patient material 
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patients were diagnosed histologically and clinically as having DLBCL; 64 de novo 
(DLBCL-de novo) and 16 transformed cases with previously diagnosed FL (DLBCL-t). Of 
the 18 cases of FL used in this study, seven subsequently underwent high grade 
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diagnosis. All samples were collected at time of initial diagnosis (i.e. prior to treatment) 
with the exception of DLBCL-t cases. Samples had >80% of tumor cells as determined by 
hematoxylin and eosin staining (not shown). Relevant ethical permission was obtained for 
the use of all samples. 
4.1.2 RNA purification and microarray analysis 
Total RNA was purified from four x 20 µm FFPE sections using the Recoverall kit from 
Ambion (Huntington, UK) in accordance with the manufacturers’ instructions. RNA (3 µg) 
were labeled and hybridized to µRNA microarrays as previously described (Lawrie et al. 
2008) using tonsillar material (pooled from twelve healthy individuals) as a common 
reference in a dye-balanced design.  
Image analysis was carried out with BlueFuse software (BlueGnome, Cambridge, UK). Raw 
image data were global median-normalized within arrays and normalized between arrays 
using the LIMMA package (Smyth & Speed 2003). The normalized log ratios (average of 
four replicates per probe) were used for subsequent analysis in Genespring 7.2 (Agilent 
Technologies, CA, US). ANOVA analysis was used to identify microRNAs differentially 
expressed between sample types and P values were adjusted using the Benjamini-Hodgberg 
correction method. Differentially expressed genes were tested for their ability to predict 
sample class using the leave-one-out cross-validation support vector machine (SVM) 
function in Genespring. 
4.2 Results & discussion 
4.2.1 MicroRNA expression is distinct between DLBCL and FL  
In order to investigate differences in microRNA expression between FL and DLBCL 
samples, and because de novo and transformed DLBCL are indistinguishable histologically, 
we initially compared expression in all DLBCL cases (n = 80) with that of all FL cases (n = 
18). Thirty microRNAs were found to be differentially expressed (P < 0.05) (Table 1). 
Expression values of these microRNAs correctly predicted 95/97 (98%) of cases as DLBCL 
or FL by SVM, and clustered the cases distinctly (Fig. 2A).  
The study by Roehle et al identified 10 microRNAs that were differentially expressed 
between FL and DLBCL cases (Roehle et al. 2008). Only two of these microRNAs (miR-150 
and miR-135a) were found to be differentially expressed (P < 0.05) in our patient cohort, 
although another two microRNAs, miR-92 and miR-125b, had P values of < 0.1. These 10 
microRNAs correctly predicted 74/97 (76%) of cases according to diagnosis.  
Roehle’s study, however, compared de novo cases of DLBCL with FL cases that did not 
undergo subsequent transformation. Therefore, in order to compare the data directly we 
used the same sample types (64 DLBCL-de novo and 11 FL-nt cases) to re-analyze the data. 
This resulted in 26 differentially expressed (P < 0.05) microRNAs (Table 2), 14 of which were 
also present in the previous list (Table 1). These microRNAs correctly predicted 73/75 (97%) 
of cases in this cohort (c.f. 60/75 (80%) with the 10 microRNA signature (Roehle et al. 2008)) 
and 92/97 (95%) of cases in the extended cohort. Again, the two sets of samples were found 
to cluster distinctly using the 26-microRNA signature (Fig. 2B).  
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microRNA P value Up Fold change 
hsa-miR-200c 8.20E-08 DLBCL 9.39 
hsa-miR-518a 1.23E-03 DLBCL 3.15 
hsa-miR-638 8.05E-04 DLBCL 3.09 
hsa-miR-205 4.36E-02 DLBCL 2.85 
hsa-miR-223 1.42E-02 DLBCL 2.75 
hsa-miR-573 2.79E-02 DLBCL 2.35 
hsa-miR-135b 3.83E-02 DLBCL 1.63 
hsa-miR-133a 8.65E-03 DLBCL 1.38 
hsa-miR-135a 3.72E-02 DLBCL 1.38 
hsa-miR-451 3.67E-03 DLBCL 1.38 
hsa-miR-27b 2.12E-06 DLBCL 1.21 
hsa-miR-27a 4.62E-07 DLBCL 1.13 
hsa-miR-18b 1.03E-02 DLBCL 0.93 
hsa-miR-199b 3.23E-03 DLBCL 0.83 
hsa-miR-19a 1.20E-02 DLBCL 0.80 
hsa-miR-210 1.10E-02 DLBCL 0.75 
hsa-miR-19b 7.60E-04 DLBCL 0.75 
hsa-miR-99a 9.00E-05 DLBCL 0.72 
hsa-miR-100 1.07E-02 DLBCL 0.51 
hsa-miR-361 3.57E-02 FL 0.58 
hsa-miR-29c 3.07E-02 FL 0.63 
hsa-miR-26a 8.85E-03 FL 0.73 
hsa-miR-29b 4.22E-03 FL 0.76 
hsa-miR-26b 5.50E-03 FL 1.04 
hsa-miR-655 4.76E-02 FL 2.32 
hsa-miR-10b 3.10E-02 FL 2.38 
hsa-miR-634 1.19E-02 FL 2.41 
hsa-miR-593 3.30E-02 FL 2.43 
hsa-miR-28 1.47E-02 FL 2.49 
hsa-miR-150 1.45E-03 FL 3.37 
Table 1. MicroRNAs differentially expressed (P < 0.05) between DLBCL (DLBCL-de novo 
and DLBCL-t) and FL (FL-nt and FL-t) diagnoses. 
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diagnosis. All samples were collected at time of initial diagnosis (i.e. prior to treatment) 
with the exception of DLBCL-t cases. Samples had >80% of tumor cells as determined by 
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the use of all samples. 
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Ambion (Huntington, UK) in accordance with the manufacturers’ instructions. RNA (3 µg) 
were labeled and hybridized to µRNA microarrays as previously described (Lawrie et al. 
2008) using tonsillar material (pooled from twelve healthy individuals) as a common 
reference in a dye-balanced design.  
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microRNA P value Up Fold change 
hsa-miR-200c 8.20E-08 DLBCL 9.39 
hsa-miR-518a 1.23E-03 DLBCL 3.15 
hsa-miR-638 8.05E-04 DLBCL 3.09 
hsa-miR-205 4.36E-02 DLBCL 2.85 
hsa-miR-223 1.42E-02 DLBCL 2.75 
hsa-miR-573 2.79E-02 DLBCL 2.35 
hsa-miR-135b 3.83E-02 DLBCL 1.63 
hsa-miR-133a 8.65E-03 DLBCL 1.38 
hsa-miR-135a 3.72E-02 DLBCL 1.38 
hsa-miR-451 3.67E-03 DLBCL 1.38 
hsa-miR-27b 2.12E-06 DLBCL 1.21 
hsa-miR-27a 4.62E-07 DLBCL 1.13 
hsa-miR-18b 1.03E-02 DLBCL 0.93 
hsa-miR-199b 3.23E-03 DLBCL 0.83 
hsa-miR-19a 1.20E-02 DLBCL 0.80 
hsa-miR-210 1.10E-02 DLBCL 0.75 
hsa-miR-19b 7.60E-04 DLBCL 0.75 
hsa-miR-99a 9.00E-05 DLBCL 0.72 
hsa-miR-100 1.07E-02 DLBCL 0.51 
hsa-miR-361 3.57E-02 FL 0.58 
hsa-miR-29c 3.07E-02 FL 0.63 
hsa-miR-26a 8.85E-03 FL 0.73 
hsa-miR-29b 4.22E-03 FL 0.76 
hsa-miR-26b 5.50E-03 FL 1.04 
hsa-miR-655 4.76E-02 FL 2.32 
hsa-miR-10b 3.10E-02 FL 2.38 
hsa-miR-634 1.19E-02 FL 2.41 
hsa-miR-593 3.30E-02 FL 2.43 
hsa-miR-28 1.47E-02 FL 2.49 
hsa-miR-150 1.45E-03 FL 3.37 
Table 1. MicroRNAs differentially expressed (P < 0.05) between DLBCL (DLBCL-de novo 
and DLBCL-t) and FL (FL-nt and FL-t) diagnoses. 
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microRNA P value Up Fold change 
hsa-miR-200c 4.58E-06 DLBCL 10.03 
hsa-miR-638 5.30E-04 DLBCL 3.31 
hsa-miR-518a 3.85E-02 DLBCL 2.88 
hsa-miR-199a 1.57E-02 DLBCL 2.67 
hsa-miR-93 3.74E-02 DLBCL 2.64 
hsa-miR-22 1.94E-02 DLBCL 2.46 
hsa-miR-34a 3.92E-02 DLBCL 2.39 
hsa-miR-362 4.68E-02 DLBCL 2.30 
hsa-miR-206 3.93E-02 DLBCL 1.73 
hsa-miR-451 3.23E-03 DLBCL 1.49 
hsa-miR-636 8.55E-03 DLBCL 1.17 
hsa-miR-92 4.05E-02 DLBCL 1.08 
hsa-miR-27b 6.85E-04 DLBCL 1.04 
hsa-miR-199b 1.15E-04 DLBCL 1.03 
hsa-miR-27a 4.03E-04 DLBCL 0.97 
hsa-miR-24 2.04E-02 DLBCL 0.75 
hsa-miR-106a 1.16E-02 DLBCL 0.73 
hsa-miR-20a 2.62E-02 DLBCL 0.67 
hsa-miR-19b 4.95E-03 DLBCL 0.64 
hsa-miR-99a 9.55E-03 DLBCL 0.56 
hsa-miR-18b 3.27E-02 DLBCL 0.54 
hsa-miR-100 1.95E-02 DLBCL 0.43 
hsa-miR-26b 1.88E-02 FL 1.42 
hsa-miR-217 2.84E-02 FL 2.44 
hsa-miR-634 9.50E-04 FL 2.54 
hsa-miR-150 4.55E-02 FL 3.46 
Table 2. MicroRNAs differentially expressed (P < 0.05) between de novo DLBCL and non-
transforming FL cases. Members of the miR-17-92 cluster (and homologous clusters) are 
depicted in bold type. 
Interestingly, six of the microRNAs that were identified as being up-regulated in DLBCL-de 
novo cases compared to FL-nt are encoded by the miR-17-92 and/or homologous clusters 
(average fold-increase of 1.05 (range 0.54-2.64)) (He et al. 2005). The other four microRNAs 
encoded by these clusters, miR-17-5p, miR-19a, miR-25 and miR-106b, had P values of 0.067, 
0.087, 0.064 and 0.391 respectively. The miR-17-92 cluster is encoded at the 13q31 locus, a 
region commonly amplified in lymphomas and ectopic expression of miR-17-92 greatly 
accelerated lymphogenesis in a murine model (He et al. 2005). Moreover, direct binding of 
the c-myc protein up-regulates miR-17-92 expression (O'Donnell et al. 2005) and over-
expression of c-myc has been demonstrated in the majority (66.6%) of DLBCL cases (Aref et 
al. 2004), which has also been associated with poorer outcome (Pagnano et al. 2001). An 
increased level of this cluster in DLBCL compared to FL is consistent with a more aggressive 
clinical phenotype of DLBCL.  
 




Fig. 2. Cluster analysis of microRNAs differentially expressed between FL and DLBCL. 
(A) All DLBCL cases (n = 80) and FL cases (n = 18). (B) Only de novo cases (DLBCL-de novo 
(n = 64)) and cases of FL that did not undergo transformation (FL-nt (n = 11)). Reproduced 
from (Lawrie et al. 2009). 
4.2.2 Histological transformation of FL is associated with changes in microRNA 
expression 
To investigate whether changes in microRNA expression were associated with 
transformation we first looked at differences between de novo (DLBCL-de novo (n = 64) and 
transformed (DLBCL-t (n = 16)) cases of DLBCL. Fourteen microRNAs (Table 3) were found 
to be differentially expressed (P < 0.05). These microRNAs correctly predicted 
transformation status in 73/80 (91%) of samples. Only one of these was up-regulated in 
DLBCL-t (miR-491). Four of the microRNAs down-regulated in DLBCL-t are encoded by the 
miR-17-92 cluster suggesting an involvement of the cluster in high grade transformation. An 
alternative explanation is that because the cluster was also found to be down-regulated in 
FL compared with DLBCL-de novo (Table 2), the expression pattern of these microRNAs in 
DLBCL-t cases reflects that of antecedent FL. This latter hypothesis is consistent with gene 
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expression profile studies that found that DLBCL-t cases were more closely related to FL 
than DLBCL-de novo cases (Lossos et al. 2002).  
 
microRNA P value Up Fold change 
hsa-miR-491 2.11E-02 trans 2.54 
hsa-miR-27a 3.90E-02 de novo 0.47 
hsa-miR-19b 3.77E-03 de novo 0.60 
hsa-miR-25 3.84E-02 de novo 0.67 
hsa-miR-18a 1.24E-02 de novo 0.72 
hsa-miR-636 2.73E-02 de novo 1.06 
hsa-miR-92 1.94E-02 de novo 1.14 
hsa-miR-621 2.29E-02 de novo 1.98 
hsa-miR-526c 2.44E-02 de novo 2.38 
hsa-miR-766 2.75E-02 de novo 2.58 
hsa-miR-299-5p 4.76E-02 de novo 2.61 
hsa-miR-380-3p 5.94E-03 de novo 2.65 
hsa-miR-129 2.98E-02 de novo 2.70 
hsa-miR-588 9.05E-03 de novo 2.80 
 
Table 3. MicroRNAs differentially expressed (P < 0.05) between DLBCL-de novo and 
DLBCL-t cases. 
Next we compared FL cases that subsequently underwent high grade transformation (FL-t 
(n = 7)) with cases that did not (FL-nt (n = 11)). Six microRNAs were differentially expressed 
(P < 0.05) between these two groups (Table 4), whose expression levels correctly predicted 
16/18 (89%) of cases.  
 
microRNA P value Up   
hsa-miR-223 1.43E-03 FL-nt 1.51 
hsa-miR-217 5.56E-03 FL-nt 2.56 
hsa-miR-222 1.41E-02 FL-t 1.26 
hsa-let-7i 2.09E-02 FL-t 2.45 
hsa-miR-221 2.34E-02 FL-t 3.14 
hsa-let-7b 2.46E-02 FL-t 3.18 
 
Table 4. MicroRNAs differentially expressed (P < 0.05) between FL cases that subsequently 
underwent high grade transformation (FL-t) and those that did not (FL-nt). Median follow-
up time 60 months (range 52-132 months). 
Let-7b, let-7i, miR-221 and miR-222 were up-regulated in FL-t whilst miR-223 and miR-217 
were down-regulated (Fig. 3). Members of the let-7 family have been shown to target c-myc 
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expression in Burkitt lymphoma (Sampson et al. 2007) and decreased c-myc expression has 
been associated with high grade transformation of FL to DLBCL (Lossos et al. 2002). 
Interestingly, up-regulated microRNAs miR-221 and miR-222 target the tumor suppressor 
molecule p27(Kip1) (le Sage et al. 2007) whilst down-regulated miR-223 has been shown to 
target Stathmin, a known oncogene (Alli et al. 2007). Although the number of cases in this 
analysis was small, and requires further validation, these data open up the exciting 
possibility that microRNA expression could be used to predict FL patients at risk of 






Fig. 3. Expression levels of microRNAs differentially expressed between FL-t and FL-nt 
cases. P values were calculated by independent t-test. Reproduced from (Lawrie et al. 2009). 
5. Conclusion 
In this chapter we have discussed some of the clinico-scientific issues pertaining to follicular 
lymphoma and the role that microRNAs may play in both its pathogenesis and in particular 
histological high grade transformation. As is outlined in this article there are in fact only two 
pieces of research published to date that have investigated microRNA expression in FL, and 
hence some caution should be applied when drawing conclusions about the role/potential 
of specific microRNAs in this disease, as clearly much more research is required. 
Nonetheless, these studies do present some interesting insights and offer the tantalizing 
possibility that microRNAs may deliver novel biomarkers that can identify FL patients at 
risk of transformation where other molecular techniques have failed. 
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1. Introduction 
In 1958, Denis Burkitt described B cell lymphomas in 2- to 14-year-old African children from 
malaria-endemic areas.1 In 1964, Michael Anthony Epstein and Yvonne Barr found that 
immortalized B lymphocyte cell lines derived from these tumors spontaneously released a 
herpesvirus.2 Thus, Epstein-Barr virus (EBV) was discovered by examining electron 
micrographs of cells cultured from Burkitt’s lymphoma; its unusual geographic distribution 
indicated a viral etiology. It was Gertrud and Werner Henle who demonstrated that EBV is 
ubiquitous in the human population.3 Far from having a restricted distribution, EBV, a 
member of the -herpesvirus family, was found to be widespread in all human populations 
and to persist in the vast majority of individuals as a lifelong, asymptomatic infection of B 
lymphocytes. Therefore, EBV is usually the cause of clinically inconspicuous infections, 
although it can cause infectious mononucleosis. The most severe, albeit rare, result of EBV 
infection is malignant transformation and the development of cancer in various forms, 
including Burkitt’s lymphoma and nasopharyngeal carcinoma, the latter of which is one of 
the most common cancers in China.4 The link between EBV and “endemic” Burkitt’s 
lymphoma proved constant and became the first of an unexpectedly wide range of 
associations discovered between this virus and tumors.5 As a ubiquitous human pathogen, 
EBV is responsible for several lymphoid malignancies, including a subset of Burkitt’s 
lymphoma, acquired Immune deficiency syndrome (AIDS)-associated lymphoma, 
Hodgkin’s lymphoma, post-transplant lymphoma, age-associated B cell lymphoma, and 
peripheral T and NK cell lymphomas.6,7 
1.1 EBV infection 
The primary site of EBV infection is the oropharyngeal cavity.8 Children and teenagers are 
often infected after oral contact, hence the nickname “kissing disease”. Like other 
herpesviruses, infection with EBV can exhibit two distinct patterns, or states, of gene 
expression. During acute (lytic) EBV infection, the virus sequentially expresses its entire 
repertoire of genes. In this lytic state, linear, double-stranded viral genomes are produced 
and packaged into virions that spread infection from cell to cell. Shortly after the initial 
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micrographs of cells cultured from Burkitt’s lymphoma; its unusual geographic distribution 
indicated a viral etiology. It was Gertrud and Werner Henle who demonstrated that EBV is 
ubiquitous in the human population.3 Far from having a restricted distribution, EBV, a 
member of the -herpesvirus family, was found to be widespread in all human populations 
and to persist in the vast majority of individuals as a lifelong, asymptomatic infection of B 
lymphocytes. Therefore, EBV is usually the cause of clinically inconspicuous infections, 
although it can cause infectious mononucleosis. The most severe, albeit rare, result of EBV 
infection is malignant transformation and the development of cancer in various forms, 
including Burkitt’s lymphoma and nasopharyngeal carcinoma, the latter of which is one of 
the most common cancers in China.4 The link between EBV and “endemic” Burkitt’s 
lymphoma proved constant and became the first of an unexpectedly wide range of 
associations discovered between this virus and tumors.5 As a ubiquitous human pathogen, 
EBV is responsible for several lymphoid malignancies, including a subset of Burkitt’s 
lymphoma, acquired Immune deficiency syndrome (AIDS)-associated lymphoma, 
Hodgkin’s lymphoma, post-transplant lymphoma, age-associated B cell lymphoma, and 
peripheral T and NK cell lymphomas.6,7 
1.1 EBV infection 
The primary site of EBV infection is the oropharyngeal cavity.8 Children and teenagers are 
often infected after oral contact, hence the nickname “kissing disease”. Like other 
herpesviruses, infection with EBV can exhibit two distinct patterns, or states, of gene 
expression. During acute (lytic) EBV infection, the virus sequentially expresses its entire 
repertoire of genes. In this lytic state, linear, double-stranded viral genomes are produced 
and packaged into virions that spread infection from cell to cell. Shortly after the initial 
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infection, EBV enters into a latent state, whereupon only select “latent” genes are expressed, 
thereby evading host immune surveillance mechanisms, and establishing a lifelong, 
persistent infection in the host.9 During latency, only a few viral genes are transcribed, no 
viral progeny are produced, and infected cells are protected from apoptotic stimuli and, in 
some circumstances, driven to proliferate. Based on serology, about 95% of the world’s adult 
population is infected with EBV, and following primary infection, hosts remain lifelong 
carriers of the virus.10 In developed countries, exposure to EBV occurs relatively late; only 
50–70% of adolescents and young adults are EBV seropositive. About 30% of seronegative 
individuals will later develop infectious mononucleosis as a result of primary EBV infection. 
This disease is characterized by fever, pharyngitis, generalized lymphadenopathy, 
splenomegaly, intense asthenia, hyper-lymphocytosis (>50%) with atypical lymphocytes, 
and elevated transaminase levels. In developing countries, EBV antibodies are acquired 
early in life and the disease is mostly asymptomatic. 
1.2 EBV-related cancer 
EBV has been etiologically linked to a variety of human cancers, such as Burkitt’s 
lymphoma, nasopharyngeal carcinoma (NPC), Hodgkin’s disease, and more recently with 
sporadic cases of gastric adenocarcinoma and invasive breast carcinoma.11,12 Nearly 100% of 
NPC tumors, 90% of Burkitt’s lymphoma tumors of African origin, and 40–60% of 
Hodgkin’s and non-Hodgkin’s lymphomas contain EBV episomes. Clonality of the EBV 
genome has been confirmed in these tumors, suggesting that the tumors arose from a single 
EBV-infected cell, and that EBV infection is a very early, if not causal, event. EBV is also 
commonly associated with lymphoproliferative diseases in patients with congenital or 
acquired immunodeficiencies. Examples include X-linked lymphoproliferative syndrome, 
human immunodeficiency virus (HIV)-related non-Hodgkin’s lymphoma, and perhaps 
most importantly post-transplantation lymphoproliferative disease.5 
Burkitt’s lymphoma is a malignant tumor associated with EBV that is endemic to central 
parts of Africa and New Guinea with an annual incidence of 6–7 cases per 100,000 and a 
peak incidence in children of 6 or 7 years of age. The epidemiological involvement of EBV in 
Burkitt’s lymphoma was first suspected due to the presence of the EBV viral genome in 
tumor cells and elevated antibody titers against EBV viral capsid antigen in cancer patients. 
The highest prevalence of Burkitt’s lymphoma occurs in the “lymphoma belt,” a region that 
extends from West Africa to East Africa, between the 10th degree north and 10th degree 
south of the equator, and continues south along the eastern coast of Africa. This area is 
characterized by high temperature and humidity, which is likely the reason why an 
association between malaria and Burkitt’s lymphoma was once suspected. In African 
countries within the lymphoma belt, such as Uganda, the association of Burkitt’s lymphoma 
with EBV is very strong (97%), whereas it is less so elsewhere (e.g., 85% in Algeria and 10–
15% in France and the USA). (World Health Organization, WHO) 
NPC incidence rates are less than 1 per 100,000 in most populations, except for those in 
southern China, where an annual incidence of more than 20 cases per 100,000 is reported.4 
Isolated northern populations, such as Eskimos and Greenlanders, also have high 
incidences. Moderate incidences occur in North Africa, Israel, Kuwait, the Sudan, and parts 
of Kenya and Uganda. Men are twice as likely to develop NPC as women. The rate of 
incidence generally increases at ages 20–50 years. In the USA, Chinese-Americans comprise 
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the majority of NPC patients, along with workers exposed to fumes, smoke, and chemicals, 
implicating a role for chemical carcinogenesis. Studies assessing nutrition and diets have 
demonstrated an association between eating highly salted foods and NPC. Vitamin C 
deficiency at a young age may also be a contributing factor. Finally, a study of human 
leukocyte antigen (HLA) haplotypes revealed a genetically distinct subpopulation in 
southern China, with an increased frequency of haplotype A-2/B-Sin-2, which may account 
for the higher disease incidence in that area. (WHO) 
1.3 Cytotoxic T lymphocyte therapy for EBV-related cancer 
EBV, together with human herpesvirus (HHV)-8 (also known as Kaposi sarcoma-associated 
virus), belongs to the genus Lymphocryptovirus in the subfamily Gammaherpesvirinae of the 
family Herpesviridae. These are complex, enveloped, DNA viruses, which multiply in the 
nucleus of the host cell. EBV infects resting human B lymphocytes and epithelial cells, 
multiplies in the latter, and establishes latent infection in memory B lymphocytes. Thus, 
infected individuals may produce virions, carry virus-specific cytotoxic T lymphocytes 
(CTLs), produce EBV-specific antibodies, and yet harbor latently infected memory B cells. 
EBV-infected individuals maintain the latent EBV genome as an episome that expresses only 
part of its genetic information, including EBV nuclear antigens (EBNA)-1 (a latent DNA 
replication factor), EBNA-2 (a transcriptional activator), and EBNA-3A and -3C (involved in 
the establishment of latency). Also expressed are latent membrane protein (LMP)-1 and 
LMP-2, which play major roles in the maintenance of latency and escape from the host 
immune response. Latently infected cells do not express the B7 coactivator receptor and, 
therefore, are not targeted by CTLs. When peripheral blood from an infected individual is 
cultured, latently infected B cells replicate and become immortalized lymphoblasts that can 
be indefinitely propagated in the laboratory.13 
In a previous study, CTL therapy was proven to be safe and effective as a treatment for 
patients with EBV-related cancers, and was found to enable the complete remission of patients 
who failed all previous standard treatments. The first clinical trials using EBV-specific CTLs 
tested their utility for both prophylaxis and treatment of post-transplant lymphoproliferative 
diseases arising in stem cell transplant or solid organ transplant recipients.5 
Nucleoside analogs, such as acyclovir (ACV) and ganciclovir (GCV), are often used as 
antiviral drugs against acute EBV and other herpesvirus infections.14 The virally encoded 
thymidine kinase enzyme converts these analogs into their phosphate forms, which, after 
conversion into their triphosphate form by host kinases, are then incorporated into newly 
synthesized DNA, leading to the premature termination of DNA synthesis and apoptosis of 
the infected cell. The EBV thymidine kinase, however, is only expressed during lytic 
replication of the virus. Because EBV maintains a latent state of replication in all EBV-
associated malignancies, nucleoside analog drugs have very limited, or no, cytopathic effect 
on virus-infected cells. Novel therapeutic approaches to target EBV-infected tumor cells, 
which include inducing lytic replication of EBV followed by treatment with nucleoside 
analogs, have been proposed. 
Arginine butyrate induces the expression of the viral thymidine kinase gene in EBV-
positive, immunoblastic, non-Hodgkin’s lymphoma cell lines and lymphoblastic cell lines 
(LCLs) and acts synergistically with GCV to inhibit cell proliferation and decrease cell 
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viability.15 Various other agents have also been used to induce lytic replication of the EBV 
genome. For example, treatment of EBV-positive lymphoblastoid cells, or primary central 
nervous system lymphoma, with γ-irradiation promotes GCV-susceptibility of target cells.15 
Other studies successfully used 5-azacytidine, gemcitabine, doxorubicin, or a combination of 
anti-CD20 monoclonal antibody (Rituximab) and dexamethasone to induce lytic-phase gene 
expression and sensitize EBV-infected tumor cells to GCV or other nucleoside analogs.15 
Butyric acid, a short-chain fatty acid, and its derivatives have been experimentally 
employed in attempts to treat leukemias and other diseases. Butyrate induces the expression 
of certain EBV lytic proteins, including the thymidine kinase enzyme, from latent EBV-
infected cells.16 The inhibitory effect of butyrate on histone deacetylase (HDAC) is required 
for this effect. In previous clinical studies, systemic administration of arginine butyrate was 
used to induce expression of the latent EBV thymidine kinase in the tumors of patients with 
EBV-positive post-transplantation lymphoproliferative disease or non-Hodgkin’s 
lymphomas, followed by treatment with GCV.16,17   
Bortezomib, a proteasome inhibitor, also activates EBV lytic gene expression.18 Bortezomib 
leads to increased levels of CCAAT/enhancer-binding protein β (C/EBPβ) in a variety of 
tumor cell lines.18 C/EBPβ activates the promoter of the EBV lytic switch gene ZTA (BZLF1). 
Bortezomib treatment leads to increased binding of C/EBP to sites within the ZTA 
promoter. Knockdown of C/EBPβ inhibits bortezomib activation of EBV lytic gene 
expression.18 Bortezomib also induces the unfolded protein response (UPR). Thapsigargin, 
an inducer of the UPR that does not interfere with proteasome function, also induces EBV 
lytic gene expression.18,19 The effect of thapsigargin on EBV lytic gene expression is also 
inhibited upon C/EBPβ knock-down.18 Therefore, C/EBPβ mediates the activation of EBV 
lytic gene expression associated with bortezomib and thapsigargin.18 
Pretreatment of naturally infected EBV tumor cell lines (from Burkitt’s lymphoma and 
gastric carcinoma) with bortezomib activates viral gene expression.20 Marked changes in 
tumor growth are also achieved in naturally infected Kaposi’s sarcoma herpesvirus tumors 
after pretreatment with bortezomib.20 Bortezomib-induced, enzyme-targeted radiation 
therapy illustrates the potential of pharmacological modulation of tumor gene expression 
for targeted radiotherapy. 
There is increasing interest in the pharmacologic activation of lytic viral gene expression in 
tumors. Several therapeutic strategies requiring activation of EBV lytic genes for tumor cell 
lysis have been described, but concerns have been raised about the possible adverse effects 
of viral gene activation patients treated with pharmacologic activators. 
2. EBV-encoded miRNA 
2.1 miRNA 
Micro (mi)RNAs are small, non-coding, single-stranded RNAs of approximately 21 to 25 
nucleotides (nt) in length. They post-transcriptionally regulate mRNA expression in animals 
and plants and are transcribed from the non-coding regions of genes in all multi-cellular 
organisms and certain viruses and are often phylogenetically conserved across species.21,22 
EBV was the first human virus found to encode miRNA.23 EBV encodes 44 viral miRNAs 
and a small RNA. EBV-encoded miRNAs are located within the BHRF1 and BamHI A 
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rightward transcript (BART) loci of the EBV genome. The BHRF1 cluster of miRNAs 
includes BHRF1-1, BHRF1-2, BHRF1-3, and BHRF1-4.22-24 The other EBV-encoded miRNAs 
are encoded by BART cluster 1 and BART cluster 2, except miR-BART2, which is expressed 
from a sight outside of the BART clusters.22-25 miRNAs bind to the 3’ untranslated region 
(UTR) of mRNA and interfere with their translation, leading to downregulated protein 
expression levels. EBV-encoded miRNAs have been found in various EBV-associated 
carcinomas and lymphomas, such as NPC, gastric carcinoma, diffuse large B cell lymphoma, 
nasal NK/T cell lymphoma, and Hodgkin’s lymphoma.23,26 Viral miRNAs play vital roles in 
immunogenesis, host cell survival and proliferation, differentiation, lymphomagenesis, and 
regulation of viral infection and latency.23,27-29 
2.2 EBV miRNA-mediated regulation of viral infection states 
During lytic infection, EBV genomes are amplified into 1000 copies per cell with the help of 
replication proteins.30 EBV expresses six replication proteins, the most important of which are 
BZLF1 and BALF5. BALF5 is a catalytic DNA polymerase encoded by the balf5 gene during 
lytic infection;30 it is not present in latent infection. This DNA polymerase is a single-stranded 
DNA binding protein, which functions within viral replication factories in the nucleus, likely 
generating replication forks on the replicating EBV genome. EBV-encoded miR-BART2 is 
expressed at low levels during latency, prevents aberrant expression of BALF5 mRNA, and 
prevents inadvertent viral replication.31 The sequence of miR-BART2 is perfectly 
complementary to the 3’UTR of BALF5 mRNA. Therefore, miR-BART2 serves as an inhibitor 
of viral DNA replication through the degradation of BALF5 mRNA. The miRNA-guided 
cleavage of mRNA requires an association with Ago2,32 which is a member of the Argonuate 
family of proteins and a part of the RNA-induced silencing complex (RISC). Upon its 
association with Ago2, miR-BART2 guides the sequence-specific cleavage of BALF5 mRNA. 
This miR-BART2-guided cleavage is substantially reduced after induction of the lytic cycle in 
EBV-infected cells.31 The amount of miR-BART2 is reduced during lytic infection, and this 
causes a de-repression of BALF5 protein expression.31 However, it is unclear whether the miR-
BART2-mediated regulation of viral replication is fully controlled by BALF5 protein or not. 
Another regulator of the shift from EBV latency to lytic infection is miR-BART6, which itself 
is regulated by RNA editing.33 Editing of the wild-type primary (pri)-miR-BART6 sequence 
dramatically reduces the loading of miR-BART6-5p onto RISC, without affecting the 
processing of precursor (pre) or mature miRNAs.33 Editing of pri-miRNA might affect the 
selection and loading of the guide strand onto RISC.34 miR-BART6-5p silences Dicer through 
multiple target sites located in the 3’UTR of Dicer mRNA, but miR-BART6-3p is unable to 
perform this function.33 
In EBV-infected human cells, Dicer protein levels are substantially reduced by miR-BART6-
5p,33 suggesting that miR-BART6-5p may indirectly regulate the biogenesis of all miRNAs. It 
may even affect the latency of EBV by modulating the expression of viral proteins, including 
EBNA2, LMP1, RTA, and ZTA. EBNA2 is required for the transition from the less 
immunologically confrontational type I or type II latency to the more immunity-stimulating 
type III latency, which occurs through the upregulation of all latent EBV genes and the 
transformation of infected B lymphocytes.35,36 However, EBNA2 deficiency is observed in type 
I and type II latency.35,36 Low-level expression of LMP1 is also observed in type II latency, but 
is absent in type I. LMP1 controls the NF-B signaling pathway and the growth and apoptosis 
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of host cells. RTA and ZTA proteins initiate lytic infection of EBV. Thus, it is clear that miR-
BART6-5p regulates EBV infection and latency by suppressing RTA and ZTA protein 
expression. To modulate protein expression, miR-BART6-5p downregulates viral promoters, 
such as Cp and Wp, which are characteristic of type III latency, and reduces transcriptional 
activity via its silencing effect on Dicer. Mutation and adenosine-to-inosine (A-to-I) editing are 
adaptive mechanisms that antagonize miR-BART6 activities and affect the latent state of viral 
infection.33 Therefore, we conclude that miR-BART6-5p, and its mutant or edited versions, are 
critical for the establishment and maintenance of latent EBV infection. 
2.3 EBV miRNA-mediated host cell survival 
The miR-BART5 miRNA promotes host cell survival by regulating the p53 upregulated 
modulator of apoptosis (PUMA) protein.37 PUMA is an apoptotic protein belonging to the 
“BH3-only” group of the Bcl-2 family and is encoded by the BBC3 gene.38-40 PUMA is 
regulated by the tumor suppressor p53 and is involved in both p53-mediated and non-
mediated apoptosis via independent signaling pathways. PUMA is an important downstream 
regulator of p53, both of which are master regulators of host cell growth and apoptosis. PUMA 
function is downregulated or absent in cancer cells, but the absence of PUMA activity alone is 
not sufficient for the spontaneous formation of malignancies.41-45 PUMA has four isoforms (i.e., 
, , , and ), which share the same 3’UTR.39 Only PUMA- and PUMA- have pro-apoptotic 
activity. The PUMA 3’UTR sequence is perfectly complementary to miR-BART5. Thus, 
binding of miR-BART5 and the PUMA 3’UTR suppresses the expression of the pro-apoptotic 
protein. PUMA- protein expression is also reduced by pre-miR-BART5.37 Abundant 
expression of miR-BART5 in NPC cells is correlated with significant downregulation of PUMA 
in 60% of NPC tissues.37 By this mechanism, miR-BART5 induces anti-apoptotic activity in 
NPC cells, EBV-infected gastric carcinoma cells, and EBV-infected epithelial cells.37 Therefore, 
miR-BART5 may be a good target for anti-cancer therapy in EBV-infected cancer cells. 
LMP1 is a viral protein expressed during the type III latency period of EBV infection.35,36 
LMP1 promotes cell growth, resistance to serum deprivation-induced apoptosis, and 
phenotypic changes in epithelial cells and B cell transformation. It activates the NF-B, JNK, 
JAK/STAT, p38/MAP, and RAS/MAPK pathways and regulates host gene expression.5 NF-
B transcription factors influence proliferation, apoptosis, oncogenesis, and inflammation.46 
Low levels of LMP1 activate NF-B, but with increasing amounts of LMP1, NF-B activation 
reaches a plateau, after which small increases in LMP1 reduces NF-κB activity.47 Thus, a 
threshold level of LMP1 can maintain peak NF-B activity. LMP1 regulates the level of NF-
B activity by modulating the UPR pathway and autophagy. BARTI cluster miRNAs 
negatively regulate LMP1 expression, limiting inappropriately high levels, thereby 
preventing apoptosis that would otherwise result from LMP1-mediated changes in the UPR. 
Such BART1 cluster miRNAs include BART16, BART17-5p, and BART1-5p, which target 
sites within the 3’UTR of LMP1 mRNA.47 These miRNAs regulate LMP1 expression at the 
post-transcriptional level, regulating NF-B-mediated gene expression. Therefore, the 
negative regulation of LMP1 expression by BART1 cluster miRNAs may affect EBV-
associated cancer development by balancing the effect of LMP1 on cellular proliferation. 
BHRF1 is a latent protein expressed in growth-transformed cells that contributes to virus-
associated lymphomagenesis.48 miR-BHRF1 downregulates this protein, modulates cell 
transformation,49 and promotes B cell proliferation after EBV infection. EBV-infected B cells 
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lacking miR-BHRF1 progress less efficiently into the cell cycle and eventually die by 
apoptosis.49 miR-BHRF1 is constitutively expressed in LCLs.49 Without miR-BHRF1, the 
proportion of G1/G0 cells increases while the numbers of S-phase cells decreases,49 
indicating a definite role of miR-BHRF1 in the control of proliferation of latently infected 
cells. miR-BHRF1 acts at a stage of the EBV life cycle when multiple EBV-encoded 
oncogenes become activated. 
2.4 EBV-encoded miRNAs regulate immune evasion 
Major histocompatibility complex (MHC) class I polypeptide-related sequence B (MICB) 
protein is a ligand for the NKG2D type II receptor, which is a stress-induced immune 
molecule.50,51 B cells and endothelial cells, which are targets of EBV, both express this 
protein. Binding of MICB activates NK, CD8+ , and  T cells.52 MICB is upregulated at 
the cell surface due to various insults, such as viral infection, tumor transformation, heat 
shock, and DNA damage. Thus, it would be beneficial for a virus to downregulate the 
expression of this protein ligand to avoid immune detection. Previous studies have shown 
that downregulated MICB expression leads to reduced lysis of infected cells by NK cells.53 
EBV-expressed miR-BART2-5p has potential binding sites in the MICB mRNA 3’UTR.54 EBV 
downregulates MICB via miR-BART2-5p, resulting in decreased NK cell-mediated lysis, to 
avoid detection by immune cells. 
miR-BHLF1-1 is expressed from the 5’UTR, and miR-BHLF1-2 and miR-BHLF1-3 are 
expressed from the 3’UTR, of the bhrf1 gene in EBV-infected cells.28 miR-BHLF1-3 is 
markedly elevated in EBV-infected, type III latent cell lines28 and is also detected in EBV-
positive primary effusion lymphoma and AIDS-related diffuse large B cell lymphoma.28 
BHRF1 miRNA is characteristic of EBV type III latent infections.55 EBV miR-BHRF1-3 
regulates host immunity by downregulating the interferon (IFN)-inducible T cell attracting 
chemokine (I-TAC; also known as CXCL-11). CXCL-11/I-TAC belongs to the CXC family of 
chemokines, and both IFN-β and IFN-γ strongly induce its transcription.56 CXCL-11/I-TAC 
promotes cell-mediated immunity by attracting activated T cells. The 3’UTR of CXCL-11/I-
TAC mRNA is 100% complementary to the sequence of miR-BART1-3 and, therefore, serves 
as a target of miR-BART1-3. miR-BART1-3 inversely regulates the expression of CXCL-11/I-
TAC; the anti-sense sequence of miR-BART1-3 has the reverse effect.23 miR-BART1-3 
significantly reduces the expression of CXCL-11/I-TAC at both the mRNA and protein 
levels.28 Thus, as cellular chemokines can be targets of viral miRNA, EBV-mediated 
regulation of antigen processing and presentation, and the downregulation of CTL cytokine 
networks, may occur through such a mechanism. 
2.5 Small nucleolar RNAs encoded by the EBV genome 
A small nucleolar (sno)RNA, named v-snoRNA1, has been identified within the EBV 
genome in EBV-infected B lymphocytes.57 snoRNAs, 60–300 nt in length, guide nucleotide 
modifications of ribosomal (r)RNAs, i.e., 2’O-ribose methylation or pseudouridylation, that 
are located in subnuclear compartments.58,59 snoRNAs are subdivided into the C/D box and 
H/ACA box classes. The majority of snoRNAs located within introns of protein-encoding 
genes are processed by splicing, followed by endo- and exonucleolytic cleavage.60-62 
However, some of them are orphan snoRNAs that lack rRNA or small modulatory 
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of host cells. RTA and ZTA proteins initiate lytic infection of EBV. Thus, it is clear that miR-
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miR-BART5 may be a good target for anti-cancer therapy in EBV-infected cancer cells. 
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B transcription factors influence proliferation, apoptosis, oncogenesis, and inflammation.46 
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preventing apoptosis that would otherwise result from LMP1-mediated changes in the UPR. 
Such BART1 cluster miRNAs include BART16, BART17-5p, and BART1-5p, which target 
sites within the 3’UTR of LMP1 mRNA.47 These miRNAs regulate LMP1 expression at the 
post-transcriptional level, regulating NF-B-mediated gene expression. Therefore, the 
negative regulation of LMP1 expression by BART1 cluster miRNAs may affect EBV-
associated cancer development by balancing the effect of LMP1 on cellular proliferation. 
BHRF1 is a latent protein expressed in growth-transformed cells that contributes to virus-
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lacking miR-BHRF1 progress less efficiently into the cell cycle and eventually die by 
apoptosis.49 miR-BHRF1 is constitutively expressed in LCLs.49 Without miR-BHRF1, the 
proportion of G1/G0 cells increases while the numbers of S-phase cells decreases,49 
indicating a definite role of miR-BHRF1 in the control of proliferation of latently infected 
cells. miR-BHRF1 acts at a stage of the EBV life cycle when multiple EBV-encoded 
oncogenes become activated. 
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Major histocompatibility complex (MHC) class I polypeptide-related sequence B (MICB) 
protein is a ligand for the NKG2D type II receptor, which is a stress-induced immune 
molecule.50,51 B cells and endothelial cells, which are targets of EBV, both express this 
protein. Binding of MICB activates NK, CD8+ , and  T cells.52 MICB is upregulated at 
the cell surface due to various insults, such as viral infection, tumor transformation, heat 
shock, and DNA damage. Thus, it would be beneficial for a virus to downregulate the 
expression of this protein ligand to avoid immune detection. Previous studies have shown 
that downregulated MICB expression leads to reduced lysis of infected cells by NK cells.53 
EBV-expressed miR-BART2-5p has potential binding sites in the MICB mRNA 3’UTR.54 EBV 
downregulates MICB via miR-BART2-5p, resulting in decreased NK cell-mediated lysis, to 
avoid detection by immune cells. 
miR-BHLF1-1 is expressed from the 5’UTR, and miR-BHLF1-2 and miR-BHLF1-3 are 
expressed from the 3’UTR, of the bhrf1 gene in EBV-infected cells.28 miR-BHLF1-3 is 
markedly elevated in EBV-infected, type III latent cell lines28 and is also detected in EBV-
positive primary effusion lymphoma and AIDS-related diffuse large B cell lymphoma.28 
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chemokine (I-TAC; also known as CXCL-11). CXCL-11/I-TAC belongs to the CXC family of 
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TAC; the anti-sense sequence of miR-BART1-3 has the reverse effect.23 miR-BART1-3 
significantly reduces the expression of CXCL-11/I-TAC at both the mRNA and protein 
levels.28 Thus, as cellular chemokines can be targets of viral miRNA, EBV-mediated 
regulation of antigen processing and presentation, and the downregulation of CTL cytokine 
networks, may occur through such a mechanism. 
2.5 Small nucleolar RNAs encoded by the EBV genome 
A small nucleolar (sno)RNA, named v-snoRNA1, has been identified within the EBV 
genome in EBV-infected B lymphocytes.57 snoRNAs, 60–300 nt in length, guide nucleotide 
modifications of ribosomal (r)RNAs, i.e., 2’O-ribose methylation or pseudouridylation, that 
are located in subnuclear compartments.58,59 snoRNAs are subdivided into the C/D box and 
H/ACA box classes. The majority of snoRNAs located within introns of protein-encoding 
genes are processed by splicing, followed by endo- and exonucleolytic cleavage.60-62 
However, some of them are orphan snoRNAs that lack rRNA or small modulatory 
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(sm)RNA targets. v-snoRNA is processed into 24 nt long miRNAs, which then target the 
3’UTR of viral DNA polymerase mRNA. 
The v-snoRNA1 gene is located within the BART sense stand of the EBV genome.57 Both v-
snoRNA1 and miR-BART2 arise from the same intron. Although v-snoRNA1 is an integral 
part of the EBV latent transcription program, it is highly expressed during lytic infection. 
The 3’UTR of the BHLF5 mRNA is fully complementary to v-snoRNA1, so v-snoRNA1 
binds and cleaves BALF5 mRNA, enabling its exonucleolytic degradation.57 It is unclear 
whether v-snoRNA1 serves an important function during the viral life cycle. 
3. Editing and mutation of EBV-encoded miRNAs 
Recently widespread RNA-DNA differences in the human transcriptome were found. It also 
occurs to miRNAs including EBV-encoded miRNAs.63 
3.1 RNA editing 
RNA editing is carried out by enzymes that target mRNA post-transcriptionally, such as 
adenosine deaminases that act on RNA (ADARs, which convert adenosine to inosine, which 
is subsequently recognized by translation machinery as a guanosine, i.e., A-to-G mutation) 
and apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC) proteins, 
which convert cytidine to uridine (i.e., C-to-U mutation). Editing of pri-miR-142, the 
primary transcript form of miR-142 that is expressed in hematopoietic tissues, results in 
suppression of its processing by Drosha.64 The mutated pri-miR-142 is degraded by Tudor-
SN, a component of RISC and also a ribonuclease that is specific to inosine-containing 
double-stranded (ds)RNAs. Mature miR-142 is substantially upregulated in ADAR1- or 
ADAR2-null mice,64 demonstrating that RNA editing helps control miRNA biogenesis. 
Kawahara et al. found that primary transcripts of certain miRNA genes are subject to RNA 
editing that converts adenosine to inosine. By way of ADAR, tissue-specific A-to-I editing of 
miR-376 cluster transcripts lead to the predominant expression of edited miR-376 isoform 
RNAs. One highly edited site is located in the middle of the 5'-proximal “seed” region of 
miR-376 critical for its hybridization to its targets, providing evidence that the mutated miR-
376 specifically targets a set of genes that is different than those targeted by wild-type miR-
376.65 Mutated miR-376 represses phosphoribosyl pyrophosphate synthetase 1, an enzyme 
involved in the uric-acid synthesis pathway. 
Iizasa et al. reported that the primary transcripts of four EBV miRNAs, including miR-
BART6, are subject to A-to-I editing. Moreover, it was demonstrated that editing of pri-miR-
BART6, as well as mutations of miR-BART6, found in latently EBV-infected cells prevented 
its loading onto functionally active RISC.33 As mentioned, miR-BART6 targets Dicer and 
affects the latent state of EBV viral infection. Therefore, regulation of miR-BART6 expression 
and function through A-to-I editing may be critical for the establishment or maintenance of 
latent EBV infection. 
3.2 Mutation of the EBV genome affects encoded miRNAs 
Sequence variation in the EBV genome has been extensively studied for a long time; in 
particular, BLRF1 and other genes have been reported to have sequence variation in EBV-
infected cancer patients.66 Mechanistic analysis of this sequence variability has recently been 
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reported by Suspène et al.67 Human APOBEC3 cytidine deaminases target and edit single-
stranded DNA, which can be of viral, mitochondrial, or nuclear origin. Retroviral genomes, 
such those of HIV, deficient in the vif gene, and hepatitis B virus, are particularly vulnerable. 
The genomes of DNA viruses, such as herpesviruses, are also subject to editing. This is the 
case for herpes simplex virus type 1 (HSV-1), at least in tissue culture, where APOBEC3C 
(A3C) overexpression reduces viral titers and the particle/plaque forming unit (PFU) ratio 
by approximately 10-fold. A3A, A3G, and activation-induced cytidine deaminase (AICDA) 
can edit what is thought to be a small fraction of HSV genome in an experimental setting 
without seriously impacting viral titers. Hyper-editing was found to occur in HSV genomes 
recovered from four of eight uncultured buccal lesions, but the phenomenon was not 
restricted to HSV; hyper-mutated EBV genomes were readily recovered from four of five 
established cell lines, indicating that episomes are also vulnerable to editing 67. These 
findings suggest that the widely expressed A3C cytidine deaminase can function as a 
restriction factor for some human herpesviruses. 
Other studies reported sequence variation in BART miRNAs.68 The significance of these 
mutations and their effect on miRNA processing, as well as the mechanism of mutation, 
whether it is mediated by A3C, members of other APOBEC families, or other mechanisms, 
have yet to be determined. 
4. Regulation of EBV-encoded miRNA processing 
4.1 Processing of miRNAs under normal versus cancerous conditions 
The mechanism of miRNA biosynthesis involves sequential endonucleolytic cleavages 
mediated by two RNase III enzymes, Drosha and Dicer (Fig.1 ). Following transcription by 
RNA pol II, Drosha processes the primary miRNA transcript (pri-miRNA) into a 60–100 nt 
hairpin structure, termed the precursor miRNA (pre-miRNA), in the nucleus (Fig. 1). 
Following cleavage by Drosha, the pre-miRNA is transported out of the nucleus through an 
interaction with Exportin-5 and Ran-GTP. Then, the pre-miRNA undergoes further 
processing catalyzed by Dicer (Fig. 1). This cleavage event gives rise to an approximately 22 
nt dsRNA product containing the mature miRNA guide strand and the miRNA* passenger 
strand (Fig. 1). Then, the mature miRNA guide strand is loaded onto the RISC, while the 
passenger strand is degraded (Fig. 1). 
Although substantial progress has been made in understanding the basic mechanism of 
miRNA biogenesis, less is known about the mechanisms that regulate miRNA biogenesis 
and how these systems might be deregulated during oncogenesis. Several studies have 
reported that various regulatory mechanisms of miRNA biosynthesis are potentially 
involved in carcinogenesis.69 
The tumor suppressor protein p53 was recently found to modulate miRNA processing 
through its association with p68 and Drosha.70,71 Under conditions of DNA damage, several 
miRNAs, such as miR-143 and miR-16, are post-transcriptionally induced. This process 
requires p53, as p53-null HCT116 cells do not induce miRNAs in response to DNA 
damage.72 Co-immunoprecipitation studies have indicated that p53 is present in a complex 
with both Drosha and p68, and the addition of p53 to in vitro pri-miRNA processing assays 
enhances the activity of Drosha. Interestingly, several p53 mutant-containing cells that are 
linked to oncogenesis have low post-transcriptional miRNA expression.72 
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(sm)RNA targets. v-snoRNA is processed into 24 nt long miRNAs, which then target the 
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binds and cleaves BALF5 mRNA, enabling its exonucleolytic degradation.57 It is unclear 
whether v-snoRNA1 serves an important function during the viral life cycle. 
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adenosine deaminases that act on RNA (ADARs, which convert adenosine to inosine, which 
is subsequently recognized by translation machinery as a guanosine, i.e., A-to-G mutation) 
and apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC) proteins, 
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primary transcript form of miR-142 that is expressed in hematopoietic tissues, results in 
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SN, a component of RISC and also a ribonuclease that is specific to inosine-containing 
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BART6, as well as mutations of miR-BART6, found in latently EBV-infected cells prevented 
its loading onto functionally active RISC.33 As mentioned, miR-BART6 targets Dicer and 
affects the latent state of EBV viral infection. Therefore, regulation of miR-BART6 expression 
and function through A-to-I editing may be critical for the establishment or maintenance of 
latent EBV infection. 
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Sequence variation in the EBV genome has been extensively studied for a long time; in 
particular, BLRF1 and other genes have been reported to have sequence variation in EBV-
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reported by Suspène et al.67 Human APOBEC3 cytidine deaminases target and edit single-
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The genomes of DNA viruses, such as herpesviruses, are also subject to editing. This is the 
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(A3C) overexpression reduces viral titers and the particle/plaque forming unit (PFU) ratio 
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without seriously impacting viral titers. Hyper-editing was found to occur in HSV genomes 
recovered from four of eight uncultured buccal lesions, but the phenomenon was not 
restricted to HSV; hyper-mutated EBV genomes were readily recovered from four of five 
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findings suggest that the widely expressed A3C cytidine deaminase can function as a 
restriction factor for some human herpesviruses. 
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mutations and their effect on miRNA processing, as well as the mechanism of mutation, 
whether it is mediated by A3C, members of other APOBEC families, or other mechanisms, 
have yet to be determined. 
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The mechanism of miRNA biosynthesis involves sequential endonucleolytic cleavages 
mediated by two RNase III enzymes, Drosha and Dicer (Fig.1 ). Following transcription by 
RNA pol II, Drosha processes the primary miRNA transcript (pri-miRNA) into a 60–100 nt 
hairpin structure, termed the precursor miRNA (pre-miRNA), in the nucleus (Fig. 1). 
Following cleavage by Drosha, the pre-miRNA is transported out of the nucleus through an 
interaction with Exportin-5 and Ran-GTP. Then, the pre-miRNA undergoes further 
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strand (Fig. 1). Then, the mature miRNA guide strand is loaded onto the RISC, while the 
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Although substantial progress has been made in understanding the basic mechanism of 
miRNA biogenesis, less is known about the mechanisms that regulate miRNA biogenesis 
and how these systems might be deregulated during oncogenesis. Several studies have 
reported that various regulatory mechanisms of miRNA biosynthesis are potentially 
involved in carcinogenesis.69 
The tumor suppressor protein p53 was recently found to modulate miRNA processing 
through its association with p68 and Drosha.70,71 Under conditions of DNA damage, several 
miRNAs, such as miR-143 and miR-16, are post-transcriptionally induced. This process 
requires p53, as p53-null HCT116 cells do not induce miRNAs in response to DNA 
damage.72 Co-immunoprecipitation studies have indicated that p53 is present in a complex 
with both Drosha and p68, and the addition of p53 to in vitro pri-miRNA processing assays 
enhances the activity of Drosha. Interestingly, several p53 mutant-containing cells that are 
linked to oncogenesis have low post-transcriptional miRNA expression.72 
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Biogenesis of miRNA 
 
Fig. 1. Processing machinery of miRNA 
miRNA genes are transcribed by RNA polymerase II or III into long primary (pri) miRNA 
transcripts, processed by the nuclear nuclease Drosha into ~60 bp hairpins termed precursor 
(pre) miRNAs, and further cleaved in the cytosol by the Dicer nuclease into mature 
miRNAs. Mature miRNAs are then incorporated into the multiprotein RNA-induced 
silencing complex (RISC), exerting post-transcriptional repression of target mRNAs, either 
by inducing mRNA cleavage, mRNA degradation or blocking mRNA translation. 
4.2 Processing of EBV-encoded miRNAs 
For EBV-encoded miRNAs, several regulatory processes have been reported68. Almost all of 
the EBV-encoded miRNAs originate from one of three sequence clusters. Two of the three 
clusters of miRNAs are made from the BARTs, a set of alternatively spliced transcripts that 
are highly abundant in NPC, but have not been shown to produce a detectable protein. 
Edwards et al. investigated the mechanism of BART-derived miRNA processing by 
comparing the processed miRNAs with the original BART transcript and residual 
transcripts after processing.68 First, they showed that residual pieces of the intron sequence 
were detectable in the nucleus of cells that express the miRNAs. Characterization of these 
residual pieces indicated that the miRNAs were produced from one large initial transcript 
prior to splicing and that a specific spliced form of the transcript favored the production of 
miRNAs. Second, they found that miR-BART12 is not detected at all, even though the 
primary transcript is abundant. Third, pre-miR-BART5 could be detected in all cell lines and 
tumors tested, despite low or undetectable expression of the mature miR-BART5, indicating 
that the processing of pre-miR-BART5 was inhibited. 
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function target viral Host target
BLHF1-1 transformation BFLF2 LILRB-5,E2F1,p53,CBFA2T2 BHRF1
BLHF1-2 transformation BFLF2 PIK3R1 BHRF1
BLHF1-3 transformation BFLF2 CXCL11,PRF1,TGIF,NSEP1 BHRF1
BART1-5p Cancer development LMP1 CXCL12 BART Cluster1
BART2-5p viral replication BALF5、LMP1 MIC B, Bim
BART3 LMP1 IPO7, Bim BART Cluster1
BART4 LMP1 Bim BART Cluster1
BART5 Host cell survival LMP1 PUMA, Bim BART Cluster1
BART6 maintain viral latency LMP1 Dicer, Bim BART Cluster1









BART16 Cancer development LMP1 TOMM22 BART Cluster1





BART22 LMP2 BART Cluster2  
Table 1. 
Amoroso et al. reported that the levels of the different BART miRNAs vary up to 50-fold 
within a given cell line.73 However, this variation cannot be explained by differential 
miRNA turnover, as all EBV miRNAs appear to be remarkably stable, suggesting that 
miRNA maturation is a key step in regulating steady-state levels of EBV miRNAs. Future 
studies should further investigate the mechanism of miRNA transcript processing in EBV-
infected cells, highlighting any differences between the three types of latent infections. 
5. Secretory EBV-encoded miRNAs 
5.1 Secretory miRNAs 
Cellular and viral miRNAs control gene expression by repressing the translation of mRNAs 
into protein, a process that is tightly regulated in healthy cells, but is deregulated in 
cancerous and virus-infected cells. Curiously, miRNAs are not strictly intracellular, but are 
also secreted through the release of small vesicles called exosomes and, therefore, exist 
extracellularly in the peripheral blood and in cell culture media.74 It has been suggested that 
exosome-associated miRNAs play a role in intercellular communication 74, although 
concrete evidence for this has been lacking. The dynamics of miRNA secretion via exosomes 
and the proposed transfer mechanisms remain poorly understood. In addition, it is unclear 
whether miRNAs are secreted in physiologically relevant amounts. 
5.2 Existence of secretory EBV-encoded miRNAs 
Pegtel et al. were the first to show that exosomes deliver viral miRNAs to non-infected 
cells.75 They used EBV B95.8-immortalized LCLs and demonstrated that exosomes contained 
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Biogenesis of miRNA 
 
Fig. 1. Processing machinery of miRNA 
miRNA genes are transcribed by RNA polymerase II or III into long primary (pri) miRNA 
transcripts, processed by the nuclear nuclease Drosha into ~60 bp hairpins termed precursor 
(pre) miRNAs, and further cleaved in the cytosol by the Dicer nuclease into mature 
miRNAs. Mature miRNAs are then incorporated into the multiprotein RNA-induced 
silencing complex (RISC), exerting post-transcriptional repression of target mRNAs, either 
by inducing mRNA cleavage, mRNA degradation or blocking mRNA translation. 
4.2 Processing of EBV-encoded miRNAs 
For EBV-encoded miRNAs, several regulatory processes have been reported68. Almost all of 
the EBV-encoded miRNAs originate from one of three sequence clusters. Two of the three 
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residual pieces indicated that the miRNAs were produced from one large initial transcript 
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that the processing of pre-miR-BART5 was inhibited. 
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BHRF1 miRNAs, which could target the CXCL11/ITAC gene in nearby uninfected cells. 
Furthermore, they showed that non-B cells in EBV-infected patients with elevated viral 
loads contained EBV miRNAs, demonstrating that exosomes apparently transfer miRNAs in 
vivo to uninfected cells. These findings were confirmed by two studies that demonstrated 
the release of exosomes from NPC cells. Gourzones et al. showed that EBV miR-BARTs 
present within exosomes can be detected in the serum of mice xenografted with human 
NPC cells and that the sera of NPC patients also contain BART miRNAs.76 
6. Concluding remarks 
EBV-related cancers are generally difficult to cure. Despite extensive studies based on well-
known concepts and methods, the molecular basis by which EBV mediates tumorigenesis 
and eludes immunosurveillance remains unclear. Mouse models of EBV-mediated 
lymphoproliferative disease have recently revealed that EBV infection of B cells is necessary, 
but not sufficient, for tumorigenesis, as all peripheral mononuclear cells are needed to 
generate tumors in these mice.77 Immune cells are also indispensable for EBV-mediated 
tumorigenesis . The relationship between these cells and EBV-infected cells with regard to 
tumorigenesis remains unclear. Moreover, the mechanism of drug resistance, which causes 
poor prognosis of EBV-related tumors, has not yet been elucidated. Therefore, it is 
important to study the tumor biology of EBV-related tumors from a fresh perspective, such 
as EBV-encoded miRNAs. 
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1. Introduction  
Lymphoproliferative disorders (LPDs) represent a heterogeneous group of expanding, 
monoclonal or oligoclonal, lymphoid cells that occur in the setting of immune dysfunction. 
They are sometimes equated with "immunoproliferative disorders", but technically LPDs are 
a subset of immunoproliferative disorders, along with hypergammaglobulinemia and 
paraproteinemias. Several inherited gene mutations have been identified to cause 
lymphoproliferative disorders. Acquired and iatrogenic causes are also responsible for the 
appearance of these diseases. 
The most common examples of LPDs are chronic lymphocytic leukemia, acute 
lymphoblastic leukemia, lymphomas/leukemias (including follicular lymphoma and hairy 
cell leukemia) and multiple myeloma, although less common LPDs such as post-transplant 
lymphoproliferative disorder, Waldenström's macroglobulinemia, Wiskott-Aldrich 
syndrome and Autoimmune LymphoProliferative Syndrome (ALPS) also belong to the 
same group of disorders. 
A few basic current facts for the incidence rates, the prognosis and the treatment of the most 
common LPDs will be briefly mentioned in the beginning of this chapter. Following that, the 
recent advances in understanding the pathogenesis of these diseases coming from 
experimental animal studies will be reviewed in a greater detail. After all, understanding 
the mechanisms of neoplasia has always been a prerequisite for developing more effective 
treatments for cancer patients, and the sophisticated animal models available in our days 
have played a major role in enhancing this knowledge. We have developed an animal model 
for Waldenström's macroglobulinemia (WM), which is one of the less common LPDs. This 
will also be presented in detail as an example of the challenges met in developing an animal 
model that should emulate the human disease, or at least important aspects of it. By 
introducing core biopsies of WM patients into immunodeficient mice bearing human bone 
fragments, we established an animal model mimicking important aspects of the disease in 
humans.  
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2. Lymphoproliferative disorders 
2.1 Chronic lymphocytic leukemia  
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in North America 
and Europe; it is less frequent in Asia and Africa (Linet et al., 2006). The reported age-
adjusted incidence rate of CLL in the United States between 1975 and 2006 was 4.43 per 
100,000 persons (Horner et al., 2009). However, because of its long asymptomatic period, the 
incidence of CLL is under-reported in cancer registries (Dores et al., 2007). 
Despite this uncertainty, it is clear that the incidence of CLL rises dramatically with age and 
that it is more common in men than women (Dores et al., 2007; Redaelli et al., 2004). As the 
proportion of older people has increased with improved life expectancy in the Western 
world, the CLL burden has also increased. The American Cancer Society projected 15,490 
new cases for 2009, a substantial increase from the 11,168 new cases reported in 2005 (U.S. 
Cancer Statistics Working group, 2009). The disease burden is also significant in the 
European Union, with an estimated 46,000 individuals in 2006 living with CLL 5 years post-
diagnosis (Watson et al., 2008). 
CLL is characterized by a variable clinical course (Rozman & Montserrat, 1995) with some 
patients having an aggressive malignancy and others a slow, nonprogressive disease and a 
virtually normal life expectancy. Ideally, a detailed diagnostic workup of a CLL case should 
include the identification of standardized and reliable prognostic factors. Predicting the 
outcome of CLL with a statistically significant level of success will provide the basis for 
individualized therapeutic approaches and patient-adjusted disease management policies. 
Indeed, several prognostic factors, including serum (Hallek et al., 1999) and cytogenetic 
alteration markers (Dohner et al., 2000), have been used to assist individual CLL patient 
prognosis. 
2.2 Acute lymphoblastic leukemia 
There are two types of acute leukemia: acute myelogenous leukemia (AML) and acute 
lymphoblastic leukemia (ALL); (Ashfaq et al., 2010). Acute myelogenous leukemia (AML) is 
a clonal, malignant disease of hematopoietic tissue that is characterized by the proliferation 
of abnormal (leukemic) blast cells, principally in the marrow, and by impaired production of 
normal blood cells (Lichtman & Liesveld, 2001). It is the most common acute leukemia 
affecting adults, and its incidence increases with age. AML accounts for nearly one-third of 
all new cases of leukemia (Ashfaq et al., 2010). 
Acute lymphoblastic leukemia is a neoplastic disease that results from somatic mutation in a 
single lymphoid progenitor cell at one of several discrete stages of development. The 
immunophenotype of the leukemic cells at diagnosis reflects the level of differentiation 
achieved by the dominant clone (Pui, 2001). At diagnosis the leukemic cells not only have 
replaced normal marrow cells but have disseminated to various extramedullary sites. 
Studies suggest that the activation of telomerase in leukemic cells contribute to their growth 
advantage and to disease progression (Ohyashiki et al., 1997; Shay et al., 1996). 
ALL represents about 12 percent of all leukemias diagnosed in the US, and 60 percent of all 
cases occur in persons younger than 20 years (SEER, 1998). ALL is the most common 
malignancy diagnosed in patients under the age of 15 years, accounting for one-fourth of all 
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cancers and 76 percent of all leukemias in this age group (Gurney et al., 1996). Data from UK 
showed that there were 691 new cases of ALL and 255 deaths from ALL in 2006 (Cancer 
Research U.K., 2010). Each year, around 3,250 children are diagnosed with leukemia, of 
which about 2,400 are ALL cases (Smith et al., 2000). In the USA, survival rate for children 
with ALL has improved markedly since the early 1970s and is now approximately 80%, but 
incidence rates have not decreased and have, in fact, increased by 0.8% annually from 1975 
to 2007 (SEER, 2010). Worldwide, according to the World Health Organization (WHO), there 
were 33,142 deaths from leukemia among children under age 15 in 2004, and childhood (<15 
years) leukemia caused 1,228,075 disability adjusted life years (WHO, 2010).  
Identifying risk factors for childhood leukemia is an important step in the reduction of the 
overall burden of childhood diseases. Though it has been studied intensively, the etiology of 
childhood leukemia is not well established. A two-hit model was proposed by Greaves in 
which prenatal chromosome alterations and postnatal genetic alterations are necessary for 
childhood leukemia development (Greaves, 2002). Genetic susceptibility and environmental 
factors play potential roles in this process (Eden, 2010). Ionizing radiation has been 
significantly linked to childhood leukemia (Bailey et al., 2010). Evidence for an association 
with benzene exposure or with parental smoking and alcohol consumption is less 
convincing (Liu et al., 2011) . 
Treatment for the majority of ALL subtypes consists of three phases: induction, 
intensification (consolidation) therapy, and continuation (maintenance) treatment. Although 
two-thirds of childhood cases are curable with only 12 months of treatment, the vast 
majority of patients undergo therapy for two years or more (Pui & Evans, 2006). Across 
medical institutions, chemotherapeutic agents used vary in type and amount, with the most 
common being methotrexate (MTX), cytosine arabinoside (cytarabine), anthracyclines (such 
as doxorubicin), asparaginase, mercaptopurine, vincristine, and corticosteroids, presented 
alone or in combination (Pui & Evans, 2006). Leukemic cells are transported by the 
circulatory system to nearly every organ system, including the Central Nervous System 
(CNS). The most common form of CNS prophylaxis was cranial irradiation, or cranial 
radiation therapy (CRT), which has largely been replaced by intrathecal (IT) and systemic 
chemotherapy. This change has been made in an effort to eliminate radiation-specific 
damage to the CNS (Stehbens et al., 1991). Recent regimens have tested whether CRT can be 
eliminated completely from standard treatment. To date, this has been successful, although 
alterations in long-term outcome are just beginning to unfold (Pui et al., 2009). Efforts like 
this are being made to eliminate the possible complications of any form of ALL treatment. 
2.3 Lymphomas/leukemias  
Despite remarkable advances in diagnosis and treatment, lymphoma continues to rank as a 
leading cause of cancer-related mortality. Recent cancer statistics for the United States 
project non-Hodgkin lymphoma (NHL) to be the sixth most commonly diagnosed cancer in 
2010 in both men and women, and the eighth and sixth leading cause of cancer-related 
death in men and women, respectively (Jemal et al., 2010). Based on data from national 
cancer registries, 65,540 new cases of NHL and 20,210 deaths from NHL are estimated to 
occur in 2010. In contrast, Hodgkin lymphoma (HL) is less common (8,490 estimated new 
cases in 2010) and is associated with fewer deaths (1,320 estimated deaths in 2010) (Jemal et 
al., 2010). In the European Union, reported NHL estimates for the year 2006 were even 
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higher, with 72,800 new cases and 33,000 deaths (Ferlay et al., 2007). In the US, on January 1, 
2008, there were approximately 167,000 HL survivors and approximately 454,000 NHL 
survivors (Howlader et al., 2011). In the Nordic European Countries (NEC: Denmark, Faroe 
Islands, Finland, Iceland, Norway, Sweden), there were approximately 10,500 HL survivors 
and approximately 31,500 NHL survivors at the end of 2007 (Engholm et al., 2011). 
Although there are similarities between these subtypes of lymphoma, the incidence and age 
of onset are quite different.  
Onset of the disease occurs most frequently between the ages of 20 and 35 years. Between 35 
and 50 years, it occurs less often especially in females, but from the age of 50 onward there is 
again a rise in incidence with age (Howlader et al., 2011). The disease occurs predominantly 
in individuals aged over 45 years and the lifetime prevalence of NHL is one in 50 (Howlader 
et al., 2011). Due to chemotherapy, radiotherapy and stem cell transplantation, the survival 
of these patients has improved substantially in the seventies and eighties, but has nowadays 
leveled off. In effect, most trials focus on maintaining the high level of cure, while reducing 
the long-term effects of treatment. To date, more than 80% of patients diagnosed with HL 
are expected to live free of disease for 5 years or more after diagnosis (National Cancer 
Institute, 2009) The overall 5-year survival rate for all types of NHL (1999–2005) is 50–60%. 
The statistics vary depending on the cell type, stage of disease at diagnosis, treatment and 
age of the patient (National Cancer Institute, 2009). 
Indolent Non-Hodgkin's lymphoma (NHL) represents a group of incurable slow growing 
lymphomas that are highly responsive to initial therapy but relapse with less responsive 
disease (Ardeshna et al., 2003; Horning, 1993; Johnson et al., 1995; Montoto et al., 2002). The 
landscape for treatment of indolent NHL has dramatically changed with the introduction of 
rituximab (Rituxan, Genetech, San Francisco, CA). Its greatest impact has been in follicular 
lymphoma (FL), which constitutes approximately 70% of indolent lymphomas and up to 
25% of all cases of NHL (Marcus et al., 2005; The Non-Hodgkin's Lymphoma Classification 
Project, 1997). Although there are no defined first line therapies for indolent NHL, rituximab 
has become a standard component in treatment of Follicular Lymphoma (FL) (Friedberg et 
al., 2009). While indolent lymphoma remains an incurable disease, recent data from the 
Surveillance Epidemiology and End Results (SEER) database and retrospective analysis of 
clinical trials in indolent NHL suggest an improved overall survival with the use of 
rituximab (Fisher et al., 2005; Liu et al., 2006; Pulte et al., 2008). It is hoped that overall 
survival can be further improved with the use of extended rituximab dosing schedules. 
2.4. Multiple Myeloma  
Multiple Myeloma (MM) is a B cell malignancy characterized by the presence of bone 
marrow infiltration by clonal plasma cells that generally secrete a monoclonal component in 
the serum or urine (Kyle & Rajkumar, 2004). It is the second most frequent hematological 
malignancy, after non Hodgkin’s lymphomas, and accounts approximately for a 10% of all 
hematological tumors and 1% of all cancers (Petrelli et al., 2009). MM is associated with a 
constellation of disease manifestations, including osteolytic lesions due to disrupted bone 
metabolism, anemia and immunosuppression due to loss of normal hematopoietic stem cell 
function, and end-organ damage due to monoclonal immunoglobulin secretion (Barlogie et 
al., 2001). The presence of somatic hypermutations of the immunoglobulin variable region 
genes in myeloma plasma cells suggests that malignant transformation occurs in a B cell that 
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has traversed the germinal centers of lymph nodes. However, the hypoproliferative nature 
of myeloma has led to the hypothesis that the bulk of the tumor arises from a transformed B 
cell with the capacity for both self-renewal and production of terminally differentiated 
progeny (Billadeau et al., 1993; Corradini et al., 1993; Szczepek et al., 1998). 
The clinical course of patients requiring therapy for myeloma varies markedly. Even with 
tandem autotransplants yielding complete remission (CR) rates in excess of 60%. Survival 
ranges from a few months to greater than 15 years. The extended time (almost 2 years) for 
those patients to achieve CR, and the even longer time to achieve magnetic resonance 
imaging (MRI)–CR, strongly suggests enormous tumor cell population heterogeneity in 
terms of drug responsiveness/resistance (Harousseau et al., 2004). 
Differential expression of traditional prognostic factors, such as 2-microglobulin (2M), 
albumin, and C-reactive protein (CRP), are thought to be responsible for only a 15%–20% of 
the outcome heterogeneity of MM. Abnormal metaphase karyotypes, present in one-third of 
newly diagnosed patients and reflecting stroma independence, have been consistently 
associated with a rapidly fatal outcome, and fewer than 10% of patients with these 
abnormalities survive > 5 years (Harousseau et al., 2004). 
Advances in molecular cytogenetics have identified primary translocations involving the 
immunoglobulin heavy chain locus at 14q32 in 40% of patients (Kuehl & Bergsagel; 2002). 
According to a consensus report of a Paris workshop on myeloma genetics, hyperdiploid 
and t(11;14)(q13,q32)-positive myeloma are associated with a good prognosis, whereas non-
hyperdiploidy, often associated with translocations other than t(11;14) and chromosome 13 
deletion, imparts a strikingly dismal prognosis (Fonseca et al., 2004). 
2.5 Other lymphoproliferative disorders 
Along with Waldenström's macroglobulinemia, there are other LPDs, which are less 
frequently observed. From this group we will describe in more details the 
lymphoproliferative disorders detected after bone marrow and organ transplantation. 
Following this treatment and among patients infected with AIDS, LPDs are believed to 
result from uncontrolled proliferation of Epstein-Barr virus (EBV)-transformed B-
lymphocytes in the setting of immune dysfunction (Cohen, 1991; Deeg & Socié, 1998; 
Goedert et al., 1998; Hoover, 1992; Kinlen, 1996; Newell et al., 1996; Opelz & Henderson, 
1993; Swinnen et al., 1990). Allogeneic bone marrow transplantation, an effective treatment 
for leukemia and other disorders, produces profound immune deficiency in the early period 
after transplantation. Post-transplant lymphoproliferative disorders (PTLD) are an 
uncommon, but frequently fatal, complication of this defective immune function (Bhatia et 
al., 1996; Deeg & Socié, 1998; Witherspoon et al., 1989). PTLD typically develop in the first 6 
months post-transplantantation as clinically aggressive lymphomas of donor origin; most 
are related to EBV (Deeg & Socié, 1998; Orazi et al., 1997; O’Reilly et al., 1996). 
Post-transplant lymphoproliferative disorders are more common if donor and recipient are 
HLA-mismatched or if T-cell depletion is used for graft-versus-host disease (GVHD) 
prophylaxis (Curtis et al., 1999). The clinical diagnosis of PTLD may be difficult because it is 
a spectrum of heterogenous histologic and clinical entities. It may present as an infectious 
mononucleosis-like illness, with fatigue and lymphadenopathy, or as a febrile illness with 
leukopenia. Almost all organs may be affected by disease. Because of the progressive nature 
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clinical trials in indolent NHL suggest an improved overall survival with the use of 
rituximab (Fisher et al., 2005; Liu et al., 2006; Pulte et al., 2008). It is hoped that overall 
survival can be further improved with the use of extended rituximab dosing schedules. 
2.4. Multiple Myeloma  
Multiple Myeloma (MM) is a B cell malignancy characterized by the presence of bone 
marrow infiltration by clonal plasma cells that generally secrete a monoclonal component in 
the serum or urine (Kyle & Rajkumar, 2004). It is the second most frequent hematological 
malignancy, after non Hodgkin’s lymphomas, and accounts approximately for a 10% of all 
hematological tumors and 1% of all cancers (Petrelli et al., 2009). MM is associated with a 
constellation of disease manifestations, including osteolytic lesions due to disrupted bone 
metabolism, anemia and immunosuppression due to loss of normal hematopoietic stem cell 
function, and end-organ damage due to monoclonal immunoglobulin secretion (Barlogie et 
al., 2001). The presence of somatic hypermutations of the immunoglobulin variable region 
genes in myeloma plasma cells suggests that malignant transformation occurs in a B cell that 
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cell with the capacity for both self-renewal and production of terminally differentiated 
progeny (Billadeau et al., 1993; Corradini et al., 1993; Szczepek et al., 1998). 
The clinical course of patients requiring therapy for myeloma varies markedly. Even with 
tandem autotransplants yielding complete remission (CR) rates in excess of 60%. Survival 
ranges from a few months to greater than 15 years. The extended time (almost 2 years) for 
those patients to achieve CR, and the even longer time to achieve magnetic resonance 
imaging (MRI)–CR, strongly suggests enormous tumor cell population heterogeneity in 
terms of drug responsiveness/resistance (Harousseau et al., 2004). 
Differential expression of traditional prognostic factors, such as 2-microglobulin (2M), 
albumin, and C-reactive protein (CRP), are thought to be responsible for only a 15%–20% of 
the outcome heterogeneity of MM. Abnormal metaphase karyotypes, present in one-third of 
newly diagnosed patients and reflecting stroma independence, have been consistently 
associated with a rapidly fatal outcome, and fewer than 10% of patients with these 
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Advances in molecular cytogenetics have identified primary translocations involving the 
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Along with Waldenström's macroglobulinemia, there are other LPDs, which are less 
frequently observed. From this group we will describe in more details the 
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Following this treatment and among patients infected with AIDS, LPDs are believed to 
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lymphocytes in the setting of immune dysfunction (Cohen, 1991; Deeg & Socié, 1998; 
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1993; Swinnen et al., 1990). Allogeneic bone marrow transplantation, an effective treatment 
for leukemia and other disorders, produces profound immune deficiency in the early period 
after transplantation. Post-transplant lymphoproliferative disorders (PTLD) are an 
uncommon, but frequently fatal, complication of this defective immune function (Bhatia et 
al., 1996; Deeg & Socié, 1998; Witherspoon et al., 1989). PTLD typically develop in the first 6 
months post-transplantantation as clinically aggressive lymphomas of donor origin; most 
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Post-transplant lymphoproliferative disorders are more common if donor and recipient are 
HLA-mismatched or if T-cell depletion is used for graft-versus-host disease (GVHD) 
prophylaxis (Curtis et al., 1999). The clinical diagnosis of PTLD may be difficult because it is 
a spectrum of heterogenous histologic and clinical entities. It may present as an infectious 
mononucleosis-like illness, with fatigue and lymphadenopathy, or as a febrile illness with 
leukopenia. Almost all organs may be affected by disease. Because of the progressive nature 
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of PTLD, the key to management may be early or even preemptive treatment with either 
anti–B-cell monoclonal antibodies (Carpenter et al., 2002; Kuehnle et al., 2000; van Esser et 
al., 2002) or donor-derived EBV-specific cytotoxic T lymphocytes (CTLs) (Gustafsson et al., 
2000; Heslop et al., 1996; Rooney et al., 1998).  
3. Animal models of lymphoproliferative disorders  
The bulk of LPD-related literature describes the different clinical manifestations 
encountered and evaluates treatment protocols. Fewer studies focus on dissecting the 
pathogenesis of LPD by developing animal models. Recent basic research is based on the 
development of genetically engineered mice or the use of immunodeficient mice as tumor 
transplant models. A few animal models other than mice have also been reported (miniature 
swine, zebrafish). 
3.1 Chronic lymphocytic leukemia  
Chronic lymphocytic leukemia cells require complex microenvironmental and immunologic 
interactions to survive and proliferate. Such interactions might be best studied in animal 
models; however, this needs extensive verification. Hofbauer et al. (2011) therefore 
investigated the composition of the T-cell compartment in the ETCL1 transgenic mouse, 
currently the most widely used murine model for CLL. TCL1 is a bona fide oncogene, 
developing a transgenic mouse model where ectopic expression driven by the lck promoter 
in the T cell compartment results in the development of mature T cell leukemias after a long 
latency period, in a pattern closely resembling human mature T cell leukemia (Virgilio et al., 
1998). Immunophenotyping and transplant approaches were used to define T-cell subsets at 
various stages of CLL. Analogous to human CLL, they observed a skewing of T-cell subsets 
from naive to antigen-experienced memory T cells that was more pronounced in lymph 
nodes than in blood. Transplantation of CLL into non-transgenic recipients was feasible 
without immunosuppression in a pure C57BL/6 background and resulted in the prominent 
skewing of the T cells of the recipient mice. Both in spontaneously developed CLL and in 
the transplantation setting, a loss in T-cell receptor diversity was observed, with a relevant 
number of clonal T-cell populations arising. This suggests that antigen-dependent 
differentiation toward the T memory pool is initiated by murine CLL cells. In summary, this 
research team characterized the T-cell phenotypes in the TCL1 transgenic mouse model and 
suggested a CLL-dependent antigen-driven skewing of T cells in these mice, making this 
model valuable for the research of the disease’s pathogenesis, since murine CLL cells react 
similarly with human CLL cells.  
The same transgenic mouse (ETCL1 transgenic mouse,) was also used by Suljagic et al. 
(2010). They have investigated whether inhibition of BCR (antigen-dependent B-cell 
receptor) signaling with the selective Syk inhibitor fostamatinib disodium (R788) had an 
affect on the growth of the leukemias that develop in the ETCL1 transgenic mouse model 
of CLL. Similarly to human CLL, these leukemias express stereotyped BCRs that react with 
autoantigens exposed on the surface of senescent or apoptotic cells, suggesting that they are 
antigen driven. They showed that R788 effectively inhibits BCR signaling in vivo, resulting 
in reduced proliferation and survival of the malignant B cells and significantly prolonged 
survival of the treated animals. The growth-inhibitory effect of R788 occurs despite the 
relatively modest cytotoxic effect in vitro and is independent of basal Syk activity, 
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suggesting that R788 functions primarily by inhibiting antigen-dependent BCR signals. 
Importantly, the effect of R788 was found to be selective for the malignant clones, as no 
disturbance in the production of normal B lymphocytes was observed. Collectively, these 
data provide further rationale for clinical trials with R788 in CLL and establish the BCR-
signaling pathway as an important therapeutic target in this disease. 
In another approach, over-expression of human TCL1, leads to the development of mature 
CD19+/CD5+/IgM+ clonal leukemia with a murine disease phenotype similar to the human 
CLL. Herein, Chen et al. (2009) review their recent study using this TCL1-driven mouse model 
for CLL and corresponding human CLL samples in a cross-species epigenomics approach to 
address the timing and relevance of epigenetic events occurring during leukemogenesis. They 
demonstrated that the mouse model recapitulates the epigenetic events that have been 
reported for human CLL, affirming the power and validity of this mouse model to study early 
epigenetic events in cancer progression. Epigenetic alterations are detected as early as three 
months after birth, far before disease manifests at about 11 months of age. These mice undergo 
NFκ-B repressor complex-mediated inactivation of the transcription factor Foxd3, whose 
targets become aberrantly methylated and silenced in both mouse and human CLL. Overall, 
their data suggest the accumulated epigenetic alterations during CLL pathogenesis as a 
consequence of gene silencing through TCL1 and NFκ-B repressor complex, suggesting the 
relevance for NFκ-B as a therapeutic target in CLL. 
Another trangenic mouse model for CLL was generated by Santanam et al. (2010). They found 
that miR-29a is up-regulated in indolent human B-CLL as compared with aggressive B-CLL 
and normal CD19(+) B cells. To study the role of miR-29 in B-CLL, they generated E-miR-29 
transgenic mice overexpressing miR-29 in mouse B cells. Flow cytometric analysis revealed a 
markedly expanded CD5(+) population in the spleen of these mice starting at 2 months of age, 
with 85% (34/40) of miR-29 transgenic mice exhibiting expanded CD5(+) B-cell populations, a 
characteristic of B-CLL. On average, 50% of B cells in these transgenic mice were CD5 positive. 
At 2 years of age the mice showed significantly enlarged spleens and an increase in the CD5(+) 
B-cell population to approximately 100%. Of 20 E-miR-29 transgenic mice followed to 24-26 
mo of age, 4 (20%) developed frank leukemia and died of the disease. These results suggest 
that the dysregulation of miR-29 can contribute to the pathogenesis of indolent B-CLL, giving 
another opportunity to clarify all of its aspects. 
The engraftment of cell lines into appropriate mice and/or the injection of fresh cells 
derived from patients have been used for the development of animal models in different 
disesases. Here, we describe one animal model where the researchers have developed a 
novel transplantable xenograft murine model of CLL by engrafting the CLL cell line MEC1 
into Rag2(-/-)gamma(c)(-/-)mice. These mice lack B, T, and natural killer (NK) cells, and, in 
contrast to nude mice that retain NK cells, appear to be optimal recipient for MEC1 cells, 
which were successfully transplanted through either subcutaneous or intravenous routes. 
The result is a novel in vivo model that has systemic involvement, develops very rapidly, 
allows the measurement of tumor burden, and has 100% engraftment efficiency. This model 
closely resembles aggressive human CLL and could be very useful for evaluating both the 
biologic basis of CLL growth and dissemination as well as the efficacy of new therapeutic 
agents (Bertilaccio  et al., 2010).  
Another model has been developed by Aydin et al. (2011), and is exploring the role of CD38 
and functionally associated molecular risk factors in a recently described CLL nonobese 
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interactions to survive and proliferate. Such interactions might be best studied in animal 
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investigated the composition of the T-cell compartment in the ETCL1 transgenic mouse, 
currently the most widely used murine model for CLL. TCL1 is a bona fide oncogene, 
developing a transgenic mouse model where ectopic expression driven by the lck promoter 
in the T cell compartment results in the development of mature T cell leukemias after a long 
latency period, in a pattern closely resembling human mature T cell leukemia (Virgilio et al., 
1998). Immunophenotyping and transplant approaches were used to define T-cell subsets at 
various stages of CLL. Analogous to human CLL, they observed a skewing of T-cell subsets 
from naive to antigen-experienced memory T cells that was more pronounced in lymph 
nodes than in blood. Transplantation of CLL into non-transgenic recipients was feasible 
without immunosuppression in a pure C57BL/6 background and resulted in the prominent 
skewing of the T cells of the recipient mice. Both in spontaneously developed CLL and in 
the transplantation setting, a loss in T-cell receptor diversity was observed, with a relevant 
number of clonal T-cell populations arising. This suggests that antigen-dependent 
differentiation toward the T memory pool is initiated by murine CLL cells. In summary, this 
research team characterized the T-cell phenotypes in the TCL1 transgenic mouse model and 
suggested a CLL-dependent antigen-driven skewing of T cells in these mice, making this 
model valuable for the research of the disease’s pathogenesis, since murine CLL cells react 
similarly with human CLL cells.  
The same transgenic mouse (ETCL1 transgenic mouse,) was also used by Suljagic et al. 
(2010). They have investigated whether inhibition of BCR (antigen-dependent B-cell 
receptor) signaling with the selective Syk inhibitor fostamatinib disodium (R788) had an 
affect on the growth of the leukemias that develop in the ETCL1 transgenic mouse model 
of CLL. Similarly to human CLL, these leukemias express stereotyped BCRs that react with 
autoantigens exposed on the surface of senescent or apoptotic cells, suggesting that they are 
antigen driven. They showed that R788 effectively inhibits BCR signaling in vivo, resulting 
in reduced proliferation and survival of the malignant B cells and significantly prolonged 
survival of the treated animals. The growth-inhibitory effect of R788 occurs despite the 
relatively modest cytotoxic effect in vitro and is independent of basal Syk activity, 
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suggesting that R788 functions primarily by inhibiting antigen-dependent BCR signals. 
Importantly, the effect of R788 was found to be selective for the malignant clones, as no 
disturbance in the production of normal B lymphocytes was observed. Collectively, these 
data provide further rationale for clinical trials with R788 in CLL and establish the BCR-
signaling pathway as an important therapeutic target in this disease. 
In another approach, over-expression of human TCL1, leads to the development of mature 
CD19+/CD5+/IgM+ clonal leukemia with a murine disease phenotype similar to the human 
CLL. Herein, Chen et al. (2009) review their recent study using this TCL1-driven mouse model 
for CLL and corresponding human CLL samples in a cross-species epigenomics approach to 
address the timing and relevance of epigenetic events occurring during leukemogenesis. They 
demonstrated that the mouse model recapitulates the epigenetic events that have been 
reported for human CLL, affirming the power and validity of this mouse model to study early 
epigenetic events in cancer progression. Epigenetic alterations are detected as early as three 
months after birth, far before disease manifests at about 11 months of age. These mice undergo 
NFκ-B repressor complex-mediated inactivation of the transcription factor Foxd3, whose 
targets become aberrantly methylated and silenced in both mouse and human CLL. Overall, 
their data suggest the accumulated epigenetic alterations during CLL pathogenesis as a 
consequence of gene silencing through TCL1 and NFκ-B repressor complex, suggesting the 
relevance for NFκ-B as a therapeutic target in CLL. 
Another trangenic mouse model for CLL was generated by Santanam et al. (2010). They found 
that miR-29a is up-regulated in indolent human B-CLL as compared with aggressive B-CLL 
and normal CD19(+) B cells. To study the role of miR-29 in B-CLL, they generated E-miR-29 
transgenic mice overexpressing miR-29 in mouse B cells. Flow cytometric analysis revealed a 
markedly expanded CD5(+) population in the spleen of these mice starting at 2 months of age, 
with 85% (34/40) of miR-29 transgenic mice exhibiting expanded CD5(+) B-cell populations, a 
characteristic of B-CLL. On average, 50% of B cells in these transgenic mice were CD5 positive. 
At 2 years of age the mice showed significantly enlarged spleens and an increase in the CD5(+) 
B-cell population to approximately 100%. Of 20 E-miR-29 transgenic mice followed to 24-26 
mo of age, 4 (20%) developed frank leukemia and died of the disease. These results suggest 
that the dysregulation of miR-29 can contribute to the pathogenesis of indolent B-CLL, giving 
another opportunity to clarify all of its aspects. 
The engraftment of cell lines into appropriate mice and/or the injection of fresh cells 
derived from patients have been used for the development of animal models in different 
disesases. Here, we describe one animal model where the researchers have developed a 
novel transplantable xenograft murine model of CLL by engrafting the CLL cell line MEC1 
into Rag2(-/-)gamma(c)(-/-)mice. These mice lack B, T, and natural killer (NK) cells, and, in 
contrast to nude mice that retain NK cells, appear to be optimal recipient for MEC1 cells, 
which were successfully transplanted through either subcutaneous or intravenous routes. 
The result is a novel in vivo model that has systemic involvement, develops very rapidly, 
allows the measurement of tumor burden, and has 100% engraftment efficiency. This model 
closely resembles aggressive human CLL and could be very useful for evaluating both the 
biologic basis of CLL growth and dissemination as well as the efficacy of new therapeutic 
agents (Bertilaccio  et al., 2010).  
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diabetic/severe combined immunodeficient xenograft model. Intravenous injection of 
peripheral blood mononuclear cells from 73 patients with CLL into 244 mice resulted in 
robust engraftment of leukemic cells into the murine spleens detected 4 weeks after 
transplantation. Leukemic cell engraftment correlated significantly (P < 0.05) with markers 
reflecting disease activity, e.g., Binet stage and lymphocyte doubling time, and the 
expression of molecular risk factors including CD38, CD49d, ZAP-70, and IgVH mutational 
status. Increased engraftment levels of CD38+ as compared to CD38- CLL cells could be 
attributed, in part, to leukemic cell proliferation as evidenced by simultaneous  
immunostaining of murine spleen sections for Ki-67 and CD20. In short-term (24 h) homing 
assays, CD38+ CLL cells migrated more efficiently to the bone marrow of the recipient 
animals than their CD38- counterparts. Finally, the expression of CD38 by the leukemic cells 
was found to be dynamic in that it was regulated not only by elements of the murine 
microenvironment but also by co-engrafting non-malignant human T cells. This model 
could be useful for evaluating the biological basis of CLL growth in the context of the 
hematopoietic microenvironment as well as for preclinical testing of novel compounds. 
Last, but not least we describe the New Zealand Black (NZB) mouse model for CLL. Is a (de 
novo) mouse model of spontaneous CLL (Phillips et al., 1992), in contrast to all other models, 
which are induced by the expression of exogenous genes (Scaglione et al., 2007). Similar to a 
subset of human patients who progress from monoclonal B lymphocytosis (MBL) to CLL, 
NZB mice develop an age-associated progression to CLL. The murine disease is linked to a 
genetic abnormality in microRNA mir-15a/16-1 locus, resulting in decreased mature miR-
15a/16 (Salerno et al., 2010).  
Similar to CLL, the disease in NZB mice is also an age-associated malignant expansion of 
poly-reactive CD5+ B-1 clones (Caligaris-Cappio & Ghia, 2007; Scaglione et al., 2007). The 
majority of B-1 clones are IgM+, B220 (CD45R)dim and CD5dim , increase with age, and often 
possess chromosomal abnormalities (Dang et al., 1996). NZB also seem to demonstrate an 
MBL-like stage at an early age, characterized by multiple clones, as seen in MBL cases 
reported by Lanasa et al. (2010). High levels of IL-10 are also correlated with the 
development of these malignant B-1 cells (Ramachandra et al., 1996). This MBL-like state in 
NZB precedes CLL, and although it exhibits similar manifestations to human MBL, NZB 
disease always progress to CLL, in contrast to humans who can have an indefinite state of 
indolent MBL disease (Lanasa et al., 2010). The NZB has also been studied as a model for 
autoimmunity (Theofilopoulos, 1996). Similar to the autoreactivity associated with CLL 
autoantibodies (Ghia et al., 2002), the NZB mouse develops a mild autoimmune reaction 
associated with B cell hyperactivity, resulting in autoimmune hemolytic anemia and 
antinuclear antibodies (Scaglione et al., 2007).  
The diversity of exisitng animal models of CLL leads to multiple options for treatment 
approaches, which is the end-point of this research. 
3.2 Acute lymphoblastic leukemia 
The non-obese diabetic/severe combined immunodeficient (NOD/SCID) xenograft mouse 
model is currently one of the most successful models for studying haematological 
malignancies such as acute lymphoblastic leukaemia (ALL) (Macor et al., 2008). In this 
typical tumor transplant model patient bone marrow leukemia cells are directly 
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transplanted into the recipient NOD/SCID mice (Lock et al., 2002). The kinetics of 
engraftment reflect the human disease, leading to bone marrow (BM) infiltration, followed 
by migration to the spleen, peripheral blood and other haematopoietic organs (Lock et al., 
2002; Kamel-Reid et al., 1989; Nijmeijer et al., 2001). However, for this model to be effective 
for studying engraftment and therapy responses at the whole genome level, careful 
molecular characterization is essential. 
In the ALL NOD/SCID xenograft model, Samuels et al. (2010) have combined all existing 
xenograft models and sought to validate species-specific gene expression. Using the human 
Affymetrix whole transcript platform they analyzed transcriptional profiles from engrafted 
tissues (e.g. bone marrow, spleen and/or peripheral blood) without prior cell separation of 
mouse cells and acquired highly reproducible profiles in xenografts from individual mice. 
The model was further tested with experimental mixtures of human and mouse cells, 
demonstrating that the presence of mouse cells does not significantly distort expression 
profiles when xenografts contain 90% or more human cells. In addition, they presented a 
novel in silico and experimental masking approach to identify probes and transcript clusters 
susceptible to cross-species hybridization. Hence, they demonstrated that species-specific 
transcriptional profiles can be obtained from xenografts when high levels of engraftment are 
achieved or with the application of transcript cluster masks. Importantly, this masking 
approach can be applied and adapted to other xenograft models where human tissue 
infiltration is lower. This model provides a powerful platform for identifying genes and 
pathways associated with ALL disease progression and response to therapy in vivo. 
A genetically defined mouse retroviral transduction/bone marrow transplantation model 
was used by Medyouf et al. (2010) to investigate the possibility for NOTCH1 to act as a 
therapeutic target. This is based on the assumption that NOTCH1 is activated by mutation 
in more than 50% of human T-cell acute lymphoblastic leukemias (T-ALLs) and inhibition of 
Notch signaling causes cell-cycle/growth arrest. The tumor suppressor phosphatase and 
tensin homolog (PTEN) is also mutated or lost in up to 20% of cases. It was recently 
observed among human T-ALL cell lines that PTEN loss correlated with resistance to Notch 
inhibition, raising concern that patients with PTEN-negative disease may fail Notch 
inhibitor therapy. They observed primary murine leukemias to remain dependent on 
NOTCH1 signaling despite Pten loss, with or without additional deletion of 
p16(Ink4a)/p19(Arf). They also examined 13 primary human T-ALL samples obtained at 
diagnosis and found no correlation between PTEN status and resistance to Notch inhibition. 
Furthermore, they noted  that Pten loss accelerated disease onset and produced multiclonal 
tumors, suggesting NOTCH1 activation and Pten loss may collaborate in leukemia 
induction. Thus, in contrast to previous findings with established cell lines, these results 
indicate that PTEN loss does not relieve primary T-ALL cells of their "addiction" to Notch 
signaling. They concluded that refractory/relapsed tumors that have undergone 
chemotherapy-induced mutation and/or selection may behave differently, but presumably 
will harbor many other genetic alterations besides PTEN loss. This conclusion, along others 
of the same research team provide new insight on the therapeutic management of ALL. 
Introduction of cells into syngeneic mice is also useful tool for the investigation of ALL and 
its therapeutic approach. Cultured p185(BCR-ABL)-expressing (p185+) Arf (-/-) pre-B cells 
injected into healthy syngeneic mice induces aggressive acute lymphoblastic leukemia 
(ALL) that genetically and phenotypically mimics the human disease (Boulos et al., 2011). 
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diabetic/severe combined immunodeficient xenograft model. Intravenous injection of 
peripheral blood mononuclear cells from 73 patients with CLL into 244 mice resulted in 
robust engraftment of leukemic cells into the murine spleens detected 4 weeks after 
transplantation. Leukemic cell engraftment correlated significantly (P < 0.05) with markers 
reflecting disease activity, e.g., Binet stage and lymphocyte doubling time, and the 
expression of molecular risk factors including CD38, CD49d, ZAP-70, and IgVH mutational 
status. Increased engraftment levels of CD38+ as compared to CD38- CLL cells could be 
attributed, in part, to leukemic cell proliferation as evidenced by simultaneous  
immunostaining of murine spleen sections for Ki-67 and CD20. In short-term (24 h) homing 
assays, CD38+ CLL cells migrated more efficiently to the bone marrow of the recipient 
animals than their CD38- counterparts. Finally, the expression of CD38 by the leukemic cells 
was found to be dynamic in that it was regulated not only by elements of the murine 
microenvironment but also by co-engrafting non-malignant human T cells. This model 
could be useful for evaluating the biological basis of CLL growth in the context of the 
hematopoietic microenvironment as well as for preclinical testing of novel compounds. 
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novo) mouse model of spontaneous CLL (Phillips et al., 1992), in contrast to all other models, 
which are induced by the expression of exogenous genes (Scaglione et al., 2007). Similar to a 
subset of human patients who progress from monoclonal B lymphocytosis (MBL) to CLL, 
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genetic abnormality in microRNA mir-15a/16-1 locus, resulting in decreased mature miR-
15a/16 (Salerno et al., 2010).  
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antinuclear antibodies (Scaglione et al., 2007).  
The diversity of exisitng animal models of CLL leads to multiple options for treatment 
approaches, which is the end-point of this research. 
3.2 Acute lymphoblastic leukemia 
The non-obese diabetic/severe combined immunodeficient (NOD/SCID) xenograft mouse 
model is currently one of the most successful models for studying haematological 
malignancies such as acute lymphoblastic leukaemia (ALL) (Macor et al., 2008). In this 
typical tumor transplant model patient bone marrow leukemia cells are directly 
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xenograft models and sought to validate species-specific gene expression. Using the human 
Affymetrix whole transcript platform they analyzed transcriptional profiles from engrafted 
tissues (e.g. bone marrow, spleen and/or peripheral blood) without prior cell separation of 
mouse cells and acquired highly reproducible profiles in xenografts from individual mice. 
The model was further tested with experimental mixtures of human and mouse cells, 
demonstrating that the presence of mouse cells does not significantly distort expression 
profiles when xenografts contain 90% or more human cells. In addition, they presented a 
novel in silico and experimental masking approach to identify probes and transcript clusters 
susceptible to cross-species hybridization. Hence, they demonstrated that species-specific 
transcriptional profiles can be obtained from xenografts when high levels of engraftment are 
achieved or with the application of transcript cluster masks. Importantly, this masking 
approach can be applied and adapted to other xenograft models where human tissue 
infiltration is lower. This model provides a powerful platform for identifying genes and 
pathways associated with ALL disease progression and response to therapy in vivo. 
A genetically defined mouse retroviral transduction/bone marrow transplantation model 
was used by Medyouf et al. (2010) to investigate the possibility for NOTCH1 to act as a 
therapeutic target. This is based on the assumption that NOTCH1 is activated by mutation 
in more than 50% of human T-cell acute lymphoblastic leukemias (T-ALLs) and inhibition of 
Notch signaling causes cell-cycle/growth arrest. The tumor suppressor phosphatase and 
tensin homolog (PTEN) is also mutated or lost in up to 20% of cases. It was recently 
observed among human T-ALL cell lines that PTEN loss correlated with resistance to Notch 
inhibition, raising concern that patients with PTEN-negative disease may fail Notch 
inhibitor therapy. They observed primary murine leukemias to remain dependent on 
NOTCH1 signaling despite Pten loss, with or without additional deletion of 
p16(Ink4a)/p19(Arf). They also examined 13 primary human T-ALL samples obtained at 
diagnosis and found no correlation between PTEN status and resistance to Notch inhibition. 
Furthermore, they noted  that Pten loss accelerated disease onset and produced multiclonal 
tumors, suggesting NOTCH1 activation and Pten loss may collaborate in leukemia 
induction. Thus, in contrast to previous findings with established cell lines, these results 
indicate that PTEN loss does not relieve primary T-ALL cells of their "addiction" to Notch 
signaling. They concluded that refractory/relapsed tumors that have undergone 
chemotherapy-induced mutation and/or selection may behave differently, but presumably 
will harbor many other genetic alterations besides PTEN loss. This conclusion, along others 
of the same research team provide new insight on the therapeutic management of ALL. 
Introduction of cells into syngeneic mice is also useful tool for the investigation of ALL and 
its therapeutic approach. Cultured p185(BCR-ABL)-expressing (p185+) Arf (-/-) pre-B cells 
injected into healthy syngeneic mice induces aggressive acute lymphoblastic leukemia 
(ALL) that genetically and phenotypically mimics the human disease (Boulos et al., 2011). 
 
Hematology – Science and Practice 
 
434 
They adapted the Philadelphia chromosome-positive (Ph(+)) ALL animal model for in vivo 
luminescent imaging to investigate disease progression, targeted therapeutic response, and 
ALL relapse in living mice. Mice bearing high leukemic burdens (simulating human Ph(+) 
ALL at diagnosis) entered remission on maximally intensive, twice-daily dasatinib therapy, 
but invariably relapsed with disseminated and/or central nervous system disease. Their 
research concluded that although non-tumor-cell-autonomous mechanisms can prevent full 
eradication of dasatinib-refractory ALL in this clinically relevant model, the emergence of 
resistance to BCR-ABL kinase inhibitors can be effectively circumvented by the addition of 
"conventional" chemotherapeutic agents with alternate antileukemic mechanisms of action. 
Thus, preclinical trials using multiple agents underscore the potential value of this murine 
Ph+ ALL model for efficiently and cheaply piloting combination therapies and for 
elucidating mechanisms of drug resistance, information that is much more difficult to 
extract from complex human clinical trials. 
Other researchers have combined ALL models with exogenous factors, to test their influence 
in disease. For example, Yun et al. (2010) developed animal models of obesity and leukemia 
to test whether obesity could directly accelerate acute lymphoblastic leukemia (ALL) using 
BCR/ABL transgenic and AKR/J mice weaned onto a high-fat diet. Mice were observed 
until development of progressive ALL. Although obese and control BCR/ABL mice had 
similar median survival, older obese mice had accelerated ALL onset, implying a time-
dependent effect of obesity on ALL. Obese AKR mice developed ALL significantly earlier 
than controls. The effect of obesity was not explained by WBC count, thymus/spleen 
weight, or ALL phenotype. However, obese AKR mice had higher leptin, insulin, and 
interleukin-6 levels than controls, and these obesity-related hormones all have potential 
roles in leukemia pathogenesis. In conclusion, obesity directly accelerates presentation of 
ALL, likely by increasing the risk of an early event in leukemogenesis. This is the first study 
to show that obesity can directly accelerate the progression of ALL. Thus, the observed 
associations between obesity and leukemia incidence are likely to be directly related to 
biological effects of obesity. 
Smith et al. (2010) used another animal, zebrafish, where malignant cells can be transplanted 
into sibling animals without the need for immune suppression. Using cell-transplant zebrafish 
(Langenau et al., 2003) showed that self-renewing cells are abundant in T-ALL and comprise 
0.1% to 15.9% of the T-ALL mass. Large-scale single-cell transplantation experiments 
established that T-ALLs can be initiated from a single cell and that leukemias exhibit wide 
differences in tumor-initiating potential. T-ALLs can also be introduced into clonal-outcrossed 
animals, and T-ALLs arising in mixed genetic backgrounds can be transplanted into clonal 
recipients without the need for major histocompatibility complex matching. Finally, high-
throughput imaging methods are described that allow large numbers of fluorescent transgenic 
animals to be imaged simultaneously, facilitating the rapid screening of engrafted animals. 
These experiments show that large numbers of zebrafish can be experimentally assessed by 
cell transplantation and establish new high-throughput methods to functionally interrogate 
gene pathways involved in cancer self-renewal. 
3.3 Lymphomas/leukemias  
There are numerous studies utilizing mouse models to study different lymphomas/ 
leukemias. Here, only a few representative are mentioned, since the thorough report of these 
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models is beyond the scope of this chapter. As with other LPDs, the use of knock-out 
and/or transgenic mice has been substantial to study lymphomas and leukemias. 
The first animal model we describe studies the pathogenesis of multiple hematopoietic 
malignancies simultaneously. The researchers (Zhang et al., 2011) have generated inducible 
Pten/Myc double-knockout mice (Pten(-/-)/Myc(-/-)). By comparing the hematopoietic 
phenotypes of these double-knockout mice with those of Pten(-/-) mice, they found that 
both sets of animals developed myelo- and lympho-proliferative disorders. Their study 
suggests that the deregulation of phosphoinositide 3-kinase/Akt signaling in Pten(-/-) 
hematopoietic cells protects these cells from apoptotic cell death, resulting in chronic 
proliferative disorders. Since, none of the compound-mutant mice developed acute 
leukemia or lymphoma, it is concluded that Myc is absolutely required for the development 
of acute hematopoietic malignancies. 
Other researchers (Mukherjee et al., 2011) managed to develop spontaneous T- and B-cell 
lymphomas, and leukemia in mice: Homozygous deletion of ESPL1 gene that encodes 
Separase protein (Cohesin protease Separase plays a key role in faithful segregation of sister 
chromatids by cleaving the cohesin complex at the metaphase to anaphase transition) results 
in embryonic lethality in mice and Separase overexpression lead to aneuploidy and 
tumorigenesis. By examining the ESPL1 heterozygosity using a hypomorphic mouse model 
that has reduced germline Separase activity, they reported that while ESPL1 mutant (ESPL1 
(+/hyp)) mice have a normal phenotype, in the absence of p53, mice develop spontaneous 
T- and B-cell lymphomas, and leukemia with a significantly shortened latency as compared 
to p53 null mice. Their results indicate that reduced levels of Separase act synergistically 
with loss of p53 in the initiation and progression of B- and T- cell lymphomas, which is 
aided by increased chromosomal missegregation and accumulation of genomic instability. 
ESPL1(+/hyp), p53(-/-) mice provide a new animal model for mechanistic study of 
aggressive lymphoma and also for preclinical evaluation of new agents for its therapy. 
An interesting murine model of diffuse large B-cell lymphoma (DLBCL) described by Yu et 
al. (2011), uses human DLBCL cell line LY8, to investigate its characteristics of growth  
pathogenesis and the effect of treatment protocols. LY8 cells were injected subcutaneously 
into the right flank of nude mice. Harvested tumor tissues were cut into small pieces of 1.5 
mm × 1.5 mm × 1.5 mm and implanted subcutaneously into nude mice. Tumor growth was 
monitored and the histologic characteristics were documented. Expression of LCA, CD20, 
CD79α, Ki-67, CD3, CD45RO, bcl-6, MUM-1, CD10 and bcl-2 were examined by using 
immunohistochemistry. IgH clonal rearrangement and status of three microsatellite loci 
(D14S68, D18S69, D20S199) in the xenografted tumor samples and the parental cell line LY8 
were detected using PCR amplification followed by PAGE. The subcutaneous xenograft 
DLBCL model was successfully established by using cell line LY8, and a stable growth was 
achieved up to the 9th generation. The tumor in each generation showed similar growth 
characteristics and the rate of subcutaneous tumor formation was 91.9% (114/124). The 
tumor growth was observed from the 2nd week after morphological characteristics with 
those of human DLBCL, and expressed LCA, CD20, CD79α, bcl-6, MUM-1, CD10 and bcl-2. 
The tumor of xenograft mice and cell line LY8 showed identical IgH rearrangement and 
microsatellite length. This mouse model recapitulates many features of  human DLBCL with 
high stability and repeatability. Therefore, it provides an ideal animal model for in vivo 
studies of the biological characteristics and treatment of DLBCL. 
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They adapted the Philadelphia chromosome-positive (Ph(+)) ALL animal model for in vivo 
luminescent imaging to investigate disease progression, targeted therapeutic response, and 
ALL relapse in living mice. Mice bearing high leukemic burdens (simulating human Ph(+) 
ALL at diagnosis) entered remission on maximally intensive, twice-daily dasatinib therapy, 
but invariably relapsed with disseminated and/or central nervous system disease. Their 
research concluded that although non-tumor-cell-autonomous mechanisms can prevent full 
eradication of dasatinib-refractory ALL in this clinically relevant model, the emergence of 
resistance to BCR-ABL kinase inhibitors can be effectively circumvented by the addition of 
"conventional" chemotherapeutic agents with alternate antileukemic mechanisms of action. 
Thus, preclinical trials using multiple agents underscore the potential value of this murine 
Ph+ ALL model for efficiently and cheaply piloting combination therapies and for 
elucidating mechanisms of drug resistance, information that is much more difficult to 
extract from complex human clinical trials. 
Other researchers have combined ALL models with exogenous factors, to test their influence 
in disease. For example, Yun et al. (2010) developed animal models of obesity and leukemia 
to test whether obesity could directly accelerate acute lymphoblastic leukemia (ALL) using 
BCR/ABL transgenic and AKR/J mice weaned onto a high-fat diet. Mice were observed 
until development of progressive ALL. Although obese and control BCR/ABL mice had 
similar median survival, older obese mice had accelerated ALL onset, implying a time-
dependent effect of obesity on ALL. Obese AKR mice developed ALL significantly earlier 
than controls. The effect of obesity was not explained by WBC count, thymus/spleen 
weight, or ALL phenotype. However, obese AKR mice had higher leptin, insulin, and 
interleukin-6 levels than controls, and these obesity-related hormones all have potential 
roles in leukemia pathogenesis. In conclusion, obesity directly accelerates presentation of 
ALL, likely by increasing the risk of an early event in leukemogenesis. This is the first study 
to show that obesity can directly accelerate the progression of ALL. Thus, the observed 
associations between obesity and leukemia incidence are likely to be directly related to 
biological effects of obesity. 
Smith et al. (2010) used another animal, zebrafish, where malignant cells can be transplanted 
into sibling animals without the need for immune suppression. Using cell-transplant zebrafish 
(Langenau et al., 2003) showed that self-renewing cells are abundant in T-ALL and comprise 
0.1% to 15.9% of the T-ALL mass. Large-scale single-cell transplantation experiments 
established that T-ALLs can be initiated from a single cell and that leukemias exhibit wide 
differences in tumor-initiating potential. T-ALLs can also be introduced into clonal-outcrossed 
animals, and T-ALLs arising in mixed genetic backgrounds can be transplanted into clonal 
recipients without the need for major histocompatibility complex matching. Finally, high-
throughput imaging methods are described that allow large numbers of fluorescent transgenic 
animals to be imaged simultaneously, facilitating the rapid screening of engrafted animals. 
These experiments show that large numbers of zebrafish can be experimentally assessed by 
cell transplantation and establish new high-throughput methods to functionally interrogate 
gene pathways involved in cancer self-renewal. 
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models is beyond the scope of this chapter. As with other LPDs, the use of knock-out 
and/or transgenic mice has been substantial to study lymphomas and leukemias. 
The first animal model we describe studies the pathogenesis of multiple hematopoietic 
malignancies simultaneously. The researchers (Zhang et al., 2011) have generated inducible 
Pten/Myc double-knockout mice (Pten(-/-)/Myc(-/-)). By comparing the hematopoietic 
phenotypes of these double-knockout mice with those of Pten(-/-) mice, they found that 
both sets of animals developed myelo- and lympho-proliferative disorders. Their study 
suggests that the deregulation of phosphoinositide 3-kinase/Akt signaling in Pten(-/-) 
hematopoietic cells protects these cells from apoptotic cell death, resulting in chronic 
proliferative disorders. Since, none of the compound-mutant mice developed acute 
leukemia or lymphoma, it is concluded that Myc is absolutely required for the development 
of acute hematopoietic malignancies. 
Other researchers (Mukherjee et al., 2011) managed to develop spontaneous T- and B-cell 
lymphomas, and leukemia in mice: Homozygous deletion of ESPL1 gene that encodes 
Separase protein (Cohesin protease Separase plays a key role in faithful segregation of sister 
chromatids by cleaving the cohesin complex at the metaphase to anaphase transition) results 
in embryonic lethality in mice and Separase overexpression lead to aneuploidy and 
tumorigenesis. By examining the ESPL1 heterozygosity using a hypomorphic mouse model 
that has reduced germline Separase activity, they reported that while ESPL1 mutant (ESPL1 
(+/hyp)) mice have a normal phenotype, in the absence of p53, mice develop spontaneous 
T- and B-cell lymphomas, and leukemia with a significantly shortened latency as compared 
to p53 null mice. Their results indicate that reduced levels of Separase act synergistically 
with loss of p53 in the initiation and progression of B- and T- cell lymphomas, which is 
aided by increased chromosomal missegregation and accumulation of genomic instability. 
ESPL1(+/hyp), p53(-/-) mice provide a new animal model for mechanistic study of 
aggressive lymphoma and also for preclinical evaluation of new agents for its therapy. 
An interesting murine model of diffuse large B-cell lymphoma (DLBCL) described by Yu et 
al. (2011), uses human DLBCL cell line LY8, to investigate its characteristics of growth  
pathogenesis and the effect of treatment protocols. LY8 cells were injected subcutaneously 
into the right flank of nude mice. Harvested tumor tissues were cut into small pieces of 1.5 
mm × 1.5 mm × 1.5 mm and implanted subcutaneously into nude mice. Tumor growth was 
monitored and the histologic characteristics were documented. Expression of LCA, CD20, 
CD79α, Ki-67, CD3, CD45RO, bcl-6, MUM-1, CD10 and bcl-2 were examined by using 
immunohistochemistry. IgH clonal rearrangement and status of three microsatellite loci 
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were detected using PCR amplification followed by PAGE. The subcutaneous xenograft 
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achieved up to the 9th generation. The tumor in each generation showed similar growth 
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tumor growth was observed from the 2nd week after morphological characteristics with 
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studies of the biological characteristics and treatment of DLBCL. 
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Gaurnier-Hausser et al. (2011) set out to determine whether dogs with spontaneous DLBCL 
(diffuse large B-cell lymphoma) have comparative aberrant constitutive NF-κB activity and 
to determine the therapeutic relevance of NF-κB inhibition in dogs with relapsed, resistant 
DLBCL. Constitutive canonical NF-κB activity and increased NF-κB target gene expression 
were detected in primary DLBCL tissue. NF-κB essential modulator (NEMO)-binding 
domain (NBD) peptide inhibited this activity and induced apoptosis of primary malignant B 
cells in vitro. Intratumoral injections of NBD peptide to dogs with relapsed DLBCL inhibited 
NF-κB target gene expression and reduced tumor burden. This work shows that dogs with 
spontaneous DLBCL share therapeutic relevance of NF-κB inhibition in the treatment of 
ABC-DLBCL. These results have important translational relevance for ABC-DLBCL 
treatment in human patients, and dogs with spontaneous DLBCL may represent a clinically 
relevant, spontaneous, large animal model for human ABC-DLBCL. 
Other findings suggest that increasing levels of human-derived IgG in peripheral blood from 
hu-PBL/SCID mice could be used to monitor EBV-related human B-cell lymphoma 
development in experimental animals (Tang et al., 2011). Epstein-Barr virus (EBV) has a close 
association with various types of human lymphomas. Tang et al. (2011) aimed to evaluate the 
association between human IgG concentration and EBV-associated lymphoma development in 
huPBL/SCID mice. For that, human peripheral blood lymphocytes (hu-PBL) from EBV-
seropositive donors were inoculated intraperitoneally into SCID mouse. Twenty one out of 29 
mice developed tumors in their body. Immunohistochemical staining showed that all induced 
tumors were LCA (leukocyte common antigen) positive, B-cell markers (CD20, CD79a) 
positive, and T-cell markers (both CD3 and CD45RO) negative. The tumors were diagnosed as 
human B-cell lymphomas by these morphological and immunohistochemical features. In situ 
hybridization exhibited resultant tumor cells with EBV encoded small RNA-1 (EBER-1). 
Human-derived IgG could be found in the serum of SCID mice on the 15th day following hu-
PBL transplantation, and IgG levels increased as tumor grew in 6 hu-PBL/SCID chimeras. 
These data suggest that intraperitoneal transfer of hu-PBLs from EBV+ donors to SCID mice 
leads to high human IgG levels in mouse serum and B cell lymphomas. 
3.4 Multiple Myeloma  
Plasmacytoma or myeloma can be induced in BALB/c mice by pristane oil or can develop 
spontaneously in some mouse strains (Potter, 1982; Radl, 1981). In the former, pristane oil 
induces an oil granuloma cheracterized by a chemically-induced lymphoplasmacytic 
reaction. This progresses to an autonomously growing plasmacytoma with uncontrolled 
expression of c-MYC due to its rearrangement. Generally, these plasmacytomas secrete 
monoclonal immunoglobulin of the IgA isotype. Essential monoclonal gammopathies and a 
malignancy resembling human plasma cell myeloma may arise spontaneously in inbred 
mice (Radl et al., 1988; Radl, 1991). 
Hence, the Radl model was produced using 5T myeloma cells that arose spontaneously in 
aged, inbred C57BL/KaLwRijHsd mice and is propagated by the inoculation of these 
myeloma cells into syngeneic mice. More specifically, in order to develop a better animal 
model of human myeloma bone disease, Garrett et al. (1997), have established and 
subcloned a cell line from this murine myeloma and found that it causes osteolytic bone 
lesions in mice characteristic of human myeloma bone disease. The cell line produces 
interleukin-6, but grows independent of exogenous interleukin-6. Mice inoculated 
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intravenously with the cultured cells predictably develop an identical disease to the mice 
injected intravenously with fresh bone-marrow-derived myeloma cells, including 
monoclonal gammopathy and radiologic bone lesions. They found that some of the mice 
became hypercalcemic, and the bone lesions are characterized by increased osteoclast 
activity. They found identical results when they inoculated Nu/Bg/XID mice with cultured 
murine myeloma cells. Because they can inoculate mice with precise numbers of cells and 
predict accurately when the mice will develop bone lesions, become hypercalcemic, and die, 
they considered it as a convenient model for determining the mechanisms by which the 
myeloma cells cause osteoclast activation in this model of human myeloma bone disease 
(Garrett et al., 1997; Radl et al., 1979, 1988). 
On another approach, researchers made use of two facts:  
1. Human myeloma cell lines can survive and disseminate in mice with severe combined 
immunodeficiency (SCID; Feo-Zuppardi et al., 1992; Huang et al., 1993).  
2. Fetal bone implants (SCID-hu) can sustain survival and expansion of primary human 
myeloma cells from untreated patients with a high success rate (Yaccoby et al., 1998).  
Thus, the SCID-hu model is produced, which provides a suitable in vivo read out system to 
study human myeloma biology. Tumor self-renewal capacity can be examined in relation to 
maturation stage. The contributions of host accessory cells and cytokines to disease 
manifestation and progression can also be elucidated. It is anticipated that new treatment 
principles aiming, for example, to inactivate the marrow microenvironment (e.g. 
bisphosphonates: Aparicio et al., 1998; Shipman et al., 1997) and target neoangiogenesis (e.g. 
Thalidomide: D’ Amato et al., 1994; Singhal et al., 1999) can be evaluated. Another animal 
model uses adult human bone engraftments into SCID mice. In these mice the engrafted 
human bone is injected and subsequently populated by fresh tumor cells. In that way  a 
close resemblance to human multiple myeloma has been achieved (Sjak-Shie et al., 1999).  
Similar to the extensively tested and validated SCID-hu system, which uses a human fetal 
bone (Yaccoby et al., 1998, 2002, 2006; Yaccoby & Epstein, 1999), MM cells from the majority of 
patients grow exclusively in the implanted bone and produce typical myeloma manifestations 
including stimulation of osteoclastogenesis, suppression of osteoblastogenesis, and induction 
of severe osteolytic bone disease (Fig. 1). Ethical and scientific concerns regarding the use of 
human fetal bones in the SCID-hu model of primary human myeloma prompted the 
researchers to develop a novel system that uses rabbit bones implanted subcutaneously in 
unconditioned SCID mice. Immunohistochemical analysis of the implanted bone revealed that 
the majority of bone marrow (BM) microenvironment cells such as blood vessels, osteoclasts 
and osteoblasts were of rabbit origin. The implanted bones were directly injected with 
myeloma cells from MM patients. Successful engraftment of unseparated BM cells from 85% of 
patients and CD138-selected myeloma plasma cells from 81% of patients led to the production 
of patients’ M-protein isotypes and typical myelomamanifestations (osteolytic bone lesions 
and angiogenesis of rabbit origin; Fig. 1). Myeloma cells grew exclusively in the rabbit bone, 
but were able to metastasize into another bone at a remote site in the same mouse. Cells from 
patients with extramedullary disease also grew along the outer surface of the rabbit bones. 
This demonstrates the ability of SCID-rab model, marked by a nonmyelomatous, nonhuman, 
and nonfetal microenvironment, to support the growth of CD138-expressing myeloma cells. 
This system can now be widely used to study the biology of myeloma and its manifestations 
and to develop novel therapeutic approaches for this disease (Yata & Yaccoby, 2004). 
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Gaurnier-Hausser et al. (2011) set out to determine whether dogs with spontaneous DLBCL 
(diffuse large B-cell lymphoma) have comparative aberrant constitutive NF-κB activity and 
to determine the therapeutic relevance of NF-κB inhibition in dogs with relapsed, resistant 
DLBCL. Constitutive canonical NF-κB activity and increased NF-κB target gene expression 
were detected in primary DLBCL tissue. NF-κB essential modulator (NEMO)-binding 
domain (NBD) peptide inhibited this activity and induced apoptosis of primary malignant B 
cells in vitro. Intratumoral injections of NBD peptide to dogs with relapsed DLBCL inhibited 
NF-κB target gene expression and reduced tumor burden. This work shows that dogs with 
spontaneous DLBCL share therapeutic relevance of NF-κB inhibition in the treatment of 
ABC-DLBCL. These results have important translational relevance for ABC-DLBCL 
treatment in human patients, and dogs with spontaneous DLBCL may represent a clinically 
relevant, spontaneous, large animal model for human ABC-DLBCL. 
Other findings suggest that increasing levels of human-derived IgG in peripheral blood from 
hu-PBL/SCID mice could be used to monitor EBV-related human B-cell lymphoma 
development in experimental animals (Tang et al., 2011). Epstein-Barr virus (EBV) has a close 
association with various types of human lymphomas. Tang et al. (2011) aimed to evaluate the 
association between human IgG concentration and EBV-associated lymphoma development in 
huPBL/SCID mice. For that, human peripheral blood lymphocytes (hu-PBL) from EBV-
seropositive donors were inoculated intraperitoneally into SCID mouse. Twenty one out of 29 
mice developed tumors in their body. Immunohistochemical staining showed that all induced 
tumors were LCA (leukocyte common antigen) positive, B-cell markers (CD20, CD79a) 
positive, and T-cell markers (both CD3 and CD45RO) negative. The tumors were diagnosed as 
human B-cell lymphomas by these morphological and immunohistochemical features. In situ 
hybridization exhibited resultant tumor cells with EBV encoded small RNA-1 (EBER-1). 
Human-derived IgG could be found in the serum of SCID mice on the 15th day following hu-
PBL transplantation, and IgG levels increased as tumor grew in 6 hu-PBL/SCID chimeras. 
These data suggest that intraperitoneal transfer of hu-PBLs from EBV+ donors to SCID mice 
leads to high human IgG levels in mouse serum and B cell lymphomas. 
3.4 Multiple Myeloma  
Plasmacytoma or myeloma can be induced in BALB/c mice by pristane oil or can develop 
spontaneously in some mouse strains (Potter, 1982; Radl, 1981). In the former, pristane oil 
induces an oil granuloma cheracterized by a chemically-induced lymphoplasmacytic 
reaction. This progresses to an autonomously growing plasmacytoma with uncontrolled 
expression of c-MYC due to its rearrangement. Generally, these plasmacytomas secrete 
monoclonal immunoglobulin of the IgA isotype. Essential monoclonal gammopathies and a 
malignancy resembling human plasma cell myeloma may arise spontaneously in inbred 
mice (Radl et al., 1988; Radl, 1991). 
Hence, the Radl model was produced using 5T myeloma cells that arose spontaneously in 
aged, inbred C57BL/KaLwRijHsd mice and is propagated by the inoculation of these 
myeloma cells into syngeneic mice. More specifically, in order to develop a better animal 
model of human myeloma bone disease, Garrett et al. (1997), have established and 
subcloned a cell line from this murine myeloma and found that it causes osteolytic bone 
lesions in mice characteristic of human myeloma bone disease. The cell line produces 
interleukin-6, but grows independent of exogenous interleukin-6. Mice inoculated 
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intravenously with the cultured cells predictably develop an identical disease to the mice 
injected intravenously with fresh bone-marrow-derived myeloma cells, including 
monoclonal gammopathy and radiologic bone lesions. They found that some of the mice 
became hypercalcemic, and the bone lesions are characterized by increased osteoclast 
activity. They found identical results when they inoculated Nu/Bg/XID mice with cultured 
murine myeloma cells. Because they can inoculate mice with precise numbers of cells and 
predict accurately when the mice will develop bone lesions, become hypercalcemic, and die, 
they considered it as a convenient model for determining the mechanisms by which the 
myeloma cells cause osteoclast activation in this model of human myeloma bone disease 
(Garrett et al., 1997; Radl et al., 1979, 1988). 
On another approach, researchers made use of two facts:  
1. Human myeloma cell lines can survive and disseminate in mice with severe combined 
immunodeficiency (SCID; Feo-Zuppardi et al., 1992; Huang et al., 1993).  
2. Fetal bone implants (SCID-hu) can sustain survival and expansion of primary human 
myeloma cells from untreated patients with a high success rate (Yaccoby et al., 1998).  
Thus, the SCID-hu model is produced, which provides a suitable in vivo read out system to 
study human myeloma biology. Tumor self-renewal capacity can be examined in relation to 
maturation stage. The contributions of host accessory cells and cytokines to disease 
manifestation and progression can also be elucidated. It is anticipated that new treatment 
principles aiming, for example, to inactivate the marrow microenvironment (e.g. 
bisphosphonates: Aparicio et al., 1998; Shipman et al., 1997) and target neoangiogenesis (e.g. 
Thalidomide: D’ Amato et al., 1994; Singhal et al., 1999) can be evaluated. Another animal 
model uses adult human bone engraftments into SCID mice. In these mice the engrafted 
human bone is injected and subsequently populated by fresh tumor cells. In that way  a 
close resemblance to human multiple myeloma has been achieved (Sjak-Shie et al., 1999).  
Similar to the extensively tested and validated SCID-hu system, which uses a human fetal 
bone (Yaccoby et al., 1998, 2002, 2006; Yaccoby & Epstein, 1999), MM cells from the majority of 
patients grow exclusively in the implanted bone and produce typical myeloma manifestations 
including stimulation of osteoclastogenesis, suppression of osteoblastogenesis, and induction 
of severe osteolytic bone disease (Fig. 1). Ethical and scientific concerns regarding the use of 
human fetal bones in the SCID-hu model of primary human myeloma prompted the 
researchers to develop a novel system that uses rabbit bones implanted subcutaneously in 
unconditioned SCID mice. Immunohistochemical analysis of the implanted bone revealed that 
the majority of bone marrow (BM) microenvironment cells such as blood vessels, osteoclasts 
and osteoblasts were of rabbit origin. The implanted bones were directly injected with 
myeloma cells from MM patients. Successful engraftment of unseparated BM cells from 85% of 
patients and CD138-selected myeloma plasma cells from 81% of patients led to the production 
of patients’ M-protein isotypes and typical myelomamanifestations (osteolytic bone lesions 
and angiogenesis of rabbit origin; Fig. 1). Myeloma cells grew exclusively in the rabbit bone, 
but were able to metastasize into another bone at a remote site in the same mouse. Cells from 
patients with extramedullary disease also grew along the outer surface of the rabbit bones. 
This demonstrates the ability of SCID-rab model, marked by a nonmyelomatous, nonhuman, 
and nonfetal microenvironment, to support the growth of CD138-expressing myeloma cells. 
This system can now be widely used to study the biology of myeloma and its manifestations 
and to develop novel therapeutic approaches for this disease (Yata & Yaccoby, 2004). 
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Conclusively, the SCID-hu/rab xenograft model provides a system where primary human 
myeloma cells can be injected into either a fetal human bone or rabbit bone that is implanted 
subcutaneously into an immunocompromised mouse (Yaccoby et al., 1998; Yata &Yaccoby, 
2004). This model (SCID-rab) has been used since its establishment for different studies, e.g. 
the effect of anti-DKK1 therapy on bone metabolism and tumor growth in a SCID-rab system, 
since DKK1 is a key player in MM bone disease and blocking DKK1 activity in myelomatous 
bones reduces osteolytic bone resorption, increases bone formation, and helps control MM 
growth (Yaccoby et al., 2007). 
The most recent study from Fowler et al. (2009) describes a model of myeloma in which the 
host microenvironment could be modified genetically. They demonstrated 5T myeloma 
establishment in recombination activating gene 2 (RAG-2)-deficient mice, which have 
improper B- and T-cell development. Importantly, these mice can be easily bred with 
genetically modified mice to generate double knockout mice, allowing manipulation of the 
host microenvironment at a molecular level. Inoculation of 5TGM1 myeloma cells into RAG-
2−/− mice resulted in myeloma development, which was associated with tumor growth 
within bone and an osteolytic bone disease, as assessed by microcomputed tomography 
(microCT), histology and histomorphometry. Myeloma-bearing RAG-2−/− mice displayed 
many features that were similar to both human myeloma and the original Radl 5T model. To 
demonstrate the use of this model, we have examined the effect of host-derived matrix 
metalloproteinase 9 (MMP-9) in the development of myeloma in vivo. 
 
Fig. 1. Growth patterns and typical disease manifestations of myeloma cells in the SCID-rab 
model. (a, b) Myeloma cells from the majority ofpatients grew exclusively in the rabbit BM 
(medullary disease). Radiographs (a) before and (b) 12 weeks after myeloma PCs injection 
show severe resorption of the myelomatous rabbit bone. (c) Myeloma PCs taken from 
extramedullary disease grew also on the outer surface of the implanted rabbit bone. (d) 
Increased activity of mulinucleate osteoclasts was detected in myelomatous rabbit bone by 
staining sections for TRAP. (e) These osteoclasts were of rabbit origin, as revealed by their 
reactivity with anti-rabbit macrophage antibody. (f, g) Myelomatous rabbit bone sections 
immunostained with antibody to factor VIII (f) and rabbit CD141 (g) demonstrate increased 
numbers of tumor-associated microvessels of rabbit origin (From Yata & Yaccoby, 2004, 
permission pending). 
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Inoculation of 5TGM1 myeloma cells into mice that are deficient in RAG-2 and MMP-9 
resulted in a reduction in both tumor burden and osteolytic bone disease when compared 
with RAG-2-deficient wild-type myeloma-bearing mice. The establishment of myeloma in 
RAG-2−/− mice permits molecular examination of the host contribution to myeloma 
pathogenesis in vivo. 
3.5 Other lymphoproliferative disorders 
Primates and swine have been used as experimental animals to develop animal models for 
post-transplant lymphoproliferative disorder (PTLD) one of the less frequently met LPDs.  
As previously mentioned, PTLD has been shown to be associated with Epstein-Barr virus 
(EBV) infection. Although primate animal models of PTLD and the use of molecular markers 
in its diagnosis had not yet been reported, Schmidtko et al. (2002) designed a study to evaluate 
the frequency, pathology, and molecular characteristics of PTLD in cynomolgus monkey 
kidney allograft recipients. Of 160 consecutive primate renal transplants performed, 5.6% 
developed PTLD 28-103 days after transplantation. In all cases, the lymph nodes were 
involved and effaced by an atypical polymorphous lymphoid proliferation of EBER+ B cells, 
diagnostic for PTLD. Focal staining for EBNA-2 was noted in tumor cells. In 67% (six of nine) 
the PTLD infiltrates were present in extra nodal sites, notably liver (56%), lung (44%), heart 
(44%), renal allograft (44%), and native kidney (22%). The spleen was infiltrated by PTLD cells 
in all four animals that had not undergone a pre-transplant splenectomy. The PTLD 
morphology was similar in all cases and predominantly of the polymorphous type, however, 
some of these showed areas that appeared minimally polymorphous. No cases of 
monomorphic PTLD were seen. By in situ hybridization, expression of the RNA product, 
homologous for EBV-encoded RNA (EBER) was identified in the PTLD tumor cells of all cases, 
indicating latent primate EBV- related infection. This report identifies a novel animal model of 
EBV associated PTLD in the setting of kidney transplantation, with valuable implications for 
managing and understanding human PTLD and oncogenesis (Schmidtko et al., 2002). 
Barth et al. (2009) developed another non-human primate facial composite tissue 
allotransplantation model to investigate strategies to achieve prolonged graft survival and 
immunologic responses unique to these allografts. For this reason, composite facial subunits 
consisting of skin, muscle, and bone were heterotopically transplanted to mixed lymphocyte 
reaction-mismatched Cynomolgus macaques. Tacrolimus monotherapy was administered 
via continuous intravenous infusion for 28 days then tapered to daily intramuscular doses. 
They concluded that Tacrolimus monotherapy provided prolonged rejection-free survival of 
composite facial allografts in this non-human primate model but was associated with the 
development of a high frequency of donor-derived PTLD tumors. The transplantation of a 
large volume of vascularized bone marrow in composite tissue allografts may be a risk 
factor for PTLD development. 
A high incidence of a PTLD is observed in miniature swine conditioned for allogeneic 
hematopoietic cell transplantation using a protocol involving T-cell depletion and 
cyclosporine therapy. Cho et al. (2004), designed a study to assess contributing factors to 
disease development. Forty-six animals were studied including 12 (26%) that developed 
PTLD. A number of risk factors for PTLD were examined, including degree of 
immunosuppression, degree of MHC mismatch and infection by a porcine lymphotrophic 
herpesvirus (PLHV-1). Flow cytometry was used to measure host and donor T- and B-cell 
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Conclusively, the SCID-hu/rab xenograft model provides a system where primary human 
myeloma cells can be injected into either a fetal human bone or rabbit bone that is implanted 
subcutaneously into an immunocompromised mouse (Yaccoby et al., 1998; Yata &Yaccoby, 
2004). This model (SCID-rab) has been used since its establishment for different studies, e.g. 
the effect of anti-DKK1 therapy on bone metabolism and tumor growth in a SCID-rab system, 
since DKK1 is a key player in MM bone disease and blocking DKK1 activity in myelomatous 
bones reduces osteolytic bone resorption, increases bone formation, and helps control MM 
growth (Yaccoby et al., 2007). 
The most recent study from Fowler et al. (2009) describes a model of myeloma in which the 
host microenvironment could be modified genetically. They demonstrated 5T myeloma 
establishment in recombination activating gene 2 (RAG-2)-deficient mice, which have 
improper B- and T-cell development. Importantly, these mice can be easily bred with 
genetically modified mice to generate double knockout mice, allowing manipulation of the 
host microenvironment at a molecular level. Inoculation of 5TGM1 myeloma cells into RAG-
2−/− mice resulted in myeloma development, which was associated with tumor growth 
within bone and an osteolytic bone disease, as assessed by microcomputed tomography 
(microCT), histology and histomorphometry. Myeloma-bearing RAG-2−/− mice displayed 
many features that were similar to both human myeloma and the original Radl 5T model. To 
demonstrate the use of this model, we have examined the effect of host-derived matrix 
metalloproteinase 9 (MMP-9) in the development of myeloma in vivo. 
 
Fig. 1. Growth patterns and typical disease manifestations of myeloma cells in the SCID-rab 
model. (a, b) Myeloma cells from the majority ofpatients grew exclusively in the rabbit BM 
(medullary disease). Radiographs (a) before and (b) 12 weeks after myeloma PCs injection 
show severe resorption of the myelomatous rabbit bone. (c) Myeloma PCs taken from 
extramedullary disease grew also on the outer surface of the implanted rabbit bone. (d) 
Increased activity of mulinucleate osteoclasts was detected in myelomatous rabbit bone by 
staining sections for TRAP. (e) These osteoclasts were of rabbit origin, as revealed by their 
reactivity with anti-rabbit macrophage antibody. (f, g) Myelomatous rabbit bone sections 
immunostained with antibody to factor VIII (f) and rabbit CD141 (g) demonstrate increased 
numbers of tumor-associated microvessels of rabbit origin (From Yata & Yaccoby, 2004, 
permission pending). 
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Inoculation of 5TGM1 myeloma cells into mice that are deficient in RAG-2 and MMP-9 
resulted in a reduction in both tumor burden and osteolytic bone disease when compared 
with RAG-2-deficient wild-type myeloma-bearing mice. The establishment of myeloma in 
RAG-2−/− mice permits molecular examination of the host contribution to myeloma 
pathogenesis in vivo. 
3.5 Other lymphoproliferative disorders 
Primates and swine have been used as experimental animals to develop animal models for 
post-transplant lymphoproliferative disorder (PTLD) one of the less frequently met LPDs.  
As previously mentioned, PTLD has been shown to be associated with Epstein-Barr virus 
(EBV) infection. Although primate animal models of PTLD and the use of molecular markers 
in its diagnosis had not yet been reported, Schmidtko et al. (2002) designed a study to evaluate 
the frequency, pathology, and molecular characteristics of PTLD in cynomolgus monkey 
kidney allograft recipients. Of 160 consecutive primate renal transplants performed, 5.6% 
developed PTLD 28-103 days after transplantation. In all cases, the lymph nodes were 
involved and effaced by an atypical polymorphous lymphoid proliferation of EBER+ B cells, 
diagnostic for PTLD. Focal staining for EBNA-2 was noted in tumor cells. In 67% (six of nine) 
the PTLD infiltrates were present in extra nodal sites, notably liver (56%), lung (44%), heart 
(44%), renal allograft (44%), and native kidney (22%). The spleen was infiltrated by PTLD cells 
in all four animals that had not undergone a pre-transplant splenectomy. The PTLD 
morphology was similar in all cases and predominantly of the polymorphous type, however, 
some of these showed areas that appeared minimally polymorphous. No cases of 
monomorphic PTLD were seen. By in situ hybridization, expression of the RNA product, 
homologous for EBV-encoded RNA (EBER) was identified in the PTLD tumor cells of all cases, 
indicating latent primate EBV- related infection. This report identifies a novel animal model of 
EBV associated PTLD in the setting of kidney transplantation, with valuable implications for 
managing and understanding human PTLD and oncogenesis (Schmidtko et al., 2002). 
Barth et al. (2009) developed another non-human primate facial composite tissue 
allotransplantation model to investigate strategies to achieve prolonged graft survival and 
immunologic responses unique to these allografts. For this reason, composite facial subunits 
consisting of skin, muscle, and bone were heterotopically transplanted to mixed lymphocyte 
reaction-mismatched Cynomolgus macaques. Tacrolimus monotherapy was administered 
via continuous intravenous infusion for 28 days then tapered to daily intramuscular doses. 
They concluded that Tacrolimus monotherapy provided prolonged rejection-free survival of 
composite facial allografts in this non-human primate model but was associated with the 
development of a high frequency of donor-derived PTLD tumors. The transplantation of a 
large volume of vascularized bone marrow in composite tissue allografts may be a risk 
factor for PTLD development. 
A high incidence of a PTLD is observed in miniature swine conditioned for allogeneic 
hematopoietic cell transplantation using a protocol involving T-cell depletion and 
cyclosporine therapy. Cho et al. (2004), designed a study to assess contributing factors to 
disease development. Forty-six animals were studied including 12 (26%) that developed 
PTLD. A number of risk factors for PTLD were examined, including degree of 
immunosuppression, degree of MHC mismatch and infection by a porcine lymphotrophic 
herpesvirus (PLHV-1). Flow cytometry was used to measure host and donor T- and B-cell 
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levels in the peripheral blood. Porcine lymphotrophic herpesvirus viral load was 
determined by quantitative PCR. Animals developing PTLD had significantly lower levels 
of T cells on the day of transplant. Cyclosporine levels did not differ significantly between 
animals with and without PTLD. Animals receiving transplants across a two-haplotype 
mismatch barrier showed an increased incidence of PTLD. All animals with PTLD had 
significant increases in PLHV-1 viral loads. Porcine lymphotrophic herpesvirus viral copy 
numbers remained at low levels in the absence of disease. The availability of a preclinical 
large-animal model with similarities to PTLD of humans may allow studies of the 
pathogenesis and treatment of that disorder. 
Spleen transplantation (SpTx) was also performed in miniature swine across full major 
histocompatibility complex barriers to study the tolerogenic effect of the spleen (Dor et al., 
2004). This study described the development of PTLD after allogeneic SpTx. Recipient pigs 
underwent whole body irradiation (100 cGy), thymic irradiation (700 cGy), and native 
splenectomy (day 0), and received a 45-day course of intravenous cyclosporine (trough level 
400-800 ng/ml). After SpTx, two of seven pigs developed PTLD (1 donor-type, 1 host-type). 
These two pigs had greater T cell depletion and higher trough levels of cyclosporine. Early 
changes that occurred prior to the development of clinical features of PTLD were increased 
porcine lymphotropic herpesvirus-1 viral loads in blood and tissues, and increased numbers 
of leukocytes, B cells, and total serum IgM. PTLD can occur after allogeneic SpTx in swine. 
This model may be useful in studies of the pathogenesis of PTLD. 
In another study using miniature swine (Doucette et al., 2007) the Porcine lymphotropic 
herpesvirus-1 (PLHV-1), a gamma-herpesvirus related to Epstein-Barr virus (EBV) was 
associated with development of PTLD following allogeneic stem cell or spleen 
transplantation. Oligonucleotide microarrays were designed based on known open reading 
frames (ORFs) of PLHV-1. Expression was compared by cohybridization of cDNA from 
lymph nodes of PLHV-1+ swine after allogeneic spleen transplantation between either: 1) 
PTLD-affected and PTLD-unaffected swine; or 2) PTLD-affected swine vs. samples from the 
same animal prior to diagnosis. In PTLD-affected animals, consistent upregulation (nine 
ORFs) and downregulation (four ORFs) of PLHV-1 mRNA was observed in comparison to 
those without PTLD. No differences in gene expression were discovered at the time of 
clinical PTLD diagnosis compared to six to nine days prior to diagnosis in the same animals. 
This model provides insights into the pathogenesis of PTLD and, by extension, potential 
diagnostic and therapeutic tools for human EBV-associated PTLD. 
4. Waldenström’s macroglobulinemia 
This disease was first identified by J. Waldenström when he reported two patients with a 
syndrome of oronasal bleeding, lymphadenopathy, an elevated sedimentation rate, 
hyperviscosity, normal bone films, cytopenias and a bone marrow with a predominantly 
lymphoid infiltrate (Waldenström, 1944). 
In the Revised European-American Lymphoma (REAL) classification, Waldenström 
macroglobulinemia (WM) has become viewed as a distinct clinicopathological entity, and is 
defined largely as a lymphoplasmacytic lymphoma (LPL); (Harris et al, 1994). The Second 
International Workshop on Waldenström macroglobulinemia attempted to refine further the 
working definition of the disease within the context of a LPL (Owen et al., 2003). For review, 
see Ansell et al., 2010. 
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Despite these efforts, the debate remains within the hematological and hematopathological 
communities with respect to nosology. These issues of definition have and continue to affect 
the interpretation of results within and across clinical trials as well as in basic and 
epidemiological research (Fonseca & Hayman, 2007). The same researchers (Fonseca & 
Hayman, 2007) used the definition of WM as proposed at the Second International 
Workshop on WM, with the exception that the original criterion of the presence of any 
degree of marrow involvement with a lymphoplasmacytoid infiltrate has been modified to 
allow a distinction to be made between an immunoglobulin (Ig) M monoclonal 
gammopathy of undetermined significance (MGUS) and WM. This change is based on 
analyses that have established the prognostic relevance and statistically significant survival 
differences among IgM MGUS (<10% marrow lymphoplasmacytic infiltrate) and 
symptomatic/smouldering WM and symptomatic/active WM(≥10% lymphoplasmacytic 
marrow infiltrate; usually intertrabecular). 
Thus, Waldenström macroglobulinemia is a B-cell lymphoproliferative disorder 
characterized by a lymphoplasmacytic infiltration in the bone marrow or lymphatic tissue 
and a monoclonal immunoglobulin M protein (IgM) in the serum (Dimopoulos et al., 2005; 
Owen et al., 2003). Is a rare hematological neoplasm with an overall incidence of 
approximately 5 cases per 1 million persons per year, accounting for 1–2% of haematological 
malignancies (Groves et al., 1998; Herrinton & Weiss, 1993).  
The median age at diagnosis varies between 63 and 68 years, and most patients (55%-70%) 
with newly diagnosed disease are men (Dimopoulos et al., 2000). The incidence of 
Waldenström macroglobulinemia is highest among white people and is rare in other 
population groups (Benjamin et al., 2003). More specifically, WM is rare in Blacks, who 
represent only 5% of cases, and it is also rare in those of Mexican-Mestizo descent (Groves et 
al, 1998; Herrinton & Weiss, 1993; Ruiz-Arguelles et al, 2000). To date, there is no compelling 
evidence to link WM to specific occupational or environmental exposures, tobacco or 
alcohol use (Linet et al., 1993). 
The aetiology of WM remains unknown. It appears to be primarily a sporadic disease, 
although there are multiple reports of familial clustering (Blattner et al., 1980; Brown et al., 
1967; Elves & Brown, 1968; Getaz & Staples, 1977; McMaster et al., 2005; Ogmundsdottir et 
al., 1999; Renier et al., 1989; Treon et al., 2006). McMaster et al. (2006) performed a 
genomewide linkage analysis in 11 high-risk families with WM that were informative for 
linkage (including a total of 122 individuals with DNA samples). The strongest evidence of 
linkage was found on chromosomes 1q and 4q (McMaster et al., 2006). Treon et al. (2006) 
evaluated 257 patients with previously untreated WM and found that 18,7% had at least one 
first-degree relative with either WM or another B-cell disorder. In addition, those with a 
familial history had higher percentages of bone marrow involvement, were diagnosed at a 
younger age, and were more likely to have higher IgM levels upon initial presentation 
(Treon et al., 2006). 
The greatest risk factor for the development of WM is that of having an IgM MGUS. These 
patients have 46 times greater risk of developing WM than the general population (Kyle et 
al., 2002). Factors affecting the progression from IgM MGUS to WM are unknown. 
Infiltration of the bone marrow and extramedullary sites by malignant B cells and elevated 
IgM levels account for the symptoms associated with this disease. Patients may develop 
constitutional symptoms, pancytopenia, organomegaly, neuropathy, and symptoms 
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levels in the peripheral blood. Porcine lymphotrophic herpesvirus viral load was 
determined by quantitative PCR. Animals developing PTLD had significantly lower levels 
of T cells on the day of transplant. Cyclosporine levels did not differ significantly between 
animals with and without PTLD. Animals receiving transplants across a two-haplotype 
mismatch barrier showed an increased incidence of PTLD. All animals with PTLD had 
significant increases in PLHV-1 viral loads. Porcine lymphotrophic herpesvirus viral copy 
numbers remained at low levels in the absence of disease. The availability of a preclinical 
large-animal model with similarities to PTLD of humans may allow studies of the 
pathogenesis and treatment of that disorder. 
Spleen transplantation (SpTx) was also performed in miniature swine across full major 
histocompatibility complex barriers to study the tolerogenic effect of the spleen (Dor et al., 
2004). This study described the development of PTLD after allogeneic SpTx. Recipient pigs 
underwent whole body irradiation (100 cGy), thymic irradiation (700 cGy), and native 
splenectomy (day 0), and received a 45-day course of intravenous cyclosporine (trough level 
400-800 ng/ml). After SpTx, two of seven pigs developed PTLD (1 donor-type, 1 host-type). 
These two pigs had greater T cell depletion and higher trough levels of cyclosporine. Early 
changes that occurred prior to the development of clinical features of PTLD were increased 
porcine lymphotropic herpesvirus-1 viral loads in blood and tissues, and increased numbers 
of leukocytes, B cells, and total serum IgM. PTLD can occur after allogeneic SpTx in swine. 
This model may be useful in studies of the pathogenesis of PTLD. 
In another study using miniature swine (Doucette et al., 2007) the Porcine lymphotropic 
herpesvirus-1 (PLHV-1), a gamma-herpesvirus related to Epstein-Barr virus (EBV) was 
associated with development of PTLD following allogeneic stem cell or spleen 
transplantation. Oligonucleotide microarrays were designed based on known open reading 
frames (ORFs) of PLHV-1. Expression was compared by cohybridization of cDNA from 
lymph nodes of PLHV-1+ swine after allogeneic spleen transplantation between either: 1) 
PTLD-affected and PTLD-unaffected swine; or 2) PTLD-affected swine vs. samples from the 
same animal prior to diagnosis. In PTLD-affected animals, consistent upregulation (nine 
ORFs) and downregulation (four ORFs) of PLHV-1 mRNA was observed in comparison to 
those without PTLD. No differences in gene expression were discovered at the time of 
clinical PTLD diagnosis compared to six to nine days prior to diagnosis in the same animals. 
This model provides insights into the pathogenesis of PTLD and, by extension, potential 
diagnostic and therapeutic tools for human EBV-associated PTLD. 
4. Waldenström’s macroglobulinemia 
This disease was first identified by J. Waldenström when he reported two patients with a 
syndrome of oronasal bleeding, lymphadenopathy, an elevated sedimentation rate, 
hyperviscosity, normal bone films, cytopenias and a bone marrow with a predominantly 
lymphoid infiltrate (Waldenström, 1944). 
In the Revised European-American Lymphoma (REAL) classification, Waldenström 
macroglobulinemia (WM) has become viewed as a distinct clinicopathological entity, and is 
defined largely as a lymphoplasmacytic lymphoma (LPL); (Harris et al, 1994). The Second 
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Despite these efforts, the debate remains within the hematological and hematopathological 
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associated with immunoglobulin deposition or hyperviscosity (Dimopoulos et al., 2000; 
Vijay & Gertz, 2007). However, symptoms vary considerably in individual patients. 
Although some patients present with the aforementioned symptoms, many are 
asymptomatic at the time of diagnosis. 
Waldenström macroglobulinemia is incurable with current therapy, and half of the patients 
die of disease progression; median survival is approximately 5 years (Dimopoulos et al., 1999). 
This disease is diagnosed in many patients at an advanced age, and thus approximately half of 
the patients die of causes unrelated to Waldenström macroglobulinemia. Because the disease is 
incurable and the clinical presentations, comorbidities, and causes of death vary substantially, 
the decision to treat patients and the choice of treatment can be complex. A number of 
consensus meetings have listed reasonable treatment options (Gertz et al., 2003; Treon et al., 
2006; Dimopoulos et al., 2009) but the physician is still faced with a difficult treatment decision 
in a patient with an uncommon disease. 
5. Animal models of Waldenström’s macroglobulinemia 
In 2003, the Wayne State University Waldenstrom's Macroglobulinemia xenograft model in 
mice with severe combined immune deficiency (WSU-WM-SCID) was developed (Al-Katib 
et al., 2003). The WSU-WM-SCID is a model of a more aggressive and resistant WM usually 
seen toward the late stages of disease. It is, therefore, a particularly useful tool in developing 
new therapeutic strategies for the more aggressive WM, including targeted therapy, which 
exploits unique molecular characteristics of tumor cells. The WSU-WM-SCID is the first 
preclinical animal model available for this disease. It is based on a permanent, EBV- 
IgMlambda cell line (WSU-WM) established from a patient with a 10-year history of 
Waldenstrom's macroglobulinemia. These cells are CD5(-)CD10(+)CD19(+)CD20(+)CD22(+) 
and have t(8;14) (q24;32), t(12;17) (q24;q21), 2p-. WSU-WM cells also express DNA 
topoisomerase II (alpha and beta), and are bcl(2)(+)bcl(XL)(+)bax(-). Although the tumor has 
aggressive biological behavior with c-myc-IgH rearrangement, it has retained the salient 
features of WM. The breakpoint on 8q24 is downstream of c-myc exon 3, which is not usual 
for Burkitt-type breakpoints. WSU-WM cells also express both secretory (s(u)) and 
membrane (m(u)) IgM mRNA and secrete IgM in culture supernatant. Histiologically, WSU-
WM-SCID xenograft tumors have lymphoplasmacytoid morphology. These features 
indicate biological, but not histological evolution.  
In 2005, Tassone et al., developed a novel in vivo model of human WM in severe combined 
immunodeficient (SCID) mice implanted with human fetal bone chips (SCID-hu mice) into 
which WM cells from patient bone marrow are engrafted directly into the human bone 
marrow (huBM) microenvironment. WM cells in SCID-hu mice produced human 
monoclonal paraprotein (immunoglobulin M [IgM] and/or kappa or lambda chain) 
detectable in mice sera. Immunohistochemical analysis of human bone retrieved from SCID-
hu mice showed infiltration with CD20+, IgM+, and monotypic light chain+ 
lymphoplasmacytic cells. Mast cells were observed to be associated with the infiltrate in 
these sections. Treatment of SCID-hu mice bearing WM with rituximab induced tumor 
regression, associated with a decrease in serum paraprotein. This model, therefore, 
recapitulates the in vivo biology of WM and allows the study of novel investigational drugs 
targeting WM cells in the huBM milieu. 
Model cell lines are essential tools for investigating the biology and therapeutics of cancer. 
Approximately 1500 human hematopoietic neoplastic cell lines have been described, 
Animal Models of Lymphoproliferative Disorders 
Focusing on Waldenström’s Macroglobulinemia 
 
443 
covering most major disease entities. Waldenström's macroglobulinemia (WM) is a rare 
incurable hematological neoplasm from which four cell lines have been derived. 
In 2007 a cell line, the BCWM.1 cell line (Ditzel Santos et al., 2007), which was derived from 
the long-term culture of CD19(+) selected bone marrow lymphoplasmacytic cells isolated 
from an untreated patient with WM. BCWM.1 cells morphologically resemble 
lymphoplasmacytic cells (LPC) and propagate in RPMI-1640 medium supplemented with 
10% fetal bovine serum. Phenotypic characterization by flow cytometric analysis 
demonstrated typical WM LPC characteristics: CD5(-), CD10(-), CD19(+), CD20(+), CD23(+), 
CD27(-), CD38(+), CD138(+), CD40(+), CD52(+), CD70(+), CD117(+), cIgM(+), cIgG(-),  
cIgA(-), ckappa(-), clambda(+), as well as the survival proteins APRIL and BLYS, and their 
receptors TACI, BCMA and BAFF-R. Enzyme-linked immunosorbent assay studies 
demonstrated secretion of IgMlambda and soluble CD27. Karyotypic and multicolor 
fluorescence in situ hybridization studies did not demonstrate cytogenetic abnormalities. 
Molecular analysis of BCWM.1 cells confirmed clonality by determination of IgH 
rearrangements. Inoculation of BCWM.1 cells in human bone marrow chips implanted in 
severe combined immunodeficient-hu mice led to rapid engraftment of tumor cells and 
serum detection of human IgM, lambda, and soluble CD27. These studies support the use of 
BCWM.1 cells as an appropriate model for the study of WM, which in conjunction with the 
severe combined immunodeficient-hu mouse model may be used as a convenient model for 
studies focused on both WM pathogenesis and development of targeted therapies for WM.  
In 2008, Drexler et al., summarized on the existence of three cell lines, that although are 
currently used as in vitro models, none convincingly pass muster. Mindful that candidate 
tumor cell lines sometimes arise spuriously by viral immortalization of bystander cells, they 
reviewed the extent to which WM cell lines portray established disease features in vitro. At 
closer inspection, it seems that none convincingly displays morphological, 
immunophenotypic, genotypic or biological features characteristic of WM. Rather it appears 
that two cell lines (WM1 and BCWM.1) are most probably Epstein-Barr virus-immortalized 
B-lymphoblastoid cell lines, derived from bystander B-cells. The third cell line (WSU-WM) 
carries the most common cytogenetic hallmark of Burkitt lymphoma, namely 
t(8;14)(q24;q32), while none have been shown to carry chromosome 6 deletions recently 
demonstrated as indicative of disease progression in this entity.  
Recently, Hodge et al. (2011) described the establishment of a new WM cell line, MWCL-1. 
Comprehensive genetic analyses have unequivocally confirmed a clonal relationship 
between this novel cell line and the founding tumor. MWCL-1 cells exhibit an 
immunophenotype consistent with a diverse, tumor clone composed of both small B 
lymphocytes and larger lymphoplasmacytic cells and plasma cells: CD3⁻, CD19⁺, CD20⁺, 
CD27⁺, CD38⁺, CD49D⁺, CD138⁺, cIgM⁺, and κ⁺. Cytogenetic studies identified a monoallelic 
deletion of 17p13 (TP53) in both the cell line and the primary tumor. Direct DNA 
resequencing of the remaining copy of TP53 revealed a missense mutation at exon 5 (V143A, 
GTG>GCG). In accordance with primary WM tumors, MWCL-1 cells retain the ability to 
secrete high amounts of IgM protein in the absence of an external stimulus. The genetic, 
immunophenotypic, and biologic data presented here confirm the validity of the MWCL-1 
cell line as a representative model of WM. 
Dr. Janz at Department of Pathology at University of Iowa is currently developing a mouse 
model of Waldenström's macroglobulinemia. An immunocompetent, transgenic mouse 
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model of human WM that will be useful for preclinical testing of WM drug candidates. 
Transgenic mouse models of human cancer are experimental model systems that rely on 
laboratory mice that have been genetically manipulated to render them prone to neoplasms 
that accurately recapitulate important features of their human cancer counterparts. Model 
systems of this sort: enable researchers to study the onset and progression of cancer in ways 
that cannot be pursued in human beings; advance our understanding of the molecular genetic 
and biological events that contribute to the development and spread of cancer cells; and 
provide a valuable preclinical platform for evaluating new approaches to treat and prevent 
cancer in patients. The latter is particularly important in circumstances in which drug testing 
requires an intact, immunocompetent animal that is able to produce the same kind of tumor 
microenvironment and recruit the same types of tumor bystander cells commonly found in 
human patients. To give but one example, therapeutic antibodies target cancer cells by 
recruiting normal immune cells to the site of attack; thus, the preclinical testing of these 
antibodies requires strains of laboratory mice that have a normal, fully functioning immune 
system. To that end, Janz and collaborators are generating a designer model of human WM 
designated C.IL6/BCL2/AIDnull. This model combines three crucial pathogenetic factors of 
human WM – namely the B-lymphocyte growth, differentiation and survival factor IL-6, the 
cellular oncoprotein BCL-2, and the inability of WM cells to perform immunoglobulin isotype 
switching (AIDnull) – on the genetic backgroud of BALB/c (abbreviated as C). Strain C mice are 
highly susceptible to malignant B-lymphocyte transformation (Diagram 1; 
http://www.medicine.uiowa.edu Pathology/site/research/ janz/res_projects.html; selected 
publications of Dr.Janz: de Jong & Janz, 2010; Park et al., 2005). 
 
Diagram 1. Schematic overview of the pathogenesis of lymphoplasmacytic lymphoma 
(LPL)-WM (panel A) and transgenic mouse strains that Janz et al. propose to use for 
modeling human LPL-WM in mice (panel B). 
(A) IL6 and BCL2 have been identified as "WM genes" – genes that confer genetic proclivity to 
the disease (left). Additionally, IL-6 and BCL-2 are major player in the LPL-WM cells (right) 
(B) All strains are on the same genetic background of BALB/c (C), an important 
precondition for intercrossing the various transgenes without jeopardizing crucial practical 
issues of this project, such as the ability to adoptively transfer fully transformed tumor cells 
or premalignant B-lineage cells from transgenic mice. We hypothesize that strain 
C.IL6/BCL2/AID-/- mice will develop IgM+ WM-like tumors. 
5.1 Waldenström’s macroglobulinemia in NOD/SCID mice 
Although important advances have been made in the classification of lymphomas, the 
remaining discrepancies in WM definition reflect the fact that the pathogenesis of this 
disease remains largely unknown.  
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As stated in the previous paragraph, the establishment of reliable animal models will 
significantly enhance research in dissecting the complicate pathogenesis of WM. In addition, 
suitable animal models may be used to assess the efficacy of existing treatments and 
develop novel therapeutic strategies (Al-Katib et al., 1993; 2003). Severe combined 
immunodeficient (SCID) mice injected with subcutaneous xenografts of neoplastic cells were 
originally used to study WM. However, the usefulness of these models is limited because 
they do not recapitulate typical features of WM, such as bone marrow localization. Recently 
developed SCID mouse WM models overcome this drawback, by utilizing subcutaneous 
implants of human fetal bone chips. The subsequent injection of bone marrow (BM) 
aspirates from WM patients directly into the fetal bone implants resulted in successful WM 
cell engraftment in 69% of animals (Tassone et al., 2005). Although this model offers a 
potential advantage in that human bone is used, fetal bone, which is at a state of rapid 
growth, clearly differs from adult bone. It is apparent that there are differences between the 
bone marrow of a newborn and an adult bone marrow, including apoptotic cells, T cells, B 
cells and macrophages, developing the microenvironment where the WM cells are being 
hosted. Not to mention the fact that human bone is made of cells forming temporary 
anatomical structures, called basic multicellular units that execute bone remodeling, which 
change with ageing of humans (Seeman, 2008). 
Our study was undertaken with the aim to develop a novel non-obese SCID (NOD-SCID) 
mouse model of WM. For that, pairs of bone particles derived from adult humans were 
successfully implanted intramuscularly in mice. Each mouse was implanted with a bone 
fragment taken from a neoplastic disease-free individual in the one hind limb and with a 
different biopsy taken from a WM patient, in the other. IgM producing neoplastic cells not 
only retained viability in the bone marrow of the WM bone biopsy but also metastasized to 
the normal bone marrow of the distant bone implant. The mouse model reported here 
improves on existing models of WM by recapitulating the adult human bone marrow 
microenvironment of abnormal WM neoplastic cells. 
For this reason, twenty-nine NOD-SCID mice (Charles River Laboratories, France) were 
used. The animals were housed in static microisolator cages at the bio-containment animal 
Research Facility of the G. Papanicolaou General Hospital. All experimental procedures and 
protocols were in accordance with the European Council Directive 86/609 as well as the 
national and institutional guidelines for animal care.  
Cancellous bone core fragments ranging from 16 to 22 mm3 in size were obtained from the 
femoral head of neoplastic disease-free adult humans during hip arthroplasty or 
hemiarthroplasty. Bone fragments were subsequently implanted into the right or left 
hindlimb muscles of 6 to 8 weeks-old mice (n=23), weighing 25 - 30 grams, as previously 
described (Tsingotjidou et al., 2001). To test viability of implanted tissue, implants were 
retrieved from 9 mice that were sacrificed at 4 (n=3), 8 (n=3) and 12 (n=3) weeks post-
implantation. Based on previous studies (Boynton et al., 1996) in order to detect 
hematopoietic cells of human origin mouse anti-human CD45 antibody (1:500; Dako, 
Carpinteria, CA) was used. Eight to twelve weeks following first bone implantation, the 
non-implanted hindlimb of the remaining 12 mice was also engrafted with a human bone 
biopsy taken from WM patients (see flow chart; Diagram 2). For that, bone marrow core 
needle biopsies (bone biopsies) were obtained from the posterior iliac crest of five patients 
with active WM during scheduled clinical visits. The biopsy was maintained in RPMI 
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femoral head of neoplastic disease-free adult humans during hip arthroplasty or 
hemiarthroplasty. Bone fragments were subsequently implanted into the right or left 
hindlimb muscles of 6 to 8 weeks-old mice (n=23), weighing 25 - 30 grams, as previously 
described (Tsingotjidou et al., 2001). To test viability of implanted tissue, implants were 
retrieved from 9 mice that were sacrificed at 4 (n=3), 8 (n=3) and 12 (n=3) weeks post-
implantation. Based on previous studies (Boynton et al., 1996) in order to detect 
hematopoietic cells of human origin mouse anti-human CD45 antibody (1:500; Dako, 
Carpinteria, CA) was used. Eight to twelve weeks following first bone implantation, the 
non-implanted hindlimb of the remaining 12 mice was also engrafted with a human bone 
biopsy taken from WM patients (see flow chart; Diagram 2). For that, bone marrow core 
needle biopsies (bone biopsies) were obtained from the posterior iliac crest of five patients 
with active WM during scheduled clinical visits. The biopsy was maintained in RPMI 
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medium until its use. Typically, two implants were produced from each bone biopsy. In one 
case, however, a single WM bone biopsy was large enough to be the source of 6 implants. 
All human bone biopsy donors signed Institutional Review Board-approved informed 
consent forms. Control mice received no implant (n=3) or were implanted only, either with 
non-WM (n=2) or with WM (n=3) human bone fragments (Diagram 2).  
To detect human IgM in the serum of mice, thus providing evidence for presence of human 
IgM-secreting B-cells or WM cells, mouse blood was collected from the orbital sinus of each 
mouse monthly during the experiment. Blood serum was serially tested for circulating IgM 
by ELISA (Diagnostic automation Inc., Calabasas, CA, USA).  
Mice were sacrificed at different time points ranging from 1 to 5 months following the 
implantation of WM bone biopsies (Diagram 2). At necropsy, tissues including femur, tibia, 
brain, liver, spleen, lungs, kidneys and the WM and non-WM bone grafts were collected and 
fixed in formalin. Decalcified bones together with other formalin-fixed tissues were 
processed routinely, embedded in paraffin, sectioned at 5 μm, and stained with 
haematoxylin and eosin (HE) or immunohistochemistry (IHC). The latter was performed 
with mouse monoclonal antibodies directed against human CD20 (Biogenex, San Ramon, 
CA, USA), IgM (Cell Marque, Rocklin, CA, USA), and κ and λlight chains (Novocastra 
Laboratories, Newcastle-upon-Tyne, UK). Antigens were retrieved with microwave heating 
in citrate buffer (pH 6) for CD20, or with proteinase K (DAKO, Carpinteria, CA, USA) 
digestion for 6 minutes at room temperature for IgM and κ or λ chains. Poly-HRP goat anti- 
mouse IgG (Chemikon, Temecula, CA, USA) was used as secondary antibody. Signal was 
detected with diaminobenzidine and tissues were counterstained with haematoxylin. Wild 
type mouse colon along with mesenteric lymph nodes sections were used as negative tissue 
controls, whereas positive controls were procured from bone biopsy of WM patients not 
involved in the study. Irrelevant mouse antibodies were used instead of primary antibodies 
for negative staining controls. 
We (Tsingotjidou et al., 2001) and others (Yonou et al., 2001) have previously shown that 
adult human bone retains viability after engraftment subcutaneously or within the skeletal 
muscles of immunocompromised mice. In the present study, we first sought to determine 
whether the above-mentioned model of bone engraftment was successfully reproduced. For 
that, adult human cancellous bone intramuscular implants were recovered from control 
SCID mice at 4, 8 or 12 weeks post-implantation for histological evaluation. At four weeks, 
specimens showed multifocal necrosis and fibrosis. The surface of the human bone was 
lined by small numbers of osteoblast-like cells and minute amount of newly synthesized 
osteoid. In contrast, all human bone implants from intramuscularly implanted mice were 
largely normal at the 8-week time-point. Viable osteocytes and increased numbers of 
osteoblasts forming adequate amounts of osteoid were evident. However, rare foci of 
remaining osteonecrotic and fibrotic changes were noticed. At 12 weeks after implantation, 
the histology of intramuscularly implanted bone was completely restored. The population 
and spatial distribution of osteoblasts, the amounts of newly formed bone matrix, the 
restored numbers of viable osteocytes (Fig. 2A) and the presence of active bone marrow 
cavities (Fig. 2B) were all consistent with normal bone histology. The human origin of 
haematopoietic cells populating the bone marrow of implants was confirmed by IHC using 
an antibody against human CD45 that shows no cross-reactivity with mouse CD45 protein 
(Tsingotjidou et al., 2001; Boynton et al., 1996). No human lymphoid cell was found in 
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murine tissues examined. These results suggest that human bone implant was maintained 
and thrived in the mouse skeletal muscle environment. 
 
Fig. 2. Non-WM human bone implanted in the hind limb muscles of a NOD-SCID mouse at 
12 weeks post-implantation. Higher magnification of the boxed area in A is shown in B. 
Histology of the human bone is restored. Note new bone formation with viable osteoblasts 
and bone marrow reconstitution. Haematoxylin & Eosin. Bars, A: 100 μm; B: 25 μm. 
Three animals bearing WM bone biopsy alone were sacrificed at 1 (n=1), 2 (n=1) and 3 (n=1) 
months post implantation (Diagram 2). In all three animals, the bone marrow was diffusely 
infiltrated by neoplastic cells that had lymphocytic, plasma cell or lymphoplasmacytic 
phenotype. Tumor cells were often arranged in discrete nodules. Reactive hyperplasia of 
tumor-associated mast cells was common. Necrotic areas were evident at 1 month post 
implantation, feature that was diminished afterwards (at 2 and 3 months post implantation).  
 
Diagram 2. Flow chart of the experimental design; Time at parentheses indicates the 
sacrifice point, mos=months 
Immunohistochemically, neoplastic cells were CD20 positive. IgM-positive neoplastic cells 
were also identified in large numbers. Both CD20 and IgM antibodies used for this purpose 
was against human lymphocytes and IgM. These mice also had elevated IgM in serum at 
one month following the intramuscular implantation of the biopsy. However, two months 
post-implantation, blood IgM was moderately-to-markedly reduced. In a single mouse IgM 
fell to non-detectable levels, while in the remaining moderately elevated IgM was detectable 
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up to three months following the WM bone biopsy implantation, without reaching, 
however, the high IgM levels encountered at one month post-implantation (Tsingotjidou et 
al., 2009). Control animals that received no implant (n=3) or were implanted only with non-
WM (n=2) showed no elevation in serum IgM throughout the duration of experiment. Upon 
histological and IHC examination control mice had no detectable lymphocytes or plasma 
cells in all tissues examined. 
Twelve animals (n=12) implanted with both WM and non-WM bones were monitored for 
serum IgM levels throughout the experiment. Necropsies were performed in nine of those 
(9/12) at 3 (n=5), 4 (n=3) and 5 (n=1) months following implantation of WM bone biopsies 
(Diagram 2). Histopathological and immunohistochemical analysis of WM implants in these 
mice (n=9) yielded similar results as those described in the control mice bearing WM bone 
biopsy alone (n=3), namely a CD20+, IgM+ neoplastic cell infiltrate. These results indicated 
that survival of neoplastic cells in this experimental model could be prolonged for at least 5 
months post implantation. Interestingly, histopathology and IHC analysis of the 
controlateral, non-WM implant of 4 out 9 mice revealed that the bone marrow was 
infiltrated by large numbers of neoplastic cells (Fig. 3). In order to confirm the validity of 
our findings, clonality by staining against κ- and λ- light chains was documented in two, 
randomly selected animals (W6 and W10). Cytoplasmic immunolabelling for κ- but not for 
λ-light chains was evident and restricted specifically and exclusively within the plasmacytic 
component of the tumor (Fig. 4). Thus, light chain predominance confirmed the clonality of 
neoplastic cells. Sparsely dispersed IgM positive cells were found in the bone marrow of 
tibia and femur of one animal (W10). Diffuse infiltration of WM cells was also seen in the 
liver and kidney of another animal (W44).  
 
Fig. 3. CD20-specific (A and B) and IgM-specific (C and D) immunohistochemistry of human 
bone implants. Large numbers of human CD20-positive (A) and IgM-positive (C) WM cells 
remain viable in the bone marrow of the WM bone biopsy implanted in NOD-SCID mice. 
CD20-positive (B) and IgM-positive (D) cells could also be detected at the non-WM human 
bone that was distantly implanted in the same mice. Haematoxylin counterstain, DAB 
chromogen. Bars: 25 μm.  
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Fig. 4. κ (A and B) and λ (C and D) chain immunophenotyping of neoplastic cells performed 
in consecutive histological sections taken from both WM (A and C) and non-WM (B and D) 
bone implants of the same mouse. κ-chain-positive cell predominance in both implants 
provided evidence for the clonality of neoplastic cells. Haematoxylin counterstain, DAB 
chromogen. Bars: 50 μm 
Serum IgM values in all mice implanted with both WM and non-WM bone biopsies  (n=12) 
correlated with histopathological observations and IHC analysis for neoplastic cell density 
and metastatic growth. Indeed, mice with increased neoplastic cell burden and controlateral 
bone implant metastasis (W10, W44, W52 and W6) had increased IgM values in their blood 
serum (Tsingotjidou et al., 2009). In contrast, mice with sparse neoplastic cells in the WM 
implant and no evidence of metastasis (W45, W51 and W50) had low or non-detectable 
levels of serum IgM. It is interesting that 2 out of these 3 mice received implants originating 
from patients that had the two lowest percentages of bone marrow infiltration by neoplastic 
cells (20% and 33%) among human bone biopsy donors in this study. In a single mouse 
(W46), a sudden abolishment of serum IgM levels was observed at the 4th month post 
implantation of the WM bone (Tsingotjidou et al., 2009). Histological evidence of necrosis 
found in both implanted bone fragments examined, however, explained this abnormality.  
Overall analysis of the monthly records of serum IgM values of mice used in this study 
reveals that after the second month, there is an overall progressive rise of IgM during 
months 3 and 4 post implantation of the WM biopsy (Tsingotjidou et al., 2009). 
Taken together these results suggest that the WM neoplastic cells in the bone marrow of 
adult human bone implanted in SCID mice not only survive and grow but also are capable 
of producing IgM and metastasize (Tsingotjidou et al., 2009). The relatively high value of 
IgM obtained one month after implantation is considered an artifact attributable to cell 
damage, as discussed below.  
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This study described a novel NOD-SCID mouse model of WM. Using the SCID mouse as a 
vehicle of two human adult bone intramuscular implants we demonstrated that IgM 
producing WM neoplastic cells retain viability in the bone marrow of the implant 
originating from WM patients. Interestingly, neoplastic cells not only grew but also 
metastasized to the normal bone marrow of the second distant bone implant (Fig. 3). 
A significant drawback in understanding pathogenesis of WM and developing novel 
therapeutics is the lack of animal models that recapitulate most features of human WM. 
Hence, several studies have focused in the development of animal models to study this rare 
but incurable neoplastic disease. In the past, attempts to grow WM cells in vitro or engraft 
them in immunocompromised mice have failed (Al-Katib et al., 2003). This probably was 
due to the lack of human bone marrow stromal cells, which are important elements of tumor 
microenvironment and facilitate both survival and proliferation of WM cells. Recently, 
however, important advances have been made utilizing SCID mice that were implanted 
with human fetal bone chips. The bone marrow of fetal bone implants successfully 
supported the survival and growth of WM cells derived either directly from patients 
(Tassone et al., 2005) or from a WM cell line that was established for that purpose (Santos et 
al., 2007). Both those experimental models are important, since they recapitulate a typical 
feature of the human disease, which is the bone marrow microenvironment-depended 
growth of WM cells. However, the natural niche of WM cells is the adult and not the fetal 
bone marrow that both these studies utilized for the engraftment of malignant cells. Adult 
and fetal bone marrow may differ in the pattern of growth stimuli imparted to WM cells. 
Although these differences cannot be elucidated, without elaborate research, the murine 
model of WM proposed in the present study overcomes this skepticism by simply using 
adult human bone implants. 
An interesting observation of this study was that mice implanted with a WM bone fragment, 
showed elevation of blood IgM one month following the implantation. This peak in IgM levels 
observed at the first month coincided with the period of maximum damage to the implanted 
bone particle (Tsingotjidou et al., 2001). This particular elevation, however, may not reflect an 
active secretion of IgM from WM cells, but rather be due to an initial phase of ischaemic injury 
leading to WM cell necrosis and subsequent IgM leak. Indeed, histological studies of the 
human bone implants performed in the present study matched our previous observations 
(Tsingotjidou et al., 2001), which indicated that 8-12 weeks are needed before implanted bones 
become adequately vascularized, and restore their pre-transplant normal histology. A similar 
phenomenon of IgM release is well characterized in human patients following effective anti-
neoplastic treatment, due to WM cell damage (Treon et al., 2004). For that reason, only IgM 
serum values obtained from the second month onwards were taken into consideration and 
were used as reliable indicators of disease burden of the implanted mice. 
The wide range of IgM levels observed in mice of our experiments mimic analogous 
findings in humans. Accumulated data suggest that the levels of IgM production are highly 
variable among WM patients. Therefore, such data are valuable for follow-up examinations 
of individual patients and do not represent a universal indicator of WM burden. 
Irrespectively of initial IgM levels, however, most mice used in this study showed a similar 
pattern of IgM fluctuation over time. Following an elevation of IgM at the first month and a 
subsequent reduction at the second month, which can be considered baseline, there was a 
progressive rise of IgM during months 3 and 4 post implantation of the WM biopsy.  
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An interesting feature of the WM murine model presented here is the observed metastasis of 
the malignant cells. In approximately half of mice implanted with both WM and non-WM 
bone implants, WM cells metastasized from the affected implant to the healthy one, which 
was located in the contralateral hindlimb. Human bone, albeit from unrelated individual, 
was colonized preferentially, since metastasis to murine bone was observed only in a single 
mouse. Accordingly, existing murine models of WM show either no (Santos et al., 2007) or 
rare (Tassone et al., 2005) metastases to murine tissues. It is possible, that WM cells 
engrafted in mice could infrequently acquire novel properties that allow them to traffic, 
home and survive in murine bone marrow or other tissues. Obviously, accumulated genetic 
abnormalities driven by a physical selection process, may result in WM cells able to survive 
in the murine microenvironment. However, these genetic alterations render these cells less 
appropriate to model metastatic phenomena occurring in human WM, which is 
predominately an indolent disease. The murine model developed in the present study 
overcomes inherited disadvantages of existing WM in vivo models and better recapitulates 
metastasis, since it is supporting relocation of primary WM cells derived from patients from 
one human bone implant to another.  
6. Conclusion  
The use of bone biopsies taken from different WM patients as implants in SCID mice 
appears as highly attractive biological system to study aspects of the human disease. The 
quantitative limitation of harvesting BM particles from patients restricts the possibility to 
produce large highly homogeneous experimental groups of mice, given the variability of 
biological behaviour of WM among patients. This fact is exemplified by the results of the 
present study. Indeed, high levels of serum IgM and infiltration of the contralateral non-
WM bone biopsy, by WM cells did not occur consistently in all mice. Hence, we reason that 
this model may not be suitable for screening specific therapeutic factors of WM. For such 
studies, the adult bone implant approach might still be considered if the healthy bone was 
artificially populated with WM cell line. On the other hand, the experimental design used in 
the present study may be useful for studying the pathogenesis of WM and particularly the 
interaction with the bone marrow stroma as it exists in the adult bone marrow. It may also 
be an ideal setting for studying the disease in long term, since the model allows indolent 
growth in mice, and consequently to assess the pathophysiology of epiphenomena such as 
neuropathy (work in progress). It is believed that the experimental setting as presented here 
will contribute to the unraveling of the etiology and pathogenesis of WM to the benefit of 
the patients.  
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abnormalities driven by a physical selection process, may result in WM cells able to survive 
in the murine microenvironment. However, these genetic alterations render these cells less 
appropriate to model metastatic phenomena occurring in human WM, which is 
predominately an indolent disease. The murine model developed in the present study 
overcomes inherited disadvantages of existing WM in vivo models and better recapitulates 
metastasis, since it is supporting relocation of primary WM cells derived from patients from 
one human bone implant to another.  
6. Conclusion  
The use of bone biopsies taken from different WM patients as implants in SCID mice 
appears as highly attractive biological system to study aspects of the human disease. The 
quantitative limitation of harvesting BM particles from patients restricts the possibility to 
produce large highly homogeneous experimental groups of mice, given the variability of 
biological behaviour of WM among patients. This fact is exemplified by the results of the 
present study. Indeed, high levels of serum IgM and infiltration of the contralateral non-
WM bone biopsy, by WM cells did not occur consistently in all mice. Hence, we reason that 
this model may not be suitable for screening specific therapeutic factors of WM. For such 
studies, the adult bone implant approach might still be considered if the healthy bone was 
artificially populated with WM cell line. On the other hand, the experimental design used in 
the present study may be useful for studying the pathogenesis of WM and particularly the 
interaction with the bone marrow stroma as it exists in the adult bone marrow. It may also 
be an ideal setting for studying the disease in long term, since the model allows indolent 
growth in mice, and consequently to assess the pathophysiology of epiphenomena such as 
neuropathy (work in progress). It is believed that the experimental setting as presented here 
will contribute to the unraveling of the etiology and pathogenesis of WM to the benefit of 
the patients.  
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1. Introduction 
Systemic Mastocytosis (SM) is a mast cell (MC) neoplasm of the haematopoietic tissue. It is a 
rare disorder, but perhaps its prevalence is underestimated, as MC infiltrates may often be 
undetected. The aim of this chapter is to emphasize the importance of an active and careful 
work-up through multimodality approaches in order to achieve the diagnosis of SM. This 
might increase the incidence of SM. Moreover, it must be considered that SM is frequently 
associated with a second and, in rare cases, a third clonal blood disorder that isn’t mast cell 
derived. Similar cases may be important for the correct initial evaluation and classification, 
as well as for a better risk stratification and management of patients with haematopoietic 
malignancies. Therapy could also improve, being personalized and tailored for each single 
SM patient.  
2. Disease overview  
Mastocytosis is a disorder characterised by clonal mast cells (MC) proliferation and 
accumulation. It has been described for the first time in 1869 by Nettleship and Tay as a 
form of urticaria resulting in a “brownish discoloration”. Some years later Ehrlich used 
“mastzellen“ to designate MC (Ehrlich, 1877). The term is derived from the German 
mästung, that means “to overfeed”. In fact, the MCs have metachromatic properties that 
have been originally attributed to an excessive intake of aniline dye. In 1949 Ellis reported 
the first observation of MCs infiltrating visceral organs. Hence, several reports allowed 
standardizing the definition and classification of Mastocytosis.  
According to the latest WHO classification Mastocytosis is a myeloproliferative neoplasm 
(MPN) (Vardiman, 2009). Clonal MCs proliferate, infiltrate and accumulate in skin and/or 
other organ systems. In Cutaneous Mastocytosis (CM) only skin is involved. In Systemic 
Mastocytosis (SM) at least one extracutaneous organ is infiltrated. This leads to a 
heterogeneous clinical presentation. 
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other organ systems. In Cutaneous Mastocytosis (CM) only skin is involved. In Systemic 
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heterogeneous clinical presentation. 
 




Mastocytosis is a rare disorder. Several studies reported an incidence of 5-10 cases/106 
people/year. However, there’s a risk of underestimation due to the difficulty in getting a 
diagnosis. Recently Nowak et al. have published results of a monocentric retrospective 
study, reporting that in most patients mastocytosis was correctly diagnosed over a period of 
2 years (up to 11 years in some cases), and often required consultation of three or more 
clinicians (Nowak, 2011). This was consistent with experiences reported by other authors. 
There are several possible explanations for such diagnostic delays. First, initial symptoms 
and signs are usually unspecific and overlap with many other diseases. For instance, at 
presentation some patients show neurological, psychological and psychiatric symptoms, 
leading to a misdiagnosis of somatoform disorder instead of mast cell syndrome (Amon, 
2010). Second, morphological detection of pathological MCs is not obvious, mainly if they 
exhibit atypical features, such as hypogranulation or abnormal nuclear morphology 
(Pardanani, 2011). Moreover, as the second most frequent MC disorder is SM associated 
with haematological non mast cell disorder (SM-AHNMD), extensive bone marrow 
involvement by a second haematological neoplasm may obscure or distort MC aggregates 
(Horny, 2004), delaying or obviating at all the correct diagnosis. Taken together, these 
observations suggest that clinicians should become more confident with MC syndrome and 
MC disorders, as clinical suspicion should stimulate further appropriate immunochemical 
and molecular analysis. According to this, Horny proposed a novel routine approach, using 
antibodies against neoplastic MC markers in all bone marrow trephines presenting 
Myelodisplastic Syndrome, Acute Myeloid Leukemia and Chronic Myelomonocytic 
Leukemia (Horny, 2004).  
Mastocytosis is more frequent in children, as CM. Adults represent one third of all cases and 
they are almost all affected by SM. There are no gender differences in incidence rate and 
clinical presentation. It can onset at any age, with an incidence peak in the first 2 years of life 
(Pardanani, 2011). Familiar cases have been occasionally observed. Survival is shorter in SM 
compared to the general population. However, patients classified according to the WHO 
2008 system classification show great differences in demographical and clinical features, 
prognosis and survival (Lim, 2009). Nevertheless, quality of life is generally poor 
irrespective to subgroups. 
3. Mast cells 
Typical MCs are round or oval cells. Their size is small to medium, with a low 
nucleus/cytoplasm ratio. The nucleus is round or oval, in a central position, with condensed 
chromatin. The cytoplasm is large with plenty of metachromatic granules. However 
granules may also be few or lack at all, resulting in hypo-/de-granulated mast cells. 
Atypical MCs may present an oval nucleus and a hypogranulated cytoplasm. Generally they 
are spindle-shaped or with prominent projections on membrane surface and their nucleus is 
eccentric, sometimes with two or more lobes. Cells may appear more immature, with a large 
size, a high nucleus/cytoplasm ratio and a dispersed chromatin with nucleoli. The grade of 
immatureness may allow to the diagnosis of mast lineage blasts, characterized by the virtual 
absence of cytoplasm, with or without metachromatic granules, and fine chromatin with 
nucleoli. 
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3.1 Mast cell physiology  
Mastocyte is a cell of the immune system. It derives from the haematopoietic stem cell. It is 
preferentially localized in the skin, respiratory and gastrointestinal mucosa.  
MC growth, differentiation, proliferation, survival and activation are mediated by several 
factors The most important is SCF, that interacts with the tyrosine kinase receptor KIT 
(CD117 antigen). KIT is a key protein, either in normal or in clonal MCs, and its detection is 
essential in order to identify MCs and achieve the diagnosis of mastocytosis. Therefore, a 
multimodality approach should be routinely performed, including flow cytometry, 
immunochemistry and PCR (see below).  
MCs play a main role in type I hypersensitivity reactions. Antigen-IgE complexes bind to 
the FcεRI on MC membrane and induce MC degranulation. Secretory granules contain 
histamine, tryptase, proteoglycans, TNF-α and other proteases. Tryptase is the most 
important mediator: it is virtually present in all MCs, therefore its expression on membrane 
surface identifies MCs, and serum levels may represent a useful marker of disease (see 
below).  
After MC activation and degranulation, new phospholipid derived mediators are generated 
(e.g. leukotrienes, prostaglandins and PAF). The clinical manifestations are therefore 
heterogeneous and depend on the site of reaction. Atopic responses may vary in severeness 
between transient urticarial eruption and life-threatening anaphylactic shock. Several 
dermal inflammatory diseases are MC mediated, e.g. atopic dermatitis, bullous pemphigoid 
and psoriasis. However, MCs have also important physiological fuctions, as they are 
involved in antimicrobial defense, wound healing, angiogenesis, tumor surveillance and 
graft tollerance. 
4. Pathogenesis 
In more than 90% of affected adults a recurrent somatic mutation of kit can be detected 
(Garcia-Montero et al, 2006), suggesting that KIT plays a central role in autonomous 
proliferation of MC clone as well as in normal mastocytes (Orfao et al., 2007). Usually 
mutation occurs on exon 17 and results in a substitution of aspartic acid at codon 816 with 
valine. This mutation affects the tyrosine kinase TK2 domain and activates the receptor 
independently on ligand binding and dimerisation. According to its high occurrence, WHO 
diagnostic criteria for SM include kitD816V screening. Thus, it should be always 
investigated in bone marrow or blood or other organs when mastocytosis is suspected. 
Moreover, kitD816V represents an important prognostic factor and should be considered for 
planning and personalizing the therapeutic strategy. 
The same mutation is less frequent in children, with an incidence of 42%. However, also 
most of the affected children share somatic kit point mutations that often involve exon 8 or 9, 
resulting in changes of the extracellular part of receptor (Bodemer, 2009). 
Other mutations have been reported: they usually cluster at exon 11 or 17 affecting the 
juxtamembrane regulatory domain or TK2 enzymatic domain. Sometimes they’ve been 
reported at exons 2, 8, 9, 13 or 14 involving extracellular or TK1 domains. Interestingly, it 
has been observed a significant correlation between mutation type and disorder class. In 
fact, these specific genetic alterations have not been detected in different kit related 
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neoplasms (e.g. GIST) and seem to be strictly associated with MC disorders (Orfao et al., 
2007). 
As kit is mutated in most patients without subgroup differences, the heterogeneous 
behaviour of each variant suggests that perhaps several different pathways may be involved 
in the pathogenesis and progression of the disease. Some authors have demonstrated that 
NF-κB and cyclin D3 may play a role. (Tanaka A, 2005). In addition, since a second 
haematological neoplasm is often associated with SM, the pathogenic mechanisms can be 
more difficult to understand.  
Several studies suggests that mastocytosis is a haematopoietic stem cell disease (Horny, 
2008). It can be hypothesized that kit mutation occurs at the level of leukaemia stem cell, the 
original clone that is responsible of leukaemia relapse. The occurrence of kit mutation 
confers either proliferative or mast cell lineage differentiative potential. Additional 
aberrations can then occur in the leukaemia stem cell, leading to the development of the 
associated myeloid neoplasm. Another possibility is the acquisition of kit mutation and 
transformation of a more mature leukaemia progenitor, resulting in the development of a 
synchronous mast cell malignancy (Pullarkat, 2003). Even less mature progenitors may be 
involved as also intra- and peri-lesional B and T cells have been demonstrated to carry the 
kitD816V point mutation. However, in SM patients without any associated clonal lymphoid 
disease most of the lymphocytes are reactive oligoclonal cells.  
5. Clinical findings 
Clinical features and course are variable, depending on the site and degree of infiltration 
and WHO subvariant. 
Skin is often involved. Pruritus, erithema and orticarioid lesions usually occurs after 
mechanic irritation (Darier’s sign). Hypercromic and infiltrated lesions affect body trunk, 
upper and lower limbs in 80% of adults, and head in all children. A frequent symptom is 
hypotension, often with headache and flushing, sometimes of high grade, resulting in 
syncope and shock. Diarrhoea is very common, with abdominal pain. Sometimes 
malabsorption cause a severe worseness of general conditions and must be considered 
clinically equivalent to organ damage. Bone is always involved: usually patients complain of 
bone pain, with signs of osteopenia, osteoporosis or atypical atraumatic fracture. Bone 
marrow infiltration may result in pancytopenia. Organomegaly, in particular enlargement of 
the lymph nodes, spleen and liver, may be present and causes organ damage (hepatic 
failure, low levels of albumin, etc.). Neuropsychiatric symptoms could be prevalent at 
diagnosis and they can be related to disfigurement in appearance: depression, suicide 
ideation, social and professional inefficiency have been reported (Amon, 2010). Risk of 
anaphylaxis is increased compared with health population, especially after a trigger 
exposition (physical exercise, psychic stress, alcohol, NSAID, infections and pregnancy) 
wich can result in MC activation. Based on this, it is recommended to perform a complete 
work-up after a first case of a severe anaphylactic reaction, especially in the absence of an 
evident trigger. Finally, there is a high risk of peptic ulcer. Patients must be closed 
monitored for all these symptoms in order to prevent complications and improve quality of 
life with anti-mediator drugs. Moreover, recording symptoms is a key part of staging, as 
established by WHO, and should drive the correct treatment choice and timing (WHO 2008). 
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Practically, two groups of clinical findings have been defined, the B and the C group. (Table 1). 
B stands for “burden of disease” and refers to symptoms that reflect the extension of 
disease. C stands for “cytoreduction requiring” and refers to signs of organ impairment 
indicating the need of therapy with cytostatic drugs. 
C-findings are due to extensive MC infiltration, with direct organ damage and tissue 
destruction. The presence of at least one C-finding denotes a high grade disorder, referred as 
advanced systemic mastocytosis. After excluding any other causes of organ failure, 
cytoreduction must be considered. Symptoms due to MC infiltrates may be difficult to 
distinguish from indirect symptoms due to massive mediator release. When relationship 
between MC infiltration and organ impairment is not clear, patients must be closed 
monitored with serial dosages of serum tryptase level. An increase trend confirms the 
progression of the disease and the need of cytoreduction. CD30 expression may also be of 
help, since a strong positivity in most MCs denotes more likely ASM and MCL, while a 
weak positivity suggests a diagnosis of ISM. According to this, CD30 may perhaps become a 
useful tool in grading SM (Valent, 2010). 
 
B-findings  
related to MC mediators 
C-findings  
due to direct MC infiltration 
Organ failure 
1. High MC burden Organopathy  
Marrow MCs > 30%   
Serum tryptase 
>200ng/ml   
2. Dysmyelopoiesis   
Hypercellular marrow 
with signs of 
myelodisplasia or 
myeloproliferation 
Dysmyelopoiesis, with one or 
more peripheral cytopenias 
Severe progressive 
pancytopenia 
3. Palpable Organomegaly   
Hepatomegaly 
Hepatomegaly with  
- ascites 
- abnormal liver function 
tests  
- portal hypertension 
Progression to liver failure 
Splenomegaly Splenomegaly, with hypersplenism  
Lymph node 
enlargement 
Bone lesions, with  
- osteolysis  




Malabsorption, with  
- hypoalbuminemia 
- weight loss. 
 
 
Table 1. Clinical findings (adapted from Valent et al., 2001). 
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Mastocytosis must be suspected.  
WHO updated diagnostic criteria in 2008. The demonstration of neoplastic MC infiltrates in 
skin or extracutaneous organ is the condition sine qua non. The presence of typical MCs in 
dermal multifocal aggregates or diffusely infiltrating the skin allows the diagnosis of CM. 
The involvement of at least one visceral organ denotes SM. However, other criteria must be 
satisfied, i.e. clinical or biochemical, morphologic, immunophenotypic, molecular (Table 2). 
This is important to distinguish between any reactive MC proliferation and true clonal MC 
proliferation, that means Mast Cell Activation Syndrome (MCAS) from Mastocytosis.  
Cutaneous mastocytosis (CM) usually presents as maculopapular infiltrates or diffuse 
erythrodermic rash, with thick skin or multiple nodules. Skin lesions must be biopsied to 
demonstrate the co-existence  of pathological MCs. 
The suspicion of mast cell syndrome without any cutaneous signs exclude the diagnosis of 
CM and requires bone marrow analysis to investigate the possible diagnosis of systemic 
mastocytosis (SM). Bone marrow biopsy and aspiration should always be performed in such 
cases as SM involves bone marrow in almost all affected patients. Other specimens may be 
obtained from other involved organs.  
Pathological MCs infiltrates result as aggregates of at least 15 tryptase positive MCs. This is the 
first major criterion. The following diagnostic steps are BM smear evaluation, flow cytometry 
characterization and KIT mutational analysis. Finally serum tryptase levels must be dosed.  
 
Cutaneous Mastocytosis Typical skin lesions 
 Clinical signs 
- Maculopapular cutaneous mastocytosis 
- Diffuse cutaneous mastocytosis 
- Mastocytoma 
 Microscopic 
findings Multifocal or diffuse MC infiltrates 
Systemic Mastocytosis SM criteria = 1 major + 1 minor or 3 minor criteria 
 Major criterion 
Infiltrates of >15 aggregated MCs identified through tryptase 
immune-histochemistry or other stains in sections obtained 
from bone marrow or other extracutaneous organs 
 Minor criteria 
More than 25% spindle shaped MCs in histological sections  
or more than 25% atypical MCs in BM smear 
Detection of kit 816 mutation in BM or blood or any 
extracutaneous organ 
MC coexpression of CD25 and/or CD2 with CD117 
Serum tryptase levels > 20 ng/ml
Table 2. Proposed criteria to diagnose Mastocytosis (adapted from Valent et al., 2001). 
6.1 Histology 
The typical histological mast cell lesion consists in focal typical and atypical MC aggregates 
infiltrating tissues. Giemsa or toluidine blue stains can reveal metachromatic granules, 
allowing discriminating between spindle mastocytes and fibroblasts.  
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Skin lesions are characterized by perivascular and periadnexal MC accumulation in upper 
dermis (Amon, 2010). In bone marrow compact infiltrates are perivascular, sharply 
demarcated from normal tissue, sometimes intermingled with macrophages and 
eosinophils. Spindle shaped MCs are often more than 25% of the total MCs. Rarely, 
infiltration is diffuse, with scattered cells that are difficult to recognize. In particular, in SM-
AHNMD it is not unusual for the SM component to be unrecognized due to the extensive 
infiltration of bone marrow by the AHNMD component. This is commonly seen, for 
example, in SM-acute leukemia and SM with intense eosinophilic infiltration. Monotonous 
sheets of blasts may help to detect isolated clonal MCs (Horny, 2004). On the contrary, 
infiltration due to either reactive benign-looking lymphocytes or low grade lymphomatous 
cells is usually well defined and spindle mast cells cluster in different nodular lesions (Du, 
2010). In some cases reactive well-differentiated lymphocytes have been reported to 
surround central aggregates of clonal mast cells or to be enclosed within malignant mast 
cells lesions (Kim, 2010). It must be clearly realized that MCs largely infiltrating malignant 
cells in haematopoietic disorders are clonal in most synchronous myeloid neoplasia, while 
they are reactive in all described lymphoid associated disorders so far reported. However, 
our group observed a case that may perhaps represent the first reported exception to this 
rule (see below). 
Immunochemistry is important to recognize clonal MCs and get the right diagnosis. 
Spindle-shaped instead of round mast cells are more likely pathological and 
immunochemical reactions demonstrating co-expression of KIT, tryptase and CD25 enhance 
the probability of the clonal nature of the MCs (Pardanani et al., 2011).  
6.2 Immunophenotyping 
Flow cytometry represents the gold standard to identify, enumerate and characterise human 
MCs. The co-expression of CD2 and/or CD25 with CD117 is a minor WHO criterion to 
diagnose SM (Valent et al, 2010).  
6.3 Molecular studies 
Routine diagnostics should include the screening for kitD816V. Highly sensitive techniques 
(e.g. PCR) are recommended as the detection of this specific somatic mutation has been 
recognized as a valid minor diagnostic criterion by WHO system. kitD816V may be found 
also in myeloid and, less frequently, in lymphoid cells associated within the focal MC 
lesions, particularly in ASM and  MCL. On the contrary, the same finding is rare in SM-
AHNMD and depends on the concomitant disorder. In fact, the occurrence of kitD816V 
decreases through CMML, MPN, AML and lymphoproliferative disorders respectively.  
Identification of different genetic abnormalities is not requested, since it does not have 
clinical relevance either  for diagnosis or for  therapy. However, in case of blood 
eosinophilia clinicians must consider screening for FIP1L1-PDGFRA fusion protein, since it 
predicts a great response to imatinib. Other rearrangements involving PDGFRB may be 
appropriately investigated through conventional cytogenetic analysis, allowing to the 
diagnosis of the entity defined by WHO as myeloid or lymphoid neoplasms with 
eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1 (WHO 2008). 
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predicts a great response to imatinib. Other rearrangements involving PDGFRB may be 
appropriately investigated through conventional cytogenetic analysis, allowing to the 
diagnosis of the entity defined by WHO as myeloid or lymphoid neoplasms with 
eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1 (WHO 2008). 
 




Serum tryptase dosage and levels monitoring are a useful tools for diagnosis (WHO 2008) 
and follow-up, as they correlate with MC load and activation and disease progression 
(Pardanani, 2011). Elevated levels of serum tryptase (>20ng/ml) are consistent with the 
diagnosis, representing the fourth validated minor criterion to be evaluated according WHO 
system. Very high levels (>200ng/ml) correlate with more aggressive subvariants, severe 
course and poor prognosis. Anyway, serum tryptase levels are not clinically significant in 
case of a concomitant myeloid disorder as a proportion of patients affected by AML, CML 
and MDS usually show high levels of tryptase without any detectable MC disorder. 
Serial dosages are recommended after anaphylactic or anaphylactoid episodes to distinguish 
between a transient elevation and an abnormal persistent increase. In addition, stable levels 
during follow up are consistent with stable disease (Quintas-Cardama et al., Cancer 2006). 
6.5 Further considerations 
SM diagnosis requires the presence of the major criterion together with one minor criterion 
or three isolated minor criteria (Table 2). Subvariants may be classified depending on the 
percentage of MCs in BM and PB smears and the clinical presentation. More than 20% MCs 
in BM smear denotes MCL, in the leukemic or aleukemic (more or less than 10% MC in PB 
smear) subvariants. Less than 20% MCs in BM smear connotes ISM in asymptomatic 
patients, SSM or ASM in patients suffering from B- or C-findings respectively.  
A cytomorphological grading system has been also proposed (Valent et al., 2001). At BM 
smear analysis MCs may be typical or atypical. Atypical MCs are classified either type I or 
type II according to the nuclear feature, oval or bi-/polylobed respectively. The proportion 
of atypical MCs together with metachromatic blasts define the grade of the disorder: high 
grade > 20%, low grade < 10%, intermediate grade 10-20% MCs (Valent et al., 2001). 
There are some peculiar conditions to be considered. First, sometimes a focal MC infiltrate is 
found without any MC related symptom or sign and coexists with normal skin and bone 
marrow, denoting a finding of MC tumour. If the growth pattern is destructive and the 
cytopathologycal grade is high, the diagnosis is of MC sarcoma. Otherwise, a low grade 
morphology and a respected tissue architecture denotes benign mastocytomas. 
Second, MC aggregates may be scattered. This finding is often consistent with reactive MC 
hyperplasia and occasionally may be observed during the diagnostic approach for non MC 
haematologic diseases. A WHO entity is SM-AHNMD, where a myelo-/lymphoproliferative 
disorder coexists with a clonal MC growth. Myeloid neoplasms usually share the peculiar 
pattern of diffuse cells proliferation admixed with malignant mast cells, on the contrary 
lymphoid clones are clearly distinct, with a well-cut separation between the two clonal 
components, and generally the demonstration of SM in the bone marrow is an occasional 
histological finding in patients with a previous diagnosis of LNH in a lymph node (Schipper 
et al, 2011). Thus, a diffuse MC infiltration in the fields of LNH always suggests a reactive 
MC hyperplasia (Valent, 2001). 
Also AHNMD is recommended to be investigated for biomolecular markers, in order to get 
a complete characterization and evaluate the event of therapeutic targets. 
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With regard to MCL, histology must refer to bone marrow areas away from spicules and the 
proportion of blasts must be cytomorphologically evaluated on the bone marrow smear. 
Thus histological detection of even more than 20% of blasts is not enough to make a 
diagnosis of MCL (Valent, 2010). 
7. Classification and prognosis 
MC disorders are classified in two groups: cutaneous and systemic. The former seems to 
have a good prognosis (Koga et al., 2011), the latter shows a poor prognosis. More precisely, 
in case of systemic involvement the observed survival is shorter than general population. 
The median overall survival is about 5 years (Pardanani et al., 2009), with excess deaths 
occurring between the third and the fifth year after diagnosis (Pardanani et al., 2011). 
However, prognosis is heterogeneous among SM subgroups and correlates with the WHO 
system. In fact, stratifying by the WHO classes, the Kaplan-Meier analysis allows 
distinguishing between an indolent and a rapidly progressive course. In the first case there 
is not a significant difference between affected patients and matched controls. By contrast, in 
the so-called aggressive forms median survival ranges between 2 and 41 months, depending 
on the variant (Pardanani et al. 2009).  
7.1 CM 
Cutaneous mastocytosis (CM) is a disorder characterized by accumulation of clonal mast 
cells isolated in the skin. Dermatologists are used to differentiate some clinical variants 
based on macroscopic presentation. Maculopapular Cutaneous Mastocytosis denotes the 
most frequent form, often described as urticaria pigmentosa (UP). It is the typical 
manifestation of CM, with disseminated small plaques. Sometimes lesions limits appear 
undefined and skin may be extensively involved, leading to the clinical condition referred as 
Diffuse Cutaneous Mastocytosis. Children rather than adults may carry a single blistering 
lesion known as solitary Mastocytoma, that generally goes to spontaneous regression with 
time. Other rare variants occur almost exclusively during childhood, with aspects of 
infiltration (bullae, plaques or nodules) or hyperpigmentation (Telangiectasia Macularis 
Eruptiva Perstans or TMEP) with or without erythema (Amon et al., 2010). 
7.2 SM 
Systemic mastocytosis (SM) is a disorder classified among Myeloproliferative Neoplasms by 
WHO in 2008. Unlike CM, clinical SM variants have been universally accepted and included 
in the international classification system since 2001. In addition, in 2010 Pardanani et al. 
published results of an observational study on 342 patients, leading to a formal validation of 
the WHO classification. Thus, SM subgroups are clinical evidence-based entities, with clear 
definition, characteristic features, definite prognosis and tailored management indications, 
beyond the clinical usage. 
7.2.1 ISM 
Indolent systemic mastocytosis (ISM) is the most frequent variant in adults (46%). Patients 
are young (median age 49) and usually show urticarioid skin lesions, gastrointestinal 
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symptoms and MC mediator related syndrome. Almost all affected patients show bone 
marrow involvement, but no B- nor C- findings. Prognosis is very good, life expectancy is 
similar to general population, but quality of life is definitely poor. No progression risk has 
been observed, thus no cytoreduction has to be considered and only management of 
symptoms is needed (Valent et al., 2010).  
7.2.2 SSM 
Smoldering systemic mastocytosis is a recent subvariant of ISM. B-findings are always 
present, C-findings never. It is defined by high burden of MC (tryptase levels more than 200 
ng/mL), enlarged spleen and/or lymph nodes, multilineage myelodysplasia or myeloid 
proliferation in the absence of diagnostic criteria for MDS, MPD, LMMC or AML. c-kit 
D816V should be detected in at least one non MC lineage. 14% of the patients with ISM are 
SSM affected individuals. They are older than typical ISM variant. Constitutional symptoms 
are almost constant. 23% patients are affected by a subvariant defined by isolated bone 
marrow involvement (BMM, Bone Marrow Mastocytosis), often associated with severe MC 
mediators related syndrome, including anaphylaxis. Prognosis is good, expected survival is 
even more than ten years, so symptomatic treatment may be enough. However, it must be 
stated that median survival is significantly inferior in SSM than in ISM (120 versus 301 
months respectively). Moreover, there is an up to 18% risk of progression to aggressive 
subvariants as ASM, MCL and SM-AHNMD. Thus, patients must be strictly  monitored, in 
order to switch to a cytoreductive therapeutic program if required. Cytoreduction is 
indicated even in absence of aggressive SM variants, if tryptase reach levels greater than 
1000 ng/mL or symptoms show a worsening trend. Also, recurrent anaphylaxis 
unresponsive to immunotherapy or without specific IgE suggests that splenectomy or 
cytoreduction are needed for a better control of MC burden. This is in order to prevent a 
severe adverse event, as well as in myeloproliferative disorders hydroxyurea is 
administered to prevent deep venous thrombosis/pulmonary embolism (Valent et al., 2010). 
7.2.3 ASM 
Aggressive systemic mastocytosis is less frequent (12%) and occurs generally in adults. It is 
defined by the presence of at least one C-finding, associated with constitutional symptoms 
and visceromegaly, particularly of liver, spleen and lymph nodes. Prognosis is poor, with an 
overall median survival of 41 months. Leukemic transformation occurs in 5% of the patients. 
Affected patients must be always treated. Treatment depends on clinical course. According 
to time to progression, patients should be stratified in slowly and rapidly progressing. In the 
first case the natural history is similar to SSM. In the second case the disease is difficult to 
control and its behavior is similar to MCL: early blasts may increase, satisfying diagnostic 
criteria for leukemia. In addition, in some kitD816V patients the same mutation may become 
undetectable with progression. This is somewhat similar to disease progression in acute 
myeloid leukemia. In slowly progressing ASM milder therapeutic options may be 
considered, while rapidly progressing ASM always requires heavy chemotherapeutic 
approaches, according to the rapid multiorgan failure occurring in such patients.  
Tryptase levels usually increase every day, reflecting the poor clinical course (Valent et al., 
2010). 
 




Mast cell leukemia is the most rare variant, virtually limited to adulthood. In Pardanani’s 
analysis it occurred in 1% of the patients. Median survival is 2 months. Usually MC blasts 
infiltrate extensively BM, with a range of 60-90%. High intensity chemiotherapy has to be 
administered, but patients generally result refractory (Valent et al., 2010). 
7.2.5 SM-AHNMD 
Systemic mastocytosis with an associated non-mast cell lineage disease (SM-AHNMD) is an 
heterogeneous and intriguing group of haematological malignancies, in which clonal 
proliferation of mast cells is associated with a second and, in rare cases, a third (Kim, 2010) 
clonal blood disorder that is not mast cell derived (Horny, 2008; Pardanani, 2010).  
SM-AHNMD accounts for 40% of all cases of SM. About 89% of the patients show 
concomitant myeloid neoplasms: MPN (45%), CMML (29%) and MDS (23%). Among MPN, 
there is a high prevalence FIP1L1-PDGFRA related HES. In the remaining cases (21%) SM is 
associated with lymphoma, myeloma, CLL or amyloidosis. Prognosis is poor, with a median 
overall survival of 31 months in patients with MPN compared to 15, 13 and 11 months in 
patients with CMML, MDS and AML respectively. Transformation in MC leukemia occurs 
more frequently in SM-MDS (29%) (Pardanani, 2010). 
WHO diagnostic criteria for SM remain valid, except for elevated serum tryptase levels, as 
they could be very high also in patients affected by AML, MDS and MPS without MC 
disorders. 
The pathogenesis is not clear: in SM associated with myeloid malignancies mast cells and 
myeloid cells seem to originate from the same clone (Pardanani, 2009; Garcia-Montero 2006); 
according to this, in SM-LMMC kitD816V has been shown in both components. However, in 
SM-AML the leukemic counterpart generally lacks of kit mutation, suggesting a different 
origin for the two clones. At the opposite, in SM associated with lymphoid proliferative 
disease a distinct clonal origin has been demonstrated at least in some cases (Kim, 2007). 
Moreover, it has been hypothesized that malignant mast cells may support and promote the 
growth of the associated lymphoid disorder (Merluzzi, 2010). 
Lymphoid proliferation as AHNMD component has been rarely observed. More precisely, B 
cell lymphomas associated with SM usually are low grade. To the best of our knowledge, 
the occurrence of SM and synchronous high grade lymphoma has been reported so far only 
by Schipper et al., which described a case of SM associated with diffuse large B cell 
lymphoma (SM-DLBCL) (Schipper, 2011). Interestingly, we observed another patient, which 
is unlike to represent an accidental case. In our patient the diagnosis of mast cell disease was 
made concurrently with that of lymphoma, but we cannot state whether both the 
malignancies were synchronous or occurred at different time. In addition, the 
morphological evaluation of the bone marrow revealed a peculiar pattern of diffuse large B-
cells proliferation admixed with malignant mast cells (fig. 1). Compared to what we 
observed, in Schipper et al. reported a sharp separation between the two clonal components, 
with the histological demonstration of SM in the bone marrow and DLBCL in a lymph node 
at different time. According to typical morphological findings, mastocytes appeared either 
solitary or clustered in a separate contest from malignant B cell. By contrast, our case of SM 
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with concurrent large cell lymphoma seems to be unusual because of the great overlap 
between the two clonal populations of large B lymphocytes and mastocytes. Indeed, in our 
case, the lymphoid component resulted histologically atypical and new, as diffusely 
infiltrating within the malignant proliferating mast cells. 
As expected, our case was positive for the D816V mutation in exon 17 like the vast majority 
of SM. Unfortunately, we do not know whether this mutation occurred also in clonal B cells, 
since they were not sorted from bone marrow specimen for DNA extraction. Therefore it is 
not possible to rule out any hypothesis about the pathogenesis of such an association.  
 On the therapeutical side, in SM-AHNMD it is recommended to treat SM as pure SM and 
AHNMD as pure AHNMD (Valent, 2003; Valent 2010). Accordingly, it is important a 
complete molecular characterization of both the disorders (Valent et al., 2010).  
 
Fig. 1. A-B Bone marrow sections stained with haematoxylin and eosin (A) and Giemsa (B), 
40x. C-D Immunohistochemistry on bone marrow sections with antibodies against tryptase 
to detect mast cells (C) and antibodies against CD79a to detect B lymphocytes (D), 40x. 
A great overlap between lymphocytes and mast cells lesions is observed, resulting in a 
diffuse proliferation of B-cells admixed with mast cells. 
 
Fig. 2. Immunoperoxidase staining detecting large B lymphocytes, positive for CD79a (A, 
20x; C, 40x) and exhibiting nuclear Ki-67 reactivity (B, 20x; D, 40x). 
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8. Treatment  
To date Mastocytosis is incurable, thus clinicians should personalize treatment for each 
patients in order to reduce symptoms and complications (Molderings et al., 2011).  
Exposition to triggers (animal venoms, extreme temperatures, mechanical irritation, alcohol, 
medications, etc.) should be avoided, but often no clear trigger may be identified, therefore 
active therapy must be considered (Valent et al., 2010). 
Treatment in Mastocytosis may be symptomatic or cytoreductive. Symptoms could be 
managed with both non specific and tailored drugs. Cytoreduction should be considered if 
symptoms are refractory to basic therapy, rapidly worsening or life-threatening, or in the 
presence of complications (C-finding).  
In summary, in CM and ISM therapeutic approach may be just symptomatic. In advanced 
forms of SM schedules must be personalized, depending on progression risk. In SSM and 
slowly progressing ASM IFNα and 2CdA may be appropriated. In rapidly progressing 
ASM, MCL and SM-AHNMD high intensity chemotherapy and allogeneic bone marrow 
transplantation represent the current therapeutic approach. 
8.1 Symptomatic treatment 
The so-called basic therapy consists in antihistaminic medications and MC membrane 
stabilizers. Usually relief occurs many days or weeks after the introduction of a new drug, 
therefore the persistence of symptoms does not justify an earlier shift to others therapeutic 
schedules. As each new drug can trigger a hypersensitive reaction, one drug at a time 
should be introduced (Quintas-Cardama et al., 2006). 
When first line fails, immunomodulating agents may be considered, such as prednisone, 
cyclosporine, methotrexate, and azathioprine (Quintas-Cardama et al., 2006). IFNα might be 
combined with prednisone, but it generally represents the first line agent for cytoreduction 
in ASM. 
Omalizumab, a humanized murine antibody targeted to IgE, is now available as an 
experimental option (Quintas-Cardama et al., 2006). It seems to control MC activation 
syndrome also in patients resistant to conventional fist line therapy. Recently, Molderings et 
al., reporting their experience in four patients, showed its good risk-benefit profile. Two 
patients benefit a rapid remission, the third had a progressive improvement, only the fourth 
suffered from a worsening in MC-mediators syndrome (Molderings et al., 2011). Such isolated 
experience suggests that omalizumab could represent a new promising option. 
Epinephrine on demand remains the gold standard during life-threatening anaphylactic or 
anaphylactoid episodes.  
8.2 Cytoreductive treatment 
Cytoreduction consists in single (IFNα and 2CdA) or multidrug (Fludarabine, Cytarabine, 
Mitoxantrone) approaches.  
Usually IFNα represents the first line of treatment in slowly progressing variants. Cladribine 
is the second line, sometimes associated with novel agents (e.g. Imatinib). 
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experience suggests that omalizumab could represent a new promising option. 
Epinephrine on demand remains the gold standard during life-threatening anaphylactic or 
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Cytoreduction consists in single (IFNα and 2CdA) or multidrug (Fludarabine, Cytarabine, 
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Usually IFNα represents the first line of treatment in slowly progressing variants. Cladribine 
is the second line, sometimes associated with novel agents (e.g. Imatinib). 
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In rapidly progressing variants Mito FLAG must be considered, with or without a previous 
treatment with 2CdA, in order to perform HSCT as soon as possible. In these cases BMT 
represents the only effective strategy to cure mastocytosis. If patient is ineligible, 
experimental trials remain the next option. Palliation is the last choice. 
8.3 Novel agents 
8.3.1 Tyrosine kinase inhibitors 
Tyrosine kinase inhibitors have been under investigation since several years, particularly 
imatinib, dasatinib and midostaurin. Some clinical trials have been performed and many 
reports have been described. Target therapy has been observed to reduce both MC 
proliferation and infiltration, and sometimes to normalize BM histology. However, 
mediators related syndrome improved or got complete remission just in isolated reports. 
8.3.1.1 Imatinib 
Among the TK inhibitors, Imatinib is the most studied molecule. Low doses of Imatinib can 
inhibit wild type KIT. However, since D816V alters the kinase domain conformation, 
inhibiting steric interaction between the drug and the TK domain, efficacy of imatinib on 
kitD816V SM is still controversial. A phase II study conducted by Vega-Ruiz et al., showed 
that imatinib has no significant clinical activity in patients carrying the D816V mutation. By 
contrast, in a different phase II trial Droogendij et al. observed an apparent remission in 11 
kitD816V positive SMs (Droogendij et al., 2006). Some authors underline that concomitant 
use of prednisone may perhaps justify their results (Vega-Ruiz et al., 2009). Nevertheless, in 
some of these patients the observed reduction of symptoms was only transient. The case of 
SM with wild type kit or other sporadic mutations is different, since the conformational 
structure of the TK domain does not seem to be impaired. Moreover, these patients usually 
show an objective response, consisting in reduction of seric tryptase levels and bone marrow 
MC percentage (Vega-Ruiz, 2009). In summary, on one hand available data seem to suggest 
that imatinib is active against sporadic kit mutations, on the other hand the activity on 
kitD816V is not well established yet. Accordingly, in 2006 FDA approved the use of imatinib 
in adults with ASM without the D816V mutation. 
Imatinib is also a potent competitive inhibitor of PDGFR and has been demonstrated to be 
either active or effective in FIP1L1/PDGFRA related HES. Consequently, SM patients with 
blood eosinophilia are recommended to be screened for this fusion protein. However, 
cardiogenic shock has been reported in patients with HES after the start of therapy with 
imatinib. Such an adverse event could be easily avoided by concomitant administration of 
corticosteroids during the first one or two weeks of treatment, mostly in case of 
echocardiographic abnormalities or high serum troponin levels at baseline. 
Nilotinib is another TK inhibitor that has shown an in vitro activity against kit similar to 
imatinib, but no clinical experiences have been reported yet (Quintas-Cardama et al., Cancer 
2006). 
8.3.1.2 Dasatinib 
Dasatinib is a dual SRC/ABL kinase inhibitor that is more potent than imatinib also against 
KIT. Preliminary data from either preclinical or clinical studies seemed to suggest a key role 
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in SM, independently on mutational state of kit (Shah et al., 2006). However, data are too 
limited to draw any conclusion and the efficacy of dasatinib still remains controversial. 
Some authors described long lasting histological responses (Verstovsek et al, 2007) and both 
groups of patients with wild type and kitD816V improved in symptoms and quality of life. 
Wild type kit and kitD816V improved in symptoms and quality of life. It has been proposed 
a weekly dose escalation from 20 mg QD up to 100 mg QD during the first month of therapy 
(Rondoni et al., 2007). The proportion of responses may increase administering a dose of 120 
mg QD in case of suboptimal or no response after three months of therapy. Based on this, 
the GIMEMA group is conducting an Italian multicenter phase II study in which subjects 
with SM are treating with a continuous regimen of dasatinib at a starting dose of 20 mg once 
daily. The primary endpoint is the evaluation of clinical response in terms of proportion of 
subjects experiencing a regression in B/C findings and mediator-related symptoms. The 
secondary endpoints include duration of response, progression free survival and time to 
response (GIMEMA, 2008).  
8.3.1.3 Midostaurin 
Midostaurin is a multi-kinase inhibitor with a demonstrated in vitro activity against KIT, but 
there are only sporadic observations of effectiveness in vivo. Gotlib et al. reported a case of 
MCL associated with MDS/MPD who received a transient benefit from administration of 
midostaurin (Gotlib et al., 2005). More interestingly, midostaurin seems to exhibit a synergic 
activity with nilotinib (Quintas-Cardama et al., 2006), suggesting a more attracting role of 
these small molecules, as useful tools to combine in multidrug strategies in order to avoid 
the resistance to single agent approaches. 
8.3.1.4 Other TK inhibitors 
Several more small molecules have been identified as potential agents against MC diseases: 
e.g. ATP analogs (OSI-930, MLN518, PD180970, PD180970, PD173955, AP23464 and 
AP23848), indolinone-based products (SU11652, SU11654 and SU11655) or quinoxaline 
derivatives (AGL2043). To date there are no data on clinical tolerability and efficacy yet 
(Quintas-Cardama et al., 2006). 
8.3.2 Monoclonal antibodies 
Monoclonal antibodies might play a crucial role in the future. The antiCD25 antibody 
conjugated with the pseudomonas exotoxin-A generates a potent immunotoxin with 
proapoptotic activity, associated with a significant reduction in the number of MCs (Valent 
et al., 2004). The effect is similar to that reported by other authors after in vitro exposure to 
Ontak, also known as denileukin diftitox, consisting in recombination of CD25 ligand and 
diphtheria toxin. Based on data on Ontak preclinical activity as well as clinical effectiveness 
in cutaneous T-cell lymphoma, there are ongoing phase II trials to test Ontak also in SM 
patients. 
Other monoclonal antibodies are under investigation in Mastocytosis: the antiCD25 
Daclizumab and Basiliximab, the antiCD33 Gemtuzumab with the toxic compound 
calicheamicin and the antiCD87 and antiCD45 antibodies, conjugated to 131I radioisotope or 
diphtheria toxin (Quintas-Cardama et al., Cancer 2006). 
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in SM, independently on mutational state of kit (Shah et al., 2006). However, data are too 
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conjugated with the pseudomonas exotoxin-A generates a potent immunotoxin with 
proapoptotic activity, associated with a significant reduction in the number of MCs (Valent 
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8.3.3 mTor inhibitors 
mTor inhibitors have been tested since it has been demonstrated, both in vitro and in vivo, 
that the mTor pathway is active in SM and contributes to MC survival, growing and 
proliferation (Kim et al, 2008). Preclinical observations suggest that mTor inhibitors act 
against clonal MCs. Particularly, rapamycin inhibits selectively the mTor pathway, either in 
fresh MCs collected from KITD816V patients or in KITD816 cell lines. Hence, everolimus 
was tested in a clinical trial, but it did not show any apparent significant effectiveness. 
Perhaps some more experiences must be collected to determine whether mTor inhibitors 
may play any role in SM (Quintas-Cardama et al., 2006). 
8.3.4 Future perspectives in SM therapy 
Apoptosis still remains an attractive way to be investigated. Several drugs have shown some 
activity on Bcl-2 family members, as bortezomib, obatoclax and geldanamycin. The first one 
acts promoting Bim expression, the second one is known as BH3-mimetic (Aichberger et al., 
2009), the last one inhibits the hsp90-bcl2 complex (Quintas-Cardama et al., 2006). 
9. Conclusion  
SM is a rare disorder, but its prevalence might be underestimated. Afar from drafting a 
complete and exhaustive review on mastocytosis, the aim of this chapter was to remark the 
relevance of SM. Clinical suspicion is really important and multimodality approaches must 
be considered to get the right diagnosis. Then, treatment must be personalized for each 
patient, accordingly with a careful and complete characterization of the disease. 
Prospectively, two major challenges still have to be faced in SM research: first, the molecular 
and cellular pathogenesis; second, the definition of new strategies of treatment. About the 
former goal, we do believe that reporting new cases may be of great usefulness and is 
needed to better understand the nature of the disorder. In order to this, the case we 
described may perhaps represent a paradigmatic example. Referring to treatment, several 
novel agents are under investigation. However, preliminary clinical data seem to suggest 
that the use of a single drug may be insufficient. That means that a multidrug strategy is 
needed within a multitarget approach. 
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1. Introduction 
Acute myeloid leukemia (AML) is a neoplastic disorder characterized by the clonal 
expansion of non-lymphoid hematopoietic progenitor cells with failure of normal 
hematopoiesis. Several biological and clinical parameters have been identified at diagnosis 
to classify different AML subtypes with different prognosis. In this view, genetic 
abnormalities confer the most important prognostic information. Therapeutic interventions 
based on conventional or high-dose chemotherapy have significantly improved the 
complete remission (CR) rates of acute leukemia. However, a significant portion of 
responding patients still harbors a minimal residual disease (MRD), which is often resistant 
to further pharmacological treatments and ultimately leads to disease relapse and 
progression. Although allogeneic stem cell transplantation may significantly improve the 
clinical results of AML patients who achieved complete remission, such approach has 
several and important limitations and is not applicable to all the patients. For these reasons, 
novel therapeutic approaches to improve the clinical outcome of AML patients are under 
investigation, and treatments with high compliance such as adoptive and active 
immunotherapy are desirable. Aim of the present work will be to focus the most relevant 
insights in the field. In particular, we will report about the use of natural killer (NK) cells as 
a means of adoptive immunotherapy against neoplastic cells, including AML. Moreover, we 
will discuss the role of vaccines against leukemia with particular emphasis on the 
immunogenicity of novel and promising leukemia-associated antigens. 
2. Acute Myeloid Leukemia 
Acute myeloid leukemia (AML) is a hematopoietic malignant disease rising from neoplastic 
transformation of myeloid stem cells. This causes the alteration of the normal cell 
differentiation and proliferation systems, resulting in the accumulation in bone marrow and 
peripheral blood of non-functional myeloid cells termed myeloblasts. AML may arise de 
novo or secondary to pre-existing myelodysplasia or previous chemotherapies.  
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Myeloblasts lack the normal proliferation systems and their over-proliferation and 
accumulation in bone marrow and peripheral blood cause lack of production of 
hematopoietic normal cells, this resulting in peripheral deficiency of platelets, neutrophils 
and hemoglobin. 
Prognosis of AML depends on multiple factors: age at diagnosis (age>60 years is a poor 
prognostic factor), hyperleukocytosis, cytogenetic status and molecular specific 
characteristics are the most important ones. 
AML can occur at every age, but its incidence increases with age (median age at 
presentation: 65 years). It has an annual incidence of 3.6 per 100,000.  This incidence 
increases with age, rising to 16.3 per 100,000 per year in the over 65 age group. Older adults 
typically have a highly inferior prognosis and an increased risk of therapy-related toxicity 
and mortality. 
Conventional treatment of AML is based on chemotherapy regimens and consists of several 
well-defined phases: the first one is the CR-induction cycle, based on the administration of 3 
days-anthacycline associated with 7 days-cytarabine. Its aim is to ‘empty’ bone marrow and 
allow the normal hematopoietic cells repopulation.  
Response rates with conventional chemotherapy range from 60% to 85% in young adults 
(age < 60 years), but more than 50% of these patients are going to relapse, with a five-year 
overall survival of 40%. Older patients with a diagnosis of AML have a poorer prognosis, 
with less than 10% of long survivers; this is due to biological unfavorable risk factors, such 
as unfavorable cytogenetics, which are more frequent in the elderly (Leith et al. 1997). 
One of the main cause of relapse in patients who achieved complete remission after 
chemotherapy is the persistance of a small amount of leukemic cells termed MRD. Minimal 
residual disease detection became one of the main tasks for hematologists;  
immunophenotypical and molecular markers able to discriminate normal cells from blastic 
cells allow the detection of residual leukemic cells not detected by morphologic 
examinations. 
After the induction therapy two or more consolidation cycles are needed in order to 
eradicate leukemic cells completely. Allogeneic stem cell transplantation is one of the most 
effective consolidation therapy, even if it is feasible only for fit patients and only if a suitable 
HLA-matched donor is available.  
Moreover, allogeneic stem cell transplantation is highly effective if performed after 
obtaining first CR, while its efficacy is poor in case of relapsed/refractory patients. 
Only young and fit patients can undergo stem cell transplantation because of its 
significantly high toxicity, mortality and morbidity rates. 
Attempts to effectively prime and sustain anti-tumor immunity against leukemic cells have 
recently provided promising preclinical and clinical results. Results from allogeneic stem 
cell transplantation (SCT) represent the main evidence that leukemic cells are targets of the 
immune system. In fact, since the first clinical observation that allogeneic SCT offered a 
clinical advantage over autologous transplantation due to a graft-versus-leukemia (GVL) 
effect, much more attention has been given to the role of adoptive immunotherapy over 
conditioning regimen as a means to eradicate tumor cells. In particular, donor lymphocyte 
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infusions (DLIs) are capable to restore a durable complete remission. Such results are the 
proof of principle of the crucial activity of anti-tumor immunity in controlling the growth of 
leukemic cells.  
3. Adoptive immunotherapy with natural killer cells 
Human NK cells are a subset of PB lymphocytes defined by the expression of CD56 or CD16 
and the absence of the T-cell receptor (CD3) (Robertson et al, 1990). They recognize and kill 
transformed cell lines in an MHC-unrestricted fashion and play a critical role in the innate 
immune response. Several studies demonstrated that NK function, which is distinct from 
the MHC-restricted cytolytic activity of T cells, may be relevant for the immune control of 
tumor development and growth. Although NK cell killing is MHC-unrestricted, NK cells 
display a number of activating and inhibitory receptors that ligate MHC molecules to 
modulate the immune response (Lanier et al, 1998). NK cell receptors that recognize 
antigens at the HLA-A, -B, or -C loci are members of the immunoglobulin super family and 
are termed killer immunoglobulin receptors or KIRs (Farad et al, 2002). Engagement of these 
NK cell receptors results in stimulation or inhibition of NK cell effector function, which 
ultimately depends on the net effect of activating and inhibitory receptors (Figure 1).  
 
Clinical trials attempting to utilize the anti-tumor effect of NK cells have met only modest 
success due to the lack of understanding of receptors and ligands which determine whether 
NK cells will be activated or suppressed. On the contrary, data from haploidentical T-cell 
depleted transplantation suggest that KIR mismatch with tumor MHC may significantly 
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impact on tumor cell killing, particularly in AML (Ruggeri et al, 2002). In fact, these studies 
show that AML patients with KIR ligand mismatch are significantly protected against 
leukemia relapse. In addition, preclinical and clinical investigations demonstrated that 
haploidentical KIR-mismatched NK cells play the main role as anti-leukemia effector cells 
and they exert their cytotoxic activity within 4-5 days (Ruggeri et al 2002, Ruggeri et al, 
1999). In particular, high risk AML patients with a KIR-ligand mismatch in the graft-versus-
host (GVDH) direction had a relapse rate of 0% compared to KIR-ligand matched patients 
who had a relapse rate of 75%. Given these results, haploidentical KIR-mismatch NK cells 
administered to AML patients as cell-based immunotherapy may induce NK cell-mediated 
killing of leukemia cells resulting in the elimination of residual disease in high risk AML 
patients. Furthermore, alloreactive mismatched NK cells facilitate hematopoietic 
engraftment after infusion of haploidentical stem cells, and inhibit the onset of GVHD by 
targeting host antigen-presenting cells (Ruggeri et al, 2002). Of note, the differential 
expression of activating ligands on hematopoietic and not hematopoietic tissues may 
provide an additional explanation for the observed GVL effect in the absence of GVHD. 
Partially purified haploidentical NK cells have been already used clinically and labeled with 
111In to track, in vivo, their kinetics and organ distribution in patients with renal cancer 
(Brand et al, 2004). A seminal study demonstrated that up to 1.5 x 107/haploidentical NK 
cells/Kg can be safely infused in AML and cancer patients following Fludarabine/ 
Cyclophosphamide (Flu/Cy) immunosuppressive chemotherapy and, in some cases, clinical 
responses without GVHD had been observed (Miller et al, 2005). Interestingly, circulating 
haploidentical NK cells were found, in selected patients, up to 28 days after infusion 
especially when exogenous IL-2 was given for 9 doses. In vivo expansion of NK cells was 
correlated with a high IL-15 serum concentration. In particular, in this study, 19 poor risk 
AML patients were reported who had received a cell population containing a median of 
8.50.5 X 106 and 1.750.3 X 105 NK and T cells, respectively. Five out of 19 patients achieved 
CR. NK cells adoptive immunotherapy was well tolerated and hematological and non 
hematological toxicity were mainly related to the immunosuppressive regimen and IL-2 
administration. The maximum tolerated dose of NK cells was not achieved and GVHD was 
not observed despite the relatively high number of haploidentical T cells infused. However, 
it should be noted that NK cells were only partially purified after a single round of 
depletion of CD3+ cells which resulted in less than 2 logs reduction of T cells.   
More recently, a study of haploidentical KIR-HLA mismatched NK cell transplantation in 
childhood AML reported that NK cell therapy  prolonged disease-free and overall 
survival (Rubnitz et al, 2010). In this pediatric cohort of AML patients, who underwent 
NK therapy after an  immunosuppressive regimen, the 2-year event-free survival was 
100%. Notably, all the children were considered at low-risk of relapse, with a significant 
fraction harboring good-prognosis cytogenetics. Furthermore, as children weigh less than 
adults, the median number of infused NK cells  was significantly higher than in adult trial 
and the separation procedure consisted in highly purified NK cells. These differences may 
partially explain the discrepancy in clinical results and suggest that in adult patients the 
clinical effect of NK therapy may be implemented by increasing the number of infused 
NK cells.  
We recently published the results of a clinical trial of adoptive immunotherapy with 
haploidentical KIR-mismatched NK cells in elderly patients with AML (Curti et al, 2011). 
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Thirteen AML patients, 5 with active disease, 2 in molecular relapse and 6 in morphological 
complete remission (CR);(median age 62 years, range 53-73) received highly purified 
CD56+CD3- NK cells from haploidentical KIR-ligand mismatched donors after fludarabine/ 
cyclophosphamide immunosuppressive chemotherapy, followed by IL-2. The median 
number of infused NK cells was 2.74 x 106/Kg. T cells were under 105/Kg. No NK cell-
related toxicity, including GVHD, was observed. One of the 5 patients with active disease 
achieved transient CR, whereas 4/5 patients had no clinical benefit. Both patients in 
molecular relapse achieved CR which lasted for 9 and 4 months, respectively. Three/6 
patients in CR are disease-free after 34, 32 and 18 months. After infusion, donor NK cells 
were found in the peripheral blood of all evaluable patients (peak value on day 10). They 
were also detected in bone marrow in some cases. Donor-versus-recipient alloreactive NK 
cells were demonstrated in vivo by the detection of donor-derived NK clones that killed 
recipient’s targets. Adoptively transferred NK cells were alloreactive against recipient’s 
cells, including leukemia. Taken together, these data demonstrate that infusion of purified 
NK cells is feasible in elderly patients with high risk AML. 
4. Vaccination against acute myeloid leukemia: WT1 as a novel promising 
antigen 
During the last years a number of studies have demonstrated that tumor-associated antigens 
(TAA) may be recognized by the immune system leading to the activation of tumor-specific 
cytotoxic T lymphocytes (CTLs) with the potential to eradicate tumor cells. Moreover, 
during the last decade the role of dendritic cells (DCs) as natural adjuvants of immune 
response has been deeply elucidated. The identification of a wide number of TAA, together 
with new insights into the mechanisms underlying the activation of anti-tumor immune 
response, has led to the development of novel anti-tumor vaccination strategies which are 
currently under investigation in the clinical setting. In AML, some TAA, such as PRAME, 
Wilms’ tumor gene (WT1), proteinase 3 have been recently identified. In particular, WT1, 
which  is a zinc-finger transcription factor expressed during normal ontogenesis, is 
significantly over-expressed in acute and chronic myeloid leukemia and myelodysplastic 
syndromes and it appears as an attractive target for immunotherapy.   
WT1-specific antibodies against the N-terminus portion of the WT1 protein have been found 
in the sera of AML patients, but not in healthy donors, suggesting that anti-WT1-specific 
immune response is present in these patients. Preclinical studies have clearly demonstrated 
that peptides from WT1 may be used to generate in vitro a WT1-specific cytotoxic response 
(Li et al, 2005; Pinilla-Ibarz et al, 2006; Oka et al, 2000). While a number of WT1-derived CD8 
T-cell epitopes have been reported, two peptides, namely HLA-A0201-restricted peptide 
126–134 and HLA-A24-restricted peptide 235–243, have been studied extensively. Since 
murine and human WT1 are similar, WT1 126 and WT1 235 have also been tested in animal 
models. B6 mice were injected with WT1 peptides and analyzed for the induction of a T-cell 
and B-cell mediated immune responses against WT1. This analysis revealed that WT1 
vaccination induced WT1-specific immunity, which was also capable to delay in vivo the 
growth of tumor cell lines, naturally overexpressing WT1. Recently, a National Cancer 
Institute Pilot Project assigned to WT1 the position of best and most suitable target antigen 
for cancer immunotherapy, due to a number of characteristics, such as its therapeutic 
function, immunogenicity and expression level (Cheever et al, 2009) 
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These data have prompted several groups to investigate the role of WT1 as a tumor-antigen 
in the clinical setting of cancer immunotherapy. Particularly, Oka et al conducted phase I 
clinical trials using peptide WT1-235 (CMTWNQMNL) and its analogue (CYTWNQMNL) 
for patients with overt leukemia from MDS, MDS with myelofibrosis and AML (Oka et al, 
2004). Vaccination was performed by injecting 0.3–3 mg of native or analogue peptide 235 
emulsified with the adjuvant Montanide ISA51. The vaccination resulted in an increase in 
WT1-specific CTLs followed by a rapid reduction in leukemic blast cells. No serious toxicity 
was observed, but leukemic blasts relapsed after the vaccination was stopped.  Recently, 
these investigators reported that biweekly injection of AML patients with either native or 
analogue peptide 235 along with Montanide and GM-CSF resulted in three patients 
remaining in CR for 4 years (Tsuboi et al, 2007). The WT1-235 peptide has also been shown 
to induce HLA-A0201-restricted CTL (Pinilla-Ibarz, 2006). Keilholz et al first reported that 
vaccination of a patient with recurrent AML, using HLA-A0201-restricted WT1 peptide 126 
along with KLH as an adjuvant, induced CR (Mailander et al, 2004). No haematological or 
renal toxicities were observed. Rezvani et al reported a phase I clinical trial in patients with 
AML, CML and MDS, using combined HLA-A0201-binding peptide vaccines from PR1 169–
177 and WT1 126–134. Their results show that the emergence of PR1+ or WT1+CD8+ T cells 
in patients who received WT1 vaccine was associated with a decrease in WT1 mRNA 
expression, suggesting a vaccine-driven anti-leukemia effect (Rezvani et al, 2008). An 
analogue to WT1 peptide 126–134 was generated by substituting R for Y at the position 2 
anchor motif (named WT1-A1) (Pinilla-Ibarz et al, 2006). This analogue peptide generated a 
more potent CD8 T-cell response which recognized and lysed WT1+ leukemia cells in vitro. 
In addition to the HLA-A0201 and -A24 vaccines derived from WT1 protein, Asemissen et al 
identified a highly immunogenic HLA-A1-binding WT1 peptide (317–327) that is processed 
and able to induce a CD8 T-cell response in healthy donors and patients with 
haematological malignancies (Asemissen et al, 2006).  
The German group reported about their phase 2 trial of WT1 peptide vaccination in patients 
with AML and MDS (Keilholz et al, 2009). Vaccination consisted of GM-CSF subcutaneously 
days 1 to 4, and WT1126-134 peptide and 1 mg keyhole limpet hemocyanin on day 3. 
Seventeen AML patients and 2 refractory anemia with excess blasts patients received a 
median of 11 vaccinations. Treatment was well tolerated. Objective responses in AML 
patients were 10 stable diseases (SDs) including 4 SDs with more than 50% blast reduction 
and 2 with hematologic improvement. An additional 4 patients had clinical benefit after 
initial progression, including 1 CR and 3 SDs. WT1 mRNA levels decreased at least 3-fold 
from baseline in 35% of patients. In 8 of 18 patients, WT1-tetramer+ T cells increased in 
blood and in 8 over 17 patients in bone marrow, with a median frequency in bone marrow 
of 0.18% at baseline and 0.41% at week 18. This WT1 vaccination study provides 
immunologic, molecular, and preliminary evidence of potential clinical efficacy in AML 
patients, warranting further investigations.  
Other approaches include the use of autologous DCs, generated from leukemia patients in 
CR and loaded with tumor antigens and/or the differentiation of leukaemia blasts into 
leukemic DCs. In particular, Van Tendeloo et al reported the results of a phase I/II clinical 
trial of WT1 vaccination based on antigen-loaded DCs with the induction of complete and 
molecular responses in some cases (Van Tendeloo et al, 2010). These results are promising. 
However, the clinical experience with DC-based vaccines targeting WT1 is far too limited 
and future studies are highly warranted to assess the role and the efficacy of these strategies 
of active immunotherapy in the clinical management of MRD in AML.  
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5. Conclusion 
In conclusion, the clinical results of AML patients, especially if elderly, are particularly 
dismal, although the achievement of CR with MRD after combined chemotherapy appears 
as possible in the majority of patients. Unfortunately, the persistence of MRD leads to 
progression and patients ultimately die. For these reasons, alternative approaches for the 
prevention of relapse in CR patients are necessary and are currently under active 
investigation. In particular, the role of immunological therapies in the post-remission 
management of adult AML patients, such as NK therapy and active immunization against 
relevant tumor rejection antigens, including WT1, have been recently exploited with 
promising results in terms of immunological and clinical responses. Further studies (phase 
II-III) are highly warranted to really evaluate the role of such approaches and their impact 
on overall survival of AML patients.  
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These data have prompted several groups to investigate the role of WT1 as a tumor-antigen 
in the clinical setting of cancer immunotherapy. Particularly, Oka et al conducted phase I 
clinical trials using peptide WT1-235 (CMTWNQMNL) and its analogue (CYTWNQMNL) 
for patients with overt leukemia from MDS, MDS with myelofibrosis and AML (Oka et al, 
2004). Vaccination was performed by injecting 0.3–3 mg of native or analogue peptide 235 
emulsified with the adjuvant Montanide ISA51. The vaccination resulted in an increase in 
WT1-specific CTLs followed by a rapid reduction in leukemic blast cells. No serious toxicity 
was observed, but leukemic blasts relapsed after the vaccination was stopped.  Recently, 
these investigators reported that biweekly injection of AML patients with either native or 
analogue peptide 235 along with Montanide and GM-CSF resulted in three patients 
remaining in CR for 4 years (Tsuboi et al, 2007). The WT1-235 peptide has also been shown 
to induce HLA-A0201-restricted CTL (Pinilla-Ibarz, 2006). Keilholz et al first reported that 
vaccination of a patient with recurrent AML, using HLA-A0201-restricted WT1 peptide 126 
along with KLH as an adjuvant, induced CR (Mailander et al, 2004). No haematological or 
renal toxicities were observed. Rezvani et al reported a phase I clinical trial in patients with 
AML, CML and MDS, using combined HLA-A0201-binding peptide vaccines from PR1 169–
177 and WT1 126–134. Their results show that the emergence of PR1+ or WT1+CD8+ T cells 
in patients who received WT1 vaccine was associated with a decrease in WT1 mRNA 
expression, suggesting a vaccine-driven anti-leukemia effect (Rezvani et al, 2008). An 
analogue to WT1 peptide 126–134 was generated by substituting R for Y at the position 2 
anchor motif (named WT1-A1) (Pinilla-Ibarz et al, 2006). This analogue peptide generated a 
more potent CD8 T-cell response which recognized and lysed WT1+ leukemia cells in vitro. 
In addition to the HLA-A0201 and -A24 vaccines derived from WT1 protein, Asemissen et al 
identified a highly immunogenic HLA-A1-binding WT1 peptide (317–327) that is processed 
and able to induce a CD8 T-cell response in healthy donors and patients with 
haematological malignancies (Asemissen et al, 2006).  
The German group reported about their phase 2 trial of WT1 peptide vaccination in patients 
with AML and MDS (Keilholz et al, 2009). Vaccination consisted of GM-CSF subcutaneously 
days 1 to 4, and WT1126-134 peptide and 1 mg keyhole limpet hemocyanin on day 3. 
Seventeen AML patients and 2 refractory anemia with excess blasts patients received a 
median of 11 vaccinations. Treatment was well tolerated. Objective responses in AML 
patients were 10 stable diseases (SDs) including 4 SDs with more than 50% blast reduction 
and 2 with hematologic improvement. An additional 4 patients had clinical benefit after 
initial progression, including 1 CR and 3 SDs. WT1 mRNA levels decreased at least 3-fold 
from baseline in 35% of patients. In 8 of 18 patients, WT1-tetramer+ T cells increased in 
blood and in 8 over 17 patients in bone marrow, with a median frequency in bone marrow 
of 0.18% at baseline and 0.41% at week 18. This WT1 vaccination study provides 
immunologic, molecular, and preliminary evidence of potential clinical efficacy in AML 
patients, warranting further investigations.  
Other approaches include the use of autologous DCs, generated from leukemia patients in 
CR and loaded with tumor antigens and/or the differentiation of leukaemia blasts into 
leukemic DCs. In particular, Van Tendeloo et al reported the results of a phase I/II clinical 
trial of WT1 vaccination based on antigen-loaded DCs with the induction of complete and 
molecular responses in some cases (Van Tendeloo et al, 2010). These results are promising. 
However, the clinical experience with DC-based vaccines targeting WT1 is far too limited 
and future studies are highly warranted to assess the role and the efficacy of these strategies 
of active immunotherapy in the clinical management of MRD in AML.  
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5. Conclusion 
In conclusion, the clinical results of AML patients, especially if elderly, are particularly 
dismal, although the achievement of CR with MRD after combined chemotherapy appears 
as possible in the majority of patients. Unfortunately, the persistence of MRD leads to 
progression and patients ultimately die. For these reasons, alternative approaches for the 
prevention of relapse in CR patients are necessary and are currently under active 
investigation. In particular, the role of immunological therapies in the post-remission 
management of adult AML patients, such as NK therapy and active immunization against 
relevant tumor rejection antigens, including WT1, have been recently exploited with 
promising results in terms of immunological and clinical responses. Further studies (phase 
II-III) are highly warranted to really evaluate the role of such approaches and their impact 
on overall survival of AML patients.  
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1. Introduction  
The ubiquitin-proteasomal system (UPS) is critical for the regulation of protein homeostasis 
and is composed of the protein ubiquitination system and proteasomal degradation system. 
Protein ubiquitination is referred to the process that the small protein ubiquitin is covalently 
tagged to a specific substrate protein. Once a protein is ubiquitinated, its structural 
conformation, cellular location, and biological function will change accordingly, or it will be 
delivered into the 26S proteasome complex for degradation by specific proteases. The UPS is 
extensively involved in nearly all the important cell biological activities, such as cell 
metabolism, cell proliferation, glycogen synthesis, immunological process, organogenesis, 
etc. (Ciechanover, 1998; Haglund and Dikic, 2005; Kirkin and Dikic, 2010).  
The UPS system is also widely associated with various diseases, such as inflammation, 
arthritis, heart disease and cancers (Ciechanover et al., 2000). For example, the proteasome 
has emerged as a milestone target for cancer therapy, which was further demonstrated by 
the discovery of the proteasome inhibitor bortezomib for the therapy of multiple myeloma 
(Kisselev and Goldberg, 2001; Richardson et al., 2003). Recently, in addition to the 
proteasome, the protein ubiquitination pathway is also being developed as a novel target for 
anti-cancer drugs (Bedford et al., 2011 ; Colland, 2010). In this chapter, we will discuss  the 
UPS system, its biological implications, and associated targeted drug discovery for 
hematological malignancies. 
2. The ubiquitin-proteasomal system (UPS)  
The UPS is composed by at least 6 components, including ubiquitin (Ub), ubiquitin-
activating enzymes (UBA, E1), ubiquitin-conjugating enzymes (UBC, E2), ubiquitin ligases 
(E3), proteasomes, and deubiquitinases (Dub) (Figure 1). The substrate proteins are first 
tagged with a ubiquitin chain under the guidance of E1, E2 and E3, and the produced 
polyubiquitinated proteins are then transferred to 26S proteasomes where it is degraded by 
the 20S core particles. 
2.1 Ubiquitination 
Ubiquitin is a ubiquitinously expressed small protein composed of 76 amino acids and  
it plays a central role in the UPS system. It can be linked to a substrate protein with the  
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Fig. 1. The ubiquitination-proteasomal system (UPS). The UPS is composed of 6 
components, including ubiquitin (Ub), ubiquitin-activating enzyme (E1), ubiquitin-
conjugating enzyme (E2), ubiquitin ligase (E3), deubiquitinases (Dub) and proteasomes.  
assistance of E1, E2, and E3, and can be removed from the target protein by Dubs. Ubiquitin 
is highly conserved and is expressed in most species but it is only found in eukaryotic 
organisms. This strong sequence conservation suggests that ubiquitin plays a very 
fundamental role in maintaining cell function and in species evolution. Actually, ubiquitin is 
involved in all aspects of cell biology and activities by regulating its extensive substrate 
proteins. Proteins will undergo turnover, translocation or conformational changes after they 
are covalently attached a ubiquitin, which is called ubiquitination, one of the most 
important post-translational modifications of proteins, where the carboxylic acid of the 
terminal glycine from the di-glycine motif in the activated ubiquitin forms an amide bond to 
the epsilon amine of the lysine in the substrate proteins (Ciechanover et al., 2000). In the 76 
amino acids, there are 6 lysine residues (K) including K6, K11, K27, K29, K33, K48, and K63 
as shown in Figure 2. These lysine residues are responsible for ubiquitin attachment to the 
target proteins. Theoretically, any lysine residues in a protein could be linked a ubiquitin, 
including ubiquitin itself, however, the biological function may differ and it depends on the 
ubiquitination status (Haglund and Dikic, 2005).  
Ubiquitination can be categorized into three classes based on the tagged ubiquitin (Haglund 
and Dikic, 2005; Ye and Rape, 2009): i) monoubiquitination: proteins are bound to a single 
ubiquitin, ii) multiubiquitination or poly-monoubiquitination: proteins are tagged with 
several single ubiquitin molecules; iii) polyubiquitination: proteins are attached with poly-
ubiquitin chains. These differences of ubiquitination on target proteins will regulate a 
variety of cellular processes, including protein degradation, signal transduction, membrane 
trafficking, DNA repair, chromatin remodelling, peroxisome biogenesis and viral budding 
(Ye and Rape, 2009). For example, polyubiquitin chain occurring at the 11th (K11) and 48th  
 




Fig. 2. Protein ubiquitination and functional modulation. There are 7 lysine (K) residues in 
76 amino acids of ubiquitin and each could be further conjugated to a specific protein (A). 
Monoubiquitination (B) regulates protein conformation, cellular localization and protein 
interaction. Proteins tagged with polyubiquitin-chains occurring at K11 or K48 (C) are 
subject to degradation in the 26S proteasome. Polyubiquitination at K63 (D) activates NFB 
function and is involved in DNA repair. 
lysine (K48) of ubiquitin is mainly involved in protein degradation, but the K63 
polyubiquitination is mainly responsible for modification of protein function and involved 
in signal transduction, including regulation of NFκB signal pathway, DNA repair and 
targeting to the lysosome (Ye and Rape, 2009). For other proteins polyubiquintinated at K6, 
27, 29 or 33, whether they are involved in protein degradation or DNA repair is largely 
unknown (Ye and Rape, 2009)(Figure 2). 
2.2 Ubiquitining enzymes 
The ubiquitination process is an ATP-dependent enzymatic reaction and requires at least 3 
types of enzymes, including E1, E2 and E3 as described earlier, thus the ubiquitination 
process is alternatively known as the E1-E2-E3 cascade. In the process of ubiquitination, 
ubiquitin is first activated by E1 using ATP as an energy source to form a ubiquitin-
adenylate intermediate. Subsequently, the ubiquitin is transferred to the cysteine residue, 
the E1 active site, resulting in a thioester linkage between the C-terminal carboxyl group of 
ubiquitin and the E1 cysteine sulfhydryl group. Secondly, the activated ubiquitin is 
transferred from E1 to the cysteine of an E2 via a trans(thio)esterification reaction. Finally, 
the ubiquitination cascade creates an isopeptide bond between a lysine of the target protein 
and the C-terminal glycine of ubiquitin with the coordination of an E3 which identifies 
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specific recognition modules in the target protein and is capable of interaction with both E2 
and substrate (Ye and Rape, 2009). 
In human genome, there are only two genes encoding E1, whilst E2 is encoded by 60-100 
genes, and there are ~ 1000 different E3 genes (Deshaies and Joazeiro, 2009; Schulman and 
Harper, 2009). E1 activates ubiquitin at the top level, and transfers activated ubiquitin to 
different E2. E3s identify individual substrates and specifically ligate E2-Ub complex to a 
certain target protein. These enzymes form a hierarchical structure (Figure 3) and control the 
whole ubiquitination process. In this ubiquitination cascade, E1 binds to dozens of E2s, 
which bind to hundreds of E3s, and E3s specifically target thousands of substrate proteins.  
 
Fig. 3. E1, E2 and E3 form an enzymatic cascade for protein ubiquitination. One single E1 
initiates the whole ubiquitination process, by activating Ub and transferring it to E2. There 
are around 100 E2s in human. Each E2 will deliver activated Ub to one or several E3s which 
are a large family of around 1000 members. E3s specifically identify target proteins 
(substrates) and attach Ub to individual proteins. 
There are around 100 Dubs in human cells which cleave the ubiquitin-protein bonds thus 
regulating ubiquitin-dependent metabolic pathways (Colland, 2010). Polyubiquitinated 
proteins are deubiquitinated by Dubs immediately before degradation in the proteasome. In 
addition to ubiquitin recycling, Dubs are also involved in processing of ubiquitin 
precursors, in proofreading of protein ubiquitination and in disassembly of inhibitory 
ubiquitin chains. 
2.3 The proteasome system 
The 26S proteasome is a large protein complex with molecular weight more than 2000 
kilodalton and it is composed of one 20S core particle and two 19S regulatory particles, 
where the core particle is made up of two units (at the two ends) and two β units (in the 
middle). Each of these units is composed of 7 ring-like subunits thus the total 28 subunits 
stack up to form a hollow cylinder (Figure 1). The subunits N-termini form a gate and 
serve as docking domains for the regulatory particles that block unregulated access of 
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substrates to the interior cavity (Smith et al., 2007). Proteins are lysed in the core particle but 
proteases are only found in the interior surface of the β units, especially β1, β2 and β5. 
Although these proteases share a common mechanism, each subunit dominants its 
distinctive catalytic activity due to interatomic contacts with local residues near the active 
sites of each subunit. β1, β2, and β5 mainly present caspase-like, trypsin-like, and 
chymotrypsin-like activity, respectively. Each catalytic β subunit also possesses a conserved 
lysine residue required for proteolysis. The proteasomes catalyze thousands of 
polyubiquitinated proteins, therefore, they are critical in regulatory protein function and cell 
activity. 
3. The UPS is extensively involved in hematological malignancies 
3.1 Protein ubiquitination in blood cancers 
Heavy ubiquitination levels of proteins, associated with overactivation of E1, have been 
observed both in leukemia cell lines and primary acute leukemia cells compared with the 
normal blood cells (Bedford et al., 2011; Xu et al., 2010). Additionally, blood cancer-specific 
proteins are also regulated by the UPS. For example, multiple myeloma (MM) tumor cells 
are recurrently associated with several chromosomal translocations that result in 
overexpression of transcription factors involved in the UPS pathway such as c-Maf, MafB, 
and fibroblast growth factor receptor 3 (FGFR3), which converge dysregulation of D-cyclins 
(Bergsagel and Kuehl, 2005). All these proteins could be poly-ubiquitinated and degraded in 
proteasomes. D-type cyclins are ubiquitinated under the coordination of SCF E3 ligase 
complex. The fibroblast growth factor receptor FGFR3 could also be ubiquitinated. In 
chronic leukemia, FGFR3 undergoes ubiquitination by c-Cbl, a RING finger domain-
containing E3 ligase. In chronic leukemia cells, the specific BAR-ABL fusion protein is 
ubiquitinated by c-CBL. Targeting at c-CBL, arsenic induces degradation of BCR-ABL (Mao 
et al., 2010). 
3.2 Ubiquitination enzymes and blood cancers 
E1 is responsible for the first step of the ubiquitination process by activating ubiquitin and is 
overexpressed in all leukemia and MM cell lines and primary samples. When E1 is knocked 
down, these leukemia and MM cells will go to apoptosis (Xu et al., 2010). Several E2s have 
been reported to be involved in MM development. For example, CDC34, the cell cycle 
regulator, is highly expressed in MM patient cells and cell lines in contrast to normal cells 
(Block et al., 2001). CDC34 has been implicated in the ubiquitination of p27 (Kip1), IκBα, Wee1, 
and MyoD, thus facilitating the degradation of these proteins by 26S proteasomes and 
modulating cell cycle progression. Inhibition of CDC34 enzymatic activity abrogates 
interleukin-6-induced protection against dexamethasone-induced MM cell apoptosis. 
Ubiquitin ligase E3s are the largest family in the UPS system. Various E3s are involved in 
leukemia, myeloma and lymphomas (Bernassola et al., 2008). For example, XIAP, the 
representative of the RING finger family of E3s, and Mdm2, the primary E3 ligase for p53 
ubiquitination (Jones et al., 2008), are overexpressed in various leukemic and myeloma cells 
and contribute to cell proliferation and anti-apoptotic activity. XIAP is also the most 
important enzyme that inhibits caspase-3, -6, and -7 activities and confers to drug resistance. 
Skp2 is another important E3 ligase. In CML cells, BCR-ABL fusion oncogene frequently up-
 
Hematology – Science and Practice 
 
500 
specific recognition modules in the target protein and is capable of interaction with both E2 
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regulate Skp2 expression via transcriptional activation, while treatment of Bcr-Abl kinase 
inhibitor imatinib led to G1 growth arrest accompanied with reduced Skp2 expression 
(Chen et al., 2011). SKP2 contributes to increased p27(Kip1) turnover, cell proliferation, and 
a poor prognosis in many tumor types (Zhan et al., 2007).  
3.3 Deubiquitinases and blood cancers 
Attached ubiquitin can be removed by a ubiquitin protease from targeted protein. USP9X is 
one of the most studied deubiquitinases and is probably involved in deubiquitination from 
oncoprotein MCL-1. Increased USP9X expression correlates with increased MCL1 protein in 
human follicular lymphomas and diffuse large B-cell lymphomas (Schwickart et al., 2010). 
Moreover, patients with multiple myeloma overexpressing USP9X have a poor prognosis. 
Knockdown of USP9X increases MCL1 polyubiquitination, which enhances MCL1 turnover 
and cell killing by the BH3 mimetic ABT-737, an inhibitor of MCL1 (Schwickart et al., 2010). 
Thus, USP9X has been identified as an effective prognostic and therapeutic target. Another 
important Dub is CYLD, which is a negative regulator of NFB. CYLD is located in the 16q12 
and its lower expression in MM cells is highly associated with deletion of 16q. In T cell 
leukemia, the Notch/Hes1 pathway sustains NFκB activation through CYLD repression. In 
MM cells highly expressing NFB, both the DNA copy number and protein expression of 
CYLD are markedly decreased. On the other hand, when treated with proteasome inhibitors 
such as MG132, CYLD will be accumulated in MM cells. CYLD presents as a tumor suppressor 
deubiquitinase and restoration of CYLD will sensitize cancer cell apoptosis (Jin et al., 2008). 
3.4 Proteasomes and blood cancers 
Several lines of evidence have shown that proteasome subunits in both leukemia and MM 
cells are abnormally higher than those normal or untransformed counterparts (Kumatori et 
al., 1990). Immunohistochemical staining shows considerably increased concentrations of 
proteasomes in leukemic cells from the bone marrow of patients with various types of 
leukemia and the predominant localization of these proteasomes in the nuclei. Moreover, 
enzyme immunoassay and Northern blot analysis indicate that the concentrations of 
proteasomes and their mRNA levels are consistently much higher in a variety of malignant 
human hematopoietic cell lines than in resting peripheral lymphocytes and monocytes from 
healthy adults. Proteasome expression is also increased in normal blood mononuclear cells 
during blastogenic transformation induced by phytohemagglutinin; their expression 
increased in parallel with induction of DNA synthesis and returned to the basal level with 
progress of the cell cycle. These findings strongly suggest that proteasomes are associated 
with cell cycle progression. Later studies demonstrated that proteasomes regulate a serial of 
cell cycle proteins, including p27, pRb, cyclin D, p53, p27, pro-apoptotic Bcl-2 family 
members, as well as the most important transcription factor in cell proliferation, NFB 
(Kisselev and Goldberg, 2001). Importantly, leukemia and myeloma cells are more sensitive 
to proteasome inhibitors. An early study found that the IC50 to inhibit cell proliferation in 
lymphoma is 5 times lower than normal T cells when treating cells with lactacystin, a classic 
and typical inhibitor of proteasomes (Delic et al., 1998). Another study indicated that B-CLL 
cells are about 10 times more sensitive to lactacystin than normal peripheral B lymphocytes. 
These results strongly suggest that proteasomes could be used as a drug target for myeloma 
and lymphoma therapy. 
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4. Discovery of bortezomib and its application in MM therapy 
4.1 Discovery of bortezomib as a treatment for myeloma  
Proteasomes are critical for cancer cells, therefore they could be used as a drug target for 
cancer therapy. Efforts are first made to develop such kinds of inhibitors for MM therapy. 
The seminal contribution came from Myogenic which developed a series of proteasome 
inhibitors, including MG132, one of the most common proteasome inhibitors currently used 
in research, and MG-341, which was renamed PS-341 and was further developed as a 
promising drug candidate for cancer therapy. PS-341 alone achieved an overall remission 
rate of 35% in refractory and/or relapse myeloma patients, when it was used in combination 
with other drugs such as cyclophosphamide and dexamethasone, the ORR could reach 
around 90% or greater. Following several large and multi-center clinical trials, PS-341 was 
approved by Food and Drug Administration of USA for MM in 2003, and for mantle cell 
lymphoma in 2006. PS-341 is now known as its general name bortezomib based on its 
chemical structure and is marketed as Velcade®. Recent studies also demonstrated that 
bortezomib might be particularly active against the active B cell-like diffuse large B cell 
lymphoma (ABC-DLBCL). ABC-DLBCL has a worse survival after upfront chemotherapy 
and is characterized by constitutive activation of the NFB pathway, which can inhibit 
chemotherapy. Although bortezomib alone has no activities on ABC-DLBCL, when 
administrated with chemotherapeutics, such as R-CHOP or DA-EPOCH-B, it achieved a 
superior overall response and survival according to a clinical study of 49 patients. Although 
ABC-DLBCL and GCB-DLBCL have similar poor outcome by regular chemotherapeutics, 
ABC-DLBCLs are more sensitive to bortezomib.  Bortezomib presented a high responsive 
rate (83% vs 13%) and median overall survival (10.8 vs 3.4 months) in ABC compared with 
GCB-DLBCL, respectively (Dunleavy et al., 2009). It is predictable that bortezomib as an 
inhibitor of NFB pathway will be developed for other cancer therapy.  
4.2 Molecular mechanisms of bortezomib in the treatment of myeloma  
Bortezomib is a dipeptide containing phenylalanine and leucine in which the carboxylic 
group is replaced by a boronic acid group (-RB(OH)2) (Figure 4). 
 
Fig. 4. The chemical structure of bortezomib. Bortezomib is a dipeptide made up of 
phenylalanine and leucine in which boronic acid group replaces the carboxyl group. 
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Bortezomib is a potent inhibitor of proteasomes. Mechanistically, its active boron acid group 
competitively and reversibly binds to the catalytic site of the 26S proteasome with high 
affinity and specificity. Specifically, the boric acid group of bortezomib binds to and blocks 
the catalytic threonine residue in the subunits of the 20S core particle. Inhibition of 
proteasome results in accumulation of several important tumor suppressor proteins, 
including p21, p27, p53, PTEN, and IκBα. IκBα is an inhibitor of NFκB, the most important 
transcription factor in regulating cell proliferation. Normally, IκBα is bound to NFκB and 
inhibits its activity. The IκBα stability is regulated via the UPS pathway. Once IκBα is 
degraded, NFκB will be librated and translocated into the neucleus where it binds to the 
promoters of various genes and initiates their transcription and expression. IκBα/NFκB 
signaling plays a critical role in bortezomib-induced cell apoptosis. Bortezomib also 
interrupts the interaction of Mdm2 and its substrate p53, thus restoring p53 function and 
leading to cell apoptosis. Moreover, bortezomib directly acts on MM cells and alters cellular 
interactions and cytokine secretion in the bone marrow (BM) millieu to inhibit tumor cell 
growth, induce apoptosis, and overcome drug resistance. Specifically, bortezomib inhibits 
the paracrine growth of human MM cells by decreasing their adherence to bone marrow 
stromal cells (BMSCs) and related NFκB-dependent induction of interleukin-6 secretion in 
BMSCs, as well as inhibiting proliferation and growth signaling of residual adherent MM 
cells (Hideshima et al., 2001). 
4.3 Pitfalls of bortezomib in MM treatment 
Although bortezomib has made a great success in the treatment of MM and MCL, it is not a 
perfect drug, and some critical features prevent its application (Kumar and Rajkumar, 2008; 
Oerlemans et al., 2008). Firstly, it is unstable and it retains its activity for 4-8 hrs after re-
constituted, thus having to be used within 8 hours. Secondly, the drug is administrated via 
i.v. injection which should be performed by a nurse at a clinic or in a hospital, which largely 
increases the cost of the health care system.  
Thirdly, the therapeutic window of bortezomib is very narrow. The therapeutic dosage is 1.3 
mg/m2 body surface, it will produce dose-dependent toxicity when the dose reaches 1.5 
mg/m2. These adverse effects and toxicity include myelosuppression which leads to anemia, 
neutropenia and thrombocytopenia, and bortezomib-induced peripheral neuropathy, which 
occurs in more than 30% patients and this kind of neuropathy is sometimes even worse to 
affect patients’ daily activity (Richardson et al., 2006). Although these kinds of adverse 
effects are recoverable when the drug is discontinued, some patients couldn’t endure the 
severe effects. Recent studies suggest that some important genes (such as RHOBTB2 and 
SOX8) involved in the development of the nervous system (especially the peripheral 
nervous system) are upregulated by bortezomib after one cycle therapy (Cavo et al., 2010). 
Lastly, drug resistance is becoming an emerging issue. Although 35% of refractory and 
relapsed myeloma patients are generally responsive after bortezomib treatment, there are only 
4% patients with a complete remission outcome and 65% had no response. There are several 
underlying issues for bortezomib resistance. Firstly, the resistance to bortezomib is associated 
with overexpression of β5 subunits of 20S core particles, which leads to impaired binding of 
bortezomib and decreased proteasome inhibition. For example, K562 cells with a high level of 
β5 are more resistant to bortezomib than other cell lines such as OCI-AML2 expressing low 
levels of 5 (Li et al., 2010). Secondly, bortezomib resistance is also associated with mutations 
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in β5 gene. A DNA sequencing analysis in bortezomib-resistant cells revealed that the G322A 
mutation in PSMB5 gene leads to an Alanine Threonine change, which largely confers 
resistance because threonine is the target of bortezomib (Oerlemans et al., 2008). In a Jurkat cell 
model, mutations such as C323T and G326A are also reported (Lu et al., 2008). Thirdly, 
overexpression of other anti-apoptotic genes such as PSMD4 (Shaughnessy et al., 2010), a non-
ATPase subunit of the proteosomal 19S regulator, and heat shock protein 27 (HSP27) 
(Chauhan et al., 2003), an important gene protecting cell against apoptosis, are also found to be 
associated with resistance to bortezomib. Recently, an siRNA screen identified several 
important molecular modulators that sensitize bortezomib-induced cell apoptosis, including 
proteasome subunits PSMA5, PSMB2, PSMB3, and PSMB7 (Zhu et a., 2011), this is quite 
reasonable because these genes directly modulate the proteasome function. To be noted, the 
Cyclin-dependent kinase 5 (CDK5) and other 11 genes were also identified from this screen, 
but their detailed roles in bortezomib-induced cell death are yet to be studied. A most recent 
study demonstrated that impaired bortezomib binding to mutant β5 subunit of the 
proteasome is the underlying basis for bortezomib resistance in leukemia cells, while 
proteasome subunit overexpression is an essential compensatory mechanism for the impaired 
catalytic activity of these mutant proteasomes (Franke et al., 2011). 
5. Development of novel proteasomal inhibitors 
Currently, several classes of novel proteasome inhibitors have been developed and some 
have been moved to advanced clinical trials for the treatment of various blood cancers, such 
as leukemia, lymphoma, and myeloma. Although they share some common features, these 
novel inhibitors of proteasomes could be classified as: highly selective and irreversible, 
orally active, non-competitive, and natural products. The details are shown in Table 1. 
5.1 Highly selective and irreversible novel inhibitors of proteasomes 
Several promising novel proteasomal inhibitors have been extensively investigated in vivo, 
in vitro, and in clinical settings. Compared with bortezomib, these agents are highly selective 
and irreversible, such as carfilzomib, NPI-0052, and PI-083.  
5.1.1 Carfilzomib 
Carflizomib, or PR-171, is a tetrapeptide epoxyketone and a selective and irreversible 
proteasome inhibitor that primarily targets the chymotrypsin-like (CT-L) subunits in both the 
constitutive proteasome (c20S, 5) and the immunoproteasome (i20S, LMP7) (Parlati et al., 
2009). Inhibition of proteasome-mediated proteolysis results in an accumulation of 
polyubiquitinated proteins, which may lead to cell cycle arrest, induction of apoptosis, and 
inhibition of tumor growth. Compared with bortezomib, carfilzomib displays minimal cross 
reactivity on off-target enzymes, good tolerability and little side effects in multiple open-label 
clinical trials (O'Connor et al., 2009). In patients with relapsed or refractory multiple myeloma, 
twice-weekly consecutive-day single-agent carfilzomib 20 mg/m2 , escalating to 27 mg/m2 the 
second cycle was associated with a 54% overall response rate in bortezomib-naive patients and 
a 26% overall response rate in bortezomib and immunomodulatory drug refractory patients. 
The overall response rate is 20% higher than that with single bortezomib treatment. The U.S. 
Food and Drug Administration has granted fast track designation for carfilzomib to develop as 
a potential treatment of patients with relapsed and refractory multiple myeloma. 
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with overexpression of β5 subunits of 20S core particles, which leads to impaired binding of 
bortezomib and decreased proteasome inhibition. For example, K562 cells with a high level of 
β5 are more resistant to bortezomib than other cell lines such as OCI-AML2 expressing low 
levels of 5 (Li et al., 2010). Secondly, bortezomib resistance is also associated with mutations 
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in β5 gene. A DNA sequencing analysis in bortezomib-resistant cells revealed that the G322A 
mutation in PSMB5 gene leads to an Alanine Threonine change, which largely confers 
resistance because threonine is the target of bortezomib (Oerlemans et al., 2008). In a Jurkat cell 
model, mutations such as C323T and G326A are also reported (Lu et al., 2008). Thirdly, 
overexpression of other anti-apoptotic genes such as PSMD4 (Shaughnessy et al., 2010), a non-
ATPase subunit of the proteosomal 19S regulator, and heat shock protein 27 (HSP27) 
(Chauhan et al., 2003), an important gene protecting cell against apoptosis, are also found to be 
associated with resistance to bortezomib. Recently, an siRNA screen identified several 
important molecular modulators that sensitize bortezomib-induced cell apoptosis, including 
proteasome subunits PSMA5, PSMB2, PSMB3, and PSMB7 (Zhu et a., 2011), this is quite 
reasonable because these genes directly modulate the proteasome function. To be noted, the 
Cyclin-dependent kinase 5 (CDK5) and other 11 genes were also identified from this screen, 
but their detailed roles in bortezomib-induced cell death are yet to be studied. A most recent 
study demonstrated that impaired bortezomib binding to mutant β5 subunit of the 
proteasome is the underlying basis for bortezomib resistance in leukemia cells, while 
proteasome subunit overexpression is an essential compensatory mechanism for the impaired 
catalytic activity of these mutant proteasomes (Franke et al., 2011). 
5. Development of novel proteasomal inhibitors 
Currently, several classes of novel proteasome inhibitors have been developed and some 
have been moved to advanced clinical trials for the treatment of various blood cancers, such 
as leukemia, lymphoma, and myeloma. Although they share some common features, these 
novel inhibitors of proteasomes could be classified as: highly selective and irreversible, 
orally active, non-competitive, and natural products. The details are shown in Table 1. 
5.1 Highly selective and irreversible novel inhibitors of proteasomes 
Several promising novel proteasomal inhibitors have been extensively investigated in vivo, 
in vitro, and in clinical settings. Compared with bortezomib, these agents are highly selective 
and irreversible, such as carfilzomib, NPI-0052, and PI-083.  
5.1.1 Carfilzomib 
Carflizomib, or PR-171, is a tetrapeptide epoxyketone and a selective and irreversible 
proteasome inhibitor that primarily targets the chymotrypsin-like (CT-L) subunits in both the 
constitutive proteasome (c20S, 5) and the immunoproteasome (i20S, LMP7) (Parlati et al., 
2009). Inhibition of proteasome-mediated proteolysis results in an accumulation of 
polyubiquitinated proteins, which may lead to cell cycle arrest, induction of apoptosis, and 
inhibition of tumor growth. Compared with bortezomib, carfilzomib displays minimal cross 
reactivity on off-target enzymes, good tolerability and little side effects in multiple open-label 
clinical trials (O'Connor et al., 2009). In patients with relapsed or refractory multiple myeloma, 
twice-weekly consecutive-day single-agent carfilzomib 20 mg/m2 , escalating to 27 mg/m2 the 
second cycle was associated with a 54% overall response rate in bortezomib-naive patients and 
a 26% overall response rate in bortezomib and immunomodulatory drug refractory patients. 
The overall response rate is 20% higher than that with single bortezomib treatment. The U.S. 
Food and Drug Administration has granted fast track designation for carfilzomib to develop as 
a potential treatment of patients with relapsed and refractory multiple myeloma. 
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Drugs Features R&D Stage Institutes 
Highly selective and irreversible 
Carfilzomib (PR-171) Epoxomicin analog 
Minimal activity against off-target 
enzymes 
Lymphoid neoplasms and multiple 
myeloma 
Phase III for 
MM 







Marine product, -lactone-γ-lactam 
family 
More potent than Bortezomib 
MM, lymphomas, leukemias and solid 
tumors 





PI-083 From Streptomyces matensis  
Thr21,Gly47, Ala 49 of 5, Asp114 of 
6 
Cancer-selective proteasome inhibitor 
Myeloma, lung cancer, breast cancer 
Preclinical Moffitt Cancer 
Center 
Orally active 
CEP-18770 Boronic-acid based 
More sustained Pharmacodynamics 
Competes with bortezomib 
Few side effects during treatment 
Phase II for 
myeloma 
Cephalon 
PR-047 c20S, i20S 
>80% inhibition in most tissues 
High oral bioavailability 
 Proteolix  
 
Non-comparative inhibitors on 20S proteasomes 
Clioquinol Binding to a subunits of 20S  
Non-competitive inhibition 
Overcome resistance to Bortezomib 







Pristimerin Isolated from Celastrus and Maytenus 
spp. 
Tripernoid family 
C6 of Pristimerin interacts with 
hydroxyl group of N-terminal Thr of  
c20S 
Inhibits IKK, suppresses NFB, cyclin 
D 




From green tea 
Ester bond of EGCG attacked by N-
terminal Thr of 20S 
Competitively inhibits Proteasome 
with Bortezomib 
Preclinical Not available 
Table 1. Novel Proteasome inhibitors against blood cancers 
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5.1.2 Marizomib  
Marizomib (NPI-0052 or salinosporamide A) is a structurally and pharmacologically unique 
β-lactone-γ-lactam proteasome inhibitor produced by a marine actinomycete Salinispora 
tropica (Macherla et al., 2005). Unlike bortezomib, marizomib irreversibly binds to 
proteasomes and inhibits all three protease activities, including chymotrypsin-like (CT-L, 
5), trypsin-like (T-L, 2), and caspase-like (C-L,1). This nature is responsible for its slower 
efflux, longer duration of action, and greater cytotoxicity (Obaidat et al.). Preclinical studies 
suggest that marizomib is a more potent inducer of apoptosis in myeloma cells than 
bortezomib, and demonstrates activity in bortezomib resistant cell lines as well. In addition 
to MM, marizomib has been evaluated in models for MCL, Waldenstrom's 
macroglobulinemia (WM), chronic and acute lymphocytic leukemia, glioma, colorectal and 
pancreatic cancers, and has exhibited synergistic activities in tumor models in combination 
with bortezomib, and various histone deacetylase inhibitors (B et al., 2011; Singh et al., 
2010). Marizomib has been moved to Phase II clinical trials and achieved very good 
responses. In a Phase I study of 17 patients with relapsed and relapsed/refractory multiple 
myeloma, Drug- related adverse events have consisted principally of mild-to-moderate 
fatigue, nausea and diarrhea. More importantly, NPI-0052 does not appear to induce 
peripheral neuropathy or myelosuppression associated with bortezomib treatment 
(Hofmeister et al., 2009).  
5.2 Orally active inhibitors of proteasomes: CEP-18770, PR-047 and ONX-0912 
The i.v. administration of bortezomib largely increases the workload of the physicians and 
other medical staff and largely increases the healthcare budget. Therefore, orally active 
inhibitors of proteasomes are of great interest. Currently, several such orally active drugs 
have been developed, including CEP-18770, PR-047 and ONX-0912. 
5.2.1 CEP-18770 
CEP-18770 is a novel orally-active inhibitor of the chymotrypsin-like activity of the 
proteasome that down-modulates the NFactivity (Piva et al., 2008). CEP-18770 induces 
apoptotic cell death in MM cell lines and in primary purified CD138-positive explant 
cultures from untreated and bortezomib-treated MM patients. Importantly, CEP-18770 
exhibits a favorable cytotoxicity profile toward normal human epithelial cells, bone marrow 
progenitors, and bone marrow-derived stromal cells. Both intravenous and oral 
administration of CEP-18770 resulted in a sustained pharmacodynamic inhibition of 
proteasome activity in tumors relative to normal tissues, complete tumor regression of MM 
xenografts and improved overall median survival in a systemic model of human MM. In 
addition, CEP-18770 has a strong antiangiogenic activity in vitro, and potently represses 
RANKL-induced osteoclastogenesis. A recent study suggests that CEP-18770 enhances  
the anti-myeloma activity of bortezomib and melphalan which suggests a  
combinatorial regimen for MM therapy (Piva et al., 2008; Sanchez et al., 2010). This agent 
has moved to clinical trials for relapsed or refractory multiple myeloma 
(http://clinicaltrials.gov/ct2/show/NCT01348919) or for solid tumors and non-Hodgin’s 
lymphomas (http://clinicaltrials.gov/ct2/show/NCT00572637). 
 
Hematology – Science and Practice 
 
506 
Drugs Features R&D Stage Institutes 
Highly selective and irreversible 
Carfilzomib (PR-171) Epoxomicin analog 
Minimal activity against off-target 
enzymes 
Lymphoid neoplasms and multiple 
myeloma 
Phase III for 
MM 







Marine product, -lactone-γ-lactam 
family 
More potent than Bortezomib 
MM, lymphomas, leukemias and solid 
tumors 





PI-083 From Streptomyces matensis  
Thr21,Gly47, Ala 49 of 5, Asp114 of 
6 
Cancer-selective proteasome inhibitor 
Myeloma, lung cancer, breast cancer 
Preclinical Moffitt Cancer 
Center 
Orally active 
CEP-18770 Boronic-acid based 
More sustained Pharmacodynamics 
Competes with bortezomib 
Few side effects during treatment 
Phase II for 
myeloma 
Cephalon 
PR-047 c20S, i20S 
>80% inhibition in most tissues 
High oral bioavailability 
 Proteolix  
 
Non-comparative inhibitors on 20S proteasomes 
Clioquinol Binding to a subunits of 20S  
Non-competitive inhibition 
Overcome resistance to Bortezomib 







Pristimerin Isolated from Celastrus and Maytenus 
spp. 
Tripernoid family 
C6 of Pristimerin interacts with 
hydroxyl group of N-terminal Thr of  
c20S 
Inhibits IKK, suppresses NFB, cyclin 
D 




From green tea 
Ester bond of EGCG attacked by N-
terminal Thr of 20S 
Competitively inhibits Proteasome 
with Bortezomib 
Preclinical Not available 
Table 1. Novel Proteasome inhibitors against blood cancers 
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5.1.2 Marizomib  
Marizomib (NPI-0052 or salinosporamide A) is a structurally and pharmacologically unique 
β-lactone-γ-lactam proteasome inhibitor produced by a marine actinomycete Salinispora 
tropica (Macherla et al., 2005). Unlike bortezomib, marizomib irreversibly binds to 
proteasomes and inhibits all three protease activities, including chymotrypsin-like (CT-L, 
5), trypsin-like (T-L, 2), and caspase-like (C-L,1). This nature is responsible for its slower 
efflux, longer duration of action, and greater cytotoxicity (Obaidat et al.). Preclinical studies 
suggest that marizomib is a more potent inducer of apoptosis in myeloma cells than 
bortezomib, and demonstrates activity in bortezomib resistant cell lines as well. In addition 
to MM, marizomib has been evaluated in models for MCL, Waldenstrom's 
macroglobulinemia (WM), chronic and acute lymphocytic leukemia, glioma, colorectal and 
pancreatic cancers, and has exhibited synergistic activities in tumor models in combination 
with bortezomib, and various histone deacetylase inhibitors (B et al., 2011; Singh et al., 
2010). Marizomib has been moved to Phase II clinical trials and achieved very good 
responses. In a Phase I study of 17 patients with relapsed and relapsed/refractory multiple 
myeloma, Drug- related adverse events have consisted principally of mild-to-moderate 
fatigue, nausea and diarrhea. More importantly, NPI-0052 does not appear to induce 
peripheral neuropathy or myelosuppression associated with bortezomib treatment 
(Hofmeister et al., 2009).  
5.2 Orally active inhibitors of proteasomes: CEP-18770, PR-047 and ONX-0912 
The i.v. administration of bortezomib largely increases the workload of the physicians and 
other medical staff and largely increases the healthcare budget. Therefore, orally active 
inhibitors of proteasomes are of great interest. Currently, several such orally active drugs 
have been developed, including CEP-18770, PR-047 and ONX-0912. 
5.2.1 CEP-18770 
CEP-18770 is a novel orally-active inhibitor of the chymotrypsin-like activity of the 
proteasome that down-modulates the NFactivity (Piva et al., 2008). CEP-18770 induces 
apoptotic cell death in MM cell lines and in primary purified CD138-positive explant 
cultures from untreated and bortezomib-treated MM patients. Importantly, CEP-18770 
exhibits a favorable cytotoxicity profile toward normal human epithelial cells, bone marrow 
progenitors, and bone marrow-derived stromal cells. Both intravenous and oral 
administration of CEP-18770 resulted in a sustained pharmacodynamic inhibition of 
proteasome activity in tumors relative to normal tissues, complete tumor regression of MM 
xenografts and improved overall median survival in a systemic model of human MM. In 
addition, CEP-18770 has a strong antiangiogenic activity in vitro, and potently represses 
RANKL-induced osteoclastogenesis. A recent study suggests that CEP-18770 enhances  
the anti-myeloma activity of bortezomib and melphalan which suggests a  
combinatorial regimen for MM therapy (Piva et al., 2008; Sanchez et al., 2010). This agent 
has moved to clinical trials for relapsed or refractory multiple myeloma 
(http://clinicaltrials.gov/ct2/show/NCT01348919) or for solid tumors and non-Hodgin’s 
lymphomas (http://clinicaltrials.gov/ct2/show/NCT00572637). 
 




PR-047 is also an orally active inhibitor that selectively inhibits CT-L activity of both the 
constitutive proteasome (5) and immunoproteasome (LMP7) and demonstrated an 
absolute bioavailability of up to 39% in rodents and dogs. It was well tolerated with 
repeated oral administration at doses resulting in >80% proteasome inhibition in most 
tissues and elicited an antitumor response equivalent to intravenously administered 
carfilzomib in multiple human tumor xenograft and mouse syngeneic models (Zhou et al., 
2009). The favorable pharmacologic profile supports its further development for the 
treatment of malignant diseases. 
5.2.3 ONX-0912 
Like carfilzomib, ONX-0912 is also an epoxyketone compound with novel selective, 
irreversible inhibition activity to the immunopreteasome and constituent 20S particles. 
ONX-0912 displays great oral activity (Chauhan et al., 2010). Primary WM cells expressing 
higher level of 20S are more responsive to ONX-0912 (Roccaro et al., 2010). ONX-0912 
induces WM cell apoptosis through c-JNK activation, NFB inhibition, caspase cleavage, 
and initiation of the unfolded protein response. Moreover, ONX-0912 also reduce the 
secretion of BM-derived interleukin-6 (IL-6) and insulin-like growth factor 1 (IGF-1), thus 
inhibiting BM-induced Akt phosphorylation and phosphorylated extracellular signal-related 
kinase activation in WM cells. In addition to blood cancers, ONX-0912 also displays potent 
anticancer activity in solid tumors and a Phase I study of ONX 0912 administered orally in 
patients with advanced refractory or recurrent solid tumors is under evaluation 
(http://clinicaltrials.gov/ ct2/show/NCT01129349). 
5.3 Non-classic inhibitors: Clioquinol and 5-amino-8-hydroxyl-quinoline 
Most of the proteasomal inhibitors competitively bind to the subunits of 20S proteasome, 
for example, MG-132, bortezomib, and carfilzomib. Recently, we found that a group of 
quinoline-based agents including clioquinol, chloroquine, 5-amino-8-hydroxyl quinoline 
(5AHQ), and metfloquinoline display potent inhibition on proteasomal catalytic activity by 
a non-competitive manner (Li et al., 2010; Mao et al., 2009). Further studies indicated that 
these agents bind to the  subunits other than  subunits of the 20S core particle as 
bortezomib or MG-132 does. In analysis of its binding to purified 20S archaeal proteasomes 
from Thermoplasma acidophilium by using nuclear magnetic resonance (NMR) technology, 
chloroquine binds to the subunits with 260 Å distance from  active sites. Notably, 
chloroquine and MG132 can bind the proteasome simultaneously, further establishing that 
they exploit two completely separate binding pockets (Sprangers et al., 2008). 
The interaction of 5AHQ with produced clear spectral changes localized to residues 
Ile159, Val113, Val87, Val82, Leu112, Val89, Val134, Val24 and Leu136, which are inside the 
antechamber. In contrast, MG132 which binds the proteolytic chamber produces shifts in the 
beta rings of the full proteasome. Binding to the subunit, 5AHQ leads to a conformational 
change of the core particle and displays a non-competitive inhibition on proteasome. 5AHQ 
preferentially induced cell death in primary myeloma and leukemia cells compared with 
normal hematopoietic cells. More importantly, 5AHQ overcomes the resistance to 
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bortezomib and is equally cytotoxic to human myelomonocytic leukemia THP1/BTZ500 
cells which are 237-fold more resistant to bortezomib than wild-type THP1 cells because of 
the overexpression and mutation of the bortezomib-binding5 subunits (Li et al., 2010). 
Therefore, a group of quinoline-based small molecules can inhibit proteasomal activity in a 
non-cannoical manner. Because of their low toxicity and novel inhibition mechanism, these 
compounds could be developed for MM and leukemia therapy. Currently, clioquinol has 
been moved to clinical trials for refractory acute myeloid leukemia. 
5.4 Natural proteasomal inhibitors: Pristimerin and EGCG 
Except for small chemical compounds or peptide reagents, several natural products have 
been identified and evaluated for MM treatment in both in vivo and in vitro assays. The most 
promising candidate could be NPI-0052 or marizomib isolated from a marine actinomycete 
Salinispora tropica as described above. Here we discuss two more agents in this category 
pristimerin and (-)-epigallocatechin-3-gallate (EGCG). 
5.4.1 Prisitmerin 
Pristimerin belongs to the tripernoid family and is isolated from a traditional Chinese 
medicine called Celastrus and Maytenus spp. Nucleophilic susceptibility and in silico docking 
studies show that C6 of pristimerin is highly susceptible towards a nucleophilic attack by the 
hydroxyl group of N-terminal threonine of the proteasomal chymotrypsin subunit. This 
interaction leads to an inhibition of the chymotrypsin-like activity of a purified rabbit 20S 
proteasome (Yang et al., 2008). Pristimerin displayed similar inhibition activity in purified 
rabbit 20S proteasomes and in human prostate cancer cell lysates (Tiedemann et al., 2009). The 
IC50s are 2.2 and 3.0 in vitro and in vivo, respectively. The treatment of pristimerin in 
prostate cancer cells resulted in the accumulation of ubiquitinated proteins and three 
proteasome target proteins, Bax, p27 and B. However, myeloma cells are more sensitive to 
pristimerin. Pristimerin potently inhibits both IKK and the proteasome in MM cells with an 
IC50 of 100 nM. Pristimerin causes overt suppression of constitutive NFκB activity in myeloma 
cells that may mediate its suppression of cyclin D, thus inducing myeloma cell apoptosis. 
5.4.2 (-)-epigallocatechin-3-gallate (EGCG) 
EGCG is one of the polyphenols found in green tea extract and inhibits proteasomal activity 
(Golden et al., 2009). The ester bond of EGCG is attacked by the N-terminal threonine residue 
of the proteasome, forming a covalent EGCG-proteasome complex which has been confirmed 
by high performance liquid chromatography (HPLC) analysis. Recent studies found that 
EGCG competitively inhibits proteasomal activity in a same manner as bortezomib does, thus 
neutralizing the inhibiting activity of bortezomib and other boronic acid-based proteasome 
inhibitors. Therefore, green tea polyphenols block the anticancer effects of bortezomib and 
green tea is not encouraged for myeloma patients who are using bortezomib (Golden et al., 
2009). However, a recent study didn’t find antagonism of bortezomib in preclinical in vivo 
experiments, where EGCG or ascorbic acid plasma concentrations are commensurate with 
dietary or supplemental intake and suggest that patients receiving bortezomib treatment do 
not need to avoid normal dietary consumption of green tea, vitamin C-containing foods, or 
EGCG or vitamin C dietary supplements (Bannerman et al., 2011). 
 




PR-047 is also an orally active inhibitor that selectively inhibits CT-L activity of both the 
constitutive proteasome (5) and immunoproteasome (LMP7) and demonstrated an 
absolute bioavailability of up to 39% in rodents and dogs. It was well tolerated with 
repeated oral administration at doses resulting in >80% proteasome inhibition in most 
tissues and elicited an antitumor response equivalent to intravenously administered 
carfilzomib in multiple human tumor xenograft and mouse syngeneic models (Zhou et al., 
2009). The favorable pharmacologic profile supports its further development for the 
treatment of malignant diseases. 
5.2.3 ONX-0912 
Like carfilzomib, ONX-0912 is also an epoxyketone compound with novel selective, 
irreversible inhibition activity to the immunopreteasome and constituent 20S particles. 
ONX-0912 displays great oral activity (Chauhan et al., 2010). Primary WM cells expressing 
higher level of 20S are more responsive to ONX-0912 (Roccaro et al., 2010). ONX-0912 
induces WM cell apoptosis through c-JNK activation, NFB inhibition, caspase cleavage, 
and initiation of the unfolded protein response. Moreover, ONX-0912 also reduce the 
secretion of BM-derived interleukin-6 (IL-6) and insulin-like growth factor 1 (IGF-1), thus 
inhibiting BM-induced Akt phosphorylation and phosphorylated extracellular signal-related 
kinase activation in WM cells. In addition to blood cancers, ONX-0912 also displays potent 
anticancer activity in solid tumors and a Phase I study of ONX 0912 administered orally in 
patients with advanced refractory or recurrent solid tumors is under evaluation 
(http://clinicaltrials.gov/ ct2/show/NCT01129349). 
5.3 Non-classic inhibitors: Clioquinol and 5-amino-8-hydroxyl-quinoline 
Most of the proteasomal inhibitors competitively bind to the subunits of 20S proteasome, 
for example, MG-132, bortezomib, and carfilzomib. Recently, we found that a group of 
quinoline-based agents including clioquinol, chloroquine, 5-amino-8-hydroxyl quinoline 
(5AHQ), and metfloquinoline display potent inhibition on proteasomal catalytic activity by 
a non-competitive manner (Li et al., 2010; Mao et al., 2009). Further studies indicated that 
these agents bind to the  subunits other than  subunits of the 20S core particle as 
bortezomib or MG-132 does. In analysis of its binding to purified 20S archaeal proteasomes 
from Thermoplasma acidophilium by using nuclear magnetic resonance (NMR) technology, 
chloroquine binds to the subunits with 260 Å distance from  active sites. Notably, 
chloroquine and MG132 can bind the proteasome simultaneously, further establishing that 
they exploit two completely separate binding pockets (Sprangers et al., 2008). 
The interaction of 5AHQ with produced clear spectral changes localized to residues 
Ile159, Val113, Val87, Val82, Leu112, Val89, Val134, Val24 and Leu136, which are inside the 
antechamber. In contrast, MG132 which binds the proteolytic chamber produces shifts in the 
beta rings of the full proteasome. Binding to the subunit, 5AHQ leads to a conformational 
change of the core particle and displays a non-competitive inhibition on proteasome. 5AHQ 
preferentially induced cell death in primary myeloma and leukemia cells compared with 
normal hematopoietic cells. More importantly, 5AHQ overcomes the resistance to 
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bortezomib and is equally cytotoxic to human myelomonocytic leukemia THP1/BTZ500 
cells which are 237-fold more resistant to bortezomib than wild-type THP1 cells because of 
the overexpression and mutation of the bortezomib-binding5 subunits (Li et al., 2010). 
Therefore, a group of quinoline-based small molecules can inhibit proteasomal activity in a 
non-cannoical manner. Because of their low toxicity and novel inhibition mechanism, these 
compounds could be developed for MM and leukemia therapy. Currently, clioquinol has 
been moved to clinical trials for refractory acute myeloid leukemia. 
5.4 Natural proteasomal inhibitors: Pristimerin and EGCG 
Except for small chemical compounds or peptide reagents, several natural products have 
been identified and evaluated for MM treatment in both in vivo and in vitro assays. The most 
promising candidate could be NPI-0052 or marizomib isolated from a marine actinomycete 
Salinispora tropica as described above. Here we discuss two more agents in this category 
pristimerin and (-)-epigallocatechin-3-gallate (EGCG). 
5.4.1 Prisitmerin 
Pristimerin belongs to the tripernoid family and is isolated from a traditional Chinese 
medicine called Celastrus and Maytenus spp. Nucleophilic susceptibility and in silico docking 
studies show that C6 of pristimerin is highly susceptible towards a nucleophilic attack by the 
hydroxyl group of N-terminal threonine of the proteasomal chymotrypsin subunit. This 
interaction leads to an inhibition of the chymotrypsin-like activity of a purified rabbit 20S 
proteasome (Yang et al., 2008). Pristimerin displayed similar inhibition activity in purified 
rabbit 20S proteasomes and in human prostate cancer cell lysates (Tiedemann et al., 2009). The 
IC50s are 2.2 and 3.0 in vitro and in vivo, respectively. The treatment of pristimerin in 
prostate cancer cells resulted in the accumulation of ubiquitinated proteins and three 
proteasome target proteins, Bax, p27 and B. However, myeloma cells are more sensitive to 
pristimerin. Pristimerin potently inhibits both IKK and the proteasome in MM cells with an 
IC50 of 100 nM. Pristimerin causes overt suppression of constitutive NFκB activity in myeloma 
cells that may mediate its suppression of cyclin D, thus inducing myeloma cell apoptosis. 
5.4.2 (-)-epigallocatechin-3-gallate (EGCG) 
EGCG is one of the polyphenols found in green tea extract and inhibits proteasomal activity 
(Golden et al., 2009). The ester bond of EGCG is attacked by the N-terminal threonine residue 
of the proteasome, forming a covalent EGCG-proteasome complex which has been confirmed 
by high performance liquid chromatography (HPLC) analysis. Recent studies found that 
EGCG competitively inhibits proteasomal activity in a same manner as bortezomib does, thus 
neutralizing the inhibiting activity of bortezomib and other boronic acid-based proteasome 
inhibitors. Therefore, green tea polyphenols block the anticancer effects of bortezomib and 
green tea is not encouraged for myeloma patients who are using bortezomib (Golden et al., 
2009). However, a recent study didn’t find antagonism of bortezomib in preclinical in vivo 
experiments, where EGCG or ascorbic acid plasma concentrations are commensurate with 
dietary or supplemental intake and suggest that patients receiving bortezomib treatment do 
not need to avoid normal dietary consumption of green tea, vitamin C-containing foods, or 
EGCG or vitamin C dietary supplements (Bannerman et al., 2011). 
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6. Targeting at ubiquitination and deubiquitination systems for blood cancer 
treatment 
Proteasomes are critical components of both cancer cells and normal tissues because they 
determine the fate of most of the proteins and therefore inhibition of proteasome will also lead 
to normal cell stress and apoptosis. Thus inhibition of proteasomes indiscriminately raises 
levels of hundreds of proteins regardless to their anticancer effect. Thus, proteasomal 
inhibitors are a double-edged sword because they kill cancer cells, simultaneously, kill normal 
cells. Because proteasome-coupled protein ubiquitination is more specific, inhibition of certain 
enzymes involved in protein ubiquitination will be a more pertinent target for cancer drug 
development. There are four kinds of enzymes, E1, E2, E3 and Dubs which contain thousands 
of members in total. Currently, with the exception of E2, inhibitors of these other enzymes 
have been identified and are being evaluated for the treatment of hematological malignancies.  
6.1 Targeting at E1 for hematological malignancies 
E1 or Ubiquitin-activating enzyme (UBA) controls the protein ubiquitination by activating 
ubiquitin using ATP as an energy supplier. Knockdown of E1 by small interfering RNA 
(siRNA) strategy decreases the abundance of ubiquitinated proteins in leukemia and 
myeloma cells and induced cell death (Xu et al., 2010). Blood cancer cells including leukemia 
and myeloma are more sensitive to E1 inhibitors. A small molecule PYZD-4409, an inhibitor 
of E1, can abolish protein ubiquitination, thus inducing endoplasmic reticulum (ER) stress, 
and leading to cancer cell apoptosis. PYZD-4409 also displayed ideal anti-leukemia activity 
in vivo without untoward toxicity by decreasing tumor volume and weight (Xu et al., 2010). 
However, the same concern may arise as that already seen in bortezomib because there is 
only a single E1 protein in humans.  
6.2 Targeting at E3 for blood cancer therapies 
The E3 ligases are the largest family in the UPS system. E3s are the primary determinant of 
substrate specificity and represent the largest and most diverse class of Ub/Ub-like 
regulatory enzymes. There are 600-1000 potential E3s responsible for E2 binding, substrate 
recognition, and regulatory functions. Targeting the ubiquitin ligases promises more 
specificity because most E3s tag only a few proteins for destruction. Such drugs can, in 
theory, block degradation of its specific substrate proteins. Currently, interfering with E3-
substrate interaction is one of the leading strategies for anti-cancer drugs targeting at UPS. 
One of the most promising E3s is Skp2, the F-box protein that controls degradation of p27, 
an important tumor suppressor gene (Zhan et al., 2007).  Skp2 levels are abnormally high in 
leukemia and myeloma cells, therefore, blocking Skp2 activity might reasonably be expected 
to stop cancer cell proliferation. CpdA is such an inhibitor of Skp2 by preventing 
incorporation of Skp2 into the SCF Skp2 ligase, CpdA induces G1/S cell-cycle arrest as well 
as SCF Skp2- and p27-dependent cell killing (Chen et al., 2008). In models of MM, CpdA 
overcomes resistance to dexamethasone, doxorubicin, and melphalan, as well as to 
bortezomib, and also acted synergistically with this proteasome inhibitor. Importantly, 
CpdA is active against patient-derived plasma cells and both myeloid and lymphoblastoid 
leukemia blasts, and showed preferential activity against neoplastic cells while relatively 
sparing other marrow components (Chen et al., 2008).  
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Another interesting E3 is MdM2 which regulates p53 ubiquitination. Several inhibitors of 
MdM2 have been identified, such as Nutlins (Stuhmer et al., 2005) and MI-63 (Ding et al., 
2006; Samudio et al., 2010). By disrupting the interaction of MdM2 and p53, both Nutlins 
and MI-63 can restore p53 which further tends to promote arrest of cell cycle and apoptosis. 
These drugs are effective in inducing apoptosis of MM cells which express wild-type p53, 
unfortunately, it won’t work in cancer cells with mutated or deleted p53.   
6.3 Targeting at deubiquitinases 
Just like E3s, deubiquitinases play a tumor-suppressing or -promoting role dependent on its 
targeting protein. For example, USP9X is an oncoprotein enzyme that removes ubiquitin 
from the anti-apoptotic protein MCL-1 (Sun et al., 2011). MCL1 is overexpressed in most 
blood cancer cells, and is highly associated with cancer cell proliferation and protects cancer 
cells from apoptosis (Sun et al., 2011). MCL1 is degraded by proteasomes after poly-
ubiquitination. High expression of USP9X is seen in leukemia and MM cells. A small 
molecule called WP1130 (Kapuria et al., 2010) has been identified as a partly selective Dub 
inhibitor by directly inhibiting activity of USP9x, USP5, USP14, and UCH37, which are 
known to regulate survival protein stability and 26S proteasome function. WP1130-
mediated inhibition of tumor-activated Dubs results in downregulation of antiapoptotic and 
upregulation of proapoptotic proteins, such as Mcl-1 and p53, thus leading to cancer cell 
death (Kapuria et al., 2010).  
Although large-scale inhibitors of ubiquitination enzymes are yet to fully develop, 
successful E3 and Dub inhibitors have established the proof-of-principle that inhibition of 
ubquitinating/deubiquitinating enzymes is novel and potentially powerful strategy to 
develop anti-blood cancer drugs and is surely an area that will expand greatly in the future.  
7. Summary  
The ubiquitin-proteasome system has been widely investigated in the association of 
hematological malignancies, it is extensively involved in the development and therapy of 
blood cancers, including leukemia, lymphoma and multiple myeloma. Targeting at the UPS 
specific genes/proteins, several novel drugs have been developed including the first-
approved proteasome inhibitor-bortezomib in the treatment of myeloma and mantle cell 
lymphoma. The upcoming years will witness the introduction of more potent and more 
patient-friendly next generations of UPS inhibitors such as carfilozomib and inhibitors of 
ubiquitinating/deubiquitinating enzymes for the treatment of blood cancer patients.  
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1. Intoduction 
Heparin is an effective anti-coagulant for the prevention of venous thromboembolism and 
for the treatment of venous thrombosis and pulmonary embolism (Girolami et al., 2003; 
Hirsh et al., 2004; Shantsila et al., 2009). It is often used for patients with unstable angina and 
acute myocardial infarction, and for patients who have undergone vascular surgery 
(Battistelli et al., 2010). The administration of heparin frequently induces a reduction in 
platelet counts. This phenomenon is called heparin-induced thrombocytopenia (HIT) and be 
classified as either type I or II. To avoid confusion between the syndromes, “HIT type I” has 
been changed to “non-immune heparin associated thrombocytopenia”, and ‘‘HIT type II’’ is 
simply called ‘‘HIT’’. 
The origin of non-immune heparin associated thrombocytopenia is not yet completely 
understood, though it is thought to be caused by heparin-induced platelet clumping (Fabris 
et al., 1983; Chong & Ismail, 1989). Thrombocytopenia of this type is mild (platelet count, 
>100 x 109 cells/L), not progressive, nor associated with bleeding or thrombosis (Salzman et 
al., 1980), and is independent of any immune reaction (Chong et al., 1993a; Burgess & 
Chong, 1997; Shantsila et al., 2009). It is characterized by a transitory, slight and 
asymptomatic reduction in platelet count, occurring during the first 1-2 days of heparin 
administration. This phenomenon gradually resolves without interruption of heparin 
administration, and platelet counts gradually rises to pre-treatment levels within a few days 
without special treatment. Non-immune heparin associated thrombocytopenia may be 
related to the direct binding of heparin to platelet membranes (Salzman et al., 1980; Fabris et 
al., 1983; Chong & Ismail, 1989).  
In this view, the term HIT refers only to HIT type II. HIT is associated with a heparin-related 
immune reaction. It is a prothrombotic disease initiated by administration of heparin, and is 
related to antibody-mediated platelet activation causing thrombin generation and 
thrombotic complications. Thrombocytopenia is common in hospitalized patients, occurring 
in up to 58% of critically ill individuals, and can be caused by a variety of factors (Strauss et 
al., 2002). HIT, which is associated with significant morbidity and mortality if unrecognized, 
can be regarded as a very severe side effect of a drug, (Chong, 1992; Aster, 1995; Chong, 
2003). Unfortunately, HIT often remains unrecognized, undiagnosed, and untreated, a 
problem that can be rectified with increased awareness and a high degree of suspicion for 
HIT. Current treatment recommendations are based on recent advances in research on the 
pathophysiology and the natural history of HIT (Jang & Hursting, 2005). HIT should be 
considered a clinicopathologic syndrome (Warkentin et al., 1998; Warkentin, 2002, 2003) 
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since its diagnosis is based on both clinical criteria, such as thrombocytopenia and 
thrombosis, and laboratory data, such as platelet count dynamics and the detection of HIT 
antibodies (Shantsila et al., 2009).  
However, HIT is often difficult to diagnose because of the following phenomena: 1) 
nonimmune heparin-associated thrombocytopenia occurs in 10-30% of patients receiving 
heparin (Blank et al., 2002); 2) HIT antibody seroconversion is observed in the absence of 
thrombocytopenia or other clinical sequelae; and 3) enzyme-linked immunosorbent assay 
(ELISA) detects both clinically irrelevant (non-pathogenic) and clinically relevant 
(pathogenic) antibodies (Shantsila et al., 2009). Seroconversion of anti-HIT antibody without 
thrombocytopenia or other clinical sequela is not considered HIT, whereas a diagnosis of 
HIT can be made when anti-HIT antibody formation is accompanied by an otherwise 
unexplained platelet count fall, or by skin lesions at heparin injection sites or acute systemic 
reactions after intravenous injection of heparin (Bartholomew et al., 2005). Furthermore, HIT 
formation may also be related to the occurrence of venous limb gangrene occurring in HIT 
patients treated with oral anticoagulants (Warkentin, 1996a). A mnemonic device, the “4 Ts” 
of HIT, has been developed to remember the salient clinical features of HIT, thus facilitating 
patient assessment and HIT diagnosis (Warkentin & Heddle, 2003): the degree of 
Thrombocytopenia, the Timing of the platelet fall, the presence of Thrombosis or other 
sequelae, and oTher potential causes of thrombocytopenia (Lillo-Le Louët et al., 2004; Denys 
et al., 2008; Gruel et al., 2008).  
Despite the utility of this memory device, severe morbidity and mortality in HIT patients 
persists because of lack of awareness accompanied by a delayed diagnosis. Thus, we have 
developed the following chapter to provide an overview of HIT, focusing particularly on the 
epidemiology, pathophysiology, diagnosis, laboratory evaluation, and treatment. 
2. Overview of HIT 
HIT type II, namely, HIT, is immune-mediated and associated with a risk of thrombosis. It 
develops in approximately 5-10% of patients treated with heparin and is characterized by a 
significant reduction in platelets (levels fall by 30% or more), generally after the fifth day of 
therapy (Warkentin et al., 1998; Warkentin, 2002). Although, this phenomenon is usually 
resolved by therapy within 5-15 days, some cases may require months of treatment (Chong, 
1992; Warkentin et al., 1998; Warkentin, 2002).  
Platelet count monitoring is recommended for heparin-treated patients in whom the risk of 
HIT is high (e.g., postoperative patients) or intermediate (e.g., medical or obstetric patients 
receiving a prophylactic dose of heparin or postoperative patients receiving antithrombotic 
prophylaxis) (Chong et al., 1993a; Jang & Hursting, 2005). Shantsila et al. (2009) have 
recommended measurement of platelet counts before, and 24 h after, initiation of heparin 
therapy in patients who have received heparin within the past 100 days. Platelet counts 
should also be performed every 2-3 days in intermediate-risk patients, every other day in 
high-risk patients, and immediately in patients with systemic, cardiorespiratory, or 
neurologic symptoms that occur within 30 min after an intravenous injection of heparin.  
HIT should be suspected when thrombocytopenia (<15-20 109 cells/L, or a >50% decrease 
in platelet count) occurs during heparin administration, typically 5-14 days after initiation 
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to the risk of HIT.  
Although it is difficult to predict which heparin-exposed patients will develop HIT, one 
consistent factor is a property of heparin preparation. HIT antibodies occur at higher levels 
in patients given bovine unfractionated heparin (UFH) than in those treated with porcine 
UFH or low molecular weigh heparin (LMWH) (Green et al., 1984; Bailey et al., 1986; 
Monreal et al., 1989; Rao et al., 1989; Warkentin et al., 1995; Warkentin et al., 2003a; Lee & 
Warkentin, 2004; Denys et al., 2008; Gruel et al., 2008).  
HIT antibody formation is also influenced by the medical circumstances in which heparin is 
administered. For example, approximately 20% of heparin-exposed patients develop HIT 
antibodies after orthopedic surgery, while as many as 70% develop antibodies after 
receiving a cardiopulmonary bypass (CPB) (Amiral et al., 1996a). However, it can be 
difficult to compare results across studies because of differences in duration and route of 
anticoagulant administration, as well as patient group composition (Lee et al., 2004).  
3. Epidemiology  
There is a need for studies on HIT incidence. The work that has been done is sufficient, and 
they have so many differences that it is difficult to compare results across studies in order to 
uncover broader trends. Most HIT studies are retrospective, and differ with respect to 
patient characteristics, type of heparin preparation, duration of therapy, definition of 
thrombocytopenia, and laboratory tests used for confirm thrombocytopenia diagnosis 
(Schmitt & Adelman, 1993; Magnani, 1993; Chong, 2003). Despite these problems, it is 
possible to draw some general conclusions about HIT epidemiology.  
There are 3 characteristic profiles in the timing of the onset of thrombocytopenia. 
Approximately 70% of HIT patients are classified as “typical-onset HIT”. In these patients, 
platelet counts begin to decrease (serocnversion and initial platelet count fall) within 5-10 days 
after beginning heparin treatment (Warkentin & Kelton, 2001a). Approximately 25-30% of HIT 
patients are classified as having “Rapid-onset HIT”, which occurs when platelet counts fall 
abruptly within 24 h of starting heparin therapy (Warkentin & Kelton, 2001a; Lubenow et al., 
2002). “Rapid-onset HIT” is strongly associated with recent heparin exposure, usually within 
the preceding 100 days (Warkentin & Kelton, 2001a; Lubenow et al., 2002). Because of the 
previous exposure, patients already have circulating HIT antibodies, which cause platelet 
counts to fall quickly once heparin is re-administered. The last category of HIT, affecting 
approximately 3-5% of HIT patients, is “delayed-onset HIT” in which the onset of 
thrombocytopenia begins several days after completion of heparin treatment (Warkentin & 
Kelton, 2001b; Rice et al., 2002; Warkentin & Bernstein, 2003; Warkentin, 2004a). This type of 
syndrome is often clinically severe, as it is associated with high-titer, platelet-activating HIT 
antibodies that do not require ongoing heparin administration to exert their pathogenic effect 
(Rice et al., 2002). Furthermore, this type may occur in patients exposed to minimal amounts of 
heparin, although it has also been observed in patients exposed to large amounts of heparin 
during coronary artery bypass grafting (Rice et al., 2002; Jackson et al., 2006). Rarely, patients 
who received intravenous heparin develop acute inflammatory or cardiorespiratory 
symptoms and signs within 30 min (Warkentin, 2007).  
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since its diagnosis is based on both clinical criteria, such as thrombocytopenia and 
thrombosis, and laboratory data, such as platelet count dynamics and the detection of HIT 
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HIT severity is mainly determined by the extent of thrombotic complications (Girolami et al, 
2003). Many HIT patients develop thrombosis after receiving as an antithrombotic 
prophylaxis (Warkentin, 1996a; Wallis et al., 1999). The thrombotic event is frequently a 
worsening of pre-existing thrombosis in heparin-treated HIT patients, and this worsening of 
thrombosis may cause a new thromboembolic complication (Magnani, 1993; Warkentin & 
Kelton, 1990, 1996; Nands et al., 1997); this has been observed in approximately 20% of cases 
(Wakentin, 2004a). Development of a new thrombus or extension of an existing thrombus 
during treatment with prophylactic or therapeutic UFH or LMWH should always raise a 
suspicion of HIT (Shantsila et al., 2009). The first event to be associated with HIT was 
arterial thrombosis, which seems to be more frequent in patients with cardiovascular disease 
(Nands et al., 1997); venous complications may be common in patients undergoing post-
surgical prophylaxis (Rhodes et al., 1973; Magnani, 1993; Warkentin & Kelton, 1996;). In 
most cases, arterial complications manifest as thromboses of the large vessels, leading to 
gangrene and limb amputation, stroke, myocardial infarction, and cardiac thrombosis 
(Warkentin & Kelton, 1990; Boshkov et al., 1993; Fondu, 1995; Chong, 1995).  
Approximately 10-20% of patients who develop HIT while receiving subcutaneous 
injections of heparin experience skin lesions, ranging from painful erythematous plaques to 
skin necrosis, at the injection sites (Warkentin, 2004a; Chong, 1995). Skin lesions have been 
observed in patients without thrombocytopenia but with circulating HIT antibodies 
(Warkentin, 1996b). Occasionally, HIT associated with intravenous heparin injection also 
manifests as an acute systemic reaction developing within 5-30 min after heprin 
administration (Ansell et al., 1986; Popov et al., 1997; Warkentin, 2004a).  
Estimates of HIT prevalence among heparin-treated patients differ depending on heparin 
type. Fabris et al. (2000) found that laboratory-confirmed HIT occurs in approximately 2% of 
patients receiving UFH. Among patients given therapeutic doses of bovine UFH, HIT has 
been observed in approximately 5% of patients. This is a much higher rate than that 
observed in patients given procine UFH (1%). Prophylactic doses of porcine heparin have 
been reported to cause HIT in <1% of patients (Warkentin & Kelton, 1990). However, risk of 
HIT is relatively low in medical and obstetric patients receiving LMWH (Fabris et al., 2000). 
For instance, Warkentin (2004a) reorted that HIT was observed in 2.7% of patients treated 
with subcutaneous UFH injection, but in no patients receiving LMWH; further, thrombotic 
complications were more frequent in the former group (88.9%) than in the latter (17.8%). 
Both the bovine/procine UFH and the LMWH data were collected from medical patients 
receiving LMWH or UFH as “flushes”, e.g., oncology patients with indwelling catheters 
(Mayo et al., 1990; Kadidal et al., 1999). A randomized controlled trial that compared use of 
porcine UFH with LMWH after hip replacement surgery found that HIT was significantly 
less common among patients who received the latter treatment (Lee & Warkentin, 2004; 
Warkentin, 2004a).  
4. Pathophysiology  
Francis and colleagues have reported that HIT antibody formation in cardiac surgery 
patients who received procine UFH was significantly lower than those with bovine UFH 
(Francis et al., 2003). The IgG fraction of HIT patients serum has been found to cause in vitro 
platelet aggregation in the presence of therapeutic amounts of heparin (Rhodes et al., 1973), 





Green et al. (1978) reported that immunoglobulin-heparin complexes form only in the 
presence of platelets (Green et al., 1978), and several platelet proteins have been proposed as 
the receptors of heparin-dependent antibodies (Lynch & Howe, 1985). Multiple studies have 
found that the pro-aggregating effect of heparin depends on the degree of sulfation and the 
molecular weight of the heparin (Geinacher et al., 1992; Geinacher et al., 1993; Kelton et al., 
1994) and is mediated by the release of platelet alpha-granules (Gruel et al., 1993), which 
contain platelet factor 4 (PF4), a small, positively charged molecule produced by 
megakaryocytes. Although its biological function is unknown, it has been identified as the 
main co-factor of heparin (Amiral et al., 1992, Gentilini et al., 1999); it also binds to 
endothelial-surface glycosaminoglycans, e.g., heparin sulfate (Visentin et al., 1994; Cines et 
al., 2007). Normal blood levels of PF4 are very low, as it is only released into circulation 
following weak platelet activation. However, PF4 levels may be high in specific clinical 
circumstances, such as prosthetic hip or cardiac surgery, which are associated with platelet 
activation (Greinacher et al., 1994a). When heparin binds with PF4, it undergoes a 
conformational change and becomes immunogenic, leading to the generation of anti-
heparin/PF4 antibodies, namely, HIT antibodies (Suh et al., 1998; Ziporen et al., 1998). The 
PF4/heparin ratio is important for the constitution of the multimolecular antigenic complex, 
and the optimal PF4/heparin ratio has been reported to range from 4-6:1 (Kelton et al., 1994; 
Visentin et al., 1994; Amiral et al., 1995; Cines et al., 2007). The immunogenicity of heparin-
PF4 conjugates may form the biological basis for differences in immunogenicity between 
bovine and porcine sources of heparin: Bovine lung heparin has longer polysaccharide 
chains and a higher degree of sulfation, which could increase reactivity with PF4 (Boshkov 
et al., 1993).  
HIT antibodies activate platelets and stimulate an immunomedited endothelial lesion, 
followed by the appearance of thrombocytopenia and/or thrombosis (Fondu, 1995; 
Greinacher, 1995; Warkentin et al., 1998; Cines et al., 2007). Platelet activation is primarily 
caused by binding between the immunocomplex and FcγRIIa (CD32) receptors (Adelman et 
al., 1989; Anderson et al., 1995; Baglin, 2001), leading to degranulation and the release of 
pro-coagulant substances (e.g., serotonin, histamine, and adenosine diphosphate), 
thromboxane biosynthesis, an influx of Ca2+, and the generation of highly pro-thrombotic 
phospholipid microparticles (Chong et al., 1981; Chong et al., 1989a; Warkentin & Kelton, 
2001a). The immunocomplex can bind to Fc receptors on the surfaces of monocytes, 
neutrophils, and endothelial cells, and the binding of the immunocomplex to so many types 
of cells can contribute to the profound thrombin generation seen in patients with HIT. 
Thrombin generation can be enhanced by HIT activation of monocytes and endothelial cell 
tissue factor on the surface of monocytes and endothelial cells (Visentin et al., 1994; 
Warkentin, 1999; Newman & Chong, 2000; Pouplard et al., 2001; Arepally & Mayer, 2001). 
These thrombotic processes may lead to a hypercoagulable state, thus increasing the risk of 
severe and extensive thromboembolic complications in many patients. Additional activation 
of platelets by thrombin and other released agonists results in a further increase in the 
numbers of FcγRIIa receptors on the platelet surface, facilitating even more platelet 
activation (Chong et al., 1993b; Anderson et al., 1995). However, some reports have 
indicated that platelet activation can be blocked by the FcγRIIa receptor-specific monoclonal 
antibody (IV.3) (Kelton et al., 1988; Visentin et al, 1994).  
While IgG-class HIT antibody can be detected in most HIT patients, IgA and IgM HIT 
antibodies can be found in only a small portion of patients (Suh et al., 1997; Amiral et al., 
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1996b). Given that IgA and IgM antibodies do not activate platelets in the presence of 
heparin in vitro, and that they are unable to bind FcγRIIa, their presence in HIT patients 
could simply be coincidental, though IgM and IgA are not able to bind to FcγRIIa (Amiral et 
al., 1996a; Amiral et al., 1996b; Amiral et al., 1996c; Blank et al., 1997). These data suggest 
that platelet activation occurs independently of the IgG FcγRIIa receptor. After heparin 
administration is interrupted, the HIT antibody gradually disappears; laboratory tests for 
HIT antibodies are usually “negative” or “weakly positive” at 100 days (Shantsila et al., 
2009). For HIT to develop at this point, the HIT antibody would need to form again 
(Lubenow et al., 2002; Rice et al., 2002). Harris et al. (2008) have reported an association 
between the PLA2 polymorphism of glycoprotein IIIa and the risk of thrombosis in patients 
with HIT antibodies.  
5. Diagnosis of HIT  
The diagnosis of HIT should be based both on clinical criteria, such as the presence of 
thrombocytopenia and thrombosis, and laboratory data, such as platelet count dynamics 
and detection of HIT antibodies. However, it may be difficult to establish a general 
diagnostic protocol, given the lack of a readily accessible standard laboratory test and the 
frequent detection of elevated anti-HIT antibody levels in heparin-treated patients that 
display no clinical features of the disease (Arepally & Ortel, 2006).  
In the majority of patients with HIT, thrombocytopenia is defined as an otherwise 
unexplained >50% drop in the platelet count (Warkentin et al., 2008a); thrombocytopenia is 
generally of moderate severity, and median platelet count is approximately 50-60 x 109 
platelets/L (Jackson et al., 2006). In HIT patients, platelet counts are generally < 20 x 109 
platelets/L. Clinical presentation of HIT in patients with profound thrombocytopenia can be 
rapidly progressive and include the development of disseminated intravascular coagulation 
and microvascular thrombotic complications (Ortel, 2009). Patients are likely to suffer from 
HIT when their platelet counts drop to less than 50% of normal levels and when they 
present with thrombosis or skin lesions at heparin injection sites (Jackson et al., 2006). 
Generally, platelet count decreases and/or thrombotic events begin 5–10 days after the 
initiation of heparin therapy in heparin-hypersensitive individuals, and platelet count in 
thrombocytopenic patients may not return to initiation levels until several days later 
(Warkentin & Kelton, 2001a). In patients who have undergone operation, the expected 
pattern would show a return of normal platelet count immediately after surgery, followed 
by an unexpected drop (Warkentin, 2003). Persistent thrombocytopenia following cardiac 
bypass surgery is usually not a result of HIT, but instead may stem from other causes, such 
as postoperative complications. However, postoperative thrombocytopenia lasting for >5 
days without an apparent alternative cause may be the result of HIT (Lillo-Le et al., 2004).  
Several diagnostic algorithms have been developed to provide a more systematic approach 
to the diagnosis of HIT. Patients can be assigned an HIT score using the “4 Ts,” an 
assessment protocol and memory device focused on the salient clinical features of HIT: 
degree of Thrombocytopenia (maximum points for a platelet count fall of >50% or a nadir of 
20–100 × 109/L), the Timing of the fall in platelet count (maximum points for an onset of 5–
10 days after initiation of heparin treatment or within 1 day if there has been recent heparin 
exposure), the presence of Thrombosis or other sequelae (maximum points for new 





thrombocytopenia excluded (maximum points for no other cause event) (Warkentin, 2003, 
Warkentin et al., 2003b, Bryant et al., 2008). The “4 Ts” is useful for following the 
recommendation of Warkentin and Heddle, who suggest the employment of a clinical 
decision–making model to establish a pretest probability for HIT in patients who receive 
UFH or LMWH (Warkentin & Heddle, 2003). A diagnostic score for HIT after 
cardiopulmonary bypass surgery has also been proposed (Lillo-Le et al., 2004). Other 
studies have demonstrated the usefulness of combining the 4Ts score with laboratory testing 
when diagnosing HIT (Lillo-Le et al., 2004; Denys et al., 2008; Gruel et al., 2008); laboratory 
tests can also be used independently for confirming a clinical diagnosis.  
5.1 Laboratory testing  
Laboratory testing is necessary to confirm the diagnosis of HIT, and is most helpful in these 
patients clinically assessed to be at intermediate high clinical risk of HIT (Arepally & Ortel, 
2006). Patients who have undergone cardiopulmonary bypass surgery frequently have 
elevated antiheparin/PF4 antibody levels; among these individuals, testing should not be 
used to “screen” patients for HIT or evaluate patients assessed to have a low pre-test 
probability for HIT (Warkentin et al., 2008a). Although a lot of laboratory tests are available 
for detection of heparin-PF4 antibody, these tests have several advantages and 
disadvantages. Blood sampling for the detection of HIT antibodies was performed in 
patients with clinically suspected HIT on days 5 to 14 following the initiation of heparin 
therapy (Warkentin et al., 2008a). Although HIT antibodies are detectable in the blood for 
several weeks after heparin administration, discontinuation of heparin administration, 
samples should be collected as soon as possible because antibody levels can decrease quite 
rapidly. 
The first test developed for diagnosing HIT was the platelet aggregation test, which uses 
citrated platelet-rich plasma (PRP) and standard platelet aggregometry (Warkentin, 2004b). 
The platelet aggregation test is able to provide results quickly (Kelton et al, 1988), although 
results of this test is more influenced by heparin concentrations and donor platelet 
variability compared to those of 14C-serotonin release assay (SRA) (Warkenin & Kelton, 
1990; Chong, 1992, 1995). Accordingly, to increase sensitivity and specificity, test conditions 
need to be optimized– instance, by washed platelets (Chong et al., 1993a; Greinacher et al., 
1994a; Pouplard et al., 1999a). Washed platelet activation assays, such as the platelet SRA, 
(Sheridan et al., 1986; Warkentin et al., 1992; Warkentin, 2001; Price E et al., 2007), and the 
heparin-induced platelet activation test (Greinacher et al., 1991; Greinacher et al,. 1994a) are 
used by a few reference laboratories. In these assays, it is necessary to use of apyrase in a 
wash step for maintenance of platelet reactivity to HIT antibodies, and to resuspend in a 
calcium- and magnesium-containing buffer (Polgár et al., 1998; Warkentin, 2001). The major 
limitation of this method is its technically demanding nature (Warkentin, 2000), which limits 
its use to a few reference laboratories. In most clinical laboratories, immunological tests such 
as ELISA are used because they are easy to perform, have a rapid turnaround time, and are 
highly sensitive (Price et al., 2007). There are 2 PF4-dependent antigen assays that are 
commercially available for detecting HIT antibodies (Amiral et al., 1992; Collins et al., 1997; 
Warkentin, 2000; Warkentin et al., 2001): the Asserachrom (Stago, Asnières, France), which 
detects antibodies that react with PF4-heparin complexes, and the GTI-PF4 (GTI, Brookfield, 
WI, USA), which detects antibodies that react with PF4 bound to polyvinyl sulfonate. 
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1996b). Given that IgA and IgM antibodies do not activate platelets in the presence of 
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Prospective studies have shown that, among HIT antibody classes, only HIT-IgG antibodies 
have very high sensitivity for diagnosing clinical HIT (Warkentin et al., 2000; Lindhoff-Last 
et al., 2001). Detection of PF4-heparin antibodies is performed as followed. Unbound 
material is removed, and a chromogen is added to label the bound conjugate, producing a 
yellow color, read at 405 nm. The amount of yellow produced at the end point, as indicated 
by the optical density (OD), is proportional to the amount of antibody present. A positive 
result is reported if OD reading is 0.400 or more. Higher ELISA OD results have been shown 
to significant correlation of the serotonin release assay results and an increased risk for 
thrombosis in patients with HIT (Warkentin et al., 2008b). Furthermore, the ELISA results 
are most useful when combined with a clinical scoring system (Janatpour et al., 2007). 
Zwicker et al (2004) have reported that higher ELISA OD measurements correlated 
significantly with thrombosis, and patients with isolated HIT (HIT in the absence of 
thrombosis) and an OD level of 1.0 or more had a 6-fold increased risk of thrombosis 
compared with patients who had OD levels between 0.4 and 0.99 (Zwicker et al, 2004). The 
sensitivity of the ELISA for PF4-heparin antibodies is greater than functional assays 
(Greinacher et al., 1994b; Amiral et al., 1995; Pouplard et al., 1999b), though a “positive” 
result may not denote the same magnitude of thrombotic risk.  
5.2 Laboratory data from 2 potential HIT patients 
We examined 2 patients who experienced thrombocytopenia after being given UFH during 
percutaneous transluminal coronary angioplasty (PTCA) and cardiac surgery. For both 
individuals, we tested for HIT by measuring platelet aggregability and quantifying levels of 
both anti-heparin-PF4 complex antibody (anti-HIT antibody) and thrombin-antithrombin III 
complex (TAT). Platelet aggregation in response to 0.2 μg/mL collagen was measured using 
Born’s turbidimetric methods (Born GVR, 1962), and quantified by light transmission, as 
previously reported (Toyohira et al., 1995; Kariyazono et al., 1997; Nakamura et al., 1999); 
platelet aggregation activity was evaluated as percent maximum aggregation (MA). First 
samples were prepared by incubating the PRP of suspected HIT patients with UFH (0.2 
IU/mL), and second samples were prepared by separately adding plasma from the 2 
patients to the PRP of healthy volunteers at a ratio of 1:1, then adding UFH (0.2 IU/mL). We 
then used a commercial ELISA kit (GTI Diagnostics, Waukesha, WI, NJ, USA) to measure 
anti-heparin antibodies in these samples.  
As shown in Figure 1, platelet aggregation was much higher in the first set of sample than in 
the first control sample (without UFH); in other words, heparin had a strong positive effect 
on aggregation. As a result, MA of second sample was 68% (Figure 2), and showed strong 
aggregation. The ELISA results indicated significantly higher OD values for the 2 potential 
HIT patients than in the healthy volunteers. Furthermore, remarkably high levels of 
circulating TAT and TNF-alpha were found in the plasma of the suspected HIT patients. 
Our laboratory data indicate the likelihood that anti-HIT antibodies were present in the 
plasma of both patients. Furthermore, these data demonstrate the marked acceleration of 
blood coagulation in these patients, suggesting an increased risk of thrombosis.  
These findings support previous reports that many HIT patients are hypercoagulable and 
have greatly elevated levels of TAT (Warkentin et al., 1997; Greinacher et al., 2000); 
furthermore, this helps explain the strong relationship between HIT and venous or arterial 










Fig. 1. Platelet aggregation was stimulated by 0.2 μg/mL collagen. In case A’s PRP 
incubated without UFH (first control sample) (C). In healthy volunteer’s PRP incubated with 






Fig. 2. Anti-heparin antibody was detected by turbidimetric method. Collagen (0.2 μg/mL) 
was used as agonist. In case A’s PRP incubated without UFH (first control sample) (C). In 
healthy volunteer’s PRP was mixed with case A’s plasma following incubation without UFH 
(third control sample) (B). In healthy volunteer’s PRP was mixed with case A’s plasma 
following incubation with UFH (A).  
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 Given these findings, we propose a model for the pathophysiological mechanism of HIT 
(Figures 3 and 4). This model helps explain observations that the hypercoagulable state, 
coupled with endothelial cell dysfunction due to injury from heparin antibody, activated 
platelets, leukocytes, platelet microparticles, atherosclerosis or medical intervention, can 
lead to arterial thrombosis (Walenga et al., 2000). Furthermore, the model is supported by 
the report that anti-HIT antibodies bind to and directly activate microvascular endothelial 
cells, whereas binding to and activating macrovascular endothelial cells requires pre-

















Fig. 3. Pathophysiological mechanism of HIT (1). Stage 1; binding of heparin to PF4 induces 
the formation of a neoepitope. Stage 2; an immune response against the PF4/heparin 
complex induces antibody formation. Stage 3; the complex of PF4/heparin and specific 
antibody associates with platelets via binding of the antibody Fc part to the platelet 
immunoglobulin receptor FcγRIIa (CD32), representing the major stage in platelet activation 
in HIT. Stage 4; activated platelets shed procoagulant microparticles which enhance 



















Fig. 4. Pathophysiological mechanism of HIT (2). Stage 5; binding of released PF4 to heparan 
sulfate of endothelial cell induces the formation of PF4/glycosaminoglycans complex on the 
surface of endothelial cell. Stage 6; PF4/glycosaminoglycans complex antibody binds to 
PF4/glycosaminoglycans complex on the surface of endothelial cell, and activates 
endothelial cell. Stage 7; activation of endothelial cells lead to the release of activated factor 
X. Stage 8; thrombin generation induces thrombus formation.  
6. Management of HIT 
All heparins must be avoided when treating patients suspected to have HIT; even exposure 
to very low amounts of heparin through heparin-coated catheters and heparin flushes used 
to maintain intravenous lines may trigger HIT (Laster et al., 1989). Likewise, preparations of 
LMWH can induce severe HIT, though they do so less frequently than UFH (Warkentin et 
al., 2003a; Warkentin & Greinacher, 2003; Walenga et al., 2004). Further, the cross-reactivity 
rate between heparin and LMWH is so high that LMWH is not recommended for the 
treatment of HIT patients (Chong, 2003; Warkentin et al., 2008a). Alternative anticoagulant 
therapy must be initiated immediately, both for HIT patients diagnosed with 
thrombocytopenia alone or with thromboembolism (Warkentin & Greinacher, 2004). In 
patients in whom treatment was delayed until an HIT diagnosis could be confirmed by 
laboratory tests, the incidence of new thrombosis was approximately 10-fold higher than in 
individuals treated promptly with a direct thrombin inhibitor (Greinacher et al., 2000).  
Marked decreases of platelet counts in HIT patients require anticoagulation with an effective 
antithrombotic drug that does not cross-react in vivo with the circulating anti-heparin/PF4 
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antibodies. There are currently 3 thrombin inhibitors available for patients with HIT: 
lepirudin, argatroban, and bivalirudin, all of which directly bind and inactivate thrombin. 
Prospective cohort studies have been performed to investigate the efficacy and major 
bleeding endpoints for lepirudin (Greinacher et al., 1999a; Greinacher et al., 1999b; Lubenow 
et al., 2004; Lubenow et al., 2005)  and argatroban (Lewis et al., 2001; Lewis et al., 2003) in 
patients with HIT complicated by thrombosis. When respective historical control data were 
taken into consideration, composite end point risk rates and new thrombosis risk rates were 
0.48 and 0.28 for lepirudin, respectively, and 0.75 and 0.45 for argatroban, respectively. The 
corresponding absolute event rates were 19.2% (lepirudin) and 42.3% (argatroban) for the 
composite end point, and 7.0% (lepirudin) and 15.5% (argatroban) for new thrombosis. 
Patients who received lepirudin were less likely to require amputation than those who were 
given argatroban. Fatal bleeding after treatment with lepirudin has been found to range 
from 1.2% of patients (in a prospective study) to 3.9% of patients (in a retrospective 
observational study) (Lubenow et al., 2005; Tardy et al., 2006). Danaparoid and 
fondaparinux may also be used to manage HIT (Warkentin et al., 2008a). When abrupt 
decreases in platelet count (to <10 × 109 clls/L) are observed in patients who underwent 
angioplasty and were treated with a combination of heparin and glycoprotein IIb/IIIa 
antagonist, the recommended antagonist is always glycoprotein IIb/IIIa (Shantsila et al., 
2009) 
6.1 Lepirudin  
Lepirudin, a recombinant form of hirudin, is a direct, specific, and irreversible inhibitor of 
thrombin that is administered via intravenous injection (Greinacher & Lubenow, 2001). The 
Biggest drawback of Lepirudin is that it must be accompanied by the strict laboratory 
monitoring: activated partial thromboplastin time (aPTT) monitoring should be performed 
at 4-h intervals until it is clear that patients have reached a steady state within the normal 
range of values (Warkentin et al., 2008b). Moreover, patients should be informed that they 
have received lepirudin, since fatal anaphylactic reactions have been reported in patients re-
exposed to lepirudin during a second round of intravenous treatment (Greinacher et al., 
2003). Although similar bleeding rates have been observed in lepirudin-treated patients and 
historical control subjects, this drug has been found to significantly reduce the combined 
end point of death, limb amputation, and new thromboembolic complications in patients 
with HIT associated thrombosis (Greinacher et al., 1999a; Greinacher et al., 1999b). 
6.2 Argatroban  
Argatroban is a synthetic L-arginine-derived direct thrombin inhibitor that reversibly binds 
to the thrombin active site. Argatroban is administered by intravenous injection, with dose 
adjustment to maintain aPTT at 1.5-3.0 times the baseline value (Gosselin et al., 2004). It has 
been reported that, in HIT patients without thrombosis, treatment with argatroban produces 
a significant reduction in the composite end point, such as all-cause death, all-cause limb 
amputation, and new thrombosis at 37 days (Lewis et al., 2001; Lewis et al., 2003). In HIT 
patients who underwent lower extremity revascularization, the composite end point of 
deaths, urgent revascularization, and limb amputations developed in 25% of patients treated 
with argatroban, and 6% of patients had major bleeding episodes (Baron et al., 2008). 





argatroban therapy (Bartholomew et al., 2007). Some precautions are required when 
argatroban infusion is overlapped by warfarin anticoagulant therapy, although argatroban 
causes a further substantial increase in the international normalized ratio (INR). In addition, 
careful thought should be given to the participation of direct thrombin inhibitor to the 
patient’s INR.  
6.3 Danaparoid  
Danaparoid is approved as an alternative anticoagulant for HIT in many countries. 
Danaparoid, a heparinoid with predominantly anti-Xa activity and some anti-IIa activity, is 
a mixture of three glycosaminoglycans such as heparin sulfate, dermatan sulfate, and 
chondroitin sulfate. Danaparoid presents its anticoagulant effect by catalyzing the 
inactivation of factor Xa in the presence of antithrombin, and has a unique property of 
specific suppression of HIT antibody-induced platelet activation that is not observed with 
other drugs used for HIT treatment (Chong et al., 1989b). Tardy-Poncet et al. reported that 
major bleeding episodes in those patients treated with danaparoid were significantly fewer 
compared with those treated with lepirudin (Tardy-Poncet et al., 1999). Among the drugs 
used for the treatment of HIT, danaparoid is the only drug whose efficacy and safety have 
been confirmed by a prospective randomized controlled study (Chong et al., 2001).  
6.4 Bivalirudin  
Bivalirudin, which is not approved as an HIT treatment, is a 20-amino acid polypeptide with 
sequence homology to hirudin. Campbell et al. (2000) reported 94% procedural success in a 
series of 17 percutaneous coronary intervention patients who were given bivalirudin as a 
treatment for HIT (Campbell et al., 2000). In the Anticoagulant Therapy with Bivalirudin to 
Assist in the Performance of Percutaneous Coronary Intervention in Patients with HIT (or 
ATBAT) multicenter open-label trial (Mahaffey et al., 2003), clinical percutaneous coronary 
intervention success, defined as the absence of death, emergency bypass surgery, or Q-wave 
infarction, was achieved in 96% of patients treated with bivalirudin; further, patients 
displayed a low rate of bleeding. Cumulatively, these results indicate that bivalirudin 
therapy is safe and effective during percutaneous coronary intervention.  
6.5 Fondaparinux 
Fondaparinux, a synthetic pentasaccharide with potent indirect anti-Xa inhibitor properties, 
is used only a limited number of patients with HIT. The generation of HIT-related antigen 
depends on the polysaccharide chain length (Amiral et al., 1995). Because patients have a 
very low risk of developing HIT while receiving fondaparinux (Warkentin et al., 2005), 
platelet count monitoring is not needed during administration of this drug. Despite these 
advantages, fondaparinux cannot be recommended for in the treatment of HIT until there 
are more data demonstrating its efficacy and safety (Rota et al., 2008; Lobo et al., 2008).  
7. Conclusion 
Heparin is one of the most widely used and valuable anticoagulants for the treatment and 
prophylaxis of thrombotic complications. However, HIT is not only a common but also a 
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taken into consideration, composite end point risk rates and new thrombosis risk rates were 
0.48 and 0.28 for lepirudin, respectively, and 0.75 and 0.45 for argatroban, respectively. The 
corresponding absolute event rates were 19.2% (lepirudin) and 42.3% (argatroban) for the 
composite end point, and 7.0% (lepirudin) and 15.5% (argatroban) for new thrombosis. 
Patients who received lepirudin were less likely to require amputation than those who were 
given argatroban. Fatal bleeding after treatment with lepirudin has been found to range 
from 1.2% of patients (in a prospective study) to 3.9% of patients (in a retrospective 
observational study) (Lubenow et al., 2005; Tardy et al., 2006). Danaparoid and 
fondaparinux may also be used to manage HIT (Warkentin et al., 2008a). When abrupt 
decreases in platelet count (to <10 × 109 clls/L) are observed in patients who underwent 
angioplasty and were treated with a combination of heparin and glycoprotein IIb/IIIa 
antagonist, the recommended antagonist is always glycoprotein IIb/IIIa (Shantsila et al., 
2009) 
6.1 Lepirudin  
Lepirudin, a recombinant form of hirudin, is a direct, specific, and irreversible inhibitor of 
thrombin that is administered via intravenous injection (Greinacher & Lubenow, 2001). The 
Biggest drawback of Lepirudin is that it must be accompanied by the strict laboratory 
monitoring: activated partial thromboplastin time (aPTT) monitoring should be performed 
at 4-h intervals until it is clear that patients have reached a steady state within the normal 
range of values (Warkentin et al., 2008b). Moreover, patients should be informed that they 
have received lepirudin, since fatal anaphylactic reactions have been reported in patients re-
exposed to lepirudin during a second round of intravenous treatment (Greinacher et al., 
2003). Although similar bleeding rates have been observed in lepirudin-treated patients and 
historical control subjects, this drug has been found to significantly reduce the combined 
end point of death, limb amputation, and new thromboembolic complications in patients 
with HIT associated thrombosis (Greinacher et al., 1999a; Greinacher et al., 1999b). 
6.2 Argatroban  
Argatroban is a synthetic L-arginine-derived direct thrombin inhibitor that reversibly binds 
to the thrombin active site. Argatroban is administered by intravenous injection, with dose 
adjustment to maintain aPTT at 1.5-3.0 times the baseline value (Gosselin et al., 2004). It has 
been reported that, in HIT patients without thrombosis, treatment with argatroban produces 
a significant reduction in the composite end point, such as all-cause death, all-cause limb 
amputation, and new thrombosis at 37 days (Lewis et al., 2001; Lewis et al., 2003). In HIT 
patients who underwent lower extremity revascularization, the composite end point of 
deaths, urgent revascularization, and limb amputations developed in 25% of patients treated 
with argatroban, and 6% of patients had major bleeding episodes (Baron et al., 2008). 





argatroban therapy (Bartholomew et al., 2007). Some precautions are required when 
argatroban infusion is overlapped by warfarin anticoagulant therapy, although argatroban 
causes a further substantial increase in the international normalized ratio (INR). In addition, 
careful thought should be given to the participation of direct thrombin inhibitor to the 
patient’s INR.  
6.3 Danaparoid  
Danaparoid is approved as an alternative anticoagulant for HIT in many countries. 
Danaparoid, a heparinoid with predominantly anti-Xa activity and some anti-IIa activity, is 
a mixture of three glycosaminoglycans such as heparin sulfate, dermatan sulfate, and 
chondroitin sulfate. Danaparoid presents its anticoagulant effect by catalyzing the 
inactivation of factor Xa in the presence of antithrombin, and has a unique property of 
specific suppression of HIT antibody-induced platelet activation that is not observed with 
other drugs used for HIT treatment (Chong et al., 1989b). Tardy-Poncet et al. reported that 
major bleeding episodes in those patients treated with danaparoid were significantly fewer 
compared with those treated with lepirudin (Tardy-Poncet et al., 1999). Among the drugs 
used for the treatment of HIT, danaparoid is the only drug whose efficacy and safety have 
been confirmed by a prospective randomized controlled study (Chong et al., 2001).  
6.4 Bivalirudin  
Bivalirudin, which is not approved as an HIT treatment, is a 20-amino acid polypeptide with 
sequence homology to hirudin. Campbell et al. (2000) reported 94% procedural success in a 
series of 17 percutaneous coronary intervention patients who were given bivalirudin as a 
treatment for HIT (Campbell et al., 2000). In the Anticoagulant Therapy with Bivalirudin to 
Assist in the Performance of Percutaneous Coronary Intervention in Patients with HIT (or 
ATBAT) multicenter open-label trial (Mahaffey et al., 2003), clinical percutaneous coronary 
intervention success, defined as the absence of death, emergency bypass surgery, or Q-wave 
infarction, was achieved in 96% of patients treated with bivalirudin; further, patients 
displayed a low rate of bleeding. Cumulatively, these results indicate that bivalirudin 
therapy is safe and effective during percutaneous coronary intervention.  
6.5 Fondaparinux 
Fondaparinux, a synthetic pentasaccharide with potent indirect anti-Xa inhibitor properties, 
is used only a limited number of patients with HIT. The generation of HIT-related antigen 
depends on the polysaccharide chain length (Amiral et al., 1995). Because patients have a 
very low risk of developing HIT while receiving fondaparinux (Warkentin et al., 2005), 
platelet count monitoring is not needed during administration of this drug. Despite these 
advantages, fondaparinux cannot be recommended for in the treatment of HIT until there 
are more data demonstrating its efficacy and safety (Rota et al., 2008; Lobo et al., 2008).  
7. Conclusion 
Heparin is one of the most widely used and valuable anticoagulants for the treatment and 
prophylaxis of thrombotic complications. However, HIT is not only a common but also a 
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serious complication of heparin therapy with a high rate of morbidity and mortality. Its 
prompt clinical and laboratory recognition is necessary to stop heparin administration 
immediately and start an alternative anticoagulant. HIT antibody test results must be 
interpreted in the appropriate context of the available clinical information. Furthermore, 
additional diagnostic information is available as a result of considering the magnitude of 
a given positive test result. The diagnosis of HIT should be clearly recorded in the 
patient’s notes and marked as a serious allergy.  
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1. Introduction 
The most commonly ordered test used for managing patients worldwide is the hemogram, 
with or without the review of a peripheral smear. The measured features in a standard 
hemogram has undergone modification of the over the last 30 years with an expansion to 
the panel of tests. The initial hemogram was the hemoglobin, hematocrit, and total white cell 
count, to which platelet count, lymphocytes and neutrophils were added as the necessary 
vital dye stains and the resolution were substantially improved. The revolutionary Coulter 
principle used impedance of the cells passing through a narrow window. Newer 
instruments may used both impedance and/or flow cytometric principles. Yet the accurate 
identification of reticulocytes, measurement of cellular hemoglobin, measurement of 
immature granulocytes, lymphoid or myeloblasts, identification of clumped platelets 
interfering with identification of large platelets were all challenges to overcome. The 
hemogram provides a vital window to visualize the cellular changes associated with the 
production, release or suppression of the formed elements from the blood forming organ to 
the circulation. In this chapter, we shall not be concerned with the specific use of the 
hemogram in assessing disorders to the coagulation pathways or its use in detection of 
hematological and non-hematological tumors. Rather in the hemogram we can view data 
reflective of a broad spectrum medical conditions affecting most patients presenting to a 
physician who are then referred to a specialist for example in hematology-oncology or 
infectious diseases. 
The theme of what we are about to present is that once we go beyond qualitative changes to 
the morphology of the cellular components of blood, we have also to consider their 
quantitative characteristics expressed as measurements of size, density, and concentration, 
which results in more than a dozen composite variables, including the mean corpuscular 
volume (MCV), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular 
hemoglobin (MCH), total white cell count (WBC), total lymphocyte count, neutrophil count 
(mature granulocyte count and bands), monocytes, eosinophils, basophils, platelet count, 
and mean platelet volume (MPV), and flags to denote blasts, reticulocytes, platelet clumps, 
and so on. If you were to add the comprehensive metabolic panel, which includes 
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monovalent and divalent cations and anions, total CO2, total protein and albumin, to name 
a few, there is a potential for information overload to the physician. These data in turn have 
to be comprehended in context with vital signs, key symptoms, and an accurate medical 
history. Consequently, the limits of memory and cognition are tested in medical practice on 
a daily basis. In this chapter we will discuss problems in the interpretation of data generated 
by automated laboratory diagnostic machinery, as experienced by the physician, and how 
through better design of the software (middleware) that presents this data the situation 
could be improved.  
2. The current status of the physician-laboratory interface 
The clinical laboratory has several divisions. Microbiology and anatomic pathology are the 
oldest, and they are the least automated, but they have rigorous definitions for their 
interpretation, as is true for immunohematology. Hematology and chemistry are the most 
automated, but their interpretations are more difficult than the other disciplines. To start 
with we will consider automated chemistry, hematology, and immunology with large high-
throughput sample platforms. These analyzers have enhanced performance by interface 
with middleware, which have embedded rules to accept or reject a test result based on a 
result lying outside an assigned confidence limit, or based on a difference from a previous 
measurement within an assigned time interval in hours or days. A middleware is a 
minicomputer installed either between an instrument and a laboratory information system 
or between an instrument and a hospital information system. The middleware handles an 
enormous transaction rate of test workflow that would otherwise compete with physician 
interactions in trying to access the data output. The middleware also carries out on-line 
quality control checks, monitors the completion of panel accessions, and does “delta” checks 
for excessive differences between measurements taken in sequence. Further, depending on 
whether a test is measured from unclotted and unspun blood, or from plasma or serum 
fraction, hematology, chemistry and immunology testing are tested with different 
turnaround times (time from receipt to time to report). In all of these cases, tests from 
different core “instruments” or laboratory “facilities” of laboratory testing have to be 
interpreted without conflict in the production “silo” (the term refers to a separate mode of 
production that is separate from and not interoperable with other information sources).  
3. Data overload and unstructured 
The computer architecture that the physician uses to view the results is not open-
architecture, and the middleware solutions used to overcome the problem are insufficient in 
that the data is not recombined from the rigid lists into a structured format that readily 
enables the physician to interpret the report. Consequently the results are more often than 
not presented as the designer would prefer, and not as the end-user would like. In order to 
optimize the interface for physician, the system would have a “front-to-back” design, with 
the call up for any patient ideally consisting of a dashboard design that presents the crucial 
information that the physician would likely act on in an easily accessible manner. The 
problem of the user having to adjust to what the system confronts them with is described by 
Didner (1) in an internal Bell Labs memo approved for external release. The key point being 
that each item used has to be closely related to a corresponding criterion needed for a 
decision. Currently, improved design is heading in that direction. In removing this 
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limitation the output requirements have to be defined before the database is designed to 
produce the required output. The ability to see any other information, or to see a sequential 
visualization of the patient’s course would be steps to home in on other views. In addition, 
the amount of relevant information, even when presented well, is a cognitive challenge 
unless it is presented in a disease- or organ-system structure. So the interaction between the 
user and the electronic medical record has a significant effect on practitioner time, ability to 
minimize errors of interpretation, facilitate treatment, and manage costs. This is a correction 
for a view from the mere transmission of a body of automated tests that are generated at 
sites not near to the patient, often with a high priority reporting required from the operating 
room, the emergency room, or the intensive care units in order to make triage decisions or to 
adjust fluids or make treatment decisions. 
The reality is that clinicians are challenged by the need to view a large amount of data, with 
only a few resources available to know which of these values are relevant, or the need for 
action on a result, or its urgency. An approach (2,3), called the foresighted-practice 
guideline, aligned with concepts developed by Lawrence Weed (4). Weed emphasizes that 
the information infrastructure was lacking at the time of his writing (1997), and that tools 
are needed to extend the mind’s capability to process large numbers of relevant variables. 
The challenge then becomes how fundamental measurement theory can lead to the creation 
at the point of care of more meaningful actionable presentations of results (5). WP Fisher (6) 
refers to the creation of a context in which computational resources for meeting the 
challenges will be incorporated into the electronic medical record. The one which he chooses 
is a probabilistic conjoint (Rasch) measurement model (7), which uses scale-free standard 
measures and meets data quality standards. He illustrates this by fitting a set of data 
provided by Bernstein (19)(27 items for the diagnosis of acute myocardial infarction (AMI) 
to a Rasch multiple rating scale model testing the hypothesis that items work together to 
delineate a unidimensional measurement continuum. The results indicated that highly 
improbable observations could be discarded, data volume could be reduced based on its 
internal consistency, and that consistency could be used to increase the ability of the care 
provider to interpret the data. The use of a computer-derived algorithm has been shown to 
aid the physician (8,9). A huge amount of progress has occurred regarding model 
construction and validation in the last 11 years. An ordinal regression (adjacent category 
logit model )(10) used on the AMI problem (11) is superceded by a Latent Class Model of Jay 
Magidson and Jeroen Vermunt (LatentGOLD, Statistical Innovations, Medford, MA)(12). 
The LatentGOLD has LC Cluster models, DFactor models, and LC Regression models and 
has the advantage of allowing performance of LC analyses on data containing more than 
just a few variables. It uses the fundamental methods of model fit (13,14) established as 
Alaike (AIC)(14,15,16) and Bayes (BIC)(14) information criteria. These have not been applied 
to classifying a large and complex medical data set. 
4. Classified data a separate issue from automation 
On the other hand, automation itself may not be as important as the critical value of the 
information provided. The disciplines required in blood banking and in microbiology have 
only been recently automated, but their importance is readily understood with the exception 
of an error in blood sample, or its contamination. To an extent, blood screening has become 
a large scale production to service the user population.  
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The classification of blood types emerged at the turn of the last century firstly as a result of 
the work of Paul Ehrlich (17) establishing a groundwork for immunology, and then later 
Karl Landsteiner’s seminal work in laying the foundation for the blood groups (17). These 
works resulted in a well-defined classification of a set of identified blood group antigens 
and the absence of antibody in the individual’s serum against the blood type, with the 
exception of auto-antibody reactions.  
4.1 Microbiology classification  
Microbiology classification has its origin in the taxonomic principles set down by Bergey’s 
Manual of Determinative Bacteriology, which originated in 1857, and is maintained by 
Bergey’s Trust. It is guided by observable features that are key for separating groups and 
subgroups. The kind of features that we readily identify are gram stain positivity, colonies 
on agar, cocciform or bacillary shape, outer capsule, motility, the clusters formed, the 
metabolic features in growth media, and even the expected antibiotic reactivity. Thus, we 
have an example: in Table 1. 
 
GROUP 4 
Description: Gram Negative, Aerobic/Microaerophilic rods and cocci 
Key differences are: pigments/fluorescent, motility, growth requirements, 
denitrification, 
morphology, and oxidase, read Genera descriptions 
Examples: Acinetobacter, Pseudomonas, Beijerinckia  
GROUP 5 
Description: Facultatively Anaerobic Gram negative rods 
Key differences are: growth factors, morph., gram rxn., oxidase rxn., read Genera 
descriptions  
Examples: Family Enterobacteriaceae and Vibrionaceae 
GROUP 17 
Description: Gram-Positive Cocci 
Key differences are: oxygen requirements, morph., growth requirements (45°C and 
supplements), read Genera descriptions 
Examples: Micrococcus, Staphylococcus, Streptococcus, Enterococcus, Lactococcus 
Table 1. Typical classes of bacteria 
Table 1 does not further divide into subclasses, which requires metabolic differentiation in 
growth media.  
4.2 Feature extraction 
This further breakdown in the modern era is determined by genetically characteristic gene 
sequences that are transcribed into what we measure. Eugene Rypka contributed greatly to 
clarifying the extraction of features in a series of articles, which set the groundwork for the 
methods used today in clinical microbiology (18,19). The method he describes is termed S-
clustering, and will have a significant bearing on how we can view hematology data. He 
describes S-clustering as extracting features from endogenous data that amplify or 
maximize structural information to create distinctive classes. The method classifies by 
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taking the number of features with sufficient variety to map into a theoretic standard. The 
mapping is done by a truth table, and each variable is scaled to assign values for each: 
message choice. The number of messages and the number of choices forms an N-by N table. 
He points out that the message choice in an antibody titer would be converted from 0 + ++ 
+++ to 0 1 2 3. In looking at laboratory values the practitioner separates any test by low 
normal moderately-high high. Even though there may be a large number of measured 
values, the variety is reduced by this compression, even though there is risk of loss of 
information. Yet the real issue is how a combination of variables falls into a table with 
meaningful information. He describes how syndromic classification is uniquely valuable for 
clinical laboratory information by amplifying information in the course of making a pattern-
identifiable syndromic classification. Rudolph, Bernstein and Babb (20) used it for the 
diagnosis of acute myocardial infarction. 
5. Optimal weighting and value assigned to predictor variables 
We are interested in classifying data as essential for determining optimal decision limits for 
tests, and for analyzing variable combinations that are essential and optimal for separating 
the groups that are separated with fewest errors. This is only possible by reducing data 
uncertainty. We are concerned with accurate assignment into uniquely variable groups by 
information in test relationships. One determines the effectiveness of each variable by its 
contribution to information gain in the system. The reference or null set is the class having 
no information. Uncertainty in assigning to a classification is only relieved by providing 
sufficient information. One determines the effectiveness of each variable by its contribution 
to information gain in the system. The possibility for realizing a good model for 
approximating the effects of factors supported by data used for inference owes much to the 
discovery of Kullback-Liebler distance or “information” (21), and Akaike (22) found a 
simple relationship between K-L information and Fisher’s maximized log-likelihood 
function (23). 
5.1 Advances in applied mathematics 
Perhaps the current exponential growth of knowledge since the mapping of the human 
genome a decade ago has been enabled by parallel advances in applied mathematics, which 
has not been a part of the entrance competencies for premedical education, and is now 
taught to some extent in medical and postmedical education for a better understanding of 
modern clinical trials. The knowledge and use of the science of complexity in much of what 
we encounter is brought to account by Ray Kurzweill (24). In a univariate universe, we have 
significant control in visualizing data because we can be confident in separating unlike data 
by methods that rely on distributional assumptions, although errors in assignment can be 
substantial. The median (by rank order assignment is the best method of assignment under 
the circumstances). In reality, there is likely to be a different assignment of predictor values 
given an association with a different disease entity. In order to better define the target 
output another variable is necessary. As we attend to more associated outputs, the number 
of predictors is expanded. Now we begin to have multiple classes delineated by the 
confidence limits of the conjoint predictors. As the number of separate categories increases, 
the size of the database has to increase to limit the error in the so called model 
representation. 
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As the complexity of models have increased to using several predictors for at least two 
outputs, and the dependencies are not clear, the models used for analysis of the data are 
derived by tables and use of the goodness of fit. The development of the Akaike Information 
Criterion (15,16,21,22,23) brought together two major disciplines that had separate 
developments, information theory and statistics. The powerful tools now available are not 
dependent on distributional assumptions, and allow classification and prediction. In fact 
modeling today has a primary goal of finding an underlying structure in studied data sets. 
A sequence of exploratory programs have been developed by Statistical Innovations, a 
Boston based company founded by Jay Magidson focused on classification problems with 
complex data sets, encompassing a mixture of nominal and continuous predictors, and 
where there is a high complexity with the data sample size may approach the number of 
predictors (CORExpress® , Latent GOLD® 4.5, LG-Syntax Module, Latent GOLD® Choice , 
SI-CHAID® , GOLDMineR). Many articles can be cited concerning these advances (25-32). 
Further, IBM has introduced a software program for Predictive Analytics available in 2011.  
6. Prior experience in similarly developed taxonomies can be applied to 
hematology 
We consider a novel approach to medical inference to have considerable parallel with work 
in bacterial taxonomy, or the rapidly growing work in genomics, proteomics, and 
translational medicine. In the diagnosis of anemia, we divide these into microcytic, 
normocytic and macrocytic. We also consider whether there is proliferation of marrow 
precursors, whether there is domination of a cell line, and whether there is a suppression of 
hematopoiesis. This gives us a two dimensional model. Then we consider another, the 
release into the blood of immature cells, for intermediate to the blast stage. Keep in mind 
that the thalassemias (and hemoglobin H disease) are characterized by moderate to severe 
microcytosis, and there is no anisocytosis (variation in size), and being a genetic disorder in 
production of globin chains, there is a high RBC count, whereas, iron deficiency anemia 
(IDA) differs by lack of iron incorporation into hemoglobin so that there is a low MCV, 
anisocytosis, and a low RBC count so that the ratio (Mentzer’s index) of the MCV/RBC is 
very low with thalassemia, but not in IDA. We shall elaborate more on the creation of an 
evidence-based inference-engine that can substantially interpret the data at hand and 
convert it in real time to a “knowledge-based opinion”, which is improvable from what 
exists today by incorporating clinical features and duration of onset into the model. 
The evaluation of platelet abnormalities is somewhat more limited, but addresses the 
disorders of platelet numbers and of platelet size, and clumping. This does not discern 
abnormalities of platelet function (like von Willebrands, or drug induced). When platelets 
decrease abruptly with disseminated intravascular coagulation (DIC), as in sepsis or with 
massive trauma, the evidence is pretty good.  
6.1 Hematopoiesis 
Figure 1 is a pictorial diagram of hematopoietic cell lineages that are readily found in texts 
and cells are delineated further by identification of cell differentiation (CD) antigens. This 
lineage is expressly important for both the innate response and the humoral response to 
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injury. Our knowledge of the innate response has become more and more intimately 
associated with long term metabolic effects, constitution, and chronic inflammation.  
 
Fig. 1. A common depiction of the evolution of the myeloid and lymphoid cell lines from a 
multipotential hematopoietic stem cell. The platelets, red blood cells, mast cells and myeloid 
series are depicted as derived from a common myeloid progenitor cell. A branching from 
the myeloblast gives the granulocytic cells and the monocyte. Promyelocyte, metamyelocyte 
and myelocyte are intermediates not shown (band neutrophil is viewed as a neutrophil). 
The lymphocyte series is being more defined (as the myelocytic) that the naïve depiction by 
cell differentiation (CD) markers, and interactions are being investigated by cytokine, 
chemokine and cell signaling pathways. 
Figure 1 shows a primary separation into a lymphocytic and a myeloid series. Note that the 
erythrocyte series and platelets are shown to be in lineage from a myeloid progenitor cell. It 
is conceivable that this picture is an oversimplification, but in clinical application, it is 
readily understood. This makes sense with respect to the uncommon evolution of myeloid 
metaplasia into erythroleukemia, but the diagram doesn’t have an obvious connection for 
myelofibrosis, except for in the monocyte-macrophage linkage.  
6.2 Peripheral smear 
The peripheral smear is only viewed on the basis of flagged features seen on the hemogram. 
Blasts, indicative of release of very immature lymphocytes or myeloblasts are flagged and 
have to be reviewed by a pathologist before release, or done by the hematology supervisor 
and retained for pathologist review. In the case of children, there are numerous 
lymphocytes, and there may also be normoblasts and reticulocytes released from an active 
marrow. The presence of small mononuclear cells can be correctly identified by an 
experienced morphologist, but not necessarily by an automated cell counter. Consequently, 
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proportionately more peripheral smears are evaluated for children than for adults. The 
greatest problem in the childhood age group is infection or sepsis. The lymphocyte and 
reticulocyte counts are very high in the infant, and the peak age for acute lymphocytic 
leukemia is at two years old. This makes it far more difficult to identify myelocytes and 
metamyelocytes (not shown in Figure 1), indicators of myeloid proliferation, in children 
than adults (33). The band neutrophil has been used to signify a left shift in myelopoiesis 
associated with sepsis, but it is quite variable and has been largely disregarded. This has 
accounted for the use of an automated cell counter that is also a flow cytometer for 
improved recognition of immature neutrophils below the band count. In the case of the red 
cell series (not shown) we classify first based on the RBC count, and then on the cell size. By 
these measures we have a decrease in mature red cell count based on WHO standards, 
adjusting for menstruation and pregnancy in women. We at the same time consider whether 
the RBC is normocytic, microcytic, or macrocytic and/or megaloblastic. What about 
increased or decreased production? Thalassemia is characterized by small cells that are 
neither hypochromic, or decreased in the peripheral circulation. Platelets may be large, they 
may be excessive in number, or they may be significantly decreased.  
7. Extension of conditions and presentation to the electronic medical record 
(EMR) 
We have published on the application of an automated inference engine (34) to the Systemic 
Inflammatory Response (SIRS), a serious infection, or emerging sepsis. We can report on this 
without going over previous ground. Of considerable interest is the morbidity and mortality of 
sepsis, and the hospital costs from a late diagnosis. If missed early, it could be problematic, 
and it could be seen as a hospital complication when it is not. Improving on previous work, we 
have the opportunity to look at the contribution of a fluorescence labeled flow cytometric 
measurement of the immature granulocytes (IG)(35), which is now widely used, but has not 
been adequatedly evaluated from the perspective of diagnostic usage. We have done 
considerable work on protein-energy malnutrition (PEM)(36-38), to which the automated 
interpretation is currently in review (39). Of course, the cholesterol, lymphocyte count, serum 
albumin provide the weight of evidence with the primary diagnosis (emphysema, chronic 
renal disease, eating disorder), and transthyretin would be low and remain low for a week in 
critical care. This could be a modifier with age in providing discriminating power. 
7.1 Design of EMR 
The current design of the Electronic Medical Record (EMR) is a linear presentation of portions 
of the record by services, by diagnostic method, and by date, to cite examples. This allows 
perusal through a graphical user interface (GUI) that partitions the information or necessary 
reports in a workstation entered by keying to icons. This requires that the medical practitioner 
finds the history, medications, laboratory reports, cardiac imaging and EKGs, and radiology in 
different workspaces. The introduction of a DASHBOARD, a visual panel of essential 
information on the computer screen that is widely used in business organizations, has allowed 
a presentation of drug reactions, allergies, primary and secondary diagnoses, and critical 
information about any patient the care giver needing access to the record. The advantage of 
this innovation is obvious. The startup problem is what information is presented and how it is 
displayed, which is a source of variability and a key to its success. 
 




We are proposing an innovation that supercedes the main design elements of a 
DASHBOARD and utilizes the conjoined syndromic features of the disparate data elements. 
So the important determinant of the success of this endeavor is that it facilitates both the 
workflow and the decision-making process with a reduction of medical error. This has 
become extremely important and urgent in the 10 years since the publication “To Err is 
Human” (40), and the newly published finding that reduction of error is as elusive as 
reduction in cost. Whether they are counterproductive when approached in the wrong way 
may be subject to debate. 
7.3 Syndromic classification  
In order to clarify the concept of syndromic classification we make a distinction between 
lists of diseases that are assigned to abnormal test results and can be appended to test 
results. The oldest application has been in the identification of bacteria after culture isolation 
using growth in defined media that identify genetically determined metabolic pathways 
characteristic for each organism. A solid foundation in this work was elaborated by Rypka 
(18, 19). This was made less complicated by the genetic complement that defines its function. 
We introduce an AUTOMATED inference engine processing the data and making an 
interpretation available to the ordering physician and can anticipate an enormous impact on 
diagnosis and treatment. It addresses the complexity of inputs and enables rather than 
disables the practitioner. The method identifies outliers and combines data according to 
commonality of features. In some cases there may be conditions that are aggregated by 
similarity and dissimilarity into variants of the same condition with different treatment 
responses. How can we have confidence that we can successfully approach this problem in a 
new way? In the first place we are able to construct an interpretation of the composite data 
that is consistent with how a practitioner views multisystem pathophysiology in service of 
clinical decision-making.  
8. A new inference methodology identifies and classifies anomalies 
The main mathematical breakthroughs are provided by accurate patient profiling and 
inference methodologies in which anomalous subprofiles are extracted and compared to 
potentially relevant cases. Our methodologies organize numerical medical data profiles into 
demographics and characteristics relevant for inference and case tracking. As the model 
grows and its knowledge database is extended, the diagnostic and the prognostic become 
more accurate and precise. 
As an example, inputs from test data such as hematology results are processed for anomaly 
characterization and compared with similar anomalies in a data base of 30,000 patients, 
provide diagnostic statistics, warning flags, and risk assessment. These are based on past 
prior experience, including: diagnostics and treatment outcomes (collective experience). The 
system was trained on this database of patients, built the learning knowledge base and used 
to analysis and diagnosis 5,000 new patients. Our system identified successfully the  
main risks with very high accuracy (more than 96%) and very low false rate (less than 
0.5%)(34). 
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9. Representation and conclusion 
The main benefit is a real time assessment as well as diagnostic options based on 
comparable cases, flags for risk and potential problems as illustrated in Figure 2. Figure 2 
depicts the following case acquired on 04/21/10. The patient was diagnosed by our system 
with severe SIRS. 
 
Fig. 2. The depiction of a patient diagnosed with severe systemic inflammatory response 
syndrome (SIRS), which may evolve into multiple organ failure (MODS), and death by 
circulatory collapse (systemic shock) if not arrested, depending on systemic functional 
reserve and successive stress. The far right is a pie chart of measured effects, and primary 
and secondary diagnoses. The middle lists the diagnoses found above which there is a scale 
with the risk. The left is patient demographics.  
We anticipate that the effect of implementing this diagnostic amplifier would result in 
higher physician productivity at a time of great human resource limitations, safer 
prescribing practices, rapid identification of unusual patients, better assignment of patients 
to observation, inpatient beds, intensive care, or referral to clinic, shortened length of 
patients ICU and bed days. 
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1. Introduction  
Spleen, as a part of hematopoietic and immune system, plays an important role in the life 
cycle of blood cells. There are three major functions of the spleen and these are handled by 
three different tissues within the spleen. Reticuloendothelial tissue is responsible for 
removing old or damaged erythrocytes and cell debris from the blood stream. This same 
tissue may participate in hematopoiesis when there is an increased need for red blood cells 
and is a place where young erythrocytes produced in bone marrow undergo the process of 
maturation before releasing into the blood stream. Venous sinusoids along with the ability 
of the spleen to contract, provides a means for expelling the contained blood to meet 
increased circulatory demands in certain animals. White pulp provides lymphocytes and a 
source of plasma cells and hence antibodies for the cellular and humoral specific immune 
defenses (Dyce et al., 2002; Teske, 2000). 
Splenectomy is a surgical removal of the spleen that may be carried out in patients whose 
spleen has been ruptured by trauma or damaged by other pathological processes such as 
cancer, infections or some autoimmune diseases (Tillson, 2003). However, total removal of 
the spleen may lead to side effects such as postsplenectomy infections and sepsis, due to the 
decreased production of antibodies and phagocytes or thrombosis, due to elevated platelet 
count in blood (Bessler et al., 2004; Khan et al., 2009; Miko et al., 2003; Timens & Leemans, 
1992). Also, many studies report increased count of morphologically abnormal erythrocytes, 
immature red blood cells and pathologic erythrocyte inclusions in the peripheral blood of 
various species following splenectomy as a result of the loss of splenic filtrating function 
(Haklar et al., 1997; Resende et al., 2002; Traub et al., 1987). In addition, it has been reported 
that removal of the spleen causes significantly higher increase of reticulocyte count than 
other surgeries. This suggests that spleen may somehow hormonally regulate the release of 
red blood cells into circulation, thus after removal of spleen bone marrow releases more red 
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1. Introduction  
Spleen, as a part of hematopoietic and immune system, plays an important role in the life 
cycle of blood cells. There are three major functions of the spleen and these are handled by 
three different tissues within the spleen. Reticuloendothelial tissue is responsible for 
removing old or damaged erythrocytes and cell debris from the blood stream. This same 
tissue may participate in hematopoiesis when there is an increased need for red blood cells 
and is a place where young erythrocytes produced in bone marrow undergo the process of 
maturation before releasing into the blood stream. Venous sinusoids along with the ability 
of the spleen to contract, provides a means for expelling the contained blood to meet 
increased circulatory demands in certain animals. White pulp provides lymphocytes and a 
source of plasma cells and hence antibodies for the cellular and humoral specific immune 
defenses (Dyce et al., 2002; Teske, 2000). 
Splenectomy is a surgical removal of the spleen that may be carried out in patients whose 
spleen has been ruptured by trauma or damaged by other pathological processes such as 
cancer, infections or some autoimmune diseases (Tillson, 2003). However, total removal of 
the spleen may lead to side effects such as postsplenectomy infections and sepsis, due to the 
decreased production of antibodies and phagocytes or thrombosis, due to elevated platelet 
count in blood (Bessler et al., 2004; Khan et al., 2009; Miko et al., 2003; Timens & Leemans, 
1992). Also, many studies report increased count of morphologically abnormal erythrocytes, 
immature red blood cells and pathologic erythrocyte inclusions in the peripheral blood of 
various species following splenectomy as a result of the loss of splenic filtrating function 
(Haklar et al., 1997; Resende et al., 2002; Traub et al., 1987). In addition, it has been reported 
that removal of the spleen causes significantly higher increase of reticulocyte count than 
other surgeries. This suggests that spleen may somehow hormonally regulate the release of 
red blood cells into circulation, thus after removal of spleen bone marrow releases more red 
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blood cells as well as more immature erythrocytes into the blood stream (Knežević et al., 
2002; Lorber, 1958). Splenectomy also causes changes in number of white blood cells with 
subsequent leukocytosis (Bessler et al., 2004; Karagülle et al., 2007). Initial transient 
neutrophilia is followed by the persistent lymphocytosis and monocytosis. Increased 
leukocytosis accompanied by the significant left shift is found in patients, and often there 
are myelocytes or other precursor in the granulocytic series in their peripheral blood (Labar 
& Hauptmann, 1998; Tang et al., 2003; Zhang et al., 2002). 
Severe postoperative infections after removal of the spleen prompted a development of 
alternative methods to conserve functions of the spleen. Autologous spleen transplantation 
is a method of choice after total splenectomy in order to preserve splenic immune and 
hematopoietic functions (Marques et al., 2003; Patel et al., 1981). The effectiveness of splenic 
autotransplant depends on many factors and is still controversial (Theodorou et al., 2007). 
Studies done on rats, mice, rabbits and men report that autotransplantat's capability of 
recovering its primary function highly depends on the volume of transplanted spleen tissue 
(Karagülle et al., 2007; Miko et al., 2003; Resende & Petroianu, 2003; Tang et al., 2003). 
In the recent years there is a close cooperation between Faculty of Veterinary Medicine and 
Medical faculty in University of Zagreb. Because of close interests that both faculties have, 
combined projects and seminars have been established. One of the best examples was 
education of Medical faculty surgeons for laparoscopic cholecystectomy, liver lobectomy, 
laminectomy, and for experimental wounds surgery on our faculty, in the Clinic for 
Surgery, Orthopedics and Ophthalmology. These operative procedures were carried out on 
pigs because of its similarity in organs size. In recent years, a xenotransplantation of pig 
organs to nonhuman primates is being investigated. In order to prolong survival of primates 
that have received porcine xenografts, the same animals underwent a splenectomy to 
prevent humorally mediated immunological damage (Cozzi et al., 2000). In order to save 
human lives, it is important not only to master the precise surgical technique, but also to 
recognize all the factors that may affect the rejection or return of physiological functions of 
organs after transplantation.  
The aim of this study was to evaluate the effects of total splenectomy and autologous spleen 
transplantation in a porcine model on complete blood count and cell morphology. Also, we 
aimed to determine the functional effectiveness of autotransplanted splenic tissue by its 
capacity to remove erythrocyte having Howell-Yolly bodies from the blood stream. 
2. Materials and methods 
2.1 Animals, anaesthesia and surgery 
The experimental protocol was approved by the Department of Veterinary Science, Ministry 
of Agriculture, Republic of Croatia and was conducted in accordance with the guidelines for 
the treatment of laboratory animals. Nineteen pigs of either sex, aged three months, 
weighing 19-26 kg were used in the experiment. Food was withheld from all the pigs 12 h 
and water 2 h before the experiment. All animals were premedicated with 2 mg/kg i.m. of 
xylazine (Xylapan, Vetoquinol, Bern, Switzerland), and left auricular vein was catheterized 
percutaneously for continuous infusion of lactated Ringer's solution at a rate of 10 ml/kg/h 
(Infusion pump BIOF 3000, Biotron CO, Kangwondo, South Corea) during surgical 
procedures and for the administration of drugs. Anaesthesia was induced with 5 mg/kg i.v. 
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of ketamine (Ketaminol 10, Intervet, Boxmeer, The Netherlands) and 10 µg/kg i.v. fentanyl 
(Fentanyl-Jannsen, Jannsen Pharmaceutica, Beerse, Belgium), and animals were intubated, 
connected to a circle system and maintained on spontaneous ventilation. Anaesthesia was 
maintained with 1.5% isoflurane (Forane, Abbott, Queenborough, UK) and oxygen and 
continuous intravenous infusion of fentanyl in a dose of 0.8 µg/kg/min. Supplemental 
doses of ketamine were applied during surgery to maintain sufficient anaesthesia depth. 
Preoperative antibiotic prophylaxis was administered using 20 mg/kg ampicillin and 
sublactam i.v. (Penactam, Krka, Novo Mesto, Slovenia). 
After anaesthesia induction, animals were randomly divided into three groups: sham-
operated pigs with spleens intact (control group, n=6), splenectomized pigs (n=6), and 
splenectomized pigs with small fragments of 20% mass of the spleen autotransplanted into 
the greater omentum (n=7). 
2.2 Blood sampling and experimental protocol  
Two blood samples of each pig were taken from the v. auricularis lateralis just before surgery 
and on the first, fifth, twelfth and twenty sixth day postoperatively. Exceptionally, blood 
samples for reticulocyte, and differential white blood cell counting were also taken on the 
fortieth postoperative day. First sample was collected into the Vacutainer® tubes containing 
K3EDTA anticoagulant (BD-Vacutainer, Plymouth PL6 7BP UK) and the other was taken 
without anticoagulant and was used to make blood smears. Hematological parameters: red 
blood cell count (RBC), white blood cell count (WBC), hemoglobin concentration (Hgb), 
hematocrit (Htc), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), 
mean corpuscular hemoglobin concentration (MCHC), red blood cell distribution width 
(RDW), platelet count (PLT) and mean platelet volume (MPV) were determined using 
automated blood analyzer (SERONO-9120 Baker System). Reticulocyte counting was done 
on brilliant cresyl blue stained blood smears, and differential leukocyte count and 
morphological changes of blood cells were determined by identifying 200 consecutive 
leukocytes on May Grünwald stained blood smears using immersion objective with 1000x 
enlargement of the light microscope (Olympus BX 41). The frequency of blood cells 
immature precursor, degenerative neutrophils or increased reactive lymphocytes is reported 
as a few (5% to 10%) or moderate (11% to 30%). Similarly, semi quantitative evaluation of 
red blood cell morphology based on average number of abnormal cells per 1000x 
microscopic monolayer field was used to assess morphological changes in erythrocyte 
(Weiss, 1984). 
The results were statistically analyzed by calculating mean values, standard deviation, and 
coefficient of variability, and were presented in tables as the mean values  standard 
deviation. The significance of the differences between the results was verified using the 
Student t-test and Statistica 7.1 computer programme. 
3. Results 
3.1 Red blood cell count (RBC), hemoglobin (Hgb) and hematocrit (Htc) 
Total red blood cell count in sham-operated pigs was significantly decreased only on the 
fifth day postoperatively compared to the value before surgery. In splenectomized pigs red 
blood cell count was significantly lower on the first, fifth, twelfth and twenty sixth day 
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postoperatively compared to the value before surgery. In pigs with autologous splenic 
transplants, red blood cell count was significantly decreased on the fifth and twelfth day 
after surgery compared to the value before surgery. Hemoglobin and hematocrit values in 
sham-operated pigs were significantly decreased on the fifth day postoperatively compared 
to the values before surgery. Splenectomized pigs showed significantly lower values of 
these parameters on the fifth, twelfth and twenty sixth day postoperatively compared to the 
values before surgery. In pigs with splenic autotransplants, hemoglobin and hematocrit 
values were significantly decreased on the first, fifth and twelfth day after surgery 
compared to the values before surgery (Table 1.).  
3.2 Mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean 
corpuscular hemoglobin concentration (MCHC) and red blood cell distribution width 
(RDW) 
There were no statistical differences of mean corpuscular volume value in sham-operated pigs 
before and after surgery. Compared to the value before surgery mean corpuscular volume 
value showed significant raise in splenectomized pigs on the twelfth and twenty sixth day 
postoperatively, and in contrast autotransplanted pigs showed significantly decreased value of 
mean corpuscular volume on the first, fifth and twelfth day postoperatively. There were no 
statistical differences of mean corpuscular hemoglobin value in sham-operated pigs before and 
after surgery while mean corpuscular hemoglobin concentration value was significantly 
higher on the twelfth day after surgery compared to preoperative value. In splenectomized 
pigs significant raise in values of both parameters was noted on the fifth day postoperatively 
when compared to the values of these parameters before surgery. In pigs with splenic 
autotransplants mean corpuscular hemoglobin value was significantly decreased on the first 
and twelfth day after surgery, but the mean corpuscular hemoglobin concentration value was 
significantly raised on the fifth day after surgery when compared to preoperative values. 
There were no noted significant changes of red blood cell distribution width values except in 
sham-operated pigs on the twenty sixth day postoperatively when compared to the same 
value before surgery (Table 1.). 
3.3 Total and differential white blood cell count 
In group with autotransplanted splenic tissue on the fifth postoperative day total white 
blood cell count dropped significantly in comparison with the preoperative value as well as 
in comparison with the value measured in the control group on the same day of experiment. 
After this, on the twelfth and twenty sixth day of the experiment, significant increase of 
white blood cell count in comparison with the preoperative value was noted in all 
experimental groups of pigs (Table 1.). Changes in absolute differential count of segmented 
neutrophils followed the same pattern as those in the total white blood cell count during 
whole experimental period in each of the groups of pigs.  
Compared to the value right before surgery, rise in absolute count of unsegmented 
neutrophils was noted, with significant increase on the first and twelfth day in the control 
group, first and fifth day in splenectomized group and first, twelfth and twenty sixth day in 
group with autotransplanted splenic tissue (Table 2.).  
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Although absolute number of lymphocytes was decreasing postoperatively in all experimental 
groups of pigs, it was significantly decreased only on the fifth day in splenectomized group 
and in this group it remained at low values until the end of experimental period. In contrast, 
on the twelfth postoperative day absolute number of lymphocytes in control and 
autotransplanted group started to rise, even exceeding preoperative levels. 
Relative differential number of monocytes ranged from one to eight percent in all blood 
smears. Still, statistical analysis showed significant decrease of absolute number of 
monocytes on the fifth day after the surgery in control group compared to the value before 
operation and twelfth day after splenectomy compared to the control group of the same 
day. Relative differential number of eosinophils on blood smears ranged from zero to twelve 
percent in all groups. Only statistically significant shift in the absolute number of 
eosinophils occurred on the first day after the surgery in control group compared to values 
before the surgery. Relative number of basophils in all groups ranged from one and three 
percent and statistically significant increase in number was found on the fifth day in the 
group with autotransplanted tissue compared to the values before surgery and control 
group of the same day (Table 2.). 
3.4 Ratio of absolute differential number of neutrophils and lymphocytes (N/L) 
Compared with the preoperative values, significantly elevated neutrophil/lymphocyte ratio 
was recorded in the control group on the first, fifth and twelfth postoperative day. In 
splenectomized pigs significant elevation of neutrophil/lymphocyte ratio in respect to 
preoperative value, as well as in respect to the value of control group on the same day of the 
experiment, appeared on the fifth day postoperatively and it remained on the significantly 
higher values till the end of experimental period. On the twelfth day of the experiment 
significant decrease of neutrophil/lymphocyte ratio in comparison with the sham-operated 
pigs on the same day was reported in group with autotransplanted splenic tissue (Table 3.). 
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postoperatively compared to the value before surgery. In pigs with autologous splenic 
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0.42±0.05 ***0.33±0.03 0.38±0.01 0.30±0.09 
Splenectomy 0.37±0.03+ ***0.30±0.03+ *0.21±0.07+ *0.32±0.04 









57.87±2.33 56.56±1.13 55.7±1.3 59.8±2.66 
Splenectomy 59.04±1.48 58.57±2.54 *69.7±8.58+ *68.67±6.22 









18.63±0.49 18.74±0.28 18.4±0.65 19.85±1.21 
Splenectomy 19.1±0.42 ***19.65±0.57+ 22.13±2.81 23±3.01 










322.67±2.83 330.8±1.41 *330.25±4.11 331.5±5.19 
Splenectomy 323.6±1.41 **335.5±8.19 344.48±13.08 333.33±6.59 










23.2±3.39 22.54±2.83 22.7±2.14 *21.85±0.17 
Splenectomy 23.08±3.54 23.62±3.5 24.48±4.43 23.4±1.17 









509.33±16.26 554±46.67 389.33±19.43 272±125.73 
Splenectomy 400±147.35 534.25±381.81 ***96±25.94+++ 286.33±219.21 








10.8±2.12 10.5±0.21 11.4±1.08 12.6±1.42 
Splenectomy 11.33±0.79 ***11.65±0.87+ *12.63±1.08 10.97±1.37 
Autotransplantation ***12.43±0.42+ ***12.5±0.57++ 12.45±0.92 12.7±1.63 
All values are presented as mean values ± standard deviation. 
Statistical difference with respect to the value before surgery:*P<0.05; **P<0.01; ***P<0.001. 
Statistical difference with respect to the value in sham operated pigs on the same day of experiment: 
+P<0.05; ++P<0.01; +++P<0.001. 
Table 1. White blood cell count (WBC), red blood cell count (RBC), blood hemoglobin 
concentration (Hgb), hematocrit (Htc), mean corpuscular volume (MCV), mean corpuscular 
hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), platelet count 
(PLT), mean platelet volume (MPV) and red blood cell distribution width (RDW) in the 
peripheral blood of observed pigs during the experiment 
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Absolute differential values (109/L) are presented as mean values ± standard deviation  
Relative differential values (%) are presented as mean value, and minimum and maximum values in the 
brackets  
Statistical difference with respect to the value before surgery:*P<0.05; **P<0.01; ***P<0.001. 
Statistical difference with respect to the value in sham operated pigs on the same day of experiment: 
+P<0.05; ++P<0.01; +++P<0.001. 
Table 2. Absolute and relative white blood cell differential count in the peripheral blood of 
observed pigs during the experiment 
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Splenectomy 59.04±1.48 58.57±2.54 *69.7±8.58+ *68.67±6.22 









18.63±0.49 18.74±0.28 18.4±0.65 19.85±1.21 
Splenectomy 19.1±0.42 ***19.65±0.57+ 22.13±2.81 23±3.01 










322.67±2.83 330.8±1.41 *330.25±4.11 331.5±5.19 
Splenectomy 323.6±1.41 **335.5±8.19 344.48±13.08 333.33±6.59 










23.2±3.39 22.54±2.83 22.7±2.14 *21.85±0.17 
Splenectomy 23.08±3.54 23.62±3.5 24.48±4.43 23.4±1.17 









509.33±16.26 554±46.67 389.33±19.43 272±125.73 
Splenectomy 400±147.35 534.25±381.81 ***96±25.94+++ 286.33±219.21 








10.8±2.12 10.5±0.21 11.4±1.08 12.6±1.42 
Splenectomy 11.33±0.79 ***11.65±0.87+ *12.63±1.08 10.97±1.37 
Autotransplantation ***12.43±0.42+ ***12.5±0.57++ 12.45±0.92 12.7±1.63 
All values are presented as mean values ± standard deviation. 
Statistical difference with respect to the value before surgery:*P<0.05; **P<0.01; ***P<0.001. 
Statistical difference with respect to the value in sham operated pigs on the same day of experiment: 
+P<0.05; ++P<0.01; +++P<0.001. 
Table 1. White blood cell count (WBC), red blood cell count (RBC), blood hemoglobin 
concentration (Hgb), hematocrit (Htc), mean corpuscular volume (MCV), mean corpuscular 
hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), platelet count 
(PLT), mean platelet volume (MPV) and red blood cell distribution width (RDW) in the 
peripheral blood of observed pigs during the experiment 
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Absolute differential values (109/L) are presented as mean values ± standard deviation  
Relative differential values (%) are presented as mean value, and minimum and maximum values in the 
brackets  
Statistical difference with respect to the value before surgery:*P<0.05; **P<0.01; ***P<0.001. 
Statistical difference with respect to the value in sham operated pigs on the same day of experiment: 
+P<0.05; ++P<0.01; +++P<0.001. 
Table 2. Absolute and relative white blood cell differential count in the peripheral blood of 
observed pigs during the experiment 
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  N/L ratio 
Day 0 Day 1 Day 5 Day 12 Day 26 
Sham-operation 0.61 *1.39 *1.09 *1.25 0.76 
Splenectomy 0.61 0.83 **1.62+ ***2.13++ *1.18 
Autotransplantation 0.61 0.89 0.45++ 0.93 1.09 
Statistical difference with respect to the value before surgery: *P<0.05; **P<0.01; ***P<0.001. 
Statistical difference with respect to the value in sham operated pigs on the same day of experiment: 
+P<0.05; ++P<0.01; +++P<0.001. 
Table 3. Ratio of absolute differential number of neutrophils and lymphocytes (N/L) in the 
peripheral blood of observed pigs during the experiment 
3.5 Platelet number (PLT) and mean platelet volume (MPV) 
There were no statistical differences in platelet count in sham-operated and 
autotransplanted pigs, while on the twelfth postoperative day platelet count in 
splenectomized pigs was significantly lower in comparison with the platelet count before 
surgery, and to the value in the control group at the same experimental day. There were no 
statistical differences of mean platelet volume value in sham-operated pigs before surgery 
and the value of mean platelet volume on days after surgery. In splenectomized pigs 
significantly higher mean platelet volume value was noted on the fifth and twelfth day 
postoperatively. In autotransplanted pigs statistical differences were noted on the first and 
fifth day after the surgery in comparison with the value before surgery (Table 1.).  
3.6 Reticulocyte count (RTC) 
Prior to surgeries, reticulocyte count in all experimental pigs ranged within 0.5 to 1.5 %. On 
the first postoperative day reticulocyte count was significantly increased (2 to 4 %) when 
compared to the value before surgeries and it continued to grow simultaneously in all 
experimental groups on the fifth (4 to 8 %), twelfth (6 to 8 %) and twenty sixth (6 to 9 %) 
postoperative day. On the fortieth day after the surgery, reticulocyte count continued to 
increase in splenectomized (7 to 16 %) and autotransplanted pigs (7 to 18 %), while at the 
same time it began to decrease in sham-operated pigs (2 to 3 %), although was still 
significantly higher when compared to the preoperative value. Corrected reticulocyte count 
(reticulocyte production index - RPI) is shown in Table 4., and was extremely high on 




Day 0  Day 1 Day 5 Day 12 Day 26 
Sham-operation 0.5 1.2 2.3 3.3 1.1 
Splenectomy 0.5 1.0 2.0 1.8 4.5 
Autotransplantation 0.5 1.0 2.0 1.9 4.0 
Table 4. Reticulocyte production index (RPI) in experimental pigs 
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3.7 Morphological changes of red blood cells 
Polychromasia (the heterogeneous staining of red blood cells), as well as increased number 
of Howell-Jolly bodies (nuclear remnants found in red cells) were present on the blood films 
of all experimental groups, regardless of the surgical procedures, although both of these 
morphological changes were more manifested and frequent in pigs with total splenectomy. 
Five to seven erythrocytes containing Howell-Jolly bodies were found per 1000x microscopic 
monolayer field on the blood smears of splenectomized pigs. Erythroblasts (immature, 
nucleated red cells) sporadically appeared on the blood films of splenectomized pigs and 
pigs with transplanted autologous splenic tissue on all postoperative days. Abnormally 
shaped erythrocytes, such as leptocytes and codocytes, were found only on the blood 
smears of splenectomized pigs from the twelfth to the fortieth postoperative day.  
3.8 Morphological changes of white blood cells 
Neither morphological changes nor precursor cells were found on the blood films of 
experimental pigs prior to surgeries. On the first postoperative day a few (one to three %) 
reactive lymphocytes and a few (two to five %) metamyelocytes were found on each smear of 
control pigs. Similar results were found in the splenectomized group, but number of 
metamyelocytes was higher than in the control group (three to five %). Results found in group 
with autotransplanted tissue were almost identical to those in splenectomized group of pigs. 
On the fifth day after the surgery reactive lymphocytes were found at only one blood smear 
from the control group, but blood smears of other two groups contained averagely three to 
four reactive lymphocytes. Splenectomized group had the largest number of 
metamyelocytes (four to six %), and also contained dividing cells, while in the group with 
autotransplanted tissue number of metamyelocytes was smaller (two to five %).  
On the twelfth day after the surgery reactive lymphocytes became rarer, and were found 
only on one smear of splenectomized group, but still on almost all smears (one to two %) in 
the group with autotransplanted tissue. Metamyelocytes appeared sporadically on the blood 
smears of each experimental group. Twenty-six days after surgeries reactive lymphocytes 
were no longer noted on blood smears, and number of found metamyelocytes was 
decreasing until the fortieth postoperative day when they completely disappeared. 
4. Discussion 
4.1 Hematocrit, hemoglobin and erythrocyte count 
Sham operated pigs exhibited the fastest recovery of hematologic values after surgery. 
Although red blood cell values of autotransplanted group were significantly lower when 
compared to sham operated pigs, postoperative blood regeneration took less time than in 
splenectomized pigs. In contrast to other two surgical procedures, total splenectomy 
resulted in a greater decrease of red blood cell values, even below physiological values 
(according to Jain (1993)), which persisted for a longer period (Diagram 1.). Hemoglobin and 
hematocrit values changed codependently with the changes of red blood cell count in all 
experimental groups on all postoperative days (Diagram 2., 3.). Postoperative 
oligocythemia, followed by decrease of hemoglobin and hematocrit, as the result of blood 
 
Hematology – Science and Practice 
 
560 
  N/L ratio 
Day 0 Day 1 Day 5 Day 12 Day 26 
Sham-operation 0.61 *1.39 *1.09 *1.25 0.76 
Splenectomy 0.61 0.83 **1.62+ ***2.13++ *1.18 
Autotransplantation 0.61 0.89 0.45++ 0.93 1.09 
Statistical difference with respect to the value before surgery: *P<0.05; **P<0.01; ***P<0.001. 
Statistical difference with respect to the value in sham operated pigs on the same day of experiment: 
+P<0.05; ++P<0.01; +++P<0.001. 
Table 3. Ratio of absolute differential number of neutrophils and lymphocytes (N/L) in the 
peripheral blood of observed pigs during the experiment 
3.5 Platelet number (PLT) and mean platelet volume (MPV) 
There were no statistical differences in platelet count in sham-operated and 
autotransplanted pigs, while on the twelfth postoperative day platelet count in 
splenectomized pigs was significantly lower in comparison with the platelet count before 
surgery, and to the value in the control group at the same experimental day. There were no 
statistical differences of mean platelet volume value in sham-operated pigs before surgery 
and the value of mean platelet volume on days after surgery. In splenectomized pigs 
significantly higher mean platelet volume value was noted on the fifth and twelfth day 
postoperatively. In autotransplanted pigs statistical differences were noted on the first and 
fifth day after the surgery in comparison with the value before surgery (Table 1.).  
3.6 Reticulocyte count (RTC) 
Prior to surgeries, reticulocyte count in all experimental pigs ranged within 0.5 to 1.5 %. On 
the first postoperative day reticulocyte count was significantly increased (2 to 4 %) when 
compared to the value before surgeries and it continued to grow simultaneously in all 
experimental groups on the fifth (4 to 8 %), twelfth (6 to 8 %) and twenty sixth (6 to 9 %) 
postoperative day. On the fortieth day after the surgery, reticulocyte count continued to 
increase in splenectomized (7 to 16 %) and autotransplanted pigs (7 to 18 %), while at the 
same time it began to decrease in sham-operated pigs (2 to 3 %), although was still 
significantly higher when compared to the preoperative value. Corrected reticulocyte count 
(reticulocyte production index - RPI) is shown in Table 4., and was extremely high on 




Day 0  Day 1 Day 5 Day 12 Day 26 
Sham-operation 0.5 1.2 2.3 3.3 1.1 
Splenectomy 0.5 1.0 2.0 1.8 4.5 
Autotransplantation 0.5 1.0 2.0 1.9 4.0 
Table 4. Reticulocyte production index (RPI) in experimental pigs 
The Effects of Splenectomy and Autologous  
Spleen Transplantation on Complete Blood Count and Cell Morphology in a Porcine Model 
 
561 
3.7 Morphological changes of red blood cells 
Polychromasia (the heterogeneous staining of red blood cells), as well as increased number 
of Howell-Jolly bodies (nuclear remnants found in red cells) were present on the blood films 
of all experimental groups, regardless of the surgical procedures, although both of these 
morphological changes were more manifested and frequent in pigs with total splenectomy. 
Five to seven erythrocytes containing Howell-Jolly bodies were found per 1000x microscopic 
monolayer field on the blood smears of splenectomized pigs. Erythroblasts (immature, 
nucleated red cells) sporadically appeared on the blood films of splenectomized pigs and 
pigs with transplanted autologous splenic tissue on all postoperative days. Abnormally 
shaped erythrocytes, such as leptocytes and codocytes, were found only on the blood 
smears of splenectomized pigs from the twelfth to the fortieth postoperative day.  
3.8 Morphological changes of white blood cells 
Neither morphological changes nor precursor cells were found on the blood films of 
experimental pigs prior to surgeries. On the first postoperative day a few (one to three %) 
reactive lymphocytes and a few (two to five %) metamyelocytes were found on each smear of 
control pigs. Similar results were found in the splenectomized group, but number of 
metamyelocytes was higher than in the control group (three to five %). Results found in group 
with autotransplanted tissue were almost identical to those in splenectomized group of pigs. 
On the fifth day after the surgery reactive lymphocytes were found at only one blood smear 
from the control group, but blood smears of other two groups contained averagely three to 
four reactive lymphocytes. Splenectomized group had the largest number of 
metamyelocytes (four to six %), and also contained dividing cells, while in the group with 
autotransplanted tissue number of metamyelocytes was smaller (two to five %).  
On the twelfth day after the surgery reactive lymphocytes became rarer, and were found 
only on one smear of splenectomized group, but still on almost all smears (one to two %) in 
the group with autotransplanted tissue. Metamyelocytes appeared sporadically on the blood 
smears of each experimental group. Twenty-six days after surgeries reactive lymphocytes 
were no longer noted on blood smears, and number of found metamyelocytes was 
decreasing until the fortieth postoperative day when they completely disappeared. 
4. Discussion 
4.1 Hematocrit, hemoglobin and erythrocyte count 
Sham operated pigs exhibited the fastest recovery of hematologic values after surgery. 
Although red blood cell values of autotransplanted group were significantly lower when 
compared to sham operated pigs, postoperative blood regeneration took less time than in 
splenectomized pigs. In contrast to other two surgical procedures, total splenectomy 
resulted in a greater decrease of red blood cell values, even below physiological values 
(according to Jain (1993)), which persisted for a longer period (Diagram 1.). Hemoglobin and 
hematocrit values changed codependently with the changes of red blood cell count in all 
experimental groups on all postoperative days (Diagram 2., 3.). Postoperative 
oligocythemia, followed by decrease of hemoglobin and hematocrit, as the result of blood 
 
Hematology – Science and Practice 
 
562 
loss is a very well known founding. Durance of postoperative blood regeneration depends 
on many factors (e.g. degree of tissue lesion and trauma, blood loss and availability of 
hematopoiesis activating substances). The significant decrease of erythrocyte values and 
long postoperative recovery after total splenectomy and autotransplantation of splenic 
tissue have been documented in mice (Sipka et al., 2006), dogs (Lorber, 1958) and humans 
(Knežević et al., 2002). Results of this study suggest that observed decrease of erythrocyte 
values and postoperative recovery in each experimental group were in accordance with 
severity of surgical traumas (sham-operation, splenectomy and transplantation of 



















































Diagram 2. Changes in blood hemoglobin concentration of experimental pigs during the 
experiment 
The Effects of Splenectomy and Autologous  
























Diagram 3. Changes in hematocrit level in the blood of experimental pigs during the 
experiment 
4.2 Mean corpuscular volume, mean corpuscular hemoglobin and mean corpuscular 
hemoglobin concentration  
As previous experiments report, splenectomized patients of different species have higher 
mean corpuscular volume values than autotransplanted and sham-operated patients 
(Knežević at al., 2002, Lorber, 1958). The aging erythrocytes undergo changes in their 
plasma membrane which make them retain the fluid inside the cell, thus aged erythrocytes 
have higher mean corpuscular volume values. Total splenectomy leads to increased number 
of circulating old red blood cells. This, combined with significant reticulocytosis, led to high 
mean corpuscular volume values of splenectomized pigs in this study (Diagram 4.). Lower 
postoperative value of mean corpuscular volume in autotransplanted pigs was expected as 
the result of significantly lower concentration of hemoglobin. Surgical trauma and blood 
loss led to inadequate iron supply for the developing erythroblasts and consequently to 
limited hemoglobin synthesis. The red blood cell membrane shrinks to fit its hemoglobin 
content, thus volume of the cell decreases. 
4.3 Total and differential white blood cell count 
Leukocytosis, characterized by neutrophilia, initial lymphocytopenia and later recovery of 
lymphocyte count, was recorded postoperatively in all experimental groups (Diagram 5., 6., 
7.).  Increase in total leukocyte count after splenectomy and autotransplantation of splenic 
tissue as well as persistent leukocytosis are main characteristics of white blood cell count in 
mice (Bessler et al., 2004), rabbits (Karagülle et al., 2007) and humans (Zhang et al., 2002). 
However, in present study the differences in the degree of leukocytosis among the groups 
were not detected, except on the fifth postoperative day when a significant decline in the 
total number of leukocytes in pigs with a transplanted tissue was established compared to 
the control group at the same day of the experiment. Therefore, present leukocytosis has not 
been regarded as a change specific for splenectomy or autotransplantation rather than a 
post-injury inflammatory response due to tissue lesions during operation. 
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Diagram 4. Changes in erythrocyte mean corpuscular level of experimental pigs during the 
experiment 
Due to differential leukocyte count in various species following splenectomy diverse reports 
were published. Some authors find an increase neutrophil and lymphocyte count Tarnuzi & 
Smiley (1967), other significantly higher lymphocyte count while neutrophil count remained 
unchanged (Bessler at al., 2004). Opposite to that, Sipka at al. (2006) found a significant 
increase in neutrophil count while lymphocyte count remained unchanged. However, some 
researches found none significant changes in differential neutrophil and lymphocyte count 
in blood after splenectomy or autotransplantation of splenic tissue (Resende & Petroianu, 
2003; Shokouh-Amiri at al., 1990). In present study there does not seem to be a unique form 
of changes in differential blood count after splenectomy and autotransplantation of the 
spleen so we can conclude that the pattern of recorded changes in each experimental group 
corresponded with the degree of immune response of circulating white blood cells and 



























Diagram 5. Changes in total leukocyte count in the blood of experimental pigs during the 
experiment 
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Diagram 7. Changes in absolute lymphocyte number in the blood of experimental pigs 































Diagram 8. Changes in absolute band neutrophil number in the blood of experimental pigs 
during the experiment 
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Diagram 5. Changes in total leukocyte count in the blood of experimental pigs during the 
experiment 
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Diagram 7. Changes in absolute lymphocyte number in the blood of experimental pigs 































Diagram 8. Changes in absolute band neutrophil number in the blood of experimental pigs 
during the experiment 
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Apart from changes found in absolute neutrophil count, there were also changes in number 
of band neutrophils. Before the surgeries, relative band neutrophil count found on blood 
smears was 2.6 % in average. Compared to that value, it was evident that amount of band 
neutrophil increased during postoperative period in all groups. The largest increase was 
found in group of splenectomized pigs, where up to 28 % band neutrophils per smear were 
found (Diagram 8.). Increased number of band neutrophils, subsequent with findings of 
granulocyte precursors and dividing cells, suggest an increased bone marrow activity and 
release of immature cells, as well as their mobilization from the marginal pool. 
4.4 Ratio of absolute differential number of neutrophils and lymphocytes  
As it is well known, significant neutrophilia and lymphocytopenia occur as an immediate 
immune response following multiple traumas, surgical procedures, endotoxemia and sepsis. 
Since duration, pattern and degree of this immune response highly depend on the 
extensiveness and severity of surgical procedure, ratio of neutrophils and lymphocytes 
(N/L) can be considered as a reliable indicator of the immune response progress (Zahorec, 
2001). Although both, sham-operated and splenectomized group of pigs in our study had 
significant postoperative increases in neutrophil/lymphocyte ratio (Diagram 9.), the change 
was more pronounced in splenectomized group indicating that splenectomy imposed 
greater stress on the organism than sham operation. The lowest value of 
neutrophil/lymphocyte ratio during the research was recorded on the fifth postoperative 
day in the group of autotransplanted piglets. Described decrease came as a result of 
concurrent lymphocytopenia and neutropenia on the fifth day of the experiment in the 













Diagram 9. Changes in ratio of absolute number of segmented neutrophils and lymphocytes 
(N/L) in the blood of experimental pigs during the experiment 
4.5 Platelets  
Diverse reports on the platelet level in various species following splenectomy have been 
published. The response has been reported to be either unchanged (Resende & Petroianu, 
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2003; Resende et al., 2002) or increased (Karagülle et al., 2007; Knežević et al., 2002; Miko et 
al., 2003). As one third of total platelets is physiologically sequestered in the spleen, and 
spleen is also the site of platelet destruction, it is expected, that after their removal, 
thrombocytosis will develop. In contrast, this study demonstrates significant decrease of 
platelet number in splenectomized animals (Diagram 10.). As documented, total 
splenectomy leads to decreased number of T-lymphocytes (Smith et al., 1999; Westermann & 
Pabst, 1986) which are essential factors in the production of platelets (Mazur, 1987), so we 
can conclude that this could be the reason of thrombocytopenia that has shortly occurred in 




















Diagram 10. Changes in platelet count in the blood of experimental pigs during the 
experiment 
4.6 Reticulocytes 
Usually, the degree of reticulocytosis is related to the magnitude of hemorrhage during the 
surgery. Also, many studies report that reticulocytosis following splenectomy is more 
significant than following other surgical procedures (Knežević et al., 2002; Miko et al., 2003). 
All experimental groups in this study had the same rate of reticulocytosis growth until 
twenty sixth day after surgeries when accelerated recovery from acute postoperative anemia 
was observed in the control group of pigs, suggesting that the least blood loss and surgical 
trauma occurred during the sham operation (Diagram 11.). In contrast, number of 
reticulocytes in the pheripheral blood of splenectomized and autotransplanted pigs 
continued to grow on the twenty sixth and fortieth postoperative day as the result of 
inadequate blood filtration and prolonged life span of reticulocytes, as well as the loss of 
splenic humoral control mechanism responsible for releasing young red blood cells into the 
blood stream. Because of the different intensity of anemia determined in the experimental 
pig groups, the reticulocyte production index was calculated to avoid erroneously elevated 
reticulocyte count (Table 4.). On the first postoperative day reticulocyte production index 1 
in all three groups of pigs showed insufficient response of bone marrow to compensate 
postoperative anemia. From fifth to twelfth postoperative day reticulocyte production index 
in splenectomized and autotransplanted pigs was increased, but still insufficient for 
compensation of anemia. At the same time, higher reticulocyte production index (over 3) in 
control group was matched with recovery of red blood cell count. On the twenty sixth 
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reticulocyte count (Table 4.). On the first postoperative day reticulocyte production index 1 
in all three groups of pigs showed insufficient response of bone marrow to compensate 
postoperative anemia. From fifth to twelfth postoperative day reticulocyte production index 
in splenectomized and autotransplanted pigs was increased, but still insufficient for 
compensation of anemia. At the same time, higher reticulocyte production index (over 3) in 
control group was matched with recovery of red blood cell count. On the twenty sixth 
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postoperative day, data indicates extremely high values of reticulocyte production index in 
splenectomized and autotransplanted pigs, but that was probably due to increased 
reticulocyte production in bone marrow, and inadequate blood filtration and prolonged life 



















Diagram 11. Average percentage of reticulocytes in the peripheral blood of observed pigs 
during the experiment 
4.7 Erythrocyte morphology 
The main developments found in this study were the creation of leptocytes and codocytes 
and increased number of Howell-Jolly bodies in the peripheral blood of splenectomized pigs 
(Picture 1.). This founding is in accordance with the results of previous studies on various 
species, so we can conclude these changes were specific for splenectomized patients. Some 
authors use the number of erythrocytes containing Howell-Jolly bodies to assess 
preservation of spleen’s blood filtering function (Patel et al., 1981; Resende & Petroianu, 
2003; Resende et al., 2002), but number of oxidatively modified erythrocytes containing 
Heinz bodies can also be used for that purpose (Haklar et al., 1997). Polychromasia and 
increased number of circulating erythroblasts (Picture 2.) came as a side effect of significant 
reticulocytosis in all experimental groups. More frequent occurance of morphologically 
abnormal red blood cells on the blood films of autotransplanted pigs when compared with 
sham-operated pigs suggests that the autologous splenic tissue was not able to filtrate the 
blood effectively. 
There is still controversy about the effectiveness of regenerated splenic tissue, but the one 
conclusion of all researches done is common, that functionality and histological restitution 
of the transplanted splenic tissue depends on the amount of successfully transplanted mass 
of spleen (Haklar et al., 1997; Sipka, et al., 2006; Tang et al., 2003). In the present research the 
implant in overall amount of 20 % has not been enough for keeping filtration function of 
healthy spleen, which correlates with researches from Tang et al. (2003), who find that 
architecture of red and white pulp, as well as restitution of cardiovascular system is not 
sufficient for another seven months after transplantation.  
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Picture 1. Erythrocyte containing Howell-Jolly bodies, leptocyte and codocytes 
           
Picture 2. Polychromatophyl, reticulocyte and acydofile erythroblast 
4.8 Morphological changes of white blood cells 
On the first and fifth day of the experiment morphological evaluation of white blood cells 
revealed the presence of reactive, granulated and cytotoxic lymphocytes on the blood films 
of all experimental groups (Picture 3.). After this, morphologically altered lymphocytes 
appeared only on the twelfth postoperative day on the blood smears of pigs with 
autotransplanted splenic tissue. Most likely, in this case, inflammatory cascade and 
production of cytokines were triggered as a response to extensive tissue lesions following 
autotransplantation, thus leading to the greater number of morphologically altered 
lymphocytes in the peripheral blood. Metamyelocytes, and dividing cells appeared  
           
Picture 3. Reactive lymphocytes  
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Picture 4. Metamyelocyte, band neutrophils and band eozynophil 
sporadically in the peripheral blood of all experimental animals until the twelfth  day, but 
they were most commonly found on the blood smears of splenectomized piglets, with the 
highest frequency on the fifth day of the experiment (Picture 4.). These results correspond 
with those reported in splenectomized human patients (Labar & Hauptman, 1998).  
5. Conclusion 
All groups showed leukocytosis following the operation but this was not regarded as a change 
specific for splenectomy or autotransplantation, rather than a post-injury inflammatory 
response due to tissue lesions during operation. Increased number of band neutrophils, 
subsequent with findings of granulocyte precursors and dividing cells, suggest an increased 
bone marrow activity and release of immature cells, as well as their mobilization from the 
marginal pool. Anemia and reticulocytosis found in blood samples of all three groups of pigs 
may have been physiological results showing the classical postoperative organism reaction to 
blood loss and surgical trauma. On the other side, frequenter appearance of variations in red 
blood cell morphology such as appearance of leptocytes, codocytes and Howell-Jolly bodies on 
the blood smears of splenectomized pigs when compared with other two experimental groups 
suggests that this was a change specific for splenectomy. More frequent occurance of 
morphologically abnormal red blood cells on the blood films of autotransplanted pigs 
compared with sham-operated pigs suggests that the autologous spleen tissue was not able to 
filtrate the blood effectively. The mass of implant in overall amount of 20% has not been 
sufficient for keeping filtration function of healthy spleen, therefore should the amount of 
transplanted mass of spleen be increased.    
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1. Introduction   
Cellular components of the blood reflect specific changes in an organ or body system or 
more often, a general response of the individual to some physiological or pathological 
conditions. In this chapter, we will review the main physiological factors that should be 
considered when interpreting equine hematological profiles. The interpretation of the 
hematological profile in conjunction with history and physical findings directs the clinician 
in the selection of other diagnostic, imaging and sampling techniques. Additionally, a 
hematological profile provides invaluable information concerning the severity of the disease 
and the response to a treatment, and it helps in establishing a prognosis. Further, horses can 
have different hematological disorders, making hematology important in equine medicine. 
A special consideration should be made for equine athletes, since the assessment of a 
hematological profile is pivotal in the diagnosis of a reduced performance.  
2. Erythron 
2.1 Introduction and specific characteristics of the equine erythrocytes 
The term erythron refers to red cell precursors, the tissues in which production takes place 
and mature erythrocytes themselves and its functional unit, the red blood cell (RBC). The 
erythron is assessed from peripheral blood samples, by calculating the number of circulating 
RBC, hemoglobin concentration (HB), packed cell volume (PCV), volumetric indices, such as 
mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) and mean 
corpuscular hemoglobin concentration (MCHC), a morphological examination at 
microscopic level (Messer, 1995; Kramer, 2000) and sometimes, examination of the bone 
marrow (Lording, 2008). When interpreting an equine hematological profile, some specific 
characteristics of this species should be kept in mind.  
PCV unstable. The horse is somewhat unique compared to most other mammalians in that 
the spleen is a very capacious organ, storing between 6 and 12 L of red-cell-rich blood at rest 
(Persson, 1967; McKeever et al., 1993). Large numbers of RBCs temporally sequestered in the 
spleen can be rapidly transferred into the circulation in response to excitement (handling, 
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1. Introduction   
Cellular components of the blood reflect specific changes in an organ or body system or 
more often, a general response of the individual to some physiological or pathological 
conditions. In this chapter, we will review the main physiological factors that should be 
considered when interpreting equine hematological profiles. The interpretation of the 
hematological profile in conjunction with history and physical findings directs the clinician 
in the selection of other diagnostic, imaging and sampling techniques. Additionally, a 
hematological profile provides invaluable information concerning the severity of the disease 
and the response to a treatment, and it helps in establishing a prognosis. Further, horses can 
have different hematological disorders, making hematology important in equine medicine. 
A special consideration should be made for equine athletes, since the assessment of a 
hematological profile is pivotal in the diagnosis of a reduced performance.  
2. Erythron 
2.1 Introduction and specific characteristics of the equine erythrocytes 
The term erythron refers to red cell precursors, the tissues in which production takes place 
and mature erythrocytes themselves and its functional unit, the red blood cell (RBC). The 
erythron is assessed from peripheral blood samples, by calculating the number of circulating 
RBC, hemoglobin concentration (HB), packed cell volume (PCV), volumetric indices, such as 
mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) and mean 
corpuscular hemoglobin concentration (MCHC), a morphological examination at 
microscopic level (Messer, 1995; Kramer, 2000) and sometimes, examination of the bone 
marrow (Lording, 2008). When interpreting an equine hematological profile, some specific 
characteristics of this species should be kept in mind.  
PCV unstable. The horse is somewhat unique compared to most other mammalians in that 
the spleen is a very capacious organ, storing between 6 and 12 L of red-cell-rich blood at rest 
(Persson, 1967; McKeever et al., 1993). Large numbers of RBCs temporally sequestered in the 
spleen can be rapidly transferred into the circulation in response to excitement (handling, 
 
Hematology – Science and Practice 
 
574 
venipuncture, loss blood, twitching, and pain) and intense exercise (Persson, 1967; 1983). 
This response is induced by the release of catecholamines and therefore, the resting PCV in 
horses should be carefully assessed under different excitation levels (Persson, 1967; Schalm 
and Carlson, 1982). By contrast, tranquilizers and anesthetics decreased circulating RBCs, 
because of splenic sequestration (Jain, 1986). Comparable changes are not found in 
splenectomized horses following excitement and strenuous exercise or tranquilization 
(Kunugiyama et al., 1997).  
The intensity of changes in circulating RBC in relation to spleen activity depends on 
individual variations, age, breed and fitness level and in the case of exercise, duration and 
intensity. The time required for RBCs to return to resting values is dependent on the degree 
of the excitement, and it can vary from 40 to 60 minutes to up to several hours (Jain, 1986).  
Rouleaux formation and erythrocyte sedimentation rate. Rouleaux formation is the result of 
the aggregation of RBCs in linear stacks and depends on the number of RBCs and their 
tendency to aggregate. Rouleaux formation is a characteristic finding in healthy horses, as a 
result of weak surface changes on RBC membranes (Brockus et al., 2003). There is a positive 
correlation between the rate of rouleaux formation and the rate of setting of RBCs in 
anticoagulated blood (erythrocyte sedimentation rate). Rouleaux formation is accentuated in 
some diseases associated with hyperproteinemia, because high concentrations of plasma 
proteins, particularly fibrinogen and immunoglobulins, have an insulating effect that 
reduces the RBC surface membrane charge, promoting RBC aggregation (Schalm and 
Carlson, 1982; Brockus et al., 2003).  
Autoagglutination can be seen in some horses without hemolysis as a result of cold 
antibodies, with a maximal activity at 4-20ºC or as a result of unfractioned heparin treatment 
(Monreal et al., 1995). Macroscopically, agglutination has a granular appearance and 
microscopically, appears as grape-like clusters of RBCs. It should be differentiate from 
rouleaux by using the saline dilution test. Typically a 1:2 dilution will disperse rouleaux but 
not the autoagluttinated RBCs. Infrequently, a higher dilution (up to 1:10) may be needed to 
disperse rouleaux. Agglutination causes erroneous MCV values and RBC numbers 
determined by impedance, because the aggregates may interfere with the electronic or 
optical evaluation of the erythrocytes. Pre-treating cell suspensions from agglutinated 
heparin-treated horses with trypsin might reverse the agglutination, improving the accuracy 
of cell counts (Grondin and Dewitt, 2010).  
Absence of peripheral signs of regeneration. Life span of equine RBC in the circulation is 
approximately 140 to 150 days (Schalm and Carlson, 1982). RBCs are released from bone 
marrow as mature cells and the horse is unique in failing to release reticulocytes into 
peripheral blood when there is a regenerative response to hemorrhage or hemolysis. 
Therefore, morphological features indicative of regeneration, such as reticulocytes and 
polychromasia are rare in equine blood films. Reticulocyte counts may be performed on 
marrow aspirates in anemic horses. Values greater than 5% are consistent with accelerated 
erythropoiesis. Further, in those cases where anemia derives from decreased erythropoiesis, 
bone marrow examination may identify the cause and enable to carry out a definitive 
diagnosis (Schalm and Carlson, 1982).  
The only indication of maximally stimulated erythropoiesis in routine hematology data is 
anisocytosis and increased MCV (by up to 10 to 15 fl above baseline levels for an individual 
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horse) (Jain, 1986). Other way to evaluate regeneration is to interpret RBC distribution width 
or RDW. It is a coefficient of the degree of anisocytosis of circulating RBCs. This parameter 
will be increased in anemias with significant macrocytosis and/or microcytosis. The RDW is 
wider in healthy horses than in other species, and normal values range between 14 and 25% 
(Kramer, 2000). Similarly, assays of RBC creatine concentrations enable a more accurate 
evaluation of the erythropoietic response in horses. Mean RBC creatine concentration is 
significantly higher in young RBC populations (Wu et al., 1983), it shows a positive 
correlation with the reticulocyte count in bone marrow aspirates and a negative correlation 
with myeloid-erythroid ratio (Lording, 2008). However, it is not a common clinical 
procedure.  
The response to hemolysis is greater than following hemorrhage, although the regenerative 
capability of horses is relatively poor compared with other species (Brockus et al. 2003). 
Complete recovery from very severe hemolytic or hemorrhagic anemia may take 
approximately 1 to 2 months and 2 to 3 months respectively (Lumsden et al., 1975a,b).  
Howell-Jolly bodies. They are nuclear remnants of DNA that occasionally are seen in 
healthy equine peripheral blood films. They are small, round, purple inclusions. Increased 
number can be seen with enhanced erythropoiesis and with decreased or compromised 
splenic function (Schalm and Carlson, 1982; Kramer, 2000; Grondin and Dewitt, 2010).  
RBC morphology. Equine RBC is relatively small compared to other animal species, with a 
mean diameter of 5-6 μm and a MCV of approximately 40 to 52 fl (Lassen and Swardson, 
1995; Kramer, 2000; Grondin and Dewitt, 2010). They exhibit a mild degree of anisocytosis 
and RBC size may differ between horse breeds. Breeds dedicated to sport, such as 
Thoroughbred racehorses or Standardbred horses have an MCV lower than other breeds. 
Because HB is spread over a larger number of cells, the total surface of the red cell mass is 
increased. This adaptation of sport equine breeds appears to be a mean to achieve an easier 
gas exchange during exercise (Allen and Powell, 1983; Kramer, 2000).   
2.2 Physiological factors influencing erythron in horses 
2.2.1 Sampling handling 
In relation to the anticoagulant used, blood parameters in horses are not altered after 
anticoagulation in heparin-lithium or EDTA. On the contrary, when using sodium citrate, 
most hematological parameters significantly decrease, compared with the other 
anticoagulants (Sharif et al., 2010). 
Once the blood sample has been taken, another parameter to consider is the time to conduct 
the blood test. This should be done as soon as possible, preferably within the first 6 hours 
after collection, in order to avoid the damage caused by storage. The most common change 
associated with storage is an increase in the RBC size, a fact that artefactually leads to 
increased MCV and PCV (Allen et al., 1988). However, within limitations in some 
hematological parameters, equine blood samples stored in EDTA at 4ºC for a maximum of 
72 hrs may be adequate for blood tests (Sharif et al., 2010).  
Exposure of the sample to high temperatures or direct sunlight can cause hemolysis, 
resulting in altered RBC values (Rose and Hodgson, 1994).  
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2.2.2 Accuracy of measurements 
The accuracy of the determinations results from the characteristics of the equipment of 
analysis. Therefore, it is very important to know the sources of errors according to the type 
of equipment. It has been recommended to conduct repeated measurements, allowing a 
more reliable interpretation of the results (Persson, 1975; Jain, 1993; Rose and Hodgson, 
1994). In fact, Persson (1975) described a variation of up to 30% in baseline HB in three 
Standardbred horses in which blood samples were obtained in 7 consecutive days.  
2.2.3 Attitude and degree of excitement of the horse 
Another aspect that might influence the interpretation of RBC parameters is the attitude and 
the degree of excitement the horse has before and during blood withdrawal (Rose and 
Hodgson, 1994). Excitement leads to a rise in circulating RBC, HB and PCV. This is the result 
of the splenic contraction produced by the release of adrenaline and noradrenaline 
(Kurosawa et al., 1998). The main limiting factor is the time to collect the blood sample. 
Venipuncture for longer than 30 sec significantly alters the hemograma, as it involves 
splenic mobilization, resulting from the actions of the sympathetic-adrenal and 
hypothalamic-pituitary axis (Persson, 1967; Kurosawa et al., 1998). 
There are many physiological factors that cause stress in the horse, such as exercise (whether 
in training or competition), adverse environmental conditions, particularly high heat and 
humidity, but also dust and very cold or windy weather, long-distance transport, 
insufficient rest between athletic events, lack of sleep at shows (e.g. late night events or 
activity in the boarding barn, stall too small for the horse to lie down and rest comfortably), 
new experiences during training or competition, confinement, removal from familiar 
environment and social group, changes in daily routine when traveling and at shows, 
strange environments (e.g. boarding at shows), presence and activity of strange horses and 
people at shows and increased stress levels in the handlers and rider and weaning, among 
others (Friend, 2001).  
2.2.4 Method of venipuncture 
An early study showed that the use of vacuum tubes for blood collection can cause cell 
damage (Archer, 1977). The use of higher gauge needles leads to satisfactory results 
according to most of the authors (Jeffcott, 1977; Messer, 1995). In our experience, additional 
care should be having in blood samples taken in maximally exercised horses in order to 
avoid hemolysis. Recently, it has been demonstrated that there are not significant 
differences when comparing hematological parameters obtained using two different 
methods: venipuncture and intravenous catheter (May et al., 2010).  
2.2.5 Feeding 
Another factor to take into account when interpreting equine erythrogram is the food and 
the time of blood sampling in relation to time of feeding. Significant increases in PCV and 
total plasma proteins (TPP) are found in animals after be fed. This fact has been associated 
with loss of fluids through the saliva and other gastrointestinal fluids, as well as fluid shifts 
from the circulation to the gastrointestinal system (Kerr and Snow, 1982). Similarly, there are 
variations in RBC parameters in horses subjected to different nutritional regimes (Greppi et 
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al., 1996), as well as in animals which common salt is added to the food, supplied 8 hrs 
before blood collection. In main lines, it is recommended to avoid collecting blood samples 
within 3 hrs of feeding a large concentrate meal or hay ration or at least ensure that samples 
are collected at the same time each day.  
2.2.6 Circadian biological rhythms 
RBC parameters exhibit diurnal infradian, circadian and ultradian rhythms, both in athletic 
and sedentary horses (Gill and Rastawicka, 1986). Gill and Rastawicka (1986) described 
elevations in PCV and HB overnight in comparison to light time. Hauss (1994) relates this 
variation to the influence exerted by alternation between periods of light and darkness on 
erythropoiesis. After that, Greppi et al. (1996) corroborated these results, and they also 
found a significant effect of biological rhythms in TPP.  
2.2.7 Gender 
Hematological differences linked to gender seem to have limited importance in horses. Indeed, 
minor differences between adult females and males have been reported. However, the results 
of research in this field are subjected to controversy. Males have slightly higher RBC, HB and 
PCV, while females have higher MCH and MCHC (Jain, 1986; Hernández et al., 2008; Satué et 
al., 2009). By contrast, Gill and Rastawicka (1986) observed in Thoroughbred racehorses and 
Quarter Horses that RBC, PCV and HB were higher in mares than in males. Persson and 
Ullberg (1974) had reported that baseline hematologic values were higher in stallions than in 
mares and geldings, probably because of the effect of androgens on erythropoiesis. However, 
this feature was not seen during exercise in this paper. The authors explained these results 
indicating that mares and geldings established a hypokinetic circulation with increased 
oxygen uptake by active muscle during exercise (Persson and Ullberg, 1974).  
2.2.8 Season 
Season is an exogenous factor that modulates the dynamic of blood components in horses, 
both in cycling and pregnant mares (Gill and Wanska, 1978; Gill and Kownacka, 1979; Satué, 
2004; Satué et al., 2011). Indeed, the patterns of seasonal changes on RBC, HB and PCV in 
Thoroughbreds and Arabian horses have showed decreased values in winter (Gill and 
Wanska, 1978; Gill et al., 1979). In Carthusian mares, Satué et al. (2011) confirmed these 
results. RBC, PCV and MCV in summer were significantly higher than in spring, autumn 
and winter. However, HB in spring was significantly higher and MCV and MCH in spring 
and summer were significantly lower than in other seasons, without modifications in 
MCHC (Satué et al., 2011). These variations could be related to the effect of some factors, 
such as the breeding season (Satué et al., 2011). Furthermore, these patterns could be 
subjected to a different degree of tolerance to the cold, and dissimilar changes in ambient 
temperatures in different locations (Ruiz et al., 2004). It has been suggested that intense cold 
decreases RBC due to the reduction in the half-life (Ruiz et al., 2004).  
2.2.9 Altitude 
Horses subjected to high altitude have significantly higher RBC, HB and PCV values, 
compared to animals that live at less altitude. It is considered a compensatory mechanism 
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for the lower content of oxygen in the atmospheric air, which is proportionally reduced to 
the altitude (Wickler and Anderson, 2000).  
2.2.10 Age 
The influence of age on hematological parameters have been evaluated in different horse 
breeds (Ralston et al., 1988; McFarlane et al., 1998; Cebulj-Kadunc et al., 2002; 2003; Satué, 
2004; Hernández et al., 2008; Satué et al., 2009). Most of the studies on age with hematology 
have focused on foals from birth to 4 years of age (Harvey et al., 1984; Jain, 1993), even 
though geriatric horses have received much attention recently, probably because of the 
increase of the age population (McFarlane et al., 1998).  
Newborn foals have RBCs of fetal origin, large size and high RBC, HB and PCV. These 
parameters are reduced sharply within 12-24 hrs of life, then decline more gradually over 
the subsequent 2 weeks, and after that, they remain in the lower limit of the adult reference 
internal during the first year of life (Jain, 1986; Harvey, 1990; Grondin and Dewitt, 2010). 
The initial hematological changes in foals at birth are thought to be due to the increase in 
fetal RBC destruction, inadequate iron supplementation, needed for HB synthesis, 
catecholamine release and expansion of plasma volume as adjustments of fluid balance as a 
result of the osmotic effect of colostral immunoglobulins. Declines in these values are 
attributed to decreased RBC survival time, decreased iron delivery to the bone marrow, 
decreased stimulus for erythropoietin production as a result of higher HB saturation, 
increased blood oxygen content, and enhanced delivery of oxygen to the tissues due to 
lower 2,-3 diphosphoglycerate concentrations (Harvey, 1990). Normal adult hematological 
values are attained at 1-2 years of age. MCV are high at birth and then decrease, reaching its 
lowest values at 3-5 months of age (Jain, 1986; Harvey, 1990). They do not increase to adult 
values until approximately 1 year of age (Harvey, 1990). Microcytosis in foals has been 
attributed to a decrease in serum iron as a result of increased demand for growth. These 
RBCs may be too small to be recognized as erythrocytes by some impedance counts, hence 
generating erroneous MCV, RBC and PCV values. Mild anisocytosis is also a typical finding 
in young foals (Harvey, 1990). MCHC remains constant after birth and is similar to adult 
values (Harvey, 1990).  
Stewart et al. (1970) found that PCV and HB were lower in foals younger than 2 years. 
Between 3 and 4 years of age, there was a gradual increase in MCV and MCH and since HB 
and PCV remained unchanged during this period, the increase in MCV was accompanied by 
a slight reduction in RBC. In Carthusian pregnant mares and in Spanish Purebred horses, 
Hernández et al. (2008) and Satué et al. (2009) found a reduction of RBC with a 
compensatory increase in MCV and MCH associated with aging. These results agree with 
those presented for other equine breeds, such as Standardbreds (Jain, 1986; Ralston et al., 
1988), Lipizziano (Cebulj-Kadunc et al., 2002) and wild horses (Plotka et al., 1988). However, 
McFarlane et al. (1998) found a decreasing trend in geriatric horses, without achieving 
statistical significance. This fact was linked to a reduced regenerative capacity of the bone 
marrow (McFarlane et al., 1998).  
As indicated before, increased MCV appears to be a common finding associated with aging 
in the horse (Ralston et al., 1988; McFarlane et al., 1998; Satué, 2004) and it has been 
explained as the result of changes in the dynamics of maturation of the RBCs (McFarlane et 
al., 1998).  
 




Breed in horses exerts a significant effect on the erythron. Light horse breeds or ‘hot-blooded 
breeds’ have higher RBC, HB and PCV and blood volume compared to draft horses or ‘cold-
blooded breeds’ (Jain, 1993; Kramer, 2000; Grondin and Dewitt, 2010). Thus, PCV as low as 
24% can be found in healthy draft horses and pony breeds. Further, Thoroughbreds have 
smaller MCV than draft horses. Breeds ancestrally closer have minor differences in HB, 
MCH and MCHC (Jain, 1986). American miniature horses have lower RBC, HB and PCV but 
higher MCV, MCH and MCHC than other breeds (Harvey et al., 1984). Donkeys have 
similar RBC, HB and PCV than ponies, but much higher MCV (Jeffcott, 1977).  
2.2.12 Exercise 
Exercise has variable effects on the erythrogram, depending on exercise duration and 
intensity (short-term high intensity or maximal exercise and long-term low intensity or 
submaximal prolonged exercise), fitness and training levels and environmental conditions. 
In main lines, exercise results in increased RBC, HB and PCV. At the onset of the exercise, 
this rise derives from the mobilization of splenic RBC under the influence of the 
catecholamines. The direct effect of this increased RBC is a greater oxygen transport capacity 
and therefore, aerobic performance. Both the intensity and the duration of the exercise 
determine the magnitude of the catecholamine response (Kurosawa et al., 1998). The extent 
of the increase in PCV is a function of the exercise intensity in maximal exercises and in 
increasing-intensity exercises and a linear relationship between PCV and speed has been 
described (Persson, 1983; Muñoz et al., 1998; 1999). This relationship is maintained until the 
maximum PCV is achieved (60-65%) (Persson, 1983).  
Even though the majority of the increase in PCV in high-intensity exercises is due to the 
splenic contraction, exercise-induced fluid shifts also have a role. A decrease of 5-10% in 
plasma volume is expected in short-term and in incremental-intensity exercises (McKeever 
et al., 1993; Muñoz et al., 1998). This reduction is attributed to the loss of sweat in order to 
dissipate heat produced by muscle contraction and to the exchange of fluids between the 
different body compartments, because of changes in blood pressure (McKeever et al., 1993; 
Muñoz et al., 1998; 1999).  
The rise in PCV during exercise is linked to higher HB and RBC. If we consider the 
importance of increased HB in the oxygen transport capacity, it is plausible to think that 
increased PCV, HB and RBC leads to higher aerobic capacity and therefore, exercise 
performance (Muñoz et al., 1997). Indeed, several studies carried out in splenectomized 
horses have demonstrated a marked reduction in exercise performance (McKeever et al., 
1993; Kunugiyama et al., 1997). On the other hand, there is a close relationship between 
increased PCV and blood viscosity. As a consequence, there should be a limit in the 
elevation of PCV that offsets improved oxygen-carrying capacity (Muñoz et al., 1997). This 
fact has been implied in the loss of performance of horses with red cell hypervolemia 
(Funkquist et al., 2000).  
Other changes associated with brief maximal exercises are small increases in MCV and 
decreases in MCH and MCHC. Additionally, RBC in blood samples obtained after this type 
of exercise seems to be more resistant to osmotic stress (Smith et al., 1989), although a later 
study found a reduced RBC deformability (Geor et al., 1992).  
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On the other hand, prolonged submaximal exercise or endurance exercise leads to moderate 
increase in PCV, associated with loss of fluids because of the quantitative importance of 
sweating. In this case, the increased PCV, HB and RBC are good indices of dehydration. We 
have found that endurance horses with PCV higher than 50% are disqualified from competition 
and some of them require intensive intravenous fluid therapy (Muñoz et al., 2010; Trigo et al., 
2010). The increase in PCV should be equal to the increase in TPP. In these cases where PCV 
increases and TPP remains unchanged, other reasons different from dehydration should be 
considered in order to explain these results. In fact, we found that the most rapid endurance 
horses in competitions can have higher PCV than the slower horses. Other reason that can lead 
to increased PCV in endurance horses is pain. We studied 13 endurance horses that had 
increased PCV (PCV> 52%) with non-increased TPP (TPP<7.2 g/dl) during a competition. One 
of them had laminitis, 2 had heart arrhythmias, 2 had colic, 3 were retired from competition by 
the owners and the remaining 5 were able to finish the competition (Trigo et al., 2010).  
2.2.13 Training 
Although training has limited effects on RBC parameters at rest, some differences are found 
between horses undergoing high-intensity and endurance training. Speed-trained horses 
have higher RBC, HB and PCV, which is considered an adaptation for a greater demand for 
oxygen uptake, stimulating RBC production. However, it is very difficult to obtain a ‘true’ 
basal blood sample in these horses, because of their demeanor and nervous temperament. 
The increased excitability of a horse as it gets fitter could result in elevations of RBC, HB and 
PCV values (McKeever et al., 1993). On the other hand, regular monitoring of the hemogram 
during training has little value for assessing the fitness of the horse, but it is very helpful in 
order to detect subclinical problems that can significantly reduce exercise performance. 
Decreases in PCV have been reported as a consistent finding in horses with viral respiratory 
tract disease and in gastric ulcers (McGowan, 2008; Nieto et al., 2009).  
In Standardbred trotters, prolonged and/or intensive training can result in an excessive increase 
in red cell mass, phenomenon known as red cell hypervolemia, which results in a significant 
reduction of racing performance. Some authors have related the hypervolemia with 
overtraining (Golland et al., 2003). It has been hypothesized that increased blood viscosity leads 
to reduced capillary perfusion and inadequate utilization of oxygen by contracting muscles.  
By contrast, endurance-trained horses have lower resting RBC, PCV and HB than sprint-
trained horses (Muñoz et al., 2010; Robert et al., 2010; Trigo et al., 2010). In fact, in our 
experience, is very common to find PCV as low as 30-32% in endurance healthy horses with 
good performance (Muñoz et al., 2010). There are two main reasons to explain these results. 
Firstly, it has been indicated that feeding fibrous diets might increase water consumption 
and then plasma volume (Robert et al., 2010). The second reason is the effect of a greater 
release of aldosterone, which promotes water and electrolyte-conserving mechanisms in the 
kidneys and gastrointestinal tract (McKeever et al., 2002). These changes appear at the 
beginning of the training program, with retention of water and electrolytes after only 3 days 
of endurance training (McKeever et al., 2002). The advantage of plasma expansion in 
endurance horses is to provide extra total body water for the maintenance of cardiovascular 
and thermoregulatory stability during prolonged exercise in order to compensate the 
significant losses associated with sweating (McKeever et al., 2002; Robert et al., 2010). 
Despite these results, it is clear that hematological measurements are of little value in 
assessing the fitness or progress of endurance horses in training.  
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2.2.14 Reproductive status 
The researchers that have evaluated the hematological changes resulting from pregnancy in 
the mare have provided controversial results. Studies in Thoroughbred, Arabian, 
Carthusian, Brazilian and Breton pregnant mares have described a significant increase in 
RBC parameters during pregnancy (Berlink et al., 2000; Satué, 2004; Satué et al., 2008). There 
is not a reasonable explanation to justify these results, although it has been hypothesized 
that the increased fetal metabolic requirements might condition this response (Satué, 2004). 
In an early study, a mild anemia appeared at the end of pregnancy (Trum, 1952). This result 
agrees with studies carried out in pregnant women (Bailit et al., 2007) and other animal 
species (Steinhardt et al., 1994; Zvorc et al., 2006). The decrease of RBC parameters in 
pregnancy has been associated with an absolute gain of plasma, RBC and HB. As the 
increase in RBC and HB is slower than the rise in plasma, a relative oligocythemia is found, 
despite the increased erythropoietin concentration probably derived from placental 
prolactin. The hypervolemia of pregnancy has been associated with water and sodium 
retention after an activation of the renin-angiotensin-aldosterone axis, stimulated by 
estrogens (Satué and Domingo, 2008). The hypervolemia of pregnancy is necessary in order 
to meet the demands of the gravid uterus, to protect the mother and the fetus from the 
harmful effects of decreased venous return and to prevent the mother from suffering the 
adverse effects of blood loss during delivery (McMullin et al., 2003).  
It has been suggested that iron deficiency anemia is common in the pregnant mare. Detlef 
(1985) studied the effect of iron supplementation in pregnant mares compared with 
untreated control mares. In the treated mares, RBC and HB were not changed during 
pregnancy, whereas a decline in RBC parameters was found in the control group. 
Additionally, the foals born from supplemented mothers had higher HB and RBC than the 
foals born from the untreated mares (Detlef, 1985).  
Near the parturition, RBC parameters do not change (Taylor-Macallister et al., 1997). After 
delivery, RBC parameters increase slightly, until the total blood volume is restored by 
releasing the attachments and fetal fluids. On the other hand, lactation induces a reduction 
in RBC, HB and PCV (Harvey et al., 1994; 2005).  
2.2.15 Administration of sedatives-tranquilizers 
The administration of tranquilizing compounds, such as phenothiazine derivatives 
(acepromazina, chlorpromazine…) and adrenergic α-2 agonists (xylazine, romifidine, 
detomidine…) significantly affect the RBC parameters. These drugs lead to a relaxation of 
the smooth muscle in the splenic capsule, promoting the storage of RBC (Jeffcott, 1977). 
Further, these drugs, after an initial short phase of hypertension, have a prolonged 
hypotensive effect. Hypotension leads to increased plasma volume, with the subsequent 
hemodilution and reduced RBC parameters at rest (Jain, 1986).  
3. Leukon 
The term leukon refers to the set of data derived from total and differential count of white 
blood cells (WBC) and the analysis of WBC morphology (Grondin and Dewitt, 2010). 
Circulating WBC represents the outcome of the dynamic production of the bone marrow, 
the release of the cells to the peripheral blood and, the storage in different organs or pools. 
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Cells can coexist in different stages of maturation, being fully mature cells (neutrophils, 
NEU, eosinophils, EOS, monocytes, MON, lymphocytes, LYM and basophils, BAS) and 
immature (band neutrophils, metamyelocytes, myelocytes and progranulocytes) (Messer, 
1995; Welles, 2000; Grondin and Dewitt, 2010).  
3.1 Neutrophils 
The release of NEU from the bone marrow into the circulated depends on the tissue 
demands and the production of different humoral substances. After passing into the blood, 
NEU can be in the circulating pool or stored in the marginal pool (in the endothelium of 
several organs, such as lungs or intestine). Three main locations of the NEU can be 
described: 1) Bone marrow. There is a proliferating population of NEU, including 
promyelocytes, myelocytes, metamyelocytes, and mature ENU, prepared for release into 
peripheral blood; 2) Blood. In the blood compartment, mature NEU appear as round cells, 
10-15 μm of diameter, with clear cytoplasm, neutral or granules stain pink and with the 
nucleus polymorphic and segmented and the chromatin arranged in the form of knots; 3) 
Tissues. In inflammatory processes, there is a release of chemotactic substances that 
promotes NEU migration from the vascular bed into the tissues. Marginal pool of NEU 
adheres to the vascular endothelium, mainly in the small vessels. This fact facilitates the 
migration to the tissues, while serving as a reserve, so there is a continuous exchange 
between circulating and marginal pools (Lassen and Swardson, 1995; Grondin and Dewitt, 
2010; Smith, 2000; Welles, 2000). 
Barr bodies (sex chromatin lobe/ drumstick) can be recognized in females and resemble a 
small purple body attached to the nucleus by a thin chromatin strand. Further, in peripheral 
blood, both mature and immature or band NEU can be found. Equine band NEUs are less 
frequently seen because horses do not exhibit marked left shifts during inflammatory insults 
compared to dogs and cats. In cases of bacterial infection, the band NEUs might represent 
between 1 and 10% of the total WBC differential count (Welles, 2000). Band NEUs have a 
polymorphic nucleus, without constrains, with a less condensed chromatic pattern than the 
segmented NEUs. The cytoplasm is similar to this of the mature NEU (Jain, 1993; Welles, 
2000). Hypersegmented NEUs are rarely seen in healthy and they have five or more lobes 
separated by filaments. Prolonged storage of blood may lead to the artefactual development 
of hypersegmented NEUs. Idiopathic hypersegmentation of NEUs have been described in 
Quarter Horses that lacked evidences of clinical disease. Hyposegmented NEUs have also 
been reported in apparently healthy Arabian horses, which were diagnosed as Pelger-Huët 
anomaly (Grondin et al., 2007).  
Circulating NEUs have a half-life of 10.5 hours, renewing approximately 1.5 times per day 
(Lassen and Swardson, 1995; Welles, 2000). Then, they leave the bloodstream and migrate 
into the tissues. It is a unidirectional movement, because they do not return to the peripheral 
circulation. In the tissues, NEUs are functional for 1 to 2 days, and then, they are fagocyted 
by the monocyte-macrophage system or by the mucosal surfaces (Welles, 2000).  
3.2 Lymphocytes 
LYM are the second largest population of circulating WBCs, after NEUs and the main 
components of the immune system. They are smaller than NEUs and the other granulocytes, 
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with a dark-staining nuclei, coarse chromatin pattern and scant amount of blue cytoplasm. 
The mature cell has a diameter of 7-12 μm, an eccentric, round nucleus with a notch on some 
occasions (Latimer and Rackich, 1992). LYMs are made up to 38-66% T cells, 17-38% B cells 
with the remaining being null cells (Tizard, 2009). Occasionally, larger LYMs are present, 
and they have smooth chromatin patterns and large amounts of pale blue cytoplasm (Jain, 
1986). Reactive LYMs or immunocytes are rarely seen in health. They are slightly larger than 
small LYMs, with scalloped nuclear margins, moderately aggregated chromatin, scant to 
moderate amounts of intensely basophilic cytoplasm and sometimes, they have a pale-
staining Golgi zone (Latimer, 1999; Grondin and Dewitt, 2010). 
The half-life of LYMs varies between 20 and 200 days (Schalm and Carlson, 1982), with a 
mean duration of transit through the blood of 30 hrs. Blood LYMs have the ability to 
recirculate in the blood, lymphatic channels, lymphoid and peripheral tissues and they are 
able to have mitosis, allowing amplification of the immune response (Jain, 1986; Latimer, 
1999; Welles, 2000). Most of the LYMs are originated in the peripheral lymphoid tissues, and 
only a small percentage comes from central lymphoid tissues, i.e. bone marrow and thymus. 
The circulation time depends on the LYM subtype and the tissue of origin. T cells circulate 
more rapidly than B cells and migration through the splenic parenchyma is faster than 
through the lymph nodes (Hopkins and McConnell, 1984).  
3.3 Eosinophils 
EOS are cells slightly larger than neutrophils that contain large, reddish-orange granules in 
the cytoplasm, often obscuring the nuclei and giving a raspberry-like appearance, with a 
pale blue cytoplasm (Kramer, 2000; Smith, 2000). The lobulated nucleus seldom shows fine 
filamentation. Degranulated EOSs are vacuolated and are rarely seen in health (Latimer, 
1999; Grondin and Dewitt, 2010). The amount of EOS in peripheral blood is low, because 
most of these cells migrate into tissues, such as the bronchial mucosa, gastrointestinal 
tract…The half-life of circulating EOS is about 2 to 12 hrs (Latimer, 1999; Young, 2000).  
3.4 Monocytes 
MON are the largest WBC in circulation, with a large, broad, variable in shape nuclei (oval, 
bilobed, horseshoe) with lacy chromatin and gray-blue cytoplasm with small azurophilic 
granules. The cytoplasm can also have a few clear vacuoles of variable size, located in the 
cell periphery and with a foamy appearance (Jain, 1993; Bienzle, 2000). After their 
production in the bone marrow, MON are released into the bloodstream. In circulation, they 
distributed between the circulating and marginal pools, with a ratio of 1/3.5 between them. 
This ratio remains constant in different physiological states and in response to disease. The 
mean circulating MON life is about 8.4 hrs, and there is not exchange at the tissue level and 
blood. In the tissues, the MONs mature into macrophages, a transformation that is 
accompanied by changes in ultrastructure, in the appearance of cellular receptors or by 
metabolic changes. The half-life of macrophages ranges from several days to months 
(Bienzle, 2000; Welles, 2000). 
3.5 Basophils 
BAS are cells slightly larger than the NEUs, with a lobulated nucleus, although to a lesser 
extent than NEUs, a cytoplasm from blue to gray, with large amounts of granules 
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Cells can coexist in different stages of maturation, being fully mature cells (neutrophils, 
NEU, eosinophils, EOS, monocytes, MON, lymphocytes, LYM and basophils, BAS) and 
immature (band neutrophils, metamyelocytes, myelocytes and progranulocytes) (Messer, 
1995; Welles, 2000; Grondin and Dewitt, 2010).  
3.1 Neutrophils 
The release of NEU from the bone marrow into the circulated depends on the tissue 
demands and the production of different humoral substances. After passing into the blood, 
NEU can be in the circulating pool or stored in the marginal pool (in the endothelium of 
several organs, such as lungs or intestine). Three main locations of the NEU can be 
described: 1) Bone marrow. There is a proliferating population of NEU, including 
promyelocytes, myelocytes, metamyelocytes, and mature ENU, prepared for release into 
peripheral blood; 2) Blood. In the blood compartment, mature NEU appear as round cells, 
10-15 μm of diameter, with clear cytoplasm, neutral or granules stain pink and with the 
nucleus polymorphic and segmented and the chromatin arranged in the form of knots; 3) 
Tissues. In inflammatory processes, there is a release of chemotactic substances that 
promotes NEU migration from the vascular bed into the tissues. Marginal pool of NEU 
adheres to the vascular endothelium, mainly in the small vessels. This fact facilitates the 
migration to the tissues, while serving as a reserve, so there is a continuous exchange 
between circulating and marginal pools (Lassen and Swardson, 1995; Grondin and Dewitt, 
2010; Smith, 2000; Welles, 2000). 
Barr bodies (sex chromatin lobe/ drumstick) can be recognized in females and resemble a 
small purple body attached to the nucleus by a thin chromatin strand. Further, in peripheral 
blood, both mature and immature or band NEU can be found. Equine band NEUs are less 
frequently seen because horses do not exhibit marked left shifts during inflammatory insults 
compared to dogs and cats. In cases of bacterial infection, the band NEUs might represent 
between 1 and 10% of the total WBC differential count (Welles, 2000). Band NEUs have a 
polymorphic nucleus, without constrains, with a less condensed chromatic pattern than the 
segmented NEUs. The cytoplasm is similar to this of the mature NEU (Jain, 1993; Welles, 
2000). Hypersegmented NEUs are rarely seen in healthy and they have five or more lobes 
separated by filaments. Prolonged storage of blood may lead to the artefactual development 
of hypersegmented NEUs. Idiopathic hypersegmentation of NEUs have been described in 
Quarter Horses that lacked evidences of clinical disease. Hyposegmented NEUs have also 
been reported in apparently healthy Arabian horses, which were diagnosed as Pelger-Huët 
anomaly (Grondin et al., 2007).  
Circulating NEUs have a half-life of 10.5 hours, renewing approximately 1.5 times per day 
(Lassen and Swardson, 1995; Welles, 2000). Then, they leave the bloodstream and migrate 
into the tissues. It is a unidirectional movement, because they do not return to the peripheral 
circulation. In the tissues, NEUs are functional for 1 to 2 days, and then, they are fagocyted 
by the monocyte-macrophage system or by the mucosal surfaces (Welles, 2000).  
3.2 Lymphocytes 
LYM are the second largest population of circulating WBCs, after NEUs and the main 
components of the immune system. They are smaller than NEUs and the other granulocytes, 
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with a dark-staining nuclei, coarse chromatin pattern and scant amount of blue cytoplasm. 
The mature cell has a diameter of 7-12 μm, an eccentric, round nucleus with a notch on some 
occasions (Latimer and Rackich, 1992). LYMs are made up to 38-66% T cells, 17-38% B cells 
with the remaining being null cells (Tizard, 2009). Occasionally, larger LYMs are present, 
and they have smooth chromatin patterns and large amounts of pale blue cytoplasm (Jain, 
1986). Reactive LYMs or immunocytes are rarely seen in health. They are slightly larger than 
small LYMs, with scalloped nuclear margins, moderately aggregated chromatin, scant to 
moderate amounts of intensely basophilic cytoplasm and sometimes, they have a pale-
staining Golgi zone (Latimer, 1999; Grondin and Dewitt, 2010). 
The half-life of LYMs varies between 20 and 200 days (Schalm and Carlson, 1982), with a 
mean duration of transit through the blood of 30 hrs. Blood LYMs have the ability to 
recirculate in the blood, lymphatic channels, lymphoid and peripheral tissues and they are 
able to have mitosis, allowing amplification of the immune response (Jain, 1986; Latimer, 
1999; Welles, 2000). Most of the LYMs are originated in the peripheral lymphoid tissues, and 
only a small percentage comes from central lymphoid tissues, i.e. bone marrow and thymus. 
The circulation time depends on the LYM subtype and the tissue of origin. T cells circulate 
more rapidly than B cells and migration through the splenic parenchyma is faster than 
through the lymph nodes (Hopkins and McConnell, 1984).  
3.3 Eosinophils 
EOS are cells slightly larger than neutrophils that contain large, reddish-orange granules in 
the cytoplasm, often obscuring the nuclei and giving a raspberry-like appearance, with a 
pale blue cytoplasm (Kramer, 2000; Smith, 2000). The lobulated nucleus seldom shows fine 
filamentation. Degranulated EOSs are vacuolated and are rarely seen in health (Latimer, 
1999; Grondin and Dewitt, 2010). The amount of EOS in peripheral blood is low, because 
most of these cells migrate into tissues, such as the bronchial mucosa, gastrointestinal 
tract…The half-life of circulating EOS is about 2 to 12 hrs (Latimer, 1999; Young, 2000).  
3.4 Monocytes 
MON are the largest WBC in circulation, with a large, broad, variable in shape nuclei (oval, 
bilobed, horseshoe) with lacy chromatin and gray-blue cytoplasm with small azurophilic 
granules. The cytoplasm can also have a few clear vacuoles of variable size, located in the 
cell periphery and with a foamy appearance (Jain, 1993; Bienzle, 2000). After their 
production in the bone marrow, MON are released into the bloodstream. In circulation, they 
distributed between the circulating and marginal pools, with a ratio of 1/3.5 between them. 
This ratio remains constant in different physiological states and in response to disease. The 
mean circulating MON life is about 8.4 hrs, and there is not exchange at the tissue level and 
blood. In the tissues, the MONs mature into macrophages, a transformation that is 
accompanied by changes in ultrastructure, in the appearance of cellular receptors or by 
metabolic changes. The half-life of macrophages ranges from several days to months 
(Bienzle, 2000; Welles, 2000). 
3.5 Basophils 
BAS are cells slightly larger than the NEUs, with a lobulated nucleus, although to a lesser 
extent than NEUs, a cytoplasm from blue to gray, with large amounts of granules 
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distributed irregularly, and with an intense purple stain that vary in size and shape and can 
mask the nucleus (Jain, 1993; Kramer, 2000). 
3.6 Physiological factors influencing leukogram in horses 
There are two main WBC responses, physiological leukocytosis and stress leukocytosis. 
Physiological leukocytosis refers to changes in circulating WBC associated with the 
intervention of the sympathetic-adrenal axis resulting from splenic contraction in cases of 
fear, excitement, or high intensity exercise. There is a mobilization of the marginal pool of 
NEUs and/or LYM, because of a reduction in NEU adherence capacity, increased blood 
flow through the microvasculature and splenic contraction (Latimer, 1999). These events 
result in leukocytosis with mature neutrophilia and/or lymphocytosis. In some cases, 
eosinophilia and monocytosis are also found (Snow et al., 1983; Welles, 2000). These changes 
are transient and the marginal pool of NEUs is restored again in 20-30 min after the onset of 
the response and the LYM counts returned to baseline after 1 hr (Rossdale et al., 1982). 
Stress leukocytosis is associated with cortisol release under certain stressful situations. This 
hormone induces neutrophilia without left shift, lymphopenia and eosinopenia. 
Neutrophilia derives from the mobilization from the marginal pool, the reduced ability to 
migrate from the blood to the peripheral tissues and the increased mobilization of the 
population of bone marrow reserve. Lymphopenia is the result of LYM sequestration from 
lymphoid tissues and the eosinophenia derives from the marginalization of EOS in the 
blood vessels and the decreased release from the bone marrow (Caracostas et al., 1981; 
Welles, 2000). This response appears between 2 and 4 hours after the elevation of the 
endogenous cortisol concentrations or after exogenous administration of corticoids 
(Rossdale et al., 1982; Burguez et al., 1983). Normal values are recovered in 24 hrs. This 
response has been also found after an endurance exercise and in response to a great variety 
of pathological processes (Welles, 2000).  
3.6.1 Breed 
Minor differences have been found among equine breeds in relation to WBC, with the hot-
blooded horses having higher WBC compared to cold-blooded horses (Jain, 1986; Harvey et 
al., 1984). Thoroughbreds and Arabian have a mean NEU/LYM ratio of 1.0, whereas cold-
blooded horses and miniature horses have ratios of 1.7 and 0.67, respectively (Jain, 1986).  
3.6.2 Time of the day 
In Thoroughbred racing horses, Allen and Powell (1983) described that LYM count has 
higher in the evenings and lower in the mornings. These findings have been attributed to 
the circadian variations in the release of endogenous corticoids. It is well known that 
maximum cortisol concentrations appear in the morning (McKeever, 2011).  
3.6.3 Gender 
WBC and granulocytes are higher in females than in stallions, as recently found in Spanish 
Purebred horses (Hernández et al., 2008; Satué et al., 2009). On the contrary, previous 
researchers performed in warm-blooded horse breeds reported higher values in males and 
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in females (Lassen and Swardson, 1995; Cebulj-Kadunc et al., 2002). Other study failed to 
find significant differences between sexes (Lacerda et al., 2006).  
3.6.4 Age 
NEU number is low in the fetus (<1,500/μl, before 300 days of gestation), increases after 
birth in response to cortisol (8,000/μl) and then decrease to mean adult values (4000/μl) at 
about 4-6 months of age. Band NEU do not exceed 150/μl in healthy foals (Harvey, 1990; 
Allen et al., 1998). Foals born at term have higher NEU count than foals born prematurely. 
LYM numbers in foals are low at birth (average 1,400/μl), increase to 5,000/μl at 3 months 
of age, and reach adult values at 1 year of age (Jain, 1986; Harvey, 1990). LYMs further 
decline during adulthood while NEU count remains the same, resulting in a higher 
NEU/LYM ratio in aged horses compared to foals (Jain, 1986). The ratio NEU/LYM reaches 
values of 2/1 in geriatric horses (Jain, 1993; Lassen and Swardson, 1995; Hernández et al., 
2008). The progressive trend towards lymphopenia in geriatric horses is characterized by a 
reducing in B cells CD4+ and CD8+, in relation to immune senescence (Smith et al., 2002; 
Hernández et al., 2008; Satué et al., 2010).  
EOSs are not routinely detected in the fetus and in foals at birth, achieving a mean of 400/μl 
by 4 months of age (Harvey, 1990). EOSs count increases with aging due to prolonged 
exposure to allergens through life (Jain, 1993; Satué et al., 2009). However, McFarlane et al. 
(1998), Cebulj-Kadunc et al. (2003) and Hernández et al. (2008) did not found differences in 
EOS count between young and adult horses. Band NEU, MON and BAS do not seem to 
change with aging in horses (Harvey, 1990; Jain, 1993; Lassen and Swardson, 1995; Cebulj-
Kadunc et al., 2003; Satué, 2004; Hernández et al., 2008).  
3.6.5 Exercise 
WBC show different responses according to the type of exercise. Sprint exercise is associated 
with leukocytosis because of neutrophilia but mainly because of lymphocytosis, with a 
decrease in NEU/LYM ratio. These changes are likely secondary to catecholamine release 
and splenic contraction. At 3 hr after exercise, there is an increase in NEU/LYM ration, 
because the increase of NEU and decrease in LYM associated with cortisol concentrations. 
The NEU/LYM ratio returns to baseline values by 6 hrs after exercise (Snow et al., 1983).  
Endurance exercise is associated with leukocytosis, resulting from a neutrophilia and 
lymphopenia (Snow et al., 1982). Probably this is combined effect of increased circulating 
corticosteroids and splenic contraction. Horses that completed an endurance event at a 
faster speed have higher NEU/LYM ration than slower horses (Trigo et al., 2010). 
Additionally, it has been demonstrated that exhausted endurance horses had left shift in the 
NEUs and significantly lymphopenia (Trigo et al., 2010).  
3.6.6 Training 
Total WBC is unchanged during training for racing and for endurance events. In addition, 
there are no alterations in the proportions of the different WBC populations. Some overtrained 
horses develop eosinophenia together with clinical signs of disease, and this result has led to 
the hypothesis that EOSs may be a more sensitive indicator of training stress than other types 
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distributed irregularly, and with an intense purple stain that vary in size and shape and can 
mask the nucleus (Jain, 1993; Kramer, 2000). 
3.6 Physiological factors influencing leukogram in horses 
There are two main WBC responses, physiological leukocytosis and stress leukocytosis. 
Physiological leukocytosis refers to changes in circulating WBC associated with the 
intervention of the sympathetic-adrenal axis resulting from splenic contraction in cases of 
fear, excitement, or high intensity exercise. There is a mobilization of the marginal pool of 
NEUs and/or LYM, because of a reduction in NEU adherence capacity, increased blood 
flow through the microvasculature and splenic contraction (Latimer, 1999). These events 
result in leukocytosis with mature neutrophilia and/or lymphocytosis. In some cases, 
eosinophilia and monocytosis are also found (Snow et al., 1983; Welles, 2000). These changes 
are transient and the marginal pool of NEUs is restored again in 20-30 min after the onset of 
the response and the LYM counts returned to baseline after 1 hr (Rossdale et al., 1982). 
Stress leukocytosis is associated with cortisol release under certain stressful situations. This 
hormone induces neutrophilia without left shift, lymphopenia and eosinopenia. 
Neutrophilia derives from the mobilization from the marginal pool, the reduced ability to 
migrate from the blood to the peripheral tissues and the increased mobilization of the 
population of bone marrow reserve. Lymphopenia is the result of LYM sequestration from 
lymphoid tissues and the eosinophenia derives from the marginalization of EOS in the 
blood vessels and the decreased release from the bone marrow (Caracostas et al., 1981; 
Welles, 2000). This response appears between 2 and 4 hours after the elevation of the 
endogenous cortisol concentrations or after exogenous administration of corticoids 
(Rossdale et al., 1982; Burguez et al., 1983). Normal values are recovered in 24 hrs. This 
response has been also found after an endurance exercise and in response to a great variety 
of pathological processes (Welles, 2000).  
3.6.1 Breed 
Minor differences have been found among equine breeds in relation to WBC, with the hot-
blooded horses having higher WBC compared to cold-blooded horses (Jain, 1986; Harvey et 
al., 1984). Thoroughbreds and Arabian have a mean NEU/LYM ratio of 1.0, whereas cold-
blooded horses and miniature horses have ratios of 1.7 and 0.67, respectively (Jain, 1986).  
3.6.2 Time of the day 
In Thoroughbred racing horses, Allen and Powell (1983) described that LYM count has 
higher in the evenings and lower in the mornings. These findings have been attributed to 
the circadian variations in the release of endogenous corticoids. It is well known that 
maximum cortisol concentrations appear in the morning (McKeever, 2011).  
3.6.3 Gender 
WBC and granulocytes are higher in females than in stallions, as recently found in Spanish 
Purebred horses (Hernández et al., 2008; Satué et al., 2009). On the contrary, previous 
researchers performed in warm-blooded horse breeds reported higher values in males and 
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in females (Lassen and Swardson, 1995; Cebulj-Kadunc et al., 2002). Other study failed to 
find significant differences between sexes (Lacerda et al., 2006).  
3.6.4 Age 
NEU number is low in the fetus (<1,500/μl, before 300 days of gestation), increases after 
birth in response to cortisol (8,000/μl) and then decrease to mean adult values (4000/μl) at 
about 4-6 months of age. Band NEU do not exceed 150/μl in healthy foals (Harvey, 1990; 
Allen et al., 1998). Foals born at term have higher NEU count than foals born prematurely. 
LYM numbers in foals are low at birth (average 1,400/μl), increase to 5,000/μl at 3 months 
of age, and reach adult values at 1 year of age (Jain, 1986; Harvey, 1990). LYMs further 
decline during adulthood while NEU count remains the same, resulting in a higher 
NEU/LYM ratio in aged horses compared to foals (Jain, 1986). The ratio NEU/LYM reaches 
values of 2/1 in geriatric horses (Jain, 1993; Lassen and Swardson, 1995; Hernández et al., 
2008). The progressive trend towards lymphopenia in geriatric horses is characterized by a 
reducing in B cells CD4+ and CD8+, in relation to immune senescence (Smith et al., 2002; 
Hernández et al., 2008; Satué et al., 2010).  
EOSs are not routinely detected in the fetus and in foals at birth, achieving a mean of 400/μl 
by 4 months of age (Harvey, 1990). EOSs count increases with aging due to prolonged 
exposure to allergens through life (Jain, 1993; Satué et al., 2009). However, McFarlane et al. 
(1998), Cebulj-Kadunc et al. (2003) and Hernández et al. (2008) did not found differences in 
EOS count between young and adult horses. Band NEU, MON and BAS do not seem to 
change with aging in horses (Harvey, 1990; Jain, 1993; Lassen and Swardson, 1995; Cebulj-
Kadunc et al., 2003; Satué, 2004; Hernández et al., 2008).  
3.6.5 Exercise 
WBC show different responses according to the type of exercise. Sprint exercise is associated 
with leukocytosis because of neutrophilia but mainly because of lymphocytosis, with a 
decrease in NEU/LYM ratio. These changes are likely secondary to catecholamine release 
and splenic contraction. At 3 hr after exercise, there is an increase in NEU/LYM ration, 
because the increase of NEU and decrease in LYM associated with cortisol concentrations. 
The NEU/LYM ratio returns to baseline values by 6 hrs after exercise (Snow et al., 1983).  
Endurance exercise is associated with leukocytosis, resulting from a neutrophilia and 
lymphopenia (Snow et al., 1982). Probably this is combined effect of increased circulating 
corticosteroids and splenic contraction. Horses that completed an endurance event at a 
faster speed have higher NEU/LYM ration than slower horses (Trigo et al., 2010). 
Additionally, it has been demonstrated that exhausted endurance horses had left shift in the 
NEUs and significantly lymphopenia (Trigo et al., 2010).  
3.6.6 Training 
Total WBC is unchanged during training for racing and for endurance events. In addition, 
there are no alterations in the proportions of the different WBC populations. Some overtrained 
horses develop eosinophenia together with clinical signs of disease, and this result has led to 
the hypothesis that EOSs may be a more sensitive indicator of training stress than other types 
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of WBCs (Tyler-McGowan et al., 1999). It is important to take into account that decreased NEU 
count and later, increased LYM count is consistent with systemic or respiratory disease, that 
are common causes of loss of performance in trained horses (McGowan, 2008).  
3.6.7 Reproductive status 
Although in main lines, estrous cycle and pregnancy do not change substantially the 
leukogram (Berlink et al., 2000; Da Costa et al., 2003), some studies have found a reduction 
in WBC, NEU and EOS counts during pregnancy (Satué, 2004; Satué et al., 2010). The 
reduction in WBC in Thoroughbred mares appears during the first 4 months of pregnancy, 
with a trend toward increase from half of pregnancy and it is maintained until the time of 
delivery (Gill et al., 1994). During delivery, leukocytosis with neutrophilia, lymphopenia 
and eosinopenia appear, in association with the hypothalamic-pituitary-adrenal stimulation 
and glucocorticoid release (Silver et al., 1984; Harvey et al., 1994). However, this idea has not 
been confirmed by all the authors (Taylor-Macallister et l., 1997). Finally, lactation induces 
leucopenia with an intensity proportional to the degree of stress during the period of 
maximum milk production (Harvey et al., 1994).  
4. Platelets 
Platelets or thrombocytes are cytoplasmic fragments of megakariocytes. Equine platelets 
stain very lightly with Wright-Giemsa stain and sometimes can be difficult to discern on 
blood films. They are round, oval or elongate, measuring 2.5-3.5 μm in diameter, with light 
blue cytoplasm with fine azurophilic granules (Kramer, 2000). The survival time of equine 
platelets in circulating blood is 4-7 days (Jain, 1993). Equine platelet concentrations are some 
of the lowest reported for mammals. Finding 6-10 platelets/field of high resolution in a 
peripheral blood film indicates an adequate platelet concentration. Mean platelet volume 
(MCV) and mean platelet mass have been reported in horses: 4.3-5.6 fl and 0.47-0.96 106/fl 
respectively (Boudreaux and Ebbe, 1998).  
Morphologically, giant platelets, greater than the diameter of a RBC, are associated with 
accelerated thrombocytopoiesis. Platelet clumping indicates platelet activation and 
aggregation during blood collection, and might lead to erroneously low platelet 
concentrations. EDTA-dependent pseudo thrombocytopenia has been reported in a 
Thoroughbred gelding (Hinchcliff et al., 1993).  
4.1 Physiological factors influencing platelets in horses 
4.1.1 Anticoagulant 
The use of EDTA as anticoagulant, although it can produce aggregation in normal 
situations, it is more common in patients with severe gastrointestinal disease due to platelet 
activation by circulating endotoxins and formation of aggregates of platelets and leukocytes 
(Hinchliff et al., 1993; Saigo et al., 2005).  
4.1.2 Blood sample collection and analytical time 
Repeated venipuncture, alterations in blood flow or delay in carrying out the analysis alter 
platelet count. It is advisable to perform the analysis within the first 2 hrs after collection, as 
MPV can be altered if the EDTA-sample is kept refrigerated. On the other hand, it is 
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interesting to use sodium citrate as an anticoagulant in order to measure platelet size 
(Sellon, 1998; Seghatchian, 2006).  
4.1.3 Breed 
In Quarter Horses, Jeffcott (1977) found that the number of platelets in this breed was higher 
than in other equine breeds. A clear explanation for this result is lacking, although factors 
others than the breed should be taken into consideration. 
4.1.4 Age 
Platelet numbers in foals do not change during the first year of life. In adult horses, age 
determines a progressive decrease in platelet count (Ralston et al., 1988; Jain, 1993; Satué, 
2004; Satué et al., 2009), as well as in other species (Zinkl et al., 1990). By contrast, other 
studies in horses did not agree with these results (McFarlane et al., 1998).  
4.1.5 Exercise and training 
The effect of exercise on platelet parameters seems to be intensity dependent. Short brief or 
maximal exercise results in significant increases in platelet numbers, whereas moderate 
exercise does not appear to alter platelet numbers (Bayly et al., 1983). Further, some studies 
reported reduced platelet aggregability in response to high-intensity exercise (Bayly et al., 
1983), but other authors described increased aggregability and activation of platelets 
(Kingston et al., 2002). One possible explanation for the diverse results is the modifications 
in blood pH and hemoconcentration, with changes in ionized calcium concentrations and 
platelet activity. In addition, and given many of the methodological and technical problems 
when working with equine platelets, it is unknown if training alters platelet function.  
4.1.6 Reproductive status 
In human beings, laboratory animals and female elephants, a marked activation of the 
megakaryopoiesis has been found at the end of pregnancy. This fact continues during the 
initial weeks after delivery, possibly in association with high concentrations of estrogen, 
progesterone and other steroid hormones (Jackson et al., 1992). In the mare, most of the 
studies concluded that pregnancy does not exert significant effects on circulating platelets 
(Harvey et al., 1994; Berlink et al., 2000). However, Satué (2004) and Satué et al. (2010) 
described a progressive decline in platelet numbers during pregnancy in Carthusian 
broodmares. Hormonal dynamic during pregnancy, coupled with increased levels of 
thromboxane B2 produced by the placenta, chorion and amnion.  
While in other species delivery leads to thrombocytosis (Suárez et al., 1988; Jackson et al., 
1992), mares during delivery do not develop significant changes in platelet numbers (Harvey 
et al., 1994). This response is attributed to the combined effect of stress and increased release of 
estrogen, progesterone and other steroid hormones. Finally, lactation does not exert evident 
influence of circulation platelet numbers in mares (Harvey et al., 1994; Satué, 2004).  
5. Conclusion 
Hematological profile is frequently used in horses as an aid for the diagnosis and/or 
consequences of systemic, infectious and some parasitic diseases. It can also provide 
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of WBCs (Tyler-McGowan et al., 1999). It is important to take into account that decreased NEU 
count and later, increased LYM count is consistent with systemic or respiratory disease, that 
are common causes of loss of performance in trained horses (McGowan, 2008).  
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and glucocorticoid release (Silver et al., 1984; Harvey et al., 1994). However, this idea has not 
been confirmed by all the authors (Taylor-Macallister et l., 1997). Finally, lactation induces 
leucopenia with an intensity proportional to the degree of stress during the period of 
maximum milk production (Harvey et al., 1994).  
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stain very lightly with Wright-Giemsa stain and sometimes can be difficult to discern on 
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blue cytoplasm with fine azurophilic granules (Kramer, 2000). The survival time of equine 
platelets in circulating blood is 4-7 days (Jain, 1993). Equine platelet concentrations are some 
of the lowest reported for mammals. Finding 6-10 platelets/field of high resolution in a 
peripheral blood film indicates an adequate platelet concentration. Mean platelet volume 
(MCV) and mean platelet mass have been reported in horses: 4.3-5.6 fl and 0.47-0.96 106/fl 
respectively (Boudreaux and Ebbe, 1998).  
Morphologically, giant platelets, greater than the diameter of a RBC, are associated with 
accelerated thrombocytopoiesis. Platelet clumping indicates platelet activation and 
aggregation during blood collection, and might lead to erroneously low platelet 
concentrations. EDTA-dependent pseudo thrombocytopenia has been reported in a 
Thoroughbred gelding (Hinchcliff et al., 1993).  
4.1 Physiological factors influencing platelets in horses 
4.1.1 Anticoagulant 
The use of EDTA as anticoagulant, although it can produce aggregation in normal 
situations, it is more common in patients with severe gastrointestinal disease due to platelet 
activation by circulating endotoxins and formation of aggregates of platelets and leukocytes 
(Hinchliff et al., 1993; Saigo et al., 2005).  
4.1.2 Blood sample collection and analytical time 
Repeated venipuncture, alterations in blood flow or delay in carrying out the analysis alter 
platelet count. It is advisable to perform the analysis within the first 2 hrs after collection, as 
MPV can be altered if the EDTA-sample is kept refrigerated. On the other hand, it is 
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interesting to use sodium citrate as an anticoagulant in order to measure platelet size 
(Sellon, 1998; Seghatchian, 2006).  
4.1.3 Breed 
In Quarter Horses, Jeffcott (1977) found that the number of platelets in this breed was higher 
than in other equine breeds. A clear explanation for this result is lacking, although factors 
others than the breed should be taken into consideration. 
4.1.4 Age 
Platelet numbers in foals do not change during the first year of life. In adult horses, age 
determines a progressive decrease in platelet count (Ralston et al., 1988; Jain, 1993; Satué, 
2004; Satué et al., 2009), as well as in other species (Zinkl et al., 1990). By contrast, other 
studies in horses did not agree with these results (McFarlane et al., 1998).  
4.1.5 Exercise and training 
The effect of exercise on platelet parameters seems to be intensity dependent. Short brief or 
maximal exercise results in significant increases in platelet numbers, whereas moderate 
exercise does not appear to alter platelet numbers (Bayly et al., 1983). Further, some studies 
reported reduced platelet aggregability in response to high-intensity exercise (Bayly et al., 
1983), but other authors described increased aggregability and activation of platelets 
(Kingston et al., 2002). One possible explanation for the diverse results is the modifications 
in blood pH and hemoconcentration, with changes in ionized calcium concentrations and 
platelet activity. In addition, and given many of the methodological and technical problems 
when working with equine platelets, it is unknown if training alters platelet function.  
4.1.6 Reproductive status 
In human beings, laboratory animals and female elephants, a marked activation of the 
megakaryopoiesis has been found at the end of pregnancy. This fact continues during the 
initial weeks after delivery, possibly in association with high concentrations of estrogen, 
progesterone and other steroid hormones (Jackson et al., 1992). In the mare, most of the 
studies concluded that pregnancy does not exert significant effects on circulating platelets 
(Harvey et al., 1994; Berlink et al., 2000). However, Satué (2004) and Satué et al. (2010) 
described a progressive decline in platelet numbers during pregnancy in Carthusian 
broodmares. Hormonal dynamic during pregnancy, coupled with increased levels of 
thromboxane B2 produced by the placenta, chorion and amnion.  
While in other species delivery leads to thrombocytosis (Suárez et al., 1988; Jackson et al., 
1992), mares during delivery do not develop significant changes in platelet numbers (Harvey 
et al., 1994). This response is attributed to the combined effect of stress and increased release of 
estrogen, progesterone and other steroid hormones. Finally, lactation does not exert evident 
influence of circulation platelet numbers in mares (Harvey et al., 1994; Satué, 2004).  
5. Conclusion 
Hematological profile is frequently used in horses as an aid for the diagnosis and/or 
consequences of systemic, infectious and some parasitic diseases. It can also provide 
 
Hematology – Science and Practice 
 
588 
significant information about the response to treatment, the severity of the process and the 
metabolic state of an animal. Despite the wide use of hematology, interpretation is 
challenging because many exogenous and endogenous factors significantly modify blood 
parameters. The present chapter reviews the current knowledge of the influence of 
physiological factors on erythrocytes, leukocytes and platelets in horses.   
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